<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en-GB">
	<id>https://embryology.med.unsw.edu.au/embryology/api.php?action=feedcontributions&amp;feedformat=atom&amp;user=Z3291643</id>
	<title>Embryology - User contributions [en-gb]</title>
	<link rel="self" type="application/atom+xml" href="https://embryology.med.unsw.edu.au/embryology/api.php?action=feedcontributions&amp;feedformat=atom&amp;user=Z3291643"/>
	<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=Special:Contributions/Z3291643"/>
	<updated>2026-09-26T01:27:44Z</updated>
	<subtitle>User contributions</subtitle>
	<generator>MediaWiki 1.39.10</generator>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=User:Z3291643&amp;diff=79830</id>
		<title>User:Z3291643</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=User:Z3291643&amp;diff=79830"/>
		<updated>2011-10-27T23:39:08Z</updated>

		<summary type="html">&lt;p&gt;Z3291643: /* Lab 11 Online Assessment */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{2011Student}}&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Z3291643]] 12:55, 28 July 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 1 Assessment==&lt;br /&gt;
1.	Identify the origin of In Vitro Fertilization and the 2010 nobel prize winner associated with this technique.&lt;br /&gt;
&lt;br /&gt;
‘in vitro’ fertilization is Latin for ‘in glass’ fertilization and is a treatment for infertility, whereby the sperm fertilizes the ovum outside the body and is then implanted back into the patient’s uterus. The first successful IVF birth, Louise Brown, occurred in 1978 with the help of Patrick Steptoe and Robert Edwards. Edwards was awarded the 2010 nobel prize in medicine for his achievement. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
2.	Identify a recent paper on fertilisation and describe its key findings.&lt;br /&gt;
&lt;br /&gt;
The aim of this paper was to investigate whether age &amp;lt;=25 played a role in the reproductive outcome of women undergoing IVF. Infertile patients aged between 19 and 25 years of age were compared to infertile patients aged 30-35 years to determine primarily fertilization rates and the number of top quality embryos. The results were unexpected as the younger subjects had lower fertilization rates and reduced embryo quality.&amp;lt;ref&amp;gt;PMID 21042842&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
3.	Identify 2 congenital anomalies.&lt;br /&gt;
&lt;br /&gt;
Trisomy 21 and cleft palate&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--[[User:S8600021|Mark Hill]] 10:01, 3 August 2011 (EST) These answers are fine.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 13:02, 4 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Lab 2 Assessment==&lt;br /&gt;
1.	Identify the ZP protein that spermatozoa binds and how is this changed (altered) after fertilization. &lt;br /&gt;
&lt;br /&gt;
ZP3 acts as a receptor for the sperm. This is followed by the acrosome reaction, whereby acrosomal contents digest the ZP and allow the sperm surface proteins to bind to the ZP2. After fertilization, cortical reaction takes place where cortical granules are exocytosed. This results in the removal of carbohydrate from ZP3 and cleavage of ZP2 to harden the ZP. These changes occur to prevent polyspermy.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
2.       Identify a review and a research article related to your group topic.&lt;br /&gt;
&lt;br /&gt;
This research article showed genotype-phenotype correlations in Angelman Syndrome (AS). They have concluded that deletion patients had worse developmental outcomes than non deletion patients.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20729760&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
This review article is really comprehensive and gives a good background knowledge of AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20445456&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Z3291643]] 12:42, 11 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 3 Assessment==&lt;br /&gt;
&lt;br /&gt;
1.        What is the maternal dietary requirement for late neural development? &lt;br /&gt;
&lt;br /&gt;
Iodine. Zimmermann found that maternal deficiency of iodine can result in cognitive disability in the offspring, most severely characterized by cretinism. Fortunately, mild to moderate iodine deficiency can be corrected in primary school aged children to improve cognitive and motor functions.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21802524&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
2.        Upload a picture relating to your group project.&lt;br /&gt;
&lt;br /&gt;
[[File:UBE3A colocalizes with ASPM at the centrosome throughout mitosis.jpg|thumb|UBE3A colocalizes with ASPM at the centrosome throughout mitosis.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21633703&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
===UBE3A colocalizes with ASPM at the centrosome throughout mitosis===&lt;br /&gt;
&lt;br /&gt;
[[File:UBE3A colocalizes with ASPM at the centrosome throughout mitosis.jpg|Abnormal cytokinesis and apoptosis in UBE3A knockdown cells.|350px]]&lt;br /&gt;
&lt;br /&gt;
UBE3A colocalizes with ASPM at the centrosome. (A) Indirect immunofluorescence of HEK293 cells at interphase and different phases of mitosis stained with antibodies against ASPM and UBE3A (anti-UBE3A-sc-8926). Note colocalization of UBE3A with ASPM at the centrosome throughout mitosis (arrowheads). Note weak centrosomal staining of UBE3A in an interphase cell (arrow). (B) Indirect immunofluorescence of A549 cells stained with antibodies against UBE3A (anti-UBE3A-sc-8926) and ASPM at metaphase and telophase. Note colocalization of UBE3A with ASPM at the centrosome (arrowheads). Scale bar=2 µm.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Copyright Singhmar, Kumar. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 11:08, 18 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 4 Online Assessment==&lt;br /&gt;
&lt;br /&gt;
# '''The allantois, identified in the placental cord, is continuous with what anatomical structure?'''&lt;br /&gt;
The allantois is endodermic in origin and is the extension of the yolk sac into the connecting stalk. It's connected to the superior end of the developing bladder&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
#  '''Identify the 3 vascular shunts, and their location, in the embryonic circulation.'''&lt;br /&gt;
1. Ductus arteriosus; connects left pulmonary artery with the descending aorta&lt;br /&gt;
2. Ductus venosus; connects the portal and umbilical veins to the inferior vena cava&lt;br /&gt;
3. Foramen ovale; between left and right atria&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
# Identify the Group project sub-section that you will be researching. (Add to project page and your individual assessment page)&lt;br /&gt;
&lt;br /&gt;
; 4  Aetiology (genetic inheritance); Julia&lt;br /&gt;
; 5  Pathophysiology; Julia (as it's quite linked with aetiology anyway)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 12:59, 25 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 5 Online Assessment==&lt;br /&gt;
&lt;br /&gt;
# Which side (L/R) is most common for diaphragmatic hernia and why? &lt;br /&gt;
Posterior left side,possibly due to the fact that the left pericardioperitoneal canal is larger and closes later than the right.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 12:48, 1 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 6 Online Assessment==&lt;br /&gt;
# What week of development do the palatal shelves fuse?&lt;br /&gt;
Week 9 of early embryonic growth&lt;br /&gt;
 &lt;br /&gt;
# What early animal model helped elucidate the neural crest origin and migration of neural crest cells?&lt;br /&gt;
Migration of neural crest cells have been studied in quail-chick chimeras - transplanted quail cells have obvious nucleoli compared with chicken. It was first done by Nicole Le Douarin in the 80's&lt;br /&gt;
 &lt;br /&gt;
# What abnormality results from neural crest not migrating into the cardiac outflow tract? &lt;br /&gt;
Tetralogy of Fallot; when the outflow tract is not aligned properly, it is seen as a nonwedged aorta. Nonwedged aorta indicates tetralogy of Fallot. In addition, past studies using chick embryos have outlined that cardiac neural crest cell ablation led to this malalignment. In contrast, Farrell et al have shown that the introduction of cardiac neural crest aligned the outflow tract properly. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9933243&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 12:49, 15 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 7 Online Assessment==&lt;br /&gt;
&lt;br /&gt;
1. Are satellite cells &lt;br /&gt;
* necessary for muscle hypertrophy?&lt;br /&gt;
: No&lt;br /&gt;
 &lt;br /&gt;
* generally involved in hypertrophy?&lt;br /&gt;
: Yes&lt;br /&gt;
 &lt;br /&gt;
&lt;br /&gt;
2. Why does chronic low frequency stimulation (CLFS) cause a fast to slow fibre type shift? &lt;br /&gt;
: At the molecular level, there are exchanges of fast and slow type protein isoforms, such as calcium regulatory system, myofibrillar apparatus. The final step in CLFS induced fiber shift is the upregulation of slow myosin from the conversion of myogenic cells to slow fiber phenotype. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12500901&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;It is also known that satellite cells contribute to CLFS-induced transition of fiber types shown by the fact that CLFS increases type I fibers only after fiber necrosis. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16439424&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--Mark Hill 10:42, 16 September 2011 (EST) &lt;br /&gt;
&lt;br /&gt;
I would like each student to now also look at the following online page before the next Lab and write a comment based upon the group project assessment criteria. &lt;br /&gt;
&lt;br /&gt;
http://embryology.med.unsw.edu.au/embryology/index.php?title=Trisomy_21 &lt;br /&gt;
Paste your comment on the Trisomy 21 discussion page and also on your own student page. &lt;br /&gt;
&lt;br /&gt;
Group Assessment Criteria&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Good and concise explanation of the subheadings,however, I would've liked to see some attempt to further explain how the asspcoated congenital abnormalities occur.  &lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Lots of images, graphs and table used effectively to help reader better understand the disease. They also gave the project page some colour to make it more pleasing to the eye. Unfortunately, some images were placed (eg. John Langdon Down)in the wrong sections and interrupted the flow of the project page. &lt;br /&gt;
#* In addition, some of the images were not referred to within the project page. &lt;br /&gt;
#* Furthermore, the overall structure and layout of the page could be improved, such as putting the Diagnostic Links under diagnosis instead of the introduction&lt;br /&gt;
#* I also felt American College of Obstetricians and Gynecologists Recommendations could've been a subheading under 'screening'&lt;br /&gt;
#Content is correctly cited and referenced. &lt;br /&gt;
#* The very first image does not provide any information on the permissions to reuse the image (open access). &lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations. &lt;br /&gt;
#* Would've been better to include more self drawn diagrams and tables to further illustrate the group's knowledge of this disease&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* Lots of Pubmed articles have been used to make this page more credible and reliable &lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#* More words need to be explained in the glossary, such as 'tandem single nucleotide polymorphisms' &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 22:50, 21 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 8 Online Assessment==&lt;br /&gt;
attendance: --[[User:Z3291643|Sang Lee]] 13:04, 22 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Group 1: Turner Syndrome&lt;br /&gt;
&lt;br /&gt;
Firstly, nice progress with the group project. After reading your page, I have a good general knowledge of Turner Syndrome, so thanks. Overall, most sections were well done, though the writing style and layout could be more consistent, but you could work on that when you've finalised the content of the page. &lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: Good intro, very first image of the karyotype should include the actual statement of the 'Open access' not just 'copyright'&lt;br /&gt;
#* Epidemiology: Grammatical errors disrupt the flow of the content, in addition, graph has no copyright info, title could be improved&lt;br /&gt;
#* Etiology: Nice simple diagram of 22 eggs and 23 sperms, good example of when a picture can tell more than a thousand words! I feel there needs to be consistency either use Turner Syndrome or TS throughout the page&lt;br /&gt;
#* Clinical: liked how you have further classified the symptoms to its associated titles, nice idea; very easy to read, but a table would also be good&lt;br /&gt;
#* Diagnosis: image of TS maternal serum sampling doesn't contain {Template:2011 Student Image}, but a very good table&lt;br /&gt;
#* image of the TS X chromosome variations shouldl contain {Template:2011 Student Image}. Furthermore, if you use A-E in image descriptions, you should include A-E within the image&lt;br /&gt;
#* Research: very good layout and explanations, informative&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Could include more images especially in clinical manidestations, and some images do not fit the requirements set by Mark, as I've highlighted above &lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* seems to be cited well. However, although you have more than 100 referencees, a lot of them are repeated references, maybe you could try to use more pubmed articles, a greater variety&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations. &lt;br /&gt;
#* Glossary: could include more words such as echocardiogram&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* Although you have more than 100 referencees, a lot of them are repeated references, maybe you could try to use more pubmed articles, a greater variety&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#*  Although the content is informative, I'm left feeling like I want more variety of resources, so maybe some further research will improve the overall impression of your page &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot;&lt;br /&gt;
* consistency in writing style&lt;br /&gt;
* more images and cited correctly &lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 14:44, 24 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Group 2&lt;br /&gt;
&lt;br /&gt;
Hey Group 2, firstly, well done on putting in the effort to create this page, it really shows your dedication and cooperation as a team! Here are some points I thought you could improve on to take this page to that extra level&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: Good overview. Image would look better with a border or as a thumb&lt;br /&gt;
#* History: Image too large, again maybe a border?&lt;br /&gt;
#* Epidemiology: Need to define velocardiofacial syndrome in glossary, also break it down into subheadings, eg. Incidence, Sex, etc&lt;br /&gt;
#* Etiology: Maybe better if in a table&lt;br /&gt;
#* Pathogenesis: I liked how you broke it doen into relevant subheadings. However, on a slightly negative note, the DG Pathophysiology Diagram looks rushed; I think it would've looked better if it was neater and easier to read.&lt;br /&gt;
#* Diagnosis: I felt citing was done poorly in this section, eg. the last 4/5 sentences in the FISH technique was not referenced at all, but again, this is very easily fixed. But good to see you have put in the effort and time&lt;br /&gt;
#* Clinical: Image of normal and cleft palate, if based on a textbook, I think you still need permission to adapt it (not quite sure, please ask Mark)? Table with 'How it is caused' would be better by itself as pathophysiology. Tetralogy of Fallot needs to be fitted into this section more smoothly, at the moment, it makes this section look very cramped. Also, the image regarding Tetralogy needs the correct format for student drawn images (ie. 'I (student no.)....)&lt;br /&gt;
#* Research: Maybe break it down into subheadings&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Good images used with a nice range of self drawn images. However, no where in the page is there any reference to the images within the text.&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* I feel citation needs to be improved overall. Lots of the sections have missing citations, especially Diagnostic Tests. Also in the reference list, refs 33,40,47, 49 have nothing in it (is it meant to be like this?)&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations. &lt;br /&gt;
#* Nice drawings, though some could've done better with more effort&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* Nice range of references used&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#* It's very clear to me that you guys have worked together well and there has been good team work going on here to create this page, so well done&lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* I feel your page is too heavy with the text, although there's a lot of images as well, it just doesn't quite balance out with the text. &lt;br /&gt;
* Also felt the different colours used for the tables, although adding a splash of colour to your page, brought down the overall quality of the page. However, please keep in mind that others might really like this approach of table formatting, it's just that personally, I think you could benefit from keeping all table colours consistent.&lt;br /&gt;
* Sometimes you refer to DiGeorge Syndrome as DGS and also as DS. Small and easy to fix, adds consistency&lt;br /&gt;
* Please don't forget to add the {template} for student uploaded images&lt;br /&gt;
* Definitely needs more words in the Glossary, such as Meiosis, de novo, microarray&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 16:02, 24 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 3&lt;br /&gt;
&lt;br /&gt;
Hi, overall, a nice project page with interesting information.&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: Nice introduction, good flow and easy to read. However, image needs proper information and perhaps 'This disorder was first described by Harry F.' could be placed earlier on in the intro rather than in the middle&lt;br /&gt;
#* History: Nice section, very interesting&lt;br /&gt;
#* Epidemiology: First paragraph is good, but I feel the rest of this section doesn't quite belong here, such as the information on seizures, IQs, diagnosis. This section should focus on stats (sex/birth/ethnic/demographic/etc). Fig 2, 3 belong more in the signs and symptoms&lt;br /&gt;
#* Etiology: the '1:1000 male' contradicts the '1:500' given in epidemiology. Fig4 needs coyright information&lt;br /&gt;
#* Pathogenesis: Needs better referencing, also placing fig 5, 6 on either side doesn't look too good with the text. Perhaps place them below one another?&lt;br /&gt;
#* Signs: Seems a bit incomplete, it'll also be good to explain the image of 'pubertal gynecomastia'&lt;br /&gt;
#* Diagnosis: Sentence structure could be improved, ie. 'performed because physicians may suspect it because of clinical findings'. Information is interesting, but could be presented more clearly, perhaps in a table?&lt;br /&gt;
#* Similar defects: very nice, presented well with good information, easy to read&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Good images used with a nice range of self drawn images. However, lot of the images need to be formatted properly with required information&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* overall referencing was well done, except pathogenesis needs more referencing&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations. &lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* Nice range of references used&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#* The information is there, but maybe from now til final assessment, you could do further research in all sections, as they do seem a little short.&lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* better page layout&lt;br /&gt;
* glossary: sorry, but I feel the alphabet subheadings here are very effective as you have it in alphabetical order anyway&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 21:59, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 4&lt;br /&gt;
&lt;br /&gt;
Hey, this is a nicely structured page with interesting content that is presented well. There is a nice balance of text and image&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: good, to the point&lt;br /&gt;
#* History: Nice section, perhaps bold the years?&lt;br /&gt;
#* Epidemiology: I really liked this section, both visually and content wise. The table is easy to read and I liked your explanations for the HD prevalence, well done&lt;br /&gt;
#* Genetics: Perhaps you could have the 'CAG (cytosine-adenine-glutamine)' in the introduction when you first refer to it? Referencing is required in i'HTT and normal functions'. I really liked your subheadings, made it very easy to understand and follow &lt;br /&gt;
#* Pathogenesis: Image is too big, good subheadings, I suggest that if you write in purple to highlight some words, maybe you could do that for the whole page?&lt;br /&gt;
#* Clinical: liked the motor impairment explanations, how about explaining the cognitive and behaviour impairments as well? (it'll be worth it!)&lt;br /&gt;
#* Diagnosis: Nice content, but it just feels a bit too crowded, maybe rearrange the images and decrease image size&lt;br /&gt;
#* Treatment: Very nice section with nice images and good format!&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Good balance of images and text, though some rearrangement of images would make this page look better. Very good use of subheadings to make the content more easy to digest&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* overall referencing was well done&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
* good range of tables, images and self drawn images&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* Nice range of references used&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* just minor changes such as resizing some of the images, making the sections consistent in format&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 22:32, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 5&lt;br /&gt;
&lt;br /&gt;
Hi, I can see some progress on this page which is good, content is interesting&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: What is FMR1 gene? Need more information here, as in when was it first discovered, some stats&lt;br /&gt;
#* Epidemiology: I think screening information is extensive enough to be a section on its own&lt;br /&gt;
#* Etiology: no explanation of FMR1 gene so far, what is its normal function? Also, please refer to images used in this section&lt;br /&gt;
#* Development of the disease:nice succinct, easy to follow section. Perhaps add an image for one of the stages mentioned here?&lt;br /&gt;
#* Signs: REFERENCING!!! But, content is good and interesting&lt;br /&gt;
#* Diagnosis: An image here would be nice, and an explanation of how the technology is used to diagnose FXS&lt;br /&gt;
#* Treatment: Nice table with good information&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Need to balance out the text and image ratio, some good subheadings&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* poor referencing, which makes me question the reliability of the content in some sections&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
#* needs a lot more images&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* I feel more research needs to be done here&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* Although the content is here, there is still a lot of work needed to make this page feel complete&lt;br /&gt;
* glossary is very lacking in terminology&lt;br /&gt;
* need more images&lt;br /&gt;
* further research would be nice to explain this disease in more detail&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 23:26, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Group 6&lt;br /&gt;
Hey, nice progress with your page, all sections have similar amount of content which were interesting&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: Referencing needs to be improved here&lt;br /&gt;
#* History: content is good but too wordy. I think a summary or a simple timeline would be good&lt;br /&gt;
#* Epidemiology: Where's the reference for 3/10000 live births?&lt;br /&gt;
#* Signs: ok section, but could do with more images here&lt;br /&gt;
#* Genetics: If using abbreviations, such as TBX1 gene, you should explain what it is, ie. TBX1 gene (T-box 1). Also need to work on referencing here as well. How about organising all the content in a table? have in columns: gene, gene profile, frequency, etc.&lt;br /&gt;
#* Pathogenesis: I'm not quite sure about this, but do you need permission to adapt an image from an article? (I'm referring to the '4 defects' image)&lt;br /&gt;
#* Diagnosis: I'm sorry, but this section is a bit bland, though the content is very informative. I think some images here would be good&lt;br /&gt;
#* Treatment: Referencing! Also, personally, that green is too bright, maybe find a more neutral, soothing colour?&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Need to find more images, I feel some of the information could be more effectively presented in table formate rather than lengthy text&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* VERY poor referencing, which makes me question the reliability of the content in some sections&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
#* needs a lot more images&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* research done is evident, just need to reference&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* glossary is very lacking in terminology&lt;br /&gt;
* need more images&lt;br /&gt;
* REFERENCING!&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 23:26, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Group 8&lt;br /&gt;
Hey, well done, your page is looking really polished! Lots of very interesting information here and presented in a very easy to follow manner&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* History: I feel that you could lessen the info of Nicholas and add more current findings of the disease.&lt;br /&gt;
#* Aetiology: What is the chromosome 9 image based on? Need to work on referencing. Very good subheadings and well balanced with images&lt;br /&gt;
#* Pathogenesis: Needs more information&lt;br /&gt;
#* Neuro: What's the images based on? Good subheadings and explained well. I liked the way you gave explanations for normal function/appearance and then went on to explain abnormality associated with the structures in this disease. But you need to improve your referencing for this section&lt;br /&gt;
#* Diagnosis: Very good table and images. But need to fix the postnal diagnosis table so that it spans the length of the screen&lt;br /&gt;
#* Symptoms: table and images look too crowded&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* good subheadings, images, impressive self drawn images! Nice balanced page layout&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* needs to work on referencing&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* research done is evident, just need to reference&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* referencing&lt;br /&gt;
* better arrangement of table and images so page doesn't look too crowded&lt;br /&gt;
&lt;br /&gt;
Well done guys, nice team work!&lt;br /&gt;
--[[User:Z3291643|z3291643]] 23:50, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 9&lt;br /&gt;
&lt;br /&gt;
Hey, your page has a lot of very interesting content and some unique self drawn images. I thoroughly enjoyed this page, thanks&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: Inclusion of incidence would be nice&lt;br /&gt;
#* History: very informative and a nice simple timeline&lt;br /&gt;
#* Genetics: Good, succinct section, especially liked the table&lt;br /&gt;
#* Diagnosis: needs referencing. Is diagnosis only postnatal? What is the average age of diagnosis for this disease?&lt;br /&gt;
#* Management and Treatment: Seems a little out of place under epidemiology, I think it should be place later on &lt;br /&gt;
#* Phenotype:Reference?&lt;br /&gt;
#* Cardiac conditions: maybe give explanations for atrial and ventricular septal defect, just brief descriptions would suffice. Why is it so that males are more likely to suffer CVD than females?&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* good subheadings, interesting self drawn images. However, this page needs to find a balance in text and images&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* needs to work on referencing&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* research done is evident, just need to reference&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#* very interesting content, informative&lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* referencing&lt;br /&gt;
* more images&lt;br /&gt;
* glossary; lacking a lor of terms&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 00:10, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 10&lt;br /&gt;
&lt;br /&gt;
Hey, this is a interesting disease, with some good images to show the disease clearly. &lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: succinct introduction&lt;br /&gt;
#* History: Has interesting content, though timeline would be nice&lt;br /&gt;
#* Pathogenesis: Too brief and could be improved with an image&lt;br /&gt;
#* Signs: surely there are more symptoms here, maybe you could have subheadings to break down the symtpoms, ie. motor impairment, cognitive impairments, etc&lt;br /&gt;
#* Clinical manifestations and complications: nice section with good image used&lt;br /&gt;
#* Diagnosis: could be further explained, and an image would be nice&lt;br /&gt;
#* Treatment: Current and Future Prospects: needs referencing&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* need to balance out the text with images, could organise page better with more subheadings, more images needed &lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* needs to work on referencing!!&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
#*  more table could be used instead of lengthy explanations&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* much more research needs to be done to further explain the sections&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* referencing&lt;br /&gt;
* more images&lt;br /&gt;
* glossary; lacking a lot of terms&lt;br /&gt;
* needs much more research, lots of repetitions in referencing&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 11:02, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 11&lt;br /&gt;
&lt;br /&gt;
Hey, this is a interesting disease, with some good images to show the disease clearly. &lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: very rushed, no reference and needs much more work, it should be a succinct summary of this whole page.&lt;br /&gt;
#* History: Has interesting content, though timeline would be better incorporated under History, not a section of its own&lt;br /&gt;
#* Diagnosis: If you're abbreviating Cleft Palate to CLP, you should have it as Cleft palate (CLP). The two given tables are pretty much the same, except for different sample number. Is it really necessary to have the two tables when they're so similar? Could do well with an image&lt;br /&gt;
#* Syndromes and Anomalies associated with cleft: Nice array of images used here. Content is good (for ones you provided), but needs work on referencing. Perhaps you could organise the content into a table for easy comparison since you have more than one anomalies&lt;br /&gt;
#* Aetiology: Needs referencing, image could have a caption to explain it. Although the content is there, it's too brief and I feel it could be organised in a more effective manner, such as using number stages.&lt;br /&gt;
#* Types of Cleft Palate/Lip:very brief, please explain the points (ie. what's the differences between them? you say there are differences in severity, how so?)&lt;br /&gt;
#* Pathophysiology: need to reformat table more effectively and work on referencing&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* need to balance out the text with images, could organise page better with more subheadings &lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* needs to work on referencing!!&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
#* NO self drawn images so far&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* much more research needs to be done. sections overall are lacking substance and doesn't explain the content very well&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* referencing&lt;br /&gt;
* more images&lt;br /&gt;
* glossary; lacking a lot of terms&lt;br /&gt;
* needs much more research&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 11:02, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 9 attendence==&lt;br /&gt;
--[[User:Z3291643|z3291643]] 13:00, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 10 attendence==&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 13:15, 6 October 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 10 Online Assessment==&lt;br /&gt;
&lt;br /&gt;
1.Besides fetal alcohol syndrome, identify another environmental teratogen that can lead to hearing loss.&lt;br /&gt;
&lt;br /&gt;
Noise pollution is a big factor in hearing loss, as well as viral and bacterial infections such as meningitis. Hearing loss from meningitis can be a result of the direct effects of the infection on the brain or the body's reaction to the infection, most commonly with pneumococcal meningitis. 6% of all hearing defects in children can be attributed to bacterial meningitis, with around 72% of these children progressing to complete hearing loss by the age of three. &lt;br /&gt;
&lt;br /&gt;
2.Identify 3 factors that contribute to poor neonatal drainage of the middle ear. &lt;br /&gt;
&lt;br /&gt;
The auditory tube connects the middle ear cavity to the nasopharynx, and is different in structure in neonates vs. adults.&lt;br /&gt;
:# the eustachian tube is very horizontal (10 degrees to the horizontal axis)&lt;br /&gt;
:# only opened by a single muscle called the tensor palati muscle (compared to 2 muscles in the adult tube)&lt;br /&gt;
:# it is shorter(17-18 mm) and narrower &lt;br /&gt;
&lt;br /&gt;
3.Identify 1 genetic abnormality that affects hearing development and link to the OMIM record. (Your individual abnormality should be different from all other students)&lt;br /&gt;
* Waardenburg syndrome&lt;br /&gt;
* results in hearing loss (to variable extent)&lt;br /&gt;
* inherited in an autosomal dominant manner&lt;br /&gt;
* [http://omim.org/entry/193500 Waardenburg syndrome]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Related Links'''&lt;br /&gt;
&lt;br /&gt;
'''Animal Models'''&lt;br /&gt;
&lt;br /&gt;
* [[Mouse Knockout]] - this page explains the current use of mouse models in disrupting genes to elucidate their genetic function, including the mouse gene knockouts for alpha calcium-calmodulin kinase II (alpha CaMKII)&lt;br /&gt;
* [[2009 Group Project 4]] - this page gives an extensive overview on the history of the mouse model and its various use in embryology and genetics. In addition, it also describes mouse knockout and the role they play in current research of various human diseases&lt;br /&gt;
* [[Fly Development]] - this page describes the use of drosophila flies as developmental models&lt;br /&gt;
* [[2009 Group Project 2]] - this page gives an extensive overview on the history of the fly model and its various use in embryology and genetics&lt;br /&gt;
&lt;br /&gt;
'''Diagnosis'''&lt;br /&gt;
* [[Chorionic villus sampling]] - this page explains the process of chorionic villus sampling, its disadvantages and gives a brief overview of recent findings&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 10:20, 13 October 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 11 Online Assessment==&lt;br /&gt;
&lt;br /&gt;
1.Name the components that give rise to the interatrial septum and the passages that connect the right and left atria. &lt;br /&gt;
&lt;br /&gt;
* Components: Septum Primum, Septum secundum&lt;br /&gt;
* Passages: Foramen ovale, Foramen primum then Foramen secundum&lt;br /&gt;
&lt;br /&gt;
2.Identify the cardiac defects that arise through abnormal development of the outflow tract &lt;br /&gt;
&lt;br /&gt;
* Tetralogy of Fallot&lt;br /&gt;
* Transposition of the Great Vessels &lt;br /&gt;
* Aortic Stenosis&lt;br /&gt;
* Pulmonary Stenosis&lt;br /&gt;
* Pulmonary Atresia&lt;br /&gt;
* Patent Ductus Arteriosus&lt;br /&gt;
* Hypoplastic Left Heart Syndrome &lt;br /&gt;
* Coarctation of the Aorta&lt;br /&gt;
* Interrupted Aortic Arch&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 21:00, 13 October 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Lab 11 lab attendence===&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 13:35, 13 October 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab12 Online Assessment==&lt;br /&gt;
&lt;br /&gt;
1.Give examples of 3 systems that continue to develop postnatally. &lt;br /&gt;
* Heart (no more right to left shunting)&lt;br /&gt;
* Respiratory system; Lungs&lt;br /&gt;
* Endocrine (placenta had a major role, but at birth this placental supply shuts down and HPA and HPG (at puberty) are established. In addition, adrenal cortex matures 3 years postnatally)&lt;br /&gt;
&lt;br /&gt;
2.Identify the abnormalities detected by the Guthrie Test and link to one abnormality listed in OMIM&lt;br /&gt;
* Guthrie tests are used to detect metabolic abnormalities in new borns by testing their blood&lt;br /&gt;
* Homocystinuria ([http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=236200 OMIM])&lt;br /&gt;
&lt;br /&gt;
==''' References '''==&lt;br /&gt;
&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;/div&gt;</summary>
		<author><name>Z3291643</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=User:Z3291643&amp;diff=78703</id>
		<title>User:Z3291643</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=User:Z3291643&amp;diff=78703"/>
		<updated>2011-10-19T23:23:01Z</updated>

		<summary type="html">&lt;p&gt;Z3291643: /* Lab 11 Online Assessment */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{2011Student}}&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Z3291643]] 12:55, 28 July 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 1 Assessment==&lt;br /&gt;
1.	Identify the origin of In Vitro Fertilization and the 2010 nobel prize winner associated with this technique.&lt;br /&gt;
&lt;br /&gt;
‘in vitro’ fertilization is Latin for ‘in glass’ fertilization and is a treatment for infertility, whereby the sperm fertilizes the ovum outside the body and is then implanted back into the patient’s uterus. The first successful IVF birth, Louise Brown, occurred in 1978 with the help of Patrick Steptoe and Robert Edwards. Edwards was awarded the 2010 nobel prize in medicine for his achievement. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
2.	Identify a recent paper on fertilisation and describe its key findings.&lt;br /&gt;
&lt;br /&gt;
The aim of this paper was to investigate whether age &amp;lt;=25 played a role in the reproductive outcome of women undergoing IVF. Infertile patients aged between 19 and 25 years of age were compared to infertile patients aged 30-35 years to determine primarily fertilization rates and the number of top quality embryos. The results were unexpected as the younger subjects had lower fertilization rates and reduced embryo quality.&amp;lt;ref&amp;gt;PMID 21042842&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
3.	Identify 2 congenital anomalies.&lt;br /&gt;
&lt;br /&gt;
Trisomy 21 and cleft palate&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--[[User:S8600021|Mark Hill]] 10:01, 3 August 2011 (EST) These answers are fine.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 13:02, 4 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Lab 2 Assessment==&lt;br /&gt;
1.	Identify the ZP protein that spermatozoa binds and how is this changed (altered) after fertilization. &lt;br /&gt;
&lt;br /&gt;
ZP3 acts as a receptor for the sperm. This is followed by the acrosome reaction, whereby acrosomal contents digest the ZP and allow the sperm surface proteins to bind to the ZP2. After fertilization, cortical reaction takes place where cortical granules are exocytosed. This results in the removal of carbohydrate from ZP3 and cleavage of ZP2 to harden the ZP. These changes occur to prevent polyspermy.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
2.       Identify a review and a research article related to your group topic.&lt;br /&gt;
&lt;br /&gt;
This research article showed genotype-phenotype correlations in Angelman Syndrome (AS). They have concluded that deletion patients had worse developmental outcomes than non deletion patients.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20729760&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
This review article is really comprehensive and gives a good background knowledge of AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20445456&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Z3291643]] 12:42, 11 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 3 Assessment==&lt;br /&gt;
&lt;br /&gt;
1.        What is the maternal dietary requirement for late neural development? &lt;br /&gt;
&lt;br /&gt;
Iodine. Zimmermann found that maternal deficiency of iodine can result in cognitive disability in the offspring, most severely characterized by cretinism. Fortunately, mild to moderate iodine deficiency can be corrected in primary school aged children to improve cognitive and motor functions.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21802524&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
2.        Upload a picture relating to your group project.&lt;br /&gt;
&lt;br /&gt;
[[File:UBE3A colocalizes with ASPM at the centrosome throughout mitosis.jpg|thumb|UBE3A colocalizes with ASPM at the centrosome throughout mitosis.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21633703&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
===UBE3A colocalizes with ASPM at the centrosome throughout mitosis===&lt;br /&gt;
&lt;br /&gt;
[[File:UBE3A colocalizes with ASPM at the centrosome throughout mitosis.jpg|Abnormal cytokinesis and apoptosis in UBE3A knockdown cells.|350px]]&lt;br /&gt;
&lt;br /&gt;
UBE3A colocalizes with ASPM at the centrosome. (A) Indirect immunofluorescence of HEK293 cells at interphase and different phases of mitosis stained with antibodies against ASPM and UBE3A (anti-UBE3A-sc-8926). Note colocalization of UBE3A with ASPM at the centrosome throughout mitosis (arrowheads). Note weak centrosomal staining of UBE3A in an interphase cell (arrow). (B) Indirect immunofluorescence of A549 cells stained with antibodies against UBE3A (anti-UBE3A-sc-8926) and ASPM at metaphase and telophase. Note colocalization of UBE3A with ASPM at the centrosome (arrowheads). Scale bar=2 µm.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Copyright Singhmar, Kumar. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 11:08, 18 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 4 Online Assessment==&lt;br /&gt;
&lt;br /&gt;
# '''The allantois, identified in the placental cord, is continuous with what anatomical structure?'''&lt;br /&gt;
The allantois is endodermic in origin and is the extension of the yolk sac into the connecting stalk. It's connected to the superior end of the developing bladder&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
#  '''Identify the 3 vascular shunts, and their location, in the embryonic circulation.'''&lt;br /&gt;
1. Ductus arteriosus; connects left pulmonary artery with the descending aorta&lt;br /&gt;
2. Ductus venosus; connects the portal and umbilical veins to the inferior vena cava&lt;br /&gt;
3. Foramen ovale; between left and right atria&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
# Identify the Group project sub-section that you will be researching. (Add to project page and your individual assessment page)&lt;br /&gt;
&lt;br /&gt;
; 4  Aetiology (genetic inheritance); Julia&lt;br /&gt;
; 5  Pathophysiology; Julia (as it's quite linked with aetiology anyway)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 12:59, 25 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 5 Online Assessment==&lt;br /&gt;
&lt;br /&gt;
# Which side (L/R) is most common for diaphragmatic hernia and why? &lt;br /&gt;
Posterior left side,possibly due to the fact that the left pericardioperitoneal canal is larger and closes later than the right.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 12:48, 1 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 6 Online Assessment==&lt;br /&gt;
# What week of development do the palatal shelves fuse?&lt;br /&gt;
Week 9 of early embryonic growth&lt;br /&gt;
 &lt;br /&gt;
# What early animal model helped elucidate the neural crest origin and migration of neural crest cells?&lt;br /&gt;
Migration of neural crest cells have been studied in quail-chick chimeras - transplanted quail cells have obvious nucleoli compared with chicken. It was first done by Nicole Le Douarin in the 80's&lt;br /&gt;
 &lt;br /&gt;
# What abnormality results from neural crest not migrating into the cardiac outflow tract? &lt;br /&gt;
Tetralogy of Fallot; when the outflow tract is not aligned properly, it is seen as a nonwedged aorta. Nonwedged aorta indicates tetralogy of Fallot. In addition, past studies using chick embryos have outlined that cardiac neural crest cell ablation led to this malalignment. In contrast, Farrell et al have shown that the introduction of cardiac neural crest aligned the outflow tract properly. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9933243&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 12:49, 15 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 7 Online Assessment==&lt;br /&gt;
&lt;br /&gt;
1. Are satellite cells &lt;br /&gt;
* necessary for muscle hypertrophy?&lt;br /&gt;
: No&lt;br /&gt;
 &lt;br /&gt;
* generally involved in hypertrophy?&lt;br /&gt;
: Yes&lt;br /&gt;
 &lt;br /&gt;
&lt;br /&gt;
2. Why does chronic low frequency stimulation (CLFS) cause a fast to slow fibre type shift? &lt;br /&gt;
: At the molecular level, there are exchanges of fast and slow type protein isoforms, such as calcium regulatory system, myofibrillar apparatus. The final step in CLFS induced fiber shift is the upregulation of slow myosin from the conversion of myogenic cells to slow fiber phenotype. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12500901&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;It is also known that satellite cells contribute to CLFS-induced transition of fiber types shown by the fact that CLFS increases type I fibers only after fiber necrosis. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16439424&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--Mark Hill 10:42, 16 September 2011 (EST) &lt;br /&gt;
&lt;br /&gt;
I would like each student to now also look at the following online page before the next Lab and write a comment based upon the group project assessment criteria. &lt;br /&gt;
&lt;br /&gt;
http://embryology.med.unsw.edu.au/embryology/index.php?title=Trisomy_21 &lt;br /&gt;
Paste your comment on the Trisomy 21 discussion page and also on your own student page. &lt;br /&gt;
&lt;br /&gt;
Group Assessment Criteria&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Good and concise explanation of the subheadings,however, I would've liked to see some attempt to further explain how the asspcoated congenital abnormalities occur.  &lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Lots of images, graphs and table used effectively to help reader better understand the disease. They also gave the project page some colour to make it more pleasing to the eye. Unfortunately, some images were placed (eg. John Langdon Down)in the wrong sections and interrupted the flow of the project page. &lt;br /&gt;
#* In addition, some of the images were not referred to within the project page. &lt;br /&gt;
#* Furthermore, the overall structure and layout of the page could be improved, such as putting the Diagnostic Links under diagnosis instead of the introduction&lt;br /&gt;
#* I also felt American College of Obstetricians and Gynecologists Recommendations could've been a subheading under 'screening'&lt;br /&gt;
#Content is correctly cited and referenced. &lt;br /&gt;
#* The very first image does not provide any information on the permissions to reuse the image (open access). &lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations. &lt;br /&gt;
#* Would've been better to include more self drawn diagrams and tables to further illustrate the group's knowledge of this disease&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* Lots of Pubmed articles have been used to make this page more credible and reliable &lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#* More words need to be explained in the glossary, such as 'tandem single nucleotide polymorphisms' &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 22:50, 21 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 8 Online Assessment==&lt;br /&gt;
attendance: --[[User:Z3291643|Sang Lee]] 13:04, 22 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Group 1: Turner Syndrome&lt;br /&gt;
&lt;br /&gt;
Firstly, nice progress with the group project. After reading your page, I have a good general knowledge of Turner Syndrome, so thanks. Overall, most sections were well done, though the writing style and layout could be more consistent, but you could work on that when you've finalised the content of the page. &lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: Good intro, very first image of the karyotype should include the actual statement of the 'Open access' not just 'copyright'&lt;br /&gt;
#* Epidemiology: Grammatical errors disrupt the flow of the content, in addition, graph has no copyright info, title could be improved&lt;br /&gt;
#* Etiology: Nice simple diagram of 22 eggs and 23 sperms, good example of when a picture can tell more than a thousand words! I feel there needs to be consistency either use Turner Syndrome or TS throughout the page&lt;br /&gt;
#* Clinical: liked how you have further classified the symptoms to its associated titles, nice idea; very easy to read, but a table would also be good&lt;br /&gt;
#* Diagnosis: image of TS maternal serum sampling doesn't contain {Template:2011 Student Image}, but a very good table&lt;br /&gt;
#* image of the TS X chromosome variations shouldl contain {Template:2011 Student Image}. Furthermore, if you use A-E in image descriptions, you should include A-E within the image&lt;br /&gt;
#* Research: very good layout and explanations, informative&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Could include more images especially in clinical manidestations, and some images do not fit the requirements set by Mark, as I've highlighted above &lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* seems to be cited well. However, although you have more than 100 referencees, a lot of them are repeated references, maybe you could try to use more pubmed articles, a greater variety&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations. &lt;br /&gt;
#* Glossary: could include more words such as echocardiogram&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* Although you have more than 100 referencees, a lot of them are repeated references, maybe you could try to use more pubmed articles, a greater variety&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#*  Although the content is informative, I'm left feeling like I want more variety of resources, so maybe some further research will improve the overall impression of your page &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot;&lt;br /&gt;
* consistency in writing style&lt;br /&gt;
* more images and cited correctly &lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 14:44, 24 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Group 2&lt;br /&gt;
&lt;br /&gt;
Hey Group 2, firstly, well done on putting in the effort to create this page, it really shows your dedication and cooperation as a team! Here are some points I thought you could improve on to take this page to that extra level&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: Good overview. Image would look better with a border or as a thumb&lt;br /&gt;
#* History: Image too large, again maybe a border?&lt;br /&gt;
#* Epidemiology: Need to define velocardiofacial syndrome in glossary, also break it down into subheadings, eg. Incidence, Sex, etc&lt;br /&gt;
#* Etiology: Maybe better if in a table&lt;br /&gt;
#* Pathogenesis: I liked how you broke it doen into relevant subheadings. However, on a slightly negative note, the DG Pathophysiology Diagram looks rushed; I think it would've looked better if it was neater and easier to read.&lt;br /&gt;
#* Diagnosis: I felt citing was done poorly in this section, eg. the last 4/5 sentences in the FISH technique was not referenced at all, but again, this is very easily fixed. But good to see you have put in the effort and time&lt;br /&gt;
#* Clinical: Image of normal and cleft palate, if based on a textbook, I think you still need permission to adapt it (not quite sure, please ask Mark)? Table with 'How it is caused' would be better by itself as pathophysiology. Tetralogy of Fallot needs to be fitted into this section more smoothly, at the moment, it makes this section look very cramped. Also, the image regarding Tetralogy needs the correct format for student drawn images (ie. 'I (student no.)....)&lt;br /&gt;
#* Research: Maybe break it down into subheadings&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Good images used with a nice range of self drawn images. However, no where in the page is there any reference to the images within the text.&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* I feel citation needs to be improved overall. Lots of the sections have missing citations, especially Diagnostic Tests. Also in the reference list, refs 33,40,47, 49 have nothing in it (is it meant to be like this?)&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations. &lt;br /&gt;
#* Nice drawings, though some could've done better with more effort&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* Nice range of references used&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#* It's very clear to me that you guys have worked together well and there has been good team work going on here to create this page, so well done&lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* I feel your page is too heavy with the text, although there's a lot of images as well, it just doesn't quite balance out with the text. &lt;br /&gt;
* Also felt the different colours used for the tables, although adding a splash of colour to your page, brought down the overall quality of the page. However, please keep in mind that others might really like this approach of table formatting, it's just that personally, I think you could benefit from keeping all table colours consistent.&lt;br /&gt;
* Sometimes you refer to DiGeorge Syndrome as DGS and also as DS. Small and easy to fix, adds consistency&lt;br /&gt;
* Please don't forget to add the {template} for student uploaded images&lt;br /&gt;
* Definitely needs more words in the Glossary, such as Meiosis, de novo, microarray&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 16:02, 24 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 3&lt;br /&gt;
&lt;br /&gt;
Hi, overall, a nice project page with interesting information.&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: Nice introduction, good flow and easy to read. However, image needs proper information and perhaps 'This disorder was first described by Harry F.' could be placed earlier on in the intro rather than in the middle&lt;br /&gt;
#* History: Nice section, very interesting&lt;br /&gt;
#* Epidemiology: First paragraph is good, but I feel the rest of this section doesn't quite belong here, such as the information on seizures, IQs, diagnosis. This section should focus on stats (sex/birth/ethnic/demographic/etc). Fig 2, 3 belong more in the signs and symptoms&lt;br /&gt;
#* Etiology: the '1:1000 male' contradicts the '1:500' given in epidemiology. Fig4 needs coyright information&lt;br /&gt;
#* Pathogenesis: Needs better referencing, also placing fig 5, 6 on either side doesn't look too good with the text. Perhaps place them below one another?&lt;br /&gt;
#* Signs: Seems a bit incomplete, it'll also be good to explain the image of 'pubertal gynecomastia'&lt;br /&gt;
#* Diagnosis: Sentence structure could be improved, ie. 'performed because physicians may suspect it because of clinical findings'. Information is interesting, but could be presented more clearly, perhaps in a table?&lt;br /&gt;
#* Similar defects: very nice, presented well with good information, easy to read&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Good images used with a nice range of self drawn images. However, lot of the images need to be formatted properly with required information&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* overall referencing was well done, except pathogenesis needs more referencing&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations. &lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* Nice range of references used&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#* The information is there, but maybe from now til final assessment, you could do further research in all sections, as they do seem a little short.&lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* better page layout&lt;br /&gt;
* glossary: sorry, but I feel the alphabet subheadings here are very effective as you have it in alphabetical order anyway&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 21:59, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 4&lt;br /&gt;
&lt;br /&gt;
Hey, this is a nicely structured page with interesting content that is presented well. There is a nice balance of text and image&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: good, to the point&lt;br /&gt;
#* History: Nice section, perhaps bold the years?&lt;br /&gt;
#* Epidemiology: I really liked this section, both visually and content wise. The table is easy to read and I liked your explanations for the HD prevalence, well done&lt;br /&gt;
#* Genetics: Perhaps you could have the 'CAG (cytosine-adenine-glutamine)' in the introduction when you first refer to it? Referencing is required in i'HTT and normal functions'. I really liked your subheadings, made it very easy to understand and follow &lt;br /&gt;
#* Pathogenesis: Image is too big, good subheadings, I suggest that if you write in purple to highlight some words, maybe you could do that for the whole page?&lt;br /&gt;
#* Clinical: liked the motor impairment explanations, how about explaining the cognitive and behaviour impairments as well? (it'll be worth it!)&lt;br /&gt;
#* Diagnosis: Nice content, but it just feels a bit too crowded, maybe rearrange the images and decrease image size&lt;br /&gt;
#* Treatment: Very nice section with nice images and good format!&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Good balance of images and text, though some rearrangement of images would make this page look better. Very good use of subheadings to make the content more easy to digest&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* overall referencing was well done&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
* good range of tables, images and self drawn images&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* Nice range of references used&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* just minor changes such as resizing some of the images, making the sections consistent in format&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 22:32, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 5&lt;br /&gt;
&lt;br /&gt;
Hi, I can see some progress on this page which is good, content is interesting&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: What is FMR1 gene? Need more information here, as in when was it first discovered, some stats&lt;br /&gt;
#* Epidemiology: I think screening information is extensive enough to be a section on its own&lt;br /&gt;
#* Etiology: no explanation of FMR1 gene so far, what is its normal function? Also, please refer to images used in this section&lt;br /&gt;
#* Development of the disease:nice succinct, easy to follow section. Perhaps add an image for one of the stages mentioned here?&lt;br /&gt;
#* Signs: REFERENCING!!! But, content is good and interesting&lt;br /&gt;
#* Diagnosis: An image here would be nice, and an explanation of how the technology is used to diagnose FXS&lt;br /&gt;
#* Treatment: Nice table with good information&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Need to balance out the text and image ratio, some good subheadings&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* poor referencing, which makes me question the reliability of the content in some sections&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
#* needs a lot more images&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* I feel more research needs to be done here&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* Although the content is here, there is still a lot of work needed to make this page feel complete&lt;br /&gt;
* glossary is very lacking in terminology&lt;br /&gt;
* need more images&lt;br /&gt;
* further research would be nice to explain this disease in more detail&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 23:26, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Group 6&lt;br /&gt;
Hey, nice progress with your page, all sections have similar amount of content which were interesting&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: Referencing needs to be improved here&lt;br /&gt;
#* History: content is good but too wordy. I think a summary or a simple timeline would be good&lt;br /&gt;
#* Epidemiology: Where's the reference for 3/10000 live births?&lt;br /&gt;
#* Signs: ok section, but could do with more images here&lt;br /&gt;
#* Genetics: If using abbreviations, such as TBX1 gene, you should explain what it is, ie. TBX1 gene (T-box 1). Also need to work on referencing here as well. How about organising all the content in a table? have in columns: gene, gene profile, frequency, etc.&lt;br /&gt;
#* Pathogenesis: I'm not quite sure about this, but do you need permission to adapt an image from an article? (I'm referring to the '4 defects' image)&lt;br /&gt;
#* Diagnosis: I'm sorry, but this section is a bit bland, though the content is very informative. I think some images here would be good&lt;br /&gt;
#* Treatment: Referencing! Also, personally, that green is too bright, maybe find a more neutral, soothing colour?&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Need to find more images, I feel some of the information could be more effectively presented in table formate rather than lengthy text&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* VERY poor referencing, which makes me question the reliability of the content in some sections&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
#* needs a lot more images&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* research done is evident, just need to reference&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* glossary is very lacking in terminology&lt;br /&gt;
* need more images&lt;br /&gt;
* REFERENCING!&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 23:26, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Group 8&lt;br /&gt;
Hey, well done, your page is looking really polished! Lots of very interesting information here and presented in a very easy to follow manner&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* History: I feel that you could lessen the info of Nicholas and add more current findings of the disease.&lt;br /&gt;
#* Aetiology: What is the chromosome 9 image based on? Need to work on referencing. Very good subheadings and well balanced with images&lt;br /&gt;
#* Pathogenesis: Needs more information&lt;br /&gt;
#* Neuro: What's the images based on? Good subheadings and explained well. I liked the way you gave explanations for normal function/appearance and then went on to explain abnormality associated with the structures in this disease. But you need to improve your referencing for this section&lt;br /&gt;
#* Diagnosis: Very good table and images. But need to fix the postnal diagnosis table so that it spans the length of the screen&lt;br /&gt;
#* Symptoms: table and images look too crowded&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* good subheadings, images, impressive self drawn images! Nice balanced page layout&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* needs to work on referencing&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* research done is evident, just need to reference&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* referencing&lt;br /&gt;
* better arrangement of table and images so page doesn't look too crowded&lt;br /&gt;
&lt;br /&gt;
Well done guys, nice team work!&lt;br /&gt;
--[[User:Z3291643|z3291643]] 23:50, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 9&lt;br /&gt;
&lt;br /&gt;
Hey, your page has a lot of very interesting content and some unique self drawn images. I thoroughly enjoyed this page, thanks&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: Inclusion of incidence would be nice&lt;br /&gt;
#* History: very informative and a nice simple timeline&lt;br /&gt;
#* Genetics: Good, succinct section, especially liked the table&lt;br /&gt;
#* Diagnosis: needs referencing. Is diagnosis only postnatal? What is the average age of diagnosis for this disease?&lt;br /&gt;
#* Management and Treatment: Seems a little out of place under epidemiology, I think it should be place later on &lt;br /&gt;
#* Phenotype:Reference?&lt;br /&gt;
#* Cardiac conditions: maybe give explanations for atrial and ventricular septal defect, just brief descriptions would suffice. Why is it so that males are more likely to suffer CVD than females?&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* good subheadings, interesting self drawn images. However, this page needs to find a balance in text and images&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* needs to work on referencing&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* research done is evident, just need to reference&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#* very interesting content, informative&lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* referencing&lt;br /&gt;
* more images&lt;br /&gt;
* glossary; lacking a lor of terms&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 00:10, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 10&lt;br /&gt;
&lt;br /&gt;
Hey, this is a interesting disease, with some good images to show the disease clearly. &lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: succinct introduction&lt;br /&gt;
#* History: Has interesting content, though timeline would be nice&lt;br /&gt;
#* Pathogenesis: Too brief and could be improved with an image&lt;br /&gt;
#* Signs: surely there are more symptoms here, maybe you could have subheadings to break down the symtpoms, ie. motor impairment, cognitive impairments, etc&lt;br /&gt;
#* Clinical manifestations and complications: nice section with good image used&lt;br /&gt;
#* Diagnosis: could be further explained, and an image would be nice&lt;br /&gt;
#* Treatment: Current and Future Prospects: needs referencing&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* need to balance out the text with images, could organise page better with more subheadings, more images needed &lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* needs to work on referencing!!&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
#*  more table could be used instead of lengthy explanations&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* much more research needs to be done to further explain the sections&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* referencing&lt;br /&gt;
* more images&lt;br /&gt;
* glossary; lacking a lot of terms&lt;br /&gt;
* needs much more research, lots of repetitions in referencing&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 11:02, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 11&lt;br /&gt;
&lt;br /&gt;
Hey, this is a interesting disease, with some good images to show the disease clearly. &lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: very rushed, no reference and needs much more work, it should be a succinct summary of this whole page.&lt;br /&gt;
#* History: Has interesting content, though timeline would be better incorporated under History, not a section of its own&lt;br /&gt;
#* Diagnosis: If you're abbreviating Cleft Palate to CLP, you should have it as Cleft palate (CLP). The two given tables are pretty much the same, except for different sample number. Is it really necessary to have the two tables when they're so similar? Could do well with an image&lt;br /&gt;
#* Syndromes and Anomalies associated with cleft: Nice array of images used here. Content is good (for ones you provided), but needs work on referencing. Perhaps you could organise the content into a table for easy comparison since you have more than one anomalies&lt;br /&gt;
#* Aetiology: Needs referencing, image could have a caption to explain it. Although the content is there, it's too brief and I feel it could be organised in a more effective manner, such as using number stages.&lt;br /&gt;
#* Types of Cleft Palate/Lip:very brief, please explain the points (ie. what's the differences between them? you say there are differences in severity, how so?)&lt;br /&gt;
#* Pathophysiology: need to reformat table more effectively and work on referencing&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* need to balance out the text with images, could organise page better with more subheadings &lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* needs to work on referencing!!&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
#* NO self drawn images so far&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* much more research needs to be done. sections overall are lacking substance and doesn't explain the content very well&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* referencing&lt;br /&gt;
* more images&lt;br /&gt;
* glossary; lacking a lot of terms&lt;br /&gt;
* needs much more research&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 11:02, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 9 attendence==&lt;br /&gt;
--[[User:Z3291643|z3291643]] 13:00, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 10 attendence==&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 13:15, 6 October 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 10 Online Assessment==&lt;br /&gt;
&lt;br /&gt;
1.Besides fetal alcohol syndrome, identify another environmental teratogen that can lead to hearing loss.&lt;br /&gt;
&lt;br /&gt;
Noise pollution is a big factor in hearing loss, as well as viral and bacterial infections such as meningitis. Hearing loss from meningitis can be a result of the direct effects of the infection on the brain or the body's reaction to the infection, most commonly with pneumococcal meningitis. 6% of all hearing defects in children can be attributed to bacterial meningitis, with around 72% of these children progressing to complete hearing loss by the age of three. &lt;br /&gt;
&lt;br /&gt;
2.Identify 3 factors that contribute to poor neonatal drainage of the middle ear. &lt;br /&gt;
&lt;br /&gt;
The auditory tube connects the middle ear cavity to the nasopharynx, and is different in structure in neonates vs. adults.&lt;br /&gt;
:# the eustachian tube is very horizontal (10 degrees to the horizontal axis)&lt;br /&gt;
:# only opened by a single muscle called the tensor palati muscle (compared to 2 muscles in the adult tube)&lt;br /&gt;
:# it is shorter(17-18 mm) and narrower &lt;br /&gt;
&lt;br /&gt;
3.Identify 1 genetic abnormality that affects hearing development and link to the OMIM record. (Your individual abnormality should be different from all other students)&lt;br /&gt;
* Waardenburg syndrome&lt;br /&gt;
* results in hearing loss (to variable extent)&lt;br /&gt;
* inherited in an autosomal dominant manner&lt;br /&gt;
* [http://omim.org/entry/193500 Waardenburg syndrome]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Related Links'''&lt;br /&gt;
&lt;br /&gt;
'''Animal Models'''&lt;br /&gt;
&lt;br /&gt;
* [[Mouse Knockout]] - this page explains the current use of mouse models in disrupting genes to elucidate their genetic function, including the mouse gene knockouts for alpha calcium-calmodulin kinase II (alpha CaMKII)&lt;br /&gt;
* [[2009 Group Project 4]] - this page gives an extensive overview on the history of the mouse model and its various use in embryology and genetics. In addition, it also describes mouse knockout and the role they play in current research of various human diseases&lt;br /&gt;
* [[Fly Development]] - this page describes the use of drosophila flies as developmental models&lt;br /&gt;
* [[2009 Group Project 2]] - this page gives an extensive overview on the history of the fly model and its various use in embryology and genetics&lt;br /&gt;
&lt;br /&gt;
'''Diagnosis'''&lt;br /&gt;
* [[Chorionic villus sampling]] - this page explains the process of chorionic villus sampling, its disadvantages and gives a brief overview of recent findings&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 10:20, 13 October 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 11 Online Assessment==&lt;br /&gt;
&lt;br /&gt;
1.Name the components that give rise to the interatrial septum and the passages that connect the right and left atria. &lt;br /&gt;
&lt;br /&gt;
* Components: Septum Primum, Septum secundum&lt;br /&gt;
* Passages: Foramen ovale, Foramen primum then Foramen secundum&lt;br /&gt;
&lt;br /&gt;
2.Identify the cardiac defects that arise through abnormal development of the outflow tract &lt;br /&gt;
&lt;br /&gt;
* Tetralogy of Fallot&lt;br /&gt;
* Transposition of the Great Vessels &lt;br /&gt;
* Aortic Stenosis&lt;br /&gt;
* Pulmonary Stenosis&lt;br /&gt;
* Pulmonary Atresia&lt;br /&gt;
* Patent Ductus Arteriosus&lt;br /&gt;
* Hypoplastic Left Heart Syndrome &lt;br /&gt;
* Coarctation of the Aorta&lt;br /&gt;
* Interrupted Aortic Arch&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 21:00, 13 October 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Lab 11 lab attendence===&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 13:35, 13 October 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==''' References '''==&lt;br /&gt;
&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;/div&gt;</summary>
		<author><name>Z3291643</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=User:Z3291643&amp;diff=77989</id>
		<title>User:Z3291643</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=User:Z3291643&amp;diff=77989"/>
		<updated>2011-10-13T10:01:14Z</updated>

		<summary type="html">&lt;p&gt;Z3291643: /* Lab 11 Online Assessment */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{2011Student}}&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Z3291643]] 12:55, 28 July 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 1 Assessment==&lt;br /&gt;
1.	Identify the origin of In Vitro Fertilization and the 2010 nobel prize winner associated with this technique.&lt;br /&gt;
&lt;br /&gt;
‘in vitro’ fertilization is Latin for ‘in glass’ fertilization and is a treatment for infertility, whereby the sperm fertilizes the ovum outside the body and is then implanted back into the patient’s uterus. The first successful IVF birth, Louise Brown, occurred in 1978 with the help of Patrick Steptoe and Robert Edwards. Edwards was awarded the 2010 nobel prize in medicine for his achievement. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
2.	Identify a recent paper on fertilisation and describe its key findings.&lt;br /&gt;
&lt;br /&gt;
The aim of this paper was to investigate whether age &amp;lt;=25 played a role in the reproductive outcome of women undergoing IVF. Infertile patients aged between 19 and 25 years of age were compared to infertile patients aged 30-35 years to determine primarily fertilization rates and the number of top quality embryos. The results were unexpected as the younger subjects had lower fertilization rates and reduced embryo quality.&amp;lt;ref&amp;gt;PMID 21042842&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
3.	Identify 2 congenital anomalies.&lt;br /&gt;
&lt;br /&gt;
Trisomy 21 and cleft palate&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--[[User:S8600021|Mark Hill]] 10:01, 3 August 2011 (EST) These answers are fine.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 13:02, 4 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Lab 2 Assessment==&lt;br /&gt;
1.	Identify the ZP protein that spermatozoa binds and how is this changed (altered) after fertilization. &lt;br /&gt;
&lt;br /&gt;
ZP3 acts as a receptor for the sperm. This is followed by the acrosome reaction, whereby acrosomal contents digest the ZP and allow the sperm surface proteins to bind to the ZP2. After fertilization, cortical reaction takes place where cortical granules are exocytosed. This results in the removal of carbohydrate from ZP3 and cleavage of ZP2 to harden the ZP. These changes occur to prevent polyspermy.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
2.       Identify a review and a research article related to your group topic.&lt;br /&gt;
&lt;br /&gt;
This research article showed genotype-phenotype correlations in Angelman Syndrome (AS). They have concluded that deletion patients had worse developmental outcomes than non deletion patients.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20729760&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
This review article is really comprehensive and gives a good background knowledge of AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20445456&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Z3291643]] 12:42, 11 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 3 Assessment==&lt;br /&gt;
&lt;br /&gt;
1.        What is the maternal dietary requirement for late neural development? &lt;br /&gt;
&lt;br /&gt;
Iodine. Zimmermann found that maternal deficiency of iodine can result in cognitive disability in the offspring, most severely characterized by cretinism. Fortunately, mild to moderate iodine deficiency can be corrected in primary school aged children to improve cognitive and motor functions.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21802524&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
2.        Upload a picture relating to your group project.&lt;br /&gt;
&lt;br /&gt;
[[File:UBE3A colocalizes with ASPM at the centrosome throughout mitosis.jpg|thumb|UBE3A colocalizes with ASPM at the centrosome throughout mitosis.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21633703&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
===UBE3A colocalizes with ASPM at the centrosome throughout mitosis===&lt;br /&gt;
&lt;br /&gt;
[[File:UBE3A colocalizes with ASPM at the centrosome throughout mitosis.jpg|Abnormal cytokinesis and apoptosis in UBE3A knockdown cells.|350px]]&lt;br /&gt;
&lt;br /&gt;
UBE3A colocalizes with ASPM at the centrosome. (A) Indirect immunofluorescence of HEK293 cells at interphase and different phases of mitosis stained with antibodies against ASPM and UBE3A (anti-UBE3A-sc-8926). Note colocalization of UBE3A with ASPM at the centrosome throughout mitosis (arrowheads). Note weak centrosomal staining of UBE3A in an interphase cell (arrow). (B) Indirect immunofluorescence of A549 cells stained with antibodies against UBE3A (anti-UBE3A-sc-8926) and ASPM at metaphase and telophase. Note colocalization of UBE3A with ASPM at the centrosome (arrowheads). Scale bar=2 µm.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Copyright Singhmar, Kumar. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 11:08, 18 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 4 Online Assessment==&lt;br /&gt;
&lt;br /&gt;
# '''The allantois, identified in the placental cord, is continuous with what anatomical structure?'''&lt;br /&gt;
The allantois is endodermic in origin and is the extension of the yolk sac into the connecting stalk. It's connected to the superior end of the developing bladder&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
#  '''Identify the 3 vascular shunts, and their location, in the embryonic circulation.'''&lt;br /&gt;
1. Ductus arteriosus; connects left pulmonary artery with the descending aorta&lt;br /&gt;
2. Ductus venosus; connects the portal and umbilical veins to the inferior vena cava&lt;br /&gt;
3. Foramen ovale; between left and right atria&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
# Identify the Group project sub-section that you will be researching. (Add to project page and your individual assessment page)&lt;br /&gt;
&lt;br /&gt;
; 4  Aetiology (genetic inheritance); Julia&lt;br /&gt;
; 5  Pathophysiology; Julia (as it's quite linked with aetiology anyway)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 12:59, 25 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 5 Online Assessment==&lt;br /&gt;
&lt;br /&gt;
# Which side (L/R) is most common for diaphragmatic hernia and why? &lt;br /&gt;
Posterior left side,possibly due to the fact that the left pericardioperitoneal canal is larger and closes later than the right.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 12:48, 1 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 6 Online Assessment==&lt;br /&gt;
# What week of development do the palatal shelves fuse?&lt;br /&gt;
Week 9 of early embryonic growth&lt;br /&gt;
 &lt;br /&gt;
# What early animal model helped elucidate the neural crest origin and migration of neural crest cells?&lt;br /&gt;
Migration of neural crest cells have been studied in quail-chick chimeras - transplanted quail cells have obvious nucleoli compared with chicken. It was first done by Nicole Le Douarin in the 80's&lt;br /&gt;
 &lt;br /&gt;
# What abnormality results from neural crest not migrating into the cardiac outflow tract? &lt;br /&gt;
Tetralogy of Fallot; when the outflow tract is not aligned properly, it is seen as a nonwedged aorta. Nonwedged aorta indicates tetralogy of Fallot. In addition, past studies using chick embryos have outlined that cardiac neural crest cell ablation led to this malalignment. In contrast, Farrell et al have shown that the introduction of cardiac neural crest aligned the outflow tract properly. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9933243&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 12:49, 15 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 7 Online Assessment==&lt;br /&gt;
&lt;br /&gt;
1. Are satellite cells &lt;br /&gt;
* necessary for muscle hypertrophy?&lt;br /&gt;
: No&lt;br /&gt;
 &lt;br /&gt;
* generally involved in hypertrophy?&lt;br /&gt;
: Yes&lt;br /&gt;
 &lt;br /&gt;
&lt;br /&gt;
2. Why does chronic low frequency stimulation (CLFS) cause a fast to slow fibre type shift? &lt;br /&gt;
: At the molecular level, there are exchanges of fast and slow type protein isoforms, such as calcium regulatory system, myofibrillar apparatus. The final step in CLFS induced fiber shift is the upregulation of slow myosin from the conversion of myogenic cells to slow fiber phenotype. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12500901&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;It is also known that satellite cells contribute to CLFS-induced transition of fiber types shown by the fact that CLFS increases type I fibers only after fiber necrosis. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16439424&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--Mark Hill 10:42, 16 September 2011 (EST) &lt;br /&gt;
&lt;br /&gt;
I would like each student to now also look at the following online page before the next Lab and write a comment based upon the group project assessment criteria. &lt;br /&gt;
&lt;br /&gt;
http://embryology.med.unsw.edu.au/embryology/index.php?title=Trisomy_21 &lt;br /&gt;
Paste your comment on the Trisomy 21 discussion page and also on your own student page. &lt;br /&gt;
&lt;br /&gt;
Group Assessment Criteria&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Good and concise explanation of the subheadings,however, I would've liked to see some attempt to further explain how the asspcoated congenital abnormalities occur.  &lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Lots of images, graphs and table used effectively to help reader better understand the disease. They also gave the project page some colour to make it more pleasing to the eye. Unfortunately, some images were placed (eg. John Langdon Down)in the wrong sections and interrupted the flow of the project page. &lt;br /&gt;
#* In addition, some of the images were not referred to within the project page. &lt;br /&gt;
#* Furthermore, the overall structure and layout of the page could be improved, such as putting the Diagnostic Links under diagnosis instead of the introduction&lt;br /&gt;
#* I also felt American College of Obstetricians and Gynecologists Recommendations could've been a subheading under 'screening'&lt;br /&gt;
#Content is correctly cited and referenced. &lt;br /&gt;
#* The very first image does not provide any information on the permissions to reuse the image (open access). &lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations. &lt;br /&gt;
#* Would've been better to include more self drawn diagrams and tables to further illustrate the group's knowledge of this disease&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* Lots of Pubmed articles have been used to make this page more credible and reliable &lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#* More words need to be explained in the glossary, such as 'tandem single nucleotide polymorphisms' &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 22:50, 21 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 8 Online Assessment==&lt;br /&gt;
attendance: --[[User:Z3291643|Sang Lee]] 13:04, 22 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Group 1: Turner Syndrome&lt;br /&gt;
&lt;br /&gt;
Firstly, nice progress with the group project. After reading your page, I have a good general knowledge of Turner Syndrome, so thanks. Overall, most sections were well done, though the writing style and layout could be more consistent, but you could work on that when you've finalised the content of the page. &lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: Good intro, very first image of the karyotype should include the actual statement of the 'Open access' not just 'copyright'&lt;br /&gt;
#* Epidemiology: Grammatical errors disrupt the flow of the content, in addition, graph has no copyright info, title could be improved&lt;br /&gt;
#* Etiology: Nice simple diagram of 22 eggs and 23 sperms, good example of when a picture can tell more than a thousand words! I feel there needs to be consistency either use Turner Syndrome or TS throughout the page&lt;br /&gt;
#* Clinical: liked how you have further classified the symptoms to its associated titles, nice idea; very easy to read, but a table would also be good&lt;br /&gt;
#* Diagnosis: image of TS maternal serum sampling doesn't contain {Template:2011 Student Image}, but a very good table&lt;br /&gt;
#* image of the TS X chromosome variations shouldl contain {Template:2011 Student Image}. Furthermore, if you use A-E in image descriptions, you should include A-E within the image&lt;br /&gt;
#* Research: very good layout and explanations, informative&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Could include more images especially in clinical manidestations, and some images do not fit the requirements set by Mark, as I've highlighted above &lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* seems to be cited well. However, although you have more than 100 referencees, a lot of them are repeated references, maybe you could try to use more pubmed articles, a greater variety&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations. &lt;br /&gt;
#* Glossary: could include more words such as echocardiogram&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* Although you have more than 100 referencees, a lot of them are repeated references, maybe you could try to use more pubmed articles, a greater variety&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#*  Although the content is informative, I'm left feeling like I want more variety of resources, so maybe some further research will improve the overall impression of your page &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot;&lt;br /&gt;
* consistency in writing style&lt;br /&gt;
* more images and cited correctly &lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 14:44, 24 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Group 2&lt;br /&gt;
&lt;br /&gt;
Hey Group 2, firstly, well done on putting in the effort to create this page, it really shows your dedication and cooperation as a team! Here are some points I thought you could improve on to take this page to that extra level&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: Good overview. Image would look better with a border or as a thumb&lt;br /&gt;
#* History: Image too large, again maybe a border?&lt;br /&gt;
#* Epidemiology: Need to define velocardiofacial syndrome in glossary, also break it down into subheadings, eg. Incidence, Sex, etc&lt;br /&gt;
#* Etiology: Maybe better if in a table&lt;br /&gt;
#* Pathogenesis: I liked how you broke it doen into relevant subheadings. However, on a slightly negative note, the DG Pathophysiology Diagram looks rushed; I think it would've looked better if it was neater and easier to read.&lt;br /&gt;
#* Diagnosis: I felt citing was done poorly in this section, eg. the last 4/5 sentences in the FISH technique was not referenced at all, but again, this is very easily fixed. But good to see you have put in the effort and time&lt;br /&gt;
#* Clinical: Image of normal and cleft palate, if based on a textbook, I think you still need permission to adapt it (not quite sure, please ask Mark)? Table with 'How it is caused' would be better by itself as pathophysiology. Tetralogy of Fallot needs to be fitted into this section more smoothly, at the moment, it makes this section look very cramped. Also, the image regarding Tetralogy needs the correct format for student drawn images (ie. 'I (student no.)....)&lt;br /&gt;
#* Research: Maybe break it down into subheadings&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Good images used with a nice range of self drawn images. However, no where in the page is there any reference to the images within the text.&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* I feel citation needs to be improved overall. Lots of the sections have missing citations, especially Diagnostic Tests. Also in the reference list, refs 33,40,47, 49 have nothing in it (is it meant to be like this?)&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations. &lt;br /&gt;
#* Nice drawings, though some could've done better with more effort&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* Nice range of references used&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#* It's very clear to me that you guys have worked together well and there has been good team work going on here to create this page, so well done&lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* I feel your page is too heavy with the text, although there's a lot of images as well, it just doesn't quite balance out with the text. &lt;br /&gt;
* Also felt the different colours used for the tables, although adding a splash of colour to your page, brought down the overall quality of the page. However, please keep in mind that others might really like this approach of table formatting, it's just that personally, I think you could benefit from keeping all table colours consistent.&lt;br /&gt;
* Sometimes you refer to DiGeorge Syndrome as DGS and also as DS. Small and easy to fix, adds consistency&lt;br /&gt;
* Please don't forget to add the {template} for student uploaded images&lt;br /&gt;
* Definitely needs more words in the Glossary, such as Meiosis, de novo, microarray&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 16:02, 24 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 3&lt;br /&gt;
&lt;br /&gt;
Hi, overall, a nice project page with interesting information.&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: Nice introduction, good flow and easy to read. However, image needs proper information and perhaps 'This disorder was first described by Harry F.' could be placed earlier on in the intro rather than in the middle&lt;br /&gt;
#* History: Nice section, very interesting&lt;br /&gt;
#* Epidemiology: First paragraph is good, but I feel the rest of this section doesn't quite belong here, such as the information on seizures, IQs, diagnosis. This section should focus on stats (sex/birth/ethnic/demographic/etc). Fig 2, 3 belong more in the signs and symptoms&lt;br /&gt;
#* Etiology: the '1:1000 male' contradicts the '1:500' given in epidemiology. Fig4 needs coyright information&lt;br /&gt;
#* Pathogenesis: Needs better referencing, also placing fig 5, 6 on either side doesn't look too good with the text. Perhaps place them below one another?&lt;br /&gt;
#* Signs: Seems a bit incomplete, it'll also be good to explain the image of 'pubertal gynecomastia'&lt;br /&gt;
#* Diagnosis: Sentence structure could be improved, ie. 'performed because physicians may suspect it because of clinical findings'. Information is interesting, but could be presented more clearly, perhaps in a table?&lt;br /&gt;
#* Similar defects: very nice, presented well with good information, easy to read&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Good images used with a nice range of self drawn images. However, lot of the images need to be formatted properly with required information&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* overall referencing was well done, except pathogenesis needs more referencing&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations. &lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* Nice range of references used&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#* The information is there, but maybe from now til final assessment, you could do further research in all sections, as they do seem a little short.&lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* better page layout&lt;br /&gt;
* glossary: sorry, but I feel the alphabet subheadings here are very effective as you have it in alphabetical order anyway&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 21:59, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 4&lt;br /&gt;
&lt;br /&gt;
Hey, this is a nicely structured page with interesting content that is presented well. There is a nice balance of text and image&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: good, to the point&lt;br /&gt;
#* History: Nice section, perhaps bold the years?&lt;br /&gt;
#* Epidemiology: I really liked this section, both visually and content wise. The table is easy to read and I liked your explanations for the HD prevalence, well done&lt;br /&gt;
#* Genetics: Perhaps you could have the 'CAG (cytosine-adenine-glutamine)' in the introduction when you first refer to it? Referencing is required in i'HTT and normal functions'. I really liked your subheadings, made it very easy to understand and follow &lt;br /&gt;
#* Pathogenesis: Image is too big, good subheadings, I suggest that if you write in purple to highlight some words, maybe you could do that for the whole page?&lt;br /&gt;
#* Clinical: liked the motor impairment explanations, how about explaining the cognitive and behaviour impairments as well? (it'll be worth it!)&lt;br /&gt;
#* Diagnosis: Nice content, but it just feels a bit too crowded, maybe rearrange the images and decrease image size&lt;br /&gt;
#* Treatment: Very nice section with nice images and good format!&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Good balance of images and text, though some rearrangement of images would make this page look better. Very good use of subheadings to make the content more easy to digest&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* overall referencing was well done&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
* good range of tables, images and self drawn images&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* Nice range of references used&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* just minor changes such as resizing some of the images, making the sections consistent in format&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 22:32, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 5&lt;br /&gt;
&lt;br /&gt;
Hi, I can see some progress on this page which is good, content is interesting&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: What is FMR1 gene? Need more information here, as in when was it first discovered, some stats&lt;br /&gt;
#* Epidemiology: I think screening information is extensive enough to be a section on its own&lt;br /&gt;
#* Etiology: no explanation of FMR1 gene so far, what is its normal function? Also, please refer to images used in this section&lt;br /&gt;
#* Development of the disease:nice succinct, easy to follow section. Perhaps add an image for one of the stages mentioned here?&lt;br /&gt;
#* Signs: REFERENCING!!! But, content is good and interesting&lt;br /&gt;
#* Diagnosis: An image here would be nice, and an explanation of how the technology is used to diagnose FXS&lt;br /&gt;
#* Treatment: Nice table with good information&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Need to balance out the text and image ratio, some good subheadings&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* poor referencing, which makes me question the reliability of the content in some sections&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
#* needs a lot more images&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* I feel more research needs to be done here&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* Although the content is here, there is still a lot of work needed to make this page feel complete&lt;br /&gt;
* glossary is very lacking in terminology&lt;br /&gt;
* need more images&lt;br /&gt;
* further research would be nice to explain this disease in more detail&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 23:26, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Group 6&lt;br /&gt;
Hey, nice progress with your page, all sections have similar amount of content which were interesting&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: Referencing needs to be improved here&lt;br /&gt;
#* History: content is good but too wordy. I think a summary or a simple timeline would be good&lt;br /&gt;
#* Epidemiology: Where's the reference for 3/10000 live births?&lt;br /&gt;
#* Signs: ok section, but could do with more images here&lt;br /&gt;
#* Genetics: If using abbreviations, such as TBX1 gene, you should explain what it is, ie. TBX1 gene (T-box 1). Also need to work on referencing here as well. How about organising all the content in a table? have in columns: gene, gene profile, frequency, etc.&lt;br /&gt;
#* Pathogenesis: I'm not quite sure about this, but do you need permission to adapt an image from an article? (I'm referring to the '4 defects' image)&lt;br /&gt;
#* Diagnosis: I'm sorry, but this section is a bit bland, though the content is very informative. I think some images here would be good&lt;br /&gt;
#* Treatment: Referencing! Also, personally, that green is too bright, maybe find a more neutral, soothing colour?&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Need to find more images, I feel some of the information could be more effectively presented in table formate rather than lengthy text&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* VERY poor referencing, which makes me question the reliability of the content in some sections&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
#* needs a lot more images&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* research done is evident, just need to reference&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* glossary is very lacking in terminology&lt;br /&gt;
* need more images&lt;br /&gt;
* REFERENCING!&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 23:26, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Group 8&lt;br /&gt;
Hey, well done, your page is looking really polished! Lots of very interesting information here and presented in a very easy to follow manner&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* History: I feel that you could lessen the info of Nicholas and add more current findings of the disease.&lt;br /&gt;
#* Aetiology: What is the chromosome 9 image based on? Need to work on referencing. Very good subheadings and well balanced with images&lt;br /&gt;
#* Pathogenesis: Needs more information&lt;br /&gt;
#* Neuro: What's the images based on? Good subheadings and explained well. I liked the way you gave explanations for normal function/appearance and then went on to explain abnormality associated with the structures in this disease. But you need to improve your referencing for this section&lt;br /&gt;
#* Diagnosis: Very good table and images. But need to fix the postnal diagnosis table so that it spans the length of the screen&lt;br /&gt;
#* Symptoms: table and images look too crowded&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* good subheadings, images, impressive self drawn images! Nice balanced page layout&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* needs to work on referencing&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* research done is evident, just need to reference&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* referencing&lt;br /&gt;
* better arrangement of table and images so page doesn't look too crowded&lt;br /&gt;
&lt;br /&gt;
Well done guys, nice team work!&lt;br /&gt;
--[[User:Z3291643|z3291643]] 23:50, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 9&lt;br /&gt;
&lt;br /&gt;
Hey, your page has a lot of very interesting content and some unique self drawn images. I thoroughly enjoyed this page, thanks&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: Inclusion of incidence would be nice&lt;br /&gt;
#* History: very informative and a nice simple timeline&lt;br /&gt;
#* Genetics: Good, succinct section, especially liked the table&lt;br /&gt;
#* Diagnosis: needs referencing. Is diagnosis only postnatal? What is the average age of diagnosis for this disease?&lt;br /&gt;
#* Management and Treatment: Seems a little out of place under epidemiology, I think it should be place later on &lt;br /&gt;
#* Phenotype:Reference?&lt;br /&gt;
#* Cardiac conditions: maybe give explanations for atrial and ventricular septal defect, just brief descriptions would suffice. Why is it so that males are more likely to suffer CVD than females?&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* good subheadings, interesting self drawn images. However, this page needs to find a balance in text and images&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* needs to work on referencing&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* research done is evident, just need to reference&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#* very interesting content, informative&lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* referencing&lt;br /&gt;
* more images&lt;br /&gt;
* glossary; lacking a lor of terms&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 00:10, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 10&lt;br /&gt;
&lt;br /&gt;
Hey, this is a interesting disease, with some good images to show the disease clearly. &lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: succinct introduction&lt;br /&gt;
#* History: Has interesting content, though timeline would be nice&lt;br /&gt;
#* Pathogenesis: Too brief and could be improved with an image&lt;br /&gt;
#* Signs: surely there are more symptoms here, maybe you could have subheadings to break down the symtpoms, ie. motor impairment, cognitive impairments, etc&lt;br /&gt;
#* Clinical manifestations and complications: nice section with good image used&lt;br /&gt;
#* Diagnosis: could be further explained, and an image would be nice&lt;br /&gt;
#* Treatment: Current and Future Prospects: needs referencing&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* need to balance out the text with images, could organise page better with more subheadings, more images needed &lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* needs to work on referencing!!&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
#*  more table could be used instead of lengthy explanations&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* much more research needs to be done to further explain the sections&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* referencing&lt;br /&gt;
* more images&lt;br /&gt;
* glossary; lacking a lot of terms&lt;br /&gt;
* needs much more research, lots of repetitions in referencing&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 11:02, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 11&lt;br /&gt;
&lt;br /&gt;
Hey, this is a interesting disease, with some good images to show the disease clearly. &lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: very rushed, no reference and needs much more work, it should be a succinct summary of this whole page.&lt;br /&gt;
#* History: Has interesting content, though timeline would be better incorporated under History, not a section of its own&lt;br /&gt;
#* Diagnosis: If you're abbreviating Cleft Palate to CLP, you should have it as Cleft palate (CLP). The two given tables are pretty much the same, except for different sample number. Is it really necessary to have the two tables when they're so similar? Could do well with an image&lt;br /&gt;
#* Syndromes and Anomalies associated with cleft: Nice array of images used here. Content is good (for ones you provided), but needs work on referencing. Perhaps you could organise the content into a table for easy comparison since you have more than one anomalies&lt;br /&gt;
#* Aetiology: Needs referencing, image could have a caption to explain it. Although the content is there, it's too brief and I feel it could be organised in a more effective manner, such as using number stages.&lt;br /&gt;
#* Types of Cleft Palate/Lip:very brief, please explain the points (ie. what's the differences between them? you say there are differences in severity, how so?)&lt;br /&gt;
#* Pathophysiology: need to reformat table more effectively and work on referencing&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* need to balance out the text with images, could organise page better with more subheadings &lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* needs to work on referencing!!&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
#* NO self drawn images so far&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* much more research needs to be done. sections overall are lacking substance and doesn't explain the content very well&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* referencing&lt;br /&gt;
* more images&lt;br /&gt;
* glossary; lacking a lot of terms&lt;br /&gt;
* needs much more research&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 11:02, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 9 attendence==&lt;br /&gt;
--[[User:Z3291643|z3291643]] 13:00, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 10 attendence==&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 13:15, 6 October 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 10 Online Assessment==&lt;br /&gt;
&lt;br /&gt;
1.Besides fetal alcohol syndrome, identify another environmental teratogen that can lead to hearing loss.&lt;br /&gt;
&lt;br /&gt;
Noise pollution is a big factor in hearing loss, as well as viral and bacterial infections such as meningitis. Hearing loss from meningitis can be a result of the direct effects of the infection on the brain or the body's reaction to the infection, most commonly with pneumococcal meningitis. 6% of all hearing defects in children can be attributed to bacterial meningitis, with around 72% of these children progressing to complete hearing loss by the age of three. &lt;br /&gt;
&lt;br /&gt;
2.Identify 3 factors that contribute to poor neonatal drainage of the middle ear. &lt;br /&gt;
&lt;br /&gt;
The auditory tube connects the middle ear cavity to the nasopharynx, and is different in structure in neonates vs. adults.&lt;br /&gt;
:# the eustachian tube is very horizontal (10 degrees to the horizontal axis)&lt;br /&gt;
:# only opened by a single muscle called the tensor palati muscle (compared to 2 muscles in the adult tube)&lt;br /&gt;
:# it is shorter(17-18 mm) and narrower &lt;br /&gt;
&lt;br /&gt;
3.Identify 1 genetic abnormality that affects hearing development and link to the OMIM record. (Your individual abnormality should be different from all other students)&lt;br /&gt;
* Waardenburg syndrome&lt;br /&gt;
* results in hearing loss (to variable extent)&lt;br /&gt;
* inherited in an autosomal dominant manner&lt;br /&gt;
* [http://omim.org/entry/193500 Waardenburg syndrome]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Related Links'''&lt;br /&gt;
&lt;br /&gt;
'''Animal Models'''&lt;br /&gt;
&lt;br /&gt;
* [[Mouse Knockout]] - this page explains the current use of mouse models in disrupting genes to elucidate their genetic function, including the mouse gene knockouts for alpha calcium-calmodulin kinase II (alpha CaMKII)&lt;br /&gt;
* [[2009 Group Project 4]] - this page gives an extensive overview on the history of the mouse model and its various use in embryology and genetics. In addition, it also describes mouse knockout and the role they play in current research of various human diseases&lt;br /&gt;
* [[Fly Development]] - this page describes the use of drosophila flies as developmental models&lt;br /&gt;
* [[2009 Group Project 2]] - this page gives an extensive overview on the history of the fly model and its various use in embryology and genetics&lt;br /&gt;
&lt;br /&gt;
'''Diagnosis'''&lt;br /&gt;
* [[Chorionic villus sampling]] - this page explains the process of chorionic villus sampling, its disadvantages and gives a brief overview of recent findings&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 10:20, 13 October 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 11 Online Assessment==&lt;br /&gt;
&lt;br /&gt;
1.Name the components that give rise to the interatrial septum and the passages that connect the right and left atria. &lt;br /&gt;
&lt;br /&gt;
* Components: Septum Primum, Septum secundum&lt;br /&gt;
* Passages: Foramen ovale, Foramen secundum&lt;br /&gt;
&lt;br /&gt;
2.Identify the cardiac defects that arise through abnormal development of the outflow tract &lt;br /&gt;
&lt;br /&gt;
* Tetralogy of Fallot&lt;br /&gt;
* Transposition of the Great Vessels &lt;br /&gt;
* Aortic Stenosis&lt;br /&gt;
* Pulmonary Stenosis&lt;br /&gt;
* Pulmonary Atresia&lt;br /&gt;
* Patent Ductus Arteriosus&lt;br /&gt;
* Hypoplastic Left Heart Syndrome &lt;br /&gt;
* Coarctation of the Aorta&lt;br /&gt;
* Interrupted Aortic Arch&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 21:00, 13 October 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Lab 11 lab attendence===&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 13:35, 13 October 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==''' References '''==&lt;br /&gt;
&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;/div&gt;</summary>
		<author><name>Z3291643</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=User:Z3291643&amp;diff=77857</id>
		<title>User:Z3291643</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=User:Z3291643&amp;diff=77857"/>
		<updated>2011-10-13T02:36:17Z</updated>

		<summary type="html">&lt;p&gt;Z3291643: /* Lab 10 Online Assessment */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{2011Student}}&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Z3291643]] 12:55, 28 July 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 1 Assessment==&lt;br /&gt;
1.	Identify the origin of In Vitro Fertilization and the 2010 nobel prize winner associated with this technique.&lt;br /&gt;
&lt;br /&gt;
‘in vitro’ fertilization is Latin for ‘in glass’ fertilization and is a treatment for infertility, whereby the sperm fertilizes the ovum outside the body and is then implanted back into the patient’s uterus. The first successful IVF birth, Louise Brown, occurred in 1978 with the help of Patrick Steptoe and Robert Edwards. Edwards was awarded the 2010 nobel prize in medicine for his achievement. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
2.	Identify a recent paper on fertilisation and describe its key findings.&lt;br /&gt;
&lt;br /&gt;
The aim of this paper was to investigate whether age &amp;lt;=25 played a role in the reproductive outcome of women undergoing IVF. Infertile patients aged between 19 and 25 years of age were compared to infertile patients aged 30-35 years to determine primarily fertilization rates and the number of top quality embryos. The results were unexpected as the younger subjects had lower fertilization rates and reduced embryo quality.&amp;lt;ref&amp;gt;PMID 21042842&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
3.	Identify 2 congenital anomalies.&lt;br /&gt;
&lt;br /&gt;
Trisomy 21 and cleft palate&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--[[User:S8600021|Mark Hill]] 10:01, 3 August 2011 (EST) These answers are fine.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 13:02, 4 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Lab 2 Assessment==&lt;br /&gt;
1.	Identify the ZP protein that spermatozoa binds and how is this changed (altered) after fertilization. &lt;br /&gt;
&lt;br /&gt;
ZP3 acts as a receptor for the sperm. This is followed by the acrosome reaction, whereby acrosomal contents digest the ZP and allow the sperm surface proteins to bind to the ZP2. After fertilization, cortical reaction takes place where cortical granules are exocytosed. This results in the removal of carbohydrate from ZP3 and cleavage of ZP2 to harden the ZP. These changes occur to prevent polyspermy.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
2.       Identify a review and a research article related to your group topic.&lt;br /&gt;
&lt;br /&gt;
This research article showed genotype-phenotype correlations in Angelman Syndrome (AS). They have concluded that deletion patients had worse developmental outcomes than non deletion patients.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20729760&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
This review article is really comprehensive and gives a good background knowledge of AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20445456&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Z3291643]] 12:42, 11 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 3 Assessment==&lt;br /&gt;
&lt;br /&gt;
1.        What is the maternal dietary requirement for late neural development? &lt;br /&gt;
&lt;br /&gt;
Iodine. Zimmermann found that maternal deficiency of iodine can result in cognitive disability in the offspring, most severely characterized by cretinism. Fortunately, mild to moderate iodine deficiency can be corrected in primary school aged children to improve cognitive and motor functions.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21802524&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
2.        Upload a picture relating to your group project.&lt;br /&gt;
&lt;br /&gt;
[[File:UBE3A colocalizes with ASPM at the centrosome throughout mitosis.jpg|thumb|UBE3A colocalizes with ASPM at the centrosome throughout mitosis.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21633703&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
===UBE3A colocalizes with ASPM at the centrosome throughout mitosis===&lt;br /&gt;
&lt;br /&gt;
[[File:UBE3A colocalizes with ASPM at the centrosome throughout mitosis.jpg|Abnormal cytokinesis and apoptosis in UBE3A knockdown cells.|350px]]&lt;br /&gt;
&lt;br /&gt;
UBE3A colocalizes with ASPM at the centrosome. (A) Indirect immunofluorescence of HEK293 cells at interphase and different phases of mitosis stained with antibodies against ASPM and UBE3A (anti-UBE3A-sc-8926). Note colocalization of UBE3A with ASPM at the centrosome throughout mitosis (arrowheads). Note weak centrosomal staining of UBE3A in an interphase cell (arrow). (B) Indirect immunofluorescence of A549 cells stained with antibodies against UBE3A (anti-UBE3A-sc-8926) and ASPM at metaphase and telophase. Note colocalization of UBE3A with ASPM at the centrosome (arrowheads). Scale bar=2 µm.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Copyright Singhmar, Kumar. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 11:08, 18 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 4 Online Assessment==&lt;br /&gt;
&lt;br /&gt;
# '''The allantois, identified in the placental cord, is continuous with what anatomical structure?'''&lt;br /&gt;
The allantois is endodermic in origin and is the extension of the yolk sac into the connecting stalk. It's connected to the superior end of the developing bladder&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
#  '''Identify the 3 vascular shunts, and their location, in the embryonic circulation.'''&lt;br /&gt;
1. Ductus arteriosus; connects left pulmonary artery with the descending aorta&lt;br /&gt;
2. Ductus venosus; connects the portal and umbilical veins to the inferior vena cava&lt;br /&gt;
3. Foramen ovale; between left and right atria&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
# Identify the Group project sub-section that you will be researching. (Add to project page and your individual assessment page)&lt;br /&gt;
&lt;br /&gt;
; 4  Aetiology (genetic inheritance); Julia&lt;br /&gt;
; 5  Pathophysiology; Julia (as it's quite linked with aetiology anyway)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 12:59, 25 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 5 Online Assessment==&lt;br /&gt;
&lt;br /&gt;
# Which side (L/R) is most common for diaphragmatic hernia and why? &lt;br /&gt;
Posterior left side,possibly due to the fact that the left pericardioperitoneal canal is larger and closes later than the right.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 12:48, 1 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 6 Online Assessment==&lt;br /&gt;
# What week of development do the palatal shelves fuse?&lt;br /&gt;
Week 9 of early embryonic growth&lt;br /&gt;
 &lt;br /&gt;
# What early animal model helped elucidate the neural crest origin and migration of neural crest cells?&lt;br /&gt;
Migration of neural crest cells have been studied in quail-chick chimeras - transplanted quail cells have obvious nucleoli compared with chicken. It was first done by Nicole Le Douarin in the 80's&lt;br /&gt;
 &lt;br /&gt;
# What abnormality results from neural crest not migrating into the cardiac outflow tract? &lt;br /&gt;
Tetralogy of Fallot; when the outflow tract is not aligned properly, it is seen as a nonwedged aorta. Nonwedged aorta indicates tetralogy of Fallot. In addition, past studies using chick embryos have outlined that cardiac neural crest cell ablation led to this malalignment. In contrast, Farrell et al have shown that the introduction of cardiac neural crest aligned the outflow tract properly. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9933243&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 12:49, 15 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 7 Online Assessment==&lt;br /&gt;
&lt;br /&gt;
1. Are satellite cells &lt;br /&gt;
* necessary for muscle hypertrophy?&lt;br /&gt;
: No&lt;br /&gt;
 &lt;br /&gt;
* generally involved in hypertrophy?&lt;br /&gt;
: Yes&lt;br /&gt;
 &lt;br /&gt;
&lt;br /&gt;
2. Why does chronic low frequency stimulation (CLFS) cause a fast to slow fibre type shift? &lt;br /&gt;
: At the molecular level, there are exchanges of fast and slow type protein isoforms, such as calcium regulatory system, myofibrillar apparatus. The final step in CLFS induced fiber shift is the upregulation of slow myosin from the conversion of myogenic cells to slow fiber phenotype. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12500901&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;It is also known that satellite cells contribute to CLFS-induced transition of fiber types shown by the fact that CLFS increases type I fibers only after fiber necrosis. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16439424&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--Mark Hill 10:42, 16 September 2011 (EST) &lt;br /&gt;
&lt;br /&gt;
I would like each student to now also look at the following online page before the next Lab and write a comment based upon the group project assessment criteria. &lt;br /&gt;
&lt;br /&gt;
http://embryology.med.unsw.edu.au/embryology/index.php?title=Trisomy_21 &lt;br /&gt;
Paste your comment on the Trisomy 21 discussion page and also on your own student page. &lt;br /&gt;
&lt;br /&gt;
Group Assessment Criteria&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Good and concise explanation of the subheadings,however, I would've liked to see some attempt to further explain how the asspcoated congenital abnormalities occur.  &lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Lots of images, graphs and table used effectively to help reader better understand the disease. They also gave the project page some colour to make it more pleasing to the eye. Unfortunately, some images were placed (eg. John Langdon Down)in the wrong sections and interrupted the flow of the project page. &lt;br /&gt;
#* In addition, some of the images were not referred to within the project page. &lt;br /&gt;
#* Furthermore, the overall structure and layout of the page could be improved, such as putting the Diagnostic Links under diagnosis instead of the introduction&lt;br /&gt;
#* I also felt American College of Obstetricians and Gynecologists Recommendations could've been a subheading under 'screening'&lt;br /&gt;
#Content is correctly cited and referenced. &lt;br /&gt;
#* The very first image does not provide any information on the permissions to reuse the image (open access). &lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations. &lt;br /&gt;
#* Would've been better to include more self drawn diagrams and tables to further illustrate the group's knowledge of this disease&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* Lots of Pubmed articles have been used to make this page more credible and reliable &lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#* More words need to be explained in the glossary, such as 'tandem single nucleotide polymorphisms' &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 22:50, 21 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 8 Online Assessment==&lt;br /&gt;
attendance: --[[User:Z3291643|Sang Lee]] 13:04, 22 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Group 1: Turner Syndrome&lt;br /&gt;
&lt;br /&gt;
Firstly, nice progress with the group project. After reading your page, I have a good general knowledge of Turner Syndrome, so thanks. Overall, most sections were well done, though the writing style and layout could be more consistent, but you could work on that when you've finalised the content of the page. &lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: Good intro, very first image of the karyotype should include the actual statement of the 'Open access' not just 'copyright'&lt;br /&gt;
#* Epidemiology: Grammatical errors disrupt the flow of the content, in addition, graph has no copyright info, title could be improved&lt;br /&gt;
#* Etiology: Nice simple diagram of 22 eggs and 23 sperms, good example of when a picture can tell more than a thousand words! I feel there needs to be consistency either use Turner Syndrome or TS throughout the page&lt;br /&gt;
#* Clinical: liked how you have further classified the symptoms to its associated titles, nice idea; very easy to read, but a table would also be good&lt;br /&gt;
#* Diagnosis: image of TS maternal serum sampling doesn't contain {Template:2011 Student Image}, but a very good table&lt;br /&gt;
#* image of the TS X chromosome variations shouldl contain {Template:2011 Student Image}. Furthermore, if you use A-E in image descriptions, you should include A-E within the image&lt;br /&gt;
#* Research: very good layout and explanations, informative&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Could include more images especially in clinical manidestations, and some images do not fit the requirements set by Mark, as I've highlighted above &lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* seems to be cited well. However, although you have more than 100 referencees, a lot of them are repeated references, maybe you could try to use more pubmed articles, a greater variety&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations. &lt;br /&gt;
#* Glossary: could include more words such as echocardiogram&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* Although you have more than 100 referencees, a lot of them are repeated references, maybe you could try to use more pubmed articles, a greater variety&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#*  Although the content is informative, I'm left feeling like I want more variety of resources, so maybe some further research will improve the overall impression of your page &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot;&lt;br /&gt;
* consistency in writing style&lt;br /&gt;
* more images and cited correctly &lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 14:44, 24 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Group 2&lt;br /&gt;
&lt;br /&gt;
Hey Group 2, firstly, well done on putting in the effort to create this page, it really shows your dedication and cooperation as a team! Here are some points I thought you could improve on to take this page to that extra level&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: Good overview. Image would look better with a border or as a thumb&lt;br /&gt;
#* History: Image too large, again maybe a border?&lt;br /&gt;
#* Epidemiology: Need to define velocardiofacial syndrome in glossary, also break it down into subheadings, eg. Incidence, Sex, etc&lt;br /&gt;
#* Etiology: Maybe better if in a table&lt;br /&gt;
#* Pathogenesis: I liked how you broke it doen into relevant subheadings. However, on a slightly negative note, the DG Pathophysiology Diagram looks rushed; I think it would've looked better if it was neater and easier to read.&lt;br /&gt;
#* Diagnosis: I felt citing was done poorly in this section, eg. the last 4/5 sentences in the FISH technique was not referenced at all, but again, this is very easily fixed. But good to see you have put in the effort and time&lt;br /&gt;
#* Clinical: Image of normal and cleft palate, if based on a textbook, I think you still need permission to adapt it (not quite sure, please ask Mark)? Table with 'How it is caused' would be better by itself as pathophysiology. Tetralogy of Fallot needs to be fitted into this section more smoothly, at the moment, it makes this section look very cramped. Also, the image regarding Tetralogy needs the correct format for student drawn images (ie. 'I (student no.)....)&lt;br /&gt;
#* Research: Maybe break it down into subheadings&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Good images used with a nice range of self drawn images. However, no where in the page is there any reference to the images within the text.&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* I feel citation needs to be improved overall. Lots of the sections have missing citations, especially Diagnostic Tests. Also in the reference list, refs 33,40,47, 49 have nothing in it (is it meant to be like this?)&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations. &lt;br /&gt;
#* Nice drawings, though some could've done better with more effort&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* Nice range of references used&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#* It's very clear to me that you guys have worked together well and there has been good team work going on here to create this page, so well done&lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* I feel your page is too heavy with the text, although there's a lot of images as well, it just doesn't quite balance out with the text. &lt;br /&gt;
* Also felt the different colours used for the tables, although adding a splash of colour to your page, brought down the overall quality of the page. However, please keep in mind that others might really like this approach of table formatting, it's just that personally, I think you could benefit from keeping all table colours consistent.&lt;br /&gt;
* Sometimes you refer to DiGeorge Syndrome as DGS and also as DS. Small and easy to fix, adds consistency&lt;br /&gt;
* Please don't forget to add the {template} for student uploaded images&lt;br /&gt;
* Definitely needs more words in the Glossary, such as Meiosis, de novo, microarray&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 16:02, 24 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 3&lt;br /&gt;
&lt;br /&gt;
Hi, overall, a nice project page with interesting information.&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: Nice introduction, good flow and easy to read. However, image needs proper information and perhaps 'This disorder was first described by Harry F.' could be placed earlier on in the intro rather than in the middle&lt;br /&gt;
#* History: Nice section, very interesting&lt;br /&gt;
#* Epidemiology: First paragraph is good, but I feel the rest of this section doesn't quite belong here, such as the information on seizures, IQs, diagnosis. This section should focus on stats (sex/birth/ethnic/demographic/etc). Fig 2, 3 belong more in the signs and symptoms&lt;br /&gt;
#* Etiology: the '1:1000 male' contradicts the '1:500' given in epidemiology. Fig4 needs coyright information&lt;br /&gt;
#* Pathogenesis: Needs better referencing, also placing fig 5, 6 on either side doesn't look too good with the text. Perhaps place them below one another?&lt;br /&gt;
#* Signs: Seems a bit incomplete, it'll also be good to explain the image of 'pubertal gynecomastia'&lt;br /&gt;
#* Diagnosis: Sentence structure could be improved, ie. 'performed because physicians may suspect it because of clinical findings'. Information is interesting, but could be presented more clearly, perhaps in a table?&lt;br /&gt;
#* Similar defects: very nice, presented well with good information, easy to read&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Good images used with a nice range of self drawn images. However, lot of the images need to be formatted properly with required information&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* overall referencing was well done, except pathogenesis needs more referencing&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations. &lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* Nice range of references used&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#* The information is there, but maybe from now til final assessment, you could do further research in all sections, as they do seem a little short.&lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* better page layout&lt;br /&gt;
* glossary: sorry, but I feel the alphabet subheadings here are very effective as you have it in alphabetical order anyway&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 21:59, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 4&lt;br /&gt;
&lt;br /&gt;
Hey, this is a nicely structured page with interesting content that is presented well. There is a nice balance of text and image&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: good, to the point&lt;br /&gt;
#* History: Nice section, perhaps bold the years?&lt;br /&gt;
#* Epidemiology: I really liked this section, both visually and content wise. The table is easy to read and I liked your explanations for the HD prevalence, well done&lt;br /&gt;
#* Genetics: Perhaps you could have the 'CAG (cytosine-adenine-glutamine)' in the introduction when you first refer to it? Referencing is required in i'HTT and normal functions'. I really liked your subheadings, made it very easy to understand and follow &lt;br /&gt;
#* Pathogenesis: Image is too big, good subheadings, I suggest that if you write in purple to highlight some words, maybe you could do that for the whole page?&lt;br /&gt;
#* Clinical: liked the motor impairment explanations, how about explaining the cognitive and behaviour impairments as well? (it'll be worth it!)&lt;br /&gt;
#* Diagnosis: Nice content, but it just feels a bit too crowded, maybe rearrange the images and decrease image size&lt;br /&gt;
#* Treatment: Very nice section with nice images and good format!&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Good balance of images and text, though some rearrangement of images would make this page look better. Very good use of subheadings to make the content more easy to digest&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* overall referencing was well done&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
* good range of tables, images and self drawn images&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* Nice range of references used&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* just minor changes such as resizing some of the images, making the sections consistent in format&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 22:32, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 5&lt;br /&gt;
&lt;br /&gt;
Hi, I can see some progress on this page which is good, content is interesting&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: What is FMR1 gene? Need more information here, as in when was it first discovered, some stats&lt;br /&gt;
#* Epidemiology: I think screening information is extensive enough to be a section on its own&lt;br /&gt;
#* Etiology: no explanation of FMR1 gene so far, what is its normal function? Also, please refer to images used in this section&lt;br /&gt;
#* Development of the disease:nice succinct, easy to follow section. Perhaps add an image for one of the stages mentioned here?&lt;br /&gt;
#* Signs: REFERENCING!!! But, content is good and interesting&lt;br /&gt;
#* Diagnosis: An image here would be nice, and an explanation of how the technology is used to diagnose FXS&lt;br /&gt;
#* Treatment: Nice table with good information&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Need to balance out the text and image ratio, some good subheadings&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* poor referencing, which makes me question the reliability of the content in some sections&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
#* needs a lot more images&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* I feel more research needs to be done here&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* Although the content is here, there is still a lot of work needed to make this page feel complete&lt;br /&gt;
* glossary is very lacking in terminology&lt;br /&gt;
* need more images&lt;br /&gt;
* further research would be nice to explain this disease in more detail&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 23:26, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Group 6&lt;br /&gt;
Hey, nice progress with your page, all sections have similar amount of content which were interesting&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: Referencing needs to be improved here&lt;br /&gt;
#* History: content is good but too wordy. I think a summary or a simple timeline would be good&lt;br /&gt;
#* Epidemiology: Where's the reference for 3/10000 live births?&lt;br /&gt;
#* Signs: ok section, but could do with more images here&lt;br /&gt;
#* Genetics: If using abbreviations, such as TBX1 gene, you should explain what it is, ie. TBX1 gene (T-box 1). Also need to work on referencing here as well. How about organising all the content in a table? have in columns: gene, gene profile, frequency, etc.&lt;br /&gt;
#* Pathogenesis: I'm not quite sure about this, but do you need permission to adapt an image from an article? (I'm referring to the '4 defects' image)&lt;br /&gt;
#* Diagnosis: I'm sorry, but this section is a bit bland, though the content is very informative. I think some images here would be good&lt;br /&gt;
#* Treatment: Referencing! Also, personally, that green is too bright, maybe find a more neutral, soothing colour?&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Need to find more images, I feel some of the information could be more effectively presented in table formate rather than lengthy text&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* VERY poor referencing, which makes me question the reliability of the content in some sections&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
#* needs a lot more images&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* research done is evident, just need to reference&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* glossary is very lacking in terminology&lt;br /&gt;
* need more images&lt;br /&gt;
* REFERENCING!&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 23:26, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Group 8&lt;br /&gt;
Hey, well done, your page is looking really polished! Lots of very interesting information here and presented in a very easy to follow manner&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* History: I feel that you could lessen the info of Nicholas and add more current findings of the disease.&lt;br /&gt;
#* Aetiology: What is the chromosome 9 image based on? Need to work on referencing. Very good subheadings and well balanced with images&lt;br /&gt;
#* Pathogenesis: Needs more information&lt;br /&gt;
#* Neuro: What's the images based on? Good subheadings and explained well. I liked the way you gave explanations for normal function/appearance and then went on to explain abnormality associated with the structures in this disease. But you need to improve your referencing for this section&lt;br /&gt;
#* Diagnosis: Very good table and images. But need to fix the postnal diagnosis table so that it spans the length of the screen&lt;br /&gt;
#* Symptoms: table and images look too crowded&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* good subheadings, images, impressive self drawn images! Nice balanced page layout&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* needs to work on referencing&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* research done is evident, just need to reference&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* referencing&lt;br /&gt;
* better arrangement of table and images so page doesn't look too crowded&lt;br /&gt;
&lt;br /&gt;
Well done guys, nice team work!&lt;br /&gt;
--[[User:Z3291643|z3291643]] 23:50, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 9&lt;br /&gt;
&lt;br /&gt;
Hey, your page has a lot of very interesting content and some unique self drawn images. I thoroughly enjoyed this page, thanks&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: Inclusion of incidence would be nice&lt;br /&gt;
#* History: very informative and a nice simple timeline&lt;br /&gt;
#* Genetics: Good, succinct section, especially liked the table&lt;br /&gt;
#* Diagnosis: needs referencing. Is diagnosis only postnatal? What is the average age of diagnosis for this disease?&lt;br /&gt;
#* Management and Treatment: Seems a little out of place under epidemiology, I think it should be place later on &lt;br /&gt;
#* Phenotype:Reference?&lt;br /&gt;
#* Cardiac conditions: maybe give explanations for atrial and ventricular septal defect, just brief descriptions would suffice. Why is it so that males are more likely to suffer CVD than females?&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* good subheadings, interesting self drawn images. However, this page needs to find a balance in text and images&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* needs to work on referencing&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* research done is evident, just need to reference&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#* very interesting content, informative&lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* referencing&lt;br /&gt;
* more images&lt;br /&gt;
* glossary; lacking a lor of terms&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 00:10, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 10&lt;br /&gt;
&lt;br /&gt;
Hey, this is a interesting disease, with some good images to show the disease clearly. &lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: succinct introduction&lt;br /&gt;
#* History: Has interesting content, though timeline would be nice&lt;br /&gt;
#* Pathogenesis: Too brief and could be improved with an image&lt;br /&gt;
#* Signs: surely there are more symptoms here, maybe you could have subheadings to break down the symtpoms, ie. motor impairment, cognitive impairments, etc&lt;br /&gt;
#* Clinical manifestations and complications: nice section with good image used&lt;br /&gt;
#* Diagnosis: could be further explained, and an image would be nice&lt;br /&gt;
#* Treatment: Current and Future Prospects: needs referencing&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* need to balance out the text with images, could organise page better with more subheadings, more images needed &lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* needs to work on referencing!!&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
#*  more table could be used instead of lengthy explanations&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* much more research needs to be done to further explain the sections&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* referencing&lt;br /&gt;
* more images&lt;br /&gt;
* glossary; lacking a lot of terms&lt;br /&gt;
* needs much more research, lots of repetitions in referencing&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 11:02, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 11&lt;br /&gt;
&lt;br /&gt;
Hey, this is a interesting disease, with some good images to show the disease clearly. &lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: very rushed, no reference and needs much more work, it should be a succinct summary of this whole page.&lt;br /&gt;
#* History: Has interesting content, though timeline would be better incorporated under History, not a section of its own&lt;br /&gt;
#* Diagnosis: If you're abbreviating Cleft Palate to CLP, you should have it as Cleft palate (CLP). The two given tables are pretty much the same, except for different sample number. Is it really necessary to have the two tables when they're so similar? Could do well with an image&lt;br /&gt;
#* Syndromes and Anomalies associated with cleft: Nice array of images used here. Content is good (for ones you provided), but needs work on referencing. Perhaps you could organise the content into a table for easy comparison since you have more than one anomalies&lt;br /&gt;
#* Aetiology: Needs referencing, image could have a caption to explain it. Although the content is there, it's too brief and I feel it could be organised in a more effective manner, such as using number stages.&lt;br /&gt;
#* Types of Cleft Palate/Lip:very brief, please explain the points (ie. what's the differences between them? you say there are differences in severity, how so?)&lt;br /&gt;
#* Pathophysiology: need to reformat table more effectively and work on referencing&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* need to balance out the text with images, could organise page better with more subheadings &lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* needs to work on referencing!!&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
#* NO self drawn images so far&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* much more research needs to be done. sections overall are lacking substance and doesn't explain the content very well&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* referencing&lt;br /&gt;
* more images&lt;br /&gt;
* glossary; lacking a lot of terms&lt;br /&gt;
* needs much more research&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 11:02, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 9 attendence==&lt;br /&gt;
--[[User:Z3291643|z3291643]] 13:00, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 10 attendence==&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 13:15, 6 October 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 10 Online Assessment==&lt;br /&gt;
&lt;br /&gt;
1.Besides fetal alcohol syndrome, identify another environmental teratogen that can lead to hearing loss.&lt;br /&gt;
&lt;br /&gt;
Noise pollution is a big factor in hearing loss, as well as viral and bacterial infections such as meningitis. Hearing loss from meningitis can be a result of the direct effects of the infection on the brain or the body's reaction to the infection, most commonly with pneumococcal meningitis. 6% of all hearing defects in children can be attributed to bacterial meningitis, with around 72% of these children progressing to complete hearing loss by the age of three. &lt;br /&gt;
&lt;br /&gt;
2.Identify 3 factors that contribute to poor neonatal drainage of the middle ear. &lt;br /&gt;
&lt;br /&gt;
The auditory tube connects the middle ear cavity to the nasopharynx, and is different in structure in neonates vs. adults.&lt;br /&gt;
:# the eustachian tube is very horizontal (10 degrees to the horizontal axis)&lt;br /&gt;
:# only opened by a single muscle called the tensor palati muscle (compared to 2 muscles in the adult tube)&lt;br /&gt;
:# it is shorter(17-18 mm) and narrower &lt;br /&gt;
&lt;br /&gt;
3.Identify 1 genetic abnormality that affects hearing development and link to the OMIM record. (Your individual abnormality should be different from all other students)&lt;br /&gt;
* Waardenburg syndrome&lt;br /&gt;
* results in hearing loss (to variable extent)&lt;br /&gt;
* inherited in an autosomal dominant manner&lt;br /&gt;
* [http://omim.org/entry/193500 Waardenburg syndrome]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Related Links'''&lt;br /&gt;
&lt;br /&gt;
'''Animal Models'''&lt;br /&gt;
&lt;br /&gt;
* [[Mouse Knockout]] - this page explains the current use of mouse models in disrupting genes to elucidate their genetic function, including the mouse gene knockouts for alpha calcium-calmodulin kinase II (alpha CaMKII)&lt;br /&gt;
* [[2009 Group Project 4]] - this page gives an extensive overview on the history of the mouse model and its various use in embryology and genetics. In addition, it also describes mouse knockout and the role they play in current research of various human diseases&lt;br /&gt;
* [[Fly Development]] - this page describes the use of drosophila flies as developmental models&lt;br /&gt;
* [[2009 Group Project 2]] - this page gives an extensive overview on the history of the fly model and its various use in embryology and genetics&lt;br /&gt;
&lt;br /&gt;
'''Diagnosis'''&lt;br /&gt;
* [[Chorionic villus sampling]] - this page explains the process of chorionic villus sampling, its disadvantages and gives a brief overview of recent findings&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 10:20, 13 October 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 11 Online Assessment==&lt;br /&gt;
&lt;br /&gt;
===Lab 11 lab attendence===&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 13:35, 13 October 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==''' References '''==&lt;br /&gt;
&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;/div&gt;</summary>
		<author><name>Z3291643</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=File:Prader-Willi_Syndrome_patient.png&amp;diff=77852</id>
		<title>File:Prader-Willi Syndrome patient.png</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=File:Prader-Willi_Syndrome_patient.png&amp;diff=77852"/>
		<updated>2011-10-13T02:32:41Z</updated>

		<summary type="html">&lt;p&gt;Z3291643: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;==Photograph of a Prader-Willi Syndrome patient==&lt;br /&gt;
&lt;br /&gt;
A 12 year old Prader Willi Syndrome patient with the common characteristic of obesity&lt;br /&gt;
&lt;br /&gt;
===Reference===&lt;br /&gt;
&lt;br /&gt;
FRIDMAN, Cintia  and  KOIFFMANN, Célia P.. Genomic imprinting: genetic mechanisms and phenotypic consequences in Prader-Willi and Angelman syndromes. Genet. Mol. Biol. [online]. 2000, vol.23, n.4, pp. 715-724 . Available from: &amp;lt;http://www.scielo.br/scielo.php?script=sci_arttext&amp;amp;pid=S1415-47572000000400004&amp;amp;lng=en&amp;amp;nrm=iso&amp;gt;. ISSN 1415-4757.  http://dx.doi.org/10.1590/S1415-47572000000400004&lt;br /&gt;
&lt;br /&gt;
This paper is not available in Pubmed&lt;br /&gt;
&lt;br /&gt;
All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License &lt;br /&gt;
You are free:&lt;br /&gt;
to Share — to copy, distribute and transmit the work to Remix — to adapt the work &lt;br /&gt;
&lt;br /&gt;
http://creativecommons.org/licenses/by-nc/3.0/&lt;br /&gt;
&lt;br /&gt;
{{Template:2011 Student Image}}&lt;/div&gt;</summary>
		<author><name>Z3291643</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=File:Critical_region_of_Angelman_Syndrome_on_chromosome_15.png&amp;diff=77849</id>
		<title>File:Critical region of Angelman Syndrome on chromosome 15.png</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=File:Critical_region_of_Angelman_Syndrome_on_chromosome_15.png&amp;diff=77849"/>
		<updated>2011-10-13T02:31:57Z</updated>

		<summary type="html">&lt;p&gt;Z3291643: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;==Critical region of Angelman Syndrome on chromosome 15==&lt;br /&gt;
&lt;br /&gt;
Prader Willi &amp;amp; Angelman's syndromes - probes &lt;br /&gt;
Human chromosome highlighted by fluorescent probes&lt;br /&gt;
that bind to specific sequences of DNA. In this&lt;br /&gt;
FISH (fluorescence in situ hybridisation) study a&lt;br /&gt;
probe (red) from the Prader Willi and Angelman's&lt;br /&gt;
syndromes critical region (PSASCR) and a&lt;br /&gt;
chromosome 15 centromere specific probe (green)&lt;br /&gt;
show that the 15q.11&amp;gt;q13 duplication does not&lt;br /&gt;
include the PWASCR.&lt;br /&gt;
&lt;br /&gt;
===Reference===&lt;br /&gt;
&lt;br /&gt;
Images on this site are freely available for download for personal, academic teaching or study use, under one of two Creative Commons licences.&lt;br /&gt;
&lt;br /&gt;
Under the terms of the Creative Commons Licence, anyone is free to copy, distribute, and display the image, providing that the image is fully attributed to Wellcome Images and used solely for non-commercial purposes.&lt;br /&gt;
&lt;br /&gt;
http://creativecommons.org/licenses/by-nc/2.0/uk/&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{{Template:2011 Student Image}}&lt;/div&gt;</summary>
		<author><name>Z3291643</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=File:Angelman_Syndrome_Prenatal_Diagnosis.jpg&amp;diff=77846</id>
		<title>File:Angelman Syndrome Prenatal Diagnosis.jpg</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=File:Angelman_Syndrome_Prenatal_Diagnosis.jpg&amp;diff=77846"/>
		<updated>2011-10-13T02:31:15Z</updated>

		<summary type="html">&lt;p&gt;Z3291643: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;==Prenatal diagnosis flowchart for Angelman Syndrome==&lt;br /&gt;
&lt;br /&gt;
A student drawn flow chart showing the key steps involved in the prenatal diagnosis of Angelman syndrome. UPD; Uniparental Disomy.&lt;br /&gt;
&lt;br /&gt;
===Image Copyright Information===&lt;br /&gt;
&lt;br /&gt;
Illustration by z3291622. &lt;br /&gt;
&lt;br /&gt;
Beginning six months after publication, I, z3291622, grant the public the non-exclusive right to copy, distribute, or display the Work under a Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/ and http://creativecommons.org/licenses/by-nc-sa/3.0/legalcode.&lt;br /&gt;
&lt;br /&gt;
{{Student Image}}&lt;/div&gt;</summary>
		<author><name>Z3291643</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=File:Angelman_Syndrome_patient.png&amp;diff=77844</id>
		<title>File:Angelman Syndrome patient.png</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=File:Angelman_Syndrome_patient.png&amp;diff=77844"/>
		<updated>2011-10-13T02:30:12Z</updated>

		<summary type="html">&lt;p&gt;Z3291643: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;==Photograph of an Angelman Syndrome patient==&lt;br /&gt;
&lt;br /&gt;
This is a photograph of a 4 year old Angelman syndrome (AS) patient, highlighting the typical facial characteristics of AS, such as big gapped teeth&lt;br /&gt;
&lt;br /&gt;
===Reference===&lt;br /&gt;
&lt;br /&gt;
FRIDMAN, Cintia  and  KOIFFMANN, Célia P.. Genomic imprinting: genetic mechanisms and phenotypic consequences in Prader-Willi and Angelman syndromes. Genet. Mol. Biol. [online]. 2000, vol.23, n.4, pp. 715-724 . Available from: &amp;lt;http://www.scielo.br/scielo.php?script=sci_arttext&amp;amp;pid=S1415-47572000000400004&amp;amp;lng=en&amp;amp;nrm=iso&amp;gt;. ISSN 1415-4757.  http://dx.doi.org/10.1590/S1415-47572000000400004&lt;br /&gt;
&lt;br /&gt;
This paper is not available in Pubmed&lt;br /&gt;
&lt;br /&gt;
All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License &lt;br /&gt;
You are free:&lt;br /&gt;
to Share — to copy, distribute and transmit the work to Remix — to adapt the work &lt;br /&gt;
&lt;br /&gt;
http://creativecommons.org/licenses/by-nc/3.0/&lt;br /&gt;
&lt;br /&gt;
{{Template:2011 Student Image}}&lt;/div&gt;</summary>
		<author><name>Z3291643</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=File:Electroencephalography_of_Angelman_Syndrome.jpg&amp;diff=77841</id>
		<title>File:Electroencephalography of Angelman Syndrome.jpg</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=File:Electroencephalography_of_Angelman_Syndrome.jpg&amp;diff=77841"/>
		<updated>2011-10-13T02:29:22Z</updated>

		<summary type="html">&lt;p&gt;Z3291643: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;==Electroencephalography of Angelman Syndrome==&lt;br /&gt;
&lt;br /&gt;
Electroencephalography (EEG) showing Normal and abnormal EEGs in both human and mouse.&lt;br /&gt;
&lt;br /&gt;
A. &lt;br /&gt;
: Normal, Segment of routine EEG on a normal 10-yr-old male with no seizures.&lt;br /&gt;
: AS-Deletion, Background EEG of a 9.5-yr-old male, large deletion AS case.&lt;br /&gt;
: AS-Non-Deletion, Background EEG of a 10-yr-old male with a UBE3A gene loss-of-function mutation. &lt;br /&gt;
&lt;br /&gt;
The above illustrates that seizures are most severe in AS cases with deletion of the UBE3A gene.&lt;br /&gt;
&lt;br /&gt;
B.&lt;br /&gt;
: Background EEGs from mouse littermates (gabrb3+/+ and gabrb3−/−) recorded simultaneously at 2 months of age. Electrodes were placed over right and left parietal cortex and referenced to an electrode placed in the nasal bone. Bottom two EEG traces are representative examples from a gabrb3−/− mouse before (b.) and after (a.) administration of ethosuximide (400 mg/kg). Ethosuximide effectively abolished interictal spiking and normalized EEG background.&lt;br /&gt;
&lt;br /&gt;
===Reference===&lt;br /&gt;
&lt;br /&gt;
&amp;lt;pubmed&amp;gt;9763493&amp;lt;/pubmed&amp;gt;&lt;br /&gt;
&lt;br /&gt;
For permissions, please see Discussion page&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{{Template:2011 Student Image}}&lt;/div&gt;</summary>
		<author><name>Z3291643</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=File:Normal_and_Angelman_Syndrome_mice_models.jpg&amp;diff=77839</id>
		<title>File:Normal and Angelman Syndrome mice models.jpg</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=File:Normal_and_Angelman_Syndrome_mice_models.jpg&amp;diff=77839"/>
		<updated>2011-10-13T02:28:45Z</updated>

		<summary type="html">&lt;p&gt;Z3291643: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;==Normal and Angelman Syndrome mice models==&lt;br /&gt;
&lt;br /&gt;
Mouse in the center is the normal mouse with UBE3A present. Only the normal mouse exhibits the motor skills required to stay on the rotarod apparatus. In contrast, the mice on the left and right are UBE3A deficient, with the result of slight obesity and motor deficits, illustrated by their incapability to stay on the rotarod apparatus.&lt;br /&gt;
&lt;br /&gt;
===Reference===&lt;br /&gt;
&lt;br /&gt;
Illustration by z3291643, based on the findings of &amp;lt;pubmed&amp;gt;17259980&amp;lt;/pubmed&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Beginning six months after publication, I (3291643) grant the public the non-exclusive right to copy, distribute, or display the Work under a Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/ and http://creativecommons.org/licenses/by-nc-sa/3.0/legalcode&lt;br /&gt;
&lt;br /&gt;
{{Template:2011 Student Image}}&lt;/div&gt;</summary>
		<author><name>Z3291643</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=File:UBE3A_Ubiquitylation_Pathway.png&amp;diff=77835</id>
		<title>File:UBE3A Ubiquitylation Pathway.png</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=File:UBE3A_Ubiquitylation_Pathway.png&amp;diff=77835"/>
		<updated>2011-10-13T02:27:58Z</updated>

		<summary type="html">&lt;p&gt;Z3291643: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;==UBE3A Ubiquitylation Pathway==&lt;br /&gt;
&lt;br /&gt;
Ubiquitin is activated by E1 enzyme, followed by the subsequent transfer to E2 enzyme and to UBE3A. UBE3A attaches ubiquitin to the target protein for degradation by proteasome after polyubiquitylation.&lt;br /&gt;
&lt;br /&gt;
===Reference===&lt;br /&gt;
&lt;br /&gt;
Illustration by z3291643 &lt;br /&gt;
&lt;br /&gt;
Beginning six months after publication, I (3291643) grant the public the non-exclusive right to copy, distribute, or display the Work under a Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/ and http://creativecommons.org/licenses/by-nc-sa/3.0/legalcode&lt;br /&gt;
&lt;br /&gt;
{{Template:2011 Student Image}}&lt;/div&gt;</summary>
		<author><name>Z3291643</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=File:Imprint_defect_inheritance_in_Angelman_Syndrome.png&amp;diff=77833</id>
		<title>File:Imprint defect inheritance in Angelman Syndrome.png</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=File:Imprint_defect_inheritance_in_Angelman_Syndrome.png&amp;diff=77833"/>
		<updated>2011-10-13T02:27:26Z</updated>

		<summary type="html">&lt;p&gt;Z3291643: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;==Imprint defect inheritance in Angelman Syndrome==&lt;br /&gt;
&lt;br /&gt;
This family tree of the inheritance pattern of Angelman Syndrome highlights that only the carrier mother can pass on the genetic defect to her children, resulting in Angelman Syndrome. A carrier father with the genetic defect can pass it on to his children as well, but they will be clinically normal.&lt;br /&gt;
&lt;br /&gt;
===Reference===&lt;br /&gt;
&lt;br /&gt;
Illustration by z3291643. Beginning six months after publication, I (3291643) grant the public the non-exclusive right to copy, distribute, or display the Work under a Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/ and http://creativecommons.org/licenses/by-nc-sa/3.0/legalcode&lt;br /&gt;
&lt;br /&gt;
{{Template:2011 Student Image}}&lt;/div&gt;</summary>
		<author><name>Z3291643</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=File:Chromosome_15_Deletion_of_15q11.2_to_15q13.jpg&amp;diff=77831</id>
		<title>File:Chromosome 15 Deletion of 15q11.2 to 15q13.jpg</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=File:Chromosome_15_Deletion_of_15q11.2_to_15q13.jpg&amp;diff=77831"/>
		<updated>2011-10-13T02:26:46Z</updated>

		<summary type="html">&lt;p&gt;Z3291643: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;==Chromosome 15 Deletion of 15q11.2 to 15q13==&lt;br /&gt;
&lt;br /&gt;
A student drawn diagram showing chromosome 15 highlighting the designated areas where deletion occurs at the 15q11.2-15q13 segment. The UBEA3 gene resides here.&lt;br /&gt;
&lt;br /&gt;
===Image Copyright Information===&lt;br /&gt;
&lt;br /&gt;
Illustration by z3293267. &lt;br /&gt;
&lt;br /&gt;
Beginning six months after publication, I, z3293267, grant the public the non-exclusive right to copy, distribute, or display the Work under a Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/ and http://creativecommons.org/licenses/by-nc-sa/3.0/legalcode. &lt;br /&gt;
&lt;br /&gt;
This illustration was inspired by multiple sources.&lt;br /&gt;
&lt;br /&gt;
{{Student Image}}&lt;/div&gt;</summary>
		<author><name>Z3291643</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=File:Extent_of_microcephaly_in_Angelman_Syndrome_patients.png&amp;diff=77829</id>
		<title>File:Extent of microcephaly in Angelman Syndrome patients.png</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=File:Extent_of_microcephaly_in_Angelman_Syndrome_patients.png&amp;diff=77829"/>
		<updated>2011-10-13T02:25:50Z</updated>

		<summary type="html">&lt;p&gt;Z3291643: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;==Extent of microcephaly in Angelman Syndrome patients==&lt;br /&gt;
&lt;br /&gt;
Distribution of head circumference (HC) between 20 Angelman Syndrome patients with deletion and 20 Angelman Syndrome patients without deletion.&lt;br /&gt;
&lt;br /&gt;
===Reference===&lt;br /&gt;
&lt;br /&gt;
Reprinted by permission from Macmillan Publishers Ltd: [European Journal of Human Genetics] (Moncla A, Malzac P, Voelckel MA et al: Phenotype–genotype correlation in 20 deletion and 20 non-deletion Angelman syndrome patients. EJHG 1999; 7: 131-139.), copyright (1999)&lt;br /&gt;
&lt;br /&gt;
http://www.nature.com.wwwproxy0.library.unsw.edu.au/ejhg/journal/v7/n2/pdf/5200258a.pdf&lt;br /&gt;
&lt;br /&gt;
&amp;lt;pubmed&amp;gt;10196695&amp;lt;/pubmed&amp;gt;&lt;br /&gt;
&lt;br /&gt;
:'''Links:''' [http://www.nature.com/ejhg/index.html/ European Journal of Human Genetics]&lt;br /&gt;
&lt;br /&gt;
{{Template:2011 Student Image}}&lt;/div&gt;</summary>
		<author><name>Z3291643</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_7&amp;diff=77826</id>
		<title>2011 Group Project 7</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_7&amp;diff=77826"/>
		<updated>2011-10-13T02:24:04Z</updated>

		<summary type="html">&lt;p&gt;Z3291643: /* Pathogenesis */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;='''Angelman Syndrome'''=&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Introduction==&lt;br /&gt;
&lt;br /&gt;
[[File:Dr Harry Angelman.jpg|thumb|130px|right|Dr Harry Angelman.]]&lt;br /&gt;
Angelman syndrome (AS) is a rare [[#Glossary | '''neurogenetic''']] [[#Glossary | '''disorder''']] first described by Dr. Harry Angelman in 1965.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18754889&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Dr. Angelman was an English [[#Glossary | '''paediatrician''']] who first diagnosed the disease in 3 children with a developmental delay.&amp;lt;ref&amp;gt;http://www.ncbi.nlm.nih.gov/books/NBK22221/&amp;lt;/ref&amp;gt; AS occurs in 1 in 10000-20000 births, the exact number is still unknown.&amp;lt;ref name=&amp;quot;PMID7573182&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7573182&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;PMID8703225&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;8703225&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It is caused by maternal [[#Glossary | '''allele''']] disruptions of a single gene- UBE3A. Either [[#Glossary | '''mutations''']] or [[#Glossary | '''deletions''']] of the UBE3A gene results in AS. &lt;br /&gt;
&lt;br /&gt;
AS presents with well known [[#Glossary | '''phenotypes''']] during infancy and adulthood, such as [[#Glossary | '''microcephaly''']] and [[#Glossary | '''maxillary hypoplasia''']]. However, these features become more marked with age. Most frequent clinical features include delayed development,[[#Glossary | '''seizures''']],[[#Glossary | '''ataxia''']], impairment of speech, happy demeanor, behavioural problems such as hyperactivity, short attention span and sleeping difficulty.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21592595&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21484597&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;ASAwebsite&amp;quot;&amp;gt;http://www.angelmansyndrome.org/home.html&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
At present, there is no cure for the syndrome, though current research is focused at improving life quality of patients with Angelman syndrome through management of daily tasks.&amp;lt;ref&amp;gt;http://www.bbc.co.uk/health/physical_health/conditions/angelman1.shtml&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==History==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Dr. Harry Angelman first reported Angelman Syndrome on three handicapped children that were admitted to his ward in England in 1964.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt; He reported how these three independent and unconnected clinical cases all had the same characteristic features of severe developmental delay, jerky movements, seizures and a happy disposition.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt; However it was only when he stumbled upon an oil painting called ‘a Boy with a Puppet” while on a holiday in Italy he was able to connect the symptoms of all three children under one common cause.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20981772&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; He linked the happy face of the boy depicted on the painting with the jerky movements and happy disposition he observed on his three patients back in England. He reported his findings on a paper entitled “Puppet children (a report on three cases)” which was published in 1965.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
The syndrome was initially named ‘Puppet Syndrome’ but was later changed to Angelman Syndrome. Due to the extreme rarity of the syndrome and lack of sufficient clinical evidence the syndrome was soon forgotten.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt;&lt;br /&gt;
[[File:Dr Charles Williams.jpg|thumb|right|150px|Dr Charles Williams.]]&lt;br /&gt;
	&lt;br /&gt;
In 1987, a physician named Ellen Magenis, came across children with deletions on [[#Glossary | '''chromosome''']] 15 that were suffering from seizures and severe developmental delay.&amp;lt;ref&amp;gt;http://www.angelman.org/stay-informed/facts-about-angelman-syndrome---7th-edition/harry-angelman-and-the-history-of-as/&amp;lt;/ref&amp;gt; Even though genetically the children were expected to have [[#Diagnosis | '''Prader-Willi syndrome''']] that was characterised by deletions on chromosome 15, their characteristic symptoms of seizures and lack of development did not correspond with that of the syndrome. This led to the realization that these children had deletions on the maternally derived chromosome 15 and not on the paternally derived chromosome as was observed in Prader-Willi syndrome.  Thus the deleted genetic code on maternally derived chromosome 15 was identified as the genetic marker for Angelman Syndrome.&lt;br /&gt;
&lt;br /&gt;
In 1997, UBE3A gene was isolated by Dr. Joseph Wagstaff and Dr. Arthur Beaudet as the cause of Angelman Syndrome.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot; /&amp;gt; The discovery of this [[#Glossary | '''gene''']] led to the subsequent development of animal models and research aimed at finding a causal link between UBE3A gene abnormalities and characteristic features observed in Angelman Syndrome. &lt;br /&gt;
	&lt;br /&gt;
Currently, four different genetic abnormalities for Angelman Syndrome have been confirmed by genetic testing. They include: Deletion, [[#Glossary | '''Uniparental Disomy''']] (UPD), [[#Glossary | '''Imprinting''']] and UBE3A mutation.&amp;lt;ref name=&amp;quot;PMID:20211139&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Below is a timeline, summarising the key discoveries and advancements of the Angelman Syndrome:&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|- bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
!Year&lt;br /&gt;
!Milestone&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1964'''&lt;br /&gt;
|First observed by Dr Harry Angelman on three handicapped children.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot; /&amp;gt; &lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''1965'''&lt;br /&gt;
|Harry Angelman publishes his finding in a report entitled 'Puppet Children'(a report on three cases).&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1980s'''&lt;br /&gt;
|First reports of AS reaches US and research into the disorder being at the University of Florida under the direction of Dr. Charles Williams.&amp;lt;ref&amp;gt;http://www.angelmanproject.com/history.htm&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''1982'''&lt;br /&gt;
|Name changed from 'Happy Puppet' to Angelman syndrome by Williams and Frias. &lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1987'''&lt;br /&gt;
|Discovery of a genetic marker for AS – an absent genetic code on maternally derived chromosome 15. &lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''1997'''&lt;br /&gt;
|The cause of AS discovered by Dr. Joseph Wagstaff and Dr. Arthur Beaudet – mutation or deletion in the UBE3A gene.&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1998'''&lt;br /&gt;
|Transgenic mice with absent maternal UBE3A created to illustrate motor and learning deficits in addition to seizures.&amp;lt;ref name=&amp;quot;PMID9808466&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9808466&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''2007'''&lt;br /&gt;
|AS mouse model shows that neurological deficits can be reversed by decreasing levels of [[#Glossary | '''alpha-CaMKII''']] inhibitory phosphorylation.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17259980&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''2010'''&lt;br /&gt;
|Discovery of a another gene mutation in TC4 gene (on chromosome 18) in a small number of clinically diagnosed patients with no identifiable genetic alternation in UBE3A.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20184619&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''2010'''&lt;br /&gt;
|Protein named Arc identified as a target of AS gene product; UBE3A.&amp;lt;ref name=&amp;quot;PMID:20211139&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Incidence'''&lt;br /&gt;
*The current population of people diagnosed with AS is unknown but studies have estimated the number to be around 1:10,000&amp;lt;ref name=&amp;quot;PMID7573182&amp;quot; /&amp;gt; and 1:20,000&amp;lt;ref name=&amp;quot;PMID8703225&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
'''Diagnosis'''&lt;br /&gt;
*The mean age of diagnosis for patients with AS lies between 6 and 6.5 years of age.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18664077&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15741136&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Gender'''&lt;br /&gt;
* Males appear to be at higher risk for some aspects of early developmental delays in comparison to females with AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17019625&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Demography'''&lt;br /&gt;
*Europe:&lt;br /&gt;
:Denmark- 1:10,000&amp;lt;ref name=&amp;quot;PMID7573182&amp;quot; /&amp;gt;&lt;br /&gt;
:Estonia- 1:52,000&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16906556&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
:Sweden- 1:20,000&amp;lt;ref name=&amp;quot;PMID8703225&amp;quot; /&amp;gt;&lt;br /&gt;
*Australia:&lt;br /&gt;
:Western Australia- 1:40,000&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16492624&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Aetiology==&lt;br /&gt;
&lt;br /&gt;
[[File:Chromosome 15 Deletion of 15q11.2 to 15q13.jpg|thumb|100px|Chromosome 15 - The deletion occurs at 15q11.2-15q13.]]&lt;br /&gt;
&lt;br /&gt;
'''Molecular Genetics'''&lt;br /&gt;
&lt;br /&gt;
* Location: 15q11-q13&lt;br /&gt;
* Protein product: Ubiquitin protein ligase E3A&lt;br /&gt;
* Gene name: UBE3A&lt;br /&gt;
* Phenotype: Angelman Syndrome&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Genetic Causes'''&lt;br /&gt;
&lt;br /&gt;
Different genetic mechanisms lead to different clinical phenotypes of AS. The most common genetic mechanism leading to AS is the deletion or re-arrangement of maternal chromosome at [[#Glossary | '''locus''']] 15q11.2-q13,as the chromosome image shows on the right, accounting for 70% of AS occurrences.&amp;lt;ref name=&amp;quot;PMID8988171&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt; 8988171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This leads to more severe clinical phenotypes of microcephaly, motor difficulties, seizures and impaired speech development. The next most common genetic mechanism is mutation in the UBE3A gene responsible for 10% of AS cases and paternal uniparental disomy and mutation in the imprinting centre (IC), both accounting for 2-5% of AS observed.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
 &lt;br /&gt;
&lt;br /&gt;
AS is caused by the 4 major genetic mechanisms mentioned above and are thus divided into Classes I to IV based on their underlying genetic mechanism. AS patients with the clinical features of AS but no [[#Glossary | '''cytogenetic''']] or molecular abnormality in Chromosome 15q11.2-13 are grouped under Class V (summarised in table below).&amp;lt;ref name=&amp;quot;PMID8988171&amp;quot; /&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10364509&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{|  style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
! Class&lt;br /&gt;
! Mechanism&lt;br /&gt;
! Diagnostic Tests&lt;br /&gt;
! Frequency&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''Ia'''                           &lt;br /&gt;
| De novo deletion                                                                                           &lt;br /&gt;
| High resolution cytogenetics [[#Glossary | '''FISH''']]                                                                                                       &lt;br /&gt;
| 70%      &lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Ib'''&lt;br /&gt;
| Deletion due to chromosome rearrangement&lt;br /&gt;
| High resolution cytogenetics FISH&lt;br /&gt;
| &amp;lt;1%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''II'''&lt;br /&gt;
| Paternal uniparental disomy&lt;br /&gt;
| [[#Glossary | '''RFLP''']]  analysis&lt;br /&gt;
| 2%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''IIIa'''&lt;br /&gt;
| Imprinting defect with IC mutation&lt;br /&gt;
| Screening of [[#Glossary | '''IC''']]  for mutations is positive&lt;br /&gt;
| 2%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''IIIb'''&lt;br /&gt;
| Imprinting defect withouth IC mutation&lt;br /&gt;
| Screening of IC for mutations is negative&lt;br /&gt;
| 2%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''IIIc'''&lt;br /&gt;
| Mosaic imprinting defect&lt;br /&gt;
| Screening of IC for mutations is usually negative &lt;br /&gt;
| ?&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''IV'''&lt;br /&gt;
| ''UBE3A'' mutation&lt;br /&gt;
| Screening of ''UBE3A'' for mutations&lt;br /&gt;
| 5-10%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''V'''&lt;br /&gt;
| No identifiable genetic abnormality&lt;br /&gt;
| Consider other diagnoses&lt;br /&gt;
| 5-26%&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
[[File:Imprint defect inheritance in Angelman Syndrome.png|thumb|250px|Imprint defect inheritance in Angelman Syndrome]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Inheritance'''&lt;br /&gt;
&lt;br /&gt;
Angelman Syndrome from UBE3A mutations and deletions in the Imprinting Centre follow an inheritance pattern. A carrier father with the genetic defect can pass it on to his children, however, his children will be clinically normal. On the other hand, a carrier mother can pass the genetic defect onto her children, who will then have Angelman Syndrome. &lt;br /&gt;
&lt;br /&gt;
The image highlights the inheritance of Angelman Syndrome, which only results after a carrier mother passes it on to her children.&lt;br /&gt;
&lt;br /&gt;
==Pathogenesis==&lt;br /&gt;
&lt;br /&gt;
Chromosome 15 became associated with AS in the 1980s after the observation of many AS patients harboring [[#Glossary | '''microdeletions''']] of 15q11.2-15q13.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15668046&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The last decade has shed even more light in the aetiology of AS,as Kishino and Matsuura first identified UBE3A as the causative gene for AS in 1997.&amp;lt;ref name=&amp;quot;PMID:8988171&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;8988171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8988172&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Normal gene product: E6-AP ubiquitin ligase'''&lt;br /&gt;
&lt;br /&gt;
The function of UBE3A is to encode for [[#Glossary | '''E6-AP''']] ubiquitin ligase, however its function in the development of the nervous system and the process of UBE3A mutation leading to cognitive impairment in AS patients is still vague.&amp;lt;ref name=&amp;quot;PMID:20211139&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Past and current research has elucidated that E6-AP ubiquitin ligase is involved in the degradation of four proteins, listed below. Currently no protein with a direct role in [[#Glossary | '''long-term potentiation (LTP)''']] as a target of E6-AP has been identified.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12684449&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The identification of such target proteins would be a landmark discovery in further understanding of the pathogenesis, aetiology and prospective treatment strategies of AS, as LTP defects is one of the major neurological impairments of AS. &lt;br /&gt;
 &lt;br /&gt;
* p53 tumor suppressor protein &lt;br /&gt;
* yeast DNA repair protein Rad23 &lt;br /&gt;
* multicopy maintenance protein 7 subunit &lt;br /&gt;
* E6-AP&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Abnormal gene product'''&lt;br /&gt;
&lt;br /&gt;
Disruption to the gene UBE3A interferes with the normal functioning of the gene, which is its crucial role in UBE3A [[#Glossary | '''ubiquitylation''']]. Problems involving this pathway can lead to various diseases either from the loss or gain of function.&amp;lt;ref name=&amp;quot;PMID:9857172&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9857172&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In the case of AS, E6-AP is affected, leading to detrimental cognitive impairment in addition to other deficits.&amp;lt;ref name=&amp;quot;PMID:9857172&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9857172&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Regional functioning of UBE3A'''&lt;br /&gt;
&lt;br /&gt;
Despite the uncertain progression of UBE3A mutation and the neurological abnormalities characteristic of AS, animal models have illustrated the vital role of UBE3A in the normal functioning of the brain. This can be exemplified by a study which utilized a mouse model with target inactivation of the gene UBE3A resulting in the manifestation of classical features of AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11895368&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In addition, the fact that imprinting of UBE3A takes place only in specific brain regions ([[#Glossary | '''cerebellum''']] , [[#Glossary | '''olfactory tracts''']] and the [[#Glossary | '''hippocampus''']]) confirms the hypothesis that the loss of this gene would be detrimental in cognitive development.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20398390&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Most genes are inherited in copies of two, one paternal and the other maternal; however, some genes, such as UBE3A only have one functional copy as the other is silenced, coined 'imprinting'. Imprinting of the paternal copy of UBE3A takes place in some cell populations, such as the hippocampal [[#Glossary | '''neurons''']] and [[#Glossary | '''Purkinje cells''']] in the cerebellum.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9288101&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This means only the maternal UBE3A is functionally expressed in these particular brain regions. Thus a [[#Glossary | '''de novo mutation''']] in the maternal copy of the gene will result in the complete absence of functional E6-AP in the associated brain areas.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9288088&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
It is also known that UBE3A plays an important role in synaptic transmission, but exactly how it does so is still not completely understood.&amp;lt;ref name=&amp;quot;PMID:9808466&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9808466&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''UBE3A ubiquitylation'''&lt;br /&gt;
&lt;br /&gt;
As briefly mentioned above, UBE3A is a member of the E3 ubiquitin ligase family of enzymes. It is responsible for the addition of ubiquitin to the target protein for degradation of the ubiquitinated protein, as illustrated in the diagram below. These processes are required for normal human cognitive function.&amp;lt;ref name=&amp;quot;PMID:9808466&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9808466&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In this way synaptic protein [[#Glossary | '''Arc (activity-regulated cytoskeleton-associated protein)''']] is degraded to control synaptic function. Arc is a target protein of UBE3A in dendritic spines found in the hippocampal neurons.&amp;lt;ref name=&amp;quot;PMID:20668179&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20668179&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Deletion of UBE3A leads to the accumulation of Arc in neurons leading to trafficking of [[#Glossary | '''AMPA ( α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid)''']] receptors, resulting in impaired cognitive functions.&amp;lt;ref name=&amp;quot;PMID:20211139&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; [[File:UBE3A Ubiquitylation Pathway.png|thumb|350px|right|UBE3A Ubiquitylation Pathway.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
UBE3A ubiquitylation consists of:&amp;lt;ref name=&amp;quot;PMID:20668179&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20668179&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
# Activation of ubiquitin by E1 enzyme&lt;br /&gt;
# E1 ezyme transfers ubiquitin to E2 enzyme&lt;br /&gt;
# E2 enzyme transfers ubiquitin to UBE3A&lt;br /&gt;
# UBE3A attaches activated ubiquitin to target protein which is then polyubiquitylated &lt;br /&gt;
# Target protein is then degraded by 26S proteosome&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Phenotype-Genotype correlations'''&lt;br /&gt;
&lt;br /&gt;
[[File:Extent of microcephaly in Angelman Syndrome patients.png|thumb|250px|right|Extent of microcephaly in 20 AS patients with deletion and without deletion.&amp;lt;ref&amp;gt;http://www.nature.com/ejhg/index.html/&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
All AS patients show differing extents of cognitive impairment, movement disorder, characteristic behaviours and difficulty in speech and language.&amp;lt;ref name=&amp;quot;PMID:11748306&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11748306&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; However, there seems to be some phenotype-genotype correlations:&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
- 5-7Mb deletions result in the most severe phenotypes such as microcephaly, more sever [[#Glossary | '''epilepsy''']] and seizures, motor difficulties and language impairment.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9546330&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20445456&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; AS patients with large deletions also present with clinical [[#Glossary | '''hypopigmentation''']], light hair and eye colour due to the close association of OCA2 gene with UBE3A.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;16470747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Individuals under this category have in general no increased BMI&amp;lt;ref name=&amp;quot;PMID:15253756&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15253756&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This is indicated by the graph on the left, which shows more cases of AS patients with deletions having larger deviations from the mean head circumference measurement than non-deletion AS patients.&lt;br /&gt;
 &lt;br /&gt;
- AS patients with uniparental disomy (UPD) have better physical growth, fewer motor deficits and lower seizure occurrences.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16023557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
- Individuals with AS resulting from imprinting defects have the least debilitating features, such as higher developmental and language ability than AS caused by other mechanisms.&amp;lt;ref name=&amp;quot;PMID:11748306&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11748306&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
- The Body Mass Index (BMI) of 33% of the UBE3A mutation patients, and 47–64% of the patients from the classes II (UPD) and III (Imprinting defect) is above the 95th centile.&amp;lt;ref name=&amp;quot;PMID:15253756&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15253756&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Animal models'''&lt;br /&gt;
&lt;br /&gt;
* '''Drosophila'''&lt;br /&gt;
&lt;br /&gt;
Drosophila (common fruit fly) is an excellent model to use for better understanding of genetic diseases in humans as they are highly homologous to human UBE3A (hUBE3A), illustrating a high evolutionary conservation. Studies using the Drosophila model have shown that the functional absence of UBE3A resulted in decreased morphogenesis of dendritic branches. This is of interest as dendritic branches cover over 90% of the neuronal surface where [[#Glossary | '''synapse''']] between neurons occur. Proper formation and maturation of dendritic spines is also required so they come in contact with other neurons for effective transmission of neuronal signals. Thus proper formation of dendritic branching is pivitol for effective neuronal function and hence cognitive function.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18996915&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Interestingly, overexpression of dUBE3A also gave the same result, consisting of abnormal locomotion  and decreased dendritic branching in sensory neurons.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18701717&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;  This suggests a possible research field for some forms of [[#Glossary | '''autism''']] where the region containing UBE3A is duplicated, leading to delayed motor skills and seizures.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16433693&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;[[File:Normal and Angelman Syndrome mice models.jpg|thumb|250px|right|Normal and AS mice performance on the Rotarod apparatus.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
* '''Mice'''&lt;br /&gt;
&lt;br /&gt;
Absence of UBE3A in mice manifest similar phenotype to human AS, as illustrated by motor and learning deficits with inducible seizures.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21235769&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It has been shown through various mice model studies that larger deletions, ie. from UBE3A to GABRB3, more closely mirrors the large 6Mb deletions seen in human AS patients. Numerous tests, such as the Rotarod (for motor coordination and learning ability), Morris water maze test (for spatial learning and memory) and [[#Glossary | '''EEG''']] (electroencephalography), were carried out on  UBE3A null mutants, which showed the results to be abnormal or impaired.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20808828&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Other studies using mouse models have also outlined the obesity observed in 15% of AS children, albeit it is not the major characterisitics of AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17259980&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The diagram on the right clearly highlights the results obtained from such mouse model studies of AS, where the absence of UBE3A accumulated in deficits of motor function and obesity. In addition, excessive drooling and feeding difficulties were also highlighted by mice models with inactivated UBE3A, reflected by defects in fluid consumption and licking.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18413322&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Signs and Symptoms==&lt;br /&gt;
&lt;br /&gt;
Angelman Syndrome presents a variety of different phenotypes, and the presented symptoms may vary at different ages.&amp;lt;ref name=&amp;quot;PMID7625442&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7625442&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
In 1995 Williams et al. embraced the observed clinical features of AS in a consensus statement, in order to present an appliance for clinicians. The diagnostic criteria were updated in 2005.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt; The following table shows the most frequently occurring characteristics in AS patients:&lt;br /&gt;
&lt;br /&gt;
'''4 characteristics appear in 100% of the cases:'''&lt;br /&gt;
&lt;br /&gt;
*Delayed development: become apparent by the age of 6 to 12 months.&lt;br /&gt;
*Motion and or balance malfunction&lt;br /&gt;
*Behaviour patterns like unmotivated laughter, frequent excitement; often including body movements,[[File:Electroencephalography of Angelman Syndrome.jpg|thumb|350px|right|EEG of AS and normal individuals.]] [[#Glossary | '''hypermotoric''']] behaviour&lt;br /&gt;
*Impairment of speech&lt;br /&gt;
&lt;br /&gt;
'''3 characteristics appear in more than 80% of the cases:'''&lt;br /&gt;
&lt;br /&gt;
*Abnormalities in head circumference, microcephaly&lt;br /&gt;
*Seizures&lt;br /&gt;
*EEG shows specific abnormal patterns&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Angelman Syndrome individuals show the most distinct disease pattern from 2 to 16 years of age.&lt;br /&gt;
In most cases at least 8 of the symptom traits are shown.&amp;lt;ref name=&amp;quot;PMID7625442&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Behavioural Characteristics'''&lt;br /&gt;
&lt;br /&gt;
A range of substantial characteristics appear in all AS cases, regardless of the genetic mechanisms, and are often responsible for diagnosing the syndrome. According to the original name, Happy Puppet syndrome, they have shown to exhibit traits such as a happy demeanor, with frequent laughter or smiling that can easily be triggered.&amp;lt;ref name=&amp;quot;PMID12566516&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12566516&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This behaviour can already be observed in 1 to 3 month old infants.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot; /&amp;gt; Uplifted hand flapping or waving motions are associated with laughter and excitement. Other characteristics manifesting in early childhood are sleep abnormalities with reduced sleep demand, and feeding problems. Breast and bottle feeding can be difficult due to non efficient attachment to the breast, tongue thrusting and uncoordinated sucking. Furthermore, there is an affection to crinkly and reflective surfaces, like some papers or plastic materials, especially water.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID12566516 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Communication Skills'''&lt;br /&gt;
&lt;br /&gt;
Communication is challenging for AS patients due to the fact that speech impairment is present in all cases. In the majority of affected people a lack of speech development is present. Only some of them have a minimal vocabulary consisting of two or three words, a few can speak in basic sentences. Some patients use gestures to articulate themselves, the [[#Glossary | '''Picture Exchange Communication System (PECS)''']] or sign languages such as [[#Glossary | '''Makaton''']] can be used for communication. Simple demands regarding their everyday occurrence can be understood by most patients.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID12566516 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Clinical and External Characteristics'''[[File:Angelman Syndrome patient.png|thumb|200px|right|4 year old AS patient.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Developmental delays are present in all patients. Motor milestones are delayed with children managing to sit unsupported with 12 months and crawl or bottom shuffle at the age of 18-24 months. The average age for walking is 4 years,however, ranging from 18 months to 7 years.&lt;br /&gt;
The [[#Glossary | '''gait''']] is characterised as slow, and flapping hands are a common trait.  The legs remain stiff during walking, arms are inflected by the wrists and elbows. The movements can appear ataxic, jerky or lurching. The muscle tone shows abnormalities with truncal [[#Glossary | '''hypotonia''']] and [[#Glossary | '''hypertonicity''']] of the limbs and alert reflexes.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID12566516 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The most striking external traits present in patients include broad-spaced teeth, and a wide mouth, light hair and eye colour, hypopigmented skin, deep set eyes, and a flat [[#Glossary | '''occiput''']].&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Seizures in Angelman Syndrome'''&lt;br /&gt;
&lt;br /&gt;
85% of AS patients suffer from epileptic seizures during their first three years. The first appearance can be within one month up to 20 year old patients. In infants with AS epilepsy manifests with [[#Glossary | '''febrile convulsions''']] and is hard to manage during childhood.&lt;br /&gt;
The most common type of seizures within 25% of patients are [[#Glossary | '''myoclonic seizures''']], followed by [[#Glossary | '''atonic seizures''']] as the second most frequent type, then 21% experience generalised [[#Glossary | '''tonic-clonic seizures''']] and lastly [[#Glossary | '''atypical absences''']] occur in 12% of patients.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20398390&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Angelman Syndrome in adults'''&lt;br /&gt;
&lt;br /&gt;
Patients with Angelman syndrome possess normal secondary sexual characteristics, and puberty sets in at a usual time. Limb hypertonicity, and [[#Glossary | '''thoracic scoliosis''']] lead to decreasing mobility. [[#Glossary | '''Oesophagus reflux''']] might induce severe problems, and the majority suffers from obesity. Furthermore, facial traits such as a prominent lower lip [[#Glossary | '''macrostomia''']] and [[#Glossary | '''mandibular prognathism''']] get manifested in adults. &lt;br /&gt;
In some cases the communication barrier can lead to frustration, resulting in aggressive behaviour. Nonetheless, patients gain a higher concentration span with age, and their nature becomes more quiet.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Complications===&lt;br /&gt;
&lt;br /&gt;
'''Hypopigmentation and Ocular albinism'''&lt;br /&gt;
&lt;br /&gt;
OCA2 gene, also known as the P gene, is closely located to the UBE3A gene. It encodes a protein vital to tyrosine metabolism, which plays a role in pigmentation development of skin, hair and eyes. However, AS caused by the large deletion of UBE3A leads to haploinsufficiency of OCA2 gene, resulting in hypopigmentation of the skin and the eyes. In some children with severe hypopigmentation, some form of [[#Glossary | '''albinism''']] is suspected.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12749060&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; When AS is caused by another mechanism, no abnormality of the skin and eye pigmentation is observed. However, not all AS children with OCA2 gene deletion will present with obvious hypopigmentation, they may just exhibit lighter skin colour than their parents.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8302318&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Diagnosis==&lt;br /&gt;
&lt;br /&gt;
The diagnosis of Angelman Syndrome is a clinical diagnosis confirmed by laboratory testing.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This involves both prenatal and/or postnatal diagnosis. &lt;br /&gt;
&lt;br /&gt;
===Prenatal Diagnosis===&lt;br /&gt;
[[File:Angelman Syndrome Prenatal Diagnosis.jpg|thumb|250px|right|Flowchart of AS Diagnosis.]]&lt;br /&gt;
&lt;br /&gt;
Prenatal detection of deletions of 15q11.2-q13, [[#Glossary | '''Paternal UPD''']] (Uniparental Disomy), Imprinting defects and UBE3A mutations are done through DNA/chromosome/FISH analysis of fetal cells obtained by either [[#Glossary | '''Chorionic Villus Sampling''']](CVS) or [[#Glossary | '''Amniocentesis''']].&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot;/&amp;gt; &lt;br /&gt;
DNA methylation analysis using [[#Glossary | '''Amniocytes''']] is usually the first test carried out in molecular diagnosis of AS.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18059071&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; An abnormal result is followed up by either a FISH or array CGH analysis to search for a deletion on chromosome 15. If they produce a normal result, then UPD testing using DNA polymorphysims is carried out. If there is no evidence of UPD, other DNA analysis tests are used search for an imprinting centre deletion.&amp;lt;ref name=&amp;quot;PMID9792887&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9792887&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; A normal DNA methylation analysis is followed by a UBE3A sequence analysis.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt; In addition, a parent of origin test is also done to determine if the genetic disruption is of maternal origin or paternal origin. If it is maternally derived the fetus is diagnosed with AS (a paternally derived genetic disruption is indicative of Prader-Willi Syndrome).&amp;lt;ref name=&amp;quot;PMID17020468&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;17020468&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The flow chart summarizes the normal procedure used for prenatal diagnosis of AS. More information on important laboratory tests used for the diagnosis of Angelman Syndrome are provided below:&lt;br /&gt;
&lt;br /&gt;
*'''DNA Methylation Analysis'''&lt;br /&gt;
&lt;br /&gt;
Identifies approximately 80% of AS affected individuals and is usually the first test to be ordered.&amp;lt;ref name=&amp;quot;PMID7618904&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7618904&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Molecular disruptions such as deletions, paternal UPD and imprinting defects on chromosome 15 all demonstrate abnormal methylation patterns by either southern blot analysis or PCR amplification of bisulphate-treated DNA.&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot; /&amp;gt; An affected individual will only have an unmethylated (paternal) SNRPN (small nuclear ribonuclear protein-associated polypeptide N) allele compared with an unaffected individual who will have both a methylated and an unmethylated SNRPN allele.&amp;lt;ref name=&amp;quot;PMID9634532&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9634532&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
	  &lt;br /&gt;
*'''FISH (Fluorescent In Situ Hybridization)'''&lt;br /&gt;
&lt;br /&gt;
[[File:Critical_region_of_Angelman_Syndrome_on_chromosome_15.png‎|thumb|150px|right|FISH (fluorescence in situ hybridisation) image showing the critical region of Angelman Syndrome on chromosome 15.]]&lt;br /&gt;
&lt;br /&gt;
FISH analysis detects 5-7 Mb deletions in approximately 68% of affected individuals using detecting probes such as D15S10 and/or SNRPN.&amp;lt;ref name=&amp;quot;PMID7618904&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7618904&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It is also able to distinguish UPD from micro-deletions and imprinting defects. In simple terms, FISH analysis involves the binding of a fluorescent probe to a specific part of chromosome 15 and the detection of deletions within that region. FISH analysis is much more accurate in deletion detection compared to other high-resolution cytogenetics in the diagnosis of AS patients.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1511093&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
Array-based CGH is an advanced type of cytogenetic testing that can also be used to detect smaller deletions.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''UPD (Uniparental Disomy) Detection'''&lt;br /&gt;
&lt;br /&gt;
DNA Polymorphism testing detects paternal UPD in approximately 7% of affected AS individuals.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt; It is also able to distinguish between UPD and an Imprinting defect. It requires a DNA sample from the [[#Glossary | '''Proband''']] and from both parents. A homologous or non-homologous whole-arm translocation of the long arms of chromosome 15 is a sound indication for the need for prenatal UPD testing.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''IC (Imprinting Center) Analysis'''&lt;br /&gt;
&lt;br /&gt;
This type of analysis is used when individuals have an abnormal DNA methylation pattern but show normal results for  FISH, array CGH study and UPD analysis.&amp;lt;ref name=&amp;quot;PMID9792887&amp;quot;/&amp;gt; It is used to differentiate between the Imprinting defects caused by either microdeletions in the AS imprinting centre or by epigenetic mutations (that occur in maternal oogenesis or early embryogenesis).&amp;lt;ref name=&amp;quot;PMID9634532&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''Cytogenetic Testing'''&lt;br /&gt;
&lt;br /&gt;
Is used to detect a cytogenetically visible chromosomal rearrangement (large deletion, translocation or inversion) involving the 15q11.2-q13 region, which occurs in less than 1% of affected individuals.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''UBE3A Sequence Analysis'''&lt;br /&gt;
Sequence analysis of the UBE3A gene detects mutations in about 10% of the patients.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt; The test is used to detect either multiexonic (10 major coding exons of UBE3A) or whole gene deletions of UBE3A gene in individuals who produces a normal DNA methylation result but has characteristic clinical features of AS.&amp;lt;ref name=&amp;quot;PMID9792887&amp;quot;/&amp;gt;&lt;br /&gt;
This is recommended as a prenatal diagnostic tool in families that include multiple AS affected individuals because the imprinted pattern can be inherited from distant relatives.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Postnatal Diagnosis===&lt;br /&gt;
&lt;br /&gt;
Postnatal diagnosis is made though a combination of common clinical features of AS and UBESA gene sequence analysis.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt; The clinical features of AS include unsteady or shaky movements, muscle hypotonia, developmental delay and behavioral uniqueness such as frequent laughter/smiling and happy demeanor are features that are 100% consistent in all patients diagnosed with Angelman Syndrome.&amp;lt;ref name=&amp;quot;PMID18830393&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18830393&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; These clinical features become apparent between 6 months to 2 years of age. The onset of early or persistent smiling characteristic of this syndrome begin around the age of 1-3 months, but is often overlooked during infancy.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot;/&amp;gt; Thus early diagnosis of AS during infancy period is difficult because the clinical indicators of the syndrome takes time to manifest and characteristic features such as finger and hand tremors and excessive smiling/laughter are often overlooked and not considered as possible indicators of this syndrome.&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
*Rett Syndrome&lt;br /&gt;
&lt;br /&gt;
Some children with the clinical diagnosis of AS but no underlying genetic mechanism show mutations in ''MECP2'' gene, corresponding to Rett Syndrome. This should be suspected in AS test negative girls in the first few years of life.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17980307&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*Mowat-Wilson Syndrome&lt;br /&gt;
&lt;br /&gt;
Genetic mechanism is heterozygous deletion or truncation in ''ZFHX1B'' (''SIP1'') gene on 2q22. This presents with clinical features of severe intellectual disability, micrcephaly and seizures.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17958891&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Prader-Willi Syndrome patient.png|thumb|right|120px|12 year old PWS patient.]]&lt;br /&gt;
&lt;br /&gt;
*X-linked alpha-thalassemia/mental retardation syndrome (ATR-X)&lt;br /&gt;
&lt;br /&gt;
This arises from mutations in ''XNP'' gene on Xq13. ATR-X presents with severe intellectual disability, no speech development and seizures are common.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11449489&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*Phelan-McDermid Syndrome/22q13 deletion syndrome&lt;br /&gt;
&lt;br /&gt;
Deletions are usually submicroscopic and thus requires special molecular cytogenetic methods to confirm this deletion. Patients show moderate to profound intellectual disability and delay in speech development.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18505557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Related Disease'''&lt;br /&gt;
&lt;br /&gt;
*Prader-Willi Syndrome(PWS)&lt;br /&gt;
&lt;br /&gt;
PWS is a result from the absence of paternally expressed 15q11-q13 gene as a corollary of de novo deletion, maternal uniparental disomy of chromosome 15 or an imprinting defect on paternal chromosome 15 leading to the silencing of paternal alleles.&amp;lt;ref name=&amp;quot;PMID:20668179 &amp;quot;/&amp;gt; It is characterized by [[#Glossary | '''hyperphagia''']], obesity in later infancy and early childhood and difficulty in feeding during early infancy.&amp;lt;ref name=&amp;quot;PMID:20668179 &amp;quot;/&amp;gt; There is also cognitive impairment to some extent, though some PWS patients may exhibit intelligence in the normal IQ range. Behavioral phenotypes include stubbornness, manipulative tendency, obsessive compulsive characteristics.&amp;lt;ref name=&amp;quot;PMID:20668179 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Genetic Counselling==&lt;br /&gt;
&lt;br /&gt;
Genetic counselling is the process by which patients or relatives, at risk of an inherited disorder, are advised of the consequences and nature of the disorder, the probability of developing or transmitting it, and the options open to them in management and family planning. In the case for Angelman syndrome, types of risks associated are split into classes and formatted into the table below:&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20459762&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{|  style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
! Class&lt;br /&gt;
! Mechanism&lt;br /&gt;
! Risk to siblings&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! Ia                           &lt;br /&gt;
| De novo deletion                                                                                                               &lt;br /&gt;
| &amp;lt;1%                                                                                                                &lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! Ib&lt;br /&gt;
| Deletion due to chromosome rearrangement&lt;br /&gt;
| Up to 50%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! II&lt;br /&gt;
| Paternal uniparental disomy (UPD)&lt;br /&gt;
| &amp;lt;1%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! IIIa&lt;br /&gt;
| Imprinting defect with IC mutation&lt;br /&gt;
| Close to 100% if father has 15; 15 [[#Glossary | '''Robertsonian translocation''']]&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! IIIb&lt;br /&gt;
| Imprinting defect without IC mutation&lt;br /&gt;
| Up to 50% (if mother has IC deletion)&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! IIIc&lt;br /&gt;
| [[#Glossary | '''Mosaic''']] imprinting defect&lt;br /&gt;
| &amp;lt;1%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! IV&lt;br /&gt;
| ''UBE3A'' mutation&lt;br /&gt;
| Up to 50% (if mother has mutation)&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! V&lt;br /&gt;
| No identifiable genetic abnormality&lt;br /&gt;
| ?&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Ia''': Individuals with de novo deletion have 1% risk to siblings&lt;br /&gt;
&lt;br /&gt;
'''Ib''': Risk to siblings in individuals with chromosomal rearrangements is up to 50% &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9557895&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''II''': Paternal UPD with no Robertsonian translocation has a risk to sibling of less than 1%&lt;br /&gt;
&lt;br /&gt;
'''IIIa''': The risk to siblings in individuals with AS from an imprinting defect with a mutation in the imprinting center (IC) is close to 100% if father has 15;15 Robertsonian translocation&lt;br /&gt;
&lt;br /&gt;
'''IIIb''': Individuals with AS resulting from an imprinting defect without IC mutation, but with a carrier mother has a high risk to siblings of up to 50%. The mother could be phenotypically normal due to paternal inheritance of the genetic defect &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11283796&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''IIIc''': Individuals who are mosaic for the imprinting defect have less than 1% risk to siblings&lt;br /&gt;
&lt;br /&gt;
'''IV''': UBE3A mutation can be either inherited or de novo mutation. If the mother is a carrier for this genetic mutation, the risk to siblings is up to 50% &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11258627&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''V''': Individuals who present with AS clinically, but have no known underlying mechanism have an unknown risk to siblings.&lt;br /&gt;
&lt;br /&gt;
==Treatment and Management==&lt;br /&gt;
&lt;br /&gt;
Even though at present there is no known cure for Angelman syndrome, there are a number of treatments available that may alleviate symptons and improve daily life activities.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The below table describes the problems and management options that are used:&lt;br /&gt;
&lt;br /&gt;
[[File:Subtle Finger tremors-Angelman Syndrome.jpg|right|thumb|150px|A five months old boy with Angelman syndrome showing signs of Subtle Finger tremor.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
! Problems encountered&lt;br /&gt;
! Treatment and Management&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''Difficulty in feeding newborn AS babies'''&lt;br /&gt;
| Use of special nipples may improve feeding&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Oesophagus reflux'''&lt;br /&gt;
| Special motility medications requiried or upright positioning&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''Seizures'''&lt;br /&gt;
| Anticonvulsant medications&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19605773&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19453717&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Ocular problems'''&lt;br /&gt;
| Visual assessment is vital to encourage interactions and minimize chances of self-harm and autism development&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20656169&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''Drooling in developmental delayed AS patients'''&lt;br /&gt;
| Difficult to treat, but new surgical procedure on salivary duct reimplantation seems to be a promising alternative&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17699119&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Unstable children''' &lt;br /&gt;
| Physical therapy&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''AS patients become less active with increasing age'''&lt;br /&gt;
| Activity schedules to prevent scoliosis and obesity. Occupational therapy to stimulate fine motor and oral-motor control skills in conjunction to speech therapy&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Sleeping difficulty'''&lt;br /&gt;
| Sedative medication in severe cases. [[#Glossary | '''Melatonin''']] may be used to promote sleeping but some studies have found that it loses its therapeutic effects after several weeks in most AS patients&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19379289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|-&lt;br /&gt;
|colspan=&amp;quot;4&amp;quot; |&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Prognosis==&lt;br /&gt;
&lt;br /&gt;
Life expectancy of AS patients seems to be normal&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, but there is still a high degree of developmental delay and limited expressive language skills.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17019625&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This problem arises prominently in the assessment of the severity of coincidental medical conditions due to difficulties in communication. A visit to the dentist can become difficult if good communication is not conveyed between the parents, the dentist, and the child.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18271768&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Some problems require extreme measures, such as the procedure of lens implantation was performed in both eyes of a person diagnosed with AS, due to the inability to wear spectacles.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20656169&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
During adulthood, menstruation and puberty begin at around average age evidenced by females with Angelman syndrome that are fully capable of conceiving children.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11258627&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Most adult patients can feed themselves, but needed help with many other daily activities. Main troubles which have shown in adults are a tendency to become obese and start developing  thoracic scoliosis, which some adults with AS begin wheelchair bounded.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9072912&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Current and Future Research==&lt;br /&gt;
&lt;br /&gt;
Currently there is no cure for the treatment of AS, so much research is being carried out for therapeutic interventions. Findings in the last five years have suggested through various mice and fruit fly models that the absence of maternal UBE3A results in the same human AS features of neurological defects and seizures. However, more recently, studies have outlined that the symptoms of AS can be improved by modifying other gene products. In addition, restoring of a functional UBE3A protein into adult mice neurons have shown to reduce motor and neurological deficits and balance disorders. This shows promising research prospects in that improvements may be possible in human AS patients by restoring functional UBE3A proteins into their neurons. &lt;br /&gt;
&lt;br /&gt;
===Possible Treatment Pathways===&lt;br /&gt;
&lt;br /&gt;
*'''Cognitive and physical impairment'''&lt;br /&gt;
&lt;br /&gt;
Although everyone is born with two copies of the gene UBE3A, one maternal and one paternal copy, it is only the maternal UBE3A that is used in the brain. Most AS patients have a genetic mutation on the maternal chromosome 15 that results in dysfunctional UBE3A.&amp;lt;ref&amp;gt;http://www.cureangelman.org/what-hope.html&amp;lt;/ref&amp;gt; The above research focused on turning on the father's copy of UBE3A to restore its functions. Furthermore, mouse models were utilized to show that alpha-CaMKII could be increased to compensate the loss of UBE3A and restore compromised mental and physical abilities. However, this finding still requires much more research.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17259980&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''Epilepsy'''&lt;br /&gt;
&lt;br /&gt;
There is research being done on improving certain conditions that are involved in AS by nutritional benefits. The use of [[#Glossary | '''corticosteroids''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19666884&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, [[#Glossary | '''valproate''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19453717&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and [[#Glossary | '''clonazepam''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19605773&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and having a [[#Glossary | '''ketogenic diet''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20880305&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; has all been shown to aid in the treatment of epilepsy. It has also been reported to be efficient in the treatment of other conditions, such as behavioural disorders, reduction in seizures, ataxia, sleep patterns, developmental progress and sleep disturbances. [[#Glossary | '''Levetiracetam''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17326790&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; could be used in such a situation, especially when the patient has an intolerance to valproate and clonazepam.&lt;br /&gt;
&lt;br /&gt;
*'''Betaine and Folic acid'''&lt;br /&gt;
&lt;br /&gt;
This double-blind placebo-controlled study was done to examine the potential therapeutic role of [[#Glossary | '''betaine''']] and [[#Glossary | '''folic acid''']] in the treatment of the clinical phenotypes of AS. The aim of this protocol was to increase methylation and activate the paternally inherited UBE3A in hope to compensate for the inactive maternal UBE3A. Although there were no major differences in the control and treatment groups, a small number of patients in the treatment group showed some positive outcomes.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20635355&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&lt;br /&gt;
'''albinism''': A congenital disorder distincted by the complete or partial absence of pigment in the skin, hair and eyes due to defect of an enzyme involved in the production of melanin.&lt;br /&gt;
&lt;br /&gt;
'''allele''': Dissimilar variant of one gene. Organisms have two alleles for each gene inherited from their parents, one from each of them.&lt;br /&gt;
&lt;br /&gt;
'''alpha-CaMKII''': (alpha calcium calmodulin kinase II) Compound involved in synaptic plasticity, one of the most important theories behind learning and memory. Ability of a synapse between two neurons to change in strength due to the use or disuse of transmission.&lt;br /&gt;
&lt;br /&gt;
'''Amniocytes''': Cells that are shed by the fetus during fetal development to the surrounding amniotic fluid. They are a source of fetal DNA. &lt;br /&gt;
&lt;br /&gt;
'''Amniocentesis''': (AFT or amniotic fluid test) is a prenatal diagnostic test used to detect chromosomal abnormalities in the developing fetus by extracting amniotic fluid (a source of fetal DNA) surrounding the fetus. &lt;br /&gt;
&lt;br /&gt;
'''AMPA''': (2-amino-3-(5-methyl-3-oxo-1,2- oxazol-4-yl)propanoic acid) Compound that binds to the AMPA receptor to imitate glutamate neurotransmitter.&lt;br /&gt;
&lt;br /&gt;
'''Arc''': Activity-Regulated Cytoskeleton-associated protein; involved in learning and memory.&lt;br /&gt;
&lt;br /&gt;
'''ataxia''': Lack of coordination in muscle movements.&lt;br /&gt;
&lt;br /&gt;
'''atonic seizures''': A abrupt loss of muscle tone, this can lead to the limbs loosing strength, or the head may drop to the side. The patient remains conscious during this kind of epileptic seizure.&lt;br /&gt;
&lt;br /&gt;
'''atypical absences''': Seizure leads to unconsciousness in most cases.  &lt;br /&gt;
&lt;br /&gt;
'''autism''': A neural development disorder defined by limited social interaction and communication.&lt;br /&gt;
&lt;br /&gt;
'''betaine''': Also known as  betaine anhydrous or trimethylglycine (TMG), assists the body in metabolising the amino acid, homocysteine. Can be consumed via beets, broccoli, grains, shellfish, and spinach.&lt;br /&gt;
&lt;br /&gt;
'''cerebellum''': Region of the brain that plays an important role in motor control. It is also involved in some cognitive functions such as attention and language.&lt;br /&gt;
&lt;br /&gt;
'''Chorionic Villus Sampling''': A prenatal diagnostic test used to detect chromosomal abnormalities in the developing fetus by extracting and testing chorionic villus (placental tissue). &lt;br /&gt;
&lt;br /&gt;
'''chromosome''': Structure consisting of coiled DNA with DNA associated proteins such as histones.&lt;br /&gt;
&lt;br /&gt;
'''clonazepam''': A psychoactive drug having muscle relaxant properties and treats anxiety and epilepsy.&lt;br /&gt;
&lt;br /&gt;
'''corticosteroid''': A type of steroid hormones that are produced in the adrenal cortex.&lt;br /&gt;
&lt;br /&gt;
'''cytogenetics''': Study of the structure, function and abnormality of the cell, especially the chromosome.&lt;br /&gt;
&lt;br /&gt;
'''deletion''': Lack of a part of the DNA (deoxyribonucleic acid is a nucleic acid containing information for protein synthesis), can vary form a single base to a hole gene. &lt;br /&gt;
&lt;br /&gt;
'''de novo mutation''': Change in a gene of a family member for the first time due to a mutation in the egg or sperm of the parents or in the fertilized egg (zygote).&lt;br /&gt;
&lt;br /&gt;
'''disorder''': A mental or physical health disturbance or dysfunction.&lt;br /&gt;
&lt;br /&gt;
'''EEG''': Electroencephalography is a means of measuring electrical activity along the scalp by measuring the total electrical charges fired by thousands or millions of neurons.&lt;br /&gt;
&lt;br /&gt;
'''epilepsy''': Neurological disorder characterised by recurrent impairment of brain function that can cause seizures or unconsciousness. &lt;br /&gt;
&lt;br /&gt;
'''E6-AP''': E6-AP ubiquitin-protein ligase is an enzyme encoded by UBE3A which adds ubiquitin chain to target proteins to be degraded by proteasomes.&lt;br /&gt;
&lt;br /&gt;
'''febrile convulsions''': The occurrence of high fever, especially in children.&lt;br /&gt;
&lt;br /&gt;
'''FISH''': Fluorescent in situ hybridization is a technique used to identify and localize the presence or absence of DNA sequences on the chromosome. This is achieved by using fluorescently labelled DNA sequences which then binds to complementary DNA sequence on the chromosome. After hybridization (attachment), chromosome of interest will fluoresce under the microscope.&lt;br /&gt;
&lt;br /&gt;
'''folic acid''': B vitamin that helps the body make healthy new cells. Can be consumed via leafy green vegetables, fruits, dried beans, peas and nuts.&lt;br /&gt;
&lt;br /&gt;
'''gait''': A manner of walking, stepping or running.&lt;br /&gt;
&lt;br /&gt;
'''gene''': A molecular unit of heredity of a living organism.&lt;br /&gt;
&lt;br /&gt;
'''hippocampus''': Area buried deep in the forebrain that helps regulate emotion and memory&lt;br /&gt;
&lt;br /&gt;
'''hyperphagia''': (Also referred to as Polyphagia) Excessive ingestion of food beyond the dietary and energy requirements of the body. &lt;br /&gt;
&lt;br /&gt;
'''hypermotoric''': Sudden appearance of uncontrolled movements such as striking or kicking inappropriately.&lt;br /&gt;
&lt;br /&gt;
'''hypertonicity''': Increase of muscle tension and a disability to stretch leading to an impairment of motor activity.&lt;br /&gt;
&lt;br /&gt;
'''hypopigmentation''': A lack of melanin pigments or melanocytes  affecting the colour of the skin, hair and iris. Features appear to be light-coloured due to loss of skin colour.&lt;br /&gt;
&lt;br /&gt;
'''hypotonia''': Decrease in the ability to stretch passively, due to a low muscle tone. &lt;br /&gt;
&lt;br /&gt;
'''imprinting''': This is a process to describe the modification of a maternally or paternally derived chromosome, which consequently influences the expression of certain genes on the altered chromosome.&lt;br /&gt;
&lt;br /&gt;
'''ketogenic diet''': A high-fat, low-carbohydrate diet that is used to treat epilepsy in children.&lt;br /&gt;
&lt;br /&gt;
'''levetiracetam''': An anticonvulsant drug used to treat epilepsy.&lt;br /&gt;
&lt;br /&gt;
'''locus''': Location of a gene on a chromosome(loci: plural for locus).&lt;br /&gt;
&lt;br /&gt;
'''LTP''': Long-term potentiation shares common features with long term memory. It strengthens and enhances signal transmission between neurons by improving the communication between two neurons.&lt;br /&gt;
&lt;br /&gt;
'''macrostomia''': A wide-spaced mouth.&lt;br /&gt;
&lt;br /&gt;
'''Makaton''': Language programme using symbols and signs to support speaking.&lt;br /&gt;
&lt;br /&gt;
'''mandibular prognathism''': The abnormal protrusion of the lower jaw. &lt;br /&gt;
&lt;br /&gt;
'''maxillary hypoplasia''':  The underdevelopment of the upper jaw.&lt;br /&gt;
&lt;br /&gt;
'''melatonin''': A hormone secreted by the pineal gland.&lt;br /&gt;
&lt;br /&gt;
'''microcephaly''': The circumference of the head is less than average due to abnormalities of the nervous system. This abnormality can be present at birth or emerge during the first few years of life and reduces both life expectancy and the cognitive functions of the individual affected.&lt;br /&gt;
&lt;br /&gt;
'''microdeletion''':  A genetic mutation in which a part of a chromosome or a sequence of DNA is missing.&lt;br /&gt;
&lt;br /&gt;
'''mosaic''': tissues or cells containing different mixture of genetic sequences&lt;br /&gt;
&lt;br /&gt;
'''mutation''': Event that changes the DNA (deoxyribonucleic acid is a nucleic acid, containing information for protein synthesis) or RNA (ribonucleic acid is a type of nucleic acid transmitting the information from the DNA to the proteins ) of a gene permanently.&lt;br /&gt;
&lt;br /&gt;
'''myoclonic seizures''': A quick jerk of the skeletal muscle, due to a irregular brain activity.&lt;br /&gt;
&lt;br /&gt;
'''neurogenetic''': Genetic basis of the nervous system.&lt;br /&gt;
&lt;br /&gt;
'''neuron''': Cells of the nervous system that can be electrically excited to transmit information by electrical and chemical signaling&lt;br /&gt;
&lt;br /&gt;
'''neurotransmitter''': Transmits neuronal signals to a target cell. They are first packaged in vesicles just beneath the membrane of presynaptic axon terminals and released into the synaptic cleft (space between the two interacting neurons) and enter the postsynaptic dendrite.&lt;br /&gt;
&lt;br /&gt;
'''occiput''': The back portion of the head.&lt;br /&gt;
&lt;br /&gt;
'''oesophagus reflux''': Impairment of a sphincter in the lower end of the oesophagus leads to the back flow of stomach acid into the oesophagus. Heartburn is a typical symptom.&lt;br /&gt;
&lt;br /&gt;
'''olfactory tract''': It is a pathway for the sense of smell containing axons from some of the neurons in the olfactory bulb.&lt;br /&gt;
&lt;br /&gt;
'''paediatrician''': Physicians that specialise on infants, children and adolescents.&lt;br /&gt;
&lt;br /&gt;
'''paternal UPD''': Inheritance of two copies of a chromosome from the father and none from the mother. &lt;br /&gt;
&lt;br /&gt;
'''phenotype''': Visible traites of an organism determined by genetic and environmental factors.&lt;br /&gt;
&lt;br /&gt;
'''Picture Exchange Communication System (PECS)''': Individuals communicate using images instead of words. It is frequently used by children with autism, to articulate their needs and wishes or to make comments about something.&lt;br /&gt;
&lt;br /&gt;
'''Proband''': Is the person (or animal) being studied or reported on in a genetic investigation. Most commonly it refers to the first affected family member who requires medical help for a genetic disorder. &lt;br /&gt;
&lt;br /&gt;
'''Purkinje cells''': Large neuron with many branching extensions that is found in the cortex of the cerebellum of the brain and plays a fundamental role in controlling motor movement&lt;br /&gt;
&lt;br /&gt;
'''Robertsonian translocation''': Rearrangement of the chromosome, occurs in 5 chromosome including 13,14,15,21 and 22. This type of mutation occurs in chromosomes with the centromere not at the centre, resulting in long and short arm chromosomes. Translocation breaks the chromosome at the centromere so the long arm attaches to the other long arm, and the same for the short arm happens. Cell division will result in the loss of the short arms as they do not contain important genes.&lt;br /&gt;
&lt;br /&gt;
'''seizure''': Abnormal electrical activity in the brain that can result in a variety of physical symptoms like convulsion, body shaking, loss of consciousness, confusion, and mood changes.&lt;br /&gt;
&lt;br /&gt;
'''synapse''': Allows transmission of signal between neurons for effective neuronal function.&lt;br /&gt;
&lt;br /&gt;
'''thoracic scoliosis''': The spine is curved laterally(from side to side) in the thoracic region.&lt;br /&gt;
&lt;br /&gt;
'''tonic-clonic seizures''': This type of seizure is associated with unconsciousness due to electrical discharges in a big proportion of the brain.&lt;br /&gt;
&lt;br /&gt;
'''ubiquitin''': A polypeptide found in all eukaryotic cells, that participates in a variety of cellular functions including protein recycling.&lt;br /&gt;
&lt;br /&gt;
'''Uniparental disomy''': (UPD) the inheritance of two copies of a chromosome pair or part of a chromosme from one parent and no copy from the other parent. &lt;br /&gt;
&lt;br /&gt;
'''valproate''':  A mood-stabilizing drug that is also used for treatment for epilepsy and bipolar disorder.&lt;br /&gt;
&lt;br /&gt;
==Helpful Links==&lt;br /&gt;
&lt;br /&gt;
* Australia&lt;br /&gt;
:* [http://www.angelmansyndrome.org/research.html Angelman Syndrome Association] &lt;br /&gt;
:* [http://www.angelmansyndromeqld.org/ Queensland Angelman Association]&lt;br /&gt;
&lt;br /&gt;
* America&lt;br /&gt;
:* [http://www.angelman.org/ Angelman Syndrome Foundation]&lt;br /&gt;
:* [http://rarediseasesnetwork.epi.usf.edu/arpwsc/ Rare Clinical Diseases Research Network]&lt;br /&gt;
:* [http://www.rarediseases.org/rare-disease-information/rare-diseases/byID/411/viewAbstract National Organisation for Rare Disorders]&lt;br /&gt;
:* [http://www.epilepsyfoundation.org/ Epilepsy Foundation]&lt;br /&gt;
:* [http://www.cureangelman.org/ Foundation for Angelman Syndrome Therapeutics]&lt;br /&gt;
&lt;br /&gt;
* Search Pubmed &lt;br /&gt;
:* [http://www.ncbi.nlm.nih.gov/pubmed?term=angelman%20syndrome Angelman Syndrome] &lt;br /&gt;
&lt;br /&gt;
* OMIM entries for Angelman Syndrome&lt;br /&gt;
:* [http://omim.org/entry/105830 ANGELMAN SYNDROME; AS]&lt;br /&gt;
:* [http://omim.org/entry/601623 UBIQUITIN-PROTEIN LIGASE E3A; UBE3A]&lt;br /&gt;
&lt;br /&gt;
==Related Links==&lt;br /&gt;
&lt;br /&gt;
'''Animal Models'''&lt;br /&gt;
&lt;br /&gt;
* [[Mouse Knockout]] - this page explains the current use of mouse models in disrupting genes to elucidate their genetic function, including the mouse gene knockouts for alpha calcium-calmodulin kinase II (alpha CaMKII)&lt;br /&gt;
* [[2009 Group Project 4]] - this page gives an extensive overview on the history of the mouse model and its various use in embryology and genetics. In addition, it also describes mouse knockout and the role they play in current research of various human diseases&lt;br /&gt;
* [[Fly Development]] - this page describes the use of drosophila flies as developmental models&lt;br /&gt;
* [[2009 Group Project 2]] - this page gives an extensive overview on the history of the fly model and its various use in embryology and genetics&lt;br /&gt;
&lt;br /&gt;
'''Diagnosis'''&lt;br /&gt;
* [[Chorionic villus sampling]] - this page explains the process of chorionic villus sampling, its disadvantages and gives a brief overview of recent findings&lt;br /&gt;
* [[Amniocentesis]]- this page shows some of the recent findings in this area&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&lt;br /&gt;
&amp;lt;references /&amp;gt;&lt;/div&gt;</summary>
		<author><name>Z3291643</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_7&amp;diff=77824</id>
		<title>2011 Group Project 7</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_7&amp;diff=77824"/>
		<updated>2011-10-13T02:21:14Z</updated>

		<summary type="html">&lt;p&gt;Z3291643: /* History */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;='''Angelman Syndrome'''=&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Introduction==&lt;br /&gt;
&lt;br /&gt;
[[File:Dr Harry Angelman.jpg|thumb|130px|right|Dr Harry Angelman.]]&lt;br /&gt;
Angelman syndrome (AS) is a rare [[#Glossary | '''neurogenetic''']] [[#Glossary | '''disorder''']] first described by Dr. Harry Angelman in 1965.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18754889&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Dr. Angelman was an English [[#Glossary | '''paediatrician''']] who first diagnosed the disease in 3 children with a developmental delay.&amp;lt;ref&amp;gt;http://www.ncbi.nlm.nih.gov/books/NBK22221/&amp;lt;/ref&amp;gt; AS occurs in 1 in 10000-20000 births, the exact number is still unknown.&amp;lt;ref name=&amp;quot;PMID7573182&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7573182&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;PMID8703225&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;8703225&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It is caused by maternal [[#Glossary | '''allele''']] disruptions of a single gene- UBE3A. Either [[#Glossary | '''mutations''']] or [[#Glossary | '''deletions''']] of the UBE3A gene results in AS. &lt;br /&gt;
&lt;br /&gt;
AS presents with well known [[#Glossary | '''phenotypes''']] during infancy and adulthood, such as [[#Glossary | '''microcephaly''']] and [[#Glossary | '''maxillary hypoplasia''']]. However, these features become more marked with age. Most frequent clinical features include delayed development,[[#Glossary | '''seizures''']],[[#Glossary | '''ataxia''']], impairment of speech, happy demeanor, behavioural problems such as hyperactivity, short attention span and sleeping difficulty.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21592595&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21484597&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;ASAwebsite&amp;quot;&amp;gt;http://www.angelmansyndrome.org/home.html&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
At present, there is no cure for the syndrome, though current research is focused at improving life quality of patients with Angelman syndrome through management of daily tasks.&amp;lt;ref&amp;gt;http://www.bbc.co.uk/health/physical_health/conditions/angelman1.shtml&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==History==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Dr. Harry Angelman first reported Angelman Syndrome on three handicapped children that were admitted to his ward in England in 1964.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt; He reported how these three independent and unconnected clinical cases all had the same characteristic features of severe developmental delay, jerky movements, seizures and a happy disposition.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt; However it was only when he stumbled upon an oil painting called ‘a Boy with a Puppet” while on a holiday in Italy he was able to connect the symptoms of all three children under one common cause.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20981772&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; He linked the happy face of the boy depicted on the painting with the jerky movements and happy disposition he observed on his three patients back in England. He reported his findings on a paper entitled “Puppet children (a report on three cases)” which was published in 1965.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
The syndrome was initially named ‘Puppet Syndrome’ but was later changed to Angelman Syndrome. Due to the extreme rarity of the syndrome and lack of sufficient clinical evidence the syndrome was soon forgotten.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt;&lt;br /&gt;
[[File:Dr Charles Williams.jpg|thumb|right|150px|Dr Charles Williams.]]&lt;br /&gt;
	&lt;br /&gt;
In 1987, a physician named Ellen Magenis, came across children with deletions on [[#Glossary | '''chromosome''']] 15 that were suffering from seizures and severe developmental delay.&amp;lt;ref&amp;gt;http://www.angelman.org/stay-informed/facts-about-angelman-syndrome---7th-edition/harry-angelman-and-the-history-of-as/&amp;lt;/ref&amp;gt; Even though genetically the children were expected to have [[#Diagnosis | '''Prader-Willi syndrome''']] that was characterised by deletions on chromosome 15, their characteristic symptoms of seizures and lack of development did not correspond with that of the syndrome. This led to the realization that these children had deletions on the maternally derived chromosome 15 and not on the paternally derived chromosome as was observed in Prader-Willi syndrome.  Thus the deleted genetic code on maternally derived chromosome 15 was identified as the genetic marker for Angelman Syndrome.&lt;br /&gt;
&lt;br /&gt;
In 1997, UBE3A gene was isolated by Dr. Joseph Wagstaff and Dr. Arthur Beaudet as the cause of Angelman Syndrome.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot; /&amp;gt; The discovery of this [[#Glossary | '''gene''']] led to the subsequent development of animal models and research aimed at finding a causal link between UBE3A gene abnormalities and characteristic features observed in Angelman Syndrome. &lt;br /&gt;
	&lt;br /&gt;
Currently, four different genetic abnormalities for Angelman Syndrome have been confirmed by genetic testing. They include: Deletion, [[#Glossary | '''Uniparental Disomy''']] (UPD), [[#Glossary | '''Imprinting''']] and UBE3A mutation.&amp;lt;ref name=&amp;quot;PMID:20211139&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Below is a timeline, summarising the key discoveries and advancements of the Angelman Syndrome:&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|- bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
!Year&lt;br /&gt;
!Milestone&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1964'''&lt;br /&gt;
|First observed by Dr Harry Angelman on three handicapped children.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot; /&amp;gt; &lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''1965'''&lt;br /&gt;
|Harry Angelman publishes his finding in a report entitled 'Puppet Children'(a report on three cases).&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1980s'''&lt;br /&gt;
|First reports of AS reaches US and research into the disorder being at the University of Florida under the direction of Dr. Charles Williams.&amp;lt;ref&amp;gt;http://www.angelmanproject.com/history.htm&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''1982'''&lt;br /&gt;
|Name changed from 'Happy Puppet' to Angelman syndrome by Williams and Frias. &lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1987'''&lt;br /&gt;
|Discovery of a genetic marker for AS – an absent genetic code on maternally derived chromosome 15. &lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''1997'''&lt;br /&gt;
|The cause of AS discovered by Dr. Joseph Wagstaff and Dr. Arthur Beaudet – mutation or deletion in the UBE3A gene.&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1998'''&lt;br /&gt;
|Transgenic mice with absent maternal UBE3A created to illustrate motor and learning deficits in addition to seizures.&amp;lt;ref name=&amp;quot;PMID9808466&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9808466&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''2007'''&lt;br /&gt;
|AS mouse model shows that neurological deficits can be reversed by decreasing levels of [[#Glossary | '''alpha-CaMKII''']] inhibitory phosphorylation.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17259980&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''2010'''&lt;br /&gt;
|Discovery of a another gene mutation in TC4 gene (on chromosome 18) in a small number of clinically diagnosed patients with no identifiable genetic alternation in UBE3A.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20184619&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''2010'''&lt;br /&gt;
|Protein named Arc identified as a target of AS gene product; UBE3A.&amp;lt;ref name=&amp;quot;PMID:20211139&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Incidence'''&lt;br /&gt;
*The current population of people diagnosed with AS is unknown but studies have estimated the number to be around 1:10,000&amp;lt;ref name=&amp;quot;PMID7573182&amp;quot; /&amp;gt; and 1:20,000&amp;lt;ref name=&amp;quot;PMID8703225&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
'''Diagnosis'''&lt;br /&gt;
*The mean age of diagnosis for patients with AS lies between 6 and 6.5 years of age.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18664077&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15741136&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Gender'''&lt;br /&gt;
* Males appear to be at higher risk for some aspects of early developmental delays in comparison to females with AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17019625&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Demography'''&lt;br /&gt;
*Europe:&lt;br /&gt;
:Denmark- 1:10,000&amp;lt;ref name=&amp;quot;PMID7573182&amp;quot; /&amp;gt;&lt;br /&gt;
:Estonia- 1:52,000&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16906556&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
:Sweden- 1:20,000&amp;lt;ref name=&amp;quot;PMID8703225&amp;quot; /&amp;gt;&lt;br /&gt;
*Australia:&lt;br /&gt;
:Western Australia- 1:40,000&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16492624&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Aetiology==&lt;br /&gt;
&lt;br /&gt;
[[File:Chromosome 15 Deletion of 15q11.2 to 15q13.jpg|thumb|100px|Chromosome 15 - The deletion occurs at 15q11.2-15q13.]]&lt;br /&gt;
&lt;br /&gt;
'''Molecular Genetics'''&lt;br /&gt;
&lt;br /&gt;
* Location: 15q11-q13&lt;br /&gt;
* Protein product: Ubiquitin protein ligase E3A&lt;br /&gt;
* Gene name: UBE3A&lt;br /&gt;
* Phenotype: Angelman Syndrome&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Genetic Causes'''&lt;br /&gt;
&lt;br /&gt;
Different genetic mechanisms lead to different clinical phenotypes of AS. The most common genetic mechanism leading to AS is the deletion or re-arrangement of maternal chromosome at [[#Glossary | '''locus''']] 15q11.2-q13,as the chromosome image shows on the right, accounting for 70% of AS occurrences.&amp;lt;ref name=&amp;quot;PMID8988171&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt; 8988171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This leads to more severe clinical phenotypes of microcephaly, motor difficulties, seizures and impaired speech development. The next most common genetic mechanism is mutation in the UBE3A gene responsible for 10% of AS cases and paternal uniparental disomy and mutation in the imprinting centre (IC), both accounting for 2-5% of AS observed.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
 &lt;br /&gt;
&lt;br /&gt;
AS is caused by the 4 major genetic mechanisms mentioned above and are thus divided into Classes I to IV based on their underlying genetic mechanism. AS patients with the clinical features of AS but no [[#Glossary | '''cytogenetic''']] or molecular abnormality in Chromosome 15q11.2-13 are grouped under Class V (summarised in table below).&amp;lt;ref name=&amp;quot;PMID8988171&amp;quot; /&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10364509&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{|  style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
! Class&lt;br /&gt;
! Mechanism&lt;br /&gt;
! Diagnostic Tests&lt;br /&gt;
! Frequency&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''Ia'''                           &lt;br /&gt;
| De novo deletion                                                                                           &lt;br /&gt;
| High resolution cytogenetics [[#Glossary | '''FISH''']]                                                                                                       &lt;br /&gt;
| 70%      &lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Ib'''&lt;br /&gt;
| Deletion due to chromosome rearrangement&lt;br /&gt;
| High resolution cytogenetics FISH&lt;br /&gt;
| &amp;lt;1%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''II'''&lt;br /&gt;
| Paternal uniparental disomy&lt;br /&gt;
| [[#Glossary | '''RFLP''']]  analysis&lt;br /&gt;
| 2%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''IIIa'''&lt;br /&gt;
| Imprinting defect with IC mutation&lt;br /&gt;
| Screening of [[#Glossary | '''IC''']]  for mutations is positive&lt;br /&gt;
| 2%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''IIIb'''&lt;br /&gt;
| Imprinting defect withouth IC mutation&lt;br /&gt;
| Screening of IC for mutations is negative&lt;br /&gt;
| 2%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''IIIc'''&lt;br /&gt;
| Mosaic imprinting defect&lt;br /&gt;
| Screening of IC for mutations is usually negative &lt;br /&gt;
| ?&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''IV'''&lt;br /&gt;
| ''UBE3A'' mutation&lt;br /&gt;
| Screening of ''UBE3A'' for mutations&lt;br /&gt;
| 5-10%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''V'''&lt;br /&gt;
| No identifiable genetic abnormality&lt;br /&gt;
| Consider other diagnoses&lt;br /&gt;
| 5-26%&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
[[File:Imprint defect inheritance in Angelman Syndrome.png|thumb|250px|Imprint defect inheritance in Angelman Syndrome]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Inheritance'''&lt;br /&gt;
&lt;br /&gt;
Angelman Syndrome from UBE3A mutations and deletions in the Imprinting Centre follow an inheritance pattern. A carrier father with the genetic defect can pass it on to his children, however, his children will be clinically normal. On the other hand, a carrier mother can pass the genetic defect onto her children, who will then have Angelman Syndrome. &lt;br /&gt;
&lt;br /&gt;
The image highlights the inheritance of Angelman Syndrome, which only results after a carrier mother passes it on to her children.&lt;br /&gt;
&lt;br /&gt;
==Pathogenesis==&lt;br /&gt;
&lt;br /&gt;
Chromosome 15 became associated with AS in the 1980s after the observation of many AS patients harboring [[#Glossary | '''microdeletions''']] of 15q11.2-15q13.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15668046&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The last decade has shed even more light in the aetiology of AS,as Kishino and Matsuura first identified UBE3A as the causative gene for AS in 1997.&amp;lt;ref name=&amp;quot;PMID:8988171&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;8988171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8988172&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Normal gene product: E6-AP ubiquitin ligase'''&lt;br /&gt;
&lt;br /&gt;
The function of UBE3A is to encode for [[#Glossary | '''E6-AP''']] ubiquitin ligase, however its function in the development of the nervous system and the process of UBE3A mutation leading to cognitive impairment in AS patients is still vague.&amp;lt;ref name=&amp;quot;PMID:20211139&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Past and current research has elucidated that E6-AP ubiquitin ligase is involved in the degradation of four proteins, listed below. Currently no protein with a direct role in [[#Glossary | '''long-term potentiation (LTP)''']] as a target of E6-AP has been identified.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12684449&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The identification of such target proteins would be a landmark discovery in further understanding of the pathogenesis, aetiology and prospective treatment strategies of AS, as LTP defects is one of the major neurological impairments of AS. &lt;br /&gt;
 &lt;br /&gt;
* p53 tumor suppressor protein &lt;br /&gt;
* yeast DNA repair protein Rad23 &lt;br /&gt;
* multicopy maintenance protein 7 subunit &lt;br /&gt;
* E6-AP&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Abnormal gene product'''&lt;br /&gt;
&lt;br /&gt;
Disruption to the gene UBE3A interferes with the normal functioning of the gene, which is its crucial role in UBE3A [[#Glossary | '''ubiquitylation''']]. Problems involving this pathway can lead to various diseases either from the loss or gain of function.&amp;lt;ref name=&amp;quot;PMID:9857172&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9857172&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In the case of AS, E6-AP is affected, leading to detrimental cognitive impairment in addition to other deficits.&amp;lt;ref name=&amp;quot;PMID:9857172&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9857172&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Regional functioning of UBE3A'''&lt;br /&gt;
&lt;br /&gt;
Despite the uncertain progression of UBE3A mutation and the neurological abnormalities characteristic of AS, animal models have illustrated the vital role of UBE3A in the normal functioning of the brain. This can be exemplified by a study which utilized a mouse model with target inactivation of the gene UBE3A resulting in the manifestation of classical features of AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11895368&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In addition, the fact that imprinting of UBE3A takes place only in specific brain regions ([[#Glossary | '''cerebellum''']] , [[#Glossary | '''olfactory tracts''']] and the [[#Glossary | '''hippocampus''']]) confirms the hypothesis that the loss of this gene would be detrimental in cognitive development.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20398390&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Most genes are inherited in copies of two, one paternal and the other maternal; however, some genes, such as UBE3A only have one functional copy as the other is silenced, coined 'imprinting'. Imprinting of the paternal copy of UBE3A takes place in some cell populations, such as the hippocampal [[#Glossary | '''neurons''']] and [[#Glossary | '''Purkinje cells''']] in the cerebellum.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9288101&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This means only the maternal UBE3A is functionally expressed in these particular brain regions. Thus a [[#Glossary | '''de novo mutation''']] in the maternal copy of the gene will result in the complete absence of functional E6-AP in the associated brain areas.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9288088&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
It is also known that UBE3A plays an important role in synaptic transmission, but exactly how it does so is still not completely understood.&amp;lt;ref name=&amp;quot;PMID:9808466&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9808466&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''UBE3A ubiquitylation'''&lt;br /&gt;
&lt;br /&gt;
As briefly mentioned above, UBE3A is a member of the E3 ubiquitin ligase family of enzymes. It is responsible for the addition of ubiquitin to the target protein for degradation of the ubiquitinated protein, as illustrated in the diagram below. These processes are required for normal human cognitive function.&amp;lt;ref name=&amp;quot;PMID:9808466&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9808466&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In this way synaptic protein [[#Glossary | '''Arc (activity-regulated cytoskeleton-associated protein)''']] is degraded to control synaptic function. Arc is a target protein of UBE3A in dendritic spines found in the hippocampal neurons.&amp;lt;ref name=&amp;quot;PMID:20668179&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20668179&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Deletion of UBE3A leads to the accumulation of Arc in neurons leading to trafficking of [[#Glossary | '''AMPA ( α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid)''']] receptors, resulting in impaired cognitive functions.&amp;lt;ref name=&amp;quot;PMID:20211139&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; [[File:UBE3A Ubiquitylation Pathway.png|thumb|350px|right|UBE3A Ubiquitylation Pathway.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
UBE3A ubiquitylation consists of:&amp;lt;ref name=&amp;quot;PMID:20668179&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20668179&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
# Activation of ubiquitin by E1 enzyme&lt;br /&gt;
# E1 ezyme transfers ubiquitin to E2 enzyme&lt;br /&gt;
# E2 enzyme transfers ubiquitin to UBE3A&lt;br /&gt;
# UBE3A attaches activated ubiquitin to target protein which is then polyubiquitylated &lt;br /&gt;
# Target protein is then degraded by 26S proteosome&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Phenotype-Genotype correlations'''&lt;br /&gt;
&lt;br /&gt;
[[File:Extent of microcephaly in Angelman Syndrome patients.png|thumb|250px|right|Extent of microcephaly in 20 AS patients with deletion and without deletion.&amp;lt;ref&amp;gt;http://www.nature.com/ejhg/index.html/&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
All AS patients show differing extents of cognitive impairment, movement disorder, characteristic behaviours and difficulty in speech and language.&amp;lt;ref name=&amp;quot;PMID:11748306&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11748306&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; However, there seems to be some phenotype-genotype correlations:&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
- 5-7Mb deletions result in the most severe phenotypes such as microcephaly, more sever [[#Glossary | '''epilepsy''']] and seizures, motor difficulties and language impairment.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9546330&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20445456&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; AS patients with large deletions also present with clinical [[#Glossary | '''hypopigmentation''']], light hair and eye colour due to the close association of OCA2 gene with UBE3A.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;16470747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Individuals under this category have in general no increased BMI&amp;lt;ref name=&amp;quot;PMID:15253756&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15253756&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This is indicated by the graph on the left, which shows more cases of AS patients with deletions having larger deviations from the mean head circumference measurement than non-deletion AS patients.&lt;br /&gt;
 &lt;br /&gt;
- AS patients with uniparental disomy (UPD) have better physical growth, fewer motor deficits and lower seizure occurrences.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16023557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
- Individuals with AS resulting from imprinting defects have the least debilitating features, such as higher developmental and language ability than AS caused by other mechanisms.&amp;lt;ref name=&amp;quot;PMID:11748306&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11748306&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
- The Body Mass Index (BMI) of 33% of the UBE3A mutation patients, and 47–64% of the patients from the classes II (UPD) and III (Imprinting defect) is above the 95th centile.&amp;lt;ref name=&amp;quot;PMID:15253756&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15253756&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Animal models'''&lt;br /&gt;
&lt;br /&gt;
* '''Drosophila'''&lt;br /&gt;
&lt;br /&gt;
Drosophila (common fruit fly) is an excellent model to use for better understanding of genetic diseases in humans as they are highly homologous to human UBE3A (hUBE3A), illustrating a high evolutionary conservation. Studies using the Drosophila model have shown that the functional absence of UBE3A resulted in decreased morphogenesis of dendritic branches. This is of interest as dendritic branches cover over 90% of the neuronal surface where [[#Glossary | '''synapse''']] between neurons occur. Proper formation and maturation of dendritic spines is also required so they come in contact with other neurons for effective transmission of neuronal signals. Thus proper formation of dendritic branching is pivitol for effective neuronal function and hence cognitive function.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18996915&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Interestingly, overexpression of dUBE3A also gave the same result, consisting of abnormal locomotion  and decreased dendritic branching in sensory neurons.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18701717&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;  This suggests a possible research field for some forms of [[#Glossary | '''autism''']] where the region containing UBE3A is duplicated, leading to delayed motor skills and seizures.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16433693&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;[[File:Normal and Angelman Syndrome mice models.jpg|thumb|250px|right|Normal and AS mice performance on the Rotarod apparatus.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
* '''Mice'''&lt;br /&gt;
&lt;br /&gt;
Absence of UBE3A in mice manifest similar phenotype to human AS, as illustrated by motor and learning deficits with inducible seizures.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21235769&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It has been shown through various mice model studies that larger deletions, ie. from UBE3A to GABRB3, more closely mirrors the large 6Mb deletions seen in human AS patients. Numerous tests, such as the Rotarod (for motor coordination and learning ability), Morris water maze test (for spatial learning and memory) and [[#Glossary | '''EEG''']] (electroencephalography), were carried out on  UBE3A null mutants, which showed the results to be abnormal or impaired.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20808828&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Other studies using mouse models have also outlined the obesity observed in 15% of AS children, albeit it is not the major characterisitics of AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17259980&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The diagram on the right clearly highlights the results obtained from such mouse model studies of AS, where the absence of UBE3A accumulated in deficits of motor function and obesity. In addition, excessive drooling and feeding difficulties were also highlighted by mice models with inactivated UBE3A, reflected by defects in fluid consumption and licking.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18413322&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Signs and Symptoms==&lt;br /&gt;
&lt;br /&gt;
Angelman Syndrome presents a variety of different phenotypes, and the presented symptoms may vary at different ages.&amp;lt;ref name=&amp;quot;PMID7625442&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7625442&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
In 1995 Williams et al. embraced the observed clinical features of AS in a consensus statement, in order to present an appliance for clinicians. The diagnostic criteria were updated in 2005.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt; The following table shows the most frequently occurring characteristics in AS patients:&lt;br /&gt;
&lt;br /&gt;
'''4 characteristics appear in 100% of the cases:'''&lt;br /&gt;
&lt;br /&gt;
*Delayed development: become apparent by the age of 6 to 12 months.&lt;br /&gt;
*Motion and or balance malfunction&lt;br /&gt;
*Behaviour patterns like unmotivated laughter, frequent excitement; often including body movements,[[File:Electroencephalography of Angelman Syndrome.jpg|thumb|350px|right|EEG of AS and normal individuals.]] [[#Glossary | '''hypermotoric''']] behaviour&lt;br /&gt;
*Impairment of speech&lt;br /&gt;
&lt;br /&gt;
'''3 characteristics appear in more than 80% of the cases:'''&lt;br /&gt;
&lt;br /&gt;
*Abnormalities in head circumference, microcephaly&lt;br /&gt;
*Seizures&lt;br /&gt;
*EEG shows specific abnormal patterns&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Angelman Syndrome individuals show the most distinct disease pattern from 2 to 16 years of age.&lt;br /&gt;
In most cases at least 8 of the symptom traits are shown.&amp;lt;ref name=&amp;quot;PMID7625442&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Behavioural Characteristics'''&lt;br /&gt;
&lt;br /&gt;
A range of substantial characteristics appear in all AS cases, regardless of the genetic mechanisms, and are often responsible for diagnosing the syndrome. According to the original name, Happy Puppet syndrome, they have shown to exhibit traits such as a happy demeanor, with frequent laughter or smiling that can easily be triggered.&amp;lt;ref name=&amp;quot;PMID12566516&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12566516&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This behaviour can already be observed in 1 to 3 month old infants.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot; /&amp;gt; Uplifted hand flapping or waving motions are associated with laughter and excitement. Other characteristics manifesting in early childhood are sleep abnormalities with reduced sleep demand, and feeding problems. Breast and bottle feeding can be difficult due to non efficient attachment to the breast, tongue thrusting and uncoordinated sucking. Furthermore, there is an affection to crinkly and reflective surfaces, like some papers or plastic materials, especially water.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID12566516 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Communication Skills'''&lt;br /&gt;
&lt;br /&gt;
Communication is challenging for AS patients due to the fact that speech impairment is present in all cases. In the majority of affected people a lack of speech development is present. Only some of them have a minimal vocabulary consisting of two or three words, a few can speak in basic sentences. Some patients use gestures to articulate themselves, the [[#Glossary | '''Picture Exchange Communication System (PECS)''']] or sign languages such as [[#Glossary | '''Makaton''']] can be used for communication. Simple demands regarding their everyday occurrence can be understood by most patients.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID12566516 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Clinical and External Characteristics'''[[File:Angelman Syndrome patient.png|thumb|200px|right|4 year old AS patient.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Developmental delays are present in all patients. Motor milestones are delayed with children managing to sit unsupported with 12 months and crawl or bottom shuffle at the age of 18-24 months. The average age for walking is 4 years,however, ranging from 18 months to 7 years.&lt;br /&gt;
The [[#Glossary | '''gait''']] is characterised as slow, and flapping hands are a common trait.  The legs remain stiff during walking, arms are inflected by the wrists and elbows. The movements can appear ataxic, jerky or lurching. The muscle tone shows abnormalities with truncal [[#Glossary | '''hypotonia''']] and [[#Glossary | '''hypertonicity''']] of the limbs and alert reflexes.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID12566516 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The most striking external traits present in patients include broad-spaced teeth, and a wide mouth, light hair and eye colour, hypopigmented skin, deep set eyes, and a flat [[#Glossary | '''occiput''']].&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Seizures in Angelman Syndrome'''&lt;br /&gt;
&lt;br /&gt;
85% of AS patients suffer from epileptic seizures during their first three years. The first appearance can be within one month up to 20 year old patients. In infants with AS epilepsy manifests with [[#Glossary | '''febrile convulsions''']] and is hard to manage during childhood.&lt;br /&gt;
The most common type of seizures within 25% of patients are [[#Glossary | '''myoclonic seizures''']], followed by [[#Glossary | '''atonic seizures''']] as the second most frequent type, then 21% experience generalised [[#Glossary | '''tonic-clonic seizures''']] and lastly [[#Glossary | '''atypical absences''']] occur in 12% of patients.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20398390&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Angelman Syndrome in adults'''&lt;br /&gt;
&lt;br /&gt;
Patients with Angelman syndrome possess normal secondary sexual characteristics, and puberty sets in at a usual time. Limb hypertonicity, and [[#Glossary | '''thoracic scoliosis''']] lead to decreasing mobility. [[#Glossary | '''Oesophagus reflux''']] might induce severe problems, and the majority suffers from obesity. Furthermore, facial traits such as a prominent lower lip [[#Glossary | '''macrostomia''']] and [[#Glossary | '''mandibular prognathism''']] get manifested in adults. &lt;br /&gt;
In some cases the communication barrier can lead to frustration, resulting in aggressive behaviour. Nonetheless, patients gain a higher concentration span with age, and their nature becomes more quiet.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Complications===&lt;br /&gt;
&lt;br /&gt;
'''Hypopigmentation and Ocular albinism'''&lt;br /&gt;
&lt;br /&gt;
OCA2 gene, also known as the P gene, is closely located to the UBE3A gene. It encodes a protein vital to tyrosine metabolism, which plays a role in pigmentation development of skin, hair and eyes. However, AS caused by the large deletion of UBE3A leads to haploinsufficiency of OCA2 gene, resulting in hypopigmentation of the skin and the eyes. In some children with severe hypopigmentation, some form of [[#Glossary | '''albinism''']] is suspected.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12749060&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; When AS is caused by another mechanism, no abnormality of the skin and eye pigmentation is observed. However, not all AS children with OCA2 gene deletion will present with obvious hypopigmentation, they may just exhibit lighter skin colour than their parents.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8302318&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Diagnosis==&lt;br /&gt;
&lt;br /&gt;
The diagnosis of Angelman Syndrome is a clinical diagnosis confirmed by laboratory testing.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This involves both prenatal and/or postnatal diagnosis. &lt;br /&gt;
&lt;br /&gt;
===Prenatal Diagnosis===&lt;br /&gt;
[[File:Angelman Syndrome Prenatal Diagnosis.jpg|thumb|250px|right|Flowchart of AS Diagnosis.]]&lt;br /&gt;
&lt;br /&gt;
Prenatal detection of deletions of 15q11.2-q13, [[#Glossary | '''Paternal UPD''']] (Uniparental Disomy), Imprinting defects and UBE3A mutations are done through DNA/chromosome/FISH analysis of fetal cells obtained by either [[#Glossary | '''Chorionic Villus Sampling''']](CVS) or [[#Glossary | '''Amniocentesis''']].&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot;/&amp;gt; &lt;br /&gt;
DNA methylation analysis using [[#Glossary | '''Amniocytes''']] is usually the first test carried out in molecular diagnosis of AS.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18059071&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; An abnormal result is followed up by either a FISH or array CGH analysis to search for a deletion on chromosome 15. If they produce a normal result, then UPD testing using DNA polymorphysims is carried out. If there is no evidence of UPD, other DNA analysis tests are used search for an imprinting centre deletion.&amp;lt;ref name=&amp;quot;PMID9792887&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9792887&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; A normal DNA methylation analysis is followed by a UBE3A sequence analysis.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt; In addition, a parent of origin test is also done to determine if the genetic disruption is of maternal origin or paternal origin. If it is maternally derived the fetus is diagnosed with AS (a paternally derived genetic disruption is indicative of Prader-Willi Syndrome).&amp;lt;ref name=&amp;quot;PMID17020468&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;17020468&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The flow chart summarizes the normal procedure used for prenatal diagnosis of AS. More information on important laboratory tests used for the diagnosis of Angelman Syndrome are provided below:&lt;br /&gt;
&lt;br /&gt;
*'''DNA Methylation Analysis'''&lt;br /&gt;
&lt;br /&gt;
Identifies approximately 80% of AS affected individuals and is usually the first test to be ordered.&amp;lt;ref name=&amp;quot;PMID7618904&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7618904&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Molecular disruptions such as deletions, paternal UPD and imprinting defects on chromosome 15 all demonstrate abnormal methylation patterns by either southern blot analysis or PCR amplification of bisulphate-treated DNA.&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot; /&amp;gt; An affected individual will only have an unmethylated (paternal) SNRPN (small nuclear ribonuclear protein-associated polypeptide N) allele compared with an unaffected individual who will have both a methylated and an unmethylated SNRPN allele.&amp;lt;ref name=&amp;quot;PMID9634532&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9634532&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
	  &lt;br /&gt;
*'''FISH (Fluorescent In Situ Hybridization)'''&lt;br /&gt;
&lt;br /&gt;
[[File:Critical_region_of_Angelman_Syndrome_on_chromosome_15.png‎|thumb|150px|right|FISH (fluorescence in situ hybridisation) image showing the critical region of Angelman Syndrome on chromosome 15.]]&lt;br /&gt;
&lt;br /&gt;
FISH analysis detects 5-7 Mb deletions in approximately 68% of affected individuals using detecting probes such as D15S10 and/or SNRPN.&amp;lt;ref name=&amp;quot;PMID7618904&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7618904&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It is also able to distinguish UPD from micro-deletions and imprinting defects. In simple terms, FISH analysis involves the binding of a fluorescent probe to a specific part of chromosome 15 and the detection of deletions within that region. FISH analysis is much more accurate in deletion detection compared to other high-resolution cytogenetics in the diagnosis of AS patients.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1511093&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
Array-based CGH is an advanced type of cytogenetic testing that can also be used to detect smaller deletions.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''UPD (Uniparental Disomy) Detection'''&lt;br /&gt;
&lt;br /&gt;
DNA Polymorphism testing detects paternal UPD in approximately 7% of affected AS individuals.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt; It is also able to distinguish between UPD and an Imprinting defect. It requires a DNA sample from the [[#Glossary | '''Proband''']] and from both parents. A homologous or non-homologous whole-arm translocation of the long arms of chromosome 15 is a sound indication for the need for prenatal UPD testing.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''IC (Imprinting Center) Analysis'''&lt;br /&gt;
&lt;br /&gt;
This type of analysis is used when individuals have an abnormal DNA methylation pattern but show normal results for  FISH, array CGH study and UPD analysis.&amp;lt;ref name=&amp;quot;PMID9792887&amp;quot;/&amp;gt; It is used to differentiate between the Imprinting defects caused by either microdeletions in the AS imprinting centre or by epigenetic mutations (that occur in maternal oogenesis or early embryogenesis).&amp;lt;ref name=&amp;quot;PMID9634532&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''Cytogenetic Testing'''&lt;br /&gt;
&lt;br /&gt;
Is used to detect a cytogenetically visible chromosomal rearrangement (large deletion, translocation or inversion) involving the 15q11.2-q13 region, which occurs in less than 1% of affected individuals.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''UBE3A Sequence Analysis'''&lt;br /&gt;
Sequence analysis of the UBE3A gene detects mutations in about 10% of the patients.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt; The test is used to detect either multiexonic (10 major coding exons of UBE3A) or whole gene deletions of UBE3A gene in individuals who produces a normal DNA methylation result but has characteristic clinical features of AS.&amp;lt;ref name=&amp;quot;PMID9792887&amp;quot;/&amp;gt;&lt;br /&gt;
This is recommended as a prenatal diagnostic tool in families that include multiple AS affected individuals because the imprinted pattern can be inherited from distant relatives.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Postnatal Diagnosis===&lt;br /&gt;
&lt;br /&gt;
Postnatal diagnosis is made though a combination of common clinical features of AS and UBESA gene sequence analysis.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt; The clinical features of AS include unsteady or shaky movements, muscle hypotonia, developmental delay and behavioral uniqueness such as frequent laughter/smiling and happy demeanor are features that are 100% consistent in all patients diagnosed with Angelman Syndrome.&amp;lt;ref name=&amp;quot;PMID18830393&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18830393&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; These clinical features become apparent between 6 months to 2 years of age. The onset of early or persistent smiling characteristic of this syndrome begin around the age of 1-3 months, but is often overlooked during infancy.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot;/&amp;gt; Thus early diagnosis of AS during infancy period is difficult because the clinical indicators of the syndrome takes time to manifest and characteristic features such as finger and hand tremors and excessive smiling/laughter are often overlooked and not considered as possible indicators of this syndrome.&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
*Rett Syndrome&lt;br /&gt;
&lt;br /&gt;
Some children with the clinical diagnosis of AS but no underlying genetic mechanism show mutations in ''MECP2'' gene, corresponding to Rett Syndrome. This should be suspected in AS test negative girls in the first few years of life.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17980307&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*Mowat-Wilson Syndrome&lt;br /&gt;
&lt;br /&gt;
Genetic mechanism is heterozygous deletion or truncation in ''ZFHX1B'' (''SIP1'') gene on 2q22. This presents with clinical features of severe intellectual disability, micrcephaly and seizures.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17958891&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Prader-Willi Syndrome patient.png|thumb|right|120px|12 year old PWS patient.]]&lt;br /&gt;
&lt;br /&gt;
*X-linked alpha-thalassemia/mental retardation syndrome (ATR-X)&lt;br /&gt;
&lt;br /&gt;
This arises from mutations in ''XNP'' gene on Xq13. ATR-X presents with severe intellectual disability, no speech development and seizures are common.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11449489&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*Phelan-McDermid Syndrome/22q13 deletion syndrome&lt;br /&gt;
&lt;br /&gt;
Deletions are usually submicroscopic and thus requires special molecular cytogenetic methods to confirm this deletion. Patients show moderate to profound intellectual disability and delay in speech development.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18505557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Related Disease'''&lt;br /&gt;
&lt;br /&gt;
*Prader-Willi Syndrome(PWS)&lt;br /&gt;
&lt;br /&gt;
PWS is a result from the absence of paternally expressed 15q11-q13 gene as a corollary of de novo deletion, maternal uniparental disomy of chromosome 15 or an imprinting defect on paternal chromosome 15 leading to the silencing of paternal alleles.&amp;lt;ref name=&amp;quot;PMID:20668179 &amp;quot;/&amp;gt; It is characterized by [[#Glossary | '''hyperphagia''']], obesity in later infancy and early childhood and difficulty in feeding during early infancy.&amp;lt;ref name=&amp;quot;PMID:20668179 &amp;quot;/&amp;gt; There is also cognitive impairment to some extent, though some PWS patients may exhibit intelligence in the normal IQ range. Behavioral phenotypes include stubbornness, manipulative tendency, obsessive compulsive characteristics.&amp;lt;ref name=&amp;quot;PMID:20668179 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Genetic Counselling==&lt;br /&gt;
&lt;br /&gt;
Genetic counselling is the process by which patients or relatives, at risk of an inherited disorder, are advised of the consequences and nature of the disorder, the probability of developing or transmitting it, and the options open to them in management and family planning. In the case for Angelman syndrome, types of risks associated are split into classes and formatted into the table below:&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20459762&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{|  style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
! Class&lt;br /&gt;
! Mechanism&lt;br /&gt;
! Risk to siblings&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! Ia                           &lt;br /&gt;
| De novo deletion                                                                                                               &lt;br /&gt;
| &amp;lt;1%                                                                                                                &lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! Ib&lt;br /&gt;
| Deletion due to chromosome rearrangement&lt;br /&gt;
| Up to 50%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! II&lt;br /&gt;
| Paternal uniparental disomy (UPD)&lt;br /&gt;
| &amp;lt;1%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! IIIa&lt;br /&gt;
| Imprinting defect with IC mutation&lt;br /&gt;
| Close to 100% if father has 15; 15 [[#Glossary | '''Robertsonian translocation''']]&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! IIIb&lt;br /&gt;
| Imprinting defect without IC mutation&lt;br /&gt;
| Up to 50% (if mother has IC deletion)&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! IIIc&lt;br /&gt;
| [[#Glossary | '''Mosaic''']] imprinting defect&lt;br /&gt;
| &amp;lt;1%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! IV&lt;br /&gt;
| ''UBE3A'' mutation&lt;br /&gt;
| Up to 50% (if mother has mutation)&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! V&lt;br /&gt;
| No identifiable genetic abnormality&lt;br /&gt;
| ?&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Ia''': Individuals with de novo deletion have 1% risk to siblings&lt;br /&gt;
&lt;br /&gt;
'''Ib''': Risk to siblings in individuals with chromosomal rearrangements is up to 50% &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9557895&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''II''': Paternal UPD with no Robertsonian translocation has a risk to sibling of less than 1%&lt;br /&gt;
&lt;br /&gt;
'''IIIa''': The risk to siblings in individuals with AS from an imprinting defect with a mutation in the imprinting center (IC) is close to 100% if father has 15;15 Robertsonian translocation&lt;br /&gt;
&lt;br /&gt;
'''IIIb''': Individuals with AS resulting from an imprinting defect without IC mutation, but with a carrier mother has a high risk to siblings of up to 50%. The mother could be phenotypically normal due to paternal inheritance of the genetic defect &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11283796&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''IIIc''': Individuals who are mosaic for the imprinting defect have less than 1% risk to siblings&lt;br /&gt;
&lt;br /&gt;
'''IV''': UBE3A mutation can be either inherited or de novo mutation. If the mother is a carrier for this genetic mutation, the risk to siblings is up to 50% &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11258627&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''V''': Individuals who present with AS clinically, but have no known underlying mechanism have an unknown risk to siblings.&lt;br /&gt;
&lt;br /&gt;
==Treatment and Management==&lt;br /&gt;
&lt;br /&gt;
Even though at present there is no known cure for Angelman syndrome, there are a number of treatments available that may alleviate symptons and improve daily life activities.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The below table describes the problems and management options that are used:&lt;br /&gt;
&lt;br /&gt;
[[File:Subtle Finger tremors-Angelman Syndrome.jpg|right|thumb|150px|A five months old boy with Angelman syndrome showing signs of Subtle Finger tremor.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
! Problems encountered&lt;br /&gt;
! Treatment and Management&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''Difficulty in feeding newborn AS babies'''&lt;br /&gt;
| Use of special nipples may improve feeding&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Oesophagus reflux'''&lt;br /&gt;
| Special motility medications requiried or upright positioning&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''Seizures'''&lt;br /&gt;
| Anticonvulsant medications&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19605773&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19453717&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Ocular problems'''&lt;br /&gt;
| Visual assessment is vital to encourage interactions and minimize chances of self-harm and autism development&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20656169&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''Drooling in developmental delayed AS patients'''&lt;br /&gt;
| Difficult to treat, but new surgical procedure on salivary duct reimplantation seems to be a promising alternative&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17699119&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Unstable children''' &lt;br /&gt;
| Physical therapy&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''AS patients become less active with increasing age'''&lt;br /&gt;
| Activity schedules to prevent scoliosis and obesity. Occupational therapy to stimulate fine motor and oral-motor control skills in conjunction to speech therapy&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Sleeping difficulty'''&lt;br /&gt;
| Sedative medication in severe cases. [[#Glossary | '''Melatonin''']] may be used to promote sleeping but some studies have found that it loses its therapeutic effects after several weeks in most AS patients&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19379289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|-&lt;br /&gt;
|colspan=&amp;quot;4&amp;quot; |&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Prognosis==&lt;br /&gt;
&lt;br /&gt;
Life expectancy of AS patients seems to be normal&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, but there is still a high degree of developmental delay and limited expressive language skills.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17019625&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This problem arises prominently in the assessment of the severity of coincidental medical conditions due to difficulties in communication. A visit to the dentist can become difficult if good communication is not conveyed between the parents, the dentist, and the child.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18271768&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Some problems require extreme measures, such as the procedure of lens implantation was performed in both eyes of a person diagnosed with AS, due to the inability to wear spectacles.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20656169&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
During adulthood, menstruation and puberty begin at around average age evidenced by females with Angelman syndrome that are fully capable of conceiving children.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11258627&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Most adult patients can feed themselves, but needed help with many other daily activities. Main troubles which have shown in adults are a tendency to become obese and start developing  thoracic scoliosis, which some adults with AS begin wheelchair bounded.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9072912&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Current and Future Research==&lt;br /&gt;
&lt;br /&gt;
Currently there is no cure for the treatment of AS, so much research is being carried out for therapeutic interventions. Findings in the last five years have suggested through various mice and fruit fly models that the absence of maternal UBE3A results in the same human AS features of neurological defects and seizures. However, more recently, studies have outlined that the symptoms of AS can be improved by modifying other gene products. In addition, restoring of a functional UBE3A protein into adult mice neurons have shown to reduce motor and neurological deficits and balance disorders. This shows promising research prospects in that improvements may be possible in human AS patients by restoring functional UBE3A proteins into their neurons. &lt;br /&gt;
&lt;br /&gt;
===Possible Treatment Pathways===&lt;br /&gt;
&lt;br /&gt;
*'''Cognitive and physical impairment'''&lt;br /&gt;
&lt;br /&gt;
Although everyone is born with two copies of the gene UBE3A, one maternal and one paternal copy, it is only the maternal UBE3A that is used in the brain. Most AS patients have a genetic mutation on the maternal chromosome 15 that results in dysfunctional UBE3A.&amp;lt;ref&amp;gt;http://www.cureangelman.org/what-hope.html&amp;lt;/ref&amp;gt; The above research focused on turning on the father's copy of UBE3A to restore its functions. Furthermore, mouse models were utilized to show that alpha-CaMKII could be increased to compensate the loss of UBE3A and restore compromised mental and physical abilities. However, this finding still requires much more research.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17259980&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''Epilepsy'''&lt;br /&gt;
&lt;br /&gt;
There is research being done on improving certain conditions that are involved in AS by nutritional benefits. The use of [[#Glossary | '''corticosteroids''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19666884&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, [[#Glossary | '''valproate''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19453717&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and [[#Glossary | '''clonazepam''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19605773&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and having a [[#Glossary | '''ketogenic diet''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20880305&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; has all been shown to aid in the treatment of epilepsy. It has also been reported to be efficient in the treatment of other conditions, such as behavioural disorders, reduction in seizures, ataxia, sleep patterns, developmental progress and sleep disturbances. [[#Glossary | '''Levetiracetam''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17326790&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; could be used in such a situation, especially when the patient has an intolerance to valproate and clonazepam.&lt;br /&gt;
&lt;br /&gt;
*'''Betaine and Folic acid'''&lt;br /&gt;
&lt;br /&gt;
This double-blind placebo-controlled study was done to examine the potential therapeutic role of [[#Glossary | '''betaine''']] and [[#Glossary | '''folic acid''']] in the treatment of the clinical phenotypes of AS. The aim of this protocol was to increase methylation and activate the paternally inherited UBE3A in hope to compensate for the inactive maternal UBE3A. Although there were no major differences in the control and treatment groups, a small number of patients in the treatment group showed some positive outcomes.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20635355&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&lt;br /&gt;
'''albinism''': A congenital disorder distincted by the complete or partial absence of pigment in the skin, hair and eyes due to defect of an enzyme involved in the production of melanin.&lt;br /&gt;
&lt;br /&gt;
'''allele''': Dissimilar variant of one gene. Organisms have two alleles for each gene inherited from their parents, one from each of them.&lt;br /&gt;
&lt;br /&gt;
'''alpha-CaMKII''': (alpha calcium calmodulin kinase II) Compound involved in synaptic plasticity, one of the most important theories behind learning and memory. Ability of a synapse between two neurons to change in strength due to the use or disuse of transmission.&lt;br /&gt;
&lt;br /&gt;
'''Amniocytes''': Cells that are shed by the fetus during fetal development to the surrounding amniotic fluid. They are a source of fetal DNA. &lt;br /&gt;
&lt;br /&gt;
'''Amniocentesis''': (AFT or amniotic fluid test) is a prenatal diagnostic test used to detect chromosomal abnormalities in the developing fetus by extracting amniotic fluid (a source of fetal DNA) surrounding the fetus. &lt;br /&gt;
&lt;br /&gt;
'''AMPA''': (2-amino-3-(5-methyl-3-oxo-1,2- oxazol-4-yl)propanoic acid) Compound that binds to the AMPA receptor to imitate glutamate neurotransmitter.&lt;br /&gt;
&lt;br /&gt;
'''Arc''': Activity-Regulated Cytoskeleton-associated protein; involved in learning and memory.&lt;br /&gt;
&lt;br /&gt;
'''ataxia''': Lack of coordination in muscle movements.&lt;br /&gt;
&lt;br /&gt;
'''atonic seizures''': A abrupt loss of muscle tone, this can lead to the limbs loosing strength, or the head may drop to the side. The patient remains conscious during this kind of epileptic seizure.&lt;br /&gt;
&lt;br /&gt;
'''atypical absences''': Seizure leads to unconsciousness in most cases.  &lt;br /&gt;
&lt;br /&gt;
'''autism''': A neural development disorder defined by limited social interaction and communication.&lt;br /&gt;
&lt;br /&gt;
'''betaine''': Also known as  betaine anhydrous or trimethylglycine (TMG), assists the body in metabolising the amino acid, homocysteine. Can be consumed via beets, broccoli, grains, shellfish, and spinach.&lt;br /&gt;
&lt;br /&gt;
'''cerebellum''': Region of the brain that plays an important role in motor control. It is also involved in some cognitive functions such as attention and language.&lt;br /&gt;
&lt;br /&gt;
'''Chorionic Villus Sampling''': A prenatal diagnostic test used to detect chromosomal abnormalities in the developing fetus by extracting and testing chorionic villus (placental tissue). &lt;br /&gt;
&lt;br /&gt;
'''chromosome''': Structure consisting of coiled DNA with DNA associated proteins such as histones.&lt;br /&gt;
&lt;br /&gt;
'''clonazepam''': A psychoactive drug having muscle relaxant properties and treats anxiety and epilepsy.&lt;br /&gt;
&lt;br /&gt;
'''corticosteroid''': A type of steroid hormones that are produced in the adrenal cortex.&lt;br /&gt;
&lt;br /&gt;
'''cytogenetics''': Study of the structure, function and abnormality of the cell, especially the chromosome.&lt;br /&gt;
&lt;br /&gt;
'''deletion''': Lack of a part of the DNA (deoxyribonucleic acid is a nucleic acid containing information for protein synthesis), can vary form a single base to a hole gene. &lt;br /&gt;
&lt;br /&gt;
'''de novo mutation''': Change in a gene of a family member for the first time due to a mutation in the egg or sperm of the parents or in the fertilized egg (zygote).&lt;br /&gt;
&lt;br /&gt;
'''disorder''': A mental or physical health disturbance or dysfunction.&lt;br /&gt;
&lt;br /&gt;
'''EEG''': Electroencephalography is a means of measuring electrical activity along the scalp by measuring the total electrical charges fired by thousands or millions of neurons.&lt;br /&gt;
&lt;br /&gt;
'''epilepsy''': Neurological disorder characterised by recurrent impairment of brain function that can cause seizures or unconsciousness. &lt;br /&gt;
&lt;br /&gt;
'''E6-AP''': E6-AP ubiquitin-protein ligase is an enzyme encoded by UBE3A which adds ubiquitin chain to target proteins to be degraded by proteasomes.&lt;br /&gt;
&lt;br /&gt;
'''febrile convulsions''': The occurrence of high fever, especially in children.&lt;br /&gt;
&lt;br /&gt;
'''FISH''': Fluorescent in situ hybridization is a technique used to identify and localize the presence or absence of DNA sequences on the chromosome. This is achieved by using fluorescently labelled DNA sequences which then binds to complementary DNA sequence on the chromosome. After hybridization (attachment), chromosome of interest will fluoresce under the microscope.&lt;br /&gt;
&lt;br /&gt;
'''folic acid''': B vitamin that helps the body make healthy new cells. Can be consumed via leafy green vegetables, fruits, dried beans, peas and nuts.&lt;br /&gt;
&lt;br /&gt;
'''gait''': A manner of walking, stepping or running.&lt;br /&gt;
&lt;br /&gt;
'''gene''': A molecular unit of heredity of a living organism.&lt;br /&gt;
&lt;br /&gt;
'''hippocampus''': Area buried deep in the forebrain that helps regulate emotion and memory&lt;br /&gt;
&lt;br /&gt;
'''hyperphagia''': (Also referred to as Polyphagia) Excessive ingestion of food beyond the dietary and energy requirements of the body. &lt;br /&gt;
&lt;br /&gt;
'''hypermotoric''': Sudden appearance of uncontrolled movements such as striking or kicking inappropriately.&lt;br /&gt;
&lt;br /&gt;
'''hypertonicity''': Increase of muscle tension and a disability to stretch leading to an impairment of motor activity.&lt;br /&gt;
&lt;br /&gt;
'''hypopigmentation''': A lack of melanin pigments or melanocytes  affecting the colour of the skin, hair and iris. Features appear to be light-coloured due to loss of skin colour.&lt;br /&gt;
&lt;br /&gt;
'''hypotonia''': Decrease in the ability to stretch passively, due to a low muscle tone. &lt;br /&gt;
&lt;br /&gt;
'''imprinting''': This is a process to describe the modification of a maternally or paternally derived chromosome, which consequently influences the expression of certain genes on the altered chromosome.&lt;br /&gt;
&lt;br /&gt;
'''ketogenic diet''': A high-fat, low-carbohydrate diet that is used to treat epilepsy in children.&lt;br /&gt;
&lt;br /&gt;
'''levetiracetam''': An anticonvulsant drug used to treat epilepsy.&lt;br /&gt;
&lt;br /&gt;
'''locus''': Location of a gene on a chromosome(loci: plural for locus).&lt;br /&gt;
&lt;br /&gt;
'''LTP''': Long-term potentiation shares common features with long term memory. It strengthens and enhances signal transmission between neurons by improving the communication between two neurons.&lt;br /&gt;
&lt;br /&gt;
'''macrostomia''': A wide-spaced mouth.&lt;br /&gt;
&lt;br /&gt;
'''Makaton''': Language programme using symbols and signs to support speaking.&lt;br /&gt;
&lt;br /&gt;
'''mandibular prognathism''': The abnormal protrusion of the lower jaw. &lt;br /&gt;
&lt;br /&gt;
'''maxillary hypoplasia''':  The underdevelopment of the upper jaw.&lt;br /&gt;
&lt;br /&gt;
'''melatonin''': A hormone secreted by the pineal gland.&lt;br /&gt;
&lt;br /&gt;
'''microcephaly''': The circumference of the head is less than average due to abnormalities of the nervous system. This abnormality can be present at birth or emerge during the first few years of life and reduces both life expectancy and the cognitive functions of the individual affected.&lt;br /&gt;
&lt;br /&gt;
'''microdeletion''':  A genetic mutation in which a part of a chromosome or a sequence of DNA is missing.&lt;br /&gt;
&lt;br /&gt;
'''mosaic''': tissues or cells containing different mixture of genetic sequences&lt;br /&gt;
&lt;br /&gt;
'''mutation''': Event that changes the DNA (deoxyribonucleic acid is a nucleic acid, containing information for protein synthesis) or RNA (ribonucleic acid is a type of nucleic acid transmitting the information from the DNA to the proteins ) of a gene permanently.&lt;br /&gt;
&lt;br /&gt;
'''myoclonic seizures''': A quick jerk of the skeletal muscle, due to a irregular brain activity.&lt;br /&gt;
&lt;br /&gt;
'''neurogenetic''': Genetic basis of the nervous system.&lt;br /&gt;
&lt;br /&gt;
'''neuron''': Cells of the nervous system that can be electrically excited to transmit information by electrical and chemical signaling&lt;br /&gt;
&lt;br /&gt;
'''neurotransmitter''': Transmits neuronal signals to a target cell. They are first packaged in vesicles just beneath the membrane of presynaptic axon terminals and released into the synaptic cleft (space between the two interacting neurons) and enter the postsynaptic dendrite.&lt;br /&gt;
&lt;br /&gt;
'''occiput''': The back portion of the head.&lt;br /&gt;
&lt;br /&gt;
'''oesophagus reflux''': Impairment of a sphincter in the lower end of the oesophagus leads to the back flow of stomach acid into the oesophagus. Heartburn is a typical symptom.&lt;br /&gt;
&lt;br /&gt;
'''olfactory tract''': It is a pathway for the sense of smell containing axons from some of the neurons in the olfactory bulb.&lt;br /&gt;
&lt;br /&gt;
'''paediatrician''': Physicians that specialise on infants, children and adolescents.&lt;br /&gt;
&lt;br /&gt;
'''paternal UPD''': Inheritance of two copies of a chromosome from the father and none from the mother. &lt;br /&gt;
&lt;br /&gt;
'''phenotype''': Visible traites of an organism determined by genetic and environmental factors.&lt;br /&gt;
&lt;br /&gt;
'''Picture Exchange Communication System (PECS)''': Individuals communicate using images instead of words. It is frequently used by children with autism, to articulate their needs and wishes or to make comments about something.&lt;br /&gt;
&lt;br /&gt;
'''Proband''': Is the person (or animal) being studied or reported on in a genetic investigation. Most commonly it refers to the first affected family member who requires medical help for a genetic disorder. &lt;br /&gt;
&lt;br /&gt;
'''Purkinje cells''': Large neuron with many branching extensions that is found in the cortex of the cerebellum of the brain and plays a fundamental role in controlling motor movement&lt;br /&gt;
&lt;br /&gt;
'''Robertsonian translocation''': Rearrangement of the chromosome, occurs in 5 chromosome including 13,14,15,21 and 22. This type of mutation occurs in chromosomes with the centromere not at the centre, resulting in long and short arm chromosomes. Translocation breaks the chromosome at the centromere so the long arm attaches to the other long arm, and the same for the short arm happens. Cell division will result in the loss of the short arms as they do not contain important genes.&lt;br /&gt;
&lt;br /&gt;
'''seizure''': Abnormal electrical activity in the brain that can result in a variety of physical symptoms like convulsion, body shaking, loss of consciousness, confusion, and mood changes.&lt;br /&gt;
&lt;br /&gt;
'''synapse''': Allows transmission of signal between neurons for effective neuronal function.&lt;br /&gt;
&lt;br /&gt;
'''thoracic scoliosis''': The spine is curved laterally(from side to side) in the thoracic region.&lt;br /&gt;
&lt;br /&gt;
'''tonic-clonic seizures''': This type of seizure is associated with unconsciousness due to electrical discharges in a big proportion of the brain.&lt;br /&gt;
&lt;br /&gt;
'''ubiquitin''': A polypeptide found in all eukaryotic cells, that participates in a variety of cellular functions including protein recycling.&lt;br /&gt;
&lt;br /&gt;
'''Uniparental disomy''': (UPD) the inheritance of two copies of a chromosome pair or part of a chromosme from one parent and no copy from the other parent. &lt;br /&gt;
&lt;br /&gt;
'''valproate''':  A mood-stabilizing drug that is also used for treatment for epilepsy and bipolar disorder.&lt;br /&gt;
&lt;br /&gt;
==Helpful Links==&lt;br /&gt;
&lt;br /&gt;
* Australia&lt;br /&gt;
:* [http://www.angelmansyndrome.org/research.html Angelman Syndrome Association] &lt;br /&gt;
:* [http://www.angelmansyndromeqld.org/ Queensland Angelman Association]&lt;br /&gt;
&lt;br /&gt;
* America&lt;br /&gt;
:* [http://www.angelman.org/ Angelman Syndrome Foundation]&lt;br /&gt;
:* [http://rarediseasesnetwork.epi.usf.edu/arpwsc/ Rare Clinical Diseases Research Network]&lt;br /&gt;
:* [http://www.rarediseases.org/rare-disease-information/rare-diseases/byID/411/viewAbstract National Organisation for Rare Disorders]&lt;br /&gt;
:* [http://www.epilepsyfoundation.org/ Epilepsy Foundation]&lt;br /&gt;
:* [http://www.cureangelman.org/ Foundation for Angelman Syndrome Therapeutics]&lt;br /&gt;
&lt;br /&gt;
* Search Pubmed &lt;br /&gt;
:* [http://www.ncbi.nlm.nih.gov/pubmed?term=angelman%20syndrome Angelman Syndrome] &lt;br /&gt;
&lt;br /&gt;
* OMIM entries for Angelman Syndrome&lt;br /&gt;
:* [http://omim.org/entry/105830 ANGELMAN SYNDROME; AS]&lt;br /&gt;
:* [http://omim.org/entry/601623 UBIQUITIN-PROTEIN LIGASE E3A; UBE3A]&lt;br /&gt;
&lt;br /&gt;
==Related Links==&lt;br /&gt;
&lt;br /&gt;
'''Animal Models'''&lt;br /&gt;
&lt;br /&gt;
* [[Mouse Knockout]] - this page explains the current use of mouse models in disrupting genes to elucidate their genetic function, including the mouse gene knockouts for alpha calcium-calmodulin kinase II (alpha CaMKII)&lt;br /&gt;
* [[2009 Group Project 4]] - this page gives an extensive overview on the history of the mouse model and its various use in embryology and genetics. In addition, it also describes mouse knockout and the role they play in current research of various human diseases&lt;br /&gt;
* [[Fly Development]] - this page describes the use of drosophila flies as developmental models&lt;br /&gt;
* [[2009 Group Project 2]] - this page gives an extensive overview on the history of the fly model and its various use in embryology and genetics&lt;br /&gt;
&lt;br /&gt;
'''Diagnosis'''&lt;br /&gt;
* [[Chorionic villus sampling]] - this page explains the process of chorionic villus sampling, its disadvantages and gives a brief overview of recent findings&lt;br /&gt;
* [[Amniocentesis]]- this page shows some of the recent findings in this area&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&lt;br /&gt;
&amp;lt;references /&amp;gt;&lt;/div&gt;</summary>
		<author><name>Z3291643</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_7&amp;diff=77818</id>
		<title>2011 Group Project 7</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_7&amp;diff=77818"/>
		<updated>2011-10-13T02:17:40Z</updated>

		<summary type="html">&lt;p&gt;Z3291643: /* Genetic Counselling */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;='''Angelman Syndrome'''=&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Introduction==&lt;br /&gt;
&lt;br /&gt;
[[File:Dr Harry Angelman.jpg|thumb|130px|right|Dr Harry Angelman.]]&lt;br /&gt;
Angelman syndrome (AS) is a rare [[#Glossary | '''neurogenetic''']] [[#Glossary | '''disorder''']] first described by Dr. Harry Angelman in 1965.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18754889&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Dr. Angelman was an English [[#Glossary | '''paediatrician''']] who first diagnosed the disease in 3 children with a developmental delay.&amp;lt;ref&amp;gt;http://www.ncbi.nlm.nih.gov/books/NBK22221/&amp;lt;/ref&amp;gt; AS occurs in 1 in 10000-20000 births, the exact number is still unknown.&amp;lt;ref name=&amp;quot;PMID7573182&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7573182&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;PMID8703225&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;8703225&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It is caused by maternal [[#Glossary | '''allele''']] disruptions of a single gene- UBE3A. Either [[#Glossary | '''mutations''']] or [[#Glossary | '''deletions''']] of the UBE3A gene results in AS. &lt;br /&gt;
&lt;br /&gt;
AS presents with well known [[#Glossary | '''phenotypes''']] during infancy and adulthood, such as [[#Glossary | '''microcephaly''']] and [[#Glossary | '''maxillary hypoplasia''']]. However, these features become more marked with age. Most frequent clinical features include delayed development,[[#Glossary | '''seizures''']],[[#Glossary | '''ataxia''']], impairment of speech, happy demeanor, behavioural problems such as hyperactivity, short attention span and sleeping difficulty.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21592595&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21484597&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;ASAwebsite&amp;quot;&amp;gt;http://www.angelmansyndrome.org/home.html&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
At present, there is no cure for the syndrome, though current research is focused at improving life quality of patients with Angelman syndrome through management of daily tasks.&amp;lt;ref&amp;gt;http://www.bbc.co.uk/health/physical_health/conditions/angelman1.shtml&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==History==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Dr. Harry Angelman first reported Angelman Syndrome on three handicapped children that were admitted to his ward in England in 1964.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt; He reported how these three independent and unconnected clinical cases all had the same characteristic features of severe developmental delay, jerky movements, seizures and a happy disposition.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt; However it was only when he stumbled upon an oil painting called ‘a Boy with a Puppet” while on a holiday in Italy he was able to connect the symptoms of all three children under one common cause.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20981772&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; He linked the happy face of the boy depicted on the painting with the jerky movements and happy disposition he observed on his three patients back in England. He reported his findings on a paper entitled “Puppet children (a report on three cases)” which was published in 1965.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
The syndrome was initially named ‘Puppet Syndrome’ but was later changed to Angelman Syndrome. Due to the extreme rarity of the syndrome and lack of sufficient clinical evidence the syndrome was soon forgotten.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt;&lt;br /&gt;
[[File:Dr Charles Williams.jpg|thumb|right|150px|Dr Charles Williams.]]&lt;br /&gt;
	&lt;br /&gt;
In 1987, a physician named Ellen Magenis, came across children with deletions on [[#Glossary | '''chromosome''']] 15 that were suffering from seizures and severe developmental delay.&amp;lt;ref&amp;gt;http://www.angelman.org/stay-informed/facts-about-angelman-syndrome---7th-edition/harry-angelman-and-the-history-of-as/&amp;lt;/ref&amp;gt; Even though genetically the children were expected to have [[#Diagnosis | '''Prader-Willi syndrome''']] that was characterised by deletions on chromosome 15, their characteristic symptoms of seizures and lack of development did not correspond with that of the syndrome. This led to the realization that these children had deletions on the maternally derived chromosome 15 and not on the paternally derived chromosome as was observed in Prader-Willi syndrome.  Thus the deleted genetic code on maternally derived chromosome 15 was identified as the genetic marker for Angelman Syndrome.&lt;br /&gt;
&lt;br /&gt;
In 1997, UBE3A gene was isolated by Dr. Joseph Wagstaff and Dr. Arthur Beaudet as the cause of Angelman Syndrome.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot; /&amp;gt; The discovery of this [[#Glossary | '''gene''']] led to the subsequent development of animal models and research aimed at finding a causal link between UBE3A gene abnormalities and characteristic features observed in Angelman Syndrome. &lt;br /&gt;
	&lt;br /&gt;
Currently, four different genetic abnormalities for Angelman Syndrome have been confirmed by genetic testing. They include: Deletion, [[#Glossary | '''Uniparental Disomy''']] (UPD), [[#Glossary | '''Imprinting''']] and UBE3A mutation.&amp;lt;ref name=&amp;quot;PMID:20211139&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Below is a timeline, summarising the key discoveries and advancements of the Angelman Syndrome:&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|- bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
!Year&lt;br /&gt;
!Milestone&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1964'''&lt;br /&gt;
|First observed by Dr Harry Angelman on three handicapped children.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot; /&amp;gt; &lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''1965'''&lt;br /&gt;
|Harry Angelman publishes his finding in a report entitled 'Puppet Children'(a report on three cases).&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1980s'''&lt;br /&gt;
|First reports of AS reaches US and research into the disorder being at the University of Florida under the direction of Dr. Charles Williams.&amp;lt;ref&amp;gt;http://www.angelmanproject.com/history.htm&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''1982'''&lt;br /&gt;
|Name changed from 'Happy Puppet' to Angelman syndrome by Williams and Frias. &lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1987'''&lt;br /&gt;
|Discovery of a genetic marker for AS – an absent genetic code on maternally derived chromosome 15. &lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''1997'''&lt;br /&gt;
|The cause of AS discovered by Dr. Joseph Wagstaff and Dr. Arthur Beaudet – mutation or deletion in the UBE3A gene.&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1998'''&lt;br /&gt;
|Transgenic mice with absent maternal UBE3A created to illustrate motor and learning deficits in addition to seizures.&amp;lt;ref name=&amp;quot;PMID9808466&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9808466&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''2007'''&lt;br /&gt;
|AS mouse model shows that neurological deficits can be reversed by decreasing levels of [[#Glossary | '''alpha-CaMKII''']] inhibitory phosphorylation.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17259980&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''2010'''&lt;br /&gt;
|Discovery of a another gene mutation in TC4 gene (on chromosome 18) in a small number of clinically diagnosed patients with no identifiable genetic alternation in UBE3A.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20184619&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''2010'''&lt;br /&gt;
|Protein named Arc identified as a target of AS gene product; UBE3A.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Incidence'''&lt;br /&gt;
*The current population of people diagnosed with AS is unknown but studies have estimated the number to be around 1:10,000&amp;lt;ref name=&amp;quot;PMID7573182&amp;quot; /&amp;gt; and 1:20,000&amp;lt;ref name=&amp;quot;PMID8703225&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
'''Diagnosis'''&lt;br /&gt;
*The mean age of diagnosis for patients with AS lies between 6 and 6.5 years of age.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18664077&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15741136&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Gender'''&lt;br /&gt;
* Males appear to be at higher risk for some aspects of early developmental delays in comparison to females with AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17019625&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Demography'''&lt;br /&gt;
*Europe:&lt;br /&gt;
:Denmark- 1:10,000&amp;lt;ref name=&amp;quot;PMID7573182&amp;quot; /&amp;gt;&lt;br /&gt;
:Estonia- 1:52,000&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16906556&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
:Sweden- 1:20,000&amp;lt;ref name=&amp;quot;PMID8703225&amp;quot; /&amp;gt;&lt;br /&gt;
*Australia:&lt;br /&gt;
:Western Australia- 1:40,000&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16492624&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Aetiology==&lt;br /&gt;
&lt;br /&gt;
[[File:Chromosome 15 Deletion of 15q11.2 to 15q13.jpg|thumb|100px|Chromosome 15 - The deletion occurs at 15q11.2-15q13.]]&lt;br /&gt;
&lt;br /&gt;
'''Molecular Genetics'''&lt;br /&gt;
&lt;br /&gt;
* Location: 15q11-q13&lt;br /&gt;
* Protein product: Ubiquitin protein ligase E3A&lt;br /&gt;
* Gene name: UBE3A&lt;br /&gt;
* Phenotype: Angelman Syndrome&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Genetic Causes'''&lt;br /&gt;
&lt;br /&gt;
Different genetic mechanisms lead to different clinical phenotypes of AS. The most common genetic mechanism leading to AS is the deletion or re-arrangement of maternal chromosome at [[#Glossary | '''locus''']] 15q11.2-q13,as the chromosome image shows on the right, accounting for 70% of AS occurrences.&amp;lt;ref name=&amp;quot;PMID8988171&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt; 8988171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This leads to more severe clinical phenotypes of microcephaly, motor difficulties, seizures and impaired speech development. The next most common genetic mechanism is mutation in the UBE3A gene responsible for 10% of AS cases and paternal uniparental disomy and mutation in the imprinting centre (IC), both accounting for 2-5% of AS observed.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
 &lt;br /&gt;
&lt;br /&gt;
AS is caused by the 4 major genetic mechanisms mentioned above and are thus divided into Classes I to IV based on their underlying genetic mechanism. AS patients with the clinical features of AS but no [[#Glossary | '''cytogenetic''']] or molecular abnormality in Chromosome 15q11.2-13 are grouped under Class V (summarised in table below).&amp;lt;ref name=&amp;quot;PMID8988171&amp;quot; /&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10364509&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{|  style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
! Class&lt;br /&gt;
! Mechanism&lt;br /&gt;
! Diagnostic Tests&lt;br /&gt;
! Frequency&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''Ia'''                           &lt;br /&gt;
| De novo deletion                                                                                           &lt;br /&gt;
| High resolution cytogenetics [[#Glossary | '''FISH''']]                                                                                                       &lt;br /&gt;
| 70%      &lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Ib'''&lt;br /&gt;
| Deletion due to chromosome rearrangement&lt;br /&gt;
| High resolution cytogenetics FISH&lt;br /&gt;
| &amp;lt;1%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''II'''&lt;br /&gt;
| Paternal uniparental disomy&lt;br /&gt;
| [[#Glossary | '''RFLP''']]  analysis&lt;br /&gt;
| 2%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''IIIa'''&lt;br /&gt;
| Imprinting defect with IC mutation&lt;br /&gt;
| Screening of [[#Glossary | '''IC''']]  for mutations is positive&lt;br /&gt;
| 2%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''IIIb'''&lt;br /&gt;
| Imprinting defect withouth IC mutation&lt;br /&gt;
| Screening of IC for mutations is negative&lt;br /&gt;
| 2%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''IIIc'''&lt;br /&gt;
| Mosaic imprinting defect&lt;br /&gt;
| Screening of IC for mutations is usually negative &lt;br /&gt;
| ?&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''IV'''&lt;br /&gt;
| ''UBE3A'' mutation&lt;br /&gt;
| Screening of ''UBE3A'' for mutations&lt;br /&gt;
| 5-10%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''V'''&lt;br /&gt;
| No identifiable genetic abnormality&lt;br /&gt;
| Consider other diagnoses&lt;br /&gt;
| 5-26%&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
[[File:Imprint defect inheritance in Angelman Syndrome.png|thumb|250px|Imprint defect inheritance in Angelman Syndrome]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Inheritance'''&lt;br /&gt;
&lt;br /&gt;
Angelman Syndrome from UBE3A mutations and deletions in the Imprinting Centre follow an inheritance pattern. A carrier father with the genetic defect can pass it on to his children, however, his children will be clinically normal. On the other hand, a carrier mother can pass the genetic defect onto her children, who will then have Angelman Syndrome. &lt;br /&gt;
&lt;br /&gt;
The image highlights the inheritance of Angelman Syndrome, which only results after a carrier mother passes it on to her children.&lt;br /&gt;
&lt;br /&gt;
==Pathogenesis==&lt;br /&gt;
&lt;br /&gt;
Chromosome 15 became associated with AS in the 1980s after the observation of many AS patients harboring [[#Glossary | '''microdeletions''']] of 15q11.2-15q13.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15668046&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The last decade has shed even more light in the aetiology of AS,as Kishino and Matsuura first identified UBE3A as the causative gene for AS in 1997.&amp;lt;ref name=&amp;quot;PMID:8988171&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;8988171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8988172&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Normal gene product: E6-AP ubiquitin ligase'''&lt;br /&gt;
&lt;br /&gt;
The function of UBE3A is to encode for [[#Glossary | '''E6-AP''']] ubiquitin ligase, however its function in the development of the nervous system and the process of UBE3A mutation leading to cognitive impairment in AS patients is still vague.&amp;lt;ref name=&amp;quot;PMID:20211139&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Past and current research has elucidated that E6-AP ubiquitin ligase is involved in the degradation of four proteins, listed below. Currently no protein with a direct role in [[#Glossary | '''long-term potentiation (LTP)''']] as a target of E6-AP has been identified.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12684449&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The identification of such target proteins would be a landmark discovery in further understanding of the pathogenesis, aetiology and prospective treatment strategies of AS, as LTP defects is one of the major neurological impairments of AS. &lt;br /&gt;
 &lt;br /&gt;
* p53 tumor suppressor protein &lt;br /&gt;
* yeast DNA repair protein Rad23 &lt;br /&gt;
* multicopy maintenance protein 7 subunit &lt;br /&gt;
* E6-AP&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Abnormal gene product'''&lt;br /&gt;
&lt;br /&gt;
Disruption to the gene UBE3A interferes with the normal functioning of the gene, which is its crucial role in UBE3A [[#Glossary | '''ubiquitylation''']]. Problems involving this pathway can lead to various diseases either from the loss or gain of function.&amp;lt;ref name=&amp;quot;PMID:9857172&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9857172&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In the case of AS, E6-AP is affected, leading to detrimental cognitive impairment in addition to other deficits.&amp;lt;ref name=&amp;quot;PMID:9857172&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9857172&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Regional functioning of UBE3A'''&lt;br /&gt;
&lt;br /&gt;
Despite the uncertain progression of UBE3A mutation and the neurological abnormalities characteristic of AS, animal models have illustrated the vital role of UBE3A in the normal functioning of the brain. This can be exemplified by a study which utilized a mouse model with target inactivation of the gene UBE3A resulting in the manifestation of classical features of AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11895368&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In addition, the fact that imprinting of UBE3A takes place only in specific brain regions ([[#Glossary | '''cerebellum''']] , [[#Glossary | '''olfactory tracts''']] and the [[#Glossary | '''hippocampus''']]) confirms the hypothesis that the loss of this gene would be detrimental in cognitive development.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20398390&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Most genes are inherited in copies of two, one paternal and the other maternal; however, some genes, such as UBE3A only have one functional copy as the other is silenced, coined 'imprinting'. Imprinting of the paternal copy of UBE3A takes place in some cell populations, such as the hippocampal [[#Glossary | '''neurons''']] and [[#Glossary | '''Purkinje cells''']] in the cerebellum.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9288101&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This means only the maternal UBE3A is functionally expressed in these particular brain regions. Thus a [[#Glossary | '''de novo mutation''']] in the maternal copy of the gene will result in the complete absence of functional E6-AP in the associated brain areas.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9288088&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
It is also known that UBE3A plays an important role in synaptic transmission, but exactly how it does so is still not completely understood.&amp;lt;ref name=&amp;quot;PMID:9808466&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9808466&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''UBE3A ubiquitylation'''&lt;br /&gt;
&lt;br /&gt;
As briefly mentioned above, UBE3A is a member of the E3 ubiquitin ligase family of enzymes. It is responsible for the addition of ubiquitin to the target protein for degradation of the ubiquitinated protein, as illustrated in the diagram below. These processes are required for normal human cognitive function.&amp;lt;ref name=&amp;quot;PMID:9808466&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9808466&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In this way synaptic protein [[#Glossary | '''Arc (activity-regulated cytoskeleton-associated protein)''']] is degraded to control synaptic function. Arc is a target protein of UBE3A in dendritic spines found in the hippocampal neurons.&amp;lt;ref name=&amp;quot;PMID:20668179&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20668179&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Deletion of UBE3A leads to the accumulation of Arc in neurons leading to trafficking of [[#Glossary | '''AMPA ( α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid)''']] receptors, resulting in impaired cognitive functions.&amp;lt;ref name=&amp;quot;PMID:20211139&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; [[File:UBE3A Ubiquitylation Pathway.png|thumb|350px|right|UBE3A Ubiquitylation Pathway.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
UBE3A ubiquitylation consists of:&amp;lt;ref name=&amp;quot;PMID:20668179&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20668179&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
# Activation of ubiquitin by E1 enzyme&lt;br /&gt;
# E1 ezyme transfers ubiquitin to E2 enzyme&lt;br /&gt;
# E2 enzyme transfers ubiquitin to UBE3A&lt;br /&gt;
# UBE3A attaches activated ubiquitin to target protein which is then polyubiquitylated &lt;br /&gt;
# Target protein is then degraded by 26S proteosome&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Phenotype-Genotype correlations'''&lt;br /&gt;
&lt;br /&gt;
[[File:Extent of microcephaly in Angelman Syndrome patients.png|thumb|250px|right|Extent of microcephaly in 20 AS patients with deletion and without deletion.&amp;lt;ref&amp;gt;http://www.nature.com/ejhg/index.html/&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
All AS patients show differing extents of cognitive impairment, movement disorder, characteristic behaviours and difficulty in speech and language.&amp;lt;ref name=&amp;quot;PMID:11748306&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11748306&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; However, there seems to be some phenotype-genotype correlations:&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
- 5-7Mb deletions result in the most severe phenotypes such as microcephaly, more sever [[#Glossary | '''epilepsy''']] and seizures, motor difficulties and language impairment.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9546330&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20445456&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; AS patients with large deletions also present with clinical [[#Glossary | '''hypopigmentation''']], light hair and eye colour due to the close association of OCA2 gene with UBE3A.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;16470747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Individuals under this category have in general no increased BMI&amp;lt;ref name=&amp;quot;PMID:15253756&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15253756&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This is indicated by the graph on the left, which shows more cases of AS patients with deletions having larger deviations from the mean head circumference measurement than non-deletion AS patients.&lt;br /&gt;
 &lt;br /&gt;
- AS patients with uniparental disomy (UPD) have better physical growth, fewer motor deficits and lower seizure occurrences.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16023557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
- Individuals with AS resulting from imprinting defects have the least debilitating features, such as higher developmental and language ability than AS caused by other mechanisms.&amp;lt;ref name=&amp;quot;PMID:11748306&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11748306&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
- The Body Mass Index (BMI) of 33% of the UBE3A mutation patients, and 47–64% of the patients from the classes II (UPD) and III (Imprinting defect) is above the 95th centile.&amp;lt;ref name=&amp;quot;PMID:15253756&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15253756&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Animal models'''&lt;br /&gt;
&lt;br /&gt;
* '''Drosophila'''&lt;br /&gt;
&lt;br /&gt;
Drosophila (common fruit fly) is an excellent model to use for better understanding of genetic diseases in humans as they are highly homologous to human UBE3A (hUBE3A), illustrating a high evolutionary conservation. Studies using the Drosophila model have shown that the functional absence of UBE3A resulted in decreased morphogenesis of dendritic branches. This is of interest as dendritic branches cover over 90% of the neuronal surface where [[#Glossary | '''synapse''']] between neurons occur. Proper formation and maturation of dendritic spines is also required so they come in contact with other neurons for effective transmission of neuronal signals. Thus proper formation of dendritic branching is pivitol for effective neuronal function and hence cognitive function.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18996915&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Interestingly, overexpression of dUBE3A also gave the same result, consisting of abnormal locomotion  and decreased dendritic branching in sensory neurons.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18701717&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;  This suggests a possible research field for some forms of [[#Glossary | '''autism''']] where the region containing UBE3A is duplicated, leading to delayed motor skills and seizures.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16433693&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;[[File:Normal and Angelman Syndrome mice models.jpg|thumb|250px|right|Normal and AS mice performance on the Rotarod apparatus.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
* '''Mice'''&lt;br /&gt;
&lt;br /&gt;
Absence of UBE3A in mice manifest similar phenotype to human AS, as illustrated by motor and learning deficits with inducible seizures.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21235769&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It has been shown through various mice model studies that larger deletions, ie. from UBE3A to GABRB3, more closely mirrors the large 6Mb deletions seen in human AS patients. Numerous tests, such as the Rotarod (for motor coordination and learning ability), Morris water maze test (for spatial learning and memory) and [[#Glossary | '''EEG''']] (electroencephalography), were carried out on  UBE3A null mutants, which showed the results to be abnormal or impaired.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20808828&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Other studies using mouse models have also outlined the obesity observed in 15% of AS children, albeit it is not the major characterisitics of AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17259980&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The diagram on the right clearly highlights the results obtained from such mouse model studies of AS, where the absence of UBE3A accumulated in deficits of motor function and obesity. In addition, excessive drooling and feeding difficulties were also highlighted by mice models with inactivated UBE3A, reflected by defects in fluid consumption and licking.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18413322&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Signs and Symptoms==&lt;br /&gt;
&lt;br /&gt;
Angelman Syndrome presents a variety of different phenotypes, and the presented symptoms may vary at different ages.&amp;lt;ref name=&amp;quot;PMID7625442&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7625442&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
In 1995 Williams et al. embraced the observed clinical features of AS in a consensus statement, in order to present an appliance for clinicians. The diagnostic criteria were updated in 2005.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt; The following table shows the most frequently occurring characteristics in AS patients:&lt;br /&gt;
&lt;br /&gt;
'''4 characteristics appear in 100% of the cases:'''&lt;br /&gt;
&lt;br /&gt;
*Delayed development: become apparent by the age of 6 to 12 months.&lt;br /&gt;
*Motion and or balance malfunction&lt;br /&gt;
*Behaviour patterns like unmotivated laughter, frequent excitement; often including body movements,[[File:Electroencephalography of Angelman Syndrome.jpg|thumb|350px|right|EEG of AS and normal individuals.]] [[#Glossary | '''hypermotoric''']] behaviour&lt;br /&gt;
*Impairment of speech&lt;br /&gt;
&lt;br /&gt;
'''3 characteristics appear in more than 80% of the cases:'''&lt;br /&gt;
&lt;br /&gt;
*Abnormalities in head circumference, microcephaly&lt;br /&gt;
*Seizures&lt;br /&gt;
*EEG shows specific abnormal patterns&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Angelman Syndrome individuals show the most distinct disease pattern from 2 to 16 years of age.&lt;br /&gt;
In most cases at least 8 of the symptom traits are shown.&amp;lt;ref name=&amp;quot;PMID7625442&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Behavioural Characteristics'''&lt;br /&gt;
&lt;br /&gt;
A range of substantial characteristics appear in all AS cases, regardless of the genetic mechanisms, and are often responsible for diagnosing the syndrome. According to the original name, Happy Puppet syndrome, they have shown to exhibit traits such as a happy demeanor, with frequent laughter or smiling that can easily be triggered.&amp;lt;ref name=&amp;quot;PMID12566516&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12566516&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This behaviour can already be observed in 1 to 3 month old infants.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot; /&amp;gt; Uplifted hand flapping or waving motions are associated with laughter and excitement. Other characteristics manifesting in early childhood are sleep abnormalities with reduced sleep demand, and feeding problems. Breast and bottle feeding can be difficult due to non efficient attachment to the breast, tongue thrusting and uncoordinated sucking. Furthermore, there is an affection to crinkly and reflective surfaces, like some papers or plastic materials, especially water.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID12566516 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Communication Skills'''&lt;br /&gt;
&lt;br /&gt;
Communication is challenging for AS patients due to the fact that speech impairment is present in all cases. In the majority of affected people a lack of speech development is present. Only some of them have a minimal vocabulary consisting of two or three words, a few can speak in basic sentences. Some patients use gestures to articulate themselves, the [[#Glossary | '''Picture Exchange Communication System (PECS)''']] or sign languages such as [[#Glossary | '''Makaton''']] can be used for communication. Simple demands regarding their everyday occurrence can be understood by most patients.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID12566516 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Clinical and External Characteristics'''[[File:Angelman Syndrome patient.png|thumb|200px|right|4 year old AS patient.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Developmental delays are present in all patients. Motor milestones are delayed with children managing to sit unsupported with 12 months and crawl or bottom shuffle at the age of 18-24 months. The average age for walking is 4 years,however, ranging from 18 months to 7 years.&lt;br /&gt;
The [[#Glossary | '''gait''']] is characterised as slow, and flapping hands are a common trait.  The legs remain stiff during walking, arms are inflected by the wrists and elbows. The movements can appear ataxic, jerky or lurching. The muscle tone shows abnormalities with truncal [[#Glossary | '''hypotonia''']] and [[#Glossary | '''hypertonicity''']] of the limbs and alert reflexes.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID12566516 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The most striking external traits present in patients include broad-spaced teeth, and a wide mouth, light hair and eye colour, hypopigmented skin, deep set eyes, and a flat [[#Glossary | '''occiput''']].&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Seizures in Angelman Syndrome'''&lt;br /&gt;
&lt;br /&gt;
85% of AS patients suffer from epileptic seizures during their first three years. The first appearance can be within one month up to 20 year old patients. In infants with AS epilepsy manifests with [[#Glossary | '''febrile convulsions''']] and is hard to manage during childhood.&lt;br /&gt;
The most common type of seizures within 25% of patients are [[#Glossary | '''myoclonic seizures''']], followed by [[#Glossary | '''atonic seizures''']] as the second most frequent type, then 21% experience generalised [[#Glossary | '''tonic-clonic seizures''']] and lastly [[#Glossary | '''atypical absences''']] occur in 12% of patients.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20398390&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Angelman Syndrome in adults'''&lt;br /&gt;
&lt;br /&gt;
Patients with Angelman syndrome possess normal secondary sexual characteristics, and puberty sets in at a usual time. Limb hypertonicity, and [[#Glossary | '''thoracic scoliosis''']] lead to decreasing mobility. [[#Glossary | '''Oesophagus reflux''']] might induce severe problems, and the majority suffers from obesity. Furthermore, facial traits such as a prominent lower lip [[#Glossary | '''macrostomia''']] and [[#Glossary | '''mandibular prognathism''']] get manifested in adults. &lt;br /&gt;
In some cases the communication barrier can lead to frustration, resulting in aggressive behaviour. Nonetheless, patients gain a higher concentration span with age, and their nature becomes more quiet.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Complications===&lt;br /&gt;
&lt;br /&gt;
'''Hypopigmentation and Ocular albinism'''&lt;br /&gt;
&lt;br /&gt;
OCA2 gene, also known as the P gene, is closely located to the UBE3A gene. It encodes a protein vital to tyrosine metabolism, which plays a role in pigmentation development of skin, hair and eyes. However, AS caused by the large deletion of UBE3A leads to haploinsufficiency of OCA2 gene, resulting in hypopigmentation of the skin and the eyes. In some children with severe hypopigmentation, some form of [[#Glossary | '''albinism''']] is suspected.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12749060&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; When AS is caused by another mechanism, no abnormality of the skin and eye pigmentation is observed. However, not all AS children with OCA2 gene deletion will present with obvious hypopigmentation, they may just exhibit lighter skin colour than their parents.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8302318&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Diagnosis==&lt;br /&gt;
&lt;br /&gt;
The diagnosis of Angelman Syndrome is a clinical diagnosis confirmed by laboratory testing.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This involves both prenatal and/or postnatal diagnosis. &lt;br /&gt;
&lt;br /&gt;
===Prenatal Diagnosis===&lt;br /&gt;
[[File:Angelman Syndrome Prenatal Diagnosis.jpg|thumb|250px|right|Flowchart of AS Diagnosis.]]&lt;br /&gt;
&lt;br /&gt;
Prenatal detection of deletions of 15q11.2-q13, [[#Glossary | '''Paternal UPD''']] (Uniparental Disomy), Imprinting defects and UBE3A mutations are done through DNA/chromosome/FISH analysis of fetal cells obtained by either [[#Glossary | '''Chorionic Villus Sampling''']](CVS) or [[#Glossary | '''Amniocentesis''']].&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot;/&amp;gt; &lt;br /&gt;
DNA methylation analysis using [[#Glossary | '''Amniocytes''']] is usually the first test carried out in molecular diagnosis of AS.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18059071&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; An abnormal result is followed up by either a FISH or array CGH analysis to search for a deletion on chromosome 15. If they produce a normal result, then UPD testing using DNA polymorphysims is carried out. If there is no evidence of UPD, other DNA analysis tests are used search for an imprinting centre deletion.&amp;lt;ref name=&amp;quot;PMID9792887&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9792887&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; A normal DNA methylation analysis is followed by a UBE3A sequence analysis.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt; In addition, a parent of origin test is also done to determine if the genetic disruption is of maternal origin or paternal origin. If it is maternally derived the fetus is diagnosed with AS (a paternally derived genetic disruption is indicative of Prader-Willi Syndrome).&amp;lt;ref name=&amp;quot;PMID17020468&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;17020468&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The flow chart summarizes the normal procedure used for prenatal diagnosis of AS. More information on important laboratory tests used for the diagnosis of Angelman Syndrome are provided below:&lt;br /&gt;
&lt;br /&gt;
*'''DNA Methylation Analysis'''&lt;br /&gt;
&lt;br /&gt;
Identifies approximately 80% of AS affected individuals and is usually the first test to be ordered.&amp;lt;ref name=&amp;quot;PMID7618904&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7618904&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Molecular disruptions such as deletions, paternal UPD and imprinting defects on chromosome 15 all demonstrate abnormal methylation patterns by either southern blot analysis or PCR amplification of bisulphate-treated DNA.&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot; /&amp;gt; An affected individual will only have an unmethylated (paternal) SNRPN (small nuclear ribonuclear protein-associated polypeptide N) allele compared with an unaffected individual who will have both a methylated and an unmethylated SNRPN allele.&amp;lt;ref name=&amp;quot;PMID9634532&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9634532&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
	  &lt;br /&gt;
*'''FISH (Fluorescent In Situ Hybridization)'''&lt;br /&gt;
&lt;br /&gt;
[[File:Critical_region_of_Angelman_Syndrome_on_chromosome_15.png‎|thumb|150px|right|FISH (fluorescence in situ hybridisation) image showing the critical region of Angelman Syndrome on chromosome 15.]]&lt;br /&gt;
&lt;br /&gt;
FISH analysis detects 5-7 Mb deletions in approximately 68% of affected individuals using detecting probes such as D15S10 and/or SNRPN.&amp;lt;ref name=&amp;quot;PMID7618904&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7618904&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It is also able to distinguish UPD from micro-deletions and imprinting defects. In simple terms, FISH analysis involves the binding of a fluorescent probe to a specific part of chromosome 15 and the detection of deletions within that region. FISH analysis is much more accurate in deletion detection compared to other high-resolution cytogenetics in the diagnosis of AS patients.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1511093&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
Array-based CGH is an advanced type of cytogenetic testing that can also be used to detect smaller deletions.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''UPD (Uniparental Disomy) Detection'''&lt;br /&gt;
&lt;br /&gt;
DNA Polymorphism testing detects paternal UPD in approximately 7% of affected AS individuals.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt; It is also able to distinguish between UPD and an Imprinting defect. It requires a DNA sample from the [[#Glossary | '''Proband''']] and from both parents. A homologous or non-homologous whole-arm translocation of the long arms of chromosome 15 is a sound indication for the need for prenatal UPD testing.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''IC (Imprinting Center) Analysis'''&lt;br /&gt;
&lt;br /&gt;
This type of analysis is used when individuals have an abnormal DNA methylation pattern but show normal results for  FISH, array CGH study and UPD analysis.&amp;lt;ref name=&amp;quot;PMID9792887&amp;quot;/&amp;gt; It is used to differentiate between the Imprinting defects caused by either microdeletions in the AS imprinting centre or by epigenetic mutations (that occur in maternal oogenesis or early embryogenesis).&amp;lt;ref name=&amp;quot;PMID9634532&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''Cytogenetic Testing'''&lt;br /&gt;
&lt;br /&gt;
Is used to detect a cytogenetically visible chromosomal rearrangement (large deletion, translocation or inversion) involving the 15q11.2-q13 region, which occurs in less than 1% of affected individuals.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''UBE3A Sequence Analysis'''&lt;br /&gt;
Sequence analysis of the UBE3A gene detects mutations in about 10% of the patients.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt; The test is used to detect either multiexonic (10 major coding exons of UBE3A) or whole gene deletions of UBE3A gene in individuals who produces a normal DNA methylation result but has characteristic clinical features of AS.&amp;lt;ref name=&amp;quot;PMID9792887&amp;quot;/&amp;gt;&lt;br /&gt;
This is recommended as a prenatal diagnostic tool in families that include multiple AS affected individuals because the imprinted pattern can be inherited from distant relatives.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Postnatal Diagnosis===&lt;br /&gt;
&lt;br /&gt;
Postnatal diagnosis is made though a combination of common clinical features of AS and UBESA gene sequence analysis.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt; The clinical features of AS include unsteady or shaky movements, muscle hypotonia, developmental delay and behavioral uniqueness such as frequent laughter/smiling and happy demeanor are features that are 100% consistent in all patients diagnosed with Angelman Syndrome.&amp;lt;ref name=&amp;quot;PMID18830393&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18830393&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; These clinical features become apparent between 6 months to 2 years of age. The onset of early or persistent smiling characteristic of this syndrome begin around the age of 1-3 months, but is often overlooked during infancy.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot;/&amp;gt; Thus early diagnosis of AS during infancy period is difficult because the clinical indicators of the syndrome takes time to manifest and characteristic features such as finger and hand tremors and excessive smiling/laughter are often overlooked and not considered as possible indicators of this syndrome.&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
*Rett Syndrome&lt;br /&gt;
&lt;br /&gt;
Some children with the clinical diagnosis of AS but no underlying genetic mechanism show mutations in ''MECP2'' gene, corresponding to Rett Syndrome. This should be suspected in AS test negative girls in the first few years of life.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17980307&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*Mowat-Wilson Syndrome&lt;br /&gt;
&lt;br /&gt;
Genetic mechanism is heterozygous deletion or truncation in ''ZFHX1B'' (''SIP1'') gene on 2q22. This presents with clinical features of severe intellectual disability, micrcephaly and seizures.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17958891&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Prader-Willi Syndrome patient.png|thumb|right|120px|12 year old PWS patient.]]&lt;br /&gt;
&lt;br /&gt;
*X-linked alpha-thalassemia/mental retardation syndrome (ATR-X)&lt;br /&gt;
&lt;br /&gt;
This arises from mutations in ''XNP'' gene on Xq13. ATR-X presents with severe intellectual disability, no speech development and seizures are common.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11449489&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*Phelan-McDermid Syndrome/22q13 deletion syndrome&lt;br /&gt;
&lt;br /&gt;
Deletions are usually submicroscopic and thus requires special molecular cytogenetic methods to confirm this deletion. Patients show moderate to profound intellectual disability and delay in speech development.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18505557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Related Disease'''&lt;br /&gt;
&lt;br /&gt;
*Prader-Willi Syndrome(PWS)&lt;br /&gt;
&lt;br /&gt;
PWS is a result from the absence of paternally expressed 15q11-q13 gene as a corollary of de novo deletion, maternal uniparental disomy of chromosome 15 or an imprinting defect on paternal chromosome 15 leading to the silencing of paternal alleles.&amp;lt;ref name=&amp;quot;PMID:20668179 &amp;quot;/&amp;gt; It is characterized by [[#Glossary | '''hyperphagia''']], obesity in later infancy and early childhood and difficulty in feeding during early infancy.&amp;lt;ref name=&amp;quot;PMID:20668179 &amp;quot;/&amp;gt; There is also cognitive impairment to some extent, though some PWS patients may exhibit intelligence in the normal IQ range. Behavioral phenotypes include stubbornness, manipulative tendency, obsessive compulsive characteristics.&amp;lt;ref name=&amp;quot;PMID:20668179 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Genetic Counselling==&lt;br /&gt;
&lt;br /&gt;
Genetic counselling is the process by which patients or relatives, at risk of an inherited disorder, are advised of the consequences and nature of the disorder, the probability of developing or transmitting it, and the options open to them in management and family planning. In the case for Angelman syndrome, types of risks associated are split into classes and formatted into the table below:&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20459762&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{|  style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
! Class&lt;br /&gt;
! Mechanism&lt;br /&gt;
! Risk to siblings&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! Ia                           &lt;br /&gt;
| De novo deletion                                                                                                               &lt;br /&gt;
| &amp;lt;1%                                                                                                                &lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! Ib&lt;br /&gt;
| Deletion due to chromosome rearrangement&lt;br /&gt;
| Up to 50%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! II&lt;br /&gt;
| Paternal uniparental disomy (UPD)&lt;br /&gt;
| &amp;lt;1%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! IIIa&lt;br /&gt;
| Imprinting defect with IC mutation&lt;br /&gt;
| Close to 100% if father has 15; 15 [[#Glossary | '''Robertsonian translocation''']]&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! IIIb&lt;br /&gt;
| Imprinting defect without IC mutation&lt;br /&gt;
| Up to 50% (if mother has IC deletion)&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! IIIc&lt;br /&gt;
| [[#Glossary | '''Mosaic''']] imprinting defect&lt;br /&gt;
| &amp;lt;1%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! IV&lt;br /&gt;
| ''UBE3A'' mutation&lt;br /&gt;
| Up to 50% (if mother has mutation)&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! V&lt;br /&gt;
| No identifiable genetic abnormality&lt;br /&gt;
| ?&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Ia''': Individuals with de novo deletion have 1% risk to siblings&lt;br /&gt;
&lt;br /&gt;
'''Ib''': Risk to siblings in individuals with chromosomal rearrangements is up to 50% &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9557895&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''II''': Paternal UPD with no Robertsonian translocation has a risk to sibling of less than 1%&lt;br /&gt;
&lt;br /&gt;
'''IIIa''': The risk to siblings in individuals with AS from an imprinting defect with a mutation in the imprinting center (IC) is close to 100% if father has 15;15 Robertsonian translocation&lt;br /&gt;
&lt;br /&gt;
'''IIIb''': Individuals with AS resulting from an imprinting defect without IC mutation, but with a carrier mother has a high risk to siblings of up to 50%. The mother could be phenotypically normal due to paternal inheritance of the genetic defect &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11283796&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''IIIc''': Individuals who are mosaic for the imprinting defect have less than 1% risk to siblings&lt;br /&gt;
&lt;br /&gt;
'''IV''': UBE3A mutation can be either inherited or de novo mutation. If the mother is a carrier for this genetic mutation, the risk to siblings is up to 50% &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11258627&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''V''': Individuals who present with AS clinically, but have no known underlying mechanism have an unknown risk to siblings.&lt;br /&gt;
&lt;br /&gt;
==Treatment and Management==&lt;br /&gt;
&lt;br /&gt;
Even though at present there is no known cure for Angelman syndrome, there are a number of treatments available that may alleviate symptons and improve daily life activities.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The below table describes the problems and management options that are used:&lt;br /&gt;
&lt;br /&gt;
[[File:Subtle Finger tremors-Angelman Syndrome.jpg|right|thumb|150px|A five months old boy with Angelman syndrome showing signs of Subtle Finger tremor.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
! Problems encountered&lt;br /&gt;
! Treatment and Management&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''Difficulty in feeding newborn AS babies'''&lt;br /&gt;
| Use of special nipples may improve feeding&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Oesophagus reflux'''&lt;br /&gt;
| Special motility medications requiried or upright positioning&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''Seizures'''&lt;br /&gt;
| Anticonvulsant medications&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19605773&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19453717&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Ocular problems'''&lt;br /&gt;
| Visual assessment is vital to encourage interactions and minimize chances of self-harm and autism development&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20656169&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''Drooling in developmental delayed AS patients'''&lt;br /&gt;
| Difficult to treat, but new surgical procedure on salivary duct reimplantation seems to be a promising alternative&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17699119&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Unstable children''' &lt;br /&gt;
| Physical therapy&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''AS patients become less active with increasing age'''&lt;br /&gt;
| Activity schedules to prevent scoliosis and obesity. Occupational therapy to stimulate fine motor and oral-motor control skills in conjunction to speech therapy&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Sleeping difficulty'''&lt;br /&gt;
| Sedative medication in severe cases. [[#Glossary | '''Melatonin''']] may be used to promote sleeping but some studies have found that it loses its therapeutic effects after several weeks in most AS patients&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19379289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|-&lt;br /&gt;
|colspan=&amp;quot;4&amp;quot; |&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Prognosis==&lt;br /&gt;
&lt;br /&gt;
Life expectancy of AS patients seems to be normal&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, but there is still a high degree of developmental delay and limited expressive language skills.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17019625&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This problem arises prominently in the assessment of the severity of coincidental medical conditions due to difficulties in communication. A visit to the dentist can become difficult if good communication is not conveyed between the parents, the dentist, and the child.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18271768&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Some problems require extreme measures, such as the procedure of lens implantation was performed in both eyes of a person diagnosed with AS, due to the inability to wear spectacles.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20656169&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
During adulthood, menstruation and puberty begin at around average age evidenced by females with Angelman syndrome that are fully capable of conceiving children.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11258627&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Most adult patients can feed themselves, but needed help with many other daily activities. Main troubles which have shown in adults are a tendency to become obese and start developing  thoracic scoliosis, which some adults with AS begin wheelchair bounded.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9072912&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Current and Future Research==&lt;br /&gt;
&lt;br /&gt;
Currently there is no cure for the treatment of AS, so much research is being carried out for therapeutic interventions. Findings in the last five years have suggested through various mice and fruit fly models that the absence of maternal UBE3A results in the same human AS features of neurological defects and seizures. However, more recently, studies have outlined that the symptoms of AS can be improved by modifying other gene products. In addition, restoring of a functional UBE3A protein into adult mice neurons have shown to reduce motor and neurological deficits and balance disorders. This shows promising research prospects in that improvements may be possible in human AS patients by restoring functional UBE3A proteins into their neurons. &lt;br /&gt;
&lt;br /&gt;
===Possible Treatment Pathways===&lt;br /&gt;
&lt;br /&gt;
*'''Cognitive and physical impairment'''&lt;br /&gt;
&lt;br /&gt;
Although everyone is born with two copies of the gene UBE3A, one maternal and one paternal copy, it is only the maternal UBE3A that is used in the brain. Most AS patients have a genetic mutation on the maternal chromosome 15 that results in dysfunctional UBE3A.&amp;lt;ref&amp;gt;http://www.cureangelman.org/what-hope.html&amp;lt;/ref&amp;gt; The above research focused on turning on the father's copy of UBE3A to restore its functions. Furthermore, mouse models were utilized to show that alpha-CaMKII could be increased to compensate the loss of UBE3A and restore compromised mental and physical abilities. However, this finding still requires much more research.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17259980&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''Epilepsy'''&lt;br /&gt;
&lt;br /&gt;
There is research being done on improving certain conditions that are involved in AS by nutritional benefits. The use of [[#Glossary | '''corticosteroids''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19666884&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, [[#Glossary | '''valproate''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19453717&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and [[#Glossary | '''clonazepam''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19605773&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and having a [[#Glossary | '''ketogenic diet''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20880305&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; has all been shown to aid in the treatment of epilepsy. It has also been reported to be efficient in the treatment of other conditions, such as behavioural disorders, reduction in seizures, ataxia, sleep patterns, developmental progress and sleep disturbances. [[#Glossary | '''Levetiracetam''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17326790&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; could be used in such a situation, especially when the patient has an intolerance to valproate and clonazepam.&lt;br /&gt;
&lt;br /&gt;
*'''Betaine and Folic acid'''&lt;br /&gt;
&lt;br /&gt;
This double-blind placebo-controlled study was done to examine the potential therapeutic role of [[#Glossary | '''betaine''']] and [[#Glossary | '''folic acid''']] in the treatment of the clinical phenotypes of AS. The aim of this protocol was to increase methylation and activate the paternally inherited UBE3A in hope to compensate for the inactive maternal UBE3A. Although there were no major differences in the control and treatment groups, a small number of patients in the treatment group showed some positive outcomes.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20635355&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&lt;br /&gt;
'''albinism''': A congenital disorder distincted by the complete or partial absence of pigment in the skin, hair and eyes due to defect of an enzyme involved in the production of melanin.&lt;br /&gt;
&lt;br /&gt;
'''allele''': Dissimilar variant of one gene. Organisms have two alleles for each gene inherited from their parents, one from each of them.&lt;br /&gt;
&lt;br /&gt;
'''alpha-CaMKII''': (alpha calcium calmodulin kinase II) Compound involved in synaptic plasticity, one of the most important theories behind learning and memory. Ability of a synapse between two neurons to change in strength due to the use or disuse of transmission.&lt;br /&gt;
&lt;br /&gt;
'''Amniocytes''': Cells that are shed by the fetus during fetal development to the surrounding amniotic fluid. They are a source of fetal DNA. &lt;br /&gt;
&lt;br /&gt;
'''Amniocentesis''': (AFT or amniotic fluid test) is a prenatal diagnostic test used to detect chromosomal abnormalities in the developing fetus by extracting amniotic fluid (a source of fetal DNA) surrounding the fetus. &lt;br /&gt;
&lt;br /&gt;
'''AMPA''': (2-amino-3-(5-methyl-3-oxo-1,2- oxazol-4-yl)propanoic acid) Compound that binds to the AMPA receptor to imitate glutamate neurotransmitter.&lt;br /&gt;
&lt;br /&gt;
'''Arc''': Activity-Regulated Cytoskeleton-associated protein; involved in learning and memory.&lt;br /&gt;
&lt;br /&gt;
'''ataxia''': Lack of coordination in muscle movements.&lt;br /&gt;
&lt;br /&gt;
'''atonic seizures''': A abrupt loss of muscle tone, this can lead to the limbs loosing strength, or the head may drop to the side. The patient remains conscious during this kind of epileptic seizure.&lt;br /&gt;
&lt;br /&gt;
'''atypical absences''': Seizure leads to unconsciousness in most cases.  &lt;br /&gt;
&lt;br /&gt;
'''autism''': A neural development disorder defined by limited social interaction and communication.&lt;br /&gt;
&lt;br /&gt;
'''betaine''': Also known as  betaine anhydrous or trimethylglycine (TMG), assists the body in metabolising the amino acid, homocysteine. Can be consumed via beets, broccoli, grains, shellfish, and spinach.&lt;br /&gt;
&lt;br /&gt;
'''cerebellum''': Region of the brain that plays an important role in motor control. It is also involved in some cognitive functions such as attention and language.&lt;br /&gt;
&lt;br /&gt;
'''Chorionic Villus Sampling''': A prenatal diagnostic test used to detect chromosomal abnormalities in the developing fetus by extracting and testing chorionic villus (placental tissue). &lt;br /&gt;
&lt;br /&gt;
'''chromosome''': Structure consisting of coiled DNA with DNA associated proteins such as histones.&lt;br /&gt;
&lt;br /&gt;
'''clonazepam''': A psychoactive drug having muscle relaxant properties and treats anxiety and epilepsy.&lt;br /&gt;
&lt;br /&gt;
'''corticosteroid''': A type of steroid hormones that are produced in the adrenal cortex.&lt;br /&gt;
&lt;br /&gt;
'''cytogenetics''': Study of the structure, function and abnormality of the cell, especially the chromosome.&lt;br /&gt;
&lt;br /&gt;
'''deletion''': Lack of a part of the DNA (deoxyribonucleic acid is a nucleic acid containing information for protein synthesis), can vary form a single base to a hole gene. &lt;br /&gt;
&lt;br /&gt;
'''de novo mutation''': Change in a gene of a family member for the first time due to a mutation in the egg or sperm of the parents or in the fertilized egg (zygote).&lt;br /&gt;
&lt;br /&gt;
'''disorder''': A mental or physical health disturbance or dysfunction.&lt;br /&gt;
&lt;br /&gt;
'''EEG''': Electroencephalography is a means of measuring electrical activity along the scalp by measuring the total electrical charges fired by thousands or millions of neurons.&lt;br /&gt;
&lt;br /&gt;
'''epilepsy''': Neurological disorder characterised by recurrent impairment of brain function that can cause seizures or unconsciousness. &lt;br /&gt;
&lt;br /&gt;
'''E6-AP''': E6-AP ubiquitin-protein ligase is an enzyme encoded by UBE3A which adds ubiquitin chain to target proteins to be degraded by proteasomes.&lt;br /&gt;
&lt;br /&gt;
'''febrile convulsions''': The occurrence of high fever, especially in children.&lt;br /&gt;
&lt;br /&gt;
'''FISH''': Fluorescent in situ hybridization is a technique used to identify and localize the presence or absence of DNA sequences on the chromosome. This is achieved by using fluorescently labelled DNA sequences which then binds to complementary DNA sequence on the chromosome. After hybridization (attachment), chromosome of interest will fluoresce under the microscope.&lt;br /&gt;
&lt;br /&gt;
'''folic acid''': B vitamin that helps the body make healthy new cells. Can be consumed via leafy green vegetables, fruits, dried beans, peas and nuts.&lt;br /&gt;
&lt;br /&gt;
'''gait''': A manner of walking, stepping or running.&lt;br /&gt;
&lt;br /&gt;
'''gene''': A molecular unit of heredity of a living organism.&lt;br /&gt;
&lt;br /&gt;
'''hippocampus''': Area buried deep in the forebrain that helps regulate emotion and memory&lt;br /&gt;
&lt;br /&gt;
'''hyperphagia''': (Also referred to as Polyphagia) Excessive ingestion of food beyond the dietary and energy requirements of the body. &lt;br /&gt;
&lt;br /&gt;
'''hypermotoric''': Sudden appearance of uncontrolled movements such as striking or kicking inappropriately.&lt;br /&gt;
&lt;br /&gt;
'''hypertonicity''': Increase of muscle tension and a disability to stretch leading to an impairment of motor activity.&lt;br /&gt;
&lt;br /&gt;
'''hypopigmentation''': A lack of melanin pigments or melanocytes  affecting the colour of the skin, hair and iris. Features appear to be light-coloured due to loss of skin colour.&lt;br /&gt;
&lt;br /&gt;
'''hypotonia''': Decrease in the ability to stretch passively, due to a low muscle tone. &lt;br /&gt;
&lt;br /&gt;
'''imprinting''': This is a process to describe the modification of a maternally or paternally derived chromosome, which consequently influences the expression of certain genes on the altered chromosome.&lt;br /&gt;
&lt;br /&gt;
'''ketogenic diet''': A high-fat, low-carbohydrate diet that is used to treat epilepsy in children.&lt;br /&gt;
&lt;br /&gt;
'''levetiracetam''': An anticonvulsant drug used to treat epilepsy.&lt;br /&gt;
&lt;br /&gt;
'''locus''': Location of a gene on a chromosome(loci: plural for locus).&lt;br /&gt;
&lt;br /&gt;
'''LTP''': Long-term potentiation shares common features with long term memory. It strengthens and enhances signal transmission between neurons by improving the communication between two neurons.&lt;br /&gt;
&lt;br /&gt;
'''macrostomia''': A wide-spaced mouth.&lt;br /&gt;
&lt;br /&gt;
'''Makaton''': Language programme using symbols and signs to support speaking.&lt;br /&gt;
&lt;br /&gt;
'''mandibular prognathism''': The abnormal protrusion of the lower jaw. &lt;br /&gt;
&lt;br /&gt;
'''maxillary hypoplasia''':  The underdevelopment of the upper jaw.&lt;br /&gt;
&lt;br /&gt;
'''melatonin''': A hormone secreted by the pineal gland.&lt;br /&gt;
&lt;br /&gt;
'''microcephaly''': The circumference of the head is less than average due to abnormalities of the nervous system. This abnormality can be present at birth or emerge during the first few years of life and reduces both life expectancy and the cognitive functions of the individual affected.&lt;br /&gt;
&lt;br /&gt;
'''microdeletion''':  A genetic mutation in which a part of a chromosome or a sequence of DNA is missing.&lt;br /&gt;
&lt;br /&gt;
'''mosaic''': tissues or cells containing different mixture of genetic sequences&lt;br /&gt;
&lt;br /&gt;
'''mutation''': Event that changes the DNA (deoxyribonucleic acid is a nucleic acid, containing information for protein synthesis) or RNA (ribonucleic acid is a type of nucleic acid transmitting the information from the DNA to the proteins ) of a gene permanently.&lt;br /&gt;
&lt;br /&gt;
'''myoclonic seizures''': A quick jerk of the skeletal muscle, due to a irregular brain activity.&lt;br /&gt;
&lt;br /&gt;
'''neurogenetic''': Genetic basis of the nervous system.&lt;br /&gt;
&lt;br /&gt;
'''neuron''': Cells of the nervous system that can be electrically excited to transmit information by electrical and chemical signaling&lt;br /&gt;
&lt;br /&gt;
'''neurotransmitter''': Transmits neuronal signals to a target cell. They are first packaged in vesicles just beneath the membrane of presynaptic axon terminals and released into the synaptic cleft (space between the two interacting neurons) and enter the postsynaptic dendrite.&lt;br /&gt;
&lt;br /&gt;
'''occiput''': The back portion of the head.&lt;br /&gt;
&lt;br /&gt;
'''oesophagus reflux''': Impairment of a sphincter in the lower end of the oesophagus leads to the back flow of stomach acid into the oesophagus. Heartburn is a typical symptom.&lt;br /&gt;
&lt;br /&gt;
'''olfactory tract''': It is a pathway for the sense of smell containing axons from some of the neurons in the olfactory bulb.&lt;br /&gt;
&lt;br /&gt;
'''paediatrician''': Physicians that specialise on infants, children and adolescents.&lt;br /&gt;
&lt;br /&gt;
'''paternal UPD''': Inheritance of two copies of a chromosome from the father and none from the mother. &lt;br /&gt;
&lt;br /&gt;
'''phenotype''': Visible traites of an organism determined by genetic and environmental factors.&lt;br /&gt;
&lt;br /&gt;
'''Picture Exchange Communication System (PECS)''': Individuals communicate using images instead of words. It is frequently used by children with autism, to articulate their needs and wishes or to make comments about something.&lt;br /&gt;
&lt;br /&gt;
'''Proband''': Is the person (or animal) being studied or reported on in a genetic investigation. Most commonly it refers to the first affected family member who requires medical help for a genetic disorder. &lt;br /&gt;
&lt;br /&gt;
'''Purkinje cells''': Large neuron with many branching extensions that is found in the cortex of the cerebellum of the brain and plays a fundamental role in controlling motor movement&lt;br /&gt;
&lt;br /&gt;
'''Robertsonian translocation''': Rearrangement of the chromosome, occurs in 5 chromosome including 13,14,15,21 and 22. This type of mutation occurs in chromosomes with the centromere not at the centre, resulting in long and short arm chromosomes. Translocation breaks the chromosome at the centromere so the long arm attaches to the other long arm, and the same for the short arm happens. Cell division will result in the loss of the short arms as they do not contain important genes.&lt;br /&gt;
&lt;br /&gt;
'''seizure''': Abnormal electrical activity in the brain that can result in a variety of physical symptoms like convulsion, body shaking, loss of consciousness, confusion, and mood changes.&lt;br /&gt;
&lt;br /&gt;
'''synapse''': Allows transmission of signal between neurons for effective neuronal function.&lt;br /&gt;
&lt;br /&gt;
'''thoracic scoliosis''': The spine is curved laterally(from side to side) in the thoracic region.&lt;br /&gt;
&lt;br /&gt;
'''tonic-clonic seizures''': This type of seizure is associated with unconsciousness due to electrical discharges in a big proportion of the brain.&lt;br /&gt;
&lt;br /&gt;
'''ubiquitin''': A polypeptide found in all eukaryotic cells, that participates in a variety of cellular functions including protein recycling.&lt;br /&gt;
&lt;br /&gt;
'''Uniparental disomy''': (UPD) the inheritance of two copies of a chromosome pair or part of a chromosme from one parent and no copy from the other parent. &lt;br /&gt;
&lt;br /&gt;
'''valproate''':  A mood-stabilizing drug that is also used for treatment for epilepsy and bipolar disorder.&lt;br /&gt;
&lt;br /&gt;
==Helpful Links==&lt;br /&gt;
&lt;br /&gt;
* Australia&lt;br /&gt;
:* [http://www.angelmansyndrome.org/research.html Angelman Syndrome Association] &lt;br /&gt;
:* [http://www.angelmansyndromeqld.org/ Queensland Angelman Association]&lt;br /&gt;
&lt;br /&gt;
* America&lt;br /&gt;
:* [http://www.angelman.org/ Angelman Syndrome Foundation]&lt;br /&gt;
:* [http://rarediseasesnetwork.epi.usf.edu/arpwsc/ Rare Clinical Diseases Research Network]&lt;br /&gt;
:* [http://www.rarediseases.org/rare-disease-information/rare-diseases/byID/411/viewAbstract National Organisation for Rare Disorders]&lt;br /&gt;
:* [http://www.epilepsyfoundation.org/ Epilepsy Foundation]&lt;br /&gt;
:* [http://www.cureangelman.org/ Foundation for Angelman Syndrome Therapeutics]&lt;br /&gt;
&lt;br /&gt;
* Search Pubmed &lt;br /&gt;
:* [http://www.ncbi.nlm.nih.gov/pubmed?term=angelman%20syndrome Angelman Syndrome] &lt;br /&gt;
&lt;br /&gt;
* OMIM entries for Angelman Syndrome&lt;br /&gt;
:* [http://omim.org/entry/105830 ANGELMAN SYNDROME; AS]&lt;br /&gt;
:* [http://omim.org/entry/601623 UBIQUITIN-PROTEIN LIGASE E3A; UBE3A]&lt;br /&gt;
&lt;br /&gt;
==Related Links==&lt;br /&gt;
&lt;br /&gt;
'''Animal Models'''&lt;br /&gt;
&lt;br /&gt;
* [[Mouse Knockout]] - this page explains the current use of mouse models in disrupting genes to elucidate their genetic function, including the mouse gene knockouts for alpha calcium-calmodulin kinase II (alpha CaMKII)&lt;br /&gt;
* [[2009 Group Project 4]] - this page gives an extensive overview on the history of the mouse model and its various use in embryology and genetics. In addition, it also describes mouse knockout and the role they play in current research of various human diseases&lt;br /&gt;
* [[Fly Development]] - this page describes the use of drosophila flies as developmental models&lt;br /&gt;
* [[2009 Group Project 2]] - this page gives an extensive overview on the history of the fly model and its various use in embryology and genetics&lt;br /&gt;
&lt;br /&gt;
'''Diagnosis'''&lt;br /&gt;
* [[Chorionic villus sampling]] - this page explains the process of chorionic villus sampling, its disadvantages and gives a brief overview of recent findings&lt;br /&gt;
* [[Amniocentesis]]- this page shows some of the recent findings in this area&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&lt;br /&gt;
&amp;lt;references /&amp;gt;&lt;/div&gt;</summary>
		<author><name>Z3291643</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_7&amp;diff=77814</id>
		<title>2011 Group Project 7</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_7&amp;diff=77814"/>
		<updated>2011-10-13T02:15:16Z</updated>

		<summary type="html">&lt;p&gt;Z3291643: /* History */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;='''Angelman Syndrome'''=&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Introduction==&lt;br /&gt;
&lt;br /&gt;
[[File:Dr Harry Angelman.jpg|thumb|130px|right|Dr Harry Angelman.]]&lt;br /&gt;
Angelman syndrome (AS) is a rare [[#Glossary | '''neurogenetic''']] [[#Glossary | '''disorder''']] first described by Dr. Harry Angelman in 1965.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18754889&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Dr. Angelman was an English [[#Glossary | '''paediatrician''']] who first diagnosed the disease in 3 children with a developmental delay.&amp;lt;ref&amp;gt;http://www.ncbi.nlm.nih.gov/books/NBK22221/&amp;lt;/ref&amp;gt; AS occurs in 1 in 10000-20000 births, the exact number is still unknown.&amp;lt;ref name=&amp;quot;PMID7573182&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7573182&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;PMID8703225&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;8703225&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It is caused by maternal [[#Glossary | '''allele''']] disruptions of a single gene- UBE3A. Either [[#Glossary | '''mutations''']] or [[#Glossary | '''deletions''']] of the UBE3A gene results in AS. &lt;br /&gt;
&lt;br /&gt;
AS presents with well known [[#Glossary | '''phenotypes''']] during infancy and adulthood, such as [[#Glossary | '''microcephaly''']] and [[#Glossary | '''maxillary hypoplasia''']]. However, these features become more marked with age. Most frequent clinical features include delayed development,[[#Glossary | '''seizures''']],[[#Glossary | '''ataxia''']], impairment of speech, happy demeanor, behavioural problems such as hyperactivity, short attention span and sleeping difficulty.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21592595&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21484597&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;ASAwebsite&amp;quot;&amp;gt;http://www.angelmansyndrome.org/home.html&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
At present, there is no cure for the syndrome, though current research is focused at improving life quality of patients with Angelman syndrome through management of daily tasks.&amp;lt;ref&amp;gt;http://www.bbc.co.uk/health/physical_health/conditions/angelman1.shtml&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==History==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Dr. Harry Angelman first reported Angelman Syndrome on three handicapped children that were admitted to his ward in England in 1964.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt; He reported how these three independent and unconnected clinical cases all had the same characteristic features of severe developmental delay, jerky movements, seizures and a happy disposition.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt; However it was only when he stumbled upon an oil painting called ‘a Boy with a Puppet” while on a holiday in Italy he was able to connect the symptoms of all three children under one common cause.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20981772&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; He linked the happy face of the boy depicted on the painting with the jerky movements and happy disposition he observed on his three patients back in England. He reported his findings on a paper entitled “Puppet children (a report on three cases)” which was published in 1965.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
The syndrome was initially named ‘Puppet Syndrome’ but was later changed to Angelman Syndrome. Due to the extreme rarity of the syndrome and lack of sufficient clinical evidence the syndrome was soon forgotten.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt;&lt;br /&gt;
[[File:Dr Charles Williams.jpg|thumb|right|150px|Dr Charles Williams.]]&lt;br /&gt;
	&lt;br /&gt;
In 1987, a physician named Ellen Magenis, came across children with deletions on [[#Glossary | '''chromosome''']] 15 that were suffering from seizures and severe developmental delay.&amp;lt;ref&amp;gt;http://www.angelman.org/stay-informed/facts-about-angelman-syndrome---7th-edition/harry-angelman-and-the-history-of-as/&amp;lt;/ref&amp;gt; Even though genetically the children were expected to have [[#Diagnosis | '''Prader-Willi syndrome''']] that was characterised by deletions on chromosome 15, their characteristic symptoms of seizures and lack of development did not correspond with that of the syndrome. This led to the realization that these children had deletions on the maternally derived chromosome 15 and not on the paternally derived chromosome as was observed in Prader-Willi syndrome.  Thus the deleted genetic code on maternally derived chromosome 15 was identified as the genetic marker for Angelman Syndrome.&lt;br /&gt;
&lt;br /&gt;
In 1997, UBE3A gene was isolated by Dr. Joseph Wagstaff and Dr. Arthur Beaudet as the cause of Angelman Syndrome.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot; /&amp;gt; The discovery of this [[#Glossary | '''gene''']] led to the subsequent development of animal models and research aimed at finding a causal link between UBE3A gene abnormalities and characteristic features observed in Angelman Syndrome. &lt;br /&gt;
	&lt;br /&gt;
Currently, four different genetic abnormalities for Angelman Syndrome have been confirmed by genetic testing. They include: Deletion, [[#Glossary | '''Uniparental Disomy''']] (UPD), [[#Glossary | '''Imprinting''']] and UBE3A mutation.&amp;lt;ref name=&amp;quot;PMID:20211139&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Below is a timeline, summarising the key discoveries and advancements of the Angelman Syndrome:&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|- bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
!Year&lt;br /&gt;
!Milestone&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1964'''&lt;br /&gt;
|First observed by Dr Harry Angelman on three handicapped children.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot; /&amp;gt; &lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''1965'''&lt;br /&gt;
|Harry Angelman publishes his finding in a report entitled 'Puppet Children'(a report on three cases).&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1980s'''&lt;br /&gt;
|First reports of AS reaches US and research into the disorder being at the University of Florida under the direction of Dr. Charles Williams.&amp;lt;ref&amp;gt;http://www.angelmanproject.com/history.htm&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''1982'''&lt;br /&gt;
|Name changed from 'Happy Puppet' to Angelman syndrome by Williams and Frias. &lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1987'''&lt;br /&gt;
|Discovery of a genetic marker for AS – an absent genetic code on maternally derived chromosome 15. &lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''1997'''&lt;br /&gt;
|The cause of AS discovered by Dr. Joseph Wagstaff and Dr. Arthur Beaudet – mutation or deletion in the UBE3A gene.&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1998'''&lt;br /&gt;
|Transgenic mice with absent maternal UBE3A created to illustrate motor and learning deficits in addition to seizures.&amp;lt;ref name=&amp;quot;PMID9808466&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9808466&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''2007'''&lt;br /&gt;
|AS mouse model shows that neurological deficits can be reversed by decreasing levels of [[#Glossary | '''alpha-CaMKII''']] inhibitory phosphorylation.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17259980&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''2010'''&lt;br /&gt;
|Discovery of a another gene mutation in TC4 gene (on chromosome 18) in a small number of clinically diagnosed patients with no identifiable genetic alternation in UBE3A.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20184619&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''2010'''&lt;br /&gt;
|Protein named Arc identified as a target of AS gene product; UBE3A.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Incidence'''&lt;br /&gt;
*The current population of people diagnosed with AS is unknown but studies have estimated the number to be around 1:10,000&amp;lt;ref name=&amp;quot;PMID7573182&amp;quot; /&amp;gt; and 1:20,000&amp;lt;ref name=&amp;quot;PMID8703225&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
'''Diagnosis'''&lt;br /&gt;
*The mean age of diagnosis for patients with AS lies between 6 and 6.5 years of age.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18664077&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15741136&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Gender'''&lt;br /&gt;
* Males appear to be at higher risk for some aspects of early developmental delays in comparison to females with AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17019625&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Demography'''&lt;br /&gt;
*Europe:&lt;br /&gt;
:Denmark- 1:10,000&amp;lt;ref name=&amp;quot;PMID7573182&amp;quot; /&amp;gt;&lt;br /&gt;
:Estonia- 1:52,000&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16906556&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
:Sweden- 1:20,000&amp;lt;ref name=&amp;quot;PMID8703225&amp;quot; /&amp;gt;&lt;br /&gt;
*Australia:&lt;br /&gt;
:Western Australia- 1:40,000&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16492624&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Aetiology==&lt;br /&gt;
&lt;br /&gt;
[[File:Chromosome 15 Deletion of 15q11.2 to 15q13.jpg|thumb|100px|Chromosome 15 - The deletion occurs at 15q11.2-15q13.]]&lt;br /&gt;
&lt;br /&gt;
'''Molecular Genetics'''&lt;br /&gt;
&lt;br /&gt;
* Location: 15q11-q13&lt;br /&gt;
* Protein product: Ubiquitin protein ligase E3A&lt;br /&gt;
* Gene name: UBE3A&lt;br /&gt;
* Phenotype: Angelman Syndrome&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Genetic Causes'''&lt;br /&gt;
&lt;br /&gt;
Different genetic mechanisms lead to different clinical phenotypes of AS. The most common genetic mechanism leading to AS is the deletion or re-arrangement of maternal chromosome at [[#Glossary | '''locus''']] 15q11.2-q13,as the chromosome image shows on the right, accounting for 70% of AS occurrences.&amp;lt;ref name=&amp;quot;PMID8988171&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt; 8988171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This leads to more severe clinical phenotypes of microcephaly, motor difficulties, seizures and impaired speech development. The next most common genetic mechanism is mutation in the UBE3A gene responsible for 10% of AS cases and paternal uniparental disomy and mutation in the imprinting centre (IC), both accounting for 2-5% of AS observed.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
 &lt;br /&gt;
&lt;br /&gt;
AS is caused by the 4 major genetic mechanisms mentioned above and are thus divided into Classes I to IV based on their underlying genetic mechanism. AS patients with the clinical features of AS but no [[#Glossary | '''cytogenetic''']] or molecular abnormality in Chromosome 15q11.2-13 are grouped under Class V (summarised in table below).&amp;lt;ref name=&amp;quot;PMID8988171&amp;quot; /&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10364509&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{|  style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
! Class&lt;br /&gt;
! Mechanism&lt;br /&gt;
! Diagnostic Tests&lt;br /&gt;
! Frequency&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''Ia'''                           &lt;br /&gt;
| De novo deletion                                                                                           &lt;br /&gt;
| High resolution cytogenetics [[#Glossary | '''FISH''']]                                                                                                       &lt;br /&gt;
| 70%      &lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Ib'''&lt;br /&gt;
| Deletion due to chromosome rearrangement&lt;br /&gt;
| High resolution cytogenetics FISH&lt;br /&gt;
| &amp;lt;1%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''II'''&lt;br /&gt;
| Paternal uniparental disomy&lt;br /&gt;
| [[#Glossary | '''RFLP''']]  analysis&lt;br /&gt;
| 2%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''IIIa'''&lt;br /&gt;
| Imprinting defect with IC mutation&lt;br /&gt;
| Screening of [[#Glossary | '''IC''']]  for mutations is positive&lt;br /&gt;
| 2%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''IIIb'''&lt;br /&gt;
| Imprinting defect withouth IC mutation&lt;br /&gt;
| Screening of IC for mutations is negative&lt;br /&gt;
| 2%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''IIIc'''&lt;br /&gt;
| Mosaic imprinting defect&lt;br /&gt;
| Screening of IC for mutations is usually negative &lt;br /&gt;
| ?&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''IV'''&lt;br /&gt;
| ''UBE3A'' mutation&lt;br /&gt;
| Screening of ''UBE3A'' for mutations&lt;br /&gt;
| 5-10%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''V'''&lt;br /&gt;
| No identifiable genetic abnormality&lt;br /&gt;
| Consider other diagnoses&lt;br /&gt;
| 5-26%&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
[[File:Imprint defect inheritance in Angelman Syndrome.png|thumb|250px|Imprint defect inheritance in Angelman Syndrome]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Inheritance'''&lt;br /&gt;
&lt;br /&gt;
Angelman Syndrome from UBE3A mutations and deletions in the Imprinting Centre follow an inheritance pattern. A carrier father with the genetic defect can pass it on to his children, however, his children will be clinically normal. On the other hand, a carrier mother can pass the genetic defect onto her children, who will then have Angelman Syndrome. &lt;br /&gt;
&lt;br /&gt;
The image highlights the inheritance of Angelman Syndrome, which only results after a carrier mother passes it on to her children.&lt;br /&gt;
&lt;br /&gt;
==Pathogenesis==&lt;br /&gt;
&lt;br /&gt;
Chromosome 15 became associated with AS in the 1980s after the observation of many AS patients harboring [[#Glossary | '''microdeletions''']] of 15q11.2-15q13.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15668046&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The last decade has shed even more light in the aetiology of AS,as Kishino and Matsuura first identified UBE3A as the causative gene for AS in 1997.&amp;lt;ref name=&amp;quot;PMID:8988171&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;8988171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8988172&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Normal gene product: E6-AP ubiquitin ligase'''&lt;br /&gt;
&lt;br /&gt;
The function of UBE3A is to encode for [[#Glossary | '''E6-AP''']] ubiquitin ligase, however its function in the development of the nervous system and the process of UBE3A mutation leading to cognitive impairment in AS patients is still vague.&amp;lt;ref name=&amp;quot;PMID:20211139&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Past and current research has elucidated that E6-AP ubiquitin ligase is involved in the degradation of four proteins, listed below. Currently no protein with a direct role in [[#Glossary | '''long-term potentiation (LTP)''']] as a target of E6-AP has been identified.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12684449&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The identification of such target proteins would be a landmark discovery in further understanding of the pathogenesis, aetiology and prospective treatment strategies of AS, as LTP defects is one of the major neurological impairments of AS. &lt;br /&gt;
 &lt;br /&gt;
* p53 tumor suppressor protein &lt;br /&gt;
* yeast DNA repair protein Rad23 &lt;br /&gt;
* multicopy maintenance protein 7 subunit &lt;br /&gt;
* E6-AP&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Abnormal gene product'''&lt;br /&gt;
&lt;br /&gt;
Disruption to the gene UBE3A interferes with the normal functioning of the gene, which is its crucial role in UBE3A [[#Glossary | '''ubiquitylation''']]. Problems involving this pathway can lead to various diseases either from the loss or gain of function.&amp;lt;ref name=&amp;quot;PMID:9857172&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9857172&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In the case of AS, E6-AP is affected, leading to detrimental cognitive impairment in addition to other deficits.&amp;lt;ref name=&amp;quot;PMID:9857172&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9857172&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Regional functioning of UBE3A'''&lt;br /&gt;
&lt;br /&gt;
Despite the uncertain progression of UBE3A mutation and the neurological abnormalities characteristic of AS, animal models have illustrated the vital role of UBE3A in the normal functioning of the brain. This can be exemplified by a study which utilized a mouse model with target inactivation of the gene UBE3A resulting in the manifestation of classical features of AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11895368&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In addition, the fact that imprinting of UBE3A takes place only in specific brain regions ([[#Glossary | '''cerebellum''']] , [[#Glossary | '''olfactory tracts''']] and the [[#Glossary | '''hippocampus''']]) confirms the hypothesis that the loss of this gene would be detrimental in cognitive development.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20398390&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Most genes are inherited in copies of two, one paternal and the other maternal; however, some genes, such as UBE3A only have one functional copy as the other is silenced, coined 'imprinting'. Imprinting of the paternal copy of UBE3A takes place in some cell populations, such as the hippocampal [[#Glossary | '''neurons''']] and [[#Glossary | '''Purkinje cells''']] in the cerebellum.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9288101&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This means only the maternal UBE3A is functionally expressed in these particular brain regions. Thus a [[#Glossary | '''de novo mutation''']] in the maternal copy of the gene will result in the complete absence of functional E6-AP in the associated brain areas.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9288088&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
It is also known that UBE3A plays an important role in synaptic transmission, but exactly how it does so is still not completely understood.&amp;lt;ref name=&amp;quot;PMID:9808466&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9808466&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''UBE3A ubiquitylation'''&lt;br /&gt;
&lt;br /&gt;
As briefly mentioned above, UBE3A is a member of the E3 ubiquitin ligase family of enzymes. It is responsible for the addition of ubiquitin to the target protein for degradation of the ubiquitinated protein, as illustrated in the diagram below. These processes are required for normal human cognitive function.&amp;lt;ref name=&amp;quot;PMID:9808466&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9808466&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In this way synaptic protein [[#Glossary | '''Arc (activity-regulated cytoskeleton-associated protein)''']] is degraded to control synaptic function. Arc is a target protein of UBE3A in dendritic spines found in the hippocampal neurons.&amp;lt;ref name=&amp;quot;PMID:20668179&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20668179&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Deletion of UBE3A leads to the accumulation of Arc in neurons leading to trafficking of [[#Glossary | '''AMPA ( α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid)''']] receptors, resulting in impaired cognitive functions.&amp;lt;ref name=&amp;quot;PMID:20211139&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; [[File:UBE3A Ubiquitylation Pathway.png|thumb|350px|right|UBE3A Ubiquitylation Pathway.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
UBE3A ubiquitylation consists of:&amp;lt;ref name=&amp;quot;PMID:20668179&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20668179&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
# Activation of ubiquitin by E1 enzyme&lt;br /&gt;
# E1 ezyme transfers ubiquitin to E2 enzyme&lt;br /&gt;
# E2 enzyme transfers ubiquitin to UBE3A&lt;br /&gt;
# UBE3A attaches activated ubiquitin to target protein which is then polyubiquitylated &lt;br /&gt;
# Target protein is then degraded by 26S proteosome&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Phenotype-Genotype correlations'''&lt;br /&gt;
&lt;br /&gt;
[[File:Extent of microcephaly in Angelman Syndrome patients.png|thumb|250px|right|Extent of microcephaly in 20 AS patients with deletion and without deletion.&amp;lt;ref&amp;gt;http://www.nature.com/ejhg/index.html/&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
All AS patients show differing extents of cognitive impairment, movement disorder, characteristic behaviours and difficulty in speech and language.&amp;lt;ref name=&amp;quot;PMID:11748306&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11748306&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; However, there seems to be some phenotype-genotype correlations:&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
- 5-7Mb deletions result in the most severe phenotypes such as microcephaly, more sever [[#Glossary | '''epilepsy''']] and seizures, motor difficulties and language impairment.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9546330&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20445456&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; AS patients with large deletions also present with clinical [[#Glossary | '''hypopigmentation''']], light hair and eye colour due to the close association of OCA2 gene with UBE3A.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;16470747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Individuals under this category have in general no increased BMI&amp;lt;ref name=&amp;quot;PMID:15253756&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15253756&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This is indicated by the graph on the left, which shows more cases of AS patients with deletions having larger deviations from the mean head circumference measurement than non-deletion AS patients.&lt;br /&gt;
 &lt;br /&gt;
- AS patients with uniparental disomy (UPD) have better physical growth, fewer motor deficits and lower seizure occurrences.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16023557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
- Individuals with AS resulting from imprinting defects have the least debilitating features, such as higher developmental and language ability than AS caused by other mechanisms.&amp;lt;ref name=&amp;quot;PMID:11748306&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11748306&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
- The Body Mass Index (BMI) of 33% of the UBE3A mutation patients, and 47–64% of the patients from the classes II (UPD) and III (Imprinting defect) is above the 95th centile.&amp;lt;ref name=&amp;quot;PMID:15253756&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15253756&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Animal models'''&lt;br /&gt;
&lt;br /&gt;
* '''Drosophila'''&lt;br /&gt;
&lt;br /&gt;
Drosophila (common fruit fly) is an excellent model to use for better understanding of genetic diseases in humans as they are highly homologous to human UBE3A (hUBE3A), illustrating a high evolutionary conservation. Studies using the Drosophila model have shown that the functional absence of UBE3A resulted in decreased morphogenesis of dendritic branches. This is of interest as dendritic branches cover over 90% of the neuronal surface where [[#Glossary | '''synapse''']] between neurons occur. Proper formation and maturation of dendritic spines is also required so they come in contact with other neurons for effective transmission of neuronal signals. Thus proper formation of dendritic branching is pivitol for effective neuronal function and hence cognitive function.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18996915&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Interestingly, overexpression of dUBE3A also gave the same result, consisting of abnormal locomotion  and decreased dendritic branching in sensory neurons.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18701717&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;  This suggests a possible research field for some forms of [[#Glossary | '''autism''']] where the region containing UBE3A is duplicated, leading to delayed motor skills and seizures.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16433693&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;[[File:Normal and Angelman Syndrome mice models.jpg|thumb|250px|right|Normal and AS mice performance on the Rotarod apparatus.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
* '''Mice'''&lt;br /&gt;
&lt;br /&gt;
Absence of UBE3A in mice manifest similar phenotype to human AS, as illustrated by motor and learning deficits with inducible seizures.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21235769&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It has been shown through various mice model studies that larger deletions, ie. from UBE3A to GABRB3, more closely mirrors the large 6Mb deletions seen in human AS patients. Numerous tests, such as the Rotarod (for motor coordination and learning ability), Morris water maze test (for spatial learning and memory) and [[#Glossary | '''EEG''']] (electroencephalography), were carried out on  UBE3A null mutants, which showed the results to be abnormal or impaired.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20808828&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Other studies using mouse models have also outlined the obesity observed in 15% of AS children, albeit it is not the major characterisitics of AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17259980&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The diagram on the right clearly highlights the results obtained from such mouse model studies of AS, where the absence of UBE3A accumulated in deficits of motor function and obesity. In addition, excessive drooling and feeding difficulties were also highlighted by mice models with inactivated UBE3A, reflected by defects in fluid consumption and licking.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18413322&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Signs and Symptoms==&lt;br /&gt;
&lt;br /&gt;
Angelman Syndrome presents a variety of different phenotypes, and the presented symptoms may vary at different ages.&amp;lt;ref name=&amp;quot;PMID7625442&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7625442&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
In 1995 Williams et al. embraced the observed clinical features of AS in a consensus statement, in order to present an appliance for clinicians. The diagnostic criteria were updated in 2005.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt; The following table shows the most frequently occurring characteristics in AS patients:&lt;br /&gt;
&lt;br /&gt;
'''4 characteristics appear in 100% of the cases:'''&lt;br /&gt;
&lt;br /&gt;
*Delayed development: become apparent by the age of 6 to 12 months.&lt;br /&gt;
*Motion and or balance malfunction&lt;br /&gt;
*Behaviour patterns like unmotivated laughter, frequent excitement; often including body movements,[[File:Electroencephalography of Angelman Syndrome.jpg|thumb|350px|right|EEG of AS and normal individuals.]] [[#Glossary | '''hypermotoric''']] behaviour&lt;br /&gt;
*Impairment of speech&lt;br /&gt;
&lt;br /&gt;
'''3 characteristics appear in more than 80% of the cases:'''&lt;br /&gt;
&lt;br /&gt;
*Abnormalities in head circumference, microcephaly&lt;br /&gt;
*Seizures&lt;br /&gt;
*EEG shows specific abnormal patterns&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Angelman Syndrome individuals show the most distinct disease pattern from 2 to 16 years of age.&lt;br /&gt;
In most cases at least 8 of the symptom traits are shown.&amp;lt;ref name=&amp;quot;PMID7625442&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Behavioural Characteristics'''&lt;br /&gt;
&lt;br /&gt;
A range of substantial characteristics appear in all AS cases, regardless of the genetic mechanisms, and are often responsible for diagnosing the syndrome. According to the original name, Happy Puppet syndrome, they have shown to exhibit traits such as a happy demeanor, with frequent laughter or smiling that can easily be triggered.&amp;lt;ref name=&amp;quot;PMID12566516&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12566516&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This behaviour can already be observed in 1 to 3 month old infants.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot; /&amp;gt; Uplifted hand flapping or waving motions are associated with laughter and excitement. Other characteristics manifesting in early childhood are sleep abnormalities with reduced sleep demand, and feeding problems. Breast and bottle feeding can be difficult due to non efficient attachment to the breast, tongue thrusting and uncoordinated sucking. Furthermore, there is an affection to crinkly and reflective surfaces, like some papers or plastic materials, especially water.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID12566516 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Communication Skills'''&lt;br /&gt;
&lt;br /&gt;
Communication is challenging for AS patients due to the fact that speech impairment is present in all cases. In the majority of affected people a lack of speech development is present. Only some of them have a minimal vocabulary consisting of two or three words, a few can speak in basic sentences. Some patients use gestures to articulate themselves, the [[#Glossary | '''Picture Exchange Communication System (PECS)''']] or sign languages such as [[#Glossary | '''Makaton''']] can be used for communication. Simple demands regarding their everyday occurrence can be understood by most patients.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID12566516 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Clinical and External Characteristics'''[[File:Angelman Syndrome patient.png|thumb|200px|right|4 year old AS patient.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Developmental delays are present in all patients. Motor milestones are delayed with children managing to sit unsupported with 12 months and crawl or bottom shuffle at the age of 18-24 months. The average age for walking is 4 years,however, ranging from 18 months to 7 years.&lt;br /&gt;
The [[#Glossary | '''gait''']] is characterised as slow, and flapping hands are a common trait.  The legs remain stiff during walking, arms are inflected by the wrists and elbows. The movements can appear ataxic, jerky or lurching. The muscle tone shows abnormalities with truncal [[#Glossary | '''hypotonia''']] and [[#Glossary | '''hypertonicity''']] of the limbs and alert reflexes.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID12566516 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The most striking external traits present in patients include broad-spaced teeth, and a wide mouth, light hair and eye colour, hypopigmented skin, deep set eyes, and a flat [[#Glossary | '''occiput''']].&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Seizures in Angelman Syndrome'''&lt;br /&gt;
&lt;br /&gt;
85% of AS patients suffer from epileptic seizures during their first three years. The first appearance can be within one month up to 20 year old patients. In infants with AS epilepsy manifests with [[#Glossary | '''febrile convulsions''']] and is hard to manage during childhood.&lt;br /&gt;
The most common type of seizures within 25% of patients are [[#Glossary | '''myoclonic seizures''']], followed by [[#Glossary | '''atonic seizures''']] as the second most frequent type, then 21% experience generalised [[#Glossary | '''tonic-clonic seizures''']] and lastly [[#Glossary | '''atypical absences''']] occur in 12% of patients.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20398390&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Angelman Syndrome in adults'''&lt;br /&gt;
&lt;br /&gt;
Patients with Angelman syndrome possess normal secondary sexual characteristics, and puberty sets in at a usual time. Limb hypertonicity, and [[#Glossary | '''thoracic scoliosis''']] lead to decreasing mobility. [[#Glossary | '''Oesophagus reflux''']] might induce severe problems, and the majority suffers from obesity. Furthermore, facial traits such as a prominent lower lip [[#Glossary | '''macrostomia''']] and [[#Glossary | '''mandibular prognathism''']] get manifested in adults. &lt;br /&gt;
In some cases the communication barrier can lead to frustration, resulting in aggressive behaviour. Nonetheless, patients gain a higher concentration span with age, and their nature becomes more quiet.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Complications===&lt;br /&gt;
&lt;br /&gt;
'''Hypopigmentation and Ocular albinism'''&lt;br /&gt;
&lt;br /&gt;
OCA2 gene, also known as the P gene, is closely located to the UBE3A gene. It encodes a protein vital to tyrosine metabolism, which plays a role in pigmentation development of skin, hair and eyes. However, AS caused by the large deletion of UBE3A leads to haploinsufficiency of OCA2 gene, resulting in hypopigmentation of the skin and the eyes. In some children with severe hypopigmentation, some form of [[#Glossary | '''albinism''']] is suspected.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12749060&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; When AS is caused by another mechanism, no abnormality of the skin and eye pigmentation is observed. However, not all AS children with OCA2 gene deletion will present with obvious hypopigmentation, they may just exhibit lighter skin colour than their parents.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8302318&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Diagnosis==&lt;br /&gt;
&lt;br /&gt;
The diagnosis of Angelman Syndrome is a clinical diagnosis confirmed by laboratory testing.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This involves both prenatal and/or postnatal diagnosis. &lt;br /&gt;
&lt;br /&gt;
===Prenatal Diagnosis===&lt;br /&gt;
[[File:Angelman Syndrome Prenatal Diagnosis.jpg|thumb|250px|right|Flowchart of AS Diagnosis.]]&lt;br /&gt;
&lt;br /&gt;
Prenatal detection of deletions of 15q11.2-q13, [[#Glossary | '''Paternal UPD''']] (Uniparental Disomy), Imprinting defects and UBE3A mutations are done through DNA/chromosome/FISH analysis of fetal cells obtained by either [[#Glossary | '''Chorionic Villus Sampling''']](CVS) or [[#Glossary | '''Amniocentesis''']].&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot;/&amp;gt; &lt;br /&gt;
DNA methylation analysis using [[#Glossary | '''Amniocytes''']] is usually the first test carried out in molecular diagnosis of AS.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18059071&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; An abnormal result is followed up by either a FISH or array CGH analysis to search for a deletion on chromosome 15. If they produce a normal result, then UPD testing using DNA polymorphysims is carried out. If there is no evidence of UPD, other DNA analysis tests are used search for an imprinting centre deletion.&amp;lt;ref name=&amp;quot;PMID9792887&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9792887&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; A normal DNA methylation analysis is followed by a UBE3A sequence analysis.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt; In addition, a parent of origin test is also done to determine if the genetic disruption is of maternal origin or paternal origin. If it is maternally derived the fetus is diagnosed with AS (a paternally derived genetic disruption is indicative of Prader-Willi Syndrome).&amp;lt;ref name=&amp;quot;PMID17020468&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;17020468&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The flow chart summarizes the normal procedure used for prenatal diagnosis of AS. More information on important laboratory tests used for the diagnosis of Angelman Syndrome are provided below:&lt;br /&gt;
&lt;br /&gt;
*'''DNA Methylation Analysis'''&lt;br /&gt;
&lt;br /&gt;
Identifies approximately 80% of AS affected individuals and is usually the first test to be ordered.&amp;lt;ref name=&amp;quot;PMID7618904&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7618904&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Molecular disruptions such as deletions, paternal UPD and imprinting defects on chromosome 15 all demonstrate abnormal methylation patterns by either southern blot analysis or PCR amplification of bisulphate-treated DNA.&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot; /&amp;gt; An affected individual will only have an unmethylated (paternal) SNRPN (small nuclear ribonuclear protein-associated polypeptide N) allele compared with an unaffected individual who will have both a methylated and an unmethylated SNRPN allele.&amp;lt;ref name=&amp;quot;PMID9634532&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9634532&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
	  &lt;br /&gt;
*'''FISH (Fluorescent In Situ Hybridization)'''&lt;br /&gt;
&lt;br /&gt;
[[File:Critical_region_of_Angelman_Syndrome_on_chromosome_15.png‎|thumb|150px|right|FISH (fluorescence in situ hybridisation) image showing the critical region of Angelman Syndrome on chromosome 15.]]&lt;br /&gt;
&lt;br /&gt;
FISH analysis detects 5-7 Mb deletions in approximately 68% of affected individuals using detecting probes such as D15S10 and/or SNRPN.&amp;lt;ref name=&amp;quot;PMID7618904&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7618904&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It is also able to distinguish UPD from micro-deletions and imprinting defects. In simple terms, FISH analysis involves the binding of a fluorescent probe to a specific part of chromosome 15 and the detection of deletions within that region. FISH analysis is much more accurate in deletion detection compared to other high-resolution cytogenetics in the diagnosis of AS patients.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1511093&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
Array-based CGH is an advanced type of cytogenetic testing that can also be used to detect smaller deletions.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''UPD (Uniparental Disomy) Detection'''&lt;br /&gt;
&lt;br /&gt;
DNA Polymorphism testing detects paternal UPD in approximately 7% of affected AS individuals.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt; It is also able to distinguish between UPD and an Imprinting defect. It requires a DNA sample from the [[#Glossary | '''Proband''']] and from both parents. A homologous or non-homologous whole-arm translocation of the long arms of chromosome 15 is a sound indication for the need for prenatal UPD testing.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''IC (Imprinting Center) Analysis'''&lt;br /&gt;
&lt;br /&gt;
This type of analysis is used when individuals have an abnormal DNA methylation pattern but show normal results for  FISH, array CGH study and UPD analysis.&amp;lt;ref name=&amp;quot;PMID9792887&amp;quot;/&amp;gt; It is used to differentiate between the Imprinting defects caused by either microdeletions in the AS imprinting centre or by epigenetic mutations (that occur in maternal oogenesis or early embryogenesis).&amp;lt;ref name=&amp;quot;PMID9634532&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''Cytogenetic Testing'''&lt;br /&gt;
&lt;br /&gt;
Is used to detect a cytogenetically visible chromosomal rearrangement (large deletion, translocation or inversion) involving the 15q11.2-q13 region, which occurs in less than 1% of affected individuals.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''UBE3A Sequence Analysis'''&lt;br /&gt;
Sequence analysis of the UBE3A gene detects mutations in about 10% of the patients.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt; The test is used to detect either multiexonic (10 major coding exons of UBE3A) or whole gene deletions of UBE3A gene in individuals who produces a normal DNA methylation result but has characteristic clinical features of AS.&amp;lt;ref name=&amp;quot;PMID9792887&amp;quot;/&amp;gt;&lt;br /&gt;
This is recommended as a prenatal diagnostic tool in families that include multiple AS affected individuals because the imprinted pattern can be inherited from distant relatives.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Postnatal Diagnosis===&lt;br /&gt;
&lt;br /&gt;
Postnatal diagnosis is made though a combination of common clinical features of AS and UBESA gene sequence analysis.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt; The clinical features of AS include unsteady or shaky movements, muscle hypotonia, developmental delay and behavioral uniqueness such as frequent laughter/smiling and happy demeanor are features that are 100% consistent in all patients diagnosed with Angelman Syndrome.&amp;lt;ref name=&amp;quot;PMID18830393&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18830393&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; These clinical features become apparent between 6 months to 2 years of age. The onset of early or persistent smiling characteristic of this syndrome begin around the age of 1-3 months, but is often overlooked during infancy.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot;/&amp;gt; Thus early diagnosis of AS during infancy period is difficult because the clinical indicators of the syndrome takes time to manifest and characteristic features such as finger and hand tremors and excessive smiling/laughter are often overlooked and not considered as possible indicators of this syndrome.&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
*Rett Syndrome&lt;br /&gt;
&lt;br /&gt;
Some children with the clinical diagnosis of AS but no underlying genetic mechanism show mutations in ''MECP2'' gene, corresponding to Rett Syndrome. This should be suspected in AS test negative girls in the first few years of life.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17980307&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*Mowat-Wilson Syndrome&lt;br /&gt;
&lt;br /&gt;
Genetic mechanism is heterozygous deletion or truncation in ''ZFHX1B'' (''SIP1'') gene on 2q22. This presents with clinical features of severe intellectual disability, micrcephaly and seizures.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17958891&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Prader-Willi Syndrome patient.png|thumb|right|120px|12 year old PWS patient.]]&lt;br /&gt;
&lt;br /&gt;
*X-linked alpha-thalassemia/mental retardation syndrome (ATR-X)&lt;br /&gt;
&lt;br /&gt;
This arises from mutations in ''XNP'' gene on Xq13. ATR-X presents with severe intellectual disability, no speech development and seizures are common.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11449489&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*Phelan-McDermid Syndrome/22q13 deletion syndrome&lt;br /&gt;
&lt;br /&gt;
Deletions are usually submicroscopic and thus requires special molecular cytogenetic methods to confirm this deletion. Patients show moderate to profound intellectual disability and delay in speech development.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18505557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Related Disease'''&lt;br /&gt;
&lt;br /&gt;
*Prader-Willi Syndrome(PWS)&lt;br /&gt;
&lt;br /&gt;
PWS is a result from the absence of paternally expressed 15q11-q13 gene as a corollary of de novo deletion, maternal uniparental disomy of chromosome 15 or an imprinting defect on paternal chromosome 15 leading to the silencing of paternal alleles.&amp;lt;ref name=&amp;quot;PMID:20668179 &amp;quot;/&amp;gt; It is characterized by [[#Glossary | '''hyperphagia''']], obesity in later infancy and early childhood and difficulty in feeding during early infancy.&amp;lt;ref name=&amp;quot;PMID:20668179 &amp;quot;/&amp;gt; There is also cognitive impairment to some extent, though some PWS patients may exhibit intelligence in the normal IQ range. Behavioral phenotypes include stubbornness, manipulative tendency, obsessive compulsive characteristics.&amp;lt;ref name=&amp;quot;PMID:20668179 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Genetic Counselling==&lt;br /&gt;
&lt;br /&gt;
Genetic counselling is the process by which patients or relatives, at risk of an inherited disorder, are advised of the consequences and nature of the disorder, the probability of developing or transmitting it, and the options open to them in management and family planning. In the case for Angelman syndrome, types of risks associated are split into classes and formatted into the table below:&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20459762&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{|  style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
! Class&lt;br /&gt;
! Mechanism&lt;br /&gt;
! Risk to siblings&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! Ia                           &lt;br /&gt;
| De novo deletion                                                                                                               &lt;br /&gt;
| &amp;lt;1%                                                                                                                &lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! Ib&lt;br /&gt;
| Deletion due to chromosome rearrangement&lt;br /&gt;
| Up to 50%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! II&lt;br /&gt;
| Paternal uniparental disomy (UPD)&lt;br /&gt;
| &amp;lt;1%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! IIIa&lt;br /&gt;
| Imprinting defect with IC mutation&lt;br /&gt;
| Close to 100% if father has 15; 15 [[#Glossary | '''Robertsonian translocation''']]&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! IIIb&lt;br /&gt;
| Imprinting defect without IC mutation&lt;br /&gt;
| Up to 50% (if mother has IC deletion)&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! IIIc&lt;br /&gt;
| [[#Glossary | '''Mosaic''']] imprinting defect&lt;br /&gt;
| &amp;lt;1%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! IV&lt;br /&gt;
| ''UBE3A'' mutation&lt;br /&gt;
| Up to 50% (if mother has mutation)&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! V&lt;br /&gt;
| No identifiable genetic abnormality&lt;br /&gt;
| ?&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Ia''': Individuals with de novo deletion have 1% risk to siblings&lt;br /&gt;
&lt;br /&gt;
'''Ib''': Risk to siblings in individuals with chromosomal rearrangements is up to 50% &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9557895&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''II''': Paternal UPD with no Robertsonian translocation has a risk to sibling of less than 1%&lt;br /&gt;
&lt;br /&gt;
'''IIIa''': The risk to siblings in individuals with AS from an imprinting defect with a mutation in the imprinting center (IC) is close to 100% if father has 15;15 Robertsonian translocation&lt;br /&gt;
&lt;br /&gt;
'''IIIb''': Individuals with AS resulting from an imprinting defect without IC mutation, but with a carrier mother has a high risk to siblings of up to 50%. The mother could be phenotypically normal due to paternal inheritance of the genetic defect &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11283796&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''IIIc''': Individuals who are mosaic for the imprinting defect have less than 1% risk to siblings&lt;br /&gt;
&lt;br /&gt;
'''IV''': UBE3A mutation can be either inherited or de novo mutation. If the mother is a carrier for this genetic mutation, the risk to siblings is up to 50% &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11258627&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''V''': Individuals who present with AS clinically, but have no known underlying mechanism have an unknown risk to siblings.&lt;br /&gt;
&lt;br /&gt;
==Treatment and Management==&lt;br /&gt;
&lt;br /&gt;
Even though at present there is no known cure for Angelman syndrome, there are a number of treatments available that may alleviate symptons and improve daily life activities.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The below table describes the problems and management options that are used:&lt;br /&gt;
&lt;br /&gt;
[[File:Subtle Finger tremors-Angelman Syndrome.jpg|right|thumb|150px|A five months old boy with Angelman syndrome showing signs of Subtle Finger tremor.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
! Problems encountered&lt;br /&gt;
! Treatment and Management&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''Difficulty in feeding newborn AS babies'''&lt;br /&gt;
| Use of special nipples may improve feeding&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Oesophagus reflux'''&lt;br /&gt;
| Special motility medications requiried or upright positioning&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''Seizures'''&lt;br /&gt;
| Anticonvulsant medications&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19605773&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19453717&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Ocular problems'''&lt;br /&gt;
| Visual assessment is vital to encourage interactions and minimize chances of self-harm and autism development&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20656169&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''Drooling in developmental delayed AS patients'''&lt;br /&gt;
| Difficult to treat, but new surgical procedure on salivary duct reimplantation seems to be a promising alternative&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17699119&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Unstable children''' &lt;br /&gt;
| Physical therapy&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''AS patients become less active with increasing age'''&lt;br /&gt;
| Activity schedules to prevent scoliosis and obesity. Occupational therapy to stimulate fine motor and oral-motor control skills in conjunction to speech therapy&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Sleeping difficulty'''&lt;br /&gt;
| Sedative medication in severe cases. [[#Glossary | '''Melatonin''']] may be used to promote sleeping but some studies have found that it loses its therapeutic effects after several weeks in most AS patients&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19379289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|-&lt;br /&gt;
|colspan=&amp;quot;4&amp;quot; |&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Prognosis==&lt;br /&gt;
&lt;br /&gt;
Life expectancy of AS patients seems to be normal&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, but there is still a high degree of developmental delay and limited expressive language skills.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17019625&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This problem arises prominently in the assessment of the severity of coincidental medical conditions due to difficulties in communication. A visit to the dentist can become difficult if good communication is not conveyed between the parents, the dentist, and the child.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18271768&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Some problems require extreme measures, such as the procedure of lens implantation was performed in both eyes of a person diagnosed with AS, due to the inability to wear spectacles.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20656169&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
During adulthood, menstruation and puberty begin at around average age evidenced by females with Angelman syndrome that are fully capable of conceiving children.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11258627&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Most adult patients can feed themselves, but needed help with many other daily activities. Main troubles which have shown in adults are a tendency to become obese and start developing  thoracic scoliosis, which some adults with AS begin wheelchair bounded.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9072912&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Current and Future Research==&lt;br /&gt;
&lt;br /&gt;
Currently there is no cure for the treatment of AS, so much research is being carried out for therapeutic interventions. Findings in the last five years have suggested through various mice and fruit fly models that the absence of maternal UBE3A results in the same human AS features of neurological defects and seizures. However, more recently, studies have outlined that the symptoms of AS can be improved by modifying other gene products. In addition, restoring of a functional UBE3A protein into adult mice neurons have shown to reduce motor and neurological deficits and balance disorders. This shows promising research prospects in that improvements may be possible in human AS patients by restoring functional UBE3A proteins into their neurons. &lt;br /&gt;
&lt;br /&gt;
===Possible Treatment Pathways===&lt;br /&gt;
&lt;br /&gt;
*'''Cognitive and physical impairment'''&lt;br /&gt;
&lt;br /&gt;
Although everyone is born with two copies of the gene UBE3A, one maternal and one paternal copy, it is only the maternal UBE3A that is used in the brain. Most AS patients have a genetic mutation on the maternal chromosome 15 that results in dysfunctional UBE3A.&amp;lt;ref&amp;gt;http://www.cureangelman.org/what-hope.html&amp;lt;/ref&amp;gt; The above research focused on turning on the father's copy of UBE3A to restore its functions. Furthermore, mouse models were utilized to show that alpha-CaMKII could be increased to compensate the loss of UBE3A and restore compromised mental and physical abilities. However, this finding still requires much more research.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17259980&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''Epilepsy'''&lt;br /&gt;
&lt;br /&gt;
There is research being done on improving certain conditions that are involved in AS by nutritional benefits. The use of [[#Glossary | '''corticosteroids''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19666884&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, [[#Glossary | '''valproate''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19453717&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and [[#Glossary | '''clonazepam''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19605773&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and having a [[#Glossary | '''ketogenic diet''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20880305&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; has all been shown to aid in the treatment of epilepsy. It has also been reported to be efficient in the treatment of other conditions, such as behavioural disorders, reduction in seizures, ataxia, sleep patterns, developmental progress and sleep disturbances. [[#Glossary | '''Levetiracetam''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17326790&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; could be used in such a situation, especially when the patient has an intolerance to valproate and clonazepam.&lt;br /&gt;
&lt;br /&gt;
*'''Betaine and Folic acid'''&lt;br /&gt;
&lt;br /&gt;
This double-blind placebo-controlled study was done to examine the potential therapeutic role of [[#Glossary | '''betaine''']] and [[#Glossary | '''folic acid''']] in the treatment of the clinical phenotypes of AS. The aim of this protocol was to increase methylation and activate the paternally inherited UBE3A in hope to compensate for the inactive maternal UBE3A. Although there were no major differences in the control and treatment groups, a small number of patients in the treatment group showed some positive outcomes.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20635355&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&lt;br /&gt;
'''albinism''': A congenital disorder distincted by the complete or partial absence of pigment in the skin, hair and eyes due to defect of an enzyme involved in the production of melanin.&lt;br /&gt;
&lt;br /&gt;
'''allele''': Dissimilar variant of one gene. Organisms have two alleles for each gene inherited from their parents, one from each of them.&lt;br /&gt;
&lt;br /&gt;
'''alpha-CaMKII''': (alpha calcium calmodulin kinase II) Compound involved in synaptic plasticity, one of the most important theories behind learning and memory. Ability of a synapse between two neurons to change in strength due to the use or disuse of transmission.&lt;br /&gt;
&lt;br /&gt;
'''Amniocytes''': Cells that are shed by the fetus during fetal development to the surrounding amniotic fluid. They are a source of fetal DNA. &lt;br /&gt;
&lt;br /&gt;
'''Amniocentesis''': (AFT or amniotic fluid test) is a prenatal diagnostic test used to detect chromosomal abnormalities in the developing fetus by extracting amniotic fluid (a source of fetal DNA) surrounding the fetus. &lt;br /&gt;
&lt;br /&gt;
'''AMPA''': (2-amino-3-(5-methyl-3-oxo-1,2- oxazol-4-yl)propanoic acid) Compound that binds to the AMPA receptor to imitate glutamate neurotransmitter.&lt;br /&gt;
&lt;br /&gt;
'''Arc''': Activity-Regulated Cytoskeleton-associated protein; involved in learning and memory.&lt;br /&gt;
&lt;br /&gt;
'''ataxia''': Lack of coordination in muscle movements.&lt;br /&gt;
&lt;br /&gt;
'''atonic seizures''': A abrupt loss of muscle tone, this can lead to the limbs loosing strength, or the head may drop to the side. The patient remains conscious during this kind of epileptic seizure.&lt;br /&gt;
&lt;br /&gt;
'''atypical absences''': Seizure leads to unconsciousness in most cases.  &lt;br /&gt;
&lt;br /&gt;
'''autism''': A neural development disorder defined by limited social interaction and communication.&lt;br /&gt;
&lt;br /&gt;
'''betaine''': Also known as  betaine anhydrous or trimethylglycine (TMG), assists the body in metabolising the amino acid, homocysteine. Can be consumed via beets, broccoli, grains, shellfish, and spinach.&lt;br /&gt;
&lt;br /&gt;
'''cerebellum''': Region of the brain that plays an important role in motor control. It is also involved in some cognitive functions such as attention and language.&lt;br /&gt;
&lt;br /&gt;
'''Chorionic Villus Sampling''': A prenatal diagnostic test used to detect chromosomal abnormalities in the developing fetus by extracting and testing chorionic villus (placental tissue). &lt;br /&gt;
&lt;br /&gt;
'''chromosome''': Structure consisting of coiled DNA with DNA associated proteins such as histones.&lt;br /&gt;
&lt;br /&gt;
'''clonazepam''': A psychoactive drug having muscle relaxant properties and treats anxiety and epilepsy.&lt;br /&gt;
&lt;br /&gt;
'''corticosteroid''': A type of steroid hormones that are produced in the adrenal cortex.&lt;br /&gt;
&lt;br /&gt;
'''cytogenetics''': Study of the structure, function and abnormality of the cell, especially the chromosome.&lt;br /&gt;
&lt;br /&gt;
'''deletion''': Lack of a part of the DNA (deoxyribonucleic acid is a nucleic acid containing information for protein synthesis), can vary form a single base to a hole gene. &lt;br /&gt;
&lt;br /&gt;
'''de novo mutation''': Change in a gene of a family member for the first time due to a mutation in the egg or sperm of the parents or in the fertilized egg (zygote).&lt;br /&gt;
&lt;br /&gt;
'''disorder''': A mental or physical health disturbance or dysfunction.&lt;br /&gt;
&lt;br /&gt;
'''EEG''': Electroencephalography is a means of measuring electrical activity along the scalp by measuring the total electrical charges fired by thousands or millions of neurons.&lt;br /&gt;
&lt;br /&gt;
'''epilepsy''': Neurological disorder characterised by recurrent impairment of brain function that can cause seizures or unconsciousness. &lt;br /&gt;
&lt;br /&gt;
'''E6-AP''': E6-AP ubiquitin-protein ligase is an enzyme encoded by UBE3A which adds ubiquitin chain to target proteins to be degraded by proteasomes.&lt;br /&gt;
&lt;br /&gt;
'''febrile convulsions''': The occurrence of high fever, especially in children.&lt;br /&gt;
&lt;br /&gt;
'''FISH''': Fluorescent in situ hybridization is a technique used to identify and localize the presence or absence of DNA sequences on the chromosome. This is achieved by using fluorescently labelled DNA sequences which then binds to complementary DNA sequence on the chromosome. After hybridization (attachment), chromosome of interest will fluoresce under the microscope.&lt;br /&gt;
&lt;br /&gt;
'''folic acid''': B vitamin that helps the body make healthy new cells. Can be consumed via leafy green vegetables, fruits, dried beans, peas and nuts.&lt;br /&gt;
&lt;br /&gt;
'''gait''': A manner of walking, stepping or running.&lt;br /&gt;
&lt;br /&gt;
'''gene''': A molecular unit of heredity of a living organism.&lt;br /&gt;
&lt;br /&gt;
'''hippocampus''': Area buried deep in the forebrain that helps regulate emotion and memory&lt;br /&gt;
&lt;br /&gt;
'''hyperphagia''': (Also referred to as Polyphagia) Excessive ingestion of food beyond the dietary and energy requirements of the body. &lt;br /&gt;
&lt;br /&gt;
'''hypermotoric''': Sudden appearance of uncontrolled movements such as striking or kicking inappropriately.&lt;br /&gt;
&lt;br /&gt;
'''hypertonicity''': Increase of muscle tension and a disability to stretch leading to an impairment of motor activity.&lt;br /&gt;
&lt;br /&gt;
'''hypopigmentation''': A lack of melanin pigments or melanocytes  affecting the colour of the skin, hair and iris. Features appear to be light-coloured due to loss of skin colour.&lt;br /&gt;
&lt;br /&gt;
'''hypotonia''': Decrease in the ability to stretch passively, due to a low muscle tone. &lt;br /&gt;
&lt;br /&gt;
'''imprinting''': This is a process to describe the modification of a maternally or paternally derived chromosome, which consequently influences the expression of certain genes on the altered chromosome.&lt;br /&gt;
&lt;br /&gt;
'''ketogenic diet''': A high-fat, low-carbohydrate diet that is used to treat epilepsy in children.&lt;br /&gt;
&lt;br /&gt;
'''levetiracetam''': An anticonvulsant drug used to treat epilepsy.&lt;br /&gt;
&lt;br /&gt;
'''locus''': Location of a gene on a chromosome(loci: plural for locus).&lt;br /&gt;
&lt;br /&gt;
'''LTP''': Long-term potentiation shares common features with long term memory. It strengthens and enhances signal transmission between neurons by improving the communication between two neurons.&lt;br /&gt;
&lt;br /&gt;
'''macrostomia''': A wide-spaced mouth.&lt;br /&gt;
&lt;br /&gt;
'''Makaton''': Language programme using symbols and signs to support speaking.&lt;br /&gt;
&lt;br /&gt;
'''mandibular prognathism''': The abnormal protrusion of the lower jaw. &lt;br /&gt;
&lt;br /&gt;
'''maxillary hypoplasia''':  The underdevelopment of the upper jaw.&lt;br /&gt;
&lt;br /&gt;
'''melatonin''': A hormone secreted by the pineal gland.&lt;br /&gt;
&lt;br /&gt;
'''microcephaly''': The circumference of the head is less than average due to abnormalities of the nervous system. This abnormality can be present at birth or emerge during the first few years of life and reduces both life expectancy and the cognitive functions of the individual affected.&lt;br /&gt;
&lt;br /&gt;
'''microdeletion''':  A genetic mutation in which a part of a chromosome or a sequence of DNA is missing.&lt;br /&gt;
&lt;br /&gt;
'''mosaic''': tissues or cells containing different mixture of genetic sequences&lt;br /&gt;
&lt;br /&gt;
'''mutation''': Event that changes the DNA (deoxyribonucleic acid is a nucleic acid, containing information for protein synthesis) or RNA (ribonucleic acid is a type of nucleic acid transmitting the information from the DNA to the proteins ) of a gene permanently.&lt;br /&gt;
&lt;br /&gt;
'''myoclonic seizures''': A quick jerk of the skeletal muscle, due to a irregular brain activity.&lt;br /&gt;
&lt;br /&gt;
'''neurogenetic''': Genetic basis of the nervous system.&lt;br /&gt;
&lt;br /&gt;
'''neuron''': Cells of the nervous system that can be electrically excited to transmit information by electrical and chemical signaling&lt;br /&gt;
&lt;br /&gt;
'''neurotransmitter''': Transmits neuronal signals to a target cell. They are first packaged in vesicles just beneath the membrane of presynaptic axon terminals and released into the synaptic cleft (space between the two interacting neurons) and enter the postsynaptic dendrite.&lt;br /&gt;
&lt;br /&gt;
'''occiput''': The back portion of the head.&lt;br /&gt;
&lt;br /&gt;
'''oesophagus reflux''': Impairment of a sphincter in the lower end of the oesophagus leads to the back flow of stomach acid into the oesophagus. Heartburn is a typical symptom.&lt;br /&gt;
&lt;br /&gt;
'''olfactory tract''': It is a pathway for the sense of smell containing axons from some of the neurons in the olfactory bulb.&lt;br /&gt;
&lt;br /&gt;
'''paediatrician''': Physicians that specialise on infants, children and adolescents.&lt;br /&gt;
&lt;br /&gt;
'''paternal UPD''': Inheritance of two copies of a chromosome from the father and none from the mother. &lt;br /&gt;
&lt;br /&gt;
'''phenotype''': Visible traites of an organism determined by genetic and environmental factors.&lt;br /&gt;
&lt;br /&gt;
'''Picture Exchange Communication System (PECS)''': Individuals communicate using images instead of words. It is frequently used by children with autism, to articulate their needs and wishes or to make comments about something.&lt;br /&gt;
&lt;br /&gt;
'''Proband''': Is the person (or animal) being studied or reported on in a genetic investigation. Most commonly it refers to the first affected family member who requires medical help for a genetic disorder. &lt;br /&gt;
&lt;br /&gt;
'''Purkinje cells''': Large neuron with many branching extensions that is found in the cortex of the cerebellum of the brain and plays a fundamental role in controlling motor movement&lt;br /&gt;
&lt;br /&gt;
'''Robertsonian translocation''': Rearrangement of the chromosome, occurs in 5 chromosome including 13,14,15,21 and 22. This type of mutation occurs in chromosomes with the centromere not at the centre, resulting in long and short arm chromosomes. Translocation breaks the chromosome at the centromere so the long arm attaches to the other long arm, and the same for the short arm happens. Cell division will result in the loss of the short arms as they do not contain important genes.&lt;br /&gt;
&lt;br /&gt;
'''seizure''': Abnormal electrical activity in the brain that can result in a variety of physical symptoms like convulsion, body shaking, loss of consciousness, confusion, and mood changes.&lt;br /&gt;
&lt;br /&gt;
'''synapse''': Allows transmission of signal between neurons for effective neuronal function.&lt;br /&gt;
&lt;br /&gt;
'''thoracic scoliosis''': The spine is curved laterally(from side to side) in the thoracic region.&lt;br /&gt;
&lt;br /&gt;
'''tonic-clonic seizures''': This type of seizure is associated with unconsciousness due to electrical discharges in a big proportion of the brain.&lt;br /&gt;
&lt;br /&gt;
'''ubiquitin''': A polypeptide found in all eukaryotic cells, that participates in a variety of cellular functions including protein recycling.&lt;br /&gt;
&lt;br /&gt;
'''Uniparental disomy''': (UPD) the inheritance of two copies of a chromosome pair or part of a chromosme from one parent and no copy from the other parent. &lt;br /&gt;
&lt;br /&gt;
'''valproate''':  A mood-stabilizing drug that is also used for treatment for epilepsy and bipolar disorder.&lt;br /&gt;
&lt;br /&gt;
==Helpful Links==&lt;br /&gt;
&lt;br /&gt;
* Australia&lt;br /&gt;
:* [http://www.angelmansyndrome.org/research.html Angelman Syndrome Association] &lt;br /&gt;
:* [http://www.angelmansyndromeqld.org/ Queensland Angelman Association]&lt;br /&gt;
&lt;br /&gt;
* America&lt;br /&gt;
:* [http://www.angelman.org/ Angelman Syndrome Foundation]&lt;br /&gt;
:* [http://rarediseasesnetwork.epi.usf.edu/arpwsc/ Rare Clinical Diseases Research Network]&lt;br /&gt;
:* [http://www.rarediseases.org/rare-disease-information/rare-diseases/byID/411/viewAbstract National Organisation for Rare Disorders]&lt;br /&gt;
:* [http://www.epilepsyfoundation.org/ Epilepsy Foundation]&lt;br /&gt;
:* [http://www.cureangelman.org/ Foundation for Angelman Syndrome Therapeutics]&lt;br /&gt;
&lt;br /&gt;
* Search Pubmed &lt;br /&gt;
:* [http://www.ncbi.nlm.nih.gov/pubmed?term=angelman%20syndrome Angelman Syndrome] &lt;br /&gt;
&lt;br /&gt;
* OMIM entries for Angelman Syndrome&lt;br /&gt;
:* [http://omim.org/entry/105830 ANGELMAN SYNDROME; AS]&lt;br /&gt;
:* [http://omim.org/entry/601623 UBIQUITIN-PROTEIN LIGASE E3A; UBE3A]&lt;br /&gt;
&lt;br /&gt;
==Related Links==&lt;br /&gt;
&lt;br /&gt;
'''Animal Models'''&lt;br /&gt;
&lt;br /&gt;
* [[Mouse Knockout]] - this page explains the current use of mouse models in disrupting genes to elucidate their genetic function, including the mouse gene knockouts for alpha calcium-calmodulin kinase II (alpha CaMKII)&lt;br /&gt;
* [[2009 Group Project 4]] - this page gives an extensive overview on the history of the mouse model and its various use in embryology and genetics. In addition, it also describes mouse knockout and the role they play in current research of various human diseases&lt;br /&gt;
* [[Fly Development]] - this page describes the use of drosophila flies as developmental models&lt;br /&gt;
* [[2009 Group Project 2]] - this page gives an extensive overview on the history of the fly model and its various use in embryology and genetics&lt;br /&gt;
&lt;br /&gt;
'''Diagnosis'''&lt;br /&gt;
* [[Chorionic villus sampling]] - this page explains the process of chorionic villus sampling, its disadvantages and gives a brief overview of recent findings&lt;br /&gt;
* [[Amniocentesis]]- this page shows some of the recent findings in this area&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&lt;br /&gt;
&amp;lt;references /&amp;gt;&lt;/div&gt;</summary>
		<author><name>Z3291643</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=File:Prader-Willi_Syndrome_patient.png&amp;diff=77808</id>
		<title>File:Prader-Willi Syndrome patient.png</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=File:Prader-Willi_Syndrome_patient.png&amp;diff=77808"/>
		<updated>2011-10-13T02:11:23Z</updated>

		<summary type="html">&lt;p&gt;Z3291643: /* Reference */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;A 12 year old Prader Willi Syndrome patient with the common characteristic of obesity&lt;br /&gt;
&lt;br /&gt;
===Reference===&lt;br /&gt;
&lt;br /&gt;
FRIDMAN, Cintia  and  KOIFFMANN, Célia P.. Genomic imprinting: genetic mechanisms and phenotypic consequences in Prader-Willi and Angelman syndromes. Genet. Mol. Biol. [online]. 2000, vol.23, n.4, pp. 715-724 . Available from: &amp;lt;http://www.scielo.br/scielo.php?script=sci_arttext&amp;amp;pid=S1415-47572000000400004&amp;amp;lng=en&amp;amp;nrm=iso&amp;gt;. ISSN 1415-4757.  http://dx.doi.org/10.1590/S1415-47572000000400004&lt;br /&gt;
&lt;br /&gt;
This paper is not available in Pubmed&lt;br /&gt;
&lt;br /&gt;
All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License &lt;br /&gt;
You are free:&lt;br /&gt;
to Share — to copy, distribute and transmit the work to Remix — to adapt the work &lt;br /&gt;
&lt;br /&gt;
http://creativecommons.org/licenses/by-nc/3.0/&lt;br /&gt;
&lt;br /&gt;
{{Template:2011 Student Image}}&lt;/div&gt;</summary>
		<author><name>Z3291643</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=File:Angelman_Syndrome_patient.png&amp;diff=77803</id>
		<title>File:Angelman Syndrome patient.png</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=File:Angelman_Syndrome_patient.png&amp;diff=77803"/>
		<updated>2011-10-13T02:10:11Z</updated>

		<summary type="html">&lt;p&gt;Z3291643: /* Reference */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;This is a photograph of a 4 year old Angelman syndrome (AS) patient, highlighting the typical facial characteristics of AS, such as big gapped teeth&lt;br /&gt;
&lt;br /&gt;
===Reference===&lt;br /&gt;
&lt;br /&gt;
FRIDMAN, Cintia  and  KOIFFMANN, Célia P.. Genomic imprinting: genetic mechanisms and phenotypic consequences in Prader-Willi and Angelman syndromes. Genet. Mol. Biol. [online]. 2000, vol.23, n.4, pp. 715-724 . Available from: &amp;lt;http://www.scielo.br/scielo.php?script=sci_arttext&amp;amp;pid=S1415-47572000000400004&amp;amp;lng=en&amp;amp;nrm=iso&amp;gt;. ISSN 1415-4757.  http://dx.doi.org/10.1590/S1415-47572000000400004&lt;br /&gt;
&lt;br /&gt;
This paper is not available in Pubmed&lt;br /&gt;
&lt;br /&gt;
All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License &lt;br /&gt;
You are free:&lt;br /&gt;
to Share — to copy, distribute and transmit the work to Remix — to adapt the work &lt;br /&gt;
&lt;br /&gt;
http://creativecommons.org/licenses/by-nc/3.0/&lt;br /&gt;
&lt;br /&gt;
{{Template:2011 Student Image}}&lt;/div&gt;</summary>
		<author><name>Z3291643</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_7&amp;diff=77726</id>
		<title>2011 Group Project 7</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_7&amp;diff=77726"/>
		<updated>2011-10-13T00:00:45Z</updated>

		<summary type="html">&lt;p&gt;Z3291643: /* Pathogenesis */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;='''Angelman Syndrome'''=&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Introduction==&lt;br /&gt;
&lt;br /&gt;
[[File:Dr Harry Angelman.jpg|thumb|130px|right|Dr Harry Angelman.]]&lt;br /&gt;
Angelman syndrome (AS) is a rare [[#Glossary | '''neurogenetic''']] [[#Glossary | '''disorder''']] first described by Dr. Harry Angelman in 1965.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18754889&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Dr. Angelman was an English [[#Glossary | '''paediatrician''']] who first diagnosed the disease in 3 children with a developmental delay.&amp;lt;ref&amp;gt;http://www.ncbi.nlm.nih.gov/books/NBK22221/&amp;lt;/ref&amp;gt; AS occurs in 1 in 10000-20000 births, the exact number is still unknown.&amp;lt;ref name=&amp;quot;PMID7573182&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7573182&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;PMID8703225&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;8703225&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It is caused by maternal [[#Glossary | '''allele''']] disruptions of a single gene- UBE3A. Either [[#Glossary | '''mutations''']] or [[#Glossary | '''deletions''']] of the UBE3A gene results in AS. &lt;br /&gt;
&lt;br /&gt;
AS presents with well known [[#Glossary | '''phenotypes''']] during infancy and adulthood, such as [[#Glossary | '''microcephaly''']] and [[#Glossary | '''maxillary hypoplasia''']]. However, these features become more marked with age. Most frequent clinical features include delayed development,[[#Glossary | '''seizures''']],[[#Glossary | '''ataxia''']], impairment of speech, happy demeanor, behavioural problems such as hyperactivity, short attention span and sleeping difficulty.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21592595&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21484597&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;ASAwebsite&amp;quot;&amp;gt;http://www.angelmansyndrome.org/home.html&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
At present, there is no cure for the syndrome, though current research is focused at improving life quality of patients with Angelman syndrome through management of daily tasks.&amp;lt;ref&amp;gt;http://www.bbc.co.uk/health/physical_health/conditions/angelman1.shtml&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==History==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Dr. Harry Angelman first reported Angelman Syndrome on three handicapped children that were admitted to his ward in England in 1964.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt; He reported how these three independent and unconnected clinical cases all had the same characteristic features of severe developmental delay, jerky movements, seizures and a happy disposition.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt; However it was only when he stumbled upon an oil painting called ‘a Boy with a Puppet” while on a holiday in Italy he was able to connect the symptoms of all three children under one common cause.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20981772&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; He linked the happy face of the boy depicted on the painting with the jerky movements and happy disposition he observed on his three patients back in England. He reported his findings on a paper entitled “Puppet children (a report on three cases)” which was published in 1965.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
The syndrome was initially named ‘Puppet Syndrome’ but was later changed to Angelman Syndrome. Due to the extreme rarity of the syndrome and lack of sufficient clinical evidence the syndrome was soon forgotten.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt;&lt;br /&gt;
[[File:Dr Charles Williams.jpg|thumb|right|150px|Dr Charles Williams.]]&lt;br /&gt;
	&lt;br /&gt;
In 1987, a physician named Ellen Magenis, came across children with deletions on [[#Glossary | '''chromosome''']] 15 that were suffering from seizures and severe developmental delay.&amp;lt;ref&amp;gt;http://www.angelman.org/stay-informed/facts-about-angelman-syndrome---7th-edition/harry-angelman-and-the-history-of-as/&amp;lt;/ref&amp;gt; Even though genetically the children were expected to have [[#Diagnosis | '''Prader-Willi syndrome''']] that was characterised by deletions on chromosome 15, their characteristic symptoms of seizures and lack of development did not correspond with that of the syndrome. This led to the realization that these children had deletions on the maternally derived chromosome 15 and not on the paternally derived chromosome as was observed in Prader-Willi syndrome.  Thus the deleted genetic code on maternally derived chromosome 15 was identified as the genetic marker for Angelman Syndrome.&lt;br /&gt;
&lt;br /&gt;
In 1997, UBE3A gene was isolated by Dr. Joseph Wagstaff and Dr. Arthur Beaudet as the cause of Angelman Syndrome.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot; /&amp;gt; The discovery of this [[#Glossary | '''gene''']] led to the subsequent development of animal models and research aimed at finding a causal link between UBE3A gene abnormalities and characteristic features observed in Angelman Syndrome. &lt;br /&gt;
	&lt;br /&gt;
Currently, four different genetic abnormalities for Angelman Syndrome have been confirmed by genetic testing. They include: Deletion, [[#Glossary | '''Uniparental Disomy''']] (UPD), [[#Glossary | '''Imprinting''']] and UBE3A mutation.&amp;lt;ref name=&amp;quot;PMID20211139&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Below is a timeline, summarising the key discoveries and advancements of the Angelman Syndrome:&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|- bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
!Year&lt;br /&gt;
!Milestone&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1964'''&lt;br /&gt;
|First observed by Dr Harry Angelman on three handicapped children.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot; /&amp;gt; &lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''1965'''&lt;br /&gt;
|Harry Angelman publishes his finding in a report entitled 'Puppet Children'(a report on three cases).&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1980s'''&lt;br /&gt;
|First reports of AS reaches US and research into the disorder being at the University of Florida under the direction of Dr. Charles Williams.&amp;lt;ref&amp;gt;http://www.angelmanproject.com/history.htm&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''1982'''&lt;br /&gt;
|Name changed from 'Happy Puppet' to Angelman syndrome by Williams and Frias. &lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1987'''&lt;br /&gt;
|Discovery of a genetic marker for AS – an absent genetic code on maternally derived chromosome 15. &lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''1997'''&lt;br /&gt;
|The cause of AS discovered by Dr. Joseph Wagstaff and Dr. Arthur Beaudet – mutation or deletion in the UBE3A gene.&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1998'''&lt;br /&gt;
|Transgenic mice with absent maternal UBE3A created to illustrate motor and learning deficits in addition to seizures.&amp;lt;ref name=&amp;quot;PMID9808466&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9808466&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''2007'''&lt;br /&gt;
|AS mouse model shows that neurological deficits can be reversed by decreasing levels of [[#Glossary | '''alpha-CaMKII''']] inhibitory phosphorylation.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17259980&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''2010'''&lt;br /&gt;
|Discovery of a another gene mutation in TC4 gene (on chromosome 18) in a small number of clinically diagnosed patients with no identifiable genetic alternation in UBE3A.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20184619&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''2010'''&lt;br /&gt;
|Protein named Arc identified as a target of AS gene product; UBE3A.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Incidence'''&lt;br /&gt;
*The current population of people diagnosed with AS is unknown but studies have estimated the number to be around 1:10,000&amp;lt;ref name=&amp;quot;PMID7573182&amp;quot; /&amp;gt; and 1:20,000&amp;lt;ref name=&amp;quot;PMID8703225&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
'''Diagnosis'''&lt;br /&gt;
*The mean age of diagnosis for patients with AS lies between 6 and 6.5 years of age.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18664077&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15741136&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Gender'''&lt;br /&gt;
* Males appear to be at higher risk for some aspects of early developmental delays in comparison to females with AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17019625&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Demography'''&lt;br /&gt;
*Europe:&lt;br /&gt;
:Denmark- 1:10,000&amp;lt;ref name=&amp;quot;PMID7573182&amp;quot; /&amp;gt;&lt;br /&gt;
:Estonia- 1:52,000&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16906556&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
:Sweden- 1:20,000&amp;lt;ref name=&amp;quot;PMID8703225&amp;quot; /&amp;gt;&lt;br /&gt;
*Australia:&lt;br /&gt;
:Western Australia- 1:40,000&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16492624&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Aetiology==&lt;br /&gt;
&lt;br /&gt;
[[File:Chromosome 15 Deletion of 15q11.2 to 15q13.jpg|thumb|100px|Chromosome 15 - The deletion occurs at 15q11.2-15q13.]]&lt;br /&gt;
&lt;br /&gt;
'''Molecular Genetics'''&lt;br /&gt;
&lt;br /&gt;
* Location: 15q11-q13&lt;br /&gt;
* Protein product: Ubiquitin protein ligase E3A&lt;br /&gt;
* Gene name: UBE3A&lt;br /&gt;
* Phenotype: Angelman Syndrome&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Genetic Causes'''&lt;br /&gt;
&lt;br /&gt;
Different genetic mechanisms lead to different clinical phenotypes of AS. The most common genetic mechanism leading to AS is the deletion or re-arrangement of maternal chromosome at [[#Glossary | '''locus''']] 15q11.2-q13,as the chromosome image shows on the right, accounting for 70% of AS occurrences.&amp;lt;ref name=&amp;quot;PMID8988171&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt; 8988171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This leads to more severe clinical phenotypes of microcephaly, motor difficulties, seizures and impaired speech development. The next most common genetic mechanism is mutation in the UBE3A gene responsible for 10% of AS cases and paternal uniparental disomy and mutation in the imprinting centre (IC), both accounting for 2-5% of AS observed.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
 &lt;br /&gt;
&lt;br /&gt;
AS is caused by the 4 major genetic mechanisms mentioned above and are thus divided into Classes I to IV based on their underlying genetic mechanism. AS patients with the clinical features of AS but no [[#Glossary | '''cytogenetic''']] or molecular abnormality in Chromosome 15q11.2-13 are grouped under Class V (summarised in table below).&amp;lt;ref name=&amp;quot;PMID8988171&amp;quot; /&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10364509&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{|  style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
! Class&lt;br /&gt;
! Mechanism&lt;br /&gt;
! Diagnostic Tests&lt;br /&gt;
! Frequency&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''Ia'''                           &lt;br /&gt;
| De novo deletion                                                                                           &lt;br /&gt;
| High resolution cytogenetics [[#Glossary | '''FISH''']]                                                                                                       &lt;br /&gt;
| 70%      &lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Ib'''&lt;br /&gt;
| Deletion due to chromosome rearrangement&lt;br /&gt;
| High resolution cytogenetics FISH&lt;br /&gt;
| &amp;lt;1%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''II'''&lt;br /&gt;
| Paternal uniparental disomy&lt;br /&gt;
| [[#Glossary | '''RFLP''']]  analysis&lt;br /&gt;
| 2%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''IIIa'''&lt;br /&gt;
| Imprinting defect with IC mutation&lt;br /&gt;
| Screening of [[#Glossary | '''IC''']]  for mutations is positive&lt;br /&gt;
| 2%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''IIIb'''&lt;br /&gt;
| Imprinting defect withouth IC mutation&lt;br /&gt;
| Screening of IC for mutations is negative&lt;br /&gt;
| 2%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''IIIc'''&lt;br /&gt;
| Mosaic imprinting defect&lt;br /&gt;
| Screening of IC for mutations is usually negative &lt;br /&gt;
| ?&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''IV'''&lt;br /&gt;
| ''UBE3A'' mutation&lt;br /&gt;
| Screening of ''UBE3A'' for mutations&lt;br /&gt;
| 5-10%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''V'''&lt;br /&gt;
| No identifiable genetic abnormality&lt;br /&gt;
| Consider other diagnoses&lt;br /&gt;
| 5-26%&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
[[File:Imprint defect inheritance in Angelman Syndrome.png|thumb|250px|Imprint defect inheritance in Angelman Syndrome]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Inheritance'''&lt;br /&gt;
&lt;br /&gt;
Angelman Syndrome from UBE3A mutations and deletions in the Imprinting Centre follow an inheritance pattern. A carrier father with the genetic defect can pass it on to his children, however, his children will be clinically normal. On the other hand, a carrier mother can pass the genetic defect onto her children, who will then have Angelman Syndrome. &lt;br /&gt;
&lt;br /&gt;
The image highlights the inheritance of Angelman Syndrome, which only results after a carrier mother passes it on to her children.&lt;br /&gt;
&lt;br /&gt;
==Pathogenesis==&lt;br /&gt;
&lt;br /&gt;
Chromosome 15 became associated with AS in the 1980s after the observation of many AS patients harboring [[#Glossary | '''microdeletions''']] of 15q11.2-15q13.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15668046&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The last decade has shed even more light in the aetiology of AS,as Kishino and Matsuura first identified UBE3A as the causative gene for AS in 1997.&amp;lt;ref name=&amp;quot;PMID:8988171&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;8988171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8988172&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Normal gene product: E6-AP ubiquitin ligase'''&lt;br /&gt;
&lt;br /&gt;
The function of UBE3A is to encode for [[#Glossary | '''E6-AP''']] ubiquitin ligase, however its function in the development of the nervous system and the process of UBE3A mutation leading to cognitive impairment in AS patients is still vague.&amp;lt;ref name=&amp;quot;PMID:20211139&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Past and current research has elucidated that E6-AP ubiquitin ligase is involved in the degradation of four proteins, listed below. Currently no protein with a direct role in [[#Glossary | '''long-term potentiation (LTP)''']] as a target of E6-AP has been identified.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12684449&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The identification of such target proteins would be a landmark discovery in further understanding of the pathogenesis, aetiology and prospective treatment strategies of AS, as LTP defects is one of the major neurological impairments of AS. &lt;br /&gt;
 &lt;br /&gt;
* p53 tumor suppressor protein &lt;br /&gt;
* yeast DNA repair protein Rad23 &lt;br /&gt;
* multicopy maintenance protein 7 subunit &lt;br /&gt;
* E6-AP&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Abnormal gene product'''&lt;br /&gt;
&lt;br /&gt;
Disruption to the gene UBE3A interferes with the normal functioning of the gene, which is its crucial role in UBE3A [[#Glossary | '''ubiquitylation''']]. Problems involving this pathway can lead to various diseases either from the loss or gain of function.&amp;lt;ref name=&amp;quot;PMID:9857172&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9857172&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In the case of AS, E6-AP is affected, leading to detrimental cognitive impairment in addition to other deficits.&amp;lt;ref name=&amp;quot;PMID:9857172&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9857172&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Regional functioning of UBE3A'''&lt;br /&gt;
&lt;br /&gt;
Despite the uncertain progression of UBE3A mutation and the neurological abnormalities characteristic of AS, animal models have illustrated the vital role of UBE3A in the normal functioning of the brain. This can be exemplified by a study which utilized a mouse model with target inactivation of the gene UBE3A resulting in the manifestation of classical features of AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11895368&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In addition, the fact that imprinting of UBE3A takes place only in specific brain regions ([[#Glossary | '''cerebellum''']] , [[#Glossary | '''olfactory tracts''']] and the [[#Glossary | '''hippocampus''']]) confirms the hypothesis that the loss of this gene would be detrimental in cognitive development.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20398390&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Most genes are inherited in copies of two, one paternal and the other maternal; however, some genes, such as UBE3A only have one functional copy as the other is silenced, coined 'imprinting'. Imprinting of the paternal copy of UBE3A takes place in some cell populations, such as the hippocampal [[#Glossary | '''neurons''']] and [[#Glossary | '''Purkinje cells''']] in the cerebellum.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9288101&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This means only the maternal UBE3A is functionally expressed in these particular brain regions. Thus a [[#Glossary | '''de novo mutation''']] in the maternal copy of the gene will result in the complete absence of functional E6-AP in the associated brain areas.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9288088&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
It is also known that UBE3A plays an important role in synaptic transmission, but exactly how it does so is still not completely understood.&amp;lt;ref name=&amp;quot;PMID:9808466&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9808466&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''UBE3A ubiquitylation'''&lt;br /&gt;
&lt;br /&gt;
As briefly mentioned above, UBE3A is a member of the E3 ubiquitin ligase family of enzymes. It is responsible for the addition of ubiquitin to the target protein for degradation of the ubiquitinated protein, as illustrated in the diagram below. These processes are required for normal human cognitive function.&amp;lt;ref name=&amp;quot;PMID:9808466&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9808466&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In this way synaptic protein [[#Glossary | '''Arc (activity-regulated cytoskeleton-associated protein)''']] is degraded to control synaptic function. Arc is a target protein of UBE3A in dendritic spines found in the hippocampal neurons.&amp;lt;ref name=&amp;quot;PMID:20668179&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20668179&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Deletion of UBE3A leads to the accumulation of Arc in neurons leading to trafficking of [[#Glossary | '''AMPA ( α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid)''']] receptors, resulting in impaired cognitive functions.&amp;lt;ref name=&amp;quot;PMID:20211139&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; [[File:UBE3A Ubiquitylation Pathway.png|thumb|350px|right|UBE3A Ubiquitylation Pathway.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
UBE3A ubiquitylation consists of:&amp;lt;ref name=&amp;quot;PMID:20668179&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20668179&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
# Activation of ubiquitin by E1 enzyme&lt;br /&gt;
# E1 ezyme transfers ubiquitin to E2 enzyme&lt;br /&gt;
# E2 enzyme transfers ubiquitin to UBE3A&lt;br /&gt;
# UBE3A attaches activated ubiquitin to target protein which is then polyubiquitylated &lt;br /&gt;
# Target protein is then degraded by 26S proteosome&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Phenotype-Genotype correlations'''&lt;br /&gt;
&lt;br /&gt;
[[File:Extent of microcephaly in Angelman Syndrome patients.png|thumb|250px|right|Extent of microcephaly in 20 AS patients with deletion and without deletion.&amp;lt;ref&amp;gt;http://www.nature.com/ejhg/index.html/&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
All AS patients show differing extents of cognitive impairment, movement disorder, characteristic behaviours and difficulty in speech and language.&amp;lt;ref name=&amp;quot;PMID:11748306&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11748306&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; However, there seems to be some phenotype-genotype correlations:&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
- 5-7Mb deletions result in the most severe phenotypes such as microcephaly, more sever [[#Glossary | '''epilepsy''']] and seizures, motor difficulties and language impairment.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9546330&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20445456&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; AS patients with large deletions also present with clinical [[#Glossary | '''hypopigmentation''']], light hair and eye colour due to the close association of OCA2 gene with UBE3A.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;16470747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Individuals under this category have in general no increased BMI&amp;lt;ref name=&amp;quot;PMID:15253756&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15253756&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This is indicated by the graph on the left, which shows more cases of AS patients with deletions having larger deviations from the mean head circumference measurement than non-deletion AS patients.&lt;br /&gt;
 &lt;br /&gt;
- AS patients with uniparental disomy (UPD) have better physical growth, fewer motor deficits and lower seizure occurrences.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16023557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
- Individuals with AS resulting from imprinting defects have the least debilitating features, such as higher developmental and language ability than AS caused by other mechanisms.&amp;lt;ref name=&amp;quot;PMID:11748306&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11748306&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
- The Body Mass Index (BMI) of 33% of the UBE3A mutation patients, and 47–64% of the patients from the classes II (UPD) and III (Imprinting defect) is above the 95th centile.&amp;lt;ref name=&amp;quot;PMID:15253756&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15253756&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Animal models'''&lt;br /&gt;
&lt;br /&gt;
* '''Drosophila'''&lt;br /&gt;
&lt;br /&gt;
Drosophila (common fruit fly) is an excellent model to use for better understanding of genetic diseases in humans as they are highly homologous to human UBE3A (hUBE3A), illustrating a high evolutionary conservation. Studies using the Drosophila model have shown that the functional absence of UBE3A resulted in decreased morphogenesis of dendritic branches. This is of interest as dendritic branches cover over 90% of the neuronal surface where [[#Glossary | '''synapse''']] between neurons occur. Proper formation and maturation of dendritic spines is also required so they come in contact with other neurons for effective transmission of neuronal signals. Thus proper formation of dendritic branching is pivitol for effective neuronal function and hence cognitive function.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18996915&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Interestingly, overexpression of dUBE3A also gave the same result, consisting of abnormal locomotion  and decreased dendritic branching in sensory neurons.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18701717&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;  This suggests a possible research field for some forms of [[#Glossary | '''autism''']] where the region containing UBE3A is duplicated, leading to delayed motor skills and seizures.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16433693&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;[[File:Normal and Angelman Syndrome mice models.jpg|thumb|250px|right|Normal and AS mice performance on the Rotarod apparatus.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
* '''Mice'''&lt;br /&gt;
&lt;br /&gt;
Absence of UBE3A in mice manifest similar phenotype to human AS, as illustrated by motor and learning deficits with inducible seizures.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21235769&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It has been shown through various mice model studies that larger deletions, ie. from UBE3A to GABRB3, more closely mirrors the large 6Mb deletions seen in human AS patients. Numerous tests, such as the Rotarod (for motor coordination and learning ability), Morris water maze test (for spatial learning and memory) and [[#Glossary | '''EEG''']] (electroencephalography), were carried out on  UBE3A null mutants, which showed the results to be abnormal or impaired.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20808828&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Other studies using mouse models have also outlined the obesity observed in 15% of AS children, albeit it is not the major characterisitics of AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17259980&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The diagram on the right clearly highlights the results obtained from such mouse model studies of AS, where the absence of UBE3A accumulated in deficits of motor function and obesity. In addition, excessive drooling and feeding difficulties were also highlighted by mice models with inactivated UBE3A, reflected by defects in fluid consumption and licking.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18413322&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Signs and Symptoms==&lt;br /&gt;
&lt;br /&gt;
Angelman Syndrome presents a variety of different phenotypes, and the presented symptoms may vary at different ages.&amp;lt;ref name=&amp;quot;PMID7625442&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7625442&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
In 1995 Williams et al. embraced the observed clinical features of AS in a consensus statement, in order to present an appliance for clinicians. The diagnostic criteria were updated in 2005.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt; The following table shows the most frequently occurring characteristics in AS patients:&lt;br /&gt;
&lt;br /&gt;
'''4 characteristics appear in 100% of the cases:'''&lt;br /&gt;
&lt;br /&gt;
*Delayed development: become apparent by the age of 6 to 12 months.&lt;br /&gt;
*Motion and or balance malfunction&lt;br /&gt;
*Behaviour patterns like unmotivated laughter, frequent excitement; often including body movements,[[File:Electroencephalography of Angelman Syndrome.jpg|thumb|350px|right|EEG of AS and normal individuals.]] [[#Glossary | '''hypermotoric''']] behaviour&lt;br /&gt;
*Impairment of speech&lt;br /&gt;
&lt;br /&gt;
'''3 characteristics appear in more than 80% of the cases:'''&lt;br /&gt;
&lt;br /&gt;
*Abnormalities in head circumference, microcephaly&lt;br /&gt;
*Seizures&lt;br /&gt;
*EEG shows specific abnormal patterns&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Angelman Syndrome individuals show the most distinct disease pattern from 2 to 16 years of age.&lt;br /&gt;
In most cases at least 8 of the symptom traits are shown.&amp;lt;ref name=&amp;quot;PMID7625442&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Behavioural Characteristics'''&lt;br /&gt;
&lt;br /&gt;
A range of substantial characteristics appear in all AS cases, regardless of the genetic mechanisms, and are often responsible for diagnosing the syndrome. According to the original name, Happy Puppet syndrome, they have shown to exhibit traits such as a happy demeanor, with frequent laughter or smiling that can easily be triggered.&amp;lt;ref name=&amp;quot;PMID12566516&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12566516&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This behaviour can already be observed in 1 to 3 month old infants.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot; /&amp;gt; Uplifted hand flapping or waving motions are associated with laughter and excitement. Other characteristics manifesting in early childhood are sleep abnormalities with reduced sleep demand, and feeding problems. Breast and bottle feeding can be difficult due to non efficient attachment to the breast, tongue thrusting and uncoordinated sucking. Furthermore, there is an affection to crinkly and reflective surfaces, like some papers or plastic materials, especially water.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID12566516 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Communication Skills'''&lt;br /&gt;
&lt;br /&gt;
Communication is challenging for AS patients due to the fact that speech impairment is present in all cases. In the majority of affected people a lack of speech development is present. Only some of them have a minimal vocabulary consisting of two or three words, a few can speak in basic sentences. Some patients use gestures to articulate themselves, the [[#Glossary | '''Picture Exchange Communication System (PECS)''']] or sign languages such as [[#Glossary | '''Makaton''']] can be used for communication. Simple demands regarding their everyday occurrence can be understood by most patients.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID12566516 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Clinical and External Characteristics'''[[File:Angelman Syndrome patient.png|thumb|200px|right|4 year old AS patient.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Developmental delays are present in all patients. Motor milestones are delayed with children managing to sit unsupported with 12 months and crawl or bottom shuffle at the age of 18-24 months. The average age for walking is 4 years,however, ranging from 18 months to 7 years.&lt;br /&gt;
The [[#Glossary | '''gait''']] is characterised as slow, and flapping hands are a common trait.  The legs remain stiff during walking, arms are inflected by the wrists and elbows. The movements can appear ataxic, jerky or lurching. The muscle tone shows abnormalities with truncal [[#Glossary | '''hypotonia''']] and [[#Glossary | '''hypertonicity''']] of the limbs and alert reflexes.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID12566516 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The most striking external traits present in patients include broad-spaced teeth, and a wide mouth, light hair and eye colour, hypopigmented skin, deep set eyes, and a flat [[#Glossary | '''occiput''']].&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Seizures in Angelman Syndrome'''&lt;br /&gt;
&lt;br /&gt;
85% of AS patients suffer from epileptic seizures during their first three years. The first appearance can be within one month up to 20 year old patients. In infants with AS epilepsy manifests with [[#Glossary | '''febrile convulsions''']] and is hard to manage during childhood.&lt;br /&gt;
The most common type of seizures within 25% of patients are [[#Glossary | '''myoclonic seizures''']], followed by [[#Glossary | '''atonic seizures''']] as the second most frequent type, then 21% experience generalised [[#Glossary | '''tonic-clonic seizures''']] and lastly [[#Glossary | '''atypical absences''']] occur in 12% of patients.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20398390&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Angelman Syndrome in adults'''&lt;br /&gt;
&lt;br /&gt;
Patients with Angelman syndrome possess normal secondary sexual characteristics, and puberty sets in at a usual time. Limb hypertonicity, and [[#Glossary | '''thoracic scoliosis''']] lead to decreasing mobility. [[#Glossary | '''Oesophagus reflux''']] might induce severe problems, and the majority suffers from obesity. Furthermore, facial traits such as a prominent lower lip [[#Glossary | '''macrostomia''']] and [[#Glossary | '''mandibular prognathism''']] get manifested in adults. &lt;br /&gt;
In some cases the communication barrier can lead to frustration, resulting in aggressive behaviour. Nonetheless, patients gain a higher concentration span with age, and their nature becomes more quiet.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Complications===&lt;br /&gt;
&lt;br /&gt;
'''Hypopigmentation and Ocular albinism'''&lt;br /&gt;
&lt;br /&gt;
OCA2 gene, also known as the P gene, is closely located to the UBE3A gene. It encodes a protein vital to tyrosine metabolism, which plays a role in pigmentation development of skin, hair and eyes. However, AS caused by the large deletion of UBE3A leads to haploinsufficiency of OCA2 gene, resulting in hypopigmentation of the skin and the eyes. In some children with severe hypopigmentation, some form of [[#Glossary | '''albinism''']] is suspected.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12749060&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; When AS is caused by another mechanism, no abnormality of the skin and eye pigmentation is observed. However, not all AS children with OCA2 gene deletion will present with obvious hypopigmentation, they may just exhibit lighter skin colour than their parents.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8302318&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Diagnosis==&lt;br /&gt;
&lt;br /&gt;
The diagnosis of Angelman Syndrome is a clinical diagnosis confirmed by laboratory testing.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This involves both prenatal and/or postnatal diagnosis. &lt;br /&gt;
&lt;br /&gt;
===Prenatal Diagnosis===&lt;br /&gt;
[[File:Angelman Syndrome Prenatal Diagnosis.jpg|thumb|250px|right|Flowchart of AS Diagnosis.]]&lt;br /&gt;
&lt;br /&gt;
Prenatal detection of deletions of 15q11.2-q13, [[#Glossary | '''Paternal UPD''']] ([[#Glossary | '''Uniparental Disomy''']]), Imprinting defects and UBE3A mutations are done through DNA/chromosome/FISH analysis of fetal cells obtained by either [[#Glossary | '''Chorionic Villus Sampling''']](CVS) or [[#Glossary | '''Amniocentesis''']].&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot;/&amp;gt; &lt;br /&gt;
DNA methylation analysis using [[#Glossary | '''Amniocytes''']] is usually the first test carried out in molecular diagnosis of AS.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18059071&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; An abnormal result is followed up by either a FISH or array CGH analysis to search for a deletion on chromosome 15. If they produce a normal result, then UPD testing using DNA polymorphysims is carried out. If there is no evidence of UPD, other DNA analysis tests are used search for an imprinting centre deletion.&amp;lt;ref name=&amp;quot;PMID9792887&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9792887&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; A normal DNA methylation analysis is followed by a UBE3A sequence analysis.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt; In addition, a parent of origin test is also done to determine if the genetic disruption is of maternal origin or paternal origin. If it is maternally derived the fetus is diagnosed with AS (a paternally derived genetic disruption is indicative of Prader-Willi Syndrome).&amp;lt;ref name=&amp;quot;PMID17020468&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;17020468&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The flow chart summarizes the normal procedure used for prenatal diagnosis of AS. More information on important laboratory tests used for the diagnosis of Angelman Syndrome are provided below:&lt;br /&gt;
&lt;br /&gt;
*'''DNA Methylation Analysis'''&lt;br /&gt;
&lt;br /&gt;
Identifies approximately 80% of AS affected individuals and is usually the first test to be ordered.&amp;lt;ref name=&amp;quot;PMID7618904&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7618904&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Molecular disruptions such as deletions, paternal UPD and imprinting defects on chromosome 15 all demonstrate abnormal methylation patterns by either southern blot analysis or PCR amplification of bisulphate-treated DNA.&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot; /&amp;gt; An affected individual will only have an unmethylated (paternal) SNRPN (small nuclear ribonuclear protein-associated polypeptide N) allele compared with an unaffected individual who will have both a methylated and an unmethylated SNRPN allele.&amp;lt;ref name=&amp;quot;PMID9634532&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9634532&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
	  &lt;br /&gt;
*'''FISH (Fluorescent In Situ Hybridization)'''&lt;br /&gt;
&lt;br /&gt;
[[File:Critical_region_of_Angelman_Syndrome_on_chromosome_15.png‎|thumb|150px|right|FISH (fluorescence in situ hybridisation) image showing the critical region of Angelman Syndrome on chromosome 15.]]&lt;br /&gt;
&lt;br /&gt;
FISH analysis detects 5-7 Mb deletions in approximately 68% of affected individuals using detecting probes such as D15S10 and/or SNRPN.&amp;lt;ref name=&amp;quot;PMID7618904&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7618904&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It is also able to distinguish UPD from micro-deletions and imprinting defects. In simple terms, FISH analysis involves the binding of a fluorescent probe to a specific part of chromosome 15 and the detection of deletions within that region. FISH analysis is much more accurate in deletion detection compared to other high-resolution cytogenetics in the diagnosis of AS patients.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1511093&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
Array-based CGH is an advanced type of cytogenetic testing that can also be used to detect smaller deletions.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''UPD (Uniparental Disomy) Detection'''&lt;br /&gt;
&lt;br /&gt;
DNA Polymorphism testing detects paternal UPD in approximately 7% of affected AS individuals.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt; It is also able to distinguish between UPD and an Imprinting defect. It requires a DNA sample from the [[#Glossary | '''Proband''']] and from both parents. A homologous or non-homologous whole-arm translocation of the long arms of chromosome 15 is a sound indication for the need for prenatal UPD testing.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''IC (Imprinting Center) Analysis'''&lt;br /&gt;
&lt;br /&gt;
This type of analysis is used when individuals have an abnormal DNA methylation pattern but show normal results for  FISH, array CGH study and UPD analysis.&amp;lt;ref name=&amp;quot;PMID9792887&amp;quot;/&amp;gt; It is used to differentiate between the Imprinting defects caused by either microdeletions in the AS imprinting centre or by epigenetic mutations (that occur in maternal oogenesis or early embryogenesis).&amp;lt;ref name=&amp;quot;PMID9634532&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''Cytogenetic Testing'''&lt;br /&gt;
&lt;br /&gt;
Is used to detect a cytogenetically visible chromosomal rearrangement (large deletion, translocation or inversion) involving the 15q11.2-q13 region, which occurs in less than 1% of affected individuals.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''UBE3A Sequence Analysis'''&lt;br /&gt;
Sequence analysis of the UBE3A gene detects mutations in about 10% of the patients.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt; The test is used to detect either multiexonic (10 major coding exons of UBE3A) or whole gene deletions of UBE3A gene in individuals who produces a normal DNA methylation result but has characteristic clinical features of AS.&amp;lt;ref name=&amp;quot;PMID9792887&amp;quot;/&amp;gt;&lt;br /&gt;
This is recommended as a prenatal diagnostic tool in families that include multiple AS affected individuals because the imprinted pattern can be inherited from distant relatives.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Postnatal Diagnosis===&lt;br /&gt;
&lt;br /&gt;
Postnatal diagnosis is made though a combination of common clinical features of AS and UBESA gene sequence analysis.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt; The clinical features of AS include unsteady or shaky movements, muscle hypotonia, developmental delay and behavioral uniqueness such as frequent laughter/smiling and happy demeanor are features that are 100% consistent in all patients diagnosed with Angelman Syndrome.&amp;lt;ref name=&amp;quot;PMID18830393&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18830393&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; These clinical features become apparent between 6 months to 2 years of age. The onset of early or persistent smiling characteristic of this syndrome begin around the age of 1-3 months, but is often overlooked during infancy.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot;/&amp;gt; Thus early diagnosis of AS during infancy period is difficult because the clinical indicators of the syndrome takes time to manifest and characteristic features such as finger and hand tremors and excessive smiling/laughter are often overlooked and not considered as possible indicators of this syndrome.&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
*Rett Syndrome&lt;br /&gt;
&lt;br /&gt;
Some children with the clinical diagnosis of AS but no underlying genetic mechanism show mutations in ''MECP2'' gene, corresponding to Rett Syndrome. This should be suspected in AS test negative girls in the first few years of life.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17980307&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*Mowat-Wilson Syndrome&lt;br /&gt;
&lt;br /&gt;
Genetic mechanism is heterozygous deletion or truncation in ''ZFHX1B'' (''SIP1'') gene on 2q22. This presents with clinical features of severe intellectual disability, micrcephaly and seizures.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17958891&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Prader-Willi Syndrome patient.png|thumb|right|120px|12 year old PWS patient.]]&lt;br /&gt;
&lt;br /&gt;
*X-linked alpha-thalassemia/mental retardation syndrome (ATR-X)&lt;br /&gt;
&lt;br /&gt;
This arises from mutations in ''XNP'' gene on Xq13. ATR-X presents with severe intellectual disability, no speech development and seizures are common.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11449489&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*Phelan-McDermid Syndrome/22q13 deletion syndrome&lt;br /&gt;
&lt;br /&gt;
Deletions are usually submicroscopic and thus requires special molecular cytogenetic methods to confirm this deletion. Patients show moderate to profound intellectual disability and delay in speech development.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18505557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Related Disease'''&lt;br /&gt;
&lt;br /&gt;
*Prader-Willi Syndrome(PWS)&lt;br /&gt;
&lt;br /&gt;
PWS is a result from the absence of paternally expressed 15q11-q13 gene as a corollary of de novo deletion, maternal uniparental disomy of chromosome 15 or an imprinting defect on paternal chromosome 15 leading to the silencing of paternal alleles.&amp;lt;ref name=&amp;quot;PMID:20668179 &amp;quot;/&amp;gt; It is characterized by [[#Glossary | '''hyperphagia''']], obesity in later infancy and early childhood and difficulty in feeding during early infancy.&amp;lt;ref name=&amp;quot;PMID:20668179 &amp;quot;/&amp;gt; There is also cognitive impairment to some extent, though some PWS patients may exhibit intelligence in the normal IQ range. Behavioral phenotypes include stubbornness, manipulative tendency, obsessive compulsive characteristics.&amp;lt;ref name=&amp;quot;PMID:20668179 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Genetic Counselling==&lt;br /&gt;
&lt;br /&gt;
Genetic counselling is the process by which patients or relatives, at risk of an inherited disorder, are advised of the consequences and nature of the disorder, the probability of developing or transmitting it, and the options open to them in management and family planning. In the case for Angelman syndrome, types of risks associated are split into classes and formatted into the table below:&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20459762&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{|  style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
! Class&lt;br /&gt;
! Mechanism&lt;br /&gt;
! Risk to siblings&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! Ia                           &lt;br /&gt;
| De novo deletion                                                                                                               &lt;br /&gt;
| &amp;lt;1%                                                                                                                &lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! Ib&lt;br /&gt;
| Deletion due to chromosome rearrangement&lt;br /&gt;
| Up to 50%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! II&lt;br /&gt;
| Paternal uniparental disomy (UPD)&lt;br /&gt;
| &amp;lt;1%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! IIIa&lt;br /&gt;
| Imprinting defect with IC mutation&lt;br /&gt;
| Close to 100% if father has 15; 15 [[#Glossary | '''Robertsonian translocation''']]&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! IIIb&lt;br /&gt;
| Imprinting defect without IC mutation&lt;br /&gt;
| Up to 50% (if mother has IC deletion)&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! IIIc&lt;br /&gt;
| [[#Glossary | '''Mosaic''']] imprinting defect&lt;br /&gt;
| &amp;lt;1%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! IV&lt;br /&gt;
| ''UBE3A'' mutation&lt;br /&gt;
| Up to 50% (if mother has mutation)&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! V&lt;br /&gt;
| No identifiable genetic abnormality&lt;br /&gt;
| ?&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Ia''': Individuals with de novo deletion have 1% risk to siblings&lt;br /&gt;
&lt;br /&gt;
'''Ib''': Risk to siblings in individuals with chromosomal rearrangements is up to 50% &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9557895&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''II''': Paternal UPD with no Robertsonian translocation has a risk to sibling of less than 1%&lt;br /&gt;
&lt;br /&gt;
'''IIIa''': The risk to siblings in individuals with AS from an imprinting defect with a mutation in the imprinting center (IC) is close to 100% if father has 15;15 Robertsonian translocation&lt;br /&gt;
&lt;br /&gt;
'''IIIb''': Individuals with AS resulting from an imprinting defect without IC mutation, but with a carrier mother has a high risk to siblings of up to 50%. The mother could be phenotypically normal due to paternal inheritance of the genetic defect &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11283796&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''IIIc''': Individuals who are mosaic for the imprinting defect have less than 1% risk to siblings&lt;br /&gt;
&lt;br /&gt;
'''IV''': UBE3A mutation can be either inherited or de novo mutation. If the mother is a carrier for this genetic mutation, the risk to siblings is up to 50% &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11258627&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''V''': Individuals who present with AS clinically, but have no known underlying mechanism have an unknown risk to siblings.&lt;br /&gt;
&lt;br /&gt;
==Treatment and Management==&lt;br /&gt;
&lt;br /&gt;
Even though at present there is no known cure for Angelman syndrome, there are a number of treatments available that may alleviate symptons and improve daily life activities.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The below table describes the problems and management options that are used:&lt;br /&gt;
&lt;br /&gt;
[[File:Subtle Finger tremors-Angelman Syndrome.jpg|right|thumb|150px|A five months old boy with Angelman syndrome showing signs of Subtle Finger tremor.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
! Problems encountered&lt;br /&gt;
! Treatment and Management&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''Difficulty in feeding newborn AS babies'''&lt;br /&gt;
| Use of special nipples may improve feeding&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Oesophagus reflux'''&lt;br /&gt;
| Special motility medications requiried or upright positioning&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''Seizures'''&lt;br /&gt;
| Anticonvulsant medications&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19605773&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19453717&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Ocular problems'''&lt;br /&gt;
| Visual assessment is vital to encourage interactions and minimize chances of self-harm and autism development&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20656169&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''Drooling in developmental delayed AS patients'''&lt;br /&gt;
| Difficult to treat, but new surgical procedure on salivary duct reimplantation seems to be a promising alternative&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17699119&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Unstable children''' &lt;br /&gt;
| Physical therapy&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''AS patients become less active with increasing age'''&lt;br /&gt;
| Activity schedules to prevent scoliosis and obesity. Occupational therapy to stimulate fine motor and oral-motor control skills in conjunction to speech therapy&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Sleeping difficulty'''&lt;br /&gt;
| Sedative medication in severe cases. [[#Glossary | '''Melatonin''']] may be used to promote sleeping but some studies have found that it loses its therapeutic effects after several weeks in most AS patients&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19379289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|-&lt;br /&gt;
|colspan=&amp;quot;4&amp;quot; |&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Prognosis==&lt;br /&gt;
&lt;br /&gt;
Life expectancy of AS patients seems to be normal&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, but there is still a high degree of developmental delay and limited expressive language skills.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17019625&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This problem arises prominently in the assessment of the severity of coincidental medical conditions due to difficulties in communication. A visit to the dentist can become difficult if good communication is not conveyed between the parents, the dentist, and the child.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18271768&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Some problems require extreme measures, such as the procedure of lens implantation was performed in both eyes of a person diagnosed with AS, due to the inability to wear spectacles.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20656169&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
During adulthood, menstruation and puberty begin at around average age evidenced by females with Angelman syndrome that are fully capable of conceiving children.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11258627&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Most adult patients can feed themselves, but needed help with many other daily activities. Main troubles which have shown in adults are a tendency to become obese and start developing  thoracic scoliosis, which some adults with AS begin wheelchair bounded.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9072912&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Current and Future Research==&lt;br /&gt;
&lt;br /&gt;
Currently there is no cure for the treatment of AS, so much research is being carried out for therapeutic interventions. Findings in the last five years have suggested through various mice and fruit fly models that the absence of maternal UBE3A results in the same human AS features of neurological defects and seizures. However, more recently, studies have outlined that the symptoms of AS can be improved by modifying other gene products. In addition, restoring of a functional UBE3A protein into adult mice neurons have shown to reduce motor and neurological deficits and balance disorders. This shows promising research prospects in that improvements may be possible in human AS patients by restoring functional UBE3A proteins into their neurons. &lt;br /&gt;
&lt;br /&gt;
===Possible Treatment Pathways===&lt;br /&gt;
&lt;br /&gt;
*'''Cognitive and physical impairment'''&lt;br /&gt;
&lt;br /&gt;
Although everyone is born with two copies of the gene UBE3A, one maternal and one paternal copy, it is only the maternal UBE3A that is used in the brain. Most AS patients have a genetic mutation on the maternal chromosome 15 that results in dysfunctional UBE3A.&amp;lt;ref&amp;gt;http://www.cureangelman.org/what-hope.html&amp;lt;/ref&amp;gt; The above research focused on turning on the father's copy of UBE3A to restore its functions. Furthermore, mouse models were utilized to show that alpha-CaMKII could be increased to compensate the loss of UBE3A and restore compromised mental and physical abilities. However, this finding still requires much more research.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17259980&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''Epilepsy'''&lt;br /&gt;
&lt;br /&gt;
There is research being done on improving certain conditions that are involved in AS by nutritional benefits. The use of [[#Glossary | '''corticosteroids''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19666884&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, [[#Glossary | '''valproate''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19453717&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and [[#Glossary | '''clonazepam''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19605773&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and having a [[#Glossary | '''ketogenic diet''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20880305&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; has all been shown to aid in the treatment of epilepsy. It has also been reported to be efficient in the treatment of other conditions, such as behavioural disorders, reduction in seizures, ataxia, sleep patterns, developmental progress and sleep disturbances. [[#Glossary | '''Levetiracetam''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17326790&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; could be used in such a situation, especially when the patient has an intolerance to valproate and clonazepam.&lt;br /&gt;
&lt;br /&gt;
*'''Betaine and Folic acid'''&lt;br /&gt;
&lt;br /&gt;
This double-blind placebo-controlled study was done to examine the potential therapeutic role of [[#Glossary | '''betaine''']] and [[#Glossary | '''folic acid''']] in the treatment of the clinical phenotypes of AS. The aim of this protocol was to increase methylation and activate the paternally inherited UBE3A in hope to compensate for the inactive maternal UBE3A. Although there were no major differences in the control and treatment groups, a small number of patients in the treatment group showed some positive outcomes.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20635355&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&lt;br /&gt;
'''albinism''': A congenital disorder distincted by the complete or partial absence of pigment in the skin, hair and eyes due to defect of an enzyme involved in the production of melanin.&lt;br /&gt;
&lt;br /&gt;
'''allele''': Dissimilar variant of one gene. Organisms have two alleles for each gene inherited from their parents, one from each of them.&lt;br /&gt;
&lt;br /&gt;
'''alpha-CaMKII''': (alpha calcium calmodulin kinase II) Compound involved in synaptic plasticity, one of the most important theories behind learning and memory. Ability of a synapse between two neurons to change in strength due to the use or disuse of transmission.&lt;br /&gt;
&lt;br /&gt;
'''Amniocytes''': Cells that are shed by the fetus during fetal development to the surrounding amniotic fluid. They are a source of fetal DNA. &lt;br /&gt;
&lt;br /&gt;
'''Amniocentesis''': (AFT or amniotic fluid test) is a prenatal diagnostic test used to detect chromosomal abnormalities in the developing fetus by extracting amniotic fluid (a source of fetal DNA) surrounding the fetus. &lt;br /&gt;
&lt;br /&gt;
'''AMPA''': (2-amino-3-(5-methyl-3-oxo-1,2- oxazol-4-yl)propanoic acid) Compound that binds to the AMPA receptor to imitate glutamate neurotransmitter.&lt;br /&gt;
&lt;br /&gt;
'''Arc''': Activity-Regulated Cytoskeleton-associated protein; involved in learning and memory.&lt;br /&gt;
&lt;br /&gt;
'''ataxia''': Lack of coordination in muscle movements.&lt;br /&gt;
&lt;br /&gt;
'''atonic seizures''': A abrupt loss of muscle tone, this can lead to the limbs loosing strength, or the head may drop to the side. The patient remains conscious during this kind of epileptic seizure.&lt;br /&gt;
&lt;br /&gt;
'''atypical absences''': Seizure leads to unconsciousness in most cases.  &lt;br /&gt;
&lt;br /&gt;
'''autism''': A neural development disorder defined by limited social interaction and communication.&lt;br /&gt;
&lt;br /&gt;
'''betaine''': Also known as  betaine anhydrous or trimethylglycine (TMG), assists the body in metabolising the amino acid, homocysteine. Can be consumed via beets, broccoli, grains, shellfish, and spinach.&lt;br /&gt;
&lt;br /&gt;
'''cerebellum''': Region of the brain that plays an important role in motor control. It is also involved in some cognitive functions such as attention and language.&lt;br /&gt;
&lt;br /&gt;
'''Chorionic Villus Sampling''': A prenatal diagnostic test used to detect chromosomal abnormalities in the developing fetus by extracting and testing chorionic villus (placental tissue). &lt;br /&gt;
&lt;br /&gt;
'''chromosome''': Structure consisting of coiled DNA with DNA associated proteins such as histones.&lt;br /&gt;
&lt;br /&gt;
'''clonazepam''': A psychoactive drug having muscle relaxant properties and treats anxiety and epilepsy.&lt;br /&gt;
&lt;br /&gt;
'''corticosteroid''': A type of steroid hormones that are produced in the adrenal cortex.&lt;br /&gt;
&lt;br /&gt;
'''cytogenetics''': Study of the structure, function and abnormality of the cell, especially the chromosome.&lt;br /&gt;
&lt;br /&gt;
'''deletion''': Lack of a part of the DNA (deoxyribonucleic acid is a nucleic acid containing information for protein synthesis), can vary form a single base to a hole gene. &lt;br /&gt;
&lt;br /&gt;
'''de novo mutation''': Change in a gene of a family member for the first time due to a mutation in the egg or sperm of the parents or in the fertilized egg (zygote).&lt;br /&gt;
&lt;br /&gt;
'''disorder''': A mental or physical health disturbance or dysfunction.&lt;br /&gt;
&lt;br /&gt;
'''EEG''': Electroencephalography is a means of measuring electrical activity along the scalp by measuring the total electrical charges fired by thousands or millions of neurons.&lt;br /&gt;
&lt;br /&gt;
'''epilepsy''': Neurological disorder characterised by recurrent impairment of brain function that can cause seizures or unconsciousness. &lt;br /&gt;
&lt;br /&gt;
'''E6-AP''': E6-AP ubiquitin-protein ligase is an enzyme encoded by UBE3A which adds ubiquitin chain to target proteins to be degraded by proteasomes.&lt;br /&gt;
&lt;br /&gt;
'''febrile convulsions''': The occurrence of high fever, especially in children.&lt;br /&gt;
&lt;br /&gt;
'''FISH''': Fluorescent in situ hybridization is a technique used to identify and localize the presence or absence of DNA sequences on the chromosome. This is achieved by using fluorescently labelled DNA sequences which then binds to complementary DNA sequence on the chromosome. After hybridization (attachment), chromosome of interest will fluoresce under the microscope.&lt;br /&gt;
&lt;br /&gt;
'''folic acid''': B vitamin that helps the body make healthy new cells. Can be consumed via leafy green vegetables, fruits, dried beans, peas and nuts.&lt;br /&gt;
&lt;br /&gt;
'''gait''': A manner of walking, stepping or running.&lt;br /&gt;
&lt;br /&gt;
'''gene''': A molecular unit of heredity of a living organism.&lt;br /&gt;
&lt;br /&gt;
'''hippocampus''': Area buried deep in the forebrain that helps regulate emotion and memory&lt;br /&gt;
&lt;br /&gt;
'''hyperphagia''': (Also referred to as Polyphagia) Excessive ingestion of food beyond the dietary and energy requirements of the body. &lt;br /&gt;
&lt;br /&gt;
'''hypermotoric''': Sudden appearance of uncontrolled movements such as striking or kicking inappropriately.&lt;br /&gt;
&lt;br /&gt;
'''hypertonicity''': Increase of muscle tension and a disability to stretch leading to an impairment of motor activity.&lt;br /&gt;
&lt;br /&gt;
'''hypopigmentation''': A lack of melanin pigments or melanocytes  affecting the colour of the skin, hair and iris. Features appear to be light-coloured due to loss of skin colour.&lt;br /&gt;
&lt;br /&gt;
'''hypotonia''': Decrease in the ability to stretch passively, due to a low muscle tone. &lt;br /&gt;
&lt;br /&gt;
'''imprinting''': This is a process to describe the modification of a maternally or paternally derived chromosome, which consequently influences the expression of certain genes on the altered chromosome.&lt;br /&gt;
&lt;br /&gt;
'''ketogenic diet''': A high-fat, low-carbohydrate diet that is used to treat epilepsy in children.&lt;br /&gt;
&lt;br /&gt;
'''levetiracetam''': An anticonvulsant drug used to treat epilepsy.&lt;br /&gt;
&lt;br /&gt;
'''locus''': Location of a gene on a chromosome(loci: plural for locus).&lt;br /&gt;
&lt;br /&gt;
'''LTP''': Long-term potentiation shares common features with long term memory. It strengthens and enhances signal transmission between neurons by improving the communication between two neurons.&lt;br /&gt;
&lt;br /&gt;
'''macrostomia''': A wide-spaced mouth.&lt;br /&gt;
&lt;br /&gt;
'''Makaton''': Language programme using symbols and signs to support speaking.&lt;br /&gt;
&lt;br /&gt;
'''mandibular prognathism''': The abnormal protrusion of the lower jaw. &lt;br /&gt;
&lt;br /&gt;
'''maxillary hypoplasia''':  The underdevelopment of the upper jaw.&lt;br /&gt;
&lt;br /&gt;
'''melatonin''': A hormone secreted by the pineal gland.&lt;br /&gt;
&lt;br /&gt;
'''microcephaly''': The circumference of the head is less than average due to abnormalities of the nervous system. This abnormality can be present at birth or emerge during the first few years of life and reduces both life expectancy and the cognitive functions of the individual affected.&lt;br /&gt;
&lt;br /&gt;
'''microdeletion''':  A genetic mutation in which a part of a chromosome or a sequence of DNA is missing.&lt;br /&gt;
&lt;br /&gt;
'''mosaic''': tissues or cells containing different mixture of genetic sequences&lt;br /&gt;
&lt;br /&gt;
'''mutation''': Event that changes the DNA (deoxyribonucleic acid is a nucleic acid, containing information for protein synthesis) or RNA (ribonucleic acid is a type of nucleic acid transmitting the information from the DNA to the proteins ) of a gene permanently.&lt;br /&gt;
&lt;br /&gt;
'''myoclonic seizures''': A quick jerk of the skeletal muscle, due to a irregular brain activity.&lt;br /&gt;
&lt;br /&gt;
'''neurogenetic''': Genetic basis of the nervous system.&lt;br /&gt;
&lt;br /&gt;
'''neuron''': Cells of the nervous system that can be electrically excited to transmit information by electrical and chemical signaling&lt;br /&gt;
&lt;br /&gt;
'''neurotransmitter''': Transmits neuronal signals to a target cell. They are first packaged in vesicles just beneath the membrane of presynaptic axon terminals and released into the synaptic cleft (space between the two interacting neurons) and enter the postsynaptic dendrite.&lt;br /&gt;
&lt;br /&gt;
'''occiput''': The back portion of the head.&lt;br /&gt;
&lt;br /&gt;
'''oesophagus reflux''': Impairment of a sphincter in the lower end of the oesophagus leads to the back flow of stomach acid into the oesophagus. Heartburn is a typical symptom.&lt;br /&gt;
&lt;br /&gt;
'''olfactory tract''': It is a pathway for the sense of smell containing axons from some of the neurons in the olfactory bulb.&lt;br /&gt;
&lt;br /&gt;
'''paediatrician''': Physicians that specialise on infants, children and adolescents.&lt;br /&gt;
&lt;br /&gt;
'''paternal UPD''': Inheritance of two copies of a chromosome from the father and none from the mother. &lt;br /&gt;
&lt;br /&gt;
'''phenotype''': Visible traites of an organism determined by genetic and environmental factors.&lt;br /&gt;
&lt;br /&gt;
'''Picture Exchange Communication System (PECS)''': Individuals communicate using images instead of words. It is frequently used by children with autism, to articulate their needs and wishes or to make comments about something.&lt;br /&gt;
&lt;br /&gt;
'''Proband''': Is the person (or animal) being studied or reported on in a genetic investigation. Most commonly it refers to the first affected family member who requires medical help for a genetic disorder. &lt;br /&gt;
&lt;br /&gt;
'''Purkinje cells''': Large neuron with many branching extensions that is found in the cortex of the cerebellum of the brain and plays a fundamental role in controlling motor movement&lt;br /&gt;
&lt;br /&gt;
'''Robertsonian translocation''': Rearrangement of the chromosome, occurs in 5 chromosome including 13,14,15,21 and 22. This type of mutation occurs in chromosomes with the centromere not at the centre, resulting in long and short arm chromosomes. Translocation breaks the chromosome at the centromere so the long arm attaches to the other long arm, and the same for the short arm happens. Cell division will result in the loss of the short arms as they do not contain important genes.&lt;br /&gt;
&lt;br /&gt;
'''seizure''': Abnormal electrical activity in the brain that can result in a variety of physical symptoms like convulsion, body shaking, loss of consciousness, confusion, and mood changes.&lt;br /&gt;
&lt;br /&gt;
'''synapse''': Allows transmission of signal between neurons for effective neuronal function.&lt;br /&gt;
&lt;br /&gt;
'''thoracic scoliosis''': The spine is curved laterally(from side to side) in the thoracic region.&lt;br /&gt;
&lt;br /&gt;
'''tonic-clonic seizures''': This type of seizure is associated with unconsciousness due to electrical discharges in a big proportion of the brain.&lt;br /&gt;
&lt;br /&gt;
'''ubiquitin''': A polypeptide found in all eukaryotic cells, that participates in a variety of cellular functions including protein recycling.&lt;br /&gt;
&lt;br /&gt;
'''Uniparental disomy''': (UPD) the inheritance of two copies of a chromosome pair or part of a chromosme from one parent and no copy from the other parent. &lt;br /&gt;
&lt;br /&gt;
'''valproate''':  A mood-stabilizing drug that is also used for treatment for epilepsy and bipolar disorder.&lt;br /&gt;
&lt;br /&gt;
==Helpful Links==&lt;br /&gt;
&lt;br /&gt;
* Australia&lt;br /&gt;
:* [http://www.angelmansyndrome.org/research.html Angelman Syndrome Association] &lt;br /&gt;
:* [http://www.angelmansyndromeqld.org/ Queensland Angelman Association]&lt;br /&gt;
&lt;br /&gt;
* America&lt;br /&gt;
:* [http://www.angelman.org/ Angelman Syndrome Foundation]&lt;br /&gt;
:* [http://rarediseasesnetwork.epi.usf.edu/arpwsc/ Rare Clinical Diseases Research Network]&lt;br /&gt;
:* [http://www.rarediseases.org/rare-disease-information/rare-diseases/byID/411/viewAbstract National Organisation for Rare Disorders]&lt;br /&gt;
:* [http://www.epilepsyfoundation.org/ Epilepsy Foundation]&lt;br /&gt;
:* [http://www.cureangelman.org/ Foundation for Angelman Syndrome Therapeutics]&lt;br /&gt;
&lt;br /&gt;
* Search Pubmed &lt;br /&gt;
:* [http://www.ncbi.nlm.nih.gov/pubmed?term=angelman%20syndrome Angelman Syndrome] &lt;br /&gt;
&lt;br /&gt;
* OMIM entries for Angelman Syndrome&lt;br /&gt;
:* [http://omim.org/entry/105830 ANGELMAN SYNDROME; AS]&lt;br /&gt;
:* [http://omim.org/entry/601623 UBIQUITIN-PROTEIN LIGASE E3A; UBE3A]&lt;br /&gt;
&lt;br /&gt;
==Related Links==&lt;br /&gt;
&lt;br /&gt;
'''Animal Models'''&lt;br /&gt;
&lt;br /&gt;
* [[Mouse Knockout]] - this page explains the current use of mouse models in disrupting genes to elucidate their genetic function, including the mouse gene knockouts for alpha calcium-calmodulin kinase II (alpha CaMKII)&lt;br /&gt;
* [[2009 Group Project 4]] - this page gives an extensive overview on the history of the mouse model and its various use in embryology and genetics. In addition, it also describes mouse knockout and the role they play in current research of various human diseases&lt;br /&gt;
* [[Fly Development]] - this page describes the use of drosophila flies as developmental models&lt;br /&gt;
* [[2009 Group Project 2]] - this page gives an extensive overview on the history of the fly model and its various use in embryology and genetics&lt;br /&gt;
&lt;br /&gt;
'''Diagnosis'''&lt;br /&gt;
* [[Chorionic villus sampling]] - this page explains the process of chorionic villus sampling, its disadvantages and gives a brief overview of recent findings&lt;br /&gt;
* [[Amniocentesis]]- this page shows some of the recent findings in this area&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&lt;br /&gt;
&amp;lt;references /&amp;gt;&lt;/div&gt;</summary>
		<author><name>Z3291643</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_7&amp;diff=77723</id>
		<title>2011 Group Project 7</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_7&amp;diff=77723"/>
		<updated>2011-10-12T23:59:10Z</updated>

		<summary type="html">&lt;p&gt;Z3291643: /* Glossary */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;='''Angelman Syndrome'''=&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Introduction==&lt;br /&gt;
&lt;br /&gt;
[[File:Dr Harry Angelman.jpg|thumb|130px|right|Dr Harry Angelman.]]&lt;br /&gt;
Angelman syndrome (AS) is a rare [[#Glossary | '''neurogenetic''']] [[#Glossary | '''disorder''']] first described by Dr. Harry Angelman in 1965.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18754889&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Dr. Angelman was an English [[#Glossary | '''paediatrician''']] who first diagnosed the disease in 3 children with a developmental delay.&amp;lt;ref&amp;gt;http://www.ncbi.nlm.nih.gov/books/NBK22221/&amp;lt;/ref&amp;gt; AS occurs in 1 in 10000-20000 births, the exact number is still unknown.&amp;lt;ref name=&amp;quot;PMID7573182&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7573182&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;PMID8703225&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;8703225&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It is caused by maternal [[#Glossary | '''allele''']] disruptions of a single gene- UBE3A. Either [[#Glossary | '''mutations''']] or [[#Glossary | '''deletions''']] of the UBE3A gene results in AS. &lt;br /&gt;
&lt;br /&gt;
AS presents with well known [[#Glossary | '''phenotypes''']] during infancy and adulthood, such as [[#Glossary | '''microcephaly''']] and [[#Glossary | '''maxillary hypoplasia''']]. However, these features become more marked with age. Most frequent clinical features include delayed development,[[#Glossary | '''seizures''']],[[#Glossary | '''ataxia''']], impairment of speech, happy demeanor, behavioural problems such as hyperactivity, short attention span and sleeping difficulty.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21592595&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21484597&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;ASAwebsite&amp;quot;&amp;gt;http://www.angelmansyndrome.org/home.html&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
At present, there is no cure for the syndrome, though current research is focused at improving life quality of patients with Angelman syndrome through management of daily tasks.&amp;lt;ref&amp;gt;http://www.bbc.co.uk/health/physical_health/conditions/angelman1.shtml&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==History==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Dr. Harry Angelman first reported Angelman Syndrome on three handicapped children that were admitted to his ward in England in 1964.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt; He reported how these three independent and unconnected clinical cases all had the same characteristic features of severe developmental delay, jerky movements, seizures and a happy disposition.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt; However it was only when he stumbled upon an oil painting called ‘a Boy with a Puppet” while on a holiday in Italy he was able to connect the symptoms of all three children under one common cause.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20981772&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; He linked the happy face of the boy depicted on the painting with the jerky movements and happy disposition he observed on his three patients back in England. He reported his findings on a paper entitled “Puppet children (a report on three cases)” which was published in 1965.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
The syndrome was initially named ‘Puppet Syndrome’ but was later changed to Angelman Syndrome. Due to the extreme rarity of the syndrome and lack of sufficient clinical evidence the syndrome was soon forgotten.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt;&lt;br /&gt;
[[File:Dr Charles Williams.jpg|thumb|right|150px|Dr Charles Williams.]]&lt;br /&gt;
	&lt;br /&gt;
In 1987, a physician named Ellen Magenis, came across children with deletions on [[#Glossary | '''chromosome''']] 15 that were suffering from seizures and severe developmental delay.&amp;lt;ref&amp;gt;http://www.angelman.org/stay-informed/facts-about-angelman-syndrome---7th-edition/harry-angelman-and-the-history-of-as/&amp;lt;/ref&amp;gt; Even though genetically the children were expected to have [[#Diagnosis | '''Prader-Willi syndrome''']] that was characterised by deletions on chromosome 15, their characteristic symptoms of seizures and lack of development did not correspond with that of the syndrome. This led to the realization that these children had deletions on the maternally derived chromosome 15 and not on the paternally derived chromosome as was observed in Prader-Willi syndrome.  Thus the deleted genetic code on maternally derived chromosome 15 was identified as the genetic marker for Angelman Syndrome.&lt;br /&gt;
&lt;br /&gt;
In 1997, UBE3A gene was isolated by Dr. Joseph Wagstaff and Dr. Arthur Beaudet as the cause of Angelman Syndrome.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot; /&amp;gt; The discovery of this [[#Glossary | '''gene''']] led to the subsequent development of animal models and research aimed at finding a causal link between UBE3A gene abnormalities and characteristic features observed in Angelman Syndrome. &lt;br /&gt;
	&lt;br /&gt;
Currently, four different genetic abnormalities for Angelman Syndrome have been confirmed by genetic testing. They include: Deletion, [[#Glossary | '''Uniparental Disomy''']] (UPD), [[#Glossary | '''Imprinting''']] and UBE3A mutation.&amp;lt;ref name=&amp;quot;PMID20211139&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Below is a timeline, summarising the key discoveries and advancements of the Angelman Syndrome:&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|- bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
!Year&lt;br /&gt;
!Milestone&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1964'''&lt;br /&gt;
|First observed by Dr Harry Angelman on three handicapped children.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot; /&amp;gt; &lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''1965'''&lt;br /&gt;
|Harry Angelman publishes his finding in a report entitled 'Puppet Children'(a report on three cases).&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1980s'''&lt;br /&gt;
|First reports of AS reaches US and research into the disorder being at the University of Florida under the direction of Dr. Charles Williams.&amp;lt;ref&amp;gt;http://www.angelmanproject.com/history.htm&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''1982'''&lt;br /&gt;
|Name changed from 'Happy Puppet' to Angelman syndrome by Williams and Frias. &lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1987'''&lt;br /&gt;
|Discovery of a genetic marker for AS – an absent genetic code on maternally derived chromosome 15. &lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''1997'''&lt;br /&gt;
|The cause of AS discovered by Dr. Joseph Wagstaff and Dr. Arthur Beaudet – mutation or deletion in the UBE3A gene.&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1998'''&lt;br /&gt;
|Transgenic mice with absent maternal UBE3A created to illustrate motor and learning deficits in addition to seizures.&amp;lt;ref name=&amp;quot;PMID9808466&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9808466&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''2007'''&lt;br /&gt;
|AS mouse model shows that neurological deficits can be reversed by decreasing levels of [[#Glossary | '''alpha-CaMKII''']] inhibitory phosphorylation.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17259980&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''2010'''&lt;br /&gt;
|Discovery of a another gene mutation in TC4 gene (on chromosome 18) in a small number of clinically diagnosed patients with no identifiable genetic alternation in UBE3A.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20184619&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''2010'''&lt;br /&gt;
|Protein named Arc identified as a target of AS gene product; UBE3A.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Incidence'''&lt;br /&gt;
*The current population of people diagnosed with AS is unknown but studies have estimated the number to be around 1:10,000&amp;lt;ref name=&amp;quot;PMID7573182&amp;quot; /&amp;gt; and 1:20,000&amp;lt;ref name=&amp;quot;PMID8703225&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
'''Diagnosis'''&lt;br /&gt;
*The mean age of diagnosis for patients with AS lies between 6 and 6.5 years of age.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18664077&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15741136&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Gender'''&lt;br /&gt;
* Males appear to be at higher risk for some aspects of early developmental delays in comparison to females with AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17019625&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Demography'''&lt;br /&gt;
*Europe:&lt;br /&gt;
:Denmark- 1:10,000&amp;lt;ref name=&amp;quot;PMID7573182&amp;quot; /&amp;gt;&lt;br /&gt;
:Estonia- 1:52,000&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16906556&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
:Sweden- 1:20,000&amp;lt;ref name=&amp;quot;PMID8703225&amp;quot; /&amp;gt;&lt;br /&gt;
*Australia:&lt;br /&gt;
:Western Australia- 1:40,000&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16492624&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Aetiology==&lt;br /&gt;
&lt;br /&gt;
[[File:Chromosome 15 Deletion of 15q11.2 to 15q13.jpg|thumb|100px|Chromosome 15 - The deletion occurs at 15q11.2-15q13.]]&lt;br /&gt;
&lt;br /&gt;
'''Molecular Genetics'''&lt;br /&gt;
&lt;br /&gt;
* Location: 15q11-q13&lt;br /&gt;
* Protein product: Ubiquitin protein ligase E3A&lt;br /&gt;
* Gene name: UBE3A&lt;br /&gt;
* Phenotype: Angelman Syndrome&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Genetic Causes'''&lt;br /&gt;
&lt;br /&gt;
Different genetic mechanisms lead to different clinical phenotypes of AS. The most common genetic mechanism leading to AS is the deletion or re-arrangement of maternal chromosome at [[#Glossary | '''locus''']] 15q11.2-q13,as the chromosome image shows on the right, accounting for 70% of AS occurrences.&amp;lt;ref name=&amp;quot;PMID8988171&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt; 8988171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This leads to more severe clinical phenotypes of microcephaly, motor difficulties, seizures and impaired speech development. The next most common genetic mechanism is mutation in the UBE3A gene responsible for 10% of AS cases and paternal uniparental disomy and mutation in the imprinting centre (IC), both accounting for 2-5% of AS observed.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
 &lt;br /&gt;
&lt;br /&gt;
AS is caused by the 4 major genetic mechanisms mentioned above and are thus divided into Classes I to IV based on their underlying genetic mechanism. AS patients with the clinical features of AS but no [[#Glossary | '''cytogenetic''']] or molecular abnormality in Chromosome 15q11.2-13 are grouped under Class V (summarised in table below).&amp;lt;ref name=&amp;quot;PMID8988171&amp;quot; /&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10364509&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{|  style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
! Class&lt;br /&gt;
! Mechanism&lt;br /&gt;
! Diagnostic Tests&lt;br /&gt;
! Frequency&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''Ia'''                           &lt;br /&gt;
| De novo deletion                                                                                           &lt;br /&gt;
| High resolution cytogenetics [[#Glossary | '''FISH''']]                                                                                                       &lt;br /&gt;
| 70%      &lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Ib'''&lt;br /&gt;
| Deletion due to chromosome rearrangement&lt;br /&gt;
| High resolution cytogenetics FISH&lt;br /&gt;
| &amp;lt;1%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''II'''&lt;br /&gt;
| Paternal uniparental disomy&lt;br /&gt;
| [[#Glossary | '''RFLP''']]  analysis&lt;br /&gt;
| 2%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''IIIa'''&lt;br /&gt;
| Imprinting defect with IC mutation&lt;br /&gt;
| Screening of [[#Glossary | '''IC''']]  for mutations is positive&lt;br /&gt;
| 2%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''IIIb'''&lt;br /&gt;
| Imprinting defect withouth IC mutation&lt;br /&gt;
| Screening of IC for mutations is negative&lt;br /&gt;
| 2%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''IIIc'''&lt;br /&gt;
| Mosaic imprinting defect&lt;br /&gt;
| Screening of IC for mutations is usually negative &lt;br /&gt;
| ?&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''IV'''&lt;br /&gt;
| ''UBE3A'' mutation&lt;br /&gt;
| Screening of ''UBE3A'' for mutations&lt;br /&gt;
| 5-10%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''V'''&lt;br /&gt;
| No identifiable genetic abnormality&lt;br /&gt;
| Consider other diagnoses&lt;br /&gt;
| 5-26%&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
[[File:Imprint defect inheritance in Angelman Syndrome.png|thumb|250px|Imprint defect inheritance in Angelman Syndrome]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Inheritance'''&lt;br /&gt;
&lt;br /&gt;
Angelman Syndrome from UBE3A mutations and deletions in the Imprinting Centre follow an inheritance pattern. A carrier father with the genetic defect can pass it on to his children, however, his children will be clinically normal. On the other hand, a carrier mother can pass the genetic defect onto her children, who will then have Angelman Syndrome. &lt;br /&gt;
&lt;br /&gt;
The image highlights the inheritance of Angelman Syndrome, which only results after a carrier mother passes it on to her children.&lt;br /&gt;
&lt;br /&gt;
==Pathogenesis==&lt;br /&gt;
&lt;br /&gt;
Chromosome 15 became associated with AS in the 1980s after the observation of many AS patients harboring [[#Glossary | '''microdeletions''']] of 15q11.2-15q13.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15668046&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The last decade has shed even more light in the aetiology of AS,as Kishino and Matsuura first identified UBE3A as the causative gene for AS in 1997.&amp;lt;ref name=&amp;quot;PMID:8988171&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;8988171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8988172&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Normal gene product: E6-AP ubiquitin ligase'''&lt;br /&gt;
&lt;br /&gt;
The function of UBE3A is to encode for [[#Glossary | '''E6-AP''']] ubiquitin ligase, however its function in the development of the nervous system and the process of UBE3A mutation leading to cognitive impairment in AS patients is still vague.&amp;lt;ref name=&amp;quot;PMID:20211139&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Past and current research has elucidated that E6-AP ubiquitin ligase is involved in the degradation of four proteins, listed below. Currently no protein with a direct role in [[#Glossary | '''long-term potentiation (LTP)''']] as a target of E6-AP has been identified.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12684449&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The identification of such target proteins would be a landmark discovery in further understanding of the pathogenesis, aetiology and prospective treatment strategies of AS, as LTP defects is one of the major neurological impairments of AS. &lt;br /&gt;
 &lt;br /&gt;
* p53 tumor suppressor protein &lt;br /&gt;
* yeast DNA repair protein Rad23 &lt;br /&gt;
* multicopy maintenance protein 7 subunit &lt;br /&gt;
* E6-AP&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Abnormal gene product'''&lt;br /&gt;
&lt;br /&gt;
Disruption to the gene UBE3A interferes with the normal functioning of the gene, which is its crucial role in UBE3A [[#Glossary | '''ubiquitylation''']]. Problems involving this pathway can lead to various diseases either from the loss or gain of function.&amp;lt;ref name=&amp;quot;PMID:9857172&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9857172&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In the case of AS, E6-AP is affected, leading to detrimental cognitive impairment in addition to other deficits.&amp;lt;ref name=&amp;quot;PMID:9857172&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9857172&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Regional functioning of UBE3A'''&lt;br /&gt;
&lt;br /&gt;
Despite the uncertain progression of UBE3A mutation and the neurological abnormalities characteristic of AS, animal models have illustrated the vital role of UBE3A in the normal functioning of the brain. This can be exemplified by a study which utilized a mouse model with target inactivation of the gene UBE3A resulting in the manifestation of classical features of AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11895368&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In addition, the fact that imprinting of UBE3A takes place only in specific brain regions ([[#Glossary | '''cerebellum''']] , [[#Glossary | '''olfactory tracts''']]  and the [[#Glossary | '''hippocampus''']]) confirms the hypothesis that the loss of this gene would be detrimental in cognitive development.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20398390&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Most genes are inherited in copies of two, one paternal and the other maternal; however, some genes, such as UBE3A only have one functional copy as the other is silenced, coined 'imprinting'. Imprinting of the paternal copy of UBE3A takes place in some cell populations, such as the hippocampal [[#Glossary | '''neurons''']]and [[#Glossary | '''Purkinje cells''']] Purkinje cells in the cerebellum.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9288101&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This means only the maternal UBE3A is functionally expressed in these particular brain regions. Thus a [[#Glossary | '''de novo mutation''']] in the maternal copy of the gene will result in the complete absence of functional E6-AP in the associated brain areas.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9288088&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
It is also known that UBE3A plays an important role in synaptic transmission, but exactly how it does so is still not completely understood.&amp;lt;ref name=&amp;quot;PMID:9808466&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9808466&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''UBE3A ubiquitylation'''&lt;br /&gt;
&lt;br /&gt;
As briefly mentioned above, UBE3A is a member of the E3 ubiquitin ligase family of enzymes. It is responsible for the addition of ubiquitin to the target protein for degradation of the ubiquitinated protein, as illustrated in the diagram below. These processes are required for normal human cognitive function.&amp;lt;ref name=&amp;quot;PMID:9808466&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9808466&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In this way synaptic protein [[#Glossary | '''Arc (activity-regulated cytoskeleton-associated protein)''']] is degraded to control synaptic function. Arc is a target protein of UBE3A in dendritic spines found in the hippocampal neurons.&amp;lt;ref name=&amp;quot;PMID:20668179&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20668179&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Deletion of UBE3A leads to the accumulation of Arc in neurons leading to trafficking of [[#Glossary | '''AMPA ( α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid)''']] receptors, resulting in impaired cognitive functions.&amp;lt;ref name=&amp;quot;PMID:20211139&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; [[File:UBE3A Ubiquitylation Pathway.png|thumb|350px|right|UBE3A Ubiquitylation Pathway.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
UBE3A ubiquitylation consists of:&amp;lt;ref name=&amp;quot;PMID:20668179&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20668179&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
# Activation of ubiquitin by E1 enzyme&lt;br /&gt;
# E1 ezyme transfers ubiquitin to E2 enzyme&lt;br /&gt;
# E2 enzyme transfers ubiquitin to UBE3A&lt;br /&gt;
# UBE3A attaches activated ubiquitin to target protein which is then polyubiquitylated &lt;br /&gt;
# Target protein is then degraded by 26S proteosome&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Phenotype-Genotype correlations'''&lt;br /&gt;
&lt;br /&gt;
[[File:Extent of microcephaly in Angelman Syndrome patients.png|thumb|250px|right|Extent of microcephaly in 20 AS patients with deletion and without deletion.&amp;lt;ref&amp;gt;http://www.nature.com/ejhg/index.html/&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
All AS patients show differing extents of cognitive impairment, movement disorder, characteristic behaviours and difficulty in speech and language.&amp;lt;ref name=&amp;quot;PMID:11748306&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11748306&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; However, there seems to be some phenotype-genotype correlations:&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
- 5-7Mb deletions result in the most severe phenotypes such as microcephaly, more sever [[#Glossary | '''epilepsy''']] and seizures, motor difficulties and language impairment.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9546330&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20445456&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; AS patients with large deletions also present with clinical [[#Glossary | '''hypopigmentation''']], light hair and eye colour due to the close association of OCA2 gene with UBE3A.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;16470747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Individuals under this category have in general no increased BMI&amp;lt;ref name=&amp;quot;PMID:15253756&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15253756&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This is indicated by the graph on the left, which shows more cases of AS patients with deletions having larger deviations from the mean head circumference measurement than non-deletion AS patients.&lt;br /&gt;
 &lt;br /&gt;
- AS patients with uniparental disomy (UPD) have better physical growth, fewer motor deficits and lower seizure occurrences.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16023557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
- Individuals with AS resulting from imprinting defects have the least debilitating features, such as higher developmental and language ability than AS caused by other mechanisms.&amp;lt;ref name=&amp;quot;PMID:11748306&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11748306&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
- The Body Mass Index (BMI) of 33% of the UBE3A mutation patients, and 47–64% of the patients from the classes II (UPD) and III (Imprinting defect) is above the 95th centile.&amp;lt;ref name=&amp;quot;PMID:15253756&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15253756&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Animal models'''&lt;br /&gt;
&lt;br /&gt;
* '''Drosophila'''&lt;br /&gt;
&lt;br /&gt;
Drosophila (common fruit fly) is an excellent model to use for better understanding of genetic diseases in humans as they are highly homologous to human UBE3A (hUBE3A), illustrating a high evolutionary conservation. Studies using the Drosophila model have shown that the functional absence of UBE3A resulted in decreased morphogenesis of dendritic branches. This is of interest as dendritic branches cover over 90% of the neuronal surface where [[#Glossary | '''synapse''']] between neurons occur. Proper formation and maturation of dendritic spines is also required so they come in contact with other neurons for effective transmission of neuronal signals. Thus proper formation of dendritic branching is pivitol for effective neuronal function and hence cognitive function.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18996915&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Interestingly, overexpression of dUBE3A also gave the same result, consisting of abnormal locomotion  and decreased dendritic branching in sensory neurons.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18701717&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;  This suggests a possible research field for some forms of [[#Glossary | '''autism''']] where the region containing UBE3A is duplicated, leading to delayed motor skills and seizures.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16433693&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;[[File:Normal and Angelman Syndrome mice models.jpg|thumb|250px|right|Normal and AS mice performance on the Rotarod apparatus.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
* '''Mice'''&lt;br /&gt;
&lt;br /&gt;
Absence of UBE3A in mice manifest similar phenotype to human AS, as illustrated by motor and learning deficits with inducible seizures.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21235769&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It has been shown through various mice model studies that larger deletions, ie. from UBE3A to GABRB3, more closely mirrors the large 6Mb deletions seen in human AS patients. Numerous tests, such as the Rotarod (for motor coordination and learning ability), Morris water maze test (for spatial learning and memory) and [[#Glossary | '''EEG''']] (electroencephalography), were carried out on  UBE3A null mutants, which showed the results to be abnormal or impaired.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20808828&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Other studies using mouse models have also outlined the obesity observed in 15% of AS children, albeit it is not the major characterisitics of AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17259980&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The diagram on the right clearly highlights the results obtained from such mouse model studies of AS, where the absence of UBE3A accumulated in deficits of motor function and obesity. In addition, excessive drooling and feeding difficulties were also highlighted by mice models with inactivated UBE3A, reflected by defects in fluid consumption and licking.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18413322&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Pathophysiology===&lt;br /&gt;
&lt;br /&gt;
'''Cognitive defects'''&lt;br /&gt;
&lt;br /&gt;
[[File:Role of UBE3A in dendritic spine neuronal synapses.png|thumb|250px|right|Role of UBE3A in dendritic spine neuronal synapses.]]&lt;br /&gt;
&lt;br /&gt;
AS patients present with abnormally high UBE3A, leading to neurological impairment. Recent identification of key target proteins of Ephexin-58 (Eph-5) and Arc (Activity-Regulated Cytoskeleton-associated protein) have aided in better understanding of the progression of UBE3A to cognitive defects. These two proteins are vital in the understanding of AS as Eph-5 determines synapse numbers and Arc contributes to plasticity and synapse function.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21164477&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Studies utilizing mice models have illustrated that UBE3A null mice could not ubiquitinate Eph-5, thus increasing its levels and limiting the growth of dendritic spines by the activation of RhoA. This subsequent activation of RhoA inhibits synapse formation and results in neuronal defects.&lt;br /&gt;
&lt;br /&gt;
In contrast, mice with normally functioning UBE3A showed phosphorylated Eph-5, resulting from the interaction of two neurons via the activation of EphB signalling receptor.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21029865&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Phosphorylation of Eph-5 allows UBE3A to ubiquitinate and degrade it. This degradation of Eph-5 permits new synaptic connections to form with cells they come into contact with. However, in AS, the absence of UBE3A means Eph-5 cannot be degraded, so RhoA activity is prolonged to reduce synaptic formation.&lt;br /&gt;
&lt;br /&gt;
As mentioned previously, Arc plays a pivitol role in synapse function as it removes synaptic receptors that respond to glutamate, a [[#Glossary | '''neurotransmitter''']].&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17088211&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In UBE3A present neurons, UBE3A ubiquitinates Arc, leading to it degradation as illustrated by the diagram on the left. However, in UBE3A deficient neurons, Arc accumulates and prevents the proper synaptic communications essential for normal cognitive functions.&amp;lt;ref name=&amp;quot;PMID20211139&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Signs and Symptoms==&lt;br /&gt;
&lt;br /&gt;
Angelman Syndrome presents a variety of different phenotypes, and the presented symptoms may vary at different ages.&amp;lt;ref name=&amp;quot;PMID7625442&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7625442&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
In 1995 Williams et al. embraced the observed clinical features of AS in a consensus statement, in order to present an appliance for clinicians. The diagnostic criteria were updated in 2005.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt; The following table shows the most frequently occurring characteristics in AS patients:&lt;br /&gt;
&lt;br /&gt;
'''4 characteristics appear in 100% of the cases:'''&lt;br /&gt;
&lt;br /&gt;
*Delayed development: become apparent by the age of 6 to 12 months.&lt;br /&gt;
*Motion and or balance malfunction&lt;br /&gt;
*Behaviour patterns like unmotivated laughter, frequent excitement; often including body movements,[[File:Electroencephalography of Angelman Syndrome.jpg|thumb|350px|right|EEG of AS and normal individuals.]] [[#Glossary | '''hypermotoric''']] behaviour&lt;br /&gt;
*Impairment of speech&lt;br /&gt;
&lt;br /&gt;
'''3 characteristics appear in more than 80% of the cases:'''&lt;br /&gt;
&lt;br /&gt;
*Abnormalities in head circumference, microcephaly&lt;br /&gt;
*Seizures&lt;br /&gt;
*EEG shows specific abnormal patterns&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Angelman Syndrome individuals show the most distinct disease pattern from 2 to 16 years of age.&lt;br /&gt;
In most cases at least 8 of the symptom traits are shown.&amp;lt;ref name=&amp;quot;PMID7625442&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Behavioural Characteristics'''&lt;br /&gt;
&lt;br /&gt;
A range of substantial characteristics appear in all AS cases, regardless of the genetic mechanisms, and are often responsible for diagnosing the syndrome. According to the original name, Happy Puppet syndrome, they have shown to exhibit traits such as a happy demeanor, with frequent laughter or smiling that can easily be triggered.&amp;lt;ref name=&amp;quot;PMID12566516&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12566516&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This behaviour can already be observed in 1 to 3 month old infants.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot; /&amp;gt; Uplifted hand flapping or waving motions are associated with laughter and excitement. Other characteristics manifesting in early childhood are sleep abnormalities with reduced sleep demand, and feeding problems. Breast and bottle feeding can be difficult due to non efficient attachment to the breast, tongue thrusting and uncoordinated sucking. Furthermore, there is an affection to crinkly and reflective surfaces, like some papers or plastic materials, especially water.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID12566516 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Communication Skills'''&lt;br /&gt;
&lt;br /&gt;
Communication is challenging for AS patients due to the fact that speech impairment is present in all cases. In the majority of affected people a lack of speech development is present. Only some of them have a minimal vocabulary consisting of two or three words, a few can speak in basic sentences. Some patients use gestures to articulate themselves, the [[#Glossary | '''Picture Exchange Communication System (PECS)''']] or sign languages such as [[#Glossary | '''Makaton''']] can be used for communication. Simple demands regarding their everyday occurrence can be understood by most patients.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID12566516 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Clinical and External Characteristics'''[[File:Angelman Syndrome patient.png|thumb|200px|right|4 year old AS patient.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Developmental delays are present in all patients. Motor milestones are delayed with children managing to sit unsupported with 12 months and crawl or bottom shuffle at the age of 18-24 months. The average age for walking is 4 years,however, ranging from 18 months to 7 years.&lt;br /&gt;
The [[#Glossary | '''gait''']] is characterised as slow, and flapping hands are a common trait.  The legs remain stiff during walking, arms are inflected by the wrists and elbows. The movements can appear ataxic, jerky or lurching. The muscle tone shows abnormalities with truncal [[#Glossary | '''hypotonia''']] and [[#Glossary | '''hypertonicity''']] of the limbs and alert reflexes.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID12566516 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The most striking external traits present in patients include broad-spaced teeth, and a wide mouth, light hair and eye colour, hypopigmented skin, deep set eyes, and a flat [[#Glossary | '''occiput''']].&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Seizures in Angelman Syndrome'''&lt;br /&gt;
&lt;br /&gt;
85% of AS patients suffer from epileptic seizures during their first three years. The first appearance can be within one month up to 20 year old patients. In infants with AS epilepsy manifests with [[#Glossary | '''febrile convulsions''']] and is hard to manage during childhood.&lt;br /&gt;
The most common type of seizures within 25% of patients are [[#Glossary | '''myoclonic seizures''']], followed by [[#Glossary | '''atonic seizures''']] as the second most frequent type, then 21% experience generalised [[#Glossary | '''tonic-clonic seizures''']] and lastly [[#Glossary | '''atypical absences''']] occur in 12% of patients.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20398390&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Angelman Syndrome in adults'''&lt;br /&gt;
&lt;br /&gt;
Patients with Angelman syndrome possess normal secondary sexual characteristics, and puberty sets in at a usual time. Limb hypertonicity, and [[#Glossary | '''thoracic scoliosis''']] lead to decreasing mobility. [[#Glossary | '''Oesophagus reflux''']] might induce severe problems, and the majority suffers from obesity. Furthermore, facial traits such as a prominent lower lip [[#Glossary | '''macrostomia''']] and [[#Glossary | '''mandibular prognathism''']] get manifested in adults. &lt;br /&gt;
In some cases the communication barrier can lead to frustration, resulting in aggressive behaviour. Nonetheless, patients gain a higher concentration span with age, and their nature becomes more quiet.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Complications===&lt;br /&gt;
&lt;br /&gt;
'''Hypopigmentation and Ocular albinism'''&lt;br /&gt;
&lt;br /&gt;
OCA2 gene, also known as the P gene, is closely located to the UBE3A gene. It encodes a protein vital to tyrosine metabolism, which plays a role in pigmentation development of skin, hair and eyes. However, AS caused by the large deletion of UBE3A leads to haploinsufficiency of OCA2 gene, resulting in hypopigmentation of the skin and the eyes. In some children with severe hypopigmentation, some form of [[#Glossary | '''albinism''']] is suspected.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12749060&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; When AS is caused by another mechanism, no abnormality of the skin and eye pigmentation is observed. However, not all AS children with OCA2 gene deletion will present with obvious hypopigmentation, they may just exhibit lighter skin colour than their parents.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8302318&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Diagnosis==&lt;br /&gt;
&lt;br /&gt;
The diagnosis of Angelman Syndrome is a clinical diagnosis confirmed by laboratory testing.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This involves both prenatal and/or postnatal diagnosis. &lt;br /&gt;
&lt;br /&gt;
===Prenatal Diagnosis===&lt;br /&gt;
[[File:Angelman Syndrome Prenatal Diagnosis.jpg|thumb|250px|right|Flowchart of AS Diagnosis.]]&lt;br /&gt;
&lt;br /&gt;
Prenatal detection of deletions of 15q11.2-q13, [[#Glossary | '''Paternal UPD''']] ([[#Glossary | '''Uniparental Disomy''']]), Imprinting defects and UBE3A mutations are done through DNA/chromosome/FISH analysis of fetal cells obtained by either [[#Glossary | '''Chorionic Villus Sampling''']](CVS) or [[#Glossary | '''Amniocentesis''']].&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot;/&amp;gt; &lt;br /&gt;
DNA methylation analysis using [[#Glossary | '''Amniocytes''']] is usually the first test carried out in molecular diagnosis of AS.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18059071&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; An abnormal result is followed up by either a FISH or array CGH analysis to search for a deletion on chromosome 15. If they produce a normal result, then UPD testing using DNA polymorphysims is carried out. If there is no evidence of UPD, other DNA analysis tests are used search for an imprinting centre deletion.&amp;lt;ref name=&amp;quot;PMID9792887&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9792887&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; A normal DNA methylation analysis is followed by a UBE3A sequence analysis.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt; In addition, a parent of origin test is also done to determine if the genetic disruption is of maternal origin or paternal origin. If it is maternally derived the fetus is diagnosed with AS (a paternally derived genetic disruption is indicative of Prader-Willi Syndrome).&amp;lt;ref name=&amp;quot;PMID17020468&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;17020468&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The flow chart summarizes the normal procedure used for prenatal diagnosis of AS. More information on important laboratory tests used for the diagnosis of Angelman Syndrome are provided below:&lt;br /&gt;
&lt;br /&gt;
*'''DNA Methylation Analysis'''&lt;br /&gt;
&lt;br /&gt;
Identifies approximately 80% of AS affected individuals and is usually the first test to be ordered.&amp;lt;ref name=&amp;quot;PMID7618904&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7618904&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Molecular disruptions such as deletions, paternal UPD and imprinting defects on chromosome 15 all demonstrate abnormal methylation patterns by either southern blot analysis or PCR amplification of bisulphate-treated DNA.&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot; /&amp;gt; An affected individual will only have an unmethylated (paternal) SNRPN (small nuclear ribonuclear protein-associated polypeptide N) allele compared with an unaffected individual who will have both a methylated and an unmethylated SNRPN allele.&amp;lt;ref name=&amp;quot;PMID9634532&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9634532&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
	  &lt;br /&gt;
*'''FISH (Fluorescent In Situ Hybridization)'''&lt;br /&gt;
&lt;br /&gt;
[[File:Critical_region_of_Angelman_Syndrome_on_chromosome_15.png‎|thumb|150px|right|FISH (fluorescence in situ hybridisation) image showing the critical region of Angelman Syndrome on chromosome 15.]]&lt;br /&gt;
&lt;br /&gt;
FISH analysis detects 5-7 Mb deletions in approximately 68% of affected individuals using detecting probes such as D15S10 and/or SNRPN.&amp;lt;ref name=&amp;quot;PMID7618904&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7618904&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It is also able to distinguish UPD from micro-deletions and imprinting defects. In simple terms, FISH analysis involves the binding of a fluorescent probe to a specific part of chromosome 15 and the detection of deletions within that region. FISH analysis is much more accurate in deletion detection compared to other high-resolution cytogenetics in the diagnosis of AS patients.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1511093&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
Array-based CGH is an advanced type of cytogenetic testing that can also be used to detect smaller deletions.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''UPD (Uniparental Disomy) Detection'''&lt;br /&gt;
&lt;br /&gt;
DNA Polymorphism testing detects paternal UPD in approximately 7% of affected AS individuals.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt; It is also able to distinguish between UPD and an Imprinting defect. It requires a DNA sample from the [[#Glossary | '''Proband''']] and from both parents. A homologous or non-homologous whole-arm translocation of the long arms of chromosome 15 is a sound indication for the need for prenatal UPD testing.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''IC (Imprinting Center) Analysis'''&lt;br /&gt;
&lt;br /&gt;
This type of analysis is used when individuals have an abnormal DNA methylation pattern but show normal results for  FISH, array CGH study and UPD analysis.&amp;lt;ref name=&amp;quot;PMID9792887&amp;quot;/&amp;gt; It is used to differentiate between the Imprinting defects caused by either microdeletions in the AS imprinting centre or by epigenetic mutations (that occur in maternal oogenesis or early embryogenesis).&amp;lt;ref name=&amp;quot;PMID9634532&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''Cytogenetic Testing'''&lt;br /&gt;
&lt;br /&gt;
Is used to detect a cytogenetically visible chromosomal rearrangement (large deletion, translocation or inversion) involving the 15q11.2-q13 region, which occurs in less than 1% of affected individuals.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''UBE3A Sequence Analysis'''&lt;br /&gt;
Sequence analysis of the UBE3A gene detects mutations in about 10% of the patients.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt; The test is used to detect either multiexonic (10 major coding exons of UBE3A) or whole gene deletions of UBE3A gene in individuals who produces a normal DNA methylation result but has characteristic clinical features of AS.&amp;lt;ref name=&amp;quot;PMID9792887&amp;quot;/&amp;gt;&lt;br /&gt;
This is recommended as a prenatal diagnostic tool in families that include multiple AS affected individuals because the imprinted pattern can be inherited from distant relatives.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Postnatal Diagnosis===&lt;br /&gt;
&lt;br /&gt;
Postnatal diagnosis is made though a combination of common clinical features of AS and UBESA gene sequence analysis.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt; The clinical features of AS include unsteady or shaky movements, muscle hypotonia, developmental delay and behavioral uniqueness such as frequent laughter/smiling and happy demeanor are features that are 100% consistent in all patients diagnosed with Angelman Syndrome.&amp;lt;ref name=&amp;quot;PMID18830393&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18830393&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; These clinical features become apparent between 6 months to 2 years of age. The onset of early or persistent smiling characteristic of this syndrome begin around the age of 1-3 months, but is often overlooked during infancy.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot;/&amp;gt; Thus early diagnosis of AS during infancy period is difficult because the clinical indicators of the syndrome takes time to manifest and characteristic features such as finger and hand tremors and excessive smiling/laughter are often overlooked and not considered as possible indicators of this syndrome.&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
*Rett Syndrome&lt;br /&gt;
&lt;br /&gt;
Some children with the clinical diagnosis of AS but no underlying genetic mechanism show mutations in ''MECP2'' gene, corresponding to Rett Syndrome. This should be suspected in AS test negative girls in the first few years of life.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17980307&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*Mowat-Wilson Syndrome&lt;br /&gt;
&lt;br /&gt;
Genetic mechanism is heterozygous deletion or truncation in ''ZFHX1B'' (''SIP1'') gene on 2q22. This presents with clinical features of severe intellectual disability, micrcephaly and seizures.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17958891&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Prader-Willi Syndrome patient.png|thumb|right|120px|12 year old PWS patient.]]&lt;br /&gt;
&lt;br /&gt;
*X-linked alpha-thalassemia/mental retardation syndrome (ATR-X)&lt;br /&gt;
&lt;br /&gt;
This arises from mutations in ''XNP'' gene on Xq13. ATR-X presents with severe intellectual disability, no speech development and seizures are common.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11449489&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*Phelan-McDermid Syndrome/22q13 deletion syndrome&lt;br /&gt;
&lt;br /&gt;
Deletions are usually submicroscopic and thus requires special molecular cytogenetic methods to confirm this deletion. Patients show moderate to profound intellectual disability and delay in speech development.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18505557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Related Disease'''&lt;br /&gt;
&lt;br /&gt;
*Prader-Willi Syndrome(PWS)&lt;br /&gt;
&lt;br /&gt;
PWS is a result from the absence of paternally expressed 15q11-q13 gene as a corollary of de novo deletion, maternal uniparental disomy of chromosome 15 or an imprinting defect on paternal chromosome 15 leading to the silencing of paternal alleles.&amp;lt;ref name=&amp;quot;PMID:20668179 &amp;quot;/&amp;gt; It is characterized by [[#Glossary | '''hyperphagia''']], obesity in later infancy and early childhood and difficulty in feeding during early infancy.&amp;lt;ref name=&amp;quot;PMID:20668179 &amp;quot;/&amp;gt; There is also cognitive impairment to some extent, though some PWS patients may exhibit intelligence in the normal IQ range. Behavioral phenotypes include stubbornness, manipulative tendency, obsessive compulsive characteristics.&amp;lt;ref name=&amp;quot;PMID:20668179 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Genetic Counselling==&lt;br /&gt;
&lt;br /&gt;
Genetic counselling is the process by which patients or relatives, at risk of an inherited disorder, are advised of the consequences and nature of the disorder, the probability of developing or transmitting it, and the options open to them in management and family planning. In the case for Angelman syndrome, types of risks associated are split into classes and formatted into the table below:&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20459762&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{|  style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
! Class&lt;br /&gt;
! Mechanism&lt;br /&gt;
! Risk to siblings&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! Ia                           &lt;br /&gt;
| De novo deletion                                                                                                               &lt;br /&gt;
| &amp;lt;1%                                                                                                                &lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! Ib&lt;br /&gt;
| Deletion due to chromosome rearrangement&lt;br /&gt;
| Up to 50%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! II&lt;br /&gt;
| Paternal uniparental disomy (UPD)&lt;br /&gt;
| &amp;lt;1%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! IIIa&lt;br /&gt;
| Imprinting defect with IC mutation&lt;br /&gt;
| Close to 100% if father has 15; 15 [[#Glossary | '''Robertsonian translocation''']]&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! IIIb&lt;br /&gt;
| Imprinting defect without IC mutation&lt;br /&gt;
| Up to 50% (if mother has IC deletion)&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! IIIc&lt;br /&gt;
| [[#Glossary | '''Mosaic''']] imprinting defect&lt;br /&gt;
| &amp;lt;1%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! IV&lt;br /&gt;
| ''UBE3A'' mutation&lt;br /&gt;
| Up to 50% (if mother has mutation)&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! V&lt;br /&gt;
| No identifiable genetic abnormality&lt;br /&gt;
| ?&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Ia''': Individuals with de novo deletion have 1% risk to siblings&lt;br /&gt;
&lt;br /&gt;
'''Ib''': Risk to siblings in individuals with chromosomal rearrangements is up to 50% &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9557895&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''II''': Paternal UPD with no Robertsonian translocation has a risk to sibling of less than 1%&lt;br /&gt;
&lt;br /&gt;
'''IIIa''': The risk to siblings in individuals with AS from an imprinting defect with a mutation in the imprinting center (IC) is close to 100% if father has 15;15 Robertsonian translocation&lt;br /&gt;
&lt;br /&gt;
'''IIIb''': Individuals with AS resulting from an imprinting defect without IC mutation, but with a carrier mother has a high risk to siblings of up to 50%. The mother could be phenotypically normal due to paternal inheritance of the genetic defect &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11283796&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''IIIc''': Individuals who are mosaic for the imprinting defect have less than 1% risk to siblings&lt;br /&gt;
&lt;br /&gt;
'''IV''': UBE3A mutation can be either inherited or de novo mutation. If the mother is a carrier for this genetic mutation, the risk to siblings is up to 50% &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11258627&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''V''': Individuals who present with AS clinically, but have no known underlying mechanism have an unknown risk to siblings.&lt;br /&gt;
&lt;br /&gt;
==Treatment and Management==&lt;br /&gt;
&lt;br /&gt;
Even though at present there is no known cure for Angelman syndrome, there are a number of treatments available that may alleviate symptons and improve daily life activities.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The below table describes the problems and management options that are used:&lt;br /&gt;
&lt;br /&gt;
[[File:Subtle Finger tremors-Angelman Syndrome.jpg|right|thumb|150px|A five months old boy with Angelman syndrome showing signs of Subtle Finger tremor.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
! Problems encountered&lt;br /&gt;
! Treatment and Management&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''Difficulty in feeding newborn AS babies'''&lt;br /&gt;
| Use of special nipples may improve feeding&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Oesophagus reflux'''&lt;br /&gt;
| Special motility medications requiried or upright positioning&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''Seizures'''&lt;br /&gt;
| Anticonvulsant medications&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19605773&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19453717&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Ocular problems'''&lt;br /&gt;
| Visual assessment is vital to encourage interactions and minimize chances of self-harm and autism development&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20656169&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''Drooling in developmental delayed AS patients'''&lt;br /&gt;
| Difficult to treat, but new surgical procedure on salivary duct reimplantation seems to be a promising alternative&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17699119&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Unstable children''' &lt;br /&gt;
| Physical therapy&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''AS patients become less active with increasing age'''&lt;br /&gt;
| Activity schedules to prevent scoliosis and obesity. Occupational therapy to stimulate fine motor and oral-motor control skills in conjunction to speech therapy&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Sleeping difficulty'''&lt;br /&gt;
| Sedative medication in severe cases. [[#Glossary | '''Melatonin''']] may be used to promote sleeping but some studies have found that it loses its therapeutic effects after several weeks in most AS patients&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19379289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|-&lt;br /&gt;
|colspan=&amp;quot;4&amp;quot; |&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Prognosis==&lt;br /&gt;
&lt;br /&gt;
Life expectancy of AS patients seems to be normal&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, but there is still a high degree of developmental delay and limited expressive language skills.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17019625&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This problem arises prominently in the assessment of the severity of coincidental medical conditions due to difficulties in communication. A visit to the dentist can become difficult if good communication is not conveyed between the parents, the dentist, and the child.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18271768&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Some problems require extreme measures, such as the procedure of lens implantation was performed in both eyes of a person diagnosed with AS, due to the inability to wear spectacles.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20656169&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
During adulthood, menstruation and puberty begin at around average age evidenced by females with Angelman syndrome that are fully capable of conceiving children.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11258627&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Most adult patients can feed themselves, but needed help with many other daily activities. Main troubles which have shown in adults are a tendency to become obese and start developing  thoracic scoliosis, which some adults with AS begin wheelchair bounded.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9072912&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Current and Future Research==&lt;br /&gt;
&lt;br /&gt;
Currently there is no cure for the treatment of AS, so much research is being carried out for therapeutic interventions. Findings in the last five years have suggested through various mice and fruit fly models that the absence of maternal UBE3A results in the same human AS features of neurological defects and seizures. However, more recently, studies have outlined that the symptoms of AS can be improved by modifying other gene products. In addition, restoring of a functional UBE3A protein into adult mice neurons have shown to reduce motor and neurological deficits and balance disorders. This shows promising research prospects in that improvements may be possible in human AS patients by restoring functional UBE3A proteins into their neurons. &lt;br /&gt;
&lt;br /&gt;
===Possible Treatment Pathways===&lt;br /&gt;
&lt;br /&gt;
*'''Cognitive and physical impairment'''&lt;br /&gt;
&lt;br /&gt;
Although everyone is born with two copies of the gene UBE3A, one maternal and one paternal copy, it is only the maternal UBE3A that is used in the brain. Most AS patients have a genetic mutation on the maternal chromosome 15 that results in dysfunctional UBE3A.&amp;lt;ref&amp;gt;http://www.cureangelman.org/what-hope.html&amp;lt;/ref&amp;gt; The above research focused on turning on the father's copy of UBE3A to restore its functions. Furthermore, mouse models were utilized to show that alpha-CaMKII could be increased to compensate the loss of UBE3A and restore compromised mental and physical abilities. However, this finding still requires much more research.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17259980&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''Epilepsy'''&lt;br /&gt;
&lt;br /&gt;
There is research being done on improving certain conditions that are involved in AS by nutritional benefits. The use of [[#Glossary | '''corticosteroids''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19666884&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, [[#Glossary | '''valproate''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19453717&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and [[#Glossary | '''clonazepam''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19605773&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and having a [[#Glossary | '''ketogenic diet''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20880305&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; has all been shown to aid in the treatment of epilepsy. It has also been reported to be efficient in the treatment of other conditions, such as behavioural disorders, reduction in seizures, ataxia, sleep patterns, developmental progress and sleep disturbances. [[#Glossary | '''Levetiracetam''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17326790&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; could be used in such a situation, especially when the patient has an intolerance to valproate and clonazepam.&lt;br /&gt;
&lt;br /&gt;
*'''Betaine and Folic acid'''&lt;br /&gt;
&lt;br /&gt;
This double-blind placebo-controlled study was done to examine the potential therapeutic role of [[#Glossary | '''betaine''']] and [[#Glossary | '''folic acid''']] in the treatment of the clinical phenotypes of AS. The aim of this protocol was to increase methylation and activate the paternally inherited UBE3A in hope to compensate for the inactive maternal UBE3A. Although there were no major differences in the control and treatment groups, a small number of patients in the treatment group showed some positive outcomes.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20635355&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&lt;br /&gt;
'''albinism''': A congenital disorder distincted by the complete or partial absence of pigment in the skin, hair and eyes due to defect of an enzyme involved in the production of melanin.&lt;br /&gt;
&lt;br /&gt;
'''allele''': Dissimilar variant of one gene. Organisms have two alleles for each gene inherited from their parents, one from each of them.&lt;br /&gt;
&lt;br /&gt;
'''alpha-CaMKII''': (alpha calcium calmodulin kinase II) Compound involved in synaptic plasticity, one of the most important theories behind learning and memory. Ability of a synapse between two neurons to change in strength due to the use or disuse of transmission.&lt;br /&gt;
&lt;br /&gt;
'''Amniocytes''': Cells that are shed by the fetus during fetal development to the surrounding amniotic fluid. They are a source of fetal DNA. &lt;br /&gt;
&lt;br /&gt;
'''Amniocentesis''': (AFT or amniotic fluid test) is a prenatal diagnostic test used to detect chromosomal abnormalities in the developing fetus by extracting amniotic fluid (a source of fetal DNA) surrounding the fetus. &lt;br /&gt;
&lt;br /&gt;
'''AMPA''': (2-amino-3-(5-methyl-3-oxo-1,2- oxazol-4-yl)propanoic acid) Compound that binds to the AMPA receptor to imitate glutamate neurotransmitter.&lt;br /&gt;
&lt;br /&gt;
'''Arc''': Activity-Regulated Cytoskeleton-associated protein; involved in learning and memory.&lt;br /&gt;
&lt;br /&gt;
'''ataxia''': Lack of coordination in muscle movements.&lt;br /&gt;
&lt;br /&gt;
'''atonic seizures''': A abrupt loss of muscle tone, this can lead to the limbs loosing strength, or the head may drop to the side. The patient remains conscious during this kind of epileptic seizure.&lt;br /&gt;
&lt;br /&gt;
'''atypical absences''': Seizure leads to unconsciousness in most cases.  &lt;br /&gt;
&lt;br /&gt;
'''autism''': A neural development disorder defined by limited social interaction and communication.&lt;br /&gt;
&lt;br /&gt;
'''betaine''': Also known as  betaine anhydrous or trimethylglycine (TMG), assists the body in metabolising the amino acid, homocysteine. Can be consumed via beets, broccoli, grains, shellfish, and spinach.&lt;br /&gt;
&lt;br /&gt;
'''cerebellum''': Region of the brain that plays an important role in motor control. It is also involved in some cognitive functions such as attention and language.&lt;br /&gt;
&lt;br /&gt;
'''Chorionic Villus Sampling''': A prenatal diagnostic test used to detect chromosomal abnormalities in the developing fetus by extracting and testing chorionic villus (placental tissue). &lt;br /&gt;
&lt;br /&gt;
'''chromosome''': Structure consisting of coiled DNA with DNA associated proteins such as histones.&lt;br /&gt;
&lt;br /&gt;
'''clonazepam''': A psychoactive drug having muscle relaxant properties and treats anxiety and epilepsy.&lt;br /&gt;
&lt;br /&gt;
'''corticosteroid''': A type of steroid hormones that are produced in the adrenal cortex.&lt;br /&gt;
&lt;br /&gt;
'''cytogenetics''': Study of the structure, function and abnormality of the cell, especially the chromosome.&lt;br /&gt;
&lt;br /&gt;
'''deletion''': Lack of a part of the DNA (deoxyribonucleic acid is a nucleic acid containing information for protein synthesis), can vary form a single base to a hole gene. &lt;br /&gt;
&lt;br /&gt;
'''de novo mutation''': Change in a gene of a family member for the first time due to a mutation in the egg or sperm of the parents or in the fertilized egg (zygote).&lt;br /&gt;
&lt;br /&gt;
'''disorder''': A mental or physical health disturbance or dysfunction.&lt;br /&gt;
&lt;br /&gt;
'''EEG''': Electroencephalography is a means of measuring electrical activity along the scalp by measuring the total electrical charges fired by thousands or millions of neurons.&lt;br /&gt;
&lt;br /&gt;
'''epilepsy''': Neurological disorder characterised by recurrent impairment of brain function that can cause seizures or unconsciousness. &lt;br /&gt;
&lt;br /&gt;
'''E6-AP''': E6-AP ubiquitin-protein ligase is an enzyme encoded by UBE3A which adds ubiquitin chain to target proteins to be degraded by proteasomes.&lt;br /&gt;
&lt;br /&gt;
'''febrile convulsions''': The occurrence of high fever, especially in children.&lt;br /&gt;
&lt;br /&gt;
'''FISH''': Fluorescent in situ hybridization is a technique used to identify and localize the presence or absence of DNA sequences on the chromosome. This is achieved by using fluorescently labelled DNA sequences which then binds to complementary DNA sequence on the chromosome. After hybridization (attachment), chromosome of interest will fluoresce under the microscope.&lt;br /&gt;
&lt;br /&gt;
'''folic acid''': B vitamin that helps the body make healthy new cells. Can be consumed via leafy green vegetables, fruits, dried beans, peas and nuts.&lt;br /&gt;
&lt;br /&gt;
'''gait''': A manner of walking, stepping or running.&lt;br /&gt;
&lt;br /&gt;
'''gene''': A molecular unit of heredity of a living organism.&lt;br /&gt;
&lt;br /&gt;
'''hippocampus''': Area buried deep in the forebrain that helps regulate emotion and memory&lt;br /&gt;
&lt;br /&gt;
'''hyperphagia''': (Also referred to as Polyphagia) Excessive ingestion of food beyond the dietary and energy requirements of the body. &lt;br /&gt;
&lt;br /&gt;
'''hypermotoric''': Sudden appearance of uncontrolled movements such as striking or kicking inappropriately.&lt;br /&gt;
&lt;br /&gt;
'''hypertonicity''': Increase of muscle tension and a disability to stretch leading to an impairment of motor activity.&lt;br /&gt;
&lt;br /&gt;
'''hypopigmentation''': A lack of melanin pigments or melanocytes  affecting the colour of the skin, hair and iris. Features appear to be light-coloured due to loss of skin colour.&lt;br /&gt;
&lt;br /&gt;
'''hypotonia''': Decrease in the ability to stretch passively, due to a low muscle tone. &lt;br /&gt;
&lt;br /&gt;
'''imprinting''': This is a process to describe the modification of a maternally or paternally derived chromosome, which consequently influences the expression of certain genes on the altered chromosome.&lt;br /&gt;
&lt;br /&gt;
'''ketogenic diet''': A high-fat, low-carbohydrate diet that is used to treat epilepsy in children.&lt;br /&gt;
&lt;br /&gt;
'''levetiracetam''': An anticonvulsant drug used to treat epilepsy.&lt;br /&gt;
&lt;br /&gt;
'''locus''': Location of a gene on a chromosome(loci: plural for locus).&lt;br /&gt;
&lt;br /&gt;
'''LTP''': Long-term potentiation shares common features with long term memory. It strengthens and enhances signal transmission between neurons by improving the communication between two neurons.&lt;br /&gt;
&lt;br /&gt;
'''macrostomia''': A wide-spaced mouth.&lt;br /&gt;
&lt;br /&gt;
'''Makaton''': Language programme using symbols and signs to support speaking.&lt;br /&gt;
&lt;br /&gt;
'''mandibular prognathism''': The abnormal protrusion of the lower jaw. &lt;br /&gt;
&lt;br /&gt;
'''maxillary hypoplasia''':  The underdevelopment of the upper jaw.&lt;br /&gt;
&lt;br /&gt;
'''melatonin''': A hormone secreted by the pineal gland.&lt;br /&gt;
&lt;br /&gt;
'''microcephaly''': The circumference of the head is less than average due to abnormalities of the nervous system. This abnormality can be present at birth or emerge during the first few years of life and reduces both life expectancy and the cognitive functions of the individual affected.&lt;br /&gt;
&lt;br /&gt;
'''microdeletion''':  A genetic mutation in which a part of a chromosome or a sequence of DNA is missing.&lt;br /&gt;
&lt;br /&gt;
'''mosaic''': tissues or cells containing different mixture of genetic sequences&lt;br /&gt;
&lt;br /&gt;
'''mutation''': Event that changes the DNA (deoxyribonucleic acid is a nucleic acid, containing information for protein synthesis) or RNA (ribonucleic acid is a type of nucleic acid transmitting the information from the DNA to the proteins ) of a gene permanently.&lt;br /&gt;
&lt;br /&gt;
'''myoclonic seizures''': A quick jerk of the skeletal muscle, due to a irregular brain activity.&lt;br /&gt;
&lt;br /&gt;
'''neurogenetic''': Genetic basis of the nervous system.&lt;br /&gt;
&lt;br /&gt;
'''neuron''': Cells of the nervous system that can be electrically excited to transmit information by electrical and chemical signaling&lt;br /&gt;
&lt;br /&gt;
'''neurotransmitter''': Transmits neuronal signals to a target cell. They are first packaged in vesicles just beneath the membrane of presynaptic axon terminals and released into the synaptic cleft (space between the two interacting neurons) and enter the postsynaptic dendrite.&lt;br /&gt;
&lt;br /&gt;
'''occiput''': The back portion of the head.&lt;br /&gt;
&lt;br /&gt;
'''oesophagus reflux''': Impairment of a sphincter in the lower end of the oesophagus leads to the back flow of stomach acid into the oesophagus. Heartburn is a typical symptom.&lt;br /&gt;
&lt;br /&gt;
'''olfactory tract''': It is a pathway for the sense of smell containing axons from some of the neurons in the olfactory bulb.&lt;br /&gt;
&lt;br /&gt;
'''paediatrician''': Physicians that specialise on infants, children and adolescents.&lt;br /&gt;
&lt;br /&gt;
'''paternal UPD''': Inheritance of two copies of a chromosome from the father and none from the mother. &lt;br /&gt;
&lt;br /&gt;
'''phenotype''': Visible traites of an organism determined by genetic and environmental factors.&lt;br /&gt;
&lt;br /&gt;
'''Picture Exchange Communication System (PECS)''': Individuals communicate using images instead of words. It is frequently used by children with autism, to articulate their needs and wishes or to make comments about something.&lt;br /&gt;
&lt;br /&gt;
'''Proband''': Is the person (or animal) being studied or reported on in a genetic investigation. Most commonly it refers to the first affected family member who requires medical help for a genetic disorder. &lt;br /&gt;
&lt;br /&gt;
'''Purkinje cells''': Large neuron with many branching extensions that is found in the cortex of the cerebellum of the brain and plays a fundamental role in controlling motor movement&lt;br /&gt;
&lt;br /&gt;
'''Robertsonian translocation''': Rearrangement of the chromosome, occurs in 5 chromosome including 13,14,15,21 and 22. This type of mutation occurs in chromosomes with the centromere not at the centre, resulting in long and short arm chromosomes. Translocation breaks the chromosome at the centromere so the long arm attaches to the other long arm, and the same for the short arm happens. Cell division will result in the loss of the short arms as they do not contain important genes.&lt;br /&gt;
&lt;br /&gt;
'''seizure''': Abnormal electrical activity in the brain that can result in a variety of physical symptoms like convulsion, body shaking, loss of consciousness, confusion, and mood changes.&lt;br /&gt;
&lt;br /&gt;
'''synapse''': Allows transmission of signal between neurons for effective neuronal function.&lt;br /&gt;
&lt;br /&gt;
'''thoracic scoliosis''': The spine is curved laterally(from side to side) in the thoracic region.&lt;br /&gt;
&lt;br /&gt;
'''tonic-clonic seizures''': This type of seizure is associated with unconsciousness due to electrical discharges in a big proportion of the brain.&lt;br /&gt;
&lt;br /&gt;
'''ubiquitin''': A polypeptide found in all eukaryotic cells, that participates in a variety of cellular functions including protein recycling.&lt;br /&gt;
&lt;br /&gt;
'''Uniparental disomy''': (UPD) the inheritance of two copies of a chromosome pair or part of a chromosme from one parent and no copy from the other parent. &lt;br /&gt;
&lt;br /&gt;
'''valproate''':  A mood-stabilizing drug that is also used for treatment for epilepsy and bipolar disorder.&lt;br /&gt;
&lt;br /&gt;
==Helpful Links==&lt;br /&gt;
&lt;br /&gt;
* Australia&lt;br /&gt;
:* [http://www.angelmansyndrome.org/research.html Angelman Syndrome Association] &lt;br /&gt;
:* [http://www.angelmansyndromeqld.org/ Queensland Angelman Association]&lt;br /&gt;
&lt;br /&gt;
* America&lt;br /&gt;
:* [http://www.angelman.org/ Angelman Syndrome Foundation]&lt;br /&gt;
:* [http://rarediseasesnetwork.epi.usf.edu/arpwsc/ Rare Clinical Diseases Research Network]&lt;br /&gt;
:* [http://www.rarediseases.org/rare-disease-information/rare-diseases/byID/411/viewAbstract National Organisation for Rare Disorders]&lt;br /&gt;
:* [http://www.epilepsyfoundation.org/ Epilepsy Foundation]&lt;br /&gt;
:* [http://www.cureangelman.org/ Foundation for Angelman Syndrome Therapeutics]&lt;br /&gt;
&lt;br /&gt;
* Search Pubmed &lt;br /&gt;
:* [http://www.ncbi.nlm.nih.gov/pubmed?term=angelman%20syndrome Angelman Syndrome] &lt;br /&gt;
&lt;br /&gt;
* OMIM entries for Angelman Syndrome&lt;br /&gt;
:* [http://omim.org/entry/105830 ANGELMAN SYNDROME; AS]&lt;br /&gt;
:* [http://omim.org/entry/601623 UBIQUITIN-PROTEIN LIGASE E3A; UBE3A]&lt;br /&gt;
&lt;br /&gt;
==Related Links==&lt;br /&gt;
&lt;br /&gt;
'''Animal Models'''&lt;br /&gt;
&lt;br /&gt;
* [[Mouse Knockout]] - this page explains the current use of mouse models in disrupting genes to elucidate their genetic function, including the mouse gene knockouts for alpha calcium-calmodulin kinase II (alpha CaMKII)&lt;br /&gt;
* [[2009 Group Project 4]] - this page gives an extensive overview on the history of the mouse model and its various use in embryology and genetics. In addition, it also describes mouse knockout and the role they play in current research of various human diseases&lt;br /&gt;
* [[Fly Development]] - this page describes the use of drosophila flies as developmental models&lt;br /&gt;
* [[2009 Group Project 2]] - this page gives an extensive overview on the history of the fly model and its various use in embryology and genetics&lt;br /&gt;
&lt;br /&gt;
'''Diagnosis'''&lt;br /&gt;
* [[Chorionic villus sampling]] - this page explains the process of chorionic villus sampling, its disadvantages and gives a brief overview of recent findings&lt;br /&gt;
* [[Amniocentesis]]- this page shows some of the recent findings in this area&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&lt;br /&gt;
&amp;lt;references /&amp;gt;&lt;/div&gt;</summary>
		<author><name>Z3291643</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_7&amp;diff=77697</id>
		<title>2011 Group Project 7</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_7&amp;diff=77697"/>
		<updated>2011-10-12T23:49:32Z</updated>

		<summary type="html">&lt;p&gt;Z3291643: /* Pathogenesis */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;='''Angelman Syndrome'''=&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Introduction==&lt;br /&gt;
&lt;br /&gt;
[[File:Dr Harry Angelman.jpg|thumb|130px|right|Dr Harry Angelman.]]&lt;br /&gt;
Angelman syndrome (AS) is a rare [[#Glossary | '''neurogenetic''']] [[#Glossary | '''disorder''']] first described by Dr. Harry Angelman in 1965.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18754889&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Dr. Angelman was an English [[#Glossary | '''paediatrician''']] who first diagnosed the disease in 3 children with a developmental delay.&amp;lt;ref&amp;gt;http://www.ncbi.nlm.nih.gov/books/NBK22221/&amp;lt;/ref&amp;gt; AS occurs in 1 in 10000-20000 births, the exact number is still unknown.&amp;lt;ref name=&amp;quot;PMID7573182&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7573182&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;PMID8703225&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;8703225&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It is caused by maternal [[#Glossary | '''allele''']] disruptions of a single gene- UBE3A. Either [[#Glossary | '''mutations''']] or [[#Glossary | '''deletions''']] of the UBE3A gene results in AS. &lt;br /&gt;
&lt;br /&gt;
AS presents with well known [[#Glossary | '''phenotypes''']] during infancy and adulthood, such as [[#Glossary | '''microcephaly''']] and [[#Glossary | '''maxillary hypoplasia''']]. However, these features become more marked with age. Most frequent clinical features include delayed development,[[#Glossary | '''seizures''']],[[#Glossary | '''ataxia''']], impairment of speech, happy demeanor, behavioural problems such as hyperactivity, short attention span and sleeping difficulty.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21592595&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21484597&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;ASAwebsite&amp;quot;&amp;gt;http://www.angelmansyndrome.org/home.html&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
At present, there is no cure for the syndrome, though current research is focused at improving life quality of patients with Angelman syndrome through management of daily tasks.&amp;lt;ref&amp;gt;http://www.bbc.co.uk/health/physical_health/conditions/angelman1.shtml&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==History==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Dr. Harry Angelman first reported Angelman Syndrome on three handicapped children that were admitted to his ward in England in 1964.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt; He reported how these three independent and unconnected clinical cases all had the same characteristic features of severe developmental delay, jerky movements, seizures and a happy disposition.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt; However it was only when he stumbled upon an oil painting called ‘a Boy with a Puppet” while on a holiday in Italy he was able to connect the symptoms of all three children under one common cause.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20981772&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; He linked the happy face of the boy depicted on the painting with the jerky movements and happy disposition he observed on his three patients back in England. He reported his findings on a paper entitled “Puppet children (a report on three cases)” which was published in 1965.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
The syndrome was initially named ‘Puppet Syndrome’ but was later changed to Angelman Syndrome. Due to the extreme rarity of the syndrome and lack of sufficient clinical evidence the syndrome was soon forgotten.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt;&lt;br /&gt;
[[File:Dr Charles Williams.jpg|thumb|right|150px|Dr Charles Williams.]]&lt;br /&gt;
	&lt;br /&gt;
In 1987, a physician named Ellen Magenis, came across children with deletions on [[#Glossary | '''chromosome''']] 15 that were suffering from seizures and severe developmental delay.&amp;lt;ref&amp;gt;http://www.angelman.org/stay-informed/facts-about-angelman-syndrome---7th-edition/harry-angelman-and-the-history-of-as/&amp;lt;/ref&amp;gt; Even though genetically the children were expected to have [[#Diagnosis | '''Prader-Willi syndrome''']] that was characterised by deletions on chromosome 15, their characteristic symptoms of seizures and lack of development did not correspond with that of the syndrome. This led to the realization that these children had deletions on the maternally derived chromosome 15 and not on the paternally derived chromosome as was observed in Prader-Willi syndrome.  Thus the deleted genetic code on maternally derived chromosome 15 was identified as the genetic marker for Angelman Syndrome.&lt;br /&gt;
&lt;br /&gt;
In 1997, UBE3A gene was isolated by Dr. Joseph Wagstaff and Dr. Arthur Beaudet as the cause of Angelman Syndrome.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot; /&amp;gt; The discovery of this [[#Glossary | '''gene''']] led to the subsequent development of animal models and research aimed at finding a causal link between UBE3A gene abnormalities and characteristic features observed in Angelman Syndrome. &lt;br /&gt;
	&lt;br /&gt;
Currently, four different genetic abnormalities for Angelman Syndrome have been confirmed by genetic testing. They include: Deletion, [[#Glossary | '''Uniparental Disomy''']] (UPD), [[#Glossary | '''Imprinting''']] and UBE3A mutation.&amp;lt;ref name=&amp;quot;PMID20211139&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Below is a timeline, summarising the key discoveries and advancements of the Angelman Syndrome:&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|- bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
!Year&lt;br /&gt;
!Milestone&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1964'''&lt;br /&gt;
|First observed by Dr Harry Angelman on three handicapped children.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot; /&amp;gt; &lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''1965'''&lt;br /&gt;
|Harry Angelman publishes his finding in a report entitled 'Puppet Children'(a report on three cases).&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1980s'''&lt;br /&gt;
|First reports of AS reaches US and research into the disorder being at the University of Florida under the direction of Dr. Charles Williams.&amp;lt;ref&amp;gt;http://www.angelmanproject.com/history.htm&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''1982'''&lt;br /&gt;
|Name changed from 'Happy Puppet' to Angelman syndrome by Williams and Frias. &lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1987'''&lt;br /&gt;
|Discovery of a genetic marker for AS – an absent genetic code on maternally derived chromosome 15. &lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''1997'''&lt;br /&gt;
|The cause of AS discovered by Dr. Joseph Wagstaff and Dr. Arthur Beaudet – mutation or deletion in the UBE3A gene.&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1998'''&lt;br /&gt;
|Transgenic mice with absent maternal UBE3A created to illustrate motor and learning deficits in addition to seizures.&amp;lt;ref name=&amp;quot;PMID9808466&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9808466&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''2007'''&lt;br /&gt;
|AS mouse model shows that neurological deficits can be reversed by decreasing levels of [[#Glossary | '''alpha-CaMKII''']] inhibitory phosphorylation.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17259980&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''2010'''&lt;br /&gt;
|Discovery of a another gene mutation in TC4 gene (on chromosome 18) in a small number of clinically diagnosed patients with no identifiable genetic alternation in UBE3A.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20184619&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''2010'''&lt;br /&gt;
|Protein named Arc identified as a target of AS gene product; UBE3A.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Incidence'''&lt;br /&gt;
*The current population of people diagnosed with AS is unknown but studies have estimated the number to be around 1:10,000&amp;lt;ref name=&amp;quot;PMID7573182&amp;quot; /&amp;gt; and 1:20,000&amp;lt;ref name=&amp;quot;PMID8703225&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
'''Diagnosis'''&lt;br /&gt;
*The mean age of diagnosis for patients with AS lies between 6 and 6.5 years of age.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18664077&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15741136&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Gender'''&lt;br /&gt;
* Males appear to be at higher risk for some aspects of early developmental delays in comparison to females with AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17019625&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Demography'''&lt;br /&gt;
*Europe:&lt;br /&gt;
:Denmark- 1:10,000&amp;lt;ref name=&amp;quot;PMID7573182&amp;quot; /&amp;gt;&lt;br /&gt;
:Estonia- 1:52,000&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16906556&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
:Sweden- 1:20,000&amp;lt;ref name=&amp;quot;PMID8703225&amp;quot; /&amp;gt;&lt;br /&gt;
*Australia:&lt;br /&gt;
:Western Australia- 1:40,000&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16492624&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Aetiology==&lt;br /&gt;
&lt;br /&gt;
[[File:Chromosome 15 Deletion of 15q11.2 to 15q13.jpg|thumb|100px|Chromosome 15 - The deletion occurs at 15q11.2-15q13.]]&lt;br /&gt;
&lt;br /&gt;
'''Molecular Genetics'''&lt;br /&gt;
&lt;br /&gt;
* Location: 15q11-q13&lt;br /&gt;
* Protein product: Ubiquitin protein ligase E3A&lt;br /&gt;
* Gene name: UBE3A&lt;br /&gt;
* Phenotype: Angelman Syndrome&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Genetic Causes'''&lt;br /&gt;
&lt;br /&gt;
Different genetic mechanisms lead to different clinical phenotypes of AS. The most common genetic mechanism leading to AS is the deletion or re-arrangement of maternal chromosome at [[#Glossary | '''locus''']] 15q11.2-q13,as the chromosome image shows on the right, accounting for 70% of AS occurrences.&amp;lt;ref name=&amp;quot;PMID8988171&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt; 8988171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This leads to more severe clinical phenotypes of microcephaly, motor difficulties, seizures and impaired speech development. The next most common genetic mechanism is mutation in the UBE3A gene responsible for 10% of AS cases and paternal uniparental disomy and mutation in the imprinting centre (IC), both accounting for 2-5% of AS observed.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
 &lt;br /&gt;
&lt;br /&gt;
AS is caused by the 4 major genetic mechanisms mentioned above and are thus divided into Classes I to IV based on their underlying genetic mechanism. AS patients with the clinical features of AS but no [[#Glossary | '''cytogenetic''']] or molecular abnormality in Chromosome 15q11.2-13 are grouped under Class V (summarised in table below).&amp;lt;ref name=&amp;quot;PMID8988171&amp;quot; /&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10364509&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{|  style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
! Class&lt;br /&gt;
! Mechanism&lt;br /&gt;
! Diagnostic Tests&lt;br /&gt;
! Frequency&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''Ia'''                           &lt;br /&gt;
| De novo deletion                                                                                           &lt;br /&gt;
| High resolution cytogenetics [[#Glossary | '''FISH''']]                                                                                                       &lt;br /&gt;
| 70%      &lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Ib'''&lt;br /&gt;
| Deletion due to chromosome rearrangement&lt;br /&gt;
| High resolution cytogenetics FISH&lt;br /&gt;
| &amp;lt;1%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''II'''&lt;br /&gt;
| Paternal uniparental disomy&lt;br /&gt;
| [[#Glossary | '''RFLP''']]  analysis&lt;br /&gt;
| 2%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''IIIa'''&lt;br /&gt;
| Imprinting defect with IC mutation&lt;br /&gt;
| Screening of [[#Glossary | '''IC''']]  for mutations is positive&lt;br /&gt;
| 2%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''IIIb'''&lt;br /&gt;
| Imprinting defect withouth IC mutation&lt;br /&gt;
| Screening of IC for mutations is negative&lt;br /&gt;
| 2%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''IIIc'''&lt;br /&gt;
| Mosaic imprinting defect&lt;br /&gt;
| Screening of IC for mutations is usually negative &lt;br /&gt;
| ?&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''IV'''&lt;br /&gt;
| ''UBE3A'' mutation&lt;br /&gt;
| Screening of ''UBE3A'' for mutations&lt;br /&gt;
| 5-10%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''V'''&lt;br /&gt;
| No identifiable genetic abnormality&lt;br /&gt;
| Consider other diagnoses&lt;br /&gt;
| 5-26%&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
[[File:Imprint defect inheritance in Angelman Syndrome.png|thumb|250px|Imprint defect inheritance in Angelman Syndrome]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Inheritance'''&lt;br /&gt;
&lt;br /&gt;
Angelman Syndrome from UBE3A mutations and deletions in the Imprinting Centre follow an inheritance pattern. A carrier father with the genetic defect can pass it on to his children, however, his children will be clinically normal. On the other hand, a carrier mother can pass the genetic defect onto her children, who will then have Angelman Syndrome. &lt;br /&gt;
&lt;br /&gt;
The image highlights the inheritance of Angelman Syndrome, which only results after a carrier mother passes it on to her children.&lt;br /&gt;
&lt;br /&gt;
==Pathogenesis==&lt;br /&gt;
&lt;br /&gt;
Chromosome 15 became associated with AS in the 1980s after the observation of many AS patients harboring [[#Glossary | '''microdeletions''']] of 15q11.2-15q13.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15668046&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The last decade has shed even more light in the aetiology of AS,as Kishino and Matsuura first identified UBE3A as the causative gene for AS in 1997.&amp;lt;ref name=&amp;quot;PMID:8988171&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;8988171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8988172&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Normal gene product: E6-AP ubiquitin ligase'''&lt;br /&gt;
&lt;br /&gt;
The function of UBE3A is to encode for [[#Glossary | '''E6-AP''']] ubiquitin ligase, however its function in the development of the nervous system and the process of UBE3A mutation leading to cognitive impairment in AS patients is still vague.&amp;lt;ref name=&amp;quot;PMID:20211139&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Past and current research has elucidated that E6-AP ubiquitin ligase is involved in the degradation of four proteins, listed below. Currently no protein with a direct role in [[#Glossary | '''long-term potentiation (LTP)''']] as a target of E6-AP has been identified.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12684449&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The identification of such target proteins would be a landmark discovery in further understanding of the pathogenesis, aetiology and prospective treatment strategies of AS, as LTP defects is one of the major neurological impairments of AS. &lt;br /&gt;
 &lt;br /&gt;
* p53 tumor suppressor protein &lt;br /&gt;
* yeast DNA repair protein Rad23 &lt;br /&gt;
* multicopy maintenance protein 7 subunit &lt;br /&gt;
* E6-AP&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Abnormal gene product'''&lt;br /&gt;
&lt;br /&gt;
Disruption to the gene UBE3A interferes with the normal functioning of the gene, which is its crucial role in UBE3A [[#Glossary | '''ubiquitylation''']]. Problems involving this pathway can lead to various diseases either from the loss or gain of function.&amp;lt;ref name=&amp;quot;PMID:9857172&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9857172&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In the case of AS, E6-AP is affected, leading to detrimental cognitive impairment in addition to other deficits.&amp;lt;ref name=&amp;quot;PMID:9857172&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9857172&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Regional functioning of UBE3A'''&lt;br /&gt;
&lt;br /&gt;
Despite the uncertain progression of UBE3A mutation and the neurological abnormalities characteristic of AS, animal models have illustrated the vital role of UBE3A in the normal functioning of the brain. This can be exemplified by a study which utilized a mouse model with target inactivation of the gene UBE3A resulting in the manifestation of classical features of AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11895368&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In addition, the fact that imprinting of UBE3A takes place only in specific brain regions ([[#Glossary | '''cerebellum''']] , [[#Glossary | '''olfactory tracts''']]  and the [[#Glossary | '''hippocampus''']]) confirms the hypothesis that the loss of this gene would be detrimental in cognitive development.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20398390&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Most genes are inherited in copies of two, one paternal and the other maternal; however, some genes, such as UBE3A only have one functional copy as the other is silenced, coined 'imprinting'. Imprinting of the paternal copy of UBE3A takes place in some cell populations, such as the hippocampal [[#Glossary | '''neurons''']]and [[#Glossary | '''Purkinje cells''']] Purkinje cells in the cerebellum.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9288101&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This means only the maternal UBE3A is functionally expressed in these particular brain regions. Thus a [[#Glossary | '''de novo mutation''']] in the maternal copy of the gene will result in the complete absence of functional E6-AP in the associated brain areas.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9288088&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
It is also known that UBE3A plays an important role in synaptic transmission, but exactly how it does so is still not completely understood.&amp;lt;ref name=&amp;quot;PMID:9808466&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9808466&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''UBE3A ubiquitylation'''&lt;br /&gt;
&lt;br /&gt;
As briefly mentioned above, UBE3A is a member of the E3 ubiquitin ligase family of enzymes. It is responsible for the addition of ubiquitin to the target protein for degradation of the ubiquitinated protein, as illustrated in the diagram below. These processes are required for normal human cognitive function.&amp;lt;ref name=&amp;quot;PMID:9808466&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9808466&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In this way synaptic protein [[#Glossary | '''Arc (activity-regulated cytoskeleton-associated protein)''']] is degraded to control synaptic function. Arc is a target protein of UBE3A in dendritic spines found in the hippocampal neurons.&amp;lt;ref name=&amp;quot;PMID:20668179&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20668179&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Deletion of UBE3A leads to the accumulation of Arc in neurons leading to trafficking of [[#Glossary | '''AMPA ( α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid)''']] receptors, resulting in impaired cognitive functions.&amp;lt;ref name=&amp;quot;PMID:20211139&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; [[File:UBE3A Ubiquitylation Pathway.png|thumb|350px|right|UBE3A Ubiquitylation Pathway.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
UBE3A ubiquitylation consists of:&amp;lt;ref name=&amp;quot;PMID:20668179&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20668179&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
# Activation of ubiquitin by E1 enzyme&lt;br /&gt;
# E1 ezyme transfers ubiquitin to E2 enzyme&lt;br /&gt;
# E2 enzyme transfers ubiquitin to UBE3A&lt;br /&gt;
# UBE3A attaches activated ubiquitin to target protein which is then polyubiquitylated &lt;br /&gt;
# Target protein is then degraded by 26S proteosome&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Phenotype-Genotype correlations'''&lt;br /&gt;
&lt;br /&gt;
[[File:Extent of microcephaly in Angelman Syndrome patients.png|thumb|250px|right|Extent of microcephaly in 20 AS patients with deletion and without deletion.&amp;lt;ref&amp;gt;http://www.nature.com/ejhg/index.html/&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
All AS patients show differing extents of cognitive impairment, movement disorder, characteristic behaviours and difficulty in speech and language.&amp;lt;ref name=&amp;quot;PMID:11748306&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11748306&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; However, there seems to be some phenotype-genotype correlations:&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
- 5-7Mb deletions result in the most severe phenotypes such as microcephaly, more sever [[#Glossary | '''epilepsy''']] and seizures, motor difficulties and language impairment.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9546330&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20445456&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; AS patients with large deletions also present with clinical [[#Glossary | '''hypopigmentation''']], light hair and eye colour due to the close association of OCA2 gene with UBE3A.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;16470747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Individuals under this category have in general no increased BMI&amp;lt;ref name=&amp;quot;PMID:15253756&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15253756&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This is indicated by the graph on the left, which shows more cases of AS patients with deletions having larger deviations from the mean head circumference measurement than non-deletion AS patients.&lt;br /&gt;
 &lt;br /&gt;
- AS patients with uniparental disomy (UPD) have better physical growth, fewer motor deficits and lower seizure occurrences.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16023557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
- Individuals with AS resulting from imprinting defects have the least debilitating features, such as higher developmental and language ability than AS caused by other mechanisms.&amp;lt;ref name=&amp;quot;PMID:11748306&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11748306&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
- The Body Mass Index (BMI) of 33% of the UBE3A mutation patients, and 47–64% of the patients from the classes II (UPD) and III (Imprinting defect) is above the 95th centile.&amp;lt;ref name=&amp;quot;PMID:15253756&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15253756&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Animal models'''&lt;br /&gt;
&lt;br /&gt;
* '''Drosophila'''&lt;br /&gt;
&lt;br /&gt;
Drosophila (common fruit fly) is an excellent model to use for better understanding of genetic diseases in humans as they are highly homologous to human UBE3A (hUBE3A), illustrating a high evolutionary conservation. Studies using the Drosophila model have shown that the functional absence of UBE3A resulted in decreased morphogenesis of dendritic branches. This is of interest as dendritic branches cover over 90% of the neuronal surface where [[#Glossary | '''synapse''']] between neurons occur. Proper formation and maturation of dendritic spines is also required so they come in contact with other neurons for effective transmission of neuronal signals. Thus proper formation of dendritic branching is pivitol for effective neuronal function and hence cognitive function.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18996915&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Interestingly, overexpression of dUBE3A also gave the same result, consisting of abnormal locomotion  and decreased dendritic branching in sensory neurons.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18701717&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;  This suggests a possible research field for some forms of [[#Glossary | '''autism''']] where the region containing UBE3A is duplicated, leading to delayed motor skills and seizures.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16433693&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;[[File:Normal and Angelman Syndrome mice models.jpg|thumb|250px|right|Normal and AS mice performance on the Rotarod apparatus.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
* '''Mice'''&lt;br /&gt;
&lt;br /&gt;
Absence of UBE3A in mice manifest similar phenotype to human AS, as illustrated by motor and learning deficits with inducible seizures.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21235769&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It has been shown through various mice model studies that larger deletions, ie. from UBE3A to GABRB3, more closely mirrors the large 6Mb deletions seen in human AS patients. Numerous tests, such as the Rotarod (for motor coordination and learning ability), Morris water maze test (for spatial learning and memory) and [[#Glossary | '''EEG''']] (electroencephalography), were carried out on  UBE3A null mutants, which showed the results to be abnormal or impaired.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20808828&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Other studies using mouse models have also outlined the obesity observed in 15% of AS children, albeit it is not the major characterisitics of AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17259980&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The diagram on the right clearly highlights the results obtained from such mouse model studies of AS, where the absence of UBE3A accumulated in deficits of motor function and obesity. In addition, excessive drooling and feeding difficulties were also highlighted by mice models with inactivated UBE3A, reflected by defects in fluid consumption and licking.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18413322&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Pathophysiology===&lt;br /&gt;
&lt;br /&gt;
'''Cognitive defects'''&lt;br /&gt;
&lt;br /&gt;
[[File:Role of UBE3A in dendritic spine neuronal synapses.png|thumb|250px|right|Role of UBE3A in dendritic spine neuronal synapses.]]&lt;br /&gt;
&lt;br /&gt;
AS patients present with abnormally high UBE3A, leading to neurological impairment. Recent identification of key target proteins of Ephexin-58 (Eph-5) and Arc (Activity-Regulated Cytoskeleton-associated protein) have aided in better understanding of the progression of UBE3A to cognitive defects. These two proteins are vital in the understanding of AS as Eph-5 determines synapse numbers and Arc contributes to plasticity and synapse function.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21164477&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Studies utilizing mice models have illustrated that UBE3A null mice could not ubiquitinate Eph-5, thus increasing its levels and limiting the growth of dendritic spines by the activation of RhoA. This subsequent activation of RhoA inhibits synapse formation and results in neuronal defects.&lt;br /&gt;
&lt;br /&gt;
In contrast, mice with normally functioning UBE3A showed phosphorylated Eph-5, resulting from the interaction of two neurons via the activation of EphB signalling receptor.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21029865&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Phosphorylation of Eph-5 allows UBE3A to ubiquitinate and degrade it. This degradation of Eph-5 permits new synaptic connections to form with cells they come into contact with. However, in AS, the absence of UBE3A means Eph-5 cannot be degraded, so RhoA activity is prolonged to reduce synaptic formation.&lt;br /&gt;
&lt;br /&gt;
As mentioned previously, Arc plays a pivitol role in synapse function as it removes synaptic receptors that respond to glutamate, a [[#Glossary | '''neurotransmitter''']].&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17088211&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In UBE3A present neurons, UBE3A ubiquitinates Arc, leading to it degradation as illustrated by the diagram on the left. However, in UBE3A deficient neurons, Arc accumulates and prevents the proper synaptic communications essential for normal cognitive functions.&amp;lt;ref name=&amp;quot;PMID20211139&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Signs and Symptoms==&lt;br /&gt;
&lt;br /&gt;
Angelman Syndrome presents a variety of different phenotypes, and the presented symptoms may vary at different ages.&amp;lt;ref name=&amp;quot;PMID7625442&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7625442&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
In 1995 Williams et al. embraced the observed clinical features of AS in a consensus statement, in order to present an appliance for clinicians. The diagnostic criteria were updated in 2005.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt; The following table shows the most frequently occurring characteristics in AS patients:&lt;br /&gt;
&lt;br /&gt;
'''4 characteristics appear in 100% of the cases:'''&lt;br /&gt;
&lt;br /&gt;
*Delayed development: become apparent by the age of 6 to 12 months.&lt;br /&gt;
*Motion and or balance malfunction&lt;br /&gt;
*Behaviour patterns like unmotivated laughter, frequent excitement; often including body movements,[[File:Electroencephalography of Angelman Syndrome.jpg|thumb|350px|right|EEG of AS and normal individuals.]] [[#Glossary | '''hypermotoric''']] behaviour&lt;br /&gt;
*Impairment of speech&lt;br /&gt;
&lt;br /&gt;
'''3 characteristics appear in more than 80% of the cases:'''&lt;br /&gt;
&lt;br /&gt;
*Abnormalities in head circumference, microcephaly&lt;br /&gt;
*Seizures&lt;br /&gt;
*EEG shows specific abnormal patterns&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Angelman Syndrome individuals show the most distinct disease pattern from 2 to 16 years of age.&lt;br /&gt;
In most cases at least 8 of the symptom traits are shown.&amp;lt;ref name=&amp;quot;PMID7625442&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Behavioural Characteristics'''&lt;br /&gt;
&lt;br /&gt;
A range of substantial characteristics appear in all AS cases, regardless of the genetic mechanisms, and are often responsible for diagnosing the syndrome. According to the original name, Happy Puppet syndrome, they have shown to exhibit traits such as a happy demeanor, with frequent laughter or smiling that can easily be triggered.&amp;lt;ref name=&amp;quot;PMID12566516&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12566516&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This behaviour can already be observed in 1 to 3 month old infants.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot; /&amp;gt; Uplifted hand flapping or waving motions are associated with laughter and excitement. Other characteristics manifesting in early childhood are sleep abnormalities with reduced sleep demand, and feeding problems. Breast and bottle feeding can be difficult due to non efficient attachment to the breast, tongue thrusting and uncoordinated sucking. Furthermore, there is an affection to crinkly and reflective surfaces, like some papers or plastic materials, especially water.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID12566516 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Communication Skills'''&lt;br /&gt;
&lt;br /&gt;
Communication is challenging for AS patients due to the fact that speech impairment is present in all cases. In the majority of affected people a lack of speech development is present. Only some of them have a minimal vocabulary consisting of two or three words, a few can speak in basic sentences. Some patients use gestures to articulate themselves, the [[#Glossary | '''Picture Exchange Communication System (PECS)''']] or sign languages such as [[#Glossary | '''Makaton''']] can be used for communication. Simple demands regarding their everyday occurrence can be understood by most patients.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID12566516 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Clinical and External Characteristics'''[[File:Angelman Syndrome patient.png|thumb|200px|right|4 year old AS patient.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Developmental delays are present in all patients. Motor milestones are delayed with children managing to sit unsupported with 12 months and crawl or bottom shuffle at the age of 18-24 months. The average age for walking is 4 years,however, ranging from 18 months to 7 years.&lt;br /&gt;
The [[#Glossary | '''gait''']] is characterised as slow, and flapping hands are a common trait.  The legs remain stiff during walking, arms are inflected by the wrists and elbows. The movements can appear ataxic, jerky or lurching. The muscle tone shows abnormalities with truncal [[#Glossary | '''hypotonia''']] and [[#Glossary | '''hypertonicity''']] of the limbs and alert reflexes.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID12566516 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The most striking external traits present in patients include broad-spaced teeth, and a wide mouth, light hair and eye colour, hypopigmented skin, deep set eyes, and a flat [[#Glossary | '''occiput''']].&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Seizures in Angelman Syndrome'''&lt;br /&gt;
&lt;br /&gt;
85% of AS patients suffer from epileptic seizures during their first three years. The first appearance can be within one month up to 20 year old patients. In infants with AS epilepsy manifests with [[#Glossary | '''febrile convulsions''']] and is hard to manage during childhood.&lt;br /&gt;
The most common type of seizures within 25% of patients are [[#Glossary | '''myoclonic seizures''']], followed by [[#Glossary | '''atonic seizures''']] as the second most frequent type, then 21% experience generalised [[#Glossary | '''tonic-clonic seizures''']] and lastly [[#Glossary | '''atypical absences''']] occur in 12% of patients.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20398390&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Angelman Syndrome in adults'''&lt;br /&gt;
&lt;br /&gt;
Patients with Angelman syndrome possess normal secondary sexual characteristics, and puberty sets in at a usual time. Limb hypertonicity, and [[#Glossary | '''thoracic scoliosis''']] lead to decreasing mobility. [[#Glossary | '''Oesophagus reflux''']] might induce severe problems, and the majority suffers from obesity. Furthermore, facial traits such as a prominent lower lip [[#Glossary | '''macrostomia''']] and [[#Glossary | '''mandibular prognathism''']] get manifested in adults. &lt;br /&gt;
In some cases the communication barrier can lead to frustration, resulting in aggressive behaviour. Nonetheless, patients gain a higher concentration span with age, and their nature becomes more quiet.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Complications===&lt;br /&gt;
&lt;br /&gt;
'''Hypopigmentation and Ocular albinism'''&lt;br /&gt;
&lt;br /&gt;
OCA2 gene, also known as the P gene, is closely located to the UBE3A gene. It encodes a protein vital to tyrosine metabolism, which plays a role in pigmentation development of skin, hair and eyes. However, AS caused by the large deletion of UBE3A leads to haploinsufficiency of OCA2 gene, resulting in hypopigmentation of the skin and the eyes. In some children with severe hypopigmentation, some form of [[#Glossary | '''albinism''']] is suspected.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12749060&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; When AS is caused by another mechanism, no abnormality of the skin and eye pigmentation is observed. However, not all AS children with OCA2 gene deletion will present with obvious hypopigmentation, they may just exhibit lighter skin colour than their parents.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8302318&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Diagnosis==&lt;br /&gt;
&lt;br /&gt;
The diagnosis of Angelman Syndrome is a clinical diagnosis confirmed by laboratory testing.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This involves both prenatal and/or postnatal diagnosis. &lt;br /&gt;
&lt;br /&gt;
===Prenatal Diagnosis===&lt;br /&gt;
[[File:Angelman Syndrome Prenatal Diagnosis.jpg|thumb|250px|right|Flowchart of AS Diagnosis.]]&lt;br /&gt;
&lt;br /&gt;
Prenatal detection of deletions of 15q11.2-q13, [[#Glossary | '''Paternal UPD''']] ([[#Glossary | '''Uniparental Disomy''']]), Imprinting defects and UBE3A mutations are done through DNA/chromosome/FISH analysis of fetal cells obtained by either [[#Glossary | '''Chorionic Villus Sampling''']](CVS) or [[#Glossary | '''Amniocentesis''']].&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot;/&amp;gt; &lt;br /&gt;
DNA methylation analysis using [[#Glossary | '''Amniocytes''']] is usually the first test carried out in molecular diagnosis of AS.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18059071&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; An abnormal result is followed up by either a FISH or array CGH analysis to search for a deletion on chromosome 15. If they produce a normal result, then UPD testing using DNA polymorphysims is carried out. If there is no evidence of UPD, other DNA analysis tests are used search for an imprinting centre deletion.&amp;lt;ref name=&amp;quot;PMID9792887&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9792887&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; A normal DNA methylation analysis is followed by a UBE3A sequence analysis.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt; In addition, a parent of origin test is also done to determine if the genetic disruption is of maternal origin or paternal origin. If it is maternally derived the fetus is diagnosed with AS (a paternally derived genetic disruption is indicative of Prader-Willi Syndrome).&amp;lt;ref name=&amp;quot;PMID17020468&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;17020468&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The flow chart summarizes the normal procedure used for prenatal diagnosis of AS. More information on important laboratory tests used for the diagnosis of Angelman Syndrome are provided below:&lt;br /&gt;
&lt;br /&gt;
*'''DNA Methylation Analysis'''&lt;br /&gt;
&lt;br /&gt;
Identifies approximately 80% of AS affected individuals and is usually the first test to be ordered.&amp;lt;ref name=&amp;quot;PMID7618904&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7618904&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Molecular disruptions such as deletions, paternal UPD and imprinting defects on chromosome 15 all demonstrate abnormal methylation patterns by either southern blot analysis or PCR amplification of bisulphate-treated DNA.&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot; /&amp;gt; An affected individual will only have an unmethylated (paternal) SNRPN (small nuclear ribonuclear protein-associated polypeptide N) allele compared with an unaffected individual who will have both a methylated and an unmethylated SNRPN allele.&amp;lt;ref name=&amp;quot;PMID9634532&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9634532&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
	  &lt;br /&gt;
*'''FISH (Fluorescent In Situ Hybridization)'''&lt;br /&gt;
&lt;br /&gt;
[[File:Critical_region_of_Angelman_Syndrome_on_chromosome_15.png‎|thumb|150px|right|FISH (fluorescence in situ hybridisation) image showing the critical region of Angelman Syndrome on chromosome 15.]]&lt;br /&gt;
&lt;br /&gt;
FISH analysis detects 5-7 Mb deletions in approximately 68% of affected individuals using detecting probes such as D15S10 and/or SNRPN.&amp;lt;ref name=&amp;quot;PMID7618904&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7618904&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It is also able to distinguish UPD from micro-deletions and imprinting defects. In simple terms, FISH analysis involves the binding of a fluorescent probe to a specific part of chromosome 15 and the detection of deletions within that region. FISH analysis is much more accurate in deletion detection compared to other high-resolution cytogenetics in the diagnosis of AS patients.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1511093&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
Array-based CGH is an advanced type of cytogenetic testing that can also be used to detect smaller deletions.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''UPD (Uniparental Disomy) Detection'''&lt;br /&gt;
&lt;br /&gt;
DNA Polymorphism testing detects paternal UPD in approximately 7% of affected AS individuals.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt; It is also able to distinguish between UPD and an Imprinting defect. It requires a DNA sample from the [[#Glossary | '''Proband''']] and from both parents. A homologous or non-homologous whole-arm translocation of the long arms of chromosome 15 is a sound indication for the need for prenatal UPD testing.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''IC (Imprinting Center) Analysis'''&lt;br /&gt;
&lt;br /&gt;
This type of analysis is used when individuals have an abnormal DNA methylation pattern but show normal results for  FISH, array CGH study and UPD analysis.&amp;lt;ref name=&amp;quot;PMID9792887&amp;quot;/&amp;gt; It is used to differentiate between the Imprinting defects caused by either microdeletions in the AS imprinting centre or by epigenetic mutations (that occur in maternal oogenesis or early embryogenesis).&amp;lt;ref name=&amp;quot;PMID9634532&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''Cytogenetic Testing'''&lt;br /&gt;
&lt;br /&gt;
Is used to detect a cytogenetically visible chromosomal rearrangement (large deletion, translocation or inversion) involving the 15q11.2-q13 region, which occurs in less than 1% of affected individuals.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''UBE3A Sequence Analysis'''&lt;br /&gt;
Sequence analysis of the UBE3A gene detects mutations in about 10% of the patients.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt; The test is used to detect either multiexonic (10 major coding exons of UBE3A) or whole gene deletions of UBE3A gene in individuals who produces a normal DNA methylation result but has characteristic clinical features of AS.&amp;lt;ref name=&amp;quot;PMID9792887&amp;quot;/&amp;gt;&lt;br /&gt;
This is recommended as a prenatal diagnostic tool in families that include multiple AS affected individuals because the imprinted pattern can be inherited from distant relatives.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Postnatal Diagnosis===&lt;br /&gt;
&lt;br /&gt;
Postnatal diagnosis is made though a combination of common clinical features of AS and UBESA gene sequence analysis.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt; The clinical features of AS include unsteady or shaky movements, muscle hypotonia, developmental delay and behavioral uniqueness such as frequent laughter/smiling and happy demeanor are features that are 100% consistent in all patients diagnosed with Angelman Syndrome.&amp;lt;ref name=&amp;quot;PMID18830393&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18830393&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; These clinical features become apparent between 6 months to 2 years of age. The onset of early or persistent smiling characteristic of this syndrome begin around the age of 1-3 months, but is often overlooked during infancy.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot;/&amp;gt; Thus early diagnosis of AS during infancy period is difficult because the clinical indicators of the syndrome takes time to manifest and characteristic features such as finger and hand tremors and excessive smiling/laughter are often overlooked and not considered as possible indicators of this syndrome.&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
*Rett Syndrome&lt;br /&gt;
&lt;br /&gt;
Some children with the clinical diagnosis of AS but no underlying genetic mechanism show mutations in ''MECP2'' gene, corresponding to Rett Syndrome. This should be suspected in AS test negative girls in the first few years of life.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17980307&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*Mowat-Wilson Syndrome&lt;br /&gt;
&lt;br /&gt;
Genetic mechanism is heterozygous deletion or truncation in ''ZFHX1B'' (''SIP1'') gene on 2q22. This presents with clinical features of severe intellectual disability, micrcephaly and seizures.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17958891&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Prader-Willi Syndrome patient.png|thumb|right|120px|12 year old PWS patient.]]&lt;br /&gt;
&lt;br /&gt;
*X-linked alpha-thalassemia/mental retardation syndrome (ATR-X)&lt;br /&gt;
&lt;br /&gt;
This arises from mutations in ''XNP'' gene on Xq13. ATR-X presents with severe intellectual disability, no speech development and seizures are common.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11449489&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*Phelan-McDermid Syndrome/22q13 deletion syndrome&lt;br /&gt;
&lt;br /&gt;
Deletions are usually submicroscopic and thus requires special molecular cytogenetic methods to confirm this deletion. Patients show moderate to profound intellectual disability and delay in speech development.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18505557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Related Disease'''&lt;br /&gt;
&lt;br /&gt;
*Prader-Willi Syndrome(PWS)&lt;br /&gt;
&lt;br /&gt;
PWS is a result from the absence of paternally expressed 15q11-q13 gene as a corollary of de novo deletion, maternal uniparental disomy of chromosome 15 or an imprinting defect on paternal chromosome 15 leading to the silencing of paternal alleles.&amp;lt;ref name=&amp;quot;PMID:20668179 &amp;quot;/&amp;gt; It is characterized by [[#Glossary | '''hyperphagia''']], obesity in later infancy and early childhood and difficulty in feeding during early infancy.&amp;lt;ref name=&amp;quot;PMID:20668179 &amp;quot;/&amp;gt; There is also cognitive impairment to some extent, though some PWS patients may exhibit intelligence in the normal IQ range. Behavioral phenotypes include stubbornness, manipulative tendency, obsessive compulsive characteristics.&amp;lt;ref name=&amp;quot;PMID:20668179 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Genetic Counselling==&lt;br /&gt;
&lt;br /&gt;
Genetic counselling is the process by which patients or relatives, at risk of an inherited disorder, are advised of the consequences and nature of the disorder, the probability of developing or transmitting it, and the options open to them in management and family planning. In the case for Angelman syndrome, types of risks associated are split into classes and formatted into the table below:&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20459762&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{|  style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
! Class&lt;br /&gt;
! Mechanism&lt;br /&gt;
! Risk to siblings&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! Ia                           &lt;br /&gt;
| De novo deletion                                                                                                               &lt;br /&gt;
| &amp;lt;1%                                                                                                                &lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! Ib&lt;br /&gt;
| Deletion due to chromosome rearrangement&lt;br /&gt;
| Up to 50%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! II&lt;br /&gt;
| Paternal uniparental disomy (UPD)&lt;br /&gt;
| &amp;lt;1%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! IIIa&lt;br /&gt;
| Imprinting defect with IC mutation&lt;br /&gt;
| Close to 100% if father has 15; 15 [[#Glossary | '''Robertsonian translocation''']]&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! IIIb&lt;br /&gt;
| Imprinting defect without IC mutation&lt;br /&gt;
| Up to 50% (if mother has IC deletion)&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! IIIc&lt;br /&gt;
| [[#Glossary | '''Mosaic''']] imprinting defect&lt;br /&gt;
| &amp;lt;1%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! IV&lt;br /&gt;
| ''UBE3A'' mutation&lt;br /&gt;
| Up to 50% (if mother has mutation)&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! V&lt;br /&gt;
| No identifiable genetic abnormality&lt;br /&gt;
| ?&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Ia''': Individuals with de novo deletion have 1% risk to siblings&lt;br /&gt;
&lt;br /&gt;
'''Ib''': Risk to siblings in individuals with chromosomal rearrangements is up to 50% &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9557895&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''II''': Paternal UPD with no Robertsonian translocation has a risk to sibling of less than 1%&lt;br /&gt;
&lt;br /&gt;
'''IIIa''': The risk to siblings in individuals with AS from an imprinting defect with a mutation in the imprinting center (IC) is close to 100% if father has 15;15 Robertsonian translocation&lt;br /&gt;
&lt;br /&gt;
'''IIIb''': Individuals with AS resulting from an imprinting defect without IC mutation, but with a carrier mother has a high risk to siblings of up to 50%. The mother could be phenotypically normal due to paternal inheritance of the genetic defect &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11283796&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''IIIc''': Individuals who are mosaic for the imprinting defect have less than 1% risk to siblings&lt;br /&gt;
&lt;br /&gt;
'''IV''': UBE3A mutation can be either inherited or de novo mutation. If the mother is a carrier for this genetic mutation, the risk to siblings is up to 50% &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11258627&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''V''': Individuals who present with AS clinically, but have no known underlying mechanism have an unknown risk to siblings.&lt;br /&gt;
&lt;br /&gt;
==Treatment and Management==&lt;br /&gt;
&lt;br /&gt;
Even though at present there is no known cure for Angelman syndrome, there are a number of treatments available that may alleviate symptons and improve daily life activities.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The below table describes the problems and management options that are used:&lt;br /&gt;
&lt;br /&gt;
[[File:Subtle Finger tremors-Angelman Syndrome.jpg|right|thumb|150px|A five months old boy with Angelman syndrome showing signs of Subtle Finger tremor.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
! Problems encountered&lt;br /&gt;
! Treatment and Management&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''Difficulty in feeding newborn AS babies'''&lt;br /&gt;
| Use of special nipples may improve feeding&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Oesophagus reflux'''&lt;br /&gt;
| Special motility medications requiried or upright positioning&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''Seizures'''&lt;br /&gt;
| Anticonvulsant medications&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19605773&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19453717&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Ocular problems'''&lt;br /&gt;
| Visual assessment is vital to encourage interactions and minimize chances of self-harm and autism development&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20656169&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''Drooling in developmental delayed AS patients'''&lt;br /&gt;
| Difficult to treat, but new surgical procedure on salivary duct reimplantation seems to be a promising alternative&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17699119&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Unstable children''' &lt;br /&gt;
| Physical therapy&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''AS patients become less active with increasing age'''&lt;br /&gt;
| Activity schedules to prevent scoliosis and obesity. Occupational therapy to stimulate fine motor and oral-motor control skills in conjunction to speech therapy&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Sleeping difficulty'''&lt;br /&gt;
| Sedative medication in severe cases. [[#Glossary | '''Melatonin''']] may be used to promote sleeping but some studies have found that it loses its therapeutic effects after several weeks in most AS patients&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19379289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|-&lt;br /&gt;
|colspan=&amp;quot;4&amp;quot; |&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Prognosis==&lt;br /&gt;
&lt;br /&gt;
Life expectancy of AS patients seems to be normal&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, but there is still a high degree of developmental delay and limited expressive language skills.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17019625&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This problem arises prominently in the assessment of the severity of coincidental medical conditions due to difficulties in communication. A visit to the dentist can become difficult if good communication is not conveyed between the parents, the dentist, and the child.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18271768&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Some problems require extreme measures, such as the procedure of lens implantation was performed in both eyes of a person diagnosed with AS, due to the inability to wear spectacles.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20656169&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
During adulthood, menstruation and puberty begin at around average age evidenced by females with Angelman syndrome that are fully capable of conceiving children.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11258627&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Most adult patients can feed themselves, but needed help with many other daily activities. Main troubles which have shown in adults are a tendency to become obese and start developing  thoracic scoliosis, which some adults with AS begin wheelchair bounded.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9072912&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Current and Future Research==&lt;br /&gt;
&lt;br /&gt;
Currently there is no cure for the treatment of AS, so much research is being carried out for therapeutic interventions. Findings in the last five years have suggested through various mice and fruit fly models that the absence of maternal UBE3A results in the same human AS features of neurological defects and seizures. However, more recently, studies have outlined that the symptoms of AS can be improved by modifying other gene products. In addition, restoring of a functional UBE3A protein into adult mice neurons have shown to reduce motor and neurological deficits and balance disorders. This shows promising research prospects in that improvements may be possible in human AS patients by restoring functional UBE3A proteins into their neurons. &lt;br /&gt;
&lt;br /&gt;
===Possible Treatment Pathways===&lt;br /&gt;
&lt;br /&gt;
*'''Cognitive and physical impairment'''&lt;br /&gt;
&lt;br /&gt;
Although everyone is born with two copies of the gene UBE3A, one maternal and one paternal copy, it is only the maternal UBE3A that is used in the brain. Most AS patients have a genetic mutation on the maternal chromosome 15 that results in dysfunctional UBE3A.&amp;lt;ref&amp;gt;http://www.cureangelman.org/what-hope.html&amp;lt;/ref&amp;gt; The above research focused on turning on the father's copy of UBE3A to restore its functions. Furthermore, mouse models were utilized to show that alpha-CaMKII could be increased to compensate the loss of UBE3A and restore compromised mental and physical abilities. However, this finding still requires much more research.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17259980&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''Epilepsy'''&lt;br /&gt;
&lt;br /&gt;
There is research being done on improving certain conditions that are involved in AS by nutritional benefits. The use of [[#Glossary | '''corticosteroids''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19666884&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, [[#Glossary | '''valproate''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19453717&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and [[#Glossary | '''clonazepam''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19605773&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and having a [[#Glossary | '''ketogenic diet''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20880305&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; has all been shown to aid in the treatment of epilepsy. It has also been reported to be efficient in the treatment of other conditions, such as behavioural disorders, reduction in seizures, ataxia, sleep patterns, developmental progress and sleep disturbances. [[#Glossary | '''Levetiracetam''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17326790&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; could be used in such a situation, especially when the patient has an intolerance to valproate and clonazepam.&lt;br /&gt;
&lt;br /&gt;
*'''Betaine and Folic acid'''&lt;br /&gt;
&lt;br /&gt;
This double-blind placebo-controlled study was done to examine the potential therapeutic role of [[#Glossary | '''betaine''']] and [[#Glossary | '''folic acid''']] in the treatment of the clinical phenotypes of AS. The aim of this protocol was to increase methylation and activate the paternally inherited UBE3A in hope to compensate for the inactive maternal UBE3A. Although there were no major differences in the control and treatment groups, a small number of patients in the treatment group showed some positive outcomes.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20635355&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&lt;br /&gt;
'''albinism''': A congenital disorder distincted by the complete or partial absence of pigment in the skin, hair and eyes due to defect of an enzyme involved in the production of melanin.&lt;br /&gt;
&lt;br /&gt;
'''allele''': Dissimilar variant of one gene. Organisms have two alleles for each gene inherited from their parents, one from each of them.&lt;br /&gt;
&lt;br /&gt;
'''alpha-CaMKII''': (alpha calcium calmodulin kinase II) Compound involved in synaptic plasticity, one of the most important theories behind learning and memory. Ability of a synapse between two neurons to change in strength due to the use or disuse of transmission.&lt;br /&gt;
&lt;br /&gt;
'''Amniocytes''': Cells that are shed by the fetus during fetal development to the surrounding amniotic fluid. They are a source of fetal DNA. &lt;br /&gt;
&lt;br /&gt;
'''Amniocentesis''': (AFT or amniotic fluid test) is a prenatal diagnostic test used to detect chromosomal abnormalities in the developing fetus by extracting amniotic fluid (a source of fetal DNA) surrounding the fetus. &lt;br /&gt;
&lt;br /&gt;
'''AMPA''': (2-amino-3-(5-methyl-3-oxo-1,2- oxazol-4-yl)propanoic acid) Compound that binds to the AMPA receptor to imitate glutamate neurotransmitter.&lt;br /&gt;
&lt;br /&gt;
'''Arc''': Activity-Regulated Cytoskeleton-associated protein; involved in learning and memory.&lt;br /&gt;
&lt;br /&gt;
'''ataxia''': Lack of coordination in muscle movements.&lt;br /&gt;
&lt;br /&gt;
'''atonic seizures''': A abrupt loss of muscle tone, this can lead to the limbs loosing strength, or the head may drop to the side. The patient remains conscious during this kind of epileptic seizure.&lt;br /&gt;
&lt;br /&gt;
'''atypical absences''': Seizure leads to unconsciousness in most cases.  &lt;br /&gt;
&lt;br /&gt;
'''autism''': A neural development disorder defined by limited social interaction and communication.&lt;br /&gt;
&lt;br /&gt;
'''betaine''': Also known as  betaine anhydrous or trimethylglycine (TMG), assists the body in metabolising the amino acid, homocysteine. Can be consumed via beets, broccoli, grains, shellfish, and spinach.&lt;br /&gt;
&lt;br /&gt;
'''Chorionic Villus Sampling''': A prenatal diagnostic test used to detect chromosomal abnormalities in the developing fetus by extracting and testing chorionic villus (placental tissue). &lt;br /&gt;
&lt;br /&gt;
'''chromosome''': Structure consisting of coiled DNA with DNA associated proteins such as histones.&lt;br /&gt;
&lt;br /&gt;
'''clonazepam''': A psychoactive drug having muscle relaxant properties and treats anxiety and epilepsy.&lt;br /&gt;
&lt;br /&gt;
'''corticosteroid''': A type of steroid hormones that are produced in the adrenal cortex.&lt;br /&gt;
&lt;br /&gt;
'''cytogenetics''': Study of the structure, function and abnormality of the cell, especially the chromosome.&lt;br /&gt;
&lt;br /&gt;
'''deletion''': Lack of a part of the DNA (deoxyribonucleic acid is a nucleic acid containing information for protein synthesis), can vary form a single base to a hole gene. &lt;br /&gt;
&lt;br /&gt;
'''de novo mutation''': Change in a gene of a family member for the first time due to a mutation in the egg or sperm of the parents or in the fertilized egg (zygote).&lt;br /&gt;
&lt;br /&gt;
'''disorder''': A mental or physical health disturbance or dysfunction.&lt;br /&gt;
&lt;br /&gt;
'''EEG''': Electroencephalography is a means of measuring electrical activity along the scalp by measuring the total electrical charges fired by thousands or millions of neurons.&lt;br /&gt;
&lt;br /&gt;
'''epilepsy''': Neurological disorder characterised by recurrent impairment of brain function that can cause seizures or unconsciousness. &lt;br /&gt;
&lt;br /&gt;
'''E6-AP''': E6-AP ubiquitin-protein ligase is an enzyme encoded by UBE3A which adds ubiquitin chain to target proteins to be degraded by proteasomes.&lt;br /&gt;
&lt;br /&gt;
'''febrile convulsions''': The occurrence of high fever, especially in children.&lt;br /&gt;
&lt;br /&gt;
'''FISH''': Fluorescent in situ hybridization is a technique used to identify and localize the presence or absence of DNA sequences on the chromosome. This is achieved by using fluorescently labelled DNA sequences which then binds to complementary DNA sequence on the chromosome. After hybridization (attachment), chromosome of interest will fluoresce under the microscope.&lt;br /&gt;
&lt;br /&gt;
'''folic acid''': B vitamin that helps the body make healthy new cells. Can be consumed via leafy green vegetables, fruits, dried beans, peas and nuts.&lt;br /&gt;
&lt;br /&gt;
'''gait''': A manner of walking, stepping or running.&lt;br /&gt;
&lt;br /&gt;
'''gene''': A molecular unit of heredity of a living organism.&lt;br /&gt;
&lt;br /&gt;
'''hyperphagia''': (Also referred to as Polyphagia) Excessive ingestion of food beyond the dietary and energy requirements of the body. &lt;br /&gt;
&lt;br /&gt;
'''hypermotoric''': Sudden appearance of uncontrolled movements such as striking or kicking inappropriately.&lt;br /&gt;
&lt;br /&gt;
'''hypertonicity''': Increase of muscle tension and a disability to stretch leading to an impairment of motor activity.&lt;br /&gt;
&lt;br /&gt;
'''hypopigmentation''': A lack of melanin pigments or melanocytes  affecting the colour of the skin, hair and iris. Features appear to be light-coloured due to loss of skin colour.&lt;br /&gt;
&lt;br /&gt;
'''hypotonia''': Decrease in the ability to stretch passively, due to a low muscle tone. &lt;br /&gt;
&lt;br /&gt;
'''imprinting''': This is a process to describe the modification of a maternally or paternally derived chromosome, which consequently influences the expression of certain genes on the altered chromosome.&lt;br /&gt;
&lt;br /&gt;
'''ketogenic diet''': A high-fat, low-carbohydrate diet that is used to treat epilepsy in children.&lt;br /&gt;
&lt;br /&gt;
'''levetiracetam''': An anticonvulsant drug used to treat epilepsy.&lt;br /&gt;
&lt;br /&gt;
'''locus''': Location of a gene on a chromosome(loci: plural for locus).&lt;br /&gt;
&lt;br /&gt;
'''LTP''': Long-term potentiation shares common features with long term memory. It strengthens and enhances signal transmission between neurons by improving the communication between two neurons.&lt;br /&gt;
&lt;br /&gt;
'''macrostomia''': A wide-spaced mouth.&lt;br /&gt;
&lt;br /&gt;
'''Makaton''': Language programme using symbols and signs to support speaking.&lt;br /&gt;
&lt;br /&gt;
'''mandibular prognathism''': The abnormal protrusion of the lower jaw. &lt;br /&gt;
&lt;br /&gt;
'''maxillary hypoplasia''':  The underdevelopment of the upper jaw.&lt;br /&gt;
&lt;br /&gt;
'''melatonin''': A hormone secreted by the pineal gland.&lt;br /&gt;
&lt;br /&gt;
'''microcephaly''': The circumference of the head is less than average due to abnormalities of the nervous system. This abnormality can be present at birth or emerge during the first few years of life and reduces both life expectancy and the cognitive functions of the individual affected.&lt;br /&gt;
&lt;br /&gt;
'''microdeletion''':  A genetic mutation in which a part of a chromosome or a sequence of DNA is missing.&lt;br /&gt;
&lt;br /&gt;
'''mosaic''': tissues or cells containing different mixture of genetic sequences&lt;br /&gt;
&lt;br /&gt;
'''mutation''': Event that changes the DNA (deoxyribonucleic acid is a nucleic acid, containing information for protein synthesis) or RNA (ribonucleic acid is a type of nucleic acid transmitting the information from the DNA to the proteins ) of a gene permanently.&lt;br /&gt;
&lt;br /&gt;
'''myoclonic seizures''': A quick jerk of the skeletal muscle, due to a irregular brain activity.&lt;br /&gt;
&lt;br /&gt;
'''neurogenetic''': Genetic basis of the nervous system.&lt;br /&gt;
&lt;br /&gt;
'''neurotransmitter''': Transmits neuronal signals to a target cell. They are first packaged in vesicles just beneath the membrane of presynaptic axon terminals and released into the synaptic cleft (space between the two interacting neurons) and enter the postsynaptic dendrite.&lt;br /&gt;
&lt;br /&gt;
'''occiput''': The back portion of the head.&lt;br /&gt;
&lt;br /&gt;
'''oesophagus reflux''': Impairment of a sphincter in the lower end of the oesophagus leads to the back flow of stomach acid into the oesophagus. Heartburn is a typical symptom.&lt;br /&gt;
&lt;br /&gt;
'''paediatrician''': Physicians that specialise on infants, children and adolescents.&lt;br /&gt;
&lt;br /&gt;
'''paternal UPD''': Inheritance of two copies of a chromosome from the father and none from the mother. &lt;br /&gt;
&lt;br /&gt;
'''phenotype''': Visible traites of an organism determined by genetic and environmental factors.&lt;br /&gt;
&lt;br /&gt;
'''Picture Exchange Communication System (PECS)''': Individuals communicate using images instead of words. It is frequently used by children with autism, to articulate their needs and wishes or to make comments about something.&lt;br /&gt;
&lt;br /&gt;
'''Proband''': Is the person (or animal) being studied or reported on in a genetic investigation. Most commonly it refers to the first affected family member who requires medical help for a genetic disorder. &lt;br /&gt;
&lt;br /&gt;
'''Robertsonian translocation''': Rearrangement of the chromosome, occurs in 5 chromosome including 13,14,15,21 and 22. This type of mutation occurs in chromosomes with the centromere not at the centre, resulting in long and short arm chromosomes. Translocation breaks the chromosome at the centromere so the long arm attaches to the other long arm, and the same for the short arm happens. Cell division will result in the loss of the short arms as they do not contain important genes.&lt;br /&gt;
&lt;br /&gt;
'''seizure''': Abnormal electrical activity in the brain that can result in a variety of physical symptoms like convulsion, body shaking, loss of consciousness, confusion, and mood changes.&lt;br /&gt;
&lt;br /&gt;
'''synapse''': Allows transmission of signal between neurons for effective neuronal function.&lt;br /&gt;
&lt;br /&gt;
'''thoracic scoliosis''': The spine is curved laterally(from side to side) in the thoracic region.&lt;br /&gt;
&lt;br /&gt;
'''tonic-clonic seizures''': This type of seizure is associated with unconsciousness due to electrical discharges in a big proportion of the brain.&lt;br /&gt;
&lt;br /&gt;
'''ubiquitin''': A polypeptide found in all eukaryotic cells, that participates in a variety of cellular functions including protein recycling.&lt;br /&gt;
&lt;br /&gt;
'''Uniparental disomy''': (UPD) the inheritance of two copies of a chromosome pair or part of a chromosme from one parent and no copy from the other parent. &lt;br /&gt;
&lt;br /&gt;
'''valproate''':  A mood-stabilizing drug that is also used for treatment for epilepsy and bipolar disorder.&lt;br /&gt;
&lt;br /&gt;
==Helpful Links==&lt;br /&gt;
&lt;br /&gt;
* Australia&lt;br /&gt;
:* [http://www.angelmansyndrome.org/research.html Angelman Syndrome Association] &lt;br /&gt;
:* [http://www.angelmansyndromeqld.org/ Queensland Angelman Association]&lt;br /&gt;
&lt;br /&gt;
* America&lt;br /&gt;
:* [http://www.angelman.org/ Angelman Syndrome Foundation]&lt;br /&gt;
:* [http://rarediseasesnetwork.epi.usf.edu/arpwsc/ Rare Clinical Diseases Research Network]&lt;br /&gt;
:* [http://www.rarediseases.org/rare-disease-information/rare-diseases/byID/411/viewAbstract National Organisation for Rare Disorders]&lt;br /&gt;
:* [http://www.epilepsyfoundation.org/ Epilepsy Foundation]&lt;br /&gt;
:* [http://www.cureangelman.org/ Foundation for Angelman Syndrome Therapeutics]&lt;br /&gt;
&lt;br /&gt;
* Search Pubmed &lt;br /&gt;
:* [http://www.ncbi.nlm.nih.gov/pubmed?term=angelman%20syndrome Angelman Syndrome] &lt;br /&gt;
&lt;br /&gt;
* OMIM entries for Angelman Syndrome&lt;br /&gt;
:* [http://omim.org/entry/105830 ANGELMAN SYNDROME; AS]&lt;br /&gt;
:* [http://omim.org/entry/601623 UBIQUITIN-PROTEIN LIGASE E3A; UBE3A]&lt;br /&gt;
&lt;br /&gt;
==Related Links==&lt;br /&gt;
&lt;br /&gt;
'''Animal Models'''&lt;br /&gt;
&lt;br /&gt;
* [[Mouse Knockout]] - this page explains the current use of mouse models in disrupting genes to elucidate their genetic function, including the mouse gene knockouts for alpha calcium-calmodulin kinase II (alpha CaMKII)&lt;br /&gt;
* [[2009 Group Project 4]] - this page gives an extensive overview on the history of the mouse model and its various use in embryology and genetics. In addition, it also describes mouse knockout and the role they play in current research of various human diseases&lt;br /&gt;
* [[Fly Development]] - this page describes the use of drosophila flies as developmental models&lt;br /&gt;
* [[2009 Group Project 2]] - this page gives an extensive overview on the history of the fly model and its various use in embryology and genetics&lt;br /&gt;
&lt;br /&gt;
'''Diagnosis'''&lt;br /&gt;
* [[Chorionic villus sampling]] - this page explains the process of chorionic villus sampling, its disadvantages and gives a brief overview of recent findings&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&lt;br /&gt;
&amp;lt;references /&amp;gt;&lt;/div&gt;</summary>
		<author><name>Z3291643</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=User:Z3291643&amp;diff=77677</id>
		<title>User:Z3291643</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=User:Z3291643&amp;diff=77677"/>
		<updated>2011-10-12T23:33:17Z</updated>

		<summary type="html">&lt;p&gt;Z3291643: /* Lab 10 Online Assessment */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{2011Student}}&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Z3291643]] 12:55, 28 July 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 1 Assessment==&lt;br /&gt;
1.	Identify the origin of In Vitro Fertilization and the 2010 nobel prize winner associated with this technique.&lt;br /&gt;
&lt;br /&gt;
‘in vitro’ fertilization is Latin for ‘in glass’ fertilization and is a treatment for infertility, whereby the sperm fertilizes the ovum outside the body and is then implanted back into the patient’s uterus. The first successful IVF birth, Louise Brown, occurred in 1978 with the help of Patrick Steptoe and Robert Edwards. Edwards was awarded the 2010 nobel prize in medicine for his achievement. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
2.	Identify a recent paper on fertilisation and describe its key findings.&lt;br /&gt;
&lt;br /&gt;
The aim of this paper was to investigate whether age &amp;lt;=25 played a role in the reproductive outcome of women undergoing IVF. Infertile patients aged between 19 and 25 years of age were compared to infertile patients aged 30-35 years to determine primarily fertilization rates and the number of top quality embryos. The results were unexpected as the younger subjects had lower fertilization rates and reduced embryo quality.&amp;lt;ref&amp;gt;PMID 21042842&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
3.	Identify 2 congenital anomalies.&lt;br /&gt;
&lt;br /&gt;
Trisomy 21 and cleft palate&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--[[User:S8600021|Mark Hill]] 10:01, 3 August 2011 (EST) These answers are fine.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 13:02, 4 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Lab 2 Assessment==&lt;br /&gt;
1.	Identify the ZP protein that spermatozoa binds and how is this changed (altered) after fertilization. &lt;br /&gt;
&lt;br /&gt;
ZP3 acts as a receptor for the sperm. This is followed by the acrosome reaction, whereby acrosomal contents digest the ZP and allow the sperm surface proteins to bind to the ZP2. After fertilization, cortical reaction takes place where cortical granules are exocytosed. This results in the removal of carbohydrate from ZP3 and cleavage of ZP2 to harden the ZP. These changes occur to prevent polyspermy.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
2.       Identify a review and a research article related to your group topic.&lt;br /&gt;
&lt;br /&gt;
This research article showed genotype-phenotype correlations in Angelman Syndrome (AS). They have concluded that deletion patients had worse developmental outcomes than non deletion patients.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20729760&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
This review article is really comprehensive and gives a good background knowledge of AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20445456&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Z3291643]] 12:42, 11 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 3 Assessment==&lt;br /&gt;
&lt;br /&gt;
1.        What is the maternal dietary requirement for late neural development? &lt;br /&gt;
&lt;br /&gt;
Iodine. Zimmermann found that maternal deficiency of iodine can result in cognitive disability in the offspring, most severely characterized by cretinism. Fortunately, mild to moderate iodine deficiency can be corrected in primary school aged children to improve cognitive and motor functions.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21802524&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
2.        Upload a picture relating to your group project.&lt;br /&gt;
&lt;br /&gt;
[[File:UBE3A colocalizes with ASPM at the centrosome throughout mitosis.jpg|thumb|UBE3A colocalizes with ASPM at the centrosome throughout mitosis.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21633703&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
===UBE3A colocalizes with ASPM at the centrosome throughout mitosis===&lt;br /&gt;
&lt;br /&gt;
[[File:UBE3A colocalizes with ASPM at the centrosome throughout mitosis.jpg|Abnormal cytokinesis and apoptosis in UBE3A knockdown cells.|350px]]&lt;br /&gt;
&lt;br /&gt;
UBE3A colocalizes with ASPM at the centrosome. (A) Indirect immunofluorescence of HEK293 cells at interphase and different phases of mitosis stained with antibodies against ASPM and UBE3A (anti-UBE3A-sc-8926). Note colocalization of UBE3A with ASPM at the centrosome throughout mitosis (arrowheads). Note weak centrosomal staining of UBE3A in an interphase cell (arrow). (B) Indirect immunofluorescence of A549 cells stained with antibodies against UBE3A (anti-UBE3A-sc-8926) and ASPM at metaphase and telophase. Note colocalization of UBE3A with ASPM at the centrosome (arrowheads). Scale bar=2 µm.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Copyright Singhmar, Kumar. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 11:08, 18 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 4 Online Assessment==&lt;br /&gt;
&lt;br /&gt;
# '''The allantois, identified in the placental cord, is continuous with what anatomical structure?'''&lt;br /&gt;
The allantois is endodermic in origin and is the extension of the yolk sac into the connecting stalk. It's connected to the superior end of the developing bladder&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
#  '''Identify the 3 vascular shunts, and their location, in the embryonic circulation.'''&lt;br /&gt;
1. Ductus arteriosus; connects left pulmonary artery with the descending aorta&lt;br /&gt;
2. Ductus venosus; connects the portal and umbilical veins to the inferior vena cava&lt;br /&gt;
3. Foramen ovale; between left and right atria&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
# Identify the Group project sub-section that you will be researching. (Add to project page and your individual assessment page)&lt;br /&gt;
&lt;br /&gt;
; 4  Aetiology (genetic inheritance); Julia&lt;br /&gt;
; 5  Pathophysiology; Julia (as it's quite linked with aetiology anyway)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 12:59, 25 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 5 Online Assessment==&lt;br /&gt;
&lt;br /&gt;
# Which side (L/R) is most common for diaphragmatic hernia and why? &lt;br /&gt;
Posterior left side,possibly due to the fact that the left pericardioperitoneal canal is larger and closes later than the right.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 12:48, 1 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 6 Online Assessment==&lt;br /&gt;
# What week of development do the palatal shelves fuse?&lt;br /&gt;
Week 9 of early embryonic growth&lt;br /&gt;
 &lt;br /&gt;
# What early animal model helped elucidate the neural crest origin and migration of neural crest cells?&lt;br /&gt;
Migration of neural crest cells have been studied in quail-chick chimeras - transplanted quail cells have obvious nucleoli compared with chicken. It was first done by Nicole Le Douarin in the 80's&lt;br /&gt;
 &lt;br /&gt;
# What abnormality results from neural crest not migrating into the cardiac outflow tract? &lt;br /&gt;
Tetralogy of Fallot; when the outflow tract is not aligned properly, it is seen as a nonwedged aorta. Nonwedged aorta indicates tetralogy of Fallot. In addition, past studies using chick embryos have outlined that cardiac neural crest cell ablation led to this malalignment. In contrast, Farrell et al have shown that the introduction of cardiac neural crest aligned the outflow tract properly. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9933243&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 12:49, 15 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 7 Online Assessment==&lt;br /&gt;
&lt;br /&gt;
1. Are satellite cells &lt;br /&gt;
* necessary for muscle hypertrophy?&lt;br /&gt;
: No&lt;br /&gt;
 &lt;br /&gt;
* generally involved in hypertrophy?&lt;br /&gt;
: Yes&lt;br /&gt;
 &lt;br /&gt;
&lt;br /&gt;
2. Why does chronic low frequency stimulation (CLFS) cause a fast to slow fibre type shift? &lt;br /&gt;
: At the molecular level, there are exchanges of fast and slow type protein isoforms, such as calcium regulatory system, myofibrillar apparatus. The final step in CLFS induced fiber shift is the upregulation of slow myosin from the conversion of myogenic cells to slow fiber phenotype. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12500901&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;It is also known that satellite cells contribute to CLFS-induced transition of fiber types shown by the fact that CLFS increases type I fibers only after fiber necrosis. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16439424&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--Mark Hill 10:42, 16 September 2011 (EST) &lt;br /&gt;
&lt;br /&gt;
I would like each student to now also look at the following online page before the next Lab and write a comment based upon the group project assessment criteria. &lt;br /&gt;
&lt;br /&gt;
http://embryology.med.unsw.edu.au/embryology/index.php?title=Trisomy_21 &lt;br /&gt;
Paste your comment on the Trisomy 21 discussion page and also on your own student page. &lt;br /&gt;
&lt;br /&gt;
Group Assessment Criteria&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Good and concise explanation of the subheadings,however, I would've liked to see some attempt to further explain how the asspcoated congenital abnormalities occur.  &lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Lots of images, graphs and table used effectively to help reader better understand the disease. They also gave the project page some colour to make it more pleasing to the eye. Unfortunately, some images were placed (eg. John Langdon Down)in the wrong sections and interrupted the flow of the project page. &lt;br /&gt;
#* In addition, some of the images were not referred to within the project page. &lt;br /&gt;
#* Furthermore, the overall structure and layout of the page could be improved, such as putting the Diagnostic Links under diagnosis instead of the introduction&lt;br /&gt;
#* I also felt American College of Obstetricians and Gynecologists Recommendations could've been a subheading under 'screening'&lt;br /&gt;
#Content is correctly cited and referenced. &lt;br /&gt;
#* The very first image does not provide any information on the permissions to reuse the image (open access). &lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations. &lt;br /&gt;
#* Would've been better to include more self drawn diagrams and tables to further illustrate the group's knowledge of this disease&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* Lots of Pubmed articles have been used to make this page more credible and reliable &lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#* More words need to be explained in the glossary, such as 'tandem single nucleotide polymorphisms' &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 22:50, 21 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 8 Online Assessment==&lt;br /&gt;
attendance: --[[User:Z3291643|Sang Lee]] 13:04, 22 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Group 1: Turner Syndrome&lt;br /&gt;
&lt;br /&gt;
Firstly, nice progress with the group project. After reading your page, I have a good general knowledge of Turner Syndrome, so thanks. Overall, most sections were well done, though the writing style and layout could be more consistent, but you could work on that when you've finalised the content of the page. &lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: Good intro, very first image of the karyotype should include the actual statement of the 'Open access' not just 'copyright'&lt;br /&gt;
#* Epidemiology: Grammatical errors disrupt the flow of the content, in addition, graph has no copyright info, title could be improved&lt;br /&gt;
#* Etiology: Nice simple diagram of 22 eggs and 23 sperms, good example of when a picture can tell more than a thousand words! I feel there needs to be consistency either use Turner Syndrome or TS throughout the page&lt;br /&gt;
#* Clinical: liked how you have further classified the symptoms to its associated titles, nice idea; very easy to read, but a table would also be good&lt;br /&gt;
#* Diagnosis: image of TS maternal serum sampling doesn't contain {Template:2011 Student Image}, but a very good table&lt;br /&gt;
#* image of the TS X chromosome variations shouldl contain {Template:2011 Student Image}. Furthermore, if you use A-E in image descriptions, you should include A-E within the image&lt;br /&gt;
#* Research: very good layout and explanations, informative&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Could include more images especially in clinical manidestations, and some images do not fit the requirements set by Mark, as I've highlighted above &lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* seems to be cited well. However, although you have more than 100 referencees, a lot of them are repeated references, maybe you could try to use more pubmed articles, a greater variety&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations. &lt;br /&gt;
#* Glossary: could include more words such as echocardiogram&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* Although you have more than 100 referencees, a lot of them are repeated references, maybe you could try to use more pubmed articles, a greater variety&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#*  Although the content is informative, I'm left feeling like I want more variety of resources, so maybe some further research will improve the overall impression of your page &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot;&lt;br /&gt;
* consistency in writing style&lt;br /&gt;
* more images and cited correctly &lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 14:44, 24 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Group 2&lt;br /&gt;
&lt;br /&gt;
Hey Group 2, firstly, well done on putting in the effort to create this page, it really shows your dedication and cooperation as a team! Here are some points I thought you could improve on to take this page to that extra level&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: Good overview. Image would look better with a border or as a thumb&lt;br /&gt;
#* History: Image too large, again maybe a border?&lt;br /&gt;
#* Epidemiology: Need to define velocardiofacial syndrome in glossary, also break it down into subheadings, eg. Incidence, Sex, etc&lt;br /&gt;
#* Etiology: Maybe better if in a table&lt;br /&gt;
#* Pathogenesis: I liked how you broke it doen into relevant subheadings. However, on a slightly negative note, the DG Pathophysiology Diagram looks rushed; I think it would've looked better if it was neater and easier to read.&lt;br /&gt;
#* Diagnosis: I felt citing was done poorly in this section, eg. the last 4/5 sentences in the FISH technique was not referenced at all, but again, this is very easily fixed. But good to see you have put in the effort and time&lt;br /&gt;
#* Clinical: Image of normal and cleft palate, if based on a textbook, I think you still need permission to adapt it (not quite sure, please ask Mark)? Table with 'How it is caused' would be better by itself as pathophysiology. Tetralogy of Fallot needs to be fitted into this section more smoothly, at the moment, it makes this section look very cramped. Also, the image regarding Tetralogy needs the correct format for student drawn images (ie. 'I (student no.)....)&lt;br /&gt;
#* Research: Maybe break it down into subheadings&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Good images used with a nice range of self drawn images. However, no where in the page is there any reference to the images within the text.&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* I feel citation needs to be improved overall. Lots of the sections have missing citations, especially Diagnostic Tests. Also in the reference list, refs 33,40,47, 49 have nothing in it (is it meant to be like this?)&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations. &lt;br /&gt;
#* Nice drawings, though some could've done better with more effort&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* Nice range of references used&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#* It's very clear to me that you guys have worked together well and there has been good team work going on here to create this page, so well done&lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* I feel your page is too heavy with the text, although there's a lot of images as well, it just doesn't quite balance out with the text. &lt;br /&gt;
* Also felt the different colours used for the tables, although adding a splash of colour to your page, brought down the overall quality of the page. However, please keep in mind that others might really like this approach of table formatting, it's just that personally, I think you could benefit from keeping all table colours consistent.&lt;br /&gt;
* Sometimes you refer to DiGeorge Syndrome as DGS and also as DS. Small and easy to fix, adds consistency&lt;br /&gt;
* Please don't forget to add the {template} for student uploaded images&lt;br /&gt;
* Definitely needs more words in the Glossary, such as Meiosis, de novo, microarray&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 16:02, 24 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 3&lt;br /&gt;
&lt;br /&gt;
Hi, overall, a nice project page with interesting information.&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: Nice introduction, good flow and easy to read. However, image needs proper information and perhaps 'This disorder was first described by Harry F.' could be placed earlier on in the intro rather than in the middle&lt;br /&gt;
#* History: Nice section, very interesting&lt;br /&gt;
#* Epidemiology: First paragraph is good, but I feel the rest of this section doesn't quite belong here, such as the information on seizures, IQs, diagnosis. This section should focus on stats (sex/birth/ethnic/demographic/etc). Fig 2, 3 belong more in the signs and symptoms&lt;br /&gt;
#* Etiology: the '1:1000 male' contradicts the '1:500' given in epidemiology. Fig4 needs coyright information&lt;br /&gt;
#* Pathogenesis: Needs better referencing, also placing fig 5, 6 on either side doesn't look too good with the text. Perhaps place them below one another?&lt;br /&gt;
#* Signs: Seems a bit incomplete, it'll also be good to explain the image of 'pubertal gynecomastia'&lt;br /&gt;
#* Diagnosis: Sentence structure could be improved, ie. 'performed because physicians may suspect it because of clinical findings'. Information is interesting, but could be presented more clearly, perhaps in a table?&lt;br /&gt;
#* Similar defects: very nice, presented well with good information, easy to read&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Good images used with a nice range of self drawn images. However, lot of the images need to be formatted properly with required information&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* overall referencing was well done, except pathogenesis needs more referencing&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations. &lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* Nice range of references used&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#* The information is there, but maybe from now til final assessment, you could do further research in all sections, as they do seem a little short.&lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* better page layout&lt;br /&gt;
* glossary: sorry, but I feel the alphabet subheadings here are very effective as you have it in alphabetical order anyway&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 21:59, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 4&lt;br /&gt;
&lt;br /&gt;
Hey, this is a nicely structured page with interesting content that is presented well. There is a nice balance of text and image&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: good, to the point&lt;br /&gt;
#* History: Nice section, perhaps bold the years?&lt;br /&gt;
#* Epidemiology: I really liked this section, both visually and content wise. The table is easy to read and I liked your explanations for the HD prevalence, well done&lt;br /&gt;
#* Genetics: Perhaps you could have the 'CAG (cytosine-adenine-glutamine)' in the introduction when you first refer to it? Referencing is required in i'HTT and normal functions'. I really liked your subheadings, made it very easy to understand and follow &lt;br /&gt;
#* Pathogenesis: Image is too big, good subheadings, I suggest that if you write in purple to highlight some words, maybe you could do that for the whole page?&lt;br /&gt;
#* Clinical: liked the motor impairment explanations, how about explaining the cognitive and behaviour impairments as well? (it'll be worth it!)&lt;br /&gt;
#* Diagnosis: Nice content, but it just feels a bit too crowded, maybe rearrange the images and decrease image size&lt;br /&gt;
#* Treatment: Very nice section with nice images and good format!&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Good balance of images and text, though some rearrangement of images would make this page look better. Very good use of subheadings to make the content more easy to digest&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* overall referencing was well done&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
* good range of tables, images and self drawn images&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* Nice range of references used&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* just minor changes such as resizing some of the images, making the sections consistent in format&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 22:32, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 5&lt;br /&gt;
&lt;br /&gt;
Hi, I can see some progress on this page which is good, content is interesting&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: What is FMR1 gene? Need more information here, as in when was it first discovered, some stats&lt;br /&gt;
#* Epidemiology: I think screening information is extensive enough to be a section on its own&lt;br /&gt;
#* Etiology: no explanation of FMR1 gene so far, what is its normal function? Also, please refer to images used in this section&lt;br /&gt;
#* Development of the disease:nice succinct, easy to follow section. Perhaps add an image for one of the stages mentioned here?&lt;br /&gt;
#* Signs: REFERENCING!!! But, content is good and interesting&lt;br /&gt;
#* Diagnosis: An image here would be nice, and an explanation of how the technology is used to diagnose FXS&lt;br /&gt;
#* Treatment: Nice table with good information&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Need to balance out the text and image ratio, some good subheadings&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* poor referencing, which makes me question the reliability of the content in some sections&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
#* needs a lot more images&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* I feel more research needs to be done here&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* Although the content is here, there is still a lot of work needed to make this page feel complete&lt;br /&gt;
* glossary is very lacking in terminology&lt;br /&gt;
* need more images&lt;br /&gt;
* further research would be nice to explain this disease in more detail&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 23:26, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Group 6&lt;br /&gt;
Hey, nice progress with your page, all sections have similar amount of content which were interesting&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: Referencing needs to be improved here&lt;br /&gt;
#* History: content is good but too wordy. I think a summary or a simple timeline would be good&lt;br /&gt;
#* Epidemiology: Where's the reference for 3/10000 live births?&lt;br /&gt;
#* Signs: ok section, but could do with more images here&lt;br /&gt;
#* Genetics: If using abbreviations, such as TBX1 gene, you should explain what it is, ie. TBX1 gene (T-box 1). Also need to work on referencing here as well. How about organising all the content in a table? have in columns: gene, gene profile, frequency, etc.&lt;br /&gt;
#* Pathogenesis: I'm not quite sure about this, but do you need permission to adapt an image from an article? (I'm referring to the '4 defects' image)&lt;br /&gt;
#* Diagnosis: I'm sorry, but this section is a bit bland, though the content is very informative. I think some images here would be good&lt;br /&gt;
#* Treatment: Referencing! Also, personally, that green is too bright, maybe find a more neutral, soothing colour?&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Need to find more images, I feel some of the information could be more effectively presented in table formate rather than lengthy text&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* VERY poor referencing, which makes me question the reliability of the content in some sections&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
#* needs a lot more images&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* research done is evident, just need to reference&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* glossary is very lacking in terminology&lt;br /&gt;
* need more images&lt;br /&gt;
* REFERENCING!&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 23:26, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Group 8&lt;br /&gt;
Hey, well done, your page is looking really polished! Lots of very interesting information here and presented in a very easy to follow manner&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* History: I feel that you could lessen the info of Nicholas and add more current findings of the disease.&lt;br /&gt;
#* Aetiology: What is the chromosome 9 image based on? Need to work on referencing. Very good subheadings and well balanced with images&lt;br /&gt;
#* Pathogenesis: Needs more information&lt;br /&gt;
#* Neuro: What's the images based on? Good subheadings and explained well. I liked the way you gave explanations for normal function/appearance and then went on to explain abnormality associated with the structures in this disease. But you need to improve your referencing for this section&lt;br /&gt;
#* Diagnosis: Very good table and images. But need to fix the postnal diagnosis table so that it spans the length of the screen&lt;br /&gt;
#* Symptoms: table and images look too crowded&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* good subheadings, images, impressive self drawn images! Nice balanced page layout&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* needs to work on referencing&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* research done is evident, just need to reference&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* referencing&lt;br /&gt;
* better arrangement of table and images so page doesn't look too crowded&lt;br /&gt;
&lt;br /&gt;
Well done guys, nice team work!&lt;br /&gt;
--[[User:Z3291643|z3291643]] 23:50, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 9&lt;br /&gt;
&lt;br /&gt;
Hey, your page has a lot of very interesting content and some unique self drawn images. I thoroughly enjoyed this page, thanks&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: Inclusion of incidence would be nice&lt;br /&gt;
#* History: very informative and a nice simple timeline&lt;br /&gt;
#* Genetics: Good, succinct section, especially liked the table&lt;br /&gt;
#* Diagnosis: needs referencing. Is diagnosis only postnatal? What is the average age of diagnosis for this disease?&lt;br /&gt;
#* Management and Treatment: Seems a little out of place under epidemiology, I think it should be place later on &lt;br /&gt;
#* Phenotype:Reference?&lt;br /&gt;
#* Cardiac conditions: maybe give explanations for atrial and ventricular septal defect, just brief descriptions would suffice. Why is it so that males are more likely to suffer CVD than females?&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* good subheadings, interesting self drawn images. However, this page needs to find a balance in text and images&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* needs to work on referencing&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* research done is evident, just need to reference&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#* very interesting content, informative&lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* referencing&lt;br /&gt;
* more images&lt;br /&gt;
* glossary; lacking a lor of terms&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 00:10, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 10&lt;br /&gt;
&lt;br /&gt;
Hey, this is a interesting disease, with some good images to show the disease clearly. &lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: succinct introduction&lt;br /&gt;
#* History: Has interesting content, though timeline would be nice&lt;br /&gt;
#* Pathogenesis: Too brief and could be improved with an image&lt;br /&gt;
#* Signs: surely there are more symptoms here, maybe you could have subheadings to break down the symtpoms, ie. motor impairment, cognitive impairments, etc&lt;br /&gt;
#* Clinical manifestations and complications: nice section with good image used&lt;br /&gt;
#* Diagnosis: could be further explained, and an image would be nice&lt;br /&gt;
#* Treatment: Current and Future Prospects: needs referencing&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* need to balance out the text with images, could organise page better with more subheadings, more images needed &lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* needs to work on referencing!!&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
#*  more table could be used instead of lengthy explanations&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* much more research needs to be done to further explain the sections&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* referencing&lt;br /&gt;
* more images&lt;br /&gt;
* glossary; lacking a lot of terms&lt;br /&gt;
* needs much more research, lots of repetitions in referencing&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 11:02, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 11&lt;br /&gt;
&lt;br /&gt;
Hey, this is a interesting disease, with some good images to show the disease clearly. &lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: very rushed, no reference and needs much more work, it should be a succinct summary of this whole page.&lt;br /&gt;
#* History: Has interesting content, though timeline would be better incorporated under History, not a section of its own&lt;br /&gt;
#* Diagnosis: If you're abbreviating Cleft Palate to CLP, you should have it as Cleft palate (CLP). The two given tables are pretty much the same, except for different sample number. Is it really necessary to have the two tables when they're so similar? Could do well with an image&lt;br /&gt;
#* Syndromes and Anomalies associated with cleft: Nice array of images used here. Content is good (for ones you provided), but needs work on referencing. Perhaps you could organise the content into a table for easy comparison since you have more than one anomalies&lt;br /&gt;
#* Aetiology: Needs referencing, image could have a caption to explain it. Although the content is there, it's too brief and I feel it could be organised in a more effective manner, such as using number stages.&lt;br /&gt;
#* Types of Cleft Palate/Lip:very brief, please explain the points (ie. what's the differences between them? you say there are differences in severity, how so?)&lt;br /&gt;
#* Pathophysiology: need to reformat table more effectively and work on referencing&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* need to balance out the text with images, could organise page better with more subheadings &lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* needs to work on referencing!!&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
#* NO self drawn images so far&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* much more research needs to be done. sections overall are lacking substance and doesn't explain the content very well&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* referencing&lt;br /&gt;
* more images&lt;br /&gt;
* glossary; lacking a lot of terms&lt;br /&gt;
* needs much more research&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 11:02, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 9 attendence==&lt;br /&gt;
--[[User:Z3291643|z3291643]] 13:00, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 10 attendence==&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 13:15, 6 October 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 10 Online Assessment==&lt;br /&gt;
&lt;br /&gt;
1.Besides fetal alcohol syndrome, identify another environmental teratogen that can lead to hearing loss.&lt;br /&gt;
&lt;br /&gt;
Noise pollution is a big factor in hearing loss, as well as viral and bacterial infections such as meningitis. Hearing loss from meningitis can be a result of the direct effects of the infection on the brain or the body's reaction to the infection, most commonly with pneumococcal meningitis. 6% of all hearing defects in children can be attributed to bacterial meningitis, with around 72% of these children progressing to complete hearing loss by the age of three. &lt;br /&gt;
&lt;br /&gt;
2.Identify 3 factors that contribute to poor neonatal drainage of the middle ear. &lt;br /&gt;
&lt;br /&gt;
The auditory tube connects the middle ear cavity to the nasopharynx, and is different in structure in neonates vs. adults.&lt;br /&gt;
:# the eustachian tube is very horizontal (10 degrees to the horizontal axis)&lt;br /&gt;
:# only opened by a single muscle called the tensor palati muscle (compared to 2 muscles in the adult tube)&lt;br /&gt;
:# it is shorter(17-18 mm) and narrower &lt;br /&gt;
&lt;br /&gt;
3.Identify 1 genetic abnormality that affects hearing development and link to the OMIM record. (Your individual abnormality should be different from all other students)&lt;br /&gt;
* Waardenburg syndrome&lt;br /&gt;
* results in hearing loss (to variable extent)&lt;br /&gt;
* inherited in an autosomal dominant manner&lt;br /&gt;
* [http://omim.org/entry/193500 Waardenburg syndrome]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Related Links'''&lt;br /&gt;
&lt;br /&gt;
'''Animal Models'''&lt;br /&gt;
&lt;br /&gt;
* [[Mouse Knockout]] - this page explains the current use of mouse models in disrupting genes to elucidate their genetic function, including the mouse gene knockouts for alpha calcium-calmodulin kinase II (alpha CaMKII)&lt;br /&gt;
* [[2009 Group Project 4]] - this page gives an extensive overview on the history of the mouse model and its various use in embryology and genetics. In addition, it also describes mouse knockout and the role they play in current research of various human diseases&lt;br /&gt;
* [[Fly Development]] - this page describes the use of drosophila flies as developmental models&lt;br /&gt;
* [[2009 Group Project 2]] - this page gives an extensive overview on the history of the fly model and its various use in embryology and genetics&lt;br /&gt;
&lt;br /&gt;
'''Diagnosis'''&lt;br /&gt;
* [[Chorionic villus sampling]] - this page explains the process of chorionic villus sampling, its disadvantages and gives a brief overview of recent findings&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 10:20, 13 October 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==''' References '''==&lt;br /&gt;
&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;/div&gt;</summary>
		<author><name>Z3291643</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=User:Z3291643&amp;diff=77672</id>
		<title>User:Z3291643</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=User:Z3291643&amp;diff=77672"/>
		<updated>2011-10-12T23:29:03Z</updated>

		<summary type="html">&lt;p&gt;Z3291643: /* Lab 10 Online Assessment */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{2011Student}}&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Z3291643]] 12:55, 28 July 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 1 Assessment==&lt;br /&gt;
1.	Identify the origin of In Vitro Fertilization and the 2010 nobel prize winner associated with this technique.&lt;br /&gt;
&lt;br /&gt;
‘in vitro’ fertilization is Latin for ‘in glass’ fertilization and is a treatment for infertility, whereby the sperm fertilizes the ovum outside the body and is then implanted back into the patient’s uterus. The first successful IVF birth, Louise Brown, occurred in 1978 with the help of Patrick Steptoe and Robert Edwards. Edwards was awarded the 2010 nobel prize in medicine for his achievement. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
2.	Identify a recent paper on fertilisation and describe its key findings.&lt;br /&gt;
&lt;br /&gt;
The aim of this paper was to investigate whether age &amp;lt;=25 played a role in the reproductive outcome of women undergoing IVF. Infertile patients aged between 19 and 25 years of age were compared to infertile patients aged 30-35 years to determine primarily fertilization rates and the number of top quality embryos. The results were unexpected as the younger subjects had lower fertilization rates and reduced embryo quality.&amp;lt;ref&amp;gt;PMID 21042842&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
3.	Identify 2 congenital anomalies.&lt;br /&gt;
&lt;br /&gt;
Trisomy 21 and cleft palate&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--[[User:S8600021|Mark Hill]] 10:01, 3 August 2011 (EST) These answers are fine.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 13:02, 4 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Lab 2 Assessment==&lt;br /&gt;
1.	Identify the ZP protein that spermatozoa binds and how is this changed (altered) after fertilization. &lt;br /&gt;
&lt;br /&gt;
ZP3 acts as a receptor for the sperm. This is followed by the acrosome reaction, whereby acrosomal contents digest the ZP and allow the sperm surface proteins to bind to the ZP2. After fertilization, cortical reaction takes place where cortical granules are exocytosed. This results in the removal of carbohydrate from ZP3 and cleavage of ZP2 to harden the ZP. These changes occur to prevent polyspermy.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
2.       Identify a review and a research article related to your group topic.&lt;br /&gt;
&lt;br /&gt;
This research article showed genotype-phenotype correlations in Angelman Syndrome (AS). They have concluded that deletion patients had worse developmental outcomes than non deletion patients.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20729760&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
This review article is really comprehensive and gives a good background knowledge of AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20445456&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Z3291643]] 12:42, 11 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 3 Assessment==&lt;br /&gt;
&lt;br /&gt;
1.        What is the maternal dietary requirement for late neural development? &lt;br /&gt;
&lt;br /&gt;
Iodine. Zimmermann found that maternal deficiency of iodine can result in cognitive disability in the offspring, most severely characterized by cretinism. Fortunately, mild to moderate iodine deficiency can be corrected in primary school aged children to improve cognitive and motor functions.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21802524&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
2.        Upload a picture relating to your group project.&lt;br /&gt;
&lt;br /&gt;
[[File:UBE3A colocalizes with ASPM at the centrosome throughout mitosis.jpg|thumb|UBE3A colocalizes with ASPM at the centrosome throughout mitosis.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21633703&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
===UBE3A colocalizes with ASPM at the centrosome throughout mitosis===&lt;br /&gt;
&lt;br /&gt;
[[File:UBE3A colocalizes with ASPM at the centrosome throughout mitosis.jpg|Abnormal cytokinesis and apoptosis in UBE3A knockdown cells.|350px]]&lt;br /&gt;
&lt;br /&gt;
UBE3A colocalizes with ASPM at the centrosome. (A) Indirect immunofluorescence of HEK293 cells at interphase and different phases of mitosis stained with antibodies against ASPM and UBE3A (anti-UBE3A-sc-8926). Note colocalization of UBE3A with ASPM at the centrosome throughout mitosis (arrowheads). Note weak centrosomal staining of UBE3A in an interphase cell (arrow). (B) Indirect immunofluorescence of A549 cells stained with antibodies against UBE3A (anti-UBE3A-sc-8926) and ASPM at metaphase and telophase. Note colocalization of UBE3A with ASPM at the centrosome (arrowheads). Scale bar=2 µm.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Copyright Singhmar, Kumar. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 11:08, 18 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 4 Online Assessment==&lt;br /&gt;
&lt;br /&gt;
# '''The allantois, identified in the placental cord, is continuous with what anatomical structure?'''&lt;br /&gt;
The allantois is endodermic in origin and is the extension of the yolk sac into the connecting stalk. It's connected to the superior end of the developing bladder&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
#  '''Identify the 3 vascular shunts, and their location, in the embryonic circulation.'''&lt;br /&gt;
1. Ductus arteriosus; connects left pulmonary artery with the descending aorta&lt;br /&gt;
2. Ductus venosus; connects the portal and umbilical veins to the inferior vena cava&lt;br /&gt;
3. Foramen ovale; between left and right atria&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
# Identify the Group project sub-section that you will be researching. (Add to project page and your individual assessment page)&lt;br /&gt;
&lt;br /&gt;
; 4  Aetiology (genetic inheritance); Julia&lt;br /&gt;
; 5  Pathophysiology; Julia (as it's quite linked with aetiology anyway)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 12:59, 25 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 5 Online Assessment==&lt;br /&gt;
&lt;br /&gt;
# Which side (L/R) is most common for diaphragmatic hernia and why? &lt;br /&gt;
Posterior left side,possibly due to the fact that the left pericardioperitoneal canal is larger and closes later than the right.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 12:48, 1 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 6 Online Assessment==&lt;br /&gt;
# What week of development do the palatal shelves fuse?&lt;br /&gt;
Week 9 of early embryonic growth&lt;br /&gt;
 &lt;br /&gt;
# What early animal model helped elucidate the neural crest origin and migration of neural crest cells?&lt;br /&gt;
Migration of neural crest cells have been studied in quail-chick chimeras - transplanted quail cells have obvious nucleoli compared with chicken. It was first done by Nicole Le Douarin in the 80's&lt;br /&gt;
 &lt;br /&gt;
# What abnormality results from neural crest not migrating into the cardiac outflow tract? &lt;br /&gt;
Tetralogy of Fallot; when the outflow tract is not aligned properly, it is seen as a nonwedged aorta. Nonwedged aorta indicates tetralogy of Fallot. In addition, past studies using chick embryos have outlined that cardiac neural crest cell ablation led to this malalignment. In contrast, Farrell et al have shown that the introduction of cardiac neural crest aligned the outflow tract properly. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9933243&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 12:49, 15 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 7 Online Assessment==&lt;br /&gt;
&lt;br /&gt;
1. Are satellite cells &lt;br /&gt;
* necessary for muscle hypertrophy?&lt;br /&gt;
: No&lt;br /&gt;
 &lt;br /&gt;
* generally involved in hypertrophy?&lt;br /&gt;
: Yes&lt;br /&gt;
 &lt;br /&gt;
&lt;br /&gt;
2. Why does chronic low frequency stimulation (CLFS) cause a fast to slow fibre type shift? &lt;br /&gt;
: At the molecular level, there are exchanges of fast and slow type protein isoforms, such as calcium regulatory system, myofibrillar apparatus. The final step in CLFS induced fiber shift is the upregulation of slow myosin from the conversion of myogenic cells to slow fiber phenotype. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12500901&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;It is also known that satellite cells contribute to CLFS-induced transition of fiber types shown by the fact that CLFS increases type I fibers only after fiber necrosis. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16439424&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--Mark Hill 10:42, 16 September 2011 (EST) &lt;br /&gt;
&lt;br /&gt;
I would like each student to now also look at the following online page before the next Lab and write a comment based upon the group project assessment criteria. &lt;br /&gt;
&lt;br /&gt;
http://embryology.med.unsw.edu.au/embryology/index.php?title=Trisomy_21 &lt;br /&gt;
Paste your comment on the Trisomy 21 discussion page and also on your own student page. &lt;br /&gt;
&lt;br /&gt;
Group Assessment Criteria&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Good and concise explanation of the subheadings,however, I would've liked to see some attempt to further explain how the asspcoated congenital abnormalities occur.  &lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Lots of images, graphs and table used effectively to help reader better understand the disease. They also gave the project page some colour to make it more pleasing to the eye. Unfortunately, some images were placed (eg. John Langdon Down)in the wrong sections and interrupted the flow of the project page. &lt;br /&gt;
#* In addition, some of the images were not referred to within the project page. &lt;br /&gt;
#* Furthermore, the overall structure and layout of the page could be improved, such as putting the Diagnostic Links under diagnosis instead of the introduction&lt;br /&gt;
#* I also felt American College of Obstetricians and Gynecologists Recommendations could've been a subheading under 'screening'&lt;br /&gt;
#Content is correctly cited and referenced. &lt;br /&gt;
#* The very first image does not provide any information on the permissions to reuse the image (open access). &lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations. &lt;br /&gt;
#* Would've been better to include more self drawn diagrams and tables to further illustrate the group's knowledge of this disease&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* Lots of Pubmed articles have been used to make this page more credible and reliable &lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#* More words need to be explained in the glossary, such as 'tandem single nucleotide polymorphisms' &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 22:50, 21 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 8 Online Assessment==&lt;br /&gt;
attendance: --[[User:Z3291643|Sang Lee]] 13:04, 22 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Group 1: Turner Syndrome&lt;br /&gt;
&lt;br /&gt;
Firstly, nice progress with the group project. After reading your page, I have a good general knowledge of Turner Syndrome, so thanks. Overall, most sections were well done, though the writing style and layout could be more consistent, but you could work on that when you've finalised the content of the page. &lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: Good intro, very first image of the karyotype should include the actual statement of the 'Open access' not just 'copyright'&lt;br /&gt;
#* Epidemiology: Grammatical errors disrupt the flow of the content, in addition, graph has no copyright info, title could be improved&lt;br /&gt;
#* Etiology: Nice simple diagram of 22 eggs and 23 sperms, good example of when a picture can tell more than a thousand words! I feel there needs to be consistency either use Turner Syndrome or TS throughout the page&lt;br /&gt;
#* Clinical: liked how you have further classified the symptoms to its associated titles, nice idea; very easy to read, but a table would also be good&lt;br /&gt;
#* Diagnosis: image of TS maternal serum sampling doesn't contain {Template:2011 Student Image}, but a very good table&lt;br /&gt;
#* image of the TS X chromosome variations shouldl contain {Template:2011 Student Image}. Furthermore, if you use A-E in image descriptions, you should include A-E within the image&lt;br /&gt;
#* Research: very good layout and explanations, informative&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Could include more images especially in clinical manidestations, and some images do not fit the requirements set by Mark, as I've highlighted above &lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* seems to be cited well. However, although you have more than 100 referencees, a lot of them are repeated references, maybe you could try to use more pubmed articles, a greater variety&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations. &lt;br /&gt;
#* Glossary: could include more words such as echocardiogram&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* Although you have more than 100 referencees, a lot of them are repeated references, maybe you could try to use more pubmed articles, a greater variety&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#*  Although the content is informative, I'm left feeling like I want more variety of resources, so maybe some further research will improve the overall impression of your page &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot;&lt;br /&gt;
* consistency in writing style&lt;br /&gt;
* more images and cited correctly &lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 14:44, 24 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Group 2&lt;br /&gt;
&lt;br /&gt;
Hey Group 2, firstly, well done on putting in the effort to create this page, it really shows your dedication and cooperation as a team! Here are some points I thought you could improve on to take this page to that extra level&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: Good overview. Image would look better with a border or as a thumb&lt;br /&gt;
#* History: Image too large, again maybe a border?&lt;br /&gt;
#* Epidemiology: Need to define velocardiofacial syndrome in glossary, also break it down into subheadings, eg. Incidence, Sex, etc&lt;br /&gt;
#* Etiology: Maybe better if in a table&lt;br /&gt;
#* Pathogenesis: I liked how you broke it doen into relevant subheadings. However, on a slightly negative note, the DG Pathophysiology Diagram looks rushed; I think it would've looked better if it was neater and easier to read.&lt;br /&gt;
#* Diagnosis: I felt citing was done poorly in this section, eg. the last 4/5 sentences in the FISH technique was not referenced at all, but again, this is very easily fixed. But good to see you have put in the effort and time&lt;br /&gt;
#* Clinical: Image of normal and cleft palate, if based on a textbook, I think you still need permission to adapt it (not quite sure, please ask Mark)? Table with 'How it is caused' would be better by itself as pathophysiology. Tetralogy of Fallot needs to be fitted into this section more smoothly, at the moment, it makes this section look very cramped. Also, the image regarding Tetralogy needs the correct format for student drawn images (ie. 'I (student no.)....)&lt;br /&gt;
#* Research: Maybe break it down into subheadings&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Good images used with a nice range of self drawn images. However, no where in the page is there any reference to the images within the text.&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* I feel citation needs to be improved overall. Lots of the sections have missing citations, especially Diagnostic Tests. Also in the reference list, refs 33,40,47, 49 have nothing in it (is it meant to be like this?)&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations. &lt;br /&gt;
#* Nice drawings, though some could've done better with more effort&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* Nice range of references used&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#* It's very clear to me that you guys have worked together well and there has been good team work going on here to create this page, so well done&lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* I feel your page is too heavy with the text, although there's a lot of images as well, it just doesn't quite balance out with the text. &lt;br /&gt;
* Also felt the different colours used for the tables, although adding a splash of colour to your page, brought down the overall quality of the page. However, please keep in mind that others might really like this approach of table formatting, it's just that personally, I think you could benefit from keeping all table colours consistent.&lt;br /&gt;
* Sometimes you refer to DiGeorge Syndrome as DGS and also as DS. Small and easy to fix, adds consistency&lt;br /&gt;
* Please don't forget to add the {template} for student uploaded images&lt;br /&gt;
* Definitely needs more words in the Glossary, such as Meiosis, de novo, microarray&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 16:02, 24 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 3&lt;br /&gt;
&lt;br /&gt;
Hi, overall, a nice project page with interesting information.&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: Nice introduction, good flow and easy to read. However, image needs proper information and perhaps 'This disorder was first described by Harry F.' could be placed earlier on in the intro rather than in the middle&lt;br /&gt;
#* History: Nice section, very interesting&lt;br /&gt;
#* Epidemiology: First paragraph is good, but I feel the rest of this section doesn't quite belong here, such as the information on seizures, IQs, diagnosis. This section should focus on stats (sex/birth/ethnic/demographic/etc). Fig 2, 3 belong more in the signs and symptoms&lt;br /&gt;
#* Etiology: the '1:1000 male' contradicts the '1:500' given in epidemiology. Fig4 needs coyright information&lt;br /&gt;
#* Pathogenesis: Needs better referencing, also placing fig 5, 6 on either side doesn't look too good with the text. Perhaps place them below one another?&lt;br /&gt;
#* Signs: Seems a bit incomplete, it'll also be good to explain the image of 'pubertal gynecomastia'&lt;br /&gt;
#* Diagnosis: Sentence structure could be improved, ie. 'performed because physicians may suspect it because of clinical findings'. Information is interesting, but could be presented more clearly, perhaps in a table?&lt;br /&gt;
#* Similar defects: very nice, presented well with good information, easy to read&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Good images used with a nice range of self drawn images. However, lot of the images need to be formatted properly with required information&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* overall referencing was well done, except pathogenesis needs more referencing&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations. &lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* Nice range of references used&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#* The information is there, but maybe from now til final assessment, you could do further research in all sections, as they do seem a little short.&lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* better page layout&lt;br /&gt;
* glossary: sorry, but I feel the alphabet subheadings here are very effective as you have it in alphabetical order anyway&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 21:59, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 4&lt;br /&gt;
&lt;br /&gt;
Hey, this is a nicely structured page with interesting content that is presented well. There is a nice balance of text and image&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: good, to the point&lt;br /&gt;
#* History: Nice section, perhaps bold the years?&lt;br /&gt;
#* Epidemiology: I really liked this section, both visually and content wise. The table is easy to read and I liked your explanations for the HD prevalence, well done&lt;br /&gt;
#* Genetics: Perhaps you could have the 'CAG (cytosine-adenine-glutamine)' in the introduction when you first refer to it? Referencing is required in i'HTT and normal functions'. I really liked your subheadings, made it very easy to understand and follow &lt;br /&gt;
#* Pathogenesis: Image is too big, good subheadings, I suggest that if you write in purple to highlight some words, maybe you could do that for the whole page?&lt;br /&gt;
#* Clinical: liked the motor impairment explanations, how about explaining the cognitive and behaviour impairments as well? (it'll be worth it!)&lt;br /&gt;
#* Diagnosis: Nice content, but it just feels a bit too crowded, maybe rearrange the images and decrease image size&lt;br /&gt;
#* Treatment: Very nice section with nice images and good format!&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Good balance of images and text, though some rearrangement of images would make this page look better. Very good use of subheadings to make the content more easy to digest&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* overall referencing was well done&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
* good range of tables, images and self drawn images&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* Nice range of references used&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* just minor changes such as resizing some of the images, making the sections consistent in format&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 22:32, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 5&lt;br /&gt;
&lt;br /&gt;
Hi, I can see some progress on this page which is good, content is interesting&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: What is FMR1 gene? Need more information here, as in when was it first discovered, some stats&lt;br /&gt;
#* Epidemiology: I think screening information is extensive enough to be a section on its own&lt;br /&gt;
#* Etiology: no explanation of FMR1 gene so far, what is its normal function? Also, please refer to images used in this section&lt;br /&gt;
#* Development of the disease:nice succinct, easy to follow section. Perhaps add an image for one of the stages mentioned here?&lt;br /&gt;
#* Signs: REFERENCING!!! But, content is good and interesting&lt;br /&gt;
#* Diagnosis: An image here would be nice, and an explanation of how the technology is used to diagnose FXS&lt;br /&gt;
#* Treatment: Nice table with good information&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Need to balance out the text and image ratio, some good subheadings&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* poor referencing, which makes me question the reliability of the content in some sections&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
#* needs a lot more images&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* I feel more research needs to be done here&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* Although the content is here, there is still a lot of work needed to make this page feel complete&lt;br /&gt;
* glossary is very lacking in terminology&lt;br /&gt;
* need more images&lt;br /&gt;
* further research would be nice to explain this disease in more detail&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 23:26, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Group 6&lt;br /&gt;
Hey, nice progress with your page, all sections have similar amount of content which were interesting&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: Referencing needs to be improved here&lt;br /&gt;
#* History: content is good but too wordy. I think a summary or a simple timeline would be good&lt;br /&gt;
#* Epidemiology: Where's the reference for 3/10000 live births?&lt;br /&gt;
#* Signs: ok section, but could do with more images here&lt;br /&gt;
#* Genetics: If using abbreviations, such as TBX1 gene, you should explain what it is, ie. TBX1 gene (T-box 1). Also need to work on referencing here as well. How about organising all the content in a table? have in columns: gene, gene profile, frequency, etc.&lt;br /&gt;
#* Pathogenesis: I'm not quite sure about this, but do you need permission to adapt an image from an article? (I'm referring to the '4 defects' image)&lt;br /&gt;
#* Diagnosis: I'm sorry, but this section is a bit bland, though the content is very informative. I think some images here would be good&lt;br /&gt;
#* Treatment: Referencing! Also, personally, that green is too bright, maybe find a more neutral, soothing colour?&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Need to find more images, I feel some of the information could be more effectively presented in table formate rather than lengthy text&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* VERY poor referencing, which makes me question the reliability of the content in some sections&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
#* needs a lot more images&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* research done is evident, just need to reference&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* glossary is very lacking in terminology&lt;br /&gt;
* need more images&lt;br /&gt;
* REFERENCING!&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 23:26, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Group 8&lt;br /&gt;
Hey, well done, your page is looking really polished! Lots of very interesting information here and presented in a very easy to follow manner&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* History: I feel that you could lessen the info of Nicholas and add more current findings of the disease.&lt;br /&gt;
#* Aetiology: What is the chromosome 9 image based on? Need to work on referencing. Very good subheadings and well balanced with images&lt;br /&gt;
#* Pathogenesis: Needs more information&lt;br /&gt;
#* Neuro: What's the images based on? Good subheadings and explained well. I liked the way you gave explanations for normal function/appearance and then went on to explain abnormality associated with the structures in this disease. But you need to improve your referencing for this section&lt;br /&gt;
#* Diagnosis: Very good table and images. But need to fix the postnal diagnosis table so that it spans the length of the screen&lt;br /&gt;
#* Symptoms: table and images look too crowded&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* good subheadings, images, impressive self drawn images! Nice balanced page layout&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* needs to work on referencing&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* research done is evident, just need to reference&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* referencing&lt;br /&gt;
* better arrangement of table and images so page doesn't look too crowded&lt;br /&gt;
&lt;br /&gt;
Well done guys, nice team work!&lt;br /&gt;
--[[User:Z3291643|z3291643]] 23:50, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 9&lt;br /&gt;
&lt;br /&gt;
Hey, your page has a lot of very interesting content and some unique self drawn images. I thoroughly enjoyed this page, thanks&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: Inclusion of incidence would be nice&lt;br /&gt;
#* History: very informative and a nice simple timeline&lt;br /&gt;
#* Genetics: Good, succinct section, especially liked the table&lt;br /&gt;
#* Diagnosis: needs referencing. Is diagnosis only postnatal? What is the average age of diagnosis for this disease?&lt;br /&gt;
#* Management and Treatment: Seems a little out of place under epidemiology, I think it should be place later on &lt;br /&gt;
#* Phenotype:Reference?&lt;br /&gt;
#* Cardiac conditions: maybe give explanations for atrial and ventricular septal defect, just brief descriptions would suffice. Why is it so that males are more likely to suffer CVD than females?&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* good subheadings, interesting self drawn images. However, this page needs to find a balance in text and images&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* needs to work on referencing&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* research done is evident, just need to reference&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#* very interesting content, informative&lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* referencing&lt;br /&gt;
* more images&lt;br /&gt;
* glossary; lacking a lor of terms&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 00:10, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 10&lt;br /&gt;
&lt;br /&gt;
Hey, this is a interesting disease, with some good images to show the disease clearly. &lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: succinct introduction&lt;br /&gt;
#* History: Has interesting content, though timeline would be nice&lt;br /&gt;
#* Pathogenesis: Too brief and could be improved with an image&lt;br /&gt;
#* Signs: surely there are more symptoms here, maybe you could have subheadings to break down the symtpoms, ie. motor impairment, cognitive impairments, etc&lt;br /&gt;
#* Clinical manifestations and complications: nice section with good image used&lt;br /&gt;
#* Diagnosis: could be further explained, and an image would be nice&lt;br /&gt;
#* Treatment: Current and Future Prospects: needs referencing&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* need to balance out the text with images, could organise page better with more subheadings, more images needed &lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* needs to work on referencing!!&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
#*  more table could be used instead of lengthy explanations&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* much more research needs to be done to further explain the sections&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* referencing&lt;br /&gt;
* more images&lt;br /&gt;
* glossary; lacking a lot of terms&lt;br /&gt;
* needs much more research, lots of repetitions in referencing&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 11:02, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 11&lt;br /&gt;
&lt;br /&gt;
Hey, this is a interesting disease, with some good images to show the disease clearly. &lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: very rushed, no reference and needs much more work, it should be a succinct summary of this whole page.&lt;br /&gt;
#* History: Has interesting content, though timeline would be better incorporated under History, not a section of its own&lt;br /&gt;
#* Diagnosis: If you're abbreviating Cleft Palate to CLP, you should have it as Cleft palate (CLP). The two given tables are pretty much the same, except for different sample number. Is it really necessary to have the two tables when they're so similar? Could do well with an image&lt;br /&gt;
#* Syndromes and Anomalies associated with cleft: Nice array of images used here. Content is good (for ones you provided), but needs work on referencing. Perhaps you could organise the content into a table for easy comparison since you have more than one anomalies&lt;br /&gt;
#* Aetiology: Needs referencing, image could have a caption to explain it. Although the content is there, it's too brief and I feel it could be organised in a more effective manner, such as using number stages.&lt;br /&gt;
#* Types of Cleft Palate/Lip:very brief, please explain the points (ie. what's the differences between them? you say there are differences in severity, how so?)&lt;br /&gt;
#* Pathophysiology: need to reformat table more effectively and work on referencing&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* need to balance out the text with images, could organise page better with more subheadings &lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* needs to work on referencing!!&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
#* NO self drawn images so far&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* much more research needs to be done. sections overall are lacking substance and doesn't explain the content very well&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* referencing&lt;br /&gt;
* more images&lt;br /&gt;
* glossary; lacking a lot of terms&lt;br /&gt;
* needs much more research&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 11:02, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 9 attendence==&lt;br /&gt;
--[[User:Z3291643|z3291643]] 13:00, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 10 attendence==&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 13:15, 6 October 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 10 Online Assessment==&lt;br /&gt;
&lt;br /&gt;
1.Besides fetal alcohol syndrome, identify another environmental teratogen that can lead to hearing loss.&lt;br /&gt;
Noise pollution is a big factor in hearing loss, as well as viral and bacterial infections such as meningitis. Hearing loss from meningitis can be a result of the direct effects of the infection on the brain or the body's reaction to the infection, most commonly with pneumococcal meningitis. 6% of all hearing defects in children can be attributed to bacterial meningitis, with around 72% of these children progressing to complete hearing loss by the age of three. &lt;br /&gt;
&lt;br /&gt;
2.Identify 3 factors that contribute to poor neonatal drainage of the middle ear. &lt;br /&gt;
The auditory tube connects the middle ear cavity to the nasopharynx, and is different in structure in neonates vs. adults.&lt;br /&gt;
:# the eustachian tube is very horizontal (10 degrees to the horizontal axis)&lt;br /&gt;
:# only opened by a single muscle called the tensor palati muscle (compared to 2 muscles in the adult tube)&lt;br /&gt;
:# it is shorter(17-18 mm) and narrower &lt;br /&gt;
&lt;br /&gt;
3.Identify 1 genetic abnormality that affects hearing development and link to the OMIM record. (Your individual abnormality should be different from all other students)&lt;br /&gt;
* Waardenburg syndrome&lt;br /&gt;
* results in hearing loss (to variable extent)&lt;br /&gt;
* inherited in an autosomal dominant manner&lt;br /&gt;
* [http://omim.org/entry/193500 Waardenburg syndrome]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Related Links'''&lt;br /&gt;
&lt;br /&gt;
'''Animal Models'''&lt;br /&gt;
&lt;br /&gt;
* [[Mouse Knockout]] - this page explains the current use of mouse models in disrupting genes to elucidate their genetic function, including the mouse gene knockouts for alpha calcium-calmodulin kinase II (alpha CaMKII)&lt;br /&gt;
* [[2009 Group Project 4]] - this page gives an extensive overview on the history of the mouse model and its various use in embryology and genetics. In addition, it also describes mouse knockout and the role they play in current research of various human diseases&lt;br /&gt;
* [[Fly Development]] - this page describes the use of drosophila flies as developmental models&lt;br /&gt;
* [[2009 Group Project 2]] - this page gives an extensive overview on the history of the fly model and its various use in embryology and genetics&lt;br /&gt;
&lt;br /&gt;
'''Diagnosis'''&lt;br /&gt;
* [[Chorionic villus sampling]] - this page explains the process of chorionic villus sampling, its disadvantages and gives a brief overview of recent findings&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 10:20, 13 October 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==''' References '''==&lt;br /&gt;
&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;/div&gt;</summary>
		<author><name>Z3291643</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_7&amp;diff=77671</id>
		<title>2011 Group Project 7</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_7&amp;diff=77671"/>
		<updated>2011-10-12T23:28:56Z</updated>

		<summary type="html">&lt;p&gt;Z3291643: /* Related Links */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;='''Angelman Syndrome'''=&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Introduction==&lt;br /&gt;
&lt;br /&gt;
[[File:Dr Harry Angelman.jpg|thumb|130px|right|Dr Harry Angelman.]]&lt;br /&gt;
Angelman syndrome (AS) is a rare [[#Glossary | '''neurogenetic''']] [[#Glossary | '''disorder''']] first described by Dr. Harry Angelman in 1965.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18754889&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Dr. Angelman was an English [[#Glossary | '''paediatrician''']] who first diagnosed the disease in 3 children with a developmental delay.&amp;lt;ref&amp;gt;http://www.ncbi.nlm.nih.gov/books/NBK22221/&amp;lt;/ref&amp;gt; AS occurs in 1 in 10000-20000 births, the exact number is still unknown.&amp;lt;ref name=&amp;quot;PMID7573182&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7573182&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;PMID8703225&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;8703225&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It is caused by maternal [[#Glossary | '''allele''']] disruptions of a single gene- UBE3A. Either [[#Glossary | '''mutations''']] or [[#Glossary | '''deletions''']] of the UBE3A gene results in AS. &lt;br /&gt;
&lt;br /&gt;
AS presents with well known [[#Glossary | '''phenotypes''']] during infancy and adulthood, such as [[#Glossary | '''microcephaly''']] and [[#Glossary | '''maxillary hypoplasia''']]. However, these features become more marked with age. Most frequent clinical features include delayed development,[[#Glossary | '''seizures''']],[[#Glossary | '''ataxia''']], impairment of speech, happy demeanor, behavioural problems such as hyperactivity, short attention span and sleeping difficulty.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21592595&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21484597&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;ASAwebsite&amp;quot;&amp;gt;http://www.angelmansyndrome.org/home.html&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
At present, there is no cure for the syndrome, though current research is focused at improving life quality of patients with Angelman syndrome through management of daily tasks.&amp;lt;ref&amp;gt;http://www.bbc.co.uk/health/physical_health/conditions/angelman1.shtml&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==History==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Dr. Harry Angelman first reported Angelman Syndrome on three handicapped children that were admitted to his ward in England in 1964.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt; He reported how these three independent and unconnected clinical cases all had the same characteristic features of severe developmental delay, jerky movements, seizures and a happy disposition.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt; However it was only when he stumbled upon an oil painting called ‘a Boy with a Puppet” while on a holiday in Italy he was able to connect the symptoms of all three children under one common cause.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20981772&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; He linked the happy face of the boy depicted on the painting with the jerky movements and happy disposition he observed on his three patients back in England. He reported his findings on a paper entitled “Puppet children (a report on three cases)” which was published in 1965.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
The syndrome was initially named ‘Puppet Syndrome’ but was later changed to Angelman Syndrome. Due to the extreme rarity of the syndrome and lack of sufficient clinical evidence the syndrome was soon forgotten.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt;&lt;br /&gt;
[[File:Dr Charles Williams.jpg|thumb|right|150px|Dr Charles Williams.]]&lt;br /&gt;
	&lt;br /&gt;
In 1987, a physician named Ellen Magenis, came across children with deletions on [[#Glossary | '''chromosome''']] 15 that were suffering from seizures and severe developmental delay.&amp;lt;ref&amp;gt;http://www.angelman.org/stay-informed/facts-about-angelman-syndrome---7th-edition/harry-angelman-and-the-history-of-as/&amp;lt;/ref&amp;gt; Even though genetically the children were expected to have [[#Diagnosis | '''Prader-Willi syndrome''']] that was characterised by deletions on chromosome 15, their characteristic symptoms of seizures and lack of development did not correspond with that of the syndrome. This led to the realization that these children had deletions on the maternally derived chromosome 15 and not on the paternally derived chromosome as was observed in Prader-Willi syndrome.  Thus the deleted genetic code on maternally derived chromosome 15 was identified as the genetic marker for Angelman Syndrome.&lt;br /&gt;
&lt;br /&gt;
In 1997, UBE3A gene was isolated by Dr. Joseph Wagstaff and Dr. Arthur Beaudet as the cause of Angelman Syndrome.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot; /&amp;gt; The discovery of this [[#Glossary | '''gene''']] led to the subsequent development of animal models and research aimed at finding a causal link between UBE3A gene abnormalities and characteristic features observed in Angelman Syndrome. &lt;br /&gt;
	&lt;br /&gt;
Currently, four different genetic abnormalities for Angelman Syndrome have been confirmed by genetic testing. They include: Deletion, [[#Glossary | '''Uniparental Disomy''']] (UPD), [[#Glossary | '''Imprinting''']] and UBE3A mutation.&amp;lt;ref name=&amp;quot;PMID20211139&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Below is a timeline, summarising the key discoveries and advancements of the Angelman Syndrome:&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|- bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
!Year&lt;br /&gt;
!Milestone&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1964'''&lt;br /&gt;
|First observed by Dr Harry Angelman on three handicapped children.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot; /&amp;gt; &lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''1965'''&lt;br /&gt;
|Harry Angelman publishes his finding in a report entitled 'Puppet Children'(a report on three cases).&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1980s'''&lt;br /&gt;
|First reports of AS reaches US and research into the disorder being at the University of Florida under the direction of Dr. Charles Williams.&amp;lt;ref&amp;gt;http://www.angelmanproject.com/history.htm&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''1982'''&lt;br /&gt;
|Name changed from 'Happy Puppet' to Angelman syndrome by Williams and Frias. &lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1987'''&lt;br /&gt;
|Discovery of a genetic marker for AS – an absent genetic code on maternally derived chromosome 15. &lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''1997'''&lt;br /&gt;
|The cause of AS discovered by Dr. Joseph Wagstaff and Dr. Arthur Beaudet – mutation or deletion in the UBE3A gene.&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1998'''&lt;br /&gt;
|Transgenic mice with absent maternal UBE3A created to illustrate motor and learning deficits in addition to seizures.&amp;lt;ref name=&amp;quot;PMID9808466&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9808466&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''2007'''&lt;br /&gt;
|AS mouse model shows that neurological deficits can be reversed by decreasing levels of [[#Glossary | '''alpha-CaMKII''']] inhibitory phosphorylation.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17259980&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''2010'''&lt;br /&gt;
|Discovery of a another gene mutation in TC4 gene (on chromosome 18) in a small number of clinically diagnosed patients with no identifiable genetic alternation in UBE3A.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20184619&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''2010'''&lt;br /&gt;
|Protein named Arc identified as a target of AS gene product; UBE3A.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Incidence'''&lt;br /&gt;
*The current population of people diagnosed with AS is unknown but studies have estimated the number to be around 1:10,000&amp;lt;ref name=&amp;quot;PMID7573182&amp;quot; /&amp;gt; and 1:20,000&amp;lt;ref name=&amp;quot;PMID8703225&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
'''Diagnosis'''&lt;br /&gt;
*The mean age of diagnosis for patients with AS lies between 6 and 6.5 years of age.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18664077&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15741136&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Gender'''&lt;br /&gt;
* Males appear to be at higher risk for some aspects of early developmental delays in comparison to females with AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17019625&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Demography'''&lt;br /&gt;
*Europe:&lt;br /&gt;
:Denmark- 1:10,000&amp;lt;ref name=&amp;quot;PMID7573182&amp;quot; /&amp;gt;&lt;br /&gt;
:Estonia- 1:52,000&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16906556&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
:Sweden- 1:20,000&amp;lt;ref name=&amp;quot;PMID8703225&amp;quot; /&amp;gt;&lt;br /&gt;
*Australia:&lt;br /&gt;
:Western Australia- 1:40,000&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16492624&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Aetiology==&lt;br /&gt;
&lt;br /&gt;
[[File:Chromosome 15 Deletion of 15q11.2 to 15q13.jpg|thumb|100px|Chromosome 15 - The deletion occurs at 15q11.2-15q13.]]&lt;br /&gt;
&lt;br /&gt;
'''Molecular Genetics'''&lt;br /&gt;
&lt;br /&gt;
* Location: 15q11-q13&lt;br /&gt;
* Protein product: Ubiquitin protein ligase E3A&lt;br /&gt;
* Gene name: UBE3A&lt;br /&gt;
* Phenotype: Angelman Syndrome&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Genetic Causes'''&lt;br /&gt;
&lt;br /&gt;
Different genetic mechanisms lead to different clinical phenotypes of AS. The most common genetic mechanism leading to AS is the deletion or re-arrangement of maternal chromosome at [[#Glossary | '''locus''']] 15q11.2-q13,as the chromosome image shows on the right, accounting for 70% of AS occurrences.&amp;lt;ref name=&amp;quot;PMID8988171&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt; 8988171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This leads to more severe clinical phenotypes of microcephaly, motor difficulties, seizures and impaired speech development. The next most common genetic mechanism is mutation in the UBE3A gene responsible for 10% of AS cases and paternal uniparental disomy and mutation in the imprinting centre (IC), both accounting for 2-5% of AS observed.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
 &lt;br /&gt;
&lt;br /&gt;
AS is caused by the 4 major genetic mechanisms mentioned above and are thus divided into Classes I to IV based on their underlying genetic mechanism. AS patients with the clinical features of AS but no [[#Glossary | '''cytogenetic''']] or molecular abnormality in Chromosome 15q11.2-13 are grouped under Class V (summarised in table below).&amp;lt;ref name=&amp;quot;PMID8988171&amp;quot; /&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10364509&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{|  style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
! Class&lt;br /&gt;
! Mechanism&lt;br /&gt;
! Diagnostic Tests&lt;br /&gt;
! Frequency&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''Ia'''                           &lt;br /&gt;
| De novo deletion                                                                                           &lt;br /&gt;
| High resolution cytogenetics [[#Glossary | '''FISH''']]                                                                                                       &lt;br /&gt;
| 70%      &lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Ib'''&lt;br /&gt;
| Deletion due to chromosome rearrangement&lt;br /&gt;
| High resolution cytogenetics FISH&lt;br /&gt;
| &amp;lt;1%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''II'''&lt;br /&gt;
| Paternal uniparental disomy&lt;br /&gt;
| [[#Glossary | '''RFLP''']]  analysis&lt;br /&gt;
| 2%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''IIIa'''&lt;br /&gt;
| Imprinting defect with IC mutation&lt;br /&gt;
| Screening of [[#Glossary | '''IC''']]  for mutations is positive&lt;br /&gt;
| 2%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''IIIb'''&lt;br /&gt;
| Imprinting defect withouth IC mutation&lt;br /&gt;
| Screening of IC for mutations is negative&lt;br /&gt;
| 2%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''IIIc'''&lt;br /&gt;
| Mosaic imprinting defect&lt;br /&gt;
| Screening of IC for mutations is usually negative &lt;br /&gt;
| ?&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''IV'''&lt;br /&gt;
| ''UBE3A'' mutation&lt;br /&gt;
| Screening of ''UBE3A'' for mutations&lt;br /&gt;
| 5-10%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''V'''&lt;br /&gt;
| No identifiable genetic abnormality&lt;br /&gt;
| Consider other diagnoses&lt;br /&gt;
| 5-26%&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
[[File:Imprint defect inheritance in Angelman Syndrome.png|thumb|250px|Imprint defect inheritance in Angelman Syndrome]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Inheritance'''&lt;br /&gt;
&lt;br /&gt;
Angelman Syndrome from UBE3A mutations and deletions in the Imprinting Centre follow an inheritance pattern. A carrier father with the genetic defect can pass it on to his children, however, his children will be clinically normal. On the other hand, a carrier mother can pass the genetic defect onto her children, who will then have Angelman Syndrome. &lt;br /&gt;
&lt;br /&gt;
The image highlights the inheritance of Angelman Syndrome, which only results after a carrier mother passes it on to her children.&lt;br /&gt;
&lt;br /&gt;
==Pathogenesis==&lt;br /&gt;
&lt;br /&gt;
Chromosome 15 became associated with AS in the 1980s after the observation of many AS patients harboring [[#Glossary | '''microdeletions''']] of 15q11.2-15q13.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15668046&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The last decade has shed even more light in the aetiology of AS,as Kishino and Matsuura first identified UBE3A as the causative gene for AS in 1997.&amp;lt;ref name=&amp;quot;PMID:8988171&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;8988171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8988172&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Normal gene product: E6-AP ubiquitin ligase'''&lt;br /&gt;
&lt;br /&gt;
The function of UBE3A is to encode for [[#Glossary | '''E6-AP''']] ubiquitin ligase, however its function in the development of the nervous system and the process of UBE3A mutation leading to cognitive impairment in AS patients is still vague.&amp;lt;ref name=&amp;quot;PMID:20211139&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Past and current research has elucidated that E6-AP ubiquitin ligase is involved in the degradation of four proteins, listed below, but currently, no protein with a direct role in [[#Glossary | '''long-term potentiation (LTP)''']] as a target of E6-AP, has been identified.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12684449&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The identification of such target proteins would be a landmark discovery in further understanding of the pathogenesis, aetiology and prospective treatment strategies of AS, as LTP defects is one of the major neurological impairments of AS. &lt;br /&gt;
 &lt;br /&gt;
* p53 tumor suppressor protein &lt;br /&gt;
* yeast DNA repair protein Rad23 &lt;br /&gt;
* multicopy maintenance protein 7 subunit &lt;br /&gt;
* E6-AP&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Abnormal gene product'''&lt;br /&gt;
&lt;br /&gt;
Disruption to the gene,UBE3A, interferes with the normal functioning of the gene, which is its crucial role in UBE3A [[#Glossary | '''ubiquitylation''']]. Problems involving this pathway can lead to various diseases either from the loss or gain of function.&amp;lt;ref name=&amp;quot;PMID:9857172&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9857172&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In the case of AS, E6-AP is affected, leading to detrimental cognitive impairment in addition to other deficits.&amp;lt;ref name=&amp;quot;PMID:9857172&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9857172&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Regional functioning of UBE3A'''&lt;br /&gt;
&lt;br /&gt;
Despite the uncertain progression of UBE3A mutation and the neurological abnormalities characteristic of AS, animal models have illustrated the vital role of UBE3A in the normal functioning of the brain. This can be exemplified by a study which utilized a mouse model with target inactivation of the gene UBE3A resulting in the manifestation of classical features of AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11895368&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In addition, the fact that imprinting of UBE3A takes place only in specific brain regions (cerebellum, olfactory tracts and the hippocampus) confirms the hypothesis that the loss of this gene would be detrimental in the cognitive development.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20398390&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Most genes are inherited in copies of two, one paternal and the other maternal; however, some genes, such as UBE3A only have one functional copy as the other is silenced, coined 'imprinting'. Imprinting of the paternal copy of UBE3A takes place in some cell populations, such as the hippocampal neurons and Purkinje cells in the cerebellum.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9288101&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This means only the maternal UBE3A is functionally expressed in these particular brain regions. Thus a [[#Glossary | '''de novo mutation''']] in the maternal copy of the gene will result in the complete absence of functional E6-AP in the associated brain areas.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9288088&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
It is also known that UBE3A plays an important role in synaptic transmission, but exactly how it does so is still not completely understood.&amp;lt;ref name=&amp;quot;PMID:9808466&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9808466&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''UBE3A ubiquitylation'''&lt;br /&gt;
&lt;br /&gt;
As briefly mentioned above, UBE3A is a member of the E3 ubiquitin ligase family of enzymes, responsible for the addition of ubiquitin to the target protein for degradation of the ubiquitinated protein, as illustrated in the diagram below. These processes are required for normal human cognitive function.&amp;lt;ref name=&amp;quot;PMID:9808466&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9808466&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In this way synaptic protein [[#Glossary | '''Arc (activity-regulated cytoskeleton-associated protein)''']] is degraded to control synaptic function. Arc is a target protein of UBE3A in dendritic spines found in the hippocampal neurons.&amp;lt;ref name=&amp;quot;PMID:20668179&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20668179&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Deletion of UBE3A leads to the accumulation of Arc in neurons leading to trafficking of [[#Glossary | '''AMPA ( α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid)''']] receptors, resulting in impaired cognitive functions.&amp;lt;ref name=&amp;quot;PMID:20211139&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; [[File:UBE3A Ubiquitylation Pathway.png|thumb|350px|right|UBE3A Ubiquitylation Pathway.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
UBE3A ubiquitylation consists of:&amp;lt;ref name=&amp;quot;PMID:20668179&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20668179&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
# Activation of ubiquitin by E1 enzyme&lt;br /&gt;
# E1 ezyme transfers ubiquitin to E2 enzyme&lt;br /&gt;
# E2 enzyme transfers ubiquitin to UBE3A&lt;br /&gt;
# UBE3A attaches activated ubiquitin to target protein which is then polyubiquitylated &lt;br /&gt;
# Target protein is then degraded by 26S proteosome&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Phenotype-Genotype correlations'''&lt;br /&gt;
&lt;br /&gt;
[[File:Extent of microcephaly in Angelman Syndrome patients.png|thumb|250px|right|Extent of microcephaly in 20 AS patients with deletion and without deletion.&amp;lt;ref&amp;gt;http://www.nature.com/ejhg/index.html/&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
All AS patients show differing extents of cognitive impairment, movement disorder, characteristic behaviours and difficulty in speech and language.&amp;lt;ref name=&amp;quot;PMID:11748306&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11748306&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; However, there seems to be some phenotype-genotype correlations:&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
- 5-7Mb deletions result in the most severe phenotypes such as microcephaly, more sever [[#Glossary | '''epilepsy''']] and seizures, motor difficulties and language impairment.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9546330&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20445456&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; AS patients with large deletions also present with clinical [[#Glossary | '''hypopigmentation''']], light hair and eye colour due to the close association of OCA2 gene with UBE3A.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;16470747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Individuals under this category have in general no increased BMI&amp;lt;ref name=&amp;quot;PMID:15253756&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15253756&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This is indicated by the graph on the left, which shows more cases of AS patients with deletions having larger deviations from the mean head circumference measurement than non-deletion AS patients.&lt;br /&gt;
 &lt;br /&gt;
- AS patients with uniparental disomy (UPD) have better physical growth, fewer motor deficits and lower seizure occurrences.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16023557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
- Individuals with AS resulting from imprinting defects have the least debilitating features, such as higher developmental and language ability than AS caused by other mechanisms.&amp;lt;ref name=&amp;quot;PMID:11748306&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11748306&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
- The Body Mass Index (BMI) of 33% of the UBE3A mutation patients, and 47–64% of the patients from the classes II (UPD) and III (Imprinting defect) is above the 95th centile.&amp;lt;ref name=&amp;quot;PMID:15253756&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15253756&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Animal models'''&lt;br /&gt;
&lt;br /&gt;
* '''Drosophila'''&lt;br /&gt;
&lt;br /&gt;
Drosophila (common fruit fly) is an excellent model to use for better understanding of genetic diseases in humans as they are highly homologous to human UBE3A (hUBE3A), illustrating a high evolutionary conservation. Studies using the Drosophila model have shown that the functional absence of UBE3A resulted in decreased morphogenesis of dendritic branches. This is of interest as dendritic branches cover over 90% of the neuronal surface where [[#Glossary | '''synapse''']] between neurons occur. Proper formation and maturation of dendritic spines is also required so they come in contact with other neurons for effective transmission of neuronal signals. Thus proper formation of dendritic branching is pivitol for effective neuronal function and hence cognitive function.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18996915&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Interestingly, overexpression of dUBE3A also gave the same result, consisting of abnormal locomotion  and decreased dendritic branching in sensory neurons.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18701717&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;  This suggests a possible research field for some forms of [[#Glossary | '''autism''']] where the region containing UBE3A is duplicated, leading to delayed motor skills and seizures.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16433693&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;[[File:Normal and Angelman Syndrome mice models.jpg|thumb|250px|right|Normal and AS mice performance on the Rotarod apparatus.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
* '''Mice'''&lt;br /&gt;
&lt;br /&gt;
Absence of UBE3A in mice manifest similar phenotype to human AS, as illustrated by motor and learning deficits with inducible seizures.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21235769&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It has been shown through various mice model studies that larger deletions, ie. from UBE3A to GABRB3, more closely mirrors the large 6Mb deletions seen in human AS patients. Numerous tests, such as the Rotarod (for motor coordination and learning ability), Morris water maze test (for spatial learning and memory) and [[#Glossary | '''EEG''']] (electroencephalography), were carried out on  UBE3A null mutants, which showed the results to be abnormal or impaired.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20808828&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Other studies using mouse models have also outlined the obesity observed in 15% of AS children, albeit it is not the major characterisitics of AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17259980&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The diagram on the right clearly highlights the results obtained from such mouse model studies of AS, where the absence of UBE3A accumulated in deficits of motor function and obesity. In addition, excessive drooling and feeding difficulties were also highlighted by mice models with inactivated UBE3A, reflected by defects in fluid consumption and licking.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18413322&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Pathophysiology===&lt;br /&gt;
&lt;br /&gt;
'''Cognitive defects'''&lt;br /&gt;
&lt;br /&gt;
[[File:Role of UBE3A in dendritic spine neuronal synapses.png|thumb|250px|right|Role of UBE3A in dendritic spine neuronal synapses.]]&lt;br /&gt;
&lt;br /&gt;
AS patients present with abnormally high UBE3A, leading to neurological impairment. Recent identification of key target proteins of Ephexin-58 (Eph-5) and Arc (Activity-Regulated Cytoskeleton-associated protein) have aided in better understanding of the progression of UBE3A to cognitive defects. These two proteins are vital in the understanding of AS as Eph-5 determines synapse numbers and Arc contributes to plasticity and synapse function.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21164477&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Studies utilizing mice models have illustrated that UBE3A null mice could not ubiquitinate Eph-5, thus increasing its levels and limiting the growth of dendritic spines by the activation of RhoA. This subsequent activation of RhoA inhibits synapse formation and results in neuronal defects.&lt;br /&gt;
&lt;br /&gt;
In contrast, mice with normally functioning UBE3A showed phosphorylated Eph-5, resulting from the interaction of two neurons via the activation of EphB signalling receptor.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21029865&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Phosphorylation of Eph-5 allows UBE3A to ubiquitinate and degrade it. This degradation of Eph-5 permits new synaptic connections to form with cells they come into contact with. However, in AS, the absence of UBE3A means Eph-5 cannot be degraded, so RhoA activity is prolonged to reduce synaptic formation.&lt;br /&gt;
&lt;br /&gt;
As mentioned previously, Arc plays a pivitol role in synapse function as it removes synaptic receptors that respond to glutamate, a [[#Glossary | '''neurotransmitter''']].&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17088211&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In UBE3A present neurons, UBE3A ubiquitinates Arc, leading to it degradation as illustrated by the diagram on the left. However, in UBE3A deficient neurons, Arc accumulates and prevents the proper synaptic communications essential for normal cognitive functions.&amp;lt;ref name=&amp;quot;PMID20211139&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Signs and Symptoms==&lt;br /&gt;
&lt;br /&gt;
Angelman Syndrome presents a variety of different phenotypes, and the presented symptoms may vary at different ages.&amp;lt;ref name=&amp;quot;PMID7625442&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7625442&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
In 1995 Williams et al. embraced the observed clinical features of AS in a consensus statement, in order to present an appliance for clinicians. The diagnostic criteria were updated in 2005.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt; The following table shows the most frequently occurring characteristics in AS patients:&lt;br /&gt;
&lt;br /&gt;
'''4 characteristics appear in 100% of the cases:'''&lt;br /&gt;
&lt;br /&gt;
*Delayed development: become apparent by the age of 6 to 12 months.&lt;br /&gt;
*Motion and or balance malfunction&lt;br /&gt;
*Behaviour patterns like unmotivated laughter, frequent excitement; often including body movements,[[File:Electroencephalography of Angelman Syndrome.jpg|thumb|350px|right|EEG of AS and normal individuals.]] [[#Glossary | '''hypermotoric''']] behaviour&lt;br /&gt;
*Impairment of speech&lt;br /&gt;
&lt;br /&gt;
'''3 characteristics appear in more than 80% of the cases:'''&lt;br /&gt;
&lt;br /&gt;
*Abnormalities in head circumference, microcephaly&lt;br /&gt;
*Seizures&lt;br /&gt;
*EEG shows specific abnormal patterns&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Angelman Syndrome individuals show the most distinct disease pattern from 2 to 16 years of age.&lt;br /&gt;
In most cases at least 8 of the symptom traits are shown.&amp;lt;ref name=&amp;quot;PMID7625442&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Behavioural Characteristics'''&lt;br /&gt;
&lt;br /&gt;
A range of substantial characteristics appear in all AS cases, regardless of the genetic mechanisms, and are often responsible for diagnosing the syndrome. According to the original name, Happy Puppet syndrome, they have shown to exhibit traits such as a happy demeanor, with frequent laughter or smiling that can easily be triggered.&amp;lt;ref name=&amp;quot;PMID12566516&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12566516&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This behaviour can already be observed in 1 to 3 month old infants.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot; /&amp;gt; Uplifted hand flapping or waving motions are associated with laughter and excitement. Other characteristics manifesting in early childhood are sleep abnormalities with reduced sleep demand, and feeding problems. Breast and bottle feeding can be difficult due to non efficient attachment to the breast, tongue thrusting and uncoordinated sucking. Furthermore, there is an affection to crinkly and reflective surfaces, like some papers or plastic materials, especially water.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID12566516 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Communication Skills'''&lt;br /&gt;
&lt;br /&gt;
Communication is challenging for AS patients due to the fact that speech impairment is present in all cases. In the majority of affected people a lack of speech development is present. Only some of them have a minimal vocabulary consisting of two or three words, a few can speak in basic sentences. Some patients use gestures to articulate themselves, the [[#Glossary | '''Picture Exchange Communication System (PECS)''']] or sign languages such as [[#Glossary | '''Makaton''']] can be used for communication. Simple demands regarding their everyday occurrence can be understood by most patients.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID12566516 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Clinical and External Characteristics'''[[File:Angelman Syndrome patient.png|thumb|200px|right|4 year old AS patient.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Developmental delays are present in all patients. Motor milestones are delayed with children managing to sit unsupported with 12 months and crawl or bottom shuffle at the age of 18-24 months. The average age for walking is 4 years,however, ranging from 18 months to 7 years.&lt;br /&gt;
The [[#Glossary | '''gait''']] is characterised as slow, and flapping hands are a common trait.  The legs remain stiff during walking, arms are inflected by the wrists and elbows. The movements can appear ataxic, jerky or lurching. The muscle tone shows abnormalities with truncal [[#Glossary | '''hypotonia''']] and [[#Glossary | '''hypertonicity''']] of the limbs and alert reflexes.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID12566516 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The most striking external traits present in patients include broad-spaced teeth, and a wide mouth, light hair and eye colour, hypopigmented skin, deep set eyes, and a flat [[#Glossary | '''occiput''']].&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Seizures in Angelman Syndrome'''&lt;br /&gt;
&lt;br /&gt;
85% of AS patients suffer from epileptic seizures during their first three years. The first appearance can be within one month up to 20 year old patients. In infants with AS epilepsy manifests with [[#Glossary | '''febrile convulsions''']] and is hard to manage during childhood.&lt;br /&gt;
The most common type of seizures within 25% of patients are [[#Glossary | '''myoclonic seizures''']], followed by [[#Glossary | '''atonic seizures''']] as the second most frequent type, then 21% experience generalised [[#Glossary | '''tonic-clonic seizures''']] and lastly [[#Glossary | '''atypical absences''']] occur in 12% of patients.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20398390&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Angelman Syndrome in adults'''&lt;br /&gt;
&lt;br /&gt;
Patients with Angelman syndrome possess normal secondary sexual characteristics, and puberty sets in at a usual time. Limb hypertonicity, and [[#Glossary | '''thoracic scoliosis''']] lead to decreasing mobility. [[#Glossary | '''Oesophagus reflux''']] might induce severe problems, and the majority suffers from obesity. Furthermore, facial traits such as a prominent lower lip [[#Glossary | '''macrostomia''']] and [[#Glossary | '''mandibular prognathism''']] get manifested in adults. &lt;br /&gt;
In some cases the communication barrier can lead to frustration, resulting in aggressive behaviour. Nonetheless, patients gain a higher concentration span with age, and their nature becomes more quiet.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Complications===&lt;br /&gt;
&lt;br /&gt;
'''Hypopigmentation and Ocular albinism'''&lt;br /&gt;
&lt;br /&gt;
OCA2 gene, also known as the P gene, is closely located to the UBE3A gene. It encodes a protein vital to tyrosine metabolism, which plays a role in pigmentation development of skin, hair and eyes. However, AS caused by the large deletion of UBE3A leads to haploinsufficiency of OCA2 gene, resulting in hypopigmentation of the skin and the eyes. In some children with severe hypopigmentation, some form of [[#Glossary | '''albinism''']] is suspected.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12749060&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; When AS is caused by another mechanism, no abnormality of the skin and eye pigmentation is observed. However, not all AS children with OCA2 gene deletion will present with obvious hypopigmentation, they may just exhibit lighter skin colour than their parents.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8302318&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Diagnosis==&lt;br /&gt;
&lt;br /&gt;
The diagnosis of Angelman Syndrome is a clinical diagnosis confirmed by laboratory testing.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This involves both prenatal and/or postnatal diagnosis. &lt;br /&gt;
&lt;br /&gt;
===Prenatal Diagnosis===&lt;br /&gt;
[[File:Angelman Syndrome Prenatal Diagnosis.jpg|thumb|250px|right|Flowchart of AS Diagnosis.]]&lt;br /&gt;
&lt;br /&gt;
Prenatal detection of deletions of 15q11.2-q13, [[#Glossary | '''Paternal UPD''']] ([[#Glossary | '''Uniparental Disomy''']]), Imprinting defects and UBE3A mutations are done through DNA/chromosome/FISH analysis of fetal cells obtained by either [[#Glossary | '''Chorionic Villus Sampling''']](CVS) or [[#Glossary | '''Amniocentesis''']].&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot;/&amp;gt; &lt;br /&gt;
DNA methylation analysis using [[#Glossary | '''Amniocytes''']] is usually the first test carried out in molecular diagnosis of AS.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18059071&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; An abnormal result is followed up by either a FISH or array CGH analysis to search for a deletion on chromosome 15. If they produce a normal result, then UPD testing using DNA polymorphysims is carried out. If there is no evidence of UPD, other DNA analysis tests are used search for an imprinting centre deletion.&amp;lt;ref name=&amp;quot;PMID9792887&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9792887&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; A normal DNA methylation analysis is followed by a UBE3A sequence analysis.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt; In addition, a parent of origin test is also done to determine if the genetic disruption is of maternal origin or paternal origin. If it is maternally derived the fetus is diagnosed with AS (a paternally derived genetic disruption is indicative of Prader-Willi Syndrome).&amp;lt;ref name=&amp;quot;PMID17020468&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;17020468&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The flow chart summarizes the normal procedure used for prenatal diagnosis of AS. More information on important laboratory tests used for the diagnosis of Angelman Syndrome are provided below:&lt;br /&gt;
&lt;br /&gt;
*'''DNA Methylation Analysis'''&lt;br /&gt;
&lt;br /&gt;
Identifies approximately 80% of AS affected individuals and is usually the first test to be ordered.&amp;lt;ref name=&amp;quot;PMID7618904&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7618904&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Molecular disruptions such as deletions, paternal UPD and imprinting defects on chromosome 15 all demonstrate abnormal methylation patterns by either southern blot analysis or PCR amplification of bisulphate-treated DNA.&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot; /&amp;gt; An affected individual will only have an unmethylated (paternal) SNRPN (small nuclear ribonuclear protein-associated polypeptide N) allele compared with an unaffected individual who will have both a methylated and an unmethylated SNRPN allele.&amp;lt;ref name=&amp;quot;PMID9634532&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9634532&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
	  &lt;br /&gt;
*'''FISH (Fluorescent In Situ Hybridization)'''&lt;br /&gt;
&lt;br /&gt;
[[File:Critical_region_of_Angelman_Syndrome_on_chromosome_15.png‎|thumb|150px|right|FISH (fluorescence in situ hybridisation) image showing the critical region of Angelman Syndrome on chromosome 15.]]&lt;br /&gt;
&lt;br /&gt;
FISH analysis detects 5-7 Mb deletions in approximately 68% of affected individuals using detecting probes such as D15S10 and/or SNRPN.&amp;lt;ref name=&amp;quot;PMID7618904&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7618904&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It is also able to distinguish UPD from micro-deletions and imprinting defects. In simple terms, FISH analysis involves the binding of a fluorescent probe to a specific part of chromosome 15 and the detection of deletions within that region. FISH analysis is much more accurate in deletion detection compared to other high-resolution cytogenetics in the diagnosis of AS patients.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1511093&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
Array-based CGH is an advanced type of cytogenetic testing that can also be used to detect smaller deletions.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''UPD (Uniparental Disomy) Detection'''&lt;br /&gt;
&lt;br /&gt;
DNA Polymorphism testing detects paternal UPD in approximately 7% of affected AS individuals.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt; It is also able to distinguish between UPD and an Imprinting defect. It requires a DNA sample from the [[#Glossary | '''Proband''']] and from both parents. A homologous or non-homologous whole-arm translocation of the long arms of chromosome 15 is a sound indication for the need for prenatal UPD testing.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''IC (Imprinting Center) Analysis'''&lt;br /&gt;
&lt;br /&gt;
This type of analysis is used when individuals have an abnormal DNA methylation pattern but show normal results for  FISH, array CGH study and UPD analysis.&amp;lt;ref name=&amp;quot;PMID9792887&amp;quot;/&amp;gt; It is used to differentiate between the Imprinting defects caused by either microdeletions in the AS imprinting centre or by epigenetic mutations (that occur in maternal oogenesis or early embryogenesis).&amp;lt;ref name=&amp;quot;PMID9634532&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''Cytogenetic Testing'''&lt;br /&gt;
&lt;br /&gt;
Is used to detect a cytogenetically visible chromosomal rearrangement (large deletion, translocation or inversion) involving the 15q11.2-q13 region, which occurs in less than 1% of affected individuals.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''UBE3A Sequence Analysis'''&lt;br /&gt;
Sequence analysis of the UBE3A gene detects mutations in about 10% of the patients.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt; The test is used to detect either multiexonic (10 major coding exons of UBE3A) or whole gene deletions of UBE3A gene in individuals who produces a normal DNA methylation result but has characteristic clinical features of AS.&amp;lt;ref name=&amp;quot;PMID9792887&amp;quot;/&amp;gt;&lt;br /&gt;
This is recommended as a prenatal diagnostic tool in families that include multiple AS affected individuals because the imprinted pattern can be inherited from distant relatives.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Postnatal Diagnosis===&lt;br /&gt;
&lt;br /&gt;
Postnatal diagnosis is made though a combination of common clinical features of AS and UBESA gene sequence analysis.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt; The clinical features of AS include unsteady or shaky movements, muscle hypotonia, developmental delay and behavioral uniqueness such as frequent laughter/smiling and happy demeanor are features that are 100% consistent in all patients diagnosed with Angelman Syndrome.&amp;lt;ref name=&amp;quot;PMID18830393&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18830393&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; These clinical features become apparent between 6 months to 2 years of age. The onset of early or persistent smiling characteristic of this syndrome begin around the age of 1-3 months, but is often overlooked during infancy.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot;/&amp;gt; Thus early diagnosis of AS during infancy period is difficult because the clinical indicators of the syndrome takes time to manifest and characteristic features such as finger and hand tremors and excessive smiling/laughter are often overlooked and not considered as possible indicators of this syndrome.&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
*Rett Syndrome&lt;br /&gt;
&lt;br /&gt;
Some children with the clinical diagnosis of AS but no underlying genetic mechanism show mutations in ''MECP2'' gene, corresponding to Rett Syndrome. This should be suspected in AS test negative girls in the first few years of life.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17980307&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*Mowat-Wilson Syndrome&lt;br /&gt;
&lt;br /&gt;
Genetic mechanism is heterozygous deletion or truncation in ''ZFHX1B'' (''SIP1'') gene on 2q22. This presents with clinical features of severe intellectual disability, micrcephaly and seizures.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17958891&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Prader-Willi Syndrome patient.png|thumb|right|120px|12 year old PWS patient.]]&lt;br /&gt;
&lt;br /&gt;
*X-linked alpha-thalassemia/mental retardation syndrome (ATR-X)&lt;br /&gt;
&lt;br /&gt;
This arises from mutations in ''XNP'' gene on Xq13. ATR-X presents with severe intellectual disability, no speech development and seizures are common.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11449489&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*Phelan-McDermid Syndrome/22q13 deletion syndrome&lt;br /&gt;
&lt;br /&gt;
Deletions are usually submicroscopic and thus requires special molecular cytogenetic methods to confirm this deletion. Patients show moderate to profound intellectual disability and delay in speech development.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18505557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Related Disease'''&lt;br /&gt;
&lt;br /&gt;
*Prader-Willi Syndrome(PWS)&lt;br /&gt;
&lt;br /&gt;
PWS is a result from the absence of paternally expressed 15q11-q13 gene as a corollary of de novo deletion, maternal uniparental disomy of chromosome 15 or an imprinting defect on paternal chromosome 15 leading to the silencing of paternal alleles.&amp;lt;ref name=&amp;quot;PMID:20668179 &amp;quot;/&amp;gt; It is characterized by [[#Glossary | '''hyperphagia''']], obesity in later infancy and early childhood and difficulty in feeding during early infancy.&amp;lt;ref name=&amp;quot;PMID:20668179 &amp;quot;/&amp;gt; There is also cognitive impairment to some extent, though some PWS patients may exhibit intelligence in the normal IQ range. Behavioral phenotypes include stubbornness, manipulative tendency, obsessive compulsive characteristics.&amp;lt;ref name=&amp;quot;PMID:20668179 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Genetic Counselling==&lt;br /&gt;
&lt;br /&gt;
Genetic counselling is the process by which patients or relatives, at risk of an inherited disorder, are advised of the consequences and nature of the disorder, the probability of developing or transmitting it, and the options open to them in management and family planning. In the case for Angelman syndrome, types of risks associated are split into classes and formatted into the table below:&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20459762&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{|  style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
! Class&lt;br /&gt;
! Mechanism&lt;br /&gt;
! Risk to siblings&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! Ia                           &lt;br /&gt;
| De novo deletion                                                                                                               &lt;br /&gt;
| &amp;lt;1%                                                                                                                &lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! Ib&lt;br /&gt;
| Deletion due to chromosome rearrangement&lt;br /&gt;
| Up to 50%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! II&lt;br /&gt;
| Paternal uniparental disomy (UPD)&lt;br /&gt;
| &amp;lt;1%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! IIIa&lt;br /&gt;
| Imprinting defect with IC mutation&lt;br /&gt;
| Close to 100% if father has 15; 15 [[#Glossary | '''Robertsonian translocation''']]&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! IIIb&lt;br /&gt;
| Imprinting defect without IC mutation&lt;br /&gt;
| Up to 50% (if mother has IC deletion)&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! IIIc&lt;br /&gt;
| [[#Glossary | '''Mosaic''']] imprinting defect&lt;br /&gt;
| &amp;lt;1%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! IV&lt;br /&gt;
| ''UBE3A'' mutation&lt;br /&gt;
| Up to 50% (if mother has mutation)&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! V&lt;br /&gt;
| No identifiable genetic abnormality&lt;br /&gt;
| ?&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Ia''': Individuals with de novo deletion have 1% risk to siblings&lt;br /&gt;
&lt;br /&gt;
'''Ib''': Risk to siblings in individuals with chromosomal rearrangements is up to 50% &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9557895&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''II''': Paternal UPD with no Robertsonian translocation has a risk to sibling of less than 1%&lt;br /&gt;
&lt;br /&gt;
'''IIIa''': The risk to siblings in individuals with AS from an imprinting defect with a mutation in the imprinting center (IC) is close to 100% if father has 15;15 Robertsonian translocation&lt;br /&gt;
&lt;br /&gt;
'''IIIb''': Individuals with AS resulting from an imprinting defect without IC mutation, but with a carrier mother has a high risk to siblings of up to 50%. The mother could be phenotypically normal due to paternal inheritance of the genetic defect &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11283796&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''IIIc''': Individuals who are mosaic for the imprinting defect have less than 1% risk to siblings&lt;br /&gt;
&lt;br /&gt;
'''IV''': UBE3A mutation can be either inherited or de novo mutation. If the mother is a carrier for this genetic mutation, the risk to siblings is up to 50% &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11258627&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''V''': Individuals who present with AS clinically, but have no known underlying mechanism have an unknown risk to siblings.&lt;br /&gt;
&lt;br /&gt;
==Treatment and Management==&lt;br /&gt;
&lt;br /&gt;
Even though at present there is no known cure for Angelman syndrome, there are a number of treatments available that may alleviate symptons and improve daily life activities.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The below table describes the problems and management options that are used:&lt;br /&gt;
&lt;br /&gt;
[[File:Subtle Finger tremors-Angelman Syndrome.jpg|right|thumb|150px|A five months old boy with Angelman syndrome showing signs of Subtle Finger tremor.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
! Problems encountered&lt;br /&gt;
! Treatment and Management&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''Difficulty in feeding newborn AS babies'''&lt;br /&gt;
| Use of special nipples may improve feeding&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Oesophagus reflux'''&lt;br /&gt;
| Special motility medications requiried or upright positioning&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''Seizures'''&lt;br /&gt;
| Anticonvulsant medications&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19605773&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19453717&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Ocular problems'''&lt;br /&gt;
| Visual assessment is vital to encourage interactions and minimize chances of self-harm and autism development&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20656169&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''Drooling in developmental delayed AS patients'''&lt;br /&gt;
| Difficult to treat, but new surgical procedure on salivary duct reimplantation seems to be a promising alternative&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17699119&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Unstable children''' &lt;br /&gt;
| Physical therapy&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''AS patients become less active with increasing age'''&lt;br /&gt;
| Activity schedules to prevent scoliosis and obesity. Occupational therapy to stimulate fine motor and oral-motor control skills in conjunction to speech therapy&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Sleeping difficulty'''&lt;br /&gt;
| Sedative medication in severe cases. [[#Glossary | '''Melatonin''']] may be used to promote sleeping but some studies have found that it loses its therapeutic effects after several weeks in most AS patients&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19379289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|-&lt;br /&gt;
|colspan=&amp;quot;4&amp;quot; |&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Prognosis==&lt;br /&gt;
&lt;br /&gt;
Life expectancy of AS patients seems to be normal&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, but there is still a high degree of developmental delay and limited expressive language skills.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17019625&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This problem arises prominently in the assessment of the severity of coincidental medical conditions due to difficulties in communication. A visit to the dentist can become difficult if good communication is not conveyed between the parents, the dentist, and the child.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18271768&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Some problems require extreme measures, such as the procedure of lens implantation was performed in both eyes of a person diagnosed with AS, due to the inability to wear spectacles.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20656169&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
During adulthood, menstruation and puberty begin at around average age evidenced by females with Angelman syndrome that are fully capable of conceiving children.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11258627&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Most adult patients can feed themselves, but needed help with many other daily activities. Main troubles which have shown in adults are a tendency to become obese and start developing  thoracic scoliosis, which some adults with AS begin wheelchair bounded.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9072912&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Current and Future Research==&lt;br /&gt;
&lt;br /&gt;
Currently there is no cure for the treatment of AS, so much research is being carried out for therapeutic interventions. Findings in the last five years have suggested through various mice and fruit fly models that the absence of maternal UBE3A results in the same human AS features of neurological defects and seizures. However, more recently, studies have outlined that the symptoms of AS can be improved by modifying other gene products. In addition, restoring of a functional UBE3A protein into adult mice neurons have shown to reduce motor and neurological deficits and balance disorders. This shows promising research prospects in that improvements may be possible in human AS patients by restoring functional UBE3A proteins into their neurons. &lt;br /&gt;
&lt;br /&gt;
===Possible Treatment Pathways===&lt;br /&gt;
&lt;br /&gt;
*'''Cognitive and physical impairment'''&lt;br /&gt;
&lt;br /&gt;
Although everyone is born with two copies of the gene UBE3A, one maternal and one paternal copy, it is only the maternal UBE3A that is used in the brain. Most AS patients have a genetic mutation on the maternal chromosome 15 that results in dysfunctional UBE3A.&amp;lt;ref&amp;gt;http://www.cureangelman.org/what-hope.html&amp;lt;/ref&amp;gt; The above research focused on turning on the father's copy of UBE3A to restore its functions. Furthermore, mouse models were utilized to show that alpha-CaMKII could be increased to compensate the loss of UBE3A and restore compromised mental and physical abilities. However, this finding still requires much more research.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17259980&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''Epilepsy'''&lt;br /&gt;
&lt;br /&gt;
There is research being done on improving certain conditions that are involved in AS by nutritional benefits. The use of [[#Glossary | '''corticosteroids''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19666884&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, [[#Glossary | '''valproate''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19453717&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and [[#Glossary | '''clonazepam''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19605773&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and having a [[#Glossary | '''ketogenic diet''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20880305&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; has all been shown to aid in the treatment of epilepsy. It has also been reported to be efficient in the treatment of other conditions, such as behavioural disorders, reduction in seizures, ataxia, sleep patterns, developmental progress and sleep disturbances. [[#Glossary | '''Levetiracetam''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17326790&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; could be used in such a situation, especially when the patient has an intolerance to valproate and clonazepam.&lt;br /&gt;
&lt;br /&gt;
*'''Betaine and Folic acid'''&lt;br /&gt;
&lt;br /&gt;
This double-blind placebo-controlled study was done to examine the potential therapeutic role of [[#Glossary | '''betaine''']] and [[#Glossary | '''folic acid''']] in the treatment of the clinical phenotypes of AS. The aim of this protocol was to increase methylation and activate the paternally inherited UBE3A in hope to compensate for the inactive maternal UBE3A. Although there were no major differences in the control and treatment groups, a small number of patients in the treatment group showed some positive outcomes.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20635355&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&lt;br /&gt;
'''albinism''': A congenital disorder distincted by the complete or partial absence of pigment in the skin, hair and eyes due to defect of an enzyme involved in the production of melanin.&lt;br /&gt;
&lt;br /&gt;
'''allele''': Dissimilar variant of one gene. Organisms have two alleles for each gene inherited from their parents, one from each of them.&lt;br /&gt;
&lt;br /&gt;
'''alpha-CaMKII''': (alpha calcium calmodulin kinase II) Compound involved in synaptic plasticity, one of the most important theories behind learning and memory. Ability of a synapse between two neurons to change in strength due to the use or disuse of transmission.&lt;br /&gt;
&lt;br /&gt;
'''Amniocytes''': Cells that are shed by the fetus during fetal development to the surrounding amniotic fluid. They are a source of fetal DNA. &lt;br /&gt;
&lt;br /&gt;
'''Amniocentesis''': (AFT or amniotic fluid test) is a prenatal diagnostic test used to detect chromosomal abnormalities in the developing fetus by extracting amniotic fluid (a source of fetal DNA) surrounding the fetus. &lt;br /&gt;
&lt;br /&gt;
'''AMPA''': (2-amino-3-(5-methyl-3-oxo-1,2- oxazol-4-yl)propanoic acid) Compound that binds to the AMPA receptor to imitate glutamate neurotransmitter.&lt;br /&gt;
&lt;br /&gt;
'''Arc''': Activity-Regulated Cytoskeleton-associated protein; involved in learning and memory.&lt;br /&gt;
&lt;br /&gt;
'''ataxia''': Lack of coordination in muscle movements.&lt;br /&gt;
&lt;br /&gt;
'''atonic seizures''': A abrupt loss of muscle tone, this can lead to the limbs loosing strength, or the head may drop to the side. The patient remains conscious during this kind of epileptic seizure.&lt;br /&gt;
&lt;br /&gt;
'''atypical absences''': Seizure leads to unconsciousness in most cases.  &lt;br /&gt;
&lt;br /&gt;
'''autism''': A neural development disorder defined by limited social interaction and communication.&lt;br /&gt;
&lt;br /&gt;
'''betaine''': Also known as  betaine anhydrous or trimethylglycine (TMG), assists the body in metabolising the amino acid, homocysteine. Can be consumed via beets, broccoli, grains, shellfish, and spinach.&lt;br /&gt;
&lt;br /&gt;
'''Chorionic Villus Sampling''': A prenatal diagnostic test used to detect chromosomal abnormalities in the developing fetus by extracting and testing chorionic villus (placental tissue). &lt;br /&gt;
&lt;br /&gt;
'''chromosome''': Structure consisting of coiled DNA with DNA associated proteins such as histones.&lt;br /&gt;
&lt;br /&gt;
'''clonazepam''': A psychoactive drug having muscle relaxant properties and treats anxiety and epilepsy.&lt;br /&gt;
&lt;br /&gt;
'''corticosteroid''': A type of steroid hormones that are produced in the adrenal cortex.&lt;br /&gt;
&lt;br /&gt;
'''cytogenetics''': Study of the structure, function and abnormality of the cell, especially the chromosome.&lt;br /&gt;
&lt;br /&gt;
'''deletion''': Lack of a part of the DNA (deoxyribonucleic acid is a nucleic acid containing information for protein synthesis), can vary form a single base to a hole gene. &lt;br /&gt;
&lt;br /&gt;
'''de novo mutation''': Change in a gene of a family member for the first time due to a mutation in the egg or sperm of the parents or in the fertilized egg (zygote).&lt;br /&gt;
&lt;br /&gt;
'''disorder''': A mental or physical health disturbance or dysfunction.&lt;br /&gt;
&lt;br /&gt;
'''EEG''': Electroencephalography is a means of measuring electrical activity along the scalp by measuring the total electrical charges fired by thousands or millions of neurons.&lt;br /&gt;
&lt;br /&gt;
'''epilepsy''': Neurological disorder characterised by recurrent impairment of brain function that can cause seizures or unconsciousness. &lt;br /&gt;
&lt;br /&gt;
'''E6-AP''': E6-AP ubiquitin-protein ligase is an enzyme encoded by UBE3A which adds ubiquitin chain to target proteins to be degraded by proteasomes.&lt;br /&gt;
&lt;br /&gt;
'''febrile convulsions''': The occurrence of high fever, especially in children.&lt;br /&gt;
&lt;br /&gt;
'''FISH''': Fluorescent in situ hybridization is a technique used to identify and localize the presence or absence of DNA sequences on the chromosome. This is achieved by using fluorescently labelled DNA sequences which then binds to complementary DNA sequence on the chromosome. After hybridization (attachment), chromosome of interest will fluoresce under the microscope.&lt;br /&gt;
&lt;br /&gt;
'''folic acid''': B vitamin that helps the body make healthy new cells. Can be consumed via leafy green vegetables, fruits, dried beans, peas and nuts.&lt;br /&gt;
&lt;br /&gt;
'''gait''': A manner of walking, stepping or running.&lt;br /&gt;
&lt;br /&gt;
'''gene''': A molecular unit of heredity of a living organism.&lt;br /&gt;
&lt;br /&gt;
'''hyperphagia''': (Also referred to as Polyphagia) Excessive ingestion of food beyond the dietary and energy requirements of the body. &lt;br /&gt;
&lt;br /&gt;
'''hypermotoric''': Sudden appearance of uncontrolled movements such as striking or kicking inappropriately.&lt;br /&gt;
&lt;br /&gt;
'''hypertonicity''': Increase of muscle tension and a disability to stretch leading to an impairment of motor activity.&lt;br /&gt;
&lt;br /&gt;
'''hypopigmentation''': A lack of melanin pigments or melanocytes  affecting the colour of the skin, hair and iris. Features appear to be light-coloured due to loss of skin colour.&lt;br /&gt;
&lt;br /&gt;
'''hypotonia''': Decrease in the ability to stretch passively, due to a low muscle tone. &lt;br /&gt;
&lt;br /&gt;
'''imprinting''': This is a process to describe the modification of a maternally or paternally derived chromosome, which consequently influences the expression of certain genes on the altered chromosome.&lt;br /&gt;
&lt;br /&gt;
'''ketogenic diet''': A high-fat, low-carbohydrate diet that is used to treat epilepsy in children.&lt;br /&gt;
&lt;br /&gt;
'''levetiracetam''': An anticonvulsant drug used to treat epilepsy.&lt;br /&gt;
&lt;br /&gt;
'''locus''': Location of a gene on a chromosome(loci: plural for locus).&lt;br /&gt;
&lt;br /&gt;
'''LTP''': Long-term potentiation shares common features with long term memory. It strengthens and enhances signal transmission between neurons by improving the communication between two neurons.&lt;br /&gt;
&lt;br /&gt;
'''macrostomia''': A wide-spaced mouth.&lt;br /&gt;
&lt;br /&gt;
'''Makaton''': Language programme using symbols and signs to support speaking.&lt;br /&gt;
&lt;br /&gt;
'''mandibular prognathism''': The abnormal protrusion of the lower jaw. &lt;br /&gt;
&lt;br /&gt;
'''maxillary hypoplasia''':  The underdevelopment of the upper jaw.&lt;br /&gt;
&lt;br /&gt;
'''melatonin''': A hormone secreted by the pineal gland.&lt;br /&gt;
&lt;br /&gt;
'''microcephaly''': The circumference of the head is less than average due to abnormalities of the nervous system. This abnormality can be present at birth or emerge during the first few years of life and reduces both life expectancy and the cognitive functions of the individual affected.&lt;br /&gt;
&lt;br /&gt;
'''microdeletion''':  A genetic mutation in which a part of a chromosome or a sequence of DNA is missing.&lt;br /&gt;
&lt;br /&gt;
'''mosaic''': tissues or cells containing different mixture of genetic sequences&lt;br /&gt;
&lt;br /&gt;
'''mutation''': Event that changes the DNA (deoxyribonucleic acid is a nucleic acid, containing information for protein synthesis) or RNA (ribonucleic acid is a type of nucleic acid transmitting the information from the DNA to the proteins ) of a gene permanently.&lt;br /&gt;
&lt;br /&gt;
'''myoclonic seizures''': A quick jerk of the skeletal muscle, due to a irregular brain activity.&lt;br /&gt;
&lt;br /&gt;
'''neurogenetic''': Genetic basis of the nervous system.&lt;br /&gt;
&lt;br /&gt;
'''neurotransmitter''': Transmits neuronal signals to a target cell. They are first packaged in vesicles just beneath the membrane of presynaptic axon terminals and released into the synaptic cleft (space between the two interacting neurons) and enter the postsynaptic dendrite.&lt;br /&gt;
&lt;br /&gt;
'''occiput''': The back portion of the head.&lt;br /&gt;
&lt;br /&gt;
'''oesophagus reflux''': Impairment of a sphincter in the lower end of the oesophagus leads to the back flow of stomach acid into the oesophagus. Heartburn is a typical symptom.&lt;br /&gt;
&lt;br /&gt;
'''paediatrician''': Physicians that specialise on infants, children and adolescents.&lt;br /&gt;
&lt;br /&gt;
'''paternal UPD''': Inheritance of two copies of a chromosome from the father and none from the mother. &lt;br /&gt;
&lt;br /&gt;
'''phenotype''': Visible traites of an organism determined by genetic and environmental factors.&lt;br /&gt;
&lt;br /&gt;
'''Picture Exchange Communication System (PECS)''': Individuals communicate using images instead of words. It is frequently used by children with autism, to articulate their needs and wishes or to make comments about something.&lt;br /&gt;
&lt;br /&gt;
'''Proband''': Is the person (or animal) being studied or reported on in a genetic investigation. Most commonly it refers to the first affected family member who requires medical help for a genetic disorder. &lt;br /&gt;
&lt;br /&gt;
'''Robertsonian translocation''': Rearrangement of the chromosome, occurs in 5 chromosome including 13,14,15,21 and 22. This type of mutation occurs in chromosomes with the centromere not at the centre, resulting in long and short arm chromosomes. Translocation breaks the chromosome at the centromere so the long arm attaches to the other long arm, and the same for the short arm happens. Cell division will result in the loss of the short arms as they do not contain important genes.&lt;br /&gt;
&lt;br /&gt;
'''seizure''': Abnormal electrical activity in the brain that can result in a variety of physical symptoms like convulsion, body shaking, loss of consciousness, confusion, and mood changes.&lt;br /&gt;
&lt;br /&gt;
'''synapse''': Allows transmission of signal between neurons for effective neuronal function.&lt;br /&gt;
&lt;br /&gt;
'''thoracic scoliosis''': The spine is curved laterally(from side to side) in the thoracic region.&lt;br /&gt;
&lt;br /&gt;
'''tonic-clonic seizures''': This type of seizure is associated with unconsciousness due to electrical discharges in a big proportion of the brain.&lt;br /&gt;
&lt;br /&gt;
'''ubiquitin''': A polypeptide found in all eukaryotic cells, that participates in a variety of cellular functions including protein recycling.&lt;br /&gt;
&lt;br /&gt;
'''Uniparental disomy''': (UPD) the inheritance of two copies of a chromosome pair or part of a chromosme from one parent and no copy from the other parent. &lt;br /&gt;
&lt;br /&gt;
'''valproate''':  A mood-stabilizing drug that is also used for treatment for epilepsy and bipolar disorder.&lt;br /&gt;
&lt;br /&gt;
==Helpful Links==&lt;br /&gt;
&lt;br /&gt;
* Australia&lt;br /&gt;
:* [http://www.angelmansyndrome.org/research.html Angelman Syndrome Association] &lt;br /&gt;
:* [http://www.angelmansyndromeqld.org/ Queensland Angelman Association]&lt;br /&gt;
&lt;br /&gt;
* America&lt;br /&gt;
:* [http://www.angelman.org/ Angelman Syndrome Foundation]&lt;br /&gt;
:* [http://rarediseasesnetwork.epi.usf.edu/arpwsc/ Rare Clinical Diseases Research Network]&lt;br /&gt;
:* [http://www.rarediseases.org/rare-disease-information/rare-diseases/byID/411/viewAbstract National Organisation for Rare Disorders]&lt;br /&gt;
:* [http://www.epilepsyfoundation.org/ Epilepsy Foundation]&lt;br /&gt;
:* [http://www.cureangelman.org/ Foundation for Angelman Syndrome Therapeutics]&lt;br /&gt;
&lt;br /&gt;
* Search Pubmed &lt;br /&gt;
:* [http://www.ncbi.nlm.nih.gov/pubmed?term=angelman%20syndrome Angelman Syndrome] &lt;br /&gt;
&lt;br /&gt;
* OMIM entries for Angelman Syndrome&lt;br /&gt;
:* [http://omim.org/entry/105830 ANGELMAN SYNDROME; AS]&lt;br /&gt;
:* [http://omim.org/entry/601623 UBIQUITIN-PROTEIN LIGASE E3A; UBE3A]&lt;br /&gt;
&lt;br /&gt;
==Related Links==&lt;br /&gt;
&lt;br /&gt;
'''Animal Models'''&lt;br /&gt;
&lt;br /&gt;
* [[Mouse Knockout]] - this page explains the current use of mouse models in disrupting genes to elucidate their genetic function, including the mouse gene knockouts for alpha calcium-calmodulin kinase II (alpha CaMKII)&lt;br /&gt;
* [[2009 Group Project 4]] - this page gives an extensive overview on the history of the mouse model and its various use in embryology and genetics. In addition, it also describes mouse knockout and the role they play in current research of various human diseases&lt;br /&gt;
* [[Fly Development]] - this page describes the use of drosophila flies as developmental models&lt;br /&gt;
* [[2009 Group Project 2]] - this page gives an extensive overview on the history of the fly model and its various use in embryology and genetics&lt;br /&gt;
&lt;br /&gt;
'''Diagnosis'''&lt;br /&gt;
* [[Chorionic villus sampling]] - this page explains the process of chorionic villus sampling, its disadvantages and gives a brief overview of recent findings&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&lt;br /&gt;
&amp;lt;references /&amp;gt;&lt;/div&gt;</summary>
		<author><name>Z3291643</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=User:Z3291643&amp;diff=77661</id>
		<title>User:Z3291643</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=User:Z3291643&amp;diff=77661"/>
		<updated>2011-10-12T23:22:00Z</updated>

		<summary type="html">&lt;p&gt;Z3291643: /* Lab 10 Online Assessment */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{2011Student}}&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Z3291643]] 12:55, 28 July 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 1 Assessment==&lt;br /&gt;
1.	Identify the origin of In Vitro Fertilization and the 2010 nobel prize winner associated with this technique.&lt;br /&gt;
&lt;br /&gt;
‘in vitro’ fertilization is Latin for ‘in glass’ fertilization and is a treatment for infertility, whereby the sperm fertilizes the ovum outside the body and is then implanted back into the patient’s uterus. The first successful IVF birth, Louise Brown, occurred in 1978 with the help of Patrick Steptoe and Robert Edwards. Edwards was awarded the 2010 nobel prize in medicine for his achievement. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
2.	Identify a recent paper on fertilisation and describe its key findings.&lt;br /&gt;
&lt;br /&gt;
The aim of this paper was to investigate whether age &amp;lt;=25 played a role in the reproductive outcome of women undergoing IVF. Infertile patients aged between 19 and 25 years of age were compared to infertile patients aged 30-35 years to determine primarily fertilization rates and the number of top quality embryos. The results were unexpected as the younger subjects had lower fertilization rates and reduced embryo quality.&amp;lt;ref&amp;gt;PMID 21042842&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
3.	Identify 2 congenital anomalies.&lt;br /&gt;
&lt;br /&gt;
Trisomy 21 and cleft palate&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--[[User:S8600021|Mark Hill]] 10:01, 3 August 2011 (EST) These answers are fine.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 13:02, 4 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Lab 2 Assessment==&lt;br /&gt;
1.	Identify the ZP protein that spermatozoa binds and how is this changed (altered) after fertilization. &lt;br /&gt;
&lt;br /&gt;
ZP3 acts as a receptor for the sperm. This is followed by the acrosome reaction, whereby acrosomal contents digest the ZP and allow the sperm surface proteins to bind to the ZP2. After fertilization, cortical reaction takes place where cortical granules are exocytosed. This results in the removal of carbohydrate from ZP3 and cleavage of ZP2 to harden the ZP. These changes occur to prevent polyspermy.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
2.       Identify a review and a research article related to your group topic.&lt;br /&gt;
&lt;br /&gt;
This research article showed genotype-phenotype correlations in Angelman Syndrome (AS). They have concluded that deletion patients had worse developmental outcomes than non deletion patients.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20729760&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
This review article is really comprehensive and gives a good background knowledge of AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20445456&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Z3291643]] 12:42, 11 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 3 Assessment==&lt;br /&gt;
&lt;br /&gt;
1.        What is the maternal dietary requirement for late neural development? &lt;br /&gt;
&lt;br /&gt;
Iodine. Zimmermann found that maternal deficiency of iodine can result in cognitive disability in the offspring, most severely characterized by cretinism. Fortunately, mild to moderate iodine deficiency can be corrected in primary school aged children to improve cognitive and motor functions.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21802524&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
2.        Upload a picture relating to your group project.&lt;br /&gt;
&lt;br /&gt;
[[File:UBE3A colocalizes with ASPM at the centrosome throughout mitosis.jpg|thumb|UBE3A colocalizes with ASPM at the centrosome throughout mitosis.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21633703&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
===UBE3A colocalizes with ASPM at the centrosome throughout mitosis===&lt;br /&gt;
&lt;br /&gt;
[[File:UBE3A colocalizes with ASPM at the centrosome throughout mitosis.jpg|Abnormal cytokinesis and apoptosis in UBE3A knockdown cells.|350px]]&lt;br /&gt;
&lt;br /&gt;
UBE3A colocalizes with ASPM at the centrosome. (A) Indirect immunofluorescence of HEK293 cells at interphase and different phases of mitosis stained with antibodies against ASPM and UBE3A (anti-UBE3A-sc-8926). Note colocalization of UBE3A with ASPM at the centrosome throughout mitosis (arrowheads). Note weak centrosomal staining of UBE3A in an interphase cell (arrow). (B) Indirect immunofluorescence of A549 cells stained with antibodies against UBE3A (anti-UBE3A-sc-8926) and ASPM at metaphase and telophase. Note colocalization of UBE3A with ASPM at the centrosome (arrowheads). Scale bar=2 µm.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Copyright Singhmar, Kumar. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 11:08, 18 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 4 Online Assessment==&lt;br /&gt;
&lt;br /&gt;
# '''The allantois, identified in the placental cord, is continuous with what anatomical structure?'''&lt;br /&gt;
The allantois is endodermic in origin and is the extension of the yolk sac into the connecting stalk. It's connected to the superior end of the developing bladder&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
#  '''Identify the 3 vascular shunts, and their location, in the embryonic circulation.'''&lt;br /&gt;
1. Ductus arteriosus; connects left pulmonary artery with the descending aorta&lt;br /&gt;
2. Ductus venosus; connects the portal and umbilical veins to the inferior vena cava&lt;br /&gt;
3. Foramen ovale; between left and right atria&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
# Identify the Group project sub-section that you will be researching. (Add to project page and your individual assessment page)&lt;br /&gt;
&lt;br /&gt;
; 4  Aetiology (genetic inheritance); Julia&lt;br /&gt;
; 5  Pathophysiology; Julia (as it's quite linked with aetiology anyway)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 12:59, 25 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 5 Online Assessment==&lt;br /&gt;
&lt;br /&gt;
# Which side (L/R) is most common for diaphragmatic hernia and why? &lt;br /&gt;
Posterior left side,possibly due to the fact that the left pericardioperitoneal canal is larger and closes later than the right.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 12:48, 1 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 6 Online Assessment==&lt;br /&gt;
# What week of development do the palatal shelves fuse?&lt;br /&gt;
Week 9 of early embryonic growth&lt;br /&gt;
 &lt;br /&gt;
# What early animal model helped elucidate the neural crest origin and migration of neural crest cells?&lt;br /&gt;
Migration of neural crest cells have been studied in quail-chick chimeras - transplanted quail cells have obvious nucleoli compared with chicken. It was first done by Nicole Le Douarin in the 80's&lt;br /&gt;
 &lt;br /&gt;
# What abnormality results from neural crest not migrating into the cardiac outflow tract? &lt;br /&gt;
Tetralogy of Fallot; when the outflow tract is not aligned properly, it is seen as a nonwedged aorta. Nonwedged aorta indicates tetralogy of Fallot. In addition, past studies using chick embryos have outlined that cardiac neural crest cell ablation led to this malalignment. In contrast, Farrell et al have shown that the introduction of cardiac neural crest aligned the outflow tract properly. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9933243&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 12:49, 15 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 7 Online Assessment==&lt;br /&gt;
&lt;br /&gt;
1. Are satellite cells &lt;br /&gt;
* necessary for muscle hypertrophy?&lt;br /&gt;
: No&lt;br /&gt;
 &lt;br /&gt;
* generally involved in hypertrophy?&lt;br /&gt;
: Yes&lt;br /&gt;
 &lt;br /&gt;
&lt;br /&gt;
2. Why does chronic low frequency stimulation (CLFS) cause a fast to slow fibre type shift? &lt;br /&gt;
: At the molecular level, there are exchanges of fast and slow type protein isoforms, such as calcium regulatory system, myofibrillar apparatus. The final step in CLFS induced fiber shift is the upregulation of slow myosin from the conversion of myogenic cells to slow fiber phenotype. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12500901&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;It is also known that satellite cells contribute to CLFS-induced transition of fiber types shown by the fact that CLFS increases type I fibers only after fiber necrosis. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16439424&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--Mark Hill 10:42, 16 September 2011 (EST) &lt;br /&gt;
&lt;br /&gt;
I would like each student to now also look at the following online page before the next Lab and write a comment based upon the group project assessment criteria. &lt;br /&gt;
&lt;br /&gt;
http://embryology.med.unsw.edu.au/embryology/index.php?title=Trisomy_21 &lt;br /&gt;
Paste your comment on the Trisomy 21 discussion page and also on your own student page. &lt;br /&gt;
&lt;br /&gt;
Group Assessment Criteria&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Good and concise explanation of the subheadings,however, I would've liked to see some attempt to further explain how the asspcoated congenital abnormalities occur.  &lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Lots of images, graphs and table used effectively to help reader better understand the disease. They also gave the project page some colour to make it more pleasing to the eye. Unfortunately, some images were placed (eg. John Langdon Down)in the wrong sections and interrupted the flow of the project page. &lt;br /&gt;
#* In addition, some of the images were not referred to within the project page. &lt;br /&gt;
#* Furthermore, the overall structure and layout of the page could be improved, such as putting the Diagnostic Links under diagnosis instead of the introduction&lt;br /&gt;
#* I also felt American College of Obstetricians and Gynecologists Recommendations could've been a subheading under 'screening'&lt;br /&gt;
#Content is correctly cited and referenced. &lt;br /&gt;
#* The very first image does not provide any information on the permissions to reuse the image (open access). &lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations. &lt;br /&gt;
#* Would've been better to include more self drawn diagrams and tables to further illustrate the group's knowledge of this disease&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* Lots of Pubmed articles have been used to make this page more credible and reliable &lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#* More words need to be explained in the glossary, such as 'tandem single nucleotide polymorphisms' &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 22:50, 21 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 8 Online Assessment==&lt;br /&gt;
attendance: --[[User:Z3291643|Sang Lee]] 13:04, 22 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Group 1: Turner Syndrome&lt;br /&gt;
&lt;br /&gt;
Firstly, nice progress with the group project. After reading your page, I have a good general knowledge of Turner Syndrome, so thanks. Overall, most sections were well done, though the writing style and layout could be more consistent, but you could work on that when you've finalised the content of the page. &lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: Good intro, very first image of the karyotype should include the actual statement of the 'Open access' not just 'copyright'&lt;br /&gt;
#* Epidemiology: Grammatical errors disrupt the flow of the content, in addition, graph has no copyright info, title could be improved&lt;br /&gt;
#* Etiology: Nice simple diagram of 22 eggs and 23 sperms, good example of when a picture can tell more than a thousand words! I feel there needs to be consistency either use Turner Syndrome or TS throughout the page&lt;br /&gt;
#* Clinical: liked how you have further classified the symptoms to its associated titles, nice idea; very easy to read, but a table would also be good&lt;br /&gt;
#* Diagnosis: image of TS maternal serum sampling doesn't contain {Template:2011 Student Image}, but a very good table&lt;br /&gt;
#* image of the TS X chromosome variations shouldl contain {Template:2011 Student Image}. Furthermore, if you use A-E in image descriptions, you should include A-E within the image&lt;br /&gt;
#* Research: very good layout and explanations, informative&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Could include more images especially in clinical manidestations, and some images do not fit the requirements set by Mark, as I've highlighted above &lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* seems to be cited well. However, although you have more than 100 referencees, a lot of them are repeated references, maybe you could try to use more pubmed articles, a greater variety&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations. &lt;br /&gt;
#* Glossary: could include more words such as echocardiogram&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* Although you have more than 100 referencees, a lot of them are repeated references, maybe you could try to use more pubmed articles, a greater variety&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#*  Although the content is informative, I'm left feeling like I want more variety of resources, so maybe some further research will improve the overall impression of your page &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot;&lt;br /&gt;
* consistency in writing style&lt;br /&gt;
* more images and cited correctly &lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 14:44, 24 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Group 2&lt;br /&gt;
&lt;br /&gt;
Hey Group 2, firstly, well done on putting in the effort to create this page, it really shows your dedication and cooperation as a team! Here are some points I thought you could improve on to take this page to that extra level&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: Good overview. Image would look better with a border or as a thumb&lt;br /&gt;
#* History: Image too large, again maybe a border?&lt;br /&gt;
#* Epidemiology: Need to define velocardiofacial syndrome in glossary, also break it down into subheadings, eg. Incidence, Sex, etc&lt;br /&gt;
#* Etiology: Maybe better if in a table&lt;br /&gt;
#* Pathogenesis: I liked how you broke it doen into relevant subheadings. However, on a slightly negative note, the DG Pathophysiology Diagram looks rushed; I think it would've looked better if it was neater and easier to read.&lt;br /&gt;
#* Diagnosis: I felt citing was done poorly in this section, eg. the last 4/5 sentences in the FISH technique was not referenced at all, but again, this is very easily fixed. But good to see you have put in the effort and time&lt;br /&gt;
#* Clinical: Image of normal and cleft palate, if based on a textbook, I think you still need permission to adapt it (not quite sure, please ask Mark)? Table with 'How it is caused' would be better by itself as pathophysiology. Tetralogy of Fallot needs to be fitted into this section more smoothly, at the moment, it makes this section look very cramped. Also, the image regarding Tetralogy needs the correct format for student drawn images (ie. 'I (student no.)....)&lt;br /&gt;
#* Research: Maybe break it down into subheadings&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Good images used with a nice range of self drawn images. However, no where in the page is there any reference to the images within the text.&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* I feel citation needs to be improved overall. Lots of the sections have missing citations, especially Diagnostic Tests. Also in the reference list, refs 33,40,47, 49 have nothing in it (is it meant to be like this?)&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations. &lt;br /&gt;
#* Nice drawings, though some could've done better with more effort&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* Nice range of references used&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#* It's very clear to me that you guys have worked together well and there has been good team work going on here to create this page, so well done&lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* I feel your page is too heavy with the text, although there's a lot of images as well, it just doesn't quite balance out with the text. &lt;br /&gt;
* Also felt the different colours used for the tables, although adding a splash of colour to your page, brought down the overall quality of the page. However, please keep in mind that others might really like this approach of table formatting, it's just that personally, I think you could benefit from keeping all table colours consistent.&lt;br /&gt;
* Sometimes you refer to DiGeorge Syndrome as DGS and also as DS. Small and easy to fix, adds consistency&lt;br /&gt;
* Please don't forget to add the {template} for student uploaded images&lt;br /&gt;
* Definitely needs more words in the Glossary, such as Meiosis, de novo, microarray&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 16:02, 24 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 3&lt;br /&gt;
&lt;br /&gt;
Hi, overall, a nice project page with interesting information.&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: Nice introduction, good flow and easy to read. However, image needs proper information and perhaps 'This disorder was first described by Harry F.' could be placed earlier on in the intro rather than in the middle&lt;br /&gt;
#* History: Nice section, very interesting&lt;br /&gt;
#* Epidemiology: First paragraph is good, but I feel the rest of this section doesn't quite belong here, such as the information on seizures, IQs, diagnosis. This section should focus on stats (sex/birth/ethnic/demographic/etc). Fig 2, 3 belong more in the signs and symptoms&lt;br /&gt;
#* Etiology: the '1:1000 male' contradicts the '1:500' given in epidemiology. Fig4 needs coyright information&lt;br /&gt;
#* Pathogenesis: Needs better referencing, also placing fig 5, 6 on either side doesn't look too good with the text. Perhaps place them below one another?&lt;br /&gt;
#* Signs: Seems a bit incomplete, it'll also be good to explain the image of 'pubertal gynecomastia'&lt;br /&gt;
#* Diagnosis: Sentence structure could be improved, ie. 'performed because physicians may suspect it because of clinical findings'. Information is interesting, but could be presented more clearly, perhaps in a table?&lt;br /&gt;
#* Similar defects: very nice, presented well with good information, easy to read&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Good images used with a nice range of self drawn images. However, lot of the images need to be formatted properly with required information&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* overall referencing was well done, except pathogenesis needs more referencing&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations. &lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* Nice range of references used&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#* The information is there, but maybe from now til final assessment, you could do further research in all sections, as they do seem a little short.&lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* better page layout&lt;br /&gt;
* glossary: sorry, but I feel the alphabet subheadings here are very effective as you have it in alphabetical order anyway&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 21:59, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 4&lt;br /&gt;
&lt;br /&gt;
Hey, this is a nicely structured page with interesting content that is presented well. There is a nice balance of text and image&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: good, to the point&lt;br /&gt;
#* History: Nice section, perhaps bold the years?&lt;br /&gt;
#* Epidemiology: I really liked this section, both visually and content wise. The table is easy to read and I liked your explanations for the HD prevalence, well done&lt;br /&gt;
#* Genetics: Perhaps you could have the 'CAG (cytosine-adenine-glutamine)' in the introduction when you first refer to it? Referencing is required in i'HTT and normal functions'. I really liked your subheadings, made it very easy to understand and follow &lt;br /&gt;
#* Pathogenesis: Image is too big, good subheadings, I suggest that if you write in purple to highlight some words, maybe you could do that for the whole page?&lt;br /&gt;
#* Clinical: liked the motor impairment explanations, how about explaining the cognitive and behaviour impairments as well? (it'll be worth it!)&lt;br /&gt;
#* Diagnosis: Nice content, but it just feels a bit too crowded, maybe rearrange the images and decrease image size&lt;br /&gt;
#* Treatment: Very nice section with nice images and good format!&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Good balance of images and text, though some rearrangement of images would make this page look better. Very good use of subheadings to make the content more easy to digest&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* overall referencing was well done&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
* good range of tables, images and self drawn images&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* Nice range of references used&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* just minor changes such as resizing some of the images, making the sections consistent in format&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 22:32, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 5&lt;br /&gt;
&lt;br /&gt;
Hi, I can see some progress on this page which is good, content is interesting&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: What is FMR1 gene? Need more information here, as in when was it first discovered, some stats&lt;br /&gt;
#* Epidemiology: I think screening information is extensive enough to be a section on its own&lt;br /&gt;
#* Etiology: no explanation of FMR1 gene so far, what is its normal function? Also, please refer to images used in this section&lt;br /&gt;
#* Development of the disease:nice succinct, easy to follow section. Perhaps add an image for one of the stages mentioned here?&lt;br /&gt;
#* Signs: REFERENCING!!! But, content is good and interesting&lt;br /&gt;
#* Diagnosis: An image here would be nice, and an explanation of how the technology is used to diagnose FXS&lt;br /&gt;
#* Treatment: Nice table with good information&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Need to balance out the text and image ratio, some good subheadings&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* poor referencing, which makes me question the reliability of the content in some sections&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
#* needs a lot more images&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* I feel more research needs to be done here&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* Although the content is here, there is still a lot of work needed to make this page feel complete&lt;br /&gt;
* glossary is very lacking in terminology&lt;br /&gt;
* need more images&lt;br /&gt;
* further research would be nice to explain this disease in more detail&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 23:26, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Group 6&lt;br /&gt;
Hey, nice progress with your page, all sections have similar amount of content which were interesting&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: Referencing needs to be improved here&lt;br /&gt;
#* History: content is good but too wordy. I think a summary or a simple timeline would be good&lt;br /&gt;
#* Epidemiology: Where's the reference for 3/10000 live births?&lt;br /&gt;
#* Signs: ok section, but could do with more images here&lt;br /&gt;
#* Genetics: If using abbreviations, such as TBX1 gene, you should explain what it is, ie. TBX1 gene (T-box 1). Also need to work on referencing here as well. How about organising all the content in a table? have in columns: gene, gene profile, frequency, etc.&lt;br /&gt;
#* Pathogenesis: I'm not quite sure about this, but do you need permission to adapt an image from an article? (I'm referring to the '4 defects' image)&lt;br /&gt;
#* Diagnosis: I'm sorry, but this section is a bit bland, though the content is very informative. I think some images here would be good&lt;br /&gt;
#* Treatment: Referencing! Also, personally, that green is too bright, maybe find a more neutral, soothing colour?&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Need to find more images, I feel some of the information could be more effectively presented in table formate rather than lengthy text&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* VERY poor referencing, which makes me question the reliability of the content in some sections&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
#* needs a lot more images&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* research done is evident, just need to reference&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* glossary is very lacking in terminology&lt;br /&gt;
* need more images&lt;br /&gt;
* REFERENCING!&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 23:26, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Group 8&lt;br /&gt;
Hey, well done, your page is looking really polished! Lots of very interesting information here and presented in a very easy to follow manner&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* History: I feel that you could lessen the info of Nicholas and add more current findings of the disease.&lt;br /&gt;
#* Aetiology: What is the chromosome 9 image based on? Need to work on referencing. Very good subheadings and well balanced with images&lt;br /&gt;
#* Pathogenesis: Needs more information&lt;br /&gt;
#* Neuro: What's the images based on? Good subheadings and explained well. I liked the way you gave explanations for normal function/appearance and then went on to explain abnormality associated with the structures in this disease. But you need to improve your referencing for this section&lt;br /&gt;
#* Diagnosis: Very good table and images. But need to fix the postnal diagnosis table so that it spans the length of the screen&lt;br /&gt;
#* Symptoms: table and images look too crowded&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* good subheadings, images, impressive self drawn images! Nice balanced page layout&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* needs to work on referencing&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* research done is evident, just need to reference&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* referencing&lt;br /&gt;
* better arrangement of table and images so page doesn't look too crowded&lt;br /&gt;
&lt;br /&gt;
Well done guys, nice team work!&lt;br /&gt;
--[[User:Z3291643|z3291643]] 23:50, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 9&lt;br /&gt;
&lt;br /&gt;
Hey, your page has a lot of very interesting content and some unique self drawn images. I thoroughly enjoyed this page, thanks&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: Inclusion of incidence would be nice&lt;br /&gt;
#* History: very informative and a nice simple timeline&lt;br /&gt;
#* Genetics: Good, succinct section, especially liked the table&lt;br /&gt;
#* Diagnosis: needs referencing. Is diagnosis only postnatal? What is the average age of diagnosis for this disease?&lt;br /&gt;
#* Management and Treatment: Seems a little out of place under epidemiology, I think it should be place later on &lt;br /&gt;
#* Phenotype:Reference?&lt;br /&gt;
#* Cardiac conditions: maybe give explanations for atrial and ventricular septal defect, just brief descriptions would suffice. Why is it so that males are more likely to suffer CVD than females?&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* good subheadings, interesting self drawn images. However, this page needs to find a balance in text and images&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* needs to work on referencing&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* research done is evident, just need to reference&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#* very interesting content, informative&lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* referencing&lt;br /&gt;
* more images&lt;br /&gt;
* glossary; lacking a lor of terms&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 00:10, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 10&lt;br /&gt;
&lt;br /&gt;
Hey, this is a interesting disease, with some good images to show the disease clearly. &lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: succinct introduction&lt;br /&gt;
#* History: Has interesting content, though timeline would be nice&lt;br /&gt;
#* Pathogenesis: Too brief and could be improved with an image&lt;br /&gt;
#* Signs: surely there are more symptoms here, maybe you could have subheadings to break down the symtpoms, ie. motor impairment, cognitive impairments, etc&lt;br /&gt;
#* Clinical manifestations and complications: nice section with good image used&lt;br /&gt;
#* Diagnosis: could be further explained, and an image would be nice&lt;br /&gt;
#* Treatment: Current and Future Prospects: needs referencing&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* need to balance out the text with images, could organise page better with more subheadings, more images needed &lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* needs to work on referencing!!&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
#*  more table could be used instead of lengthy explanations&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* much more research needs to be done to further explain the sections&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* referencing&lt;br /&gt;
* more images&lt;br /&gt;
* glossary; lacking a lot of terms&lt;br /&gt;
* needs much more research, lots of repetitions in referencing&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 11:02, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 11&lt;br /&gt;
&lt;br /&gt;
Hey, this is a interesting disease, with some good images to show the disease clearly. &lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: very rushed, no reference and needs much more work, it should be a succinct summary of this whole page.&lt;br /&gt;
#* History: Has interesting content, though timeline would be better incorporated under History, not a section of its own&lt;br /&gt;
#* Diagnosis: If you're abbreviating Cleft Palate to CLP, you should have it as Cleft palate (CLP). The two given tables are pretty much the same, except for different sample number. Is it really necessary to have the two tables when they're so similar? Could do well with an image&lt;br /&gt;
#* Syndromes and Anomalies associated with cleft: Nice array of images used here. Content is good (for ones you provided), but needs work on referencing. Perhaps you could organise the content into a table for easy comparison since you have more than one anomalies&lt;br /&gt;
#* Aetiology: Needs referencing, image could have a caption to explain it. Although the content is there, it's too brief and I feel it could be organised in a more effective manner, such as using number stages.&lt;br /&gt;
#* Types of Cleft Palate/Lip:very brief, please explain the points (ie. what's the differences between them? you say there are differences in severity, how so?)&lt;br /&gt;
#* Pathophysiology: need to reformat table more effectively and work on referencing&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* need to balance out the text with images, could organise page better with more subheadings &lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* needs to work on referencing!!&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
#* NO self drawn images so far&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* much more research needs to be done. sections overall are lacking substance and doesn't explain the content very well&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* referencing&lt;br /&gt;
* more images&lt;br /&gt;
* glossary; lacking a lot of terms&lt;br /&gt;
* needs much more research&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 11:02, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 9 attendence==&lt;br /&gt;
--[[User:Z3291643|z3291643]] 13:00, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 10 attendence==&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 13:15, 6 October 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 10 Online Assessment==&lt;br /&gt;
&lt;br /&gt;
1.Besides fetal alcohol syndrome, identify another environmental teratogen that can lead to hearing loss.&lt;br /&gt;
Noise pollution is a big factor in hearing loss, as well as viral and bacterial infections such as meningitis. Hearing loss from meningitis can be a result of the direct effects of the infection on the brain or the body's reaction to the infection, most commonly with pneumococcal meningitis. 6% of all hearing defects in children can be attributed to bacterial meningitis, with around 72% of these children progressing to complete hearing loss by the age of three. &lt;br /&gt;
&lt;br /&gt;
2.Identify 3 factors that contribute to poor neonatal drainage of the middle ear. &lt;br /&gt;
The auditory tube connects the middle ear cavity to the nasopharynx, and is different in structure in neonates vs. adults.&lt;br /&gt;
:# the eustachian tube is very horizontal (10 degrees to the horizontal axis)&lt;br /&gt;
:# only opened by a single muscle called the tensor palati muscle (compared to 2 muscles in the adult tube)&lt;br /&gt;
:# it is shorter(17-18 mm) and narrower &lt;br /&gt;
&lt;br /&gt;
3.Identify 1 genetic abnormality that affects hearing development and link to the OMIM record. (Your individual abnormality should be different from all other students)&lt;br /&gt;
* Waardenburg syndrome&lt;br /&gt;
* results in hearing loss (to variable extent)&lt;br /&gt;
* inherited in an autosomal dominant manner&lt;br /&gt;
* [http://omim.org/entry/193500 Waardenburg syndrome]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Related Links'''&lt;br /&gt;
&lt;br /&gt;
'''Animal Models'''&lt;br /&gt;
&lt;br /&gt;
* [[Mouse Knockout]] - this page explains the current use of mouse models in disrupting genes to elucidate their genetic function, including the mouse gene knockouts for alpha calcium-calmodulin kinase II (alpha CaMKII)&lt;br /&gt;
* [[2009 Group Project 4]] - this page gives an extensive overview on the history of the mouse model and its various use in embryology and genetics. In addition, it also describes mouse knockout and the role they play in current research of various human diseases&lt;br /&gt;
* [[Fly Development]] - this page describes the use of drosophila flies as developmental models&lt;br /&gt;
* [[2009 Group Project 2]] - this page gives an extensive overview on the history of the fly model and its various use in embryology and genetics&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 10:20, 13 October 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==''' References '''==&lt;br /&gt;
&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;/div&gt;</summary>
		<author><name>Z3291643</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=User:Z3291643&amp;diff=77658</id>
		<title>User:Z3291643</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=User:Z3291643&amp;diff=77658"/>
		<updated>2011-10-12T23:21:20Z</updated>

		<summary type="html">&lt;p&gt;Z3291643: /* Related Links */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{2011Student}}&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Z3291643]] 12:55, 28 July 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 1 Assessment==&lt;br /&gt;
1.	Identify the origin of In Vitro Fertilization and the 2010 nobel prize winner associated with this technique.&lt;br /&gt;
&lt;br /&gt;
‘in vitro’ fertilization is Latin for ‘in glass’ fertilization and is a treatment for infertility, whereby the sperm fertilizes the ovum outside the body and is then implanted back into the patient’s uterus. The first successful IVF birth, Louise Brown, occurred in 1978 with the help of Patrick Steptoe and Robert Edwards. Edwards was awarded the 2010 nobel prize in medicine for his achievement. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
2.	Identify a recent paper on fertilisation and describe its key findings.&lt;br /&gt;
&lt;br /&gt;
The aim of this paper was to investigate whether age &amp;lt;=25 played a role in the reproductive outcome of women undergoing IVF. Infertile patients aged between 19 and 25 years of age were compared to infertile patients aged 30-35 years to determine primarily fertilization rates and the number of top quality embryos. The results were unexpected as the younger subjects had lower fertilization rates and reduced embryo quality.&amp;lt;ref&amp;gt;PMID 21042842&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
3.	Identify 2 congenital anomalies.&lt;br /&gt;
&lt;br /&gt;
Trisomy 21 and cleft palate&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--[[User:S8600021|Mark Hill]] 10:01, 3 August 2011 (EST) These answers are fine.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 13:02, 4 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Lab 2 Assessment==&lt;br /&gt;
1.	Identify the ZP protein that spermatozoa binds and how is this changed (altered) after fertilization. &lt;br /&gt;
&lt;br /&gt;
ZP3 acts as a receptor for the sperm. This is followed by the acrosome reaction, whereby acrosomal contents digest the ZP and allow the sperm surface proteins to bind to the ZP2. After fertilization, cortical reaction takes place where cortical granules are exocytosed. This results in the removal of carbohydrate from ZP3 and cleavage of ZP2 to harden the ZP. These changes occur to prevent polyspermy.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
2.       Identify a review and a research article related to your group topic.&lt;br /&gt;
&lt;br /&gt;
This research article showed genotype-phenotype correlations in Angelman Syndrome (AS). They have concluded that deletion patients had worse developmental outcomes than non deletion patients.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20729760&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
This review article is really comprehensive and gives a good background knowledge of AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20445456&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Z3291643]] 12:42, 11 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 3 Assessment==&lt;br /&gt;
&lt;br /&gt;
1.        What is the maternal dietary requirement for late neural development? &lt;br /&gt;
&lt;br /&gt;
Iodine. Zimmermann found that maternal deficiency of iodine can result in cognitive disability in the offspring, most severely characterized by cretinism. Fortunately, mild to moderate iodine deficiency can be corrected in primary school aged children to improve cognitive and motor functions.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21802524&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
2.        Upload a picture relating to your group project.&lt;br /&gt;
&lt;br /&gt;
[[File:UBE3A colocalizes with ASPM at the centrosome throughout mitosis.jpg|thumb|UBE3A colocalizes with ASPM at the centrosome throughout mitosis.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21633703&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
===UBE3A colocalizes with ASPM at the centrosome throughout mitosis===&lt;br /&gt;
&lt;br /&gt;
[[File:UBE3A colocalizes with ASPM at the centrosome throughout mitosis.jpg|Abnormal cytokinesis and apoptosis in UBE3A knockdown cells.|350px]]&lt;br /&gt;
&lt;br /&gt;
UBE3A colocalizes with ASPM at the centrosome. (A) Indirect immunofluorescence of HEK293 cells at interphase and different phases of mitosis stained with antibodies against ASPM and UBE3A (anti-UBE3A-sc-8926). Note colocalization of UBE3A with ASPM at the centrosome throughout mitosis (arrowheads). Note weak centrosomal staining of UBE3A in an interphase cell (arrow). (B) Indirect immunofluorescence of A549 cells stained with antibodies against UBE3A (anti-UBE3A-sc-8926) and ASPM at metaphase and telophase. Note colocalization of UBE3A with ASPM at the centrosome (arrowheads). Scale bar=2 µm.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Copyright Singhmar, Kumar. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 11:08, 18 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 4 Online Assessment==&lt;br /&gt;
&lt;br /&gt;
# '''The allantois, identified in the placental cord, is continuous with what anatomical structure?'''&lt;br /&gt;
The allantois is endodermic in origin and is the extension of the yolk sac into the connecting stalk. It's connected to the superior end of the developing bladder&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
#  '''Identify the 3 vascular shunts, and their location, in the embryonic circulation.'''&lt;br /&gt;
1. Ductus arteriosus; connects left pulmonary artery with the descending aorta&lt;br /&gt;
2. Ductus venosus; connects the portal and umbilical veins to the inferior vena cava&lt;br /&gt;
3. Foramen ovale; between left and right atria&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
# Identify the Group project sub-section that you will be researching. (Add to project page and your individual assessment page)&lt;br /&gt;
&lt;br /&gt;
; 4  Aetiology (genetic inheritance); Julia&lt;br /&gt;
; 5  Pathophysiology; Julia (as it's quite linked with aetiology anyway)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 12:59, 25 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 5 Online Assessment==&lt;br /&gt;
&lt;br /&gt;
# Which side (L/R) is most common for diaphragmatic hernia and why? &lt;br /&gt;
Posterior left side,possibly due to the fact that the left pericardioperitoneal canal is larger and closes later than the right.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 12:48, 1 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 6 Online Assessment==&lt;br /&gt;
# What week of development do the palatal shelves fuse?&lt;br /&gt;
Week 9 of early embryonic growth&lt;br /&gt;
 &lt;br /&gt;
# What early animal model helped elucidate the neural crest origin and migration of neural crest cells?&lt;br /&gt;
Migration of neural crest cells have been studied in quail-chick chimeras - transplanted quail cells have obvious nucleoli compared with chicken. It was first done by Nicole Le Douarin in the 80's&lt;br /&gt;
 &lt;br /&gt;
# What abnormality results from neural crest not migrating into the cardiac outflow tract? &lt;br /&gt;
Tetralogy of Fallot; when the outflow tract is not aligned properly, it is seen as a nonwedged aorta. Nonwedged aorta indicates tetralogy of Fallot. In addition, past studies using chick embryos have outlined that cardiac neural crest cell ablation led to this malalignment. In contrast, Farrell et al have shown that the introduction of cardiac neural crest aligned the outflow tract properly. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9933243&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 12:49, 15 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 7 Online Assessment==&lt;br /&gt;
&lt;br /&gt;
1. Are satellite cells &lt;br /&gt;
* necessary for muscle hypertrophy?&lt;br /&gt;
: No&lt;br /&gt;
 &lt;br /&gt;
* generally involved in hypertrophy?&lt;br /&gt;
: Yes&lt;br /&gt;
 &lt;br /&gt;
&lt;br /&gt;
2. Why does chronic low frequency stimulation (CLFS) cause a fast to slow fibre type shift? &lt;br /&gt;
: At the molecular level, there are exchanges of fast and slow type protein isoforms, such as calcium regulatory system, myofibrillar apparatus. The final step in CLFS induced fiber shift is the upregulation of slow myosin from the conversion of myogenic cells to slow fiber phenotype. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12500901&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;It is also known that satellite cells contribute to CLFS-induced transition of fiber types shown by the fact that CLFS increases type I fibers only after fiber necrosis. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16439424&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--Mark Hill 10:42, 16 September 2011 (EST) &lt;br /&gt;
&lt;br /&gt;
I would like each student to now also look at the following online page before the next Lab and write a comment based upon the group project assessment criteria. &lt;br /&gt;
&lt;br /&gt;
http://embryology.med.unsw.edu.au/embryology/index.php?title=Trisomy_21 &lt;br /&gt;
Paste your comment on the Trisomy 21 discussion page and also on your own student page. &lt;br /&gt;
&lt;br /&gt;
Group Assessment Criteria&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Good and concise explanation of the subheadings,however, I would've liked to see some attempt to further explain how the asspcoated congenital abnormalities occur.  &lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Lots of images, graphs and table used effectively to help reader better understand the disease. They also gave the project page some colour to make it more pleasing to the eye. Unfortunately, some images were placed (eg. John Langdon Down)in the wrong sections and interrupted the flow of the project page. &lt;br /&gt;
#* In addition, some of the images were not referred to within the project page. &lt;br /&gt;
#* Furthermore, the overall structure and layout of the page could be improved, such as putting the Diagnostic Links under diagnosis instead of the introduction&lt;br /&gt;
#* I also felt American College of Obstetricians and Gynecologists Recommendations could've been a subheading under 'screening'&lt;br /&gt;
#Content is correctly cited and referenced. &lt;br /&gt;
#* The very first image does not provide any information on the permissions to reuse the image (open access). &lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations. &lt;br /&gt;
#* Would've been better to include more self drawn diagrams and tables to further illustrate the group's knowledge of this disease&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* Lots of Pubmed articles have been used to make this page more credible and reliable &lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#* More words need to be explained in the glossary, such as 'tandem single nucleotide polymorphisms' &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 22:50, 21 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 8 Online Assessment==&lt;br /&gt;
attendance: --[[User:Z3291643|Sang Lee]] 13:04, 22 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Group 1: Turner Syndrome&lt;br /&gt;
&lt;br /&gt;
Firstly, nice progress with the group project. After reading your page, I have a good general knowledge of Turner Syndrome, so thanks. Overall, most sections were well done, though the writing style and layout could be more consistent, but you could work on that when you've finalised the content of the page. &lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: Good intro, very first image of the karyotype should include the actual statement of the 'Open access' not just 'copyright'&lt;br /&gt;
#* Epidemiology: Grammatical errors disrupt the flow of the content, in addition, graph has no copyright info, title could be improved&lt;br /&gt;
#* Etiology: Nice simple diagram of 22 eggs and 23 sperms, good example of when a picture can tell more than a thousand words! I feel there needs to be consistency either use Turner Syndrome or TS throughout the page&lt;br /&gt;
#* Clinical: liked how you have further classified the symptoms to its associated titles, nice idea; very easy to read, but a table would also be good&lt;br /&gt;
#* Diagnosis: image of TS maternal serum sampling doesn't contain {Template:2011 Student Image}, but a very good table&lt;br /&gt;
#* image of the TS X chromosome variations shouldl contain {Template:2011 Student Image}. Furthermore, if you use A-E in image descriptions, you should include A-E within the image&lt;br /&gt;
#* Research: very good layout and explanations, informative&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Could include more images especially in clinical manidestations, and some images do not fit the requirements set by Mark, as I've highlighted above &lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* seems to be cited well. However, although you have more than 100 referencees, a lot of them are repeated references, maybe you could try to use more pubmed articles, a greater variety&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations. &lt;br /&gt;
#* Glossary: could include more words such as echocardiogram&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* Although you have more than 100 referencees, a lot of them are repeated references, maybe you could try to use more pubmed articles, a greater variety&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#*  Although the content is informative, I'm left feeling like I want more variety of resources, so maybe some further research will improve the overall impression of your page &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot;&lt;br /&gt;
* consistency in writing style&lt;br /&gt;
* more images and cited correctly &lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 14:44, 24 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Group 2&lt;br /&gt;
&lt;br /&gt;
Hey Group 2, firstly, well done on putting in the effort to create this page, it really shows your dedication and cooperation as a team! Here are some points I thought you could improve on to take this page to that extra level&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: Good overview. Image would look better with a border or as a thumb&lt;br /&gt;
#* History: Image too large, again maybe a border?&lt;br /&gt;
#* Epidemiology: Need to define velocardiofacial syndrome in glossary, also break it down into subheadings, eg. Incidence, Sex, etc&lt;br /&gt;
#* Etiology: Maybe better if in a table&lt;br /&gt;
#* Pathogenesis: I liked how you broke it doen into relevant subheadings. However, on a slightly negative note, the DG Pathophysiology Diagram looks rushed; I think it would've looked better if it was neater and easier to read.&lt;br /&gt;
#* Diagnosis: I felt citing was done poorly in this section, eg. the last 4/5 sentences in the FISH technique was not referenced at all, but again, this is very easily fixed. But good to see you have put in the effort and time&lt;br /&gt;
#* Clinical: Image of normal and cleft palate, if based on a textbook, I think you still need permission to adapt it (not quite sure, please ask Mark)? Table with 'How it is caused' would be better by itself as pathophysiology. Tetralogy of Fallot needs to be fitted into this section more smoothly, at the moment, it makes this section look very cramped. Also, the image regarding Tetralogy needs the correct format for student drawn images (ie. 'I (student no.)....)&lt;br /&gt;
#* Research: Maybe break it down into subheadings&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Good images used with a nice range of self drawn images. However, no where in the page is there any reference to the images within the text.&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* I feel citation needs to be improved overall. Lots of the sections have missing citations, especially Diagnostic Tests. Also in the reference list, refs 33,40,47, 49 have nothing in it (is it meant to be like this?)&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations. &lt;br /&gt;
#* Nice drawings, though some could've done better with more effort&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* Nice range of references used&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#* It's very clear to me that you guys have worked together well and there has been good team work going on here to create this page, so well done&lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* I feel your page is too heavy with the text, although there's a lot of images as well, it just doesn't quite balance out with the text. &lt;br /&gt;
* Also felt the different colours used for the tables, although adding a splash of colour to your page, brought down the overall quality of the page. However, please keep in mind that others might really like this approach of table formatting, it's just that personally, I think you could benefit from keeping all table colours consistent.&lt;br /&gt;
* Sometimes you refer to DiGeorge Syndrome as DGS and also as DS. Small and easy to fix, adds consistency&lt;br /&gt;
* Please don't forget to add the {template} for student uploaded images&lt;br /&gt;
* Definitely needs more words in the Glossary, such as Meiosis, de novo, microarray&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 16:02, 24 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 3&lt;br /&gt;
&lt;br /&gt;
Hi, overall, a nice project page with interesting information.&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: Nice introduction, good flow and easy to read. However, image needs proper information and perhaps 'This disorder was first described by Harry F.' could be placed earlier on in the intro rather than in the middle&lt;br /&gt;
#* History: Nice section, very interesting&lt;br /&gt;
#* Epidemiology: First paragraph is good, but I feel the rest of this section doesn't quite belong here, such as the information on seizures, IQs, diagnosis. This section should focus on stats (sex/birth/ethnic/demographic/etc). Fig 2, 3 belong more in the signs and symptoms&lt;br /&gt;
#* Etiology: the '1:1000 male' contradicts the '1:500' given in epidemiology. Fig4 needs coyright information&lt;br /&gt;
#* Pathogenesis: Needs better referencing, also placing fig 5, 6 on either side doesn't look too good with the text. Perhaps place them below one another?&lt;br /&gt;
#* Signs: Seems a bit incomplete, it'll also be good to explain the image of 'pubertal gynecomastia'&lt;br /&gt;
#* Diagnosis: Sentence structure could be improved, ie. 'performed because physicians may suspect it because of clinical findings'. Information is interesting, but could be presented more clearly, perhaps in a table?&lt;br /&gt;
#* Similar defects: very nice, presented well with good information, easy to read&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Good images used with a nice range of self drawn images. However, lot of the images need to be formatted properly with required information&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* overall referencing was well done, except pathogenesis needs more referencing&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations. &lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* Nice range of references used&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#* The information is there, but maybe from now til final assessment, you could do further research in all sections, as they do seem a little short.&lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* better page layout&lt;br /&gt;
* glossary: sorry, but I feel the alphabet subheadings here are very effective as you have it in alphabetical order anyway&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 21:59, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 4&lt;br /&gt;
&lt;br /&gt;
Hey, this is a nicely structured page with interesting content that is presented well. There is a nice balance of text and image&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: good, to the point&lt;br /&gt;
#* History: Nice section, perhaps bold the years?&lt;br /&gt;
#* Epidemiology: I really liked this section, both visually and content wise. The table is easy to read and I liked your explanations for the HD prevalence, well done&lt;br /&gt;
#* Genetics: Perhaps you could have the 'CAG (cytosine-adenine-glutamine)' in the introduction when you first refer to it? Referencing is required in i'HTT and normal functions'. I really liked your subheadings, made it very easy to understand and follow &lt;br /&gt;
#* Pathogenesis: Image is too big, good subheadings, I suggest that if you write in purple to highlight some words, maybe you could do that for the whole page?&lt;br /&gt;
#* Clinical: liked the motor impairment explanations, how about explaining the cognitive and behaviour impairments as well? (it'll be worth it!)&lt;br /&gt;
#* Diagnosis: Nice content, but it just feels a bit too crowded, maybe rearrange the images and decrease image size&lt;br /&gt;
#* Treatment: Very nice section with nice images and good format!&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Good balance of images and text, though some rearrangement of images would make this page look better. Very good use of subheadings to make the content more easy to digest&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* overall referencing was well done&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
* good range of tables, images and self drawn images&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* Nice range of references used&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* just minor changes such as resizing some of the images, making the sections consistent in format&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 22:32, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 5&lt;br /&gt;
&lt;br /&gt;
Hi, I can see some progress on this page which is good, content is interesting&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: What is FMR1 gene? Need more information here, as in when was it first discovered, some stats&lt;br /&gt;
#* Epidemiology: I think screening information is extensive enough to be a section on its own&lt;br /&gt;
#* Etiology: no explanation of FMR1 gene so far, what is its normal function? Also, please refer to images used in this section&lt;br /&gt;
#* Development of the disease:nice succinct, easy to follow section. Perhaps add an image for one of the stages mentioned here?&lt;br /&gt;
#* Signs: REFERENCING!!! But, content is good and interesting&lt;br /&gt;
#* Diagnosis: An image here would be nice, and an explanation of how the technology is used to diagnose FXS&lt;br /&gt;
#* Treatment: Nice table with good information&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Need to balance out the text and image ratio, some good subheadings&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* poor referencing, which makes me question the reliability of the content in some sections&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
#* needs a lot more images&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* I feel more research needs to be done here&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* Although the content is here, there is still a lot of work needed to make this page feel complete&lt;br /&gt;
* glossary is very lacking in terminology&lt;br /&gt;
* need more images&lt;br /&gt;
* further research would be nice to explain this disease in more detail&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 23:26, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Group 6&lt;br /&gt;
Hey, nice progress with your page, all sections have similar amount of content which were interesting&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: Referencing needs to be improved here&lt;br /&gt;
#* History: content is good but too wordy. I think a summary or a simple timeline would be good&lt;br /&gt;
#* Epidemiology: Where's the reference for 3/10000 live births?&lt;br /&gt;
#* Signs: ok section, but could do with more images here&lt;br /&gt;
#* Genetics: If using abbreviations, such as TBX1 gene, you should explain what it is, ie. TBX1 gene (T-box 1). Also need to work on referencing here as well. How about organising all the content in a table? have in columns: gene, gene profile, frequency, etc.&lt;br /&gt;
#* Pathogenesis: I'm not quite sure about this, but do you need permission to adapt an image from an article? (I'm referring to the '4 defects' image)&lt;br /&gt;
#* Diagnosis: I'm sorry, but this section is a bit bland, though the content is very informative. I think some images here would be good&lt;br /&gt;
#* Treatment: Referencing! Also, personally, that green is too bright, maybe find a more neutral, soothing colour?&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Need to find more images, I feel some of the information could be more effectively presented in table formate rather than lengthy text&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* VERY poor referencing, which makes me question the reliability of the content in some sections&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
#* needs a lot more images&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* research done is evident, just need to reference&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* glossary is very lacking in terminology&lt;br /&gt;
* need more images&lt;br /&gt;
* REFERENCING!&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 23:26, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Group 8&lt;br /&gt;
Hey, well done, your page is looking really polished! Lots of very interesting information here and presented in a very easy to follow manner&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* History: I feel that you could lessen the info of Nicholas and add more current findings of the disease.&lt;br /&gt;
#* Aetiology: What is the chromosome 9 image based on? Need to work on referencing. Very good subheadings and well balanced with images&lt;br /&gt;
#* Pathogenesis: Needs more information&lt;br /&gt;
#* Neuro: What's the images based on? Good subheadings and explained well. I liked the way you gave explanations for normal function/appearance and then went on to explain abnormality associated with the structures in this disease. But you need to improve your referencing for this section&lt;br /&gt;
#* Diagnosis: Very good table and images. But need to fix the postnal diagnosis table so that it spans the length of the screen&lt;br /&gt;
#* Symptoms: table and images look too crowded&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* good subheadings, images, impressive self drawn images! Nice balanced page layout&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* needs to work on referencing&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* research done is evident, just need to reference&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* referencing&lt;br /&gt;
* better arrangement of table and images so page doesn't look too crowded&lt;br /&gt;
&lt;br /&gt;
Well done guys, nice team work!&lt;br /&gt;
--[[User:Z3291643|z3291643]] 23:50, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 9&lt;br /&gt;
&lt;br /&gt;
Hey, your page has a lot of very interesting content and some unique self drawn images. I thoroughly enjoyed this page, thanks&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: Inclusion of incidence would be nice&lt;br /&gt;
#* History: very informative and a nice simple timeline&lt;br /&gt;
#* Genetics: Good, succinct section, especially liked the table&lt;br /&gt;
#* Diagnosis: needs referencing. Is diagnosis only postnatal? What is the average age of diagnosis for this disease?&lt;br /&gt;
#* Management and Treatment: Seems a little out of place under epidemiology, I think it should be place later on &lt;br /&gt;
#* Phenotype:Reference?&lt;br /&gt;
#* Cardiac conditions: maybe give explanations for atrial and ventricular septal defect, just brief descriptions would suffice. Why is it so that males are more likely to suffer CVD than females?&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* good subheadings, interesting self drawn images. However, this page needs to find a balance in text and images&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* needs to work on referencing&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* research done is evident, just need to reference&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#* very interesting content, informative&lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* referencing&lt;br /&gt;
* more images&lt;br /&gt;
* glossary; lacking a lor of terms&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 00:10, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 10&lt;br /&gt;
&lt;br /&gt;
Hey, this is a interesting disease, with some good images to show the disease clearly. &lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: succinct introduction&lt;br /&gt;
#* History: Has interesting content, though timeline would be nice&lt;br /&gt;
#* Pathogenesis: Too brief and could be improved with an image&lt;br /&gt;
#* Signs: surely there are more symptoms here, maybe you could have subheadings to break down the symtpoms, ie. motor impairment, cognitive impairments, etc&lt;br /&gt;
#* Clinical manifestations and complications: nice section with good image used&lt;br /&gt;
#* Diagnosis: could be further explained, and an image would be nice&lt;br /&gt;
#* Treatment: Current and Future Prospects: needs referencing&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* need to balance out the text with images, could organise page better with more subheadings, more images needed &lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* needs to work on referencing!!&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
#*  more table could be used instead of lengthy explanations&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* much more research needs to be done to further explain the sections&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* referencing&lt;br /&gt;
* more images&lt;br /&gt;
* glossary; lacking a lot of terms&lt;br /&gt;
* needs much more research, lots of repetitions in referencing&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 11:02, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 11&lt;br /&gt;
&lt;br /&gt;
Hey, this is a interesting disease, with some good images to show the disease clearly. &lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: very rushed, no reference and needs much more work, it should be a succinct summary of this whole page.&lt;br /&gt;
#* History: Has interesting content, though timeline would be better incorporated under History, not a section of its own&lt;br /&gt;
#* Diagnosis: If you're abbreviating Cleft Palate to CLP, you should have it as Cleft palate (CLP). The two given tables are pretty much the same, except for different sample number. Is it really necessary to have the two tables when they're so similar? Could do well with an image&lt;br /&gt;
#* Syndromes and Anomalies associated with cleft: Nice array of images used here. Content is good (for ones you provided), but needs work on referencing. Perhaps you could organise the content into a table for easy comparison since you have more than one anomalies&lt;br /&gt;
#* Aetiology: Needs referencing, image could have a caption to explain it. Although the content is there, it's too brief and I feel it could be organised in a more effective manner, such as using number stages.&lt;br /&gt;
#* Types of Cleft Palate/Lip:very brief, please explain the points (ie. what's the differences between them? you say there are differences in severity, how so?)&lt;br /&gt;
#* Pathophysiology: need to reformat table more effectively and work on referencing&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* need to balance out the text with images, could organise page better with more subheadings &lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* needs to work on referencing!!&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
#* NO self drawn images so far&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* much more research needs to be done. sections overall are lacking substance and doesn't explain the content very well&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* referencing&lt;br /&gt;
* more images&lt;br /&gt;
* glossary; lacking a lot of terms&lt;br /&gt;
* needs much more research&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 11:02, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 9 attendence==&lt;br /&gt;
--[[User:Z3291643|z3291643]] 13:00, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 10 attendence==&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 13:15, 6 October 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 10 Online Assessment==&lt;br /&gt;
&lt;br /&gt;
1.Besides fetal alcohol syndrome, identify another environmental teratogen that can lead to hearing loss.&lt;br /&gt;
Noise pollution is a big factor in hearing loss, as well as viral and bacterial infections such as meningitis. Hearing loss from meningitis can be a result of the direct effects of the infection on the brain or the body's reaction to the infection, most commonly with pneumococcal meningitis. 6% of all hearing defects in children can be attributed to bacterial meningitis, with around 72% of these children progressing to complete hearing loss by the age of three. &lt;br /&gt;
&lt;br /&gt;
2.Identify 3 factors that contribute to poor neonatal drainage of the middle ear. &lt;br /&gt;
The auditory tube connects the middle ear cavity to the nasopharynx, and is different in structure in neonates vs. adults.&lt;br /&gt;
:# the eustachian tube is very horizontal (10 degrees to the horizontal axis)&lt;br /&gt;
:# only opened by a single muscle called the tensor palati muscle (compared to 2 muscles in the adult tube)&lt;br /&gt;
:# it is shorter(17-18 mm) and narrower &lt;br /&gt;
&lt;br /&gt;
3.Identify 1 genetic abnormality that affects hearing development and link to the OMIM record. (Your individual abnormality should be different from all other students)&lt;br /&gt;
* Waardenburg syndrome&lt;br /&gt;
* results in hearing loss (to variable extent)&lt;br /&gt;
* inherited in an autosomal dominant manner&lt;br /&gt;
* [http://omim.org/entry/193500 Waardenburg syndrome]&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 10:20, 13 October 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==''' References '''==&lt;br /&gt;
&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;/div&gt;</summary>
		<author><name>Z3291643</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=User:Z3291643&amp;diff=77655</id>
		<title>User:Z3291643</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=User:Z3291643&amp;diff=77655"/>
		<updated>2011-10-12T23:20:34Z</updated>

		<summary type="html">&lt;p&gt;Z3291643: /* Lab 10 Online Assessment */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{2011Student}}&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Z3291643]] 12:55, 28 July 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 1 Assessment==&lt;br /&gt;
1.	Identify the origin of In Vitro Fertilization and the 2010 nobel prize winner associated with this technique.&lt;br /&gt;
&lt;br /&gt;
‘in vitro’ fertilization is Latin for ‘in glass’ fertilization and is a treatment for infertility, whereby the sperm fertilizes the ovum outside the body and is then implanted back into the patient’s uterus. The first successful IVF birth, Louise Brown, occurred in 1978 with the help of Patrick Steptoe and Robert Edwards. Edwards was awarded the 2010 nobel prize in medicine for his achievement. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
2.	Identify a recent paper on fertilisation and describe its key findings.&lt;br /&gt;
&lt;br /&gt;
The aim of this paper was to investigate whether age &amp;lt;=25 played a role in the reproductive outcome of women undergoing IVF. Infertile patients aged between 19 and 25 years of age were compared to infertile patients aged 30-35 years to determine primarily fertilization rates and the number of top quality embryos. The results were unexpected as the younger subjects had lower fertilization rates and reduced embryo quality.&amp;lt;ref&amp;gt;PMID 21042842&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
3.	Identify 2 congenital anomalies.&lt;br /&gt;
&lt;br /&gt;
Trisomy 21 and cleft palate&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--[[User:S8600021|Mark Hill]] 10:01, 3 August 2011 (EST) These answers are fine.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 13:02, 4 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Lab 2 Assessment==&lt;br /&gt;
1.	Identify the ZP protein that spermatozoa binds and how is this changed (altered) after fertilization. &lt;br /&gt;
&lt;br /&gt;
ZP3 acts as a receptor for the sperm. This is followed by the acrosome reaction, whereby acrosomal contents digest the ZP and allow the sperm surface proteins to bind to the ZP2. After fertilization, cortical reaction takes place where cortical granules are exocytosed. This results in the removal of carbohydrate from ZP3 and cleavage of ZP2 to harden the ZP. These changes occur to prevent polyspermy.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
2.       Identify a review and a research article related to your group topic.&lt;br /&gt;
&lt;br /&gt;
This research article showed genotype-phenotype correlations in Angelman Syndrome (AS). They have concluded that deletion patients had worse developmental outcomes than non deletion patients.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20729760&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
This review article is really comprehensive and gives a good background knowledge of AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20445456&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Z3291643]] 12:42, 11 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 3 Assessment==&lt;br /&gt;
&lt;br /&gt;
1.        What is the maternal dietary requirement for late neural development? &lt;br /&gt;
&lt;br /&gt;
Iodine. Zimmermann found that maternal deficiency of iodine can result in cognitive disability in the offspring, most severely characterized by cretinism. Fortunately, mild to moderate iodine deficiency can be corrected in primary school aged children to improve cognitive and motor functions.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21802524&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
2.        Upload a picture relating to your group project.&lt;br /&gt;
&lt;br /&gt;
[[File:UBE3A colocalizes with ASPM at the centrosome throughout mitosis.jpg|thumb|UBE3A colocalizes with ASPM at the centrosome throughout mitosis.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21633703&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
===UBE3A colocalizes with ASPM at the centrosome throughout mitosis===&lt;br /&gt;
&lt;br /&gt;
[[File:UBE3A colocalizes with ASPM at the centrosome throughout mitosis.jpg|Abnormal cytokinesis and apoptosis in UBE3A knockdown cells.|350px]]&lt;br /&gt;
&lt;br /&gt;
UBE3A colocalizes with ASPM at the centrosome. (A) Indirect immunofluorescence of HEK293 cells at interphase and different phases of mitosis stained with antibodies against ASPM and UBE3A (anti-UBE3A-sc-8926). Note colocalization of UBE3A with ASPM at the centrosome throughout mitosis (arrowheads). Note weak centrosomal staining of UBE3A in an interphase cell (arrow). (B) Indirect immunofluorescence of A549 cells stained with antibodies against UBE3A (anti-UBE3A-sc-8926) and ASPM at metaphase and telophase. Note colocalization of UBE3A with ASPM at the centrosome (arrowheads). Scale bar=2 µm.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Copyright Singhmar, Kumar. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 11:08, 18 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 4 Online Assessment==&lt;br /&gt;
&lt;br /&gt;
# '''The allantois, identified in the placental cord, is continuous with what anatomical structure?'''&lt;br /&gt;
The allantois is endodermic in origin and is the extension of the yolk sac into the connecting stalk. It's connected to the superior end of the developing bladder&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
#  '''Identify the 3 vascular shunts, and their location, in the embryonic circulation.'''&lt;br /&gt;
1. Ductus arteriosus; connects left pulmonary artery with the descending aorta&lt;br /&gt;
2. Ductus venosus; connects the portal and umbilical veins to the inferior vena cava&lt;br /&gt;
3. Foramen ovale; between left and right atria&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
# Identify the Group project sub-section that you will be researching. (Add to project page and your individual assessment page)&lt;br /&gt;
&lt;br /&gt;
; 4  Aetiology (genetic inheritance); Julia&lt;br /&gt;
; 5  Pathophysiology; Julia (as it's quite linked with aetiology anyway)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 12:59, 25 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 5 Online Assessment==&lt;br /&gt;
&lt;br /&gt;
# Which side (L/R) is most common for diaphragmatic hernia and why? &lt;br /&gt;
Posterior left side,possibly due to the fact that the left pericardioperitoneal canal is larger and closes later than the right.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 12:48, 1 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 6 Online Assessment==&lt;br /&gt;
# What week of development do the palatal shelves fuse?&lt;br /&gt;
Week 9 of early embryonic growth&lt;br /&gt;
 &lt;br /&gt;
# What early animal model helped elucidate the neural crest origin and migration of neural crest cells?&lt;br /&gt;
Migration of neural crest cells have been studied in quail-chick chimeras - transplanted quail cells have obvious nucleoli compared with chicken. It was first done by Nicole Le Douarin in the 80's&lt;br /&gt;
 &lt;br /&gt;
# What abnormality results from neural crest not migrating into the cardiac outflow tract? &lt;br /&gt;
Tetralogy of Fallot; when the outflow tract is not aligned properly, it is seen as a nonwedged aorta. Nonwedged aorta indicates tetralogy of Fallot. In addition, past studies using chick embryos have outlined that cardiac neural crest cell ablation led to this malalignment. In contrast, Farrell et al have shown that the introduction of cardiac neural crest aligned the outflow tract properly. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9933243&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 12:49, 15 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 7 Online Assessment==&lt;br /&gt;
&lt;br /&gt;
1. Are satellite cells &lt;br /&gt;
* necessary for muscle hypertrophy?&lt;br /&gt;
: No&lt;br /&gt;
 &lt;br /&gt;
* generally involved in hypertrophy?&lt;br /&gt;
: Yes&lt;br /&gt;
 &lt;br /&gt;
&lt;br /&gt;
2. Why does chronic low frequency stimulation (CLFS) cause a fast to slow fibre type shift? &lt;br /&gt;
: At the molecular level, there are exchanges of fast and slow type protein isoforms, such as calcium regulatory system, myofibrillar apparatus. The final step in CLFS induced fiber shift is the upregulation of slow myosin from the conversion of myogenic cells to slow fiber phenotype. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12500901&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;It is also known that satellite cells contribute to CLFS-induced transition of fiber types shown by the fact that CLFS increases type I fibers only after fiber necrosis. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16439424&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--Mark Hill 10:42, 16 September 2011 (EST) &lt;br /&gt;
&lt;br /&gt;
I would like each student to now also look at the following online page before the next Lab and write a comment based upon the group project assessment criteria. &lt;br /&gt;
&lt;br /&gt;
http://embryology.med.unsw.edu.au/embryology/index.php?title=Trisomy_21 &lt;br /&gt;
Paste your comment on the Trisomy 21 discussion page and also on your own student page. &lt;br /&gt;
&lt;br /&gt;
Group Assessment Criteria&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Good and concise explanation of the subheadings,however, I would've liked to see some attempt to further explain how the asspcoated congenital abnormalities occur.  &lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Lots of images, graphs and table used effectively to help reader better understand the disease. They also gave the project page some colour to make it more pleasing to the eye. Unfortunately, some images were placed (eg. John Langdon Down)in the wrong sections and interrupted the flow of the project page. &lt;br /&gt;
#* In addition, some of the images were not referred to within the project page. &lt;br /&gt;
#* Furthermore, the overall structure and layout of the page could be improved, such as putting the Diagnostic Links under diagnosis instead of the introduction&lt;br /&gt;
#* I also felt American College of Obstetricians and Gynecologists Recommendations could've been a subheading under 'screening'&lt;br /&gt;
#Content is correctly cited and referenced. &lt;br /&gt;
#* The very first image does not provide any information on the permissions to reuse the image (open access). &lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations. &lt;br /&gt;
#* Would've been better to include more self drawn diagrams and tables to further illustrate the group's knowledge of this disease&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* Lots of Pubmed articles have been used to make this page more credible and reliable &lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#* More words need to be explained in the glossary, such as 'tandem single nucleotide polymorphisms' &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 22:50, 21 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 8 Online Assessment==&lt;br /&gt;
attendance: --[[User:Z3291643|Sang Lee]] 13:04, 22 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Group 1: Turner Syndrome&lt;br /&gt;
&lt;br /&gt;
Firstly, nice progress with the group project. After reading your page, I have a good general knowledge of Turner Syndrome, so thanks. Overall, most sections were well done, though the writing style and layout could be more consistent, but you could work on that when you've finalised the content of the page. &lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: Good intro, very first image of the karyotype should include the actual statement of the 'Open access' not just 'copyright'&lt;br /&gt;
#* Epidemiology: Grammatical errors disrupt the flow of the content, in addition, graph has no copyright info, title could be improved&lt;br /&gt;
#* Etiology: Nice simple diagram of 22 eggs and 23 sperms, good example of when a picture can tell more than a thousand words! I feel there needs to be consistency either use Turner Syndrome or TS throughout the page&lt;br /&gt;
#* Clinical: liked how you have further classified the symptoms to its associated titles, nice idea; very easy to read, but a table would also be good&lt;br /&gt;
#* Diagnosis: image of TS maternal serum sampling doesn't contain {Template:2011 Student Image}, but a very good table&lt;br /&gt;
#* image of the TS X chromosome variations shouldl contain {Template:2011 Student Image}. Furthermore, if you use A-E in image descriptions, you should include A-E within the image&lt;br /&gt;
#* Research: very good layout and explanations, informative&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Could include more images especially in clinical manidestations, and some images do not fit the requirements set by Mark, as I've highlighted above &lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* seems to be cited well. However, although you have more than 100 referencees, a lot of them are repeated references, maybe you could try to use more pubmed articles, a greater variety&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations. &lt;br /&gt;
#* Glossary: could include more words such as echocardiogram&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* Although you have more than 100 referencees, a lot of them are repeated references, maybe you could try to use more pubmed articles, a greater variety&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#*  Although the content is informative, I'm left feeling like I want more variety of resources, so maybe some further research will improve the overall impression of your page &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot;&lt;br /&gt;
* consistency in writing style&lt;br /&gt;
* more images and cited correctly &lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 14:44, 24 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Group 2&lt;br /&gt;
&lt;br /&gt;
Hey Group 2, firstly, well done on putting in the effort to create this page, it really shows your dedication and cooperation as a team! Here are some points I thought you could improve on to take this page to that extra level&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: Good overview. Image would look better with a border or as a thumb&lt;br /&gt;
#* History: Image too large, again maybe a border?&lt;br /&gt;
#* Epidemiology: Need to define velocardiofacial syndrome in glossary, also break it down into subheadings, eg. Incidence, Sex, etc&lt;br /&gt;
#* Etiology: Maybe better if in a table&lt;br /&gt;
#* Pathogenesis: I liked how you broke it doen into relevant subheadings. However, on a slightly negative note, the DG Pathophysiology Diagram looks rushed; I think it would've looked better if it was neater and easier to read.&lt;br /&gt;
#* Diagnosis: I felt citing was done poorly in this section, eg. the last 4/5 sentences in the FISH technique was not referenced at all, but again, this is very easily fixed. But good to see you have put in the effort and time&lt;br /&gt;
#* Clinical: Image of normal and cleft palate, if based on a textbook, I think you still need permission to adapt it (not quite sure, please ask Mark)? Table with 'How it is caused' would be better by itself as pathophysiology. Tetralogy of Fallot needs to be fitted into this section more smoothly, at the moment, it makes this section look very cramped. Also, the image regarding Tetralogy needs the correct format for student drawn images (ie. 'I (student no.)....)&lt;br /&gt;
#* Research: Maybe break it down into subheadings&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Good images used with a nice range of self drawn images. However, no where in the page is there any reference to the images within the text.&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* I feel citation needs to be improved overall. Lots of the sections have missing citations, especially Diagnostic Tests. Also in the reference list, refs 33,40,47, 49 have nothing in it (is it meant to be like this?)&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations. &lt;br /&gt;
#* Nice drawings, though some could've done better with more effort&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* Nice range of references used&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#* It's very clear to me that you guys have worked together well and there has been good team work going on here to create this page, so well done&lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* I feel your page is too heavy with the text, although there's a lot of images as well, it just doesn't quite balance out with the text. &lt;br /&gt;
* Also felt the different colours used for the tables, although adding a splash of colour to your page, brought down the overall quality of the page. However, please keep in mind that others might really like this approach of table formatting, it's just that personally, I think you could benefit from keeping all table colours consistent.&lt;br /&gt;
* Sometimes you refer to DiGeorge Syndrome as DGS and also as DS. Small and easy to fix, adds consistency&lt;br /&gt;
* Please don't forget to add the {template} for student uploaded images&lt;br /&gt;
* Definitely needs more words in the Glossary, such as Meiosis, de novo, microarray&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 16:02, 24 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 3&lt;br /&gt;
&lt;br /&gt;
Hi, overall, a nice project page with interesting information.&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: Nice introduction, good flow and easy to read. However, image needs proper information and perhaps 'This disorder was first described by Harry F.' could be placed earlier on in the intro rather than in the middle&lt;br /&gt;
#* History: Nice section, very interesting&lt;br /&gt;
#* Epidemiology: First paragraph is good, but I feel the rest of this section doesn't quite belong here, such as the information on seizures, IQs, diagnosis. This section should focus on stats (sex/birth/ethnic/demographic/etc). Fig 2, 3 belong more in the signs and symptoms&lt;br /&gt;
#* Etiology: the '1:1000 male' contradicts the '1:500' given in epidemiology. Fig4 needs coyright information&lt;br /&gt;
#* Pathogenesis: Needs better referencing, also placing fig 5, 6 on either side doesn't look too good with the text. Perhaps place them below one another?&lt;br /&gt;
#* Signs: Seems a bit incomplete, it'll also be good to explain the image of 'pubertal gynecomastia'&lt;br /&gt;
#* Diagnosis: Sentence structure could be improved, ie. 'performed because physicians may suspect it because of clinical findings'. Information is interesting, but could be presented more clearly, perhaps in a table?&lt;br /&gt;
#* Similar defects: very nice, presented well with good information, easy to read&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Good images used with a nice range of self drawn images. However, lot of the images need to be formatted properly with required information&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* overall referencing was well done, except pathogenesis needs more referencing&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations. &lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* Nice range of references used&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#* The information is there, but maybe from now til final assessment, you could do further research in all sections, as they do seem a little short.&lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* better page layout&lt;br /&gt;
* glossary: sorry, but I feel the alphabet subheadings here are very effective as you have it in alphabetical order anyway&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 21:59, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 4&lt;br /&gt;
&lt;br /&gt;
Hey, this is a nicely structured page with interesting content that is presented well. There is a nice balance of text and image&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: good, to the point&lt;br /&gt;
#* History: Nice section, perhaps bold the years?&lt;br /&gt;
#* Epidemiology: I really liked this section, both visually and content wise. The table is easy to read and I liked your explanations for the HD prevalence, well done&lt;br /&gt;
#* Genetics: Perhaps you could have the 'CAG (cytosine-adenine-glutamine)' in the introduction when you first refer to it? Referencing is required in i'HTT and normal functions'. I really liked your subheadings, made it very easy to understand and follow &lt;br /&gt;
#* Pathogenesis: Image is too big, good subheadings, I suggest that if you write in purple to highlight some words, maybe you could do that for the whole page?&lt;br /&gt;
#* Clinical: liked the motor impairment explanations, how about explaining the cognitive and behaviour impairments as well? (it'll be worth it!)&lt;br /&gt;
#* Diagnosis: Nice content, but it just feels a bit too crowded, maybe rearrange the images and decrease image size&lt;br /&gt;
#* Treatment: Very nice section with nice images and good format!&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Good balance of images and text, though some rearrangement of images would make this page look better. Very good use of subheadings to make the content more easy to digest&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* overall referencing was well done&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
* good range of tables, images and self drawn images&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* Nice range of references used&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* just minor changes such as resizing some of the images, making the sections consistent in format&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 22:32, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 5&lt;br /&gt;
&lt;br /&gt;
Hi, I can see some progress on this page which is good, content is interesting&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: What is FMR1 gene? Need more information here, as in when was it first discovered, some stats&lt;br /&gt;
#* Epidemiology: I think screening information is extensive enough to be a section on its own&lt;br /&gt;
#* Etiology: no explanation of FMR1 gene so far, what is its normal function? Also, please refer to images used in this section&lt;br /&gt;
#* Development of the disease:nice succinct, easy to follow section. Perhaps add an image for one of the stages mentioned here?&lt;br /&gt;
#* Signs: REFERENCING!!! But, content is good and interesting&lt;br /&gt;
#* Diagnosis: An image here would be nice, and an explanation of how the technology is used to diagnose FXS&lt;br /&gt;
#* Treatment: Nice table with good information&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Need to balance out the text and image ratio, some good subheadings&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* poor referencing, which makes me question the reliability of the content in some sections&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
#* needs a lot more images&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* I feel more research needs to be done here&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* Although the content is here, there is still a lot of work needed to make this page feel complete&lt;br /&gt;
* glossary is very lacking in terminology&lt;br /&gt;
* need more images&lt;br /&gt;
* further research would be nice to explain this disease in more detail&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 23:26, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Group 6&lt;br /&gt;
Hey, nice progress with your page, all sections have similar amount of content which were interesting&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: Referencing needs to be improved here&lt;br /&gt;
#* History: content is good but too wordy. I think a summary or a simple timeline would be good&lt;br /&gt;
#* Epidemiology: Where's the reference for 3/10000 live births?&lt;br /&gt;
#* Signs: ok section, but could do with more images here&lt;br /&gt;
#* Genetics: If using abbreviations, such as TBX1 gene, you should explain what it is, ie. TBX1 gene (T-box 1). Also need to work on referencing here as well. How about organising all the content in a table? have in columns: gene, gene profile, frequency, etc.&lt;br /&gt;
#* Pathogenesis: I'm not quite sure about this, but do you need permission to adapt an image from an article? (I'm referring to the '4 defects' image)&lt;br /&gt;
#* Diagnosis: I'm sorry, but this section is a bit bland, though the content is very informative. I think some images here would be good&lt;br /&gt;
#* Treatment: Referencing! Also, personally, that green is too bright, maybe find a more neutral, soothing colour?&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Need to find more images, I feel some of the information could be more effectively presented in table formate rather than lengthy text&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* VERY poor referencing, which makes me question the reliability of the content in some sections&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
#* needs a lot more images&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* research done is evident, just need to reference&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* glossary is very lacking in terminology&lt;br /&gt;
* need more images&lt;br /&gt;
* REFERENCING!&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 23:26, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Group 8&lt;br /&gt;
Hey, well done, your page is looking really polished! Lots of very interesting information here and presented in a very easy to follow manner&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* History: I feel that you could lessen the info of Nicholas and add more current findings of the disease.&lt;br /&gt;
#* Aetiology: What is the chromosome 9 image based on? Need to work on referencing. Very good subheadings and well balanced with images&lt;br /&gt;
#* Pathogenesis: Needs more information&lt;br /&gt;
#* Neuro: What's the images based on? Good subheadings and explained well. I liked the way you gave explanations for normal function/appearance and then went on to explain abnormality associated with the structures in this disease. But you need to improve your referencing for this section&lt;br /&gt;
#* Diagnosis: Very good table and images. But need to fix the postnal diagnosis table so that it spans the length of the screen&lt;br /&gt;
#* Symptoms: table and images look too crowded&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* good subheadings, images, impressive self drawn images! Nice balanced page layout&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* needs to work on referencing&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* research done is evident, just need to reference&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* referencing&lt;br /&gt;
* better arrangement of table and images so page doesn't look too crowded&lt;br /&gt;
&lt;br /&gt;
Well done guys, nice team work!&lt;br /&gt;
--[[User:Z3291643|z3291643]] 23:50, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 9&lt;br /&gt;
&lt;br /&gt;
Hey, your page has a lot of very interesting content and some unique self drawn images. I thoroughly enjoyed this page, thanks&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: Inclusion of incidence would be nice&lt;br /&gt;
#* History: very informative and a nice simple timeline&lt;br /&gt;
#* Genetics: Good, succinct section, especially liked the table&lt;br /&gt;
#* Diagnosis: needs referencing. Is diagnosis only postnatal? What is the average age of diagnosis for this disease?&lt;br /&gt;
#* Management and Treatment: Seems a little out of place under epidemiology, I think it should be place later on &lt;br /&gt;
#* Phenotype:Reference?&lt;br /&gt;
#* Cardiac conditions: maybe give explanations for atrial and ventricular septal defect, just brief descriptions would suffice. Why is it so that males are more likely to suffer CVD than females?&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* good subheadings, interesting self drawn images. However, this page needs to find a balance in text and images&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* needs to work on referencing&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* research done is evident, just need to reference&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#* very interesting content, informative&lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* referencing&lt;br /&gt;
* more images&lt;br /&gt;
* glossary; lacking a lor of terms&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 00:10, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 10&lt;br /&gt;
&lt;br /&gt;
Hey, this is a interesting disease, with some good images to show the disease clearly. &lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: succinct introduction&lt;br /&gt;
#* History: Has interesting content, though timeline would be nice&lt;br /&gt;
#* Pathogenesis: Too brief and could be improved with an image&lt;br /&gt;
#* Signs: surely there are more symptoms here, maybe you could have subheadings to break down the symtpoms, ie. motor impairment, cognitive impairments, etc&lt;br /&gt;
#* Clinical manifestations and complications: nice section with good image used&lt;br /&gt;
#* Diagnosis: could be further explained, and an image would be nice&lt;br /&gt;
#* Treatment: Current and Future Prospects: needs referencing&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* need to balance out the text with images, could organise page better with more subheadings, more images needed &lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* needs to work on referencing!!&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
#*  more table could be used instead of lengthy explanations&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* much more research needs to be done to further explain the sections&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* referencing&lt;br /&gt;
* more images&lt;br /&gt;
* glossary; lacking a lot of terms&lt;br /&gt;
* needs much more research, lots of repetitions in referencing&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 11:02, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 11&lt;br /&gt;
&lt;br /&gt;
Hey, this is a interesting disease, with some good images to show the disease clearly. &lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: very rushed, no reference and needs much more work, it should be a succinct summary of this whole page.&lt;br /&gt;
#* History: Has interesting content, though timeline would be better incorporated under History, not a section of its own&lt;br /&gt;
#* Diagnosis: If you're abbreviating Cleft Palate to CLP, you should have it as Cleft palate (CLP). The two given tables are pretty much the same, except for different sample number. Is it really necessary to have the two tables when they're so similar? Could do well with an image&lt;br /&gt;
#* Syndromes and Anomalies associated with cleft: Nice array of images used here. Content is good (for ones you provided), but needs work on referencing. Perhaps you could organise the content into a table for easy comparison since you have more than one anomalies&lt;br /&gt;
#* Aetiology: Needs referencing, image could have a caption to explain it. Although the content is there, it's too brief and I feel it could be organised in a more effective manner, such as using number stages.&lt;br /&gt;
#* Types of Cleft Palate/Lip:very brief, please explain the points (ie. what's the differences between them? you say there are differences in severity, how so?)&lt;br /&gt;
#* Pathophysiology: need to reformat table more effectively and work on referencing&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* need to balance out the text with images, could organise page better with more subheadings &lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* needs to work on referencing!!&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
#* NO self drawn images so far&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* much more research needs to be done. sections overall are lacking substance and doesn't explain the content very well&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* referencing&lt;br /&gt;
* more images&lt;br /&gt;
* glossary; lacking a lot of terms&lt;br /&gt;
* needs much more research&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 11:02, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 9 attendence==&lt;br /&gt;
--[[User:Z3291643|z3291643]] 13:00, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 10 attendence==&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 13:15, 6 October 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 10 Online Assessment==&lt;br /&gt;
&lt;br /&gt;
1.Besides fetal alcohol syndrome, identify another environmental teratogen that can lead to hearing loss.&lt;br /&gt;
Noise pollution is a big factor in hearing loss, as well as viral and bacterial infections such as meningitis. Hearing loss from meningitis can be a result of the direct effects of the infection on the brain or the body's reaction to the infection, most commonly with pneumococcal meningitis. 6% of all hearing defects in children can be attributed to bacterial meningitis, with around 72% of these children progressing to complete hearing loss by the age of three. &lt;br /&gt;
&lt;br /&gt;
2.Identify 3 factors that contribute to poor neonatal drainage of the middle ear. &lt;br /&gt;
The auditory tube connects the middle ear cavity to the nasopharynx, and is different in structure in neonates vs. adults.&lt;br /&gt;
:# the eustachian tube is very horizontal (10 degrees to the horizontal axis)&lt;br /&gt;
:# only opened by a single muscle called the tensor palati muscle (compared to 2 muscles in the adult tube)&lt;br /&gt;
:# it is shorter(17-18 mm) and narrower &lt;br /&gt;
&lt;br /&gt;
3.Identify 1 genetic abnormality that affects hearing development and link to the OMIM record. (Your individual abnormality should be different from all other students)&lt;br /&gt;
* Waardenburg syndrome&lt;br /&gt;
* results in hearing loss (to variable extent)&lt;br /&gt;
* inherited in an autosomal dominant manner&lt;br /&gt;
* [http://omim.org/entry/193500 Waardenburg syndrome]&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 10:20, 13 October 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Related Links==&lt;br /&gt;
&lt;br /&gt;
'''Animal Models'''&lt;br /&gt;
&lt;br /&gt;
* [[Mouse Knockout]] - this page explains the current use of mouse models in disrupting genes to elucidate their genetic function, including the mouse gene knockouts for alpha calcium-calmodulin kinase II (alpha CaMKII)&lt;br /&gt;
* [[2009 Group Project 4]] - this page gives an extensive overview on the history of the mouse model and its various use in embryology and genetics. In addition, it also describes mouse knockout and the role they play in current research of various human diseases&lt;br /&gt;
* [[Fly Development]] - this page describes the use of drosophila flies as developmental models&lt;br /&gt;
* [[2009 Group Project 2]] - this page gives an extensive overview on the history of the fly model and its various use in embryology and genetics&lt;br /&gt;
&lt;br /&gt;
==''' References '''==&lt;br /&gt;
&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;/div&gt;</summary>
		<author><name>Z3291643</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=User:Z3291643&amp;diff=77653</id>
		<title>User:Z3291643</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=User:Z3291643&amp;diff=77653"/>
		<updated>2011-10-12T23:19:20Z</updated>

		<summary type="html">&lt;p&gt;Z3291643: /* Lab 10 Online Assessment */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{2011Student}}&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Z3291643]] 12:55, 28 July 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 1 Assessment==&lt;br /&gt;
1.	Identify the origin of In Vitro Fertilization and the 2010 nobel prize winner associated with this technique.&lt;br /&gt;
&lt;br /&gt;
‘in vitro’ fertilization is Latin for ‘in glass’ fertilization and is a treatment for infertility, whereby the sperm fertilizes the ovum outside the body and is then implanted back into the patient’s uterus. The first successful IVF birth, Louise Brown, occurred in 1978 with the help of Patrick Steptoe and Robert Edwards. Edwards was awarded the 2010 nobel prize in medicine for his achievement. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
2.	Identify a recent paper on fertilisation and describe its key findings.&lt;br /&gt;
&lt;br /&gt;
The aim of this paper was to investigate whether age &amp;lt;=25 played a role in the reproductive outcome of women undergoing IVF. Infertile patients aged between 19 and 25 years of age were compared to infertile patients aged 30-35 years to determine primarily fertilization rates and the number of top quality embryos. The results were unexpected as the younger subjects had lower fertilization rates and reduced embryo quality.&amp;lt;ref&amp;gt;PMID 21042842&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
3.	Identify 2 congenital anomalies.&lt;br /&gt;
&lt;br /&gt;
Trisomy 21 and cleft palate&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--[[User:S8600021|Mark Hill]] 10:01, 3 August 2011 (EST) These answers are fine.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 13:02, 4 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Lab 2 Assessment==&lt;br /&gt;
1.	Identify the ZP protein that spermatozoa binds and how is this changed (altered) after fertilization. &lt;br /&gt;
&lt;br /&gt;
ZP3 acts as a receptor for the sperm. This is followed by the acrosome reaction, whereby acrosomal contents digest the ZP and allow the sperm surface proteins to bind to the ZP2. After fertilization, cortical reaction takes place where cortical granules are exocytosed. This results in the removal of carbohydrate from ZP3 and cleavage of ZP2 to harden the ZP. These changes occur to prevent polyspermy.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
2.       Identify a review and a research article related to your group topic.&lt;br /&gt;
&lt;br /&gt;
This research article showed genotype-phenotype correlations in Angelman Syndrome (AS). They have concluded that deletion patients had worse developmental outcomes than non deletion patients.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20729760&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
This review article is really comprehensive and gives a good background knowledge of AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20445456&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Z3291643]] 12:42, 11 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 3 Assessment==&lt;br /&gt;
&lt;br /&gt;
1.        What is the maternal dietary requirement for late neural development? &lt;br /&gt;
&lt;br /&gt;
Iodine. Zimmermann found that maternal deficiency of iodine can result in cognitive disability in the offspring, most severely characterized by cretinism. Fortunately, mild to moderate iodine deficiency can be corrected in primary school aged children to improve cognitive and motor functions.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21802524&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
2.        Upload a picture relating to your group project.&lt;br /&gt;
&lt;br /&gt;
[[File:UBE3A colocalizes with ASPM at the centrosome throughout mitosis.jpg|thumb|UBE3A colocalizes with ASPM at the centrosome throughout mitosis.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21633703&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
===UBE3A colocalizes with ASPM at the centrosome throughout mitosis===&lt;br /&gt;
&lt;br /&gt;
[[File:UBE3A colocalizes with ASPM at the centrosome throughout mitosis.jpg|Abnormal cytokinesis and apoptosis in UBE3A knockdown cells.|350px]]&lt;br /&gt;
&lt;br /&gt;
UBE3A colocalizes with ASPM at the centrosome. (A) Indirect immunofluorescence of HEK293 cells at interphase and different phases of mitosis stained with antibodies against ASPM and UBE3A (anti-UBE3A-sc-8926). Note colocalization of UBE3A with ASPM at the centrosome throughout mitosis (arrowheads). Note weak centrosomal staining of UBE3A in an interphase cell (arrow). (B) Indirect immunofluorescence of A549 cells stained with antibodies against UBE3A (anti-UBE3A-sc-8926) and ASPM at metaphase and telophase. Note colocalization of UBE3A with ASPM at the centrosome (arrowheads). Scale bar=2 µm.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Copyright Singhmar, Kumar. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 11:08, 18 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 4 Online Assessment==&lt;br /&gt;
&lt;br /&gt;
# '''The allantois, identified in the placental cord, is continuous with what anatomical structure?'''&lt;br /&gt;
The allantois is endodermic in origin and is the extension of the yolk sac into the connecting stalk. It's connected to the superior end of the developing bladder&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
#  '''Identify the 3 vascular shunts, and their location, in the embryonic circulation.'''&lt;br /&gt;
1. Ductus arteriosus; connects left pulmonary artery with the descending aorta&lt;br /&gt;
2. Ductus venosus; connects the portal and umbilical veins to the inferior vena cava&lt;br /&gt;
3. Foramen ovale; between left and right atria&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
# Identify the Group project sub-section that you will be researching. (Add to project page and your individual assessment page)&lt;br /&gt;
&lt;br /&gt;
; 4  Aetiology (genetic inheritance); Julia&lt;br /&gt;
; 5  Pathophysiology; Julia (as it's quite linked with aetiology anyway)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 12:59, 25 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 5 Online Assessment==&lt;br /&gt;
&lt;br /&gt;
# Which side (L/R) is most common for diaphragmatic hernia and why? &lt;br /&gt;
Posterior left side,possibly due to the fact that the left pericardioperitoneal canal is larger and closes later than the right.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 12:48, 1 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 6 Online Assessment==&lt;br /&gt;
# What week of development do the palatal shelves fuse?&lt;br /&gt;
Week 9 of early embryonic growth&lt;br /&gt;
 &lt;br /&gt;
# What early animal model helped elucidate the neural crest origin and migration of neural crest cells?&lt;br /&gt;
Migration of neural crest cells have been studied in quail-chick chimeras - transplanted quail cells have obvious nucleoli compared with chicken. It was first done by Nicole Le Douarin in the 80's&lt;br /&gt;
 &lt;br /&gt;
# What abnormality results from neural crest not migrating into the cardiac outflow tract? &lt;br /&gt;
Tetralogy of Fallot; when the outflow tract is not aligned properly, it is seen as a nonwedged aorta. Nonwedged aorta indicates tetralogy of Fallot. In addition, past studies using chick embryos have outlined that cardiac neural crest cell ablation led to this malalignment. In contrast, Farrell et al have shown that the introduction of cardiac neural crest aligned the outflow tract properly. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9933243&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 12:49, 15 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 7 Online Assessment==&lt;br /&gt;
&lt;br /&gt;
1. Are satellite cells &lt;br /&gt;
* necessary for muscle hypertrophy?&lt;br /&gt;
: No&lt;br /&gt;
 &lt;br /&gt;
* generally involved in hypertrophy?&lt;br /&gt;
: Yes&lt;br /&gt;
 &lt;br /&gt;
&lt;br /&gt;
2. Why does chronic low frequency stimulation (CLFS) cause a fast to slow fibre type shift? &lt;br /&gt;
: At the molecular level, there are exchanges of fast and slow type protein isoforms, such as calcium regulatory system, myofibrillar apparatus. The final step in CLFS induced fiber shift is the upregulation of slow myosin from the conversion of myogenic cells to slow fiber phenotype. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12500901&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;It is also known that satellite cells contribute to CLFS-induced transition of fiber types shown by the fact that CLFS increases type I fibers only after fiber necrosis. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16439424&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--Mark Hill 10:42, 16 September 2011 (EST) &lt;br /&gt;
&lt;br /&gt;
I would like each student to now also look at the following online page before the next Lab and write a comment based upon the group project assessment criteria. &lt;br /&gt;
&lt;br /&gt;
http://embryology.med.unsw.edu.au/embryology/index.php?title=Trisomy_21 &lt;br /&gt;
Paste your comment on the Trisomy 21 discussion page and also on your own student page. &lt;br /&gt;
&lt;br /&gt;
Group Assessment Criteria&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Good and concise explanation of the subheadings,however, I would've liked to see some attempt to further explain how the asspcoated congenital abnormalities occur.  &lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Lots of images, graphs and table used effectively to help reader better understand the disease. They also gave the project page some colour to make it more pleasing to the eye. Unfortunately, some images were placed (eg. John Langdon Down)in the wrong sections and interrupted the flow of the project page. &lt;br /&gt;
#* In addition, some of the images were not referred to within the project page. &lt;br /&gt;
#* Furthermore, the overall structure and layout of the page could be improved, such as putting the Diagnostic Links under diagnosis instead of the introduction&lt;br /&gt;
#* I also felt American College of Obstetricians and Gynecologists Recommendations could've been a subheading under 'screening'&lt;br /&gt;
#Content is correctly cited and referenced. &lt;br /&gt;
#* The very first image does not provide any information on the permissions to reuse the image (open access). &lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations. &lt;br /&gt;
#* Would've been better to include more self drawn diagrams and tables to further illustrate the group's knowledge of this disease&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* Lots of Pubmed articles have been used to make this page more credible and reliable &lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#* More words need to be explained in the glossary, such as 'tandem single nucleotide polymorphisms' &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 22:50, 21 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 8 Online Assessment==&lt;br /&gt;
attendance: --[[User:Z3291643|Sang Lee]] 13:04, 22 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Group 1: Turner Syndrome&lt;br /&gt;
&lt;br /&gt;
Firstly, nice progress with the group project. After reading your page, I have a good general knowledge of Turner Syndrome, so thanks. Overall, most sections were well done, though the writing style and layout could be more consistent, but you could work on that when you've finalised the content of the page. &lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: Good intro, very first image of the karyotype should include the actual statement of the 'Open access' not just 'copyright'&lt;br /&gt;
#* Epidemiology: Grammatical errors disrupt the flow of the content, in addition, graph has no copyright info, title could be improved&lt;br /&gt;
#* Etiology: Nice simple diagram of 22 eggs and 23 sperms, good example of when a picture can tell more than a thousand words! I feel there needs to be consistency either use Turner Syndrome or TS throughout the page&lt;br /&gt;
#* Clinical: liked how you have further classified the symptoms to its associated titles, nice idea; very easy to read, but a table would also be good&lt;br /&gt;
#* Diagnosis: image of TS maternal serum sampling doesn't contain {Template:2011 Student Image}, but a very good table&lt;br /&gt;
#* image of the TS X chromosome variations shouldl contain {Template:2011 Student Image}. Furthermore, if you use A-E in image descriptions, you should include A-E within the image&lt;br /&gt;
#* Research: very good layout and explanations, informative&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Could include more images especially in clinical manidestations, and some images do not fit the requirements set by Mark, as I've highlighted above &lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* seems to be cited well. However, although you have more than 100 referencees, a lot of them are repeated references, maybe you could try to use more pubmed articles, a greater variety&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations. &lt;br /&gt;
#* Glossary: could include more words such as echocardiogram&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* Although you have more than 100 referencees, a lot of them are repeated references, maybe you could try to use more pubmed articles, a greater variety&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#*  Although the content is informative, I'm left feeling like I want more variety of resources, so maybe some further research will improve the overall impression of your page &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot;&lt;br /&gt;
* consistency in writing style&lt;br /&gt;
* more images and cited correctly &lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 14:44, 24 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Group 2&lt;br /&gt;
&lt;br /&gt;
Hey Group 2, firstly, well done on putting in the effort to create this page, it really shows your dedication and cooperation as a team! Here are some points I thought you could improve on to take this page to that extra level&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: Good overview. Image would look better with a border or as a thumb&lt;br /&gt;
#* History: Image too large, again maybe a border?&lt;br /&gt;
#* Epidemiology: Need to define velocardiofacial syndrome in glossary, also break it down into subheadings, eg. Incidence, Sex, etc&lt;br /&gt;
#* Etiology: Maybe better if in a table&lt;br /&gt;
#* Pathogenesis: I liked how you broke it doen into relevant subheadings. However, on a slightly negative note, the DG Pathophysiology Diagram looks rushed; I think it would've looked better if it was neater and easier to read.&lt;br /&gt;
#* Diagnosis: I felt citing was done poorly in this section, eg. the last 4/5 sentences in the FISH technique was not referenced at all, but again, this is very easily fixed. But good to see you have put in the effort and time&lt;br /&gt;
#* Clinical: Image of normal and cleft palate, if based on a textbook, I think you still need permission to adapt it (not quite sure, please ask Mark)? Table with 'How it is caused' would be better by itself as pathophysiology. Tetralogy of Fallot needs to be fitted into this section more smoothly, at the moment, it makes this section look very cramped. Also, the image regarding Tetralogy needs the correct format for student drawn images (ie. 'I (student no.)....)&lt;br /&gt;
#* Research: Maybe break it down into subheadings&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Good images used with a nice range of self drawn images. However, no where in the page is there any reference to the images within the text.&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* I feel citation needs to be improved overall. Lots of the sections have missing citations, especially Diagnostic Tests. Also in the reference list, refs 33,40,47, 49 have nothing in it (is it meant to be like this?)&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations. &lt;br /&gt;
#* Nice drawings, though some could've done better with more effort&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* Nice range of references used&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#* It's very clear to me that you guys have worked together well and there has been good team work going on here to create this page, so well done&lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* I feel your page is too heavy with the text, although there's a lot of images as well, it just doesn't quite balance out with the text. &lt;br /&gt;
* Also felt the different colours used for the tables, although adding a splash of colour to your page, brought down the overall quality of the page. However, please keep in mind that others might really like this approach of table formatting, it's just that personally, I think you could benefit from keeping all table colours consistent.&lt;br /&gt;
* Sometimes you refer to DiGeorge Syndrome as DGS and also as DS. Small and easy to fix, adds consistency&lt;br /&gt;
* Please don't forget to add the {template} for student uploaded images&lt;br /&gt;
* Definitely needs more words in the Glossary, such as Meiosis, de novo, microarray&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 16:02, 24 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 3&lt;br /&gt;
&lt;br /&gt;
Hi, overall, a nice project page with interesting information.&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: Nice introduction, good flow and easy to read. However, image needs proper information and perhaps 'This disorder was first described by Harry F.' could be placed earlier on in the intro rather than in the middle&lt;br /&gt;
#* History: Nice section, very interesting&lt;br /&gt;
#* Epidemiology: First paragraph is good, but I feel the rest of this section doesn't quite belong here, such as the information on seizures, IQs, diagnosis. This section should focus on stats (sex/birth/ethnic/demographic/etc). Fig 2, 3 belong more in the signs and symptoms&lt;br /&gt;
#* Etiology: the '1:1000 male' contradicts the '1:500' given in epidemiology. Fig4 needs coyright information&lt;br /&gt;
#* Pathogenesis: Needs better referencing, also placing fig 5, 6 on either side doesn't look too good with the text. Perhaps place them below one another?&lt;br /&gt;
#* Signs: Seems a bit incomplete, it'll also be good to explain the image of 'pubertal gynecomastia'&lt;br /&gt;
#* Diagnosis: Sentence structure could be improved, ie. 'performed because physicians may suspect it because of clinical findings'. Information is interesting, but could be presented more clearly, perhaps in a table?&lt;br /&gt;
#* Similar defects: very nice, presented well with good information, easy to read&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Good images used with a nice range of self drawn images. However, lot of the images need to be formatted properly with required information&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* overall referencing was well done, except pathogenesis needs more referencing&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations. &lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* Nice range of references used&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#* The information is there, but maybe from now til final assessment, you could do further research in all sections, as they do seem a little short.&lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* better page layout&lt;br /&gt;
* glossary: sorry, but I feel the alphabet subheadings here are very effective as you have it in alphabetical order anyway&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 21:59, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 4&lt;br /&gt;
&lt;br /&gt;
Hey, this is a nicely structured page with interesting content that is presented well. There is a nice balance of text and image&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: good, to the point&lt;br /&gt;
#* History: Nice section, perhaps bold the years?&lt;br /&gt;
#* Epidemiology: I really liked this section, both visually and content wise. The table is easy to read and I liked your explanations for the HD prevalence, well done&lt;br /&gt;
#* Genetics: Perhaps you could have the 'CAG (cytosine-adenine-glutamine)' in the introduction when you first refer to it? Referencing is required in i'HTT and normal functions'. I really liked your subheadings, made it very easy to understand and follow &lt;br /&gt;
#* Pathogenesis: Image is too big, good subheadings, I suggest that if you write in purple to highlight some words, maybe you could do that for the whole page?&lt;br /&gt;
#* Clinical: liked the motor impairment explanations, how about explaining the cognitive and behaviour impairments as well? (it'll be worth it!)&lt;br /&gt;
#* Diagnosis: Nice content, but it just feels a bit too crowded, maybe rearrange the images and decrease image size&lt;br /&gt;
#* Treatment: Very nice section with nice images and good format!&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Good balance of images and text, though some rearrangement of images would make this page look better. Very good use of subheadings to make the content more easy to digest&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* overall referencing was well done&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
* good range of tables, images and self drawn images&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* Nice range of references used&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* just minor changes such as resizing some of the images, making the sections consistent in format&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 22:32, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 5&lt;br /&gt;
&lt;br /&gt;
Hi, I can see some progress on this page which is good, content is interesting&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: What is FMR1 gene? Need more information here, as in when was it first discovered, some stats&lt;br /&gt;
#* Epidemiology: I think screening information is extensive enough to be a section on its own&lt;br /&gt;
#* Etiology: no explanation of FMR1 gene so far, what is its normal function? Also, please refer to images used in this section&lt;br /&gt;
#* Development of the disease:nice succinct, easy to follow section. Perhaps add an image for one of the stages mentioned here?&lt;br /&gt;
#* Signs: REFERENCING!!! But, content is good and interesting&lt;br /&gt;
#* Diagnosis: An image here would be nice, and an explanation of how the technology is used to diagnose FXS&lt;br /&gt;
#* Treatment: Nice table with good information&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Need to balance out the text and image ratio, some good subheadings&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* poor referencing, which makes me question the reliability of the content in some sections&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
#* needs a lot more images&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* I feel more research needs to be done here&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* Although the content is here, there is still a lot of work needed to make this page feel complete&lt;br /&gt;
* glossary is very lacking in terminology&lt;br /&gt;
* need more images&lt;br /&gt;
* further research would be nice to explain this disease in more detail&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 23:26, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Group 6&lt;br /&gt;
Hey, nice progress with your page, all sections have similar amount of content which were interesting&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: Referencing needs to be improved here&lt;br /&gt;
#* History: content is good but too wordy. I think a summary or a simple timeline would be good&lt;br /&gt;
#* Epidemiology: Where's the reference for 3/10000 live births?&lt;br /&gt;
#* Signs: ok section, but could do with more images here&lt;br /&gt;
#* Genetics: If using abbreviations, such as TBX1 gene, you should explain what it is, ie. TBX1 gene (T-box 1). Also need to work on referencing here as well. How about organising all the content in a table? have in columns: gene, gene profile, frequency, etc.&lt;br /&gt;
#* Pathogenesis: I'm not quite sure about this, but do you need permission to adapt an image from an article? (I'm referring to the '4 defects' image)&lt;br /&gt;
#* Diagnosis: I'm sorry, but this section is a bit bland, though the content is very informative. I think some images here would be good&lt;br /&gt;
#* Treatment: Referencing! Also, personally, that green is too bright, maybe find a more neutral, soothing colour?&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Need to find more images, I feel some of the information could be more effectively presented in table formate rather than lengthy text&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* VERY poor referencing, which makes me question the reliability of the content in some sections&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
#* needs a lot more images&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* research done is evident, just need to reference&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* glossary is very lacking in terminology&lt;br /&gt;
* need more images&lt;br /&gt;
* REFERENCING!&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 23:26, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Group 8&lt;br /&gt;
Hey, well done, your page is looking really polished! Lots of very interesting information here and presented in a very easy to follow manner&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* History: I feel that you could lessen the info of Nicholas and add more current findings of the disease.&lt;br /&gt;
#* Aetiology: What is the chromosome 9 image based on? Need to work on referencing. Very good subheadings and well balanced with images&lt;br /&gt;
#* Pathogenesis: Needs more information&lt;br /&gt;
#* Neuro: What's the images based on? Good subheadings and explained well. I liked the way you gave explanations for normal function/appearance and then went on to explain abnormality associated with the structures in this disease. But you need to improve your referencing for this section&lt;br /&gt;
#* Diagnosis: Very good table and images. But need to fix the postnal diagnosis table so that it spans the length of the screen&lt;br /&gt;
#* Symptoms: table and images look too crowded&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* good subheadings, images, impressive self drawn images! Nice balanced page layout&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* needs to work on referencing&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* research done is evident, just need to reference&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* referencing&lt;br /&gt;
* better arrangement of table and images so page doesn't look too crowded&lt;br /&gt;
&lt;br /&gt;
Well done guys, nice team work!&lt;br /&gt;
--[[User:Z3291643|z3291643]] 23:50, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 9&lt;br /&gt;
&lt;br /&gt;
Hey, your page has a lot of very interesting content and some unique self drawn images. I thoroughly enjoyed this page, thanks&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: Inclusion of incidence would be nice&lt;br /&gt;
#* History: very informative and a nice simple timeline&lt;br /&gt;
#* Genetics: Good, succinct section, especially liked the table&lt;br /&gt;
#* Diagnosis: needs referencing. Is diagnosis only postnatal? What is the average age of diagnosis for this disease?&lt;br /&gt;
#* Management and Treatment: Seems a little out of place under epidemiology, I think it should be place later on &lt;br /&gt;
#* Phenotype:Reference?&lt;br /&gt;
#* Cardiac conditions: maybe give explanations for atrial and ventricular septal defect, just brief descriptions would suffice. Why is it so that males are more likely to suffer CVD than females?&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* good subheadings, interesting self drawn images. However, this page needs to find a balance in text and images&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* needs to work on referencing&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* research done is evident, just need to reference&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#* very interesting content, informative&lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* referencing&lt;br /&gt;
* more images&lt;br /&gt;
* glossary; lacking a lor of terms&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 00:10, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 10&lt;br /&gt;
&lt;br /&gt;
Hey, this is a interesting disease, with some good images to show the disease clearly. &lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: succinct introduction&lt;br /&gt;
#* History: Has interesting content, though timeline would be nice&lt;br /&gt;
#* Pathogenesis: Too brief and could be improved with an image&lt;br /&gt;
#* Signs: surely there are more symptoms here, maybe you could have subheadings to break down the symtpoms, ie. motor impairment, cognitive impairments, etc&lt;br /&gt;
#* Clinical manifestations and complications: nice section with good image used&lt;br /&gt;
#* Diagnosis: could be further explained, and an image would be nice&lt;br /&gt;
#* Treatment: Current and Future Prospects: needs referencing&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* need to balance out the text with images, could organise page better with more subheadings, more images needed &lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* needs to work on referencing!!&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
#*  more table could be used instead of lengthy explanations&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* much more research needs to be done to further explain the sections&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* referencing&lt;br /&gt;
* more images&lt;br /&gt;
* glossary; lacking a lot of terms&lt;br /&gt;
* needs much more research, lots of repetitions in referencing&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 11:02, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 11&lt;br /&gt;
&lt;br /&gt;
Hey, this is a interesting disease, with some good images to show the disease clearly. &lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: very rushed, no reference and needs much more work, it should be a succinct summary of this whole page.&lt;br /&gt;
#* History: Has interesting content, though timeline would be better incorporated under History, not a section of its own&lt;br /&gt;
#* Diagnosis: If you're abbreviating Cleft Palate to CLP, you should have it as Cleft palate (CLP). The two given tables are pretty much the same, except for different sample number. Is it really necessary to have the two tables when they're so similar? Could do well with an image&lt;br /&gt;
#* Syndromes and Anomalies associated with cleft: Nice array of images used here. Content is good (for ones you provided), but needs work on referencing. Perhaps you could organise the content into a table for easy comparison since you have more than one anomalies&lt;br /&gt;
#* Aetiology: Needs referencing, image could have a caption to explain it. Although the content is there, it's too brief and I feel it could be organised in a more effective manner, such as using number stages.&lt;br /&gt;
#* Types of Cleft Palate/Lip:very brief, please explain the points (ie. what's the differences between them? you say there are differences in severity, how so?)&lt;br /&gt;
#* Pathophysiology: need to reformat table more effectively and work on referencing&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* need to balance out the text with images, could organise page better with more subheadings &lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* needs to work on referencing!!&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
#* NO self drawn images so far&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* much more research needs to be done. sections overall are lacking substance and doesn't explain the content very well&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* referencing&lt;br /&gt;
* more images&lt;br /&gt;
* glossary; lacking a lot of terms&lt;br /&gt;
* needs much more research&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 11:02, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 9 attendence==&lt;br /&gt;
--[[User:Z3291643|z3291643]] 13:00, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 10 attendence==&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 13:15, 6 October 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Lab 10 Online Assessment==&lt;br /&gt;
&lt;br /&gt;
1.Besides fetal alcohol syndrome, identify another environmental teratogen that can lead to hearing loss.&lt;br /&gt;
Noise pollution is a big factor in hearing loss, as well as viral and bacterial infections such as meningitis. Hearing loss from meningitis can be a result of the direct effects of the infection on the brain or the body's reaction to the infection, most commonly with pneumococcal meningitis. 6% of all hearing defects in children can be attributed to bacterial meningitis, with around 72% of these children progressing to complete hearing loss by the age of three. &lt;br /&gt;
&lt;br /&gt;
2.Identify 3 factors that contribute to poor neonatal drainage of the middle ear. &lt;br /&gt;
The auditory tube connects the middle ear cavity to the nasopharynx, and is different in structure in neonates vs. adults.&lt;br /&gt;
:# the eustachian tube is very horizontal (10 degrees to the horizontal axis)&lt;br /&gt;
:# only opened by a single muscle called the tensor palati muscle (compared to 2 muscles in the adult tube)&lt;br /&gt;
:# it is shorter(17-18 mm) and narrower &lt;br /&gt;
&lt;br /&gt;
3.Identify 1 genetic abnormality that affects hearing development and link to the OMIM record. (Your individual abnormality should be different from all other students)&lt;br /&gt;
* Waardenburg syndrome&lt;br /&gt;
* results in hearing loss (to variable extent)&lt;br /&gt;
* inherited in an autosomal dominant manner&lt;br /&gt;
* [http://omim.org/entry/193500 Waardenburg syndrome]&lt;br /&gt;
&lt;br /&gt;
==Related Links==&lt;br /&gt;
&lt;br /&gt;
'''Animal Models'''&lt;br /&gt;
&lt;br /&gt;
* [[Mouse Knockout]] - this page explains the current use of mouse models in disrupting genes to elucidate their genetic function, including the mouse gene knockouts for alpha calcium-calmodulin kinase II (alpha CaMKII)&lt;br /&gt;
* [[2009 Group Project 4]] - this page gives an extensive overview on the history of the mouse model and its various use in embryology and genetics. In addition, it also describes mouse knockout and the role they play in current research of various human diseases&lt;br /&gt;
* [[Fly Development]] - this page describes the use of drosophila flies as developmental models&lt;br /&gt;
* [[2009 Group Project 2]] - this page gives an extensive overview on the history of the fly model and its various use in embryology and genetics&lt;br /&gt;
&lt;br /&gt;
==''' References '''==&lt;br /&gt;
&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;/div&gt;</summary>
		<author><name>Z3291643</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_7&amp;diff=77636</id>
		<title>2011 Group Project 7</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_7&amp;diff=77636"/>
		<updated>2011-10-12T23:13:35Z</updated>

		<summary type="html">&lt;p&gt;Z3291643: /* Aetiology */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;='''Angelman Syndrome'''=&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Introduction==&lt;br /&gt;
&lt;br /&gt;
[[File:Dr Harry Angelman.jpg|thumb|130px|right|Dr Harry Angelman.]]&lt;br /&gt;
Angelman syndrome (AS) is a rare [[#Glossary | '''neurogenetic''']] [[#Glossary | '''disorder''']] first described by Dr. Harry Angelman in 1965.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18754889&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Dr. Angelman was an English [[#Glossary | '''paediatrician''']] who first diagnosed the disease in 3 children with a developmental delay.&amp;lt;ref&amp;gt;http://www.ncbi.nlm.nih.gov/books/NBK22221/&amp;lt;/ref&amp;gt; AS occurs in 1 in 10000-20000 births, the exact number is still unknown.&amp;lt;ref name=&amp;quot;PMID7573182&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7573182&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;PMID8703225&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;8703225&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It is caused by maternal [[#Glossary | '''allele''']] disruptions of a single gene- UBE3A. Either [[#Glossary | '''mutations''']] or [[#Glossary | '''deletions''']] of the UBE3A gene results in AS. &lt;br /&gt;
&lt;br /&gt;
AS presents with well known [[#Glossary | '''phenotypes''']] during infancy and adulthood, such as [[#Glossary | '''microcephaly''']] and [[#Glossary | '''maxillary hypoplasia''']]. However, these features become more marked with age. Most frequent clinical features include delayed development,[[#Glossary | '''seizures''']],[[#Glossary | '''ataxia''']], impairment of speech, happy demeanor, behavioural problems such as hyperactivity, short attention span and sleeping difficulty.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21592595&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21484597&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;ASAwebsite&amp;quot;&amp;gt;http://www.angelmansyndrome.org/home.html&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
At present, there is no cure for the syndrome, though current research is focused at improving life quality of patients with Angelman syndrome through management of daily tasks.&amp;lt;ref&amp;gt;http://www.bbc.co.uk/health/physical_health/conditions/angelman1.shtml&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==History==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Dr. Harry Angelman first reported Angelman Syndrome on three handicapped children that were admitted to his ward in England in 1964.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt; He reported how these three independent and unconnected clinical cases all had the same characteristic features of severe developmental delay, jerky movements, seizures and a happy disposition.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt; However it was only when he stumbled upon an oil painting called ‘a Boy with a Puppet” while on a holiday in Italy he was able to connect the symptoms of all three children under one common cause.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20981772&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; He linked the happy face of the boy depicted on the painting with the jerky movements and happy disposition he observed on his three patients back in England. He reported his findings on a paper entitled “Puppet children (a report on three cases)” which was published in 1965.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
The syndrome was initially named ‘Puppet Syndrome’ but was later changed to Angelman Syndrome. Due to the extreme rarity of the syndrome and lack of sufficient clinical evidence the syndrome was soon forgotten.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt;&lt;br /&gt;
[[File:Dr Charles Williams.jpg|thumb|right|150px|Dr Charles Williams.]]&lt;br /&gt;
	&lt;br /&gt;
In 1987, a physician named Ellen Magenis, came across children with deletions on [[#Glossary | '''chromosome''']] 15 that were suffering from seizures and severe developmental delay.&amp;lt;ref&amp;gt;http://www.angelman.org/stay-informed/facts-about-angelman-syndrome---7th-edition/harry-angelman-and-the-history-of-as/&amp;lt;/ref&amp;gt; Even though genetically the children were expected to have [[#Diagnosis | '''Prader-Willi syndrome''']] that was characterised by deletions on chromosome 15, their characteristic symptoms of seizures and lack of development did not correspond with that of the syndrome. This led to the realization that these children had deletions on the maternally derived chromosome 15 and not on the paternally derived chromosome as was observed in Prader-Willi syndrome.  Thus the deleted genetic code on maternally derived chromosome 15 was identified as the genetic marker for Angelman Syndrome.&lt;br /&gt;
&lt;br /&gt;
In 1997, UBE3A gene was isolated by Dr. Joseph Wagstaff and Dr. Arthur Beaudet as the cause of Angelman Syndrome.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot; /&amp;gt; The discovery of this [[#Glossary | '''gene''']] led to the subsequent development of animal models and research aimed at finding a causal link between UBE3A gene abnormalities and characteristic features observed in Angelman Syndrome. &lt;br /&gt;
	&lt;br /&gt;
Currently, four different genetic abnormalities for Angelman Syndrome have been confirmed by genetic testing. They include: Deletion, [[#Glossary | '''Uniparental Disomy''']] (UPD), [[#Glossary | '''Imprinting''']] and UBE3A mutation.&amp;lt;ref name=&amp;quot;PMID20211139&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Below is a timeline, summarising the key discoveries and advancements of the Angelman Syndrome:&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|- bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
!Year&lt;br /&gt;
!Milestone&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1964'''&lt;br /&gt;
|First observed by Dr Harry Angelman on three handicapped children.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot; /&amp;gt; &lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''1965'''&lt;br /&gt;
|Harry Angelman publishes his finding in a report entitled 'Puppet Children'(a report on three cases).&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1980s'''&lt;br /&gt;
|First reports of AS reaches US and research into the disorder being at the University of Florida under the direction of Dr. Charles Williams.&amp;lt;ref&amp;gt;http://www.angelmanproject.com/history.htm&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''1982'''&lt;br /&gt;
|Name changed from 'Happy Puppet' to Angelman syndrome by Williams and Frias. &lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1987'''&lt;br /&gt;
|Discovery of a genetic marker for AS – an absent genetic code on maternally derived chromosome 15. &lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''1997'''&lt;br /&gt;
|The cause of AS discovered by Dr. Joseph Wagstaff and Dr. Arthur Beaudet – mutation or deletion in the UBE3A gene.&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1998'''&lt;br /&gt;
|Transgenic mice with absent maternal UBE3A created to illustrate motor and learning deficits in addition to seizures.&amp;lt;ref name=&amp;quot;PMID9808466&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9808466&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''2007'''&lt;br /&gt;
|AS mouse model shows that neurological deficits can be reversed by decreasing levels of [[#Glossary | '''alpha-CaMKII''']] inhibitory phosphorylation.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17259980&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''2010'''&lt;br /&gt;
|Discovery of a another gene mutation in TC4 gene (on chromosome 18) in a small number of clinically diagnosed patients with no identifiable genetic alternation in UBE3A.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20184619&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''2010'''&lt;br /&gt;
|Protein named Arc identified as a target of AS gene product; UBE3A.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Incidence'''&lt;br /&gt;
*The current population of people diagnosed with AS is unknown but studies have estimated the number to be around 1:10,000&amp;lt;ref name=&amp;quot;PMID7573182&amp;quot; /&amp;gt; and 1:20,000&amp;lt;ref name=&amp;quot;PMID8703225&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
'''Diagnosis'''&lt;br /&gt;
*The mean age of diagnosis for patients with AS lies between 6 and 6.5 years of age.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18664077&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15741136&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Gender'''&lt;br /&gt;
* Males appear to be at higher risk for some aspects of early developmental delays in comparison to females with AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17019625&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Demography'''&lt;br /&gt;
*Europe:&lt;br /&gt;
:Denmark- 1:10,000&amp;lt;ref name=&amp;quot;PMID7573182&amp;quot; /&amp;gt;&lt;br /&gt;
:Estonia- 1:52,000&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16906556&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
:Sweden- 1:20,000&amp;lt;ref name=&amp;quot;PMID8703225&amp;quot; /&amp;gt;&lt;br /&gt;
*Australia:&lt;br /&gt;
:Western Australia- 1:40,000&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16492624&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Aetiology==&lt;br /&gt;
&lt;br /&gt;
[[File:Chromosome 15 Deletion of 15q11.2 to 15q13.jpg|thumb|100px|Chromosome 15 - The deletion occurs at 15q11.2-15q13.]]&lt;br /&gt;
&lt;br /&gt;
'''Molecular Genetics'''&lt;br /&gt;
&lt;br /&gt;
* Location: 15q11-q13&lt;br /&gt;
* Protein product: Ubiquitin protein ligase E3A&lt;br /&gt;
* Gene name: UBE3A&lt;br /&gt;
* Phenotype: Angelman Syndrome&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Genetic Causes'''&lt;br /&gt;
&lt;br /&gt;
Different genetic mechanisms lead to different clinical phenotypes of AS. The most common genetic mechanism leading to AS is the deletion or re-arrangement of maternal chromosome at [[#Glossary | '''locus''']] 15q11.2-q13,as the chromosome image shows on the right, accounting for 70% of AS occurrences.&amp;lt;ref name=&amp;quot;PMID8988171&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt; 8988171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This leads to more severe clinical phenotypes of microcephaly, motor difficulties, seizures and impaired speech development. The next most common genetic mechanism is mutation in the UBE3A gene responsible for 10% of AS cases and paternal uniparental disomy and mutation in the imprinting centre (IC), both accounting for 2-5% of AS observed.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
 &lt;br /&gt;
&lt;br /&gt;
AS is caused by the 4 major genetic mechanisms mentioned above and are thus divided into Classes I to IV based on their underlying genetic mechanism. AS patients with the clinical features of AS but no [[#Glossary | '''cytogenetic''']] or molecular abnormality in Chromosome 15q11.2-13 are grouped under Class V (summarised in table below).&amp;lt;ref name=&amp;quot;PMID8988171&amp;quot; /&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10364509&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{|  style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
! Class&lt;br /&gt;
! Mechanism&lt;br /&gt;
! Diagnostic Tests&lt;br /&gt;
! Frequency&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''Ia'''                           &lt;br /&gt;
| De novo deletion                                                                                           &lt;br /&gt;
| High resolution cytogenetics [[#Glossary | '''FISH''']]                                                                                                       &lt;br /&gt;
| 70%      &lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Ib'''&lt;br /&gt;
| Deletion due to chromosome rearrangement&lt;br /&gt;
| High resolution cytogenetics FISH&lt;br /&gt;
| &amp;lt;1%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''II'''&lt;br /&gt;
| Paternal uniparental disomy&lt;br /&gt;
| [[#Glossary | '''RFLP''']]  analysis&lt;br /&gt;
| 2%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''IIIa'''&lt;br /&gt;
| Imprinting defect with IC mutation&lt;br /&gt;
| Screening of [[#Glossary | '''IC''']]  for mutations is positive&lt;br /&gt;
| 2%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''IIIb'''&lt;br /&gt;
| Imprinting defect withouth IC mutation&lt;br /&gt;
| Screening of IC for mutations is negative&lt;br /&gt;
| 2%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''IIIc'''&lt;br /&gt;
| Mosaic imprinting defect&lt;br /&gt;
| Screening of IC for mutations is usually negative &lt;br /&gt;
| ?&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''IV'''&lt;br /&gt;
| ''UBE3A'' mutation&lt;br /&gt;
| Screening of ''UBE3A'' for mutations&lt;br /&gt;
| 5-10%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''V'''&lt;br /&gt;
| No identifiable genetic abnormality&lt;br /&gt;
| Consider other diagnoses&lt;br /&gt;
| 5-26%&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
[[File:Imprint defect inheritance in Angelman Syndrome.png|thumb|250px|Imprint defect inheritance in Angelman Syndrome]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Inheritance'''&lt;br /&gt;
&lt;br /&gt;
Angelman Syndrome from UBE3A mutations and deletions in the Imprinting Centre follow an inheritance pattern. A carrier father with the genetic defect can pass it on to his children, however, his children will be clinically normal. On the other hand, a carrier mother can pass the genetic defect onto her children, who will then have Angelman Syndrome. &lt;br /&gt;
&lt;br /&gt;
The image highlights the inheritance of Angelman Syndrome, which only results after a carrier mother passes it on to her children.&lt;br /&gt;
&lt;br /&gt;
==Pathogenesis==&lt;br /&gt;
&lt;br /&gt;
Chromosome 15 became associated with AS in the 1980s after the observation of many AS patients harboring [[#Glossary | '''microdeletions''']] of 15q11.2-15q13.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15668046&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The last decade has shed even more light in the aetiology of AS,as Kishino and Matsuura first identified UBE3A as the causative gene for AS in 1997.&amp;lt;ref name=&amp;quot;PMID:8988171&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;8988171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8988172&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Normal gene product: E6-AP ubiquitin ligase'''&lt;br /&gt;
&lt;br /&gt;
The function of UBE3A is to encode for [[#Glossary | '''E6-AP''']] ubiquitin ligase, however its function in the development of the nervous system and the process of UBE3A mutation leading to cognitive impairment in AS patients is still vague.&amp;lt;ref name=&amp;quot;PMID:20211139&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Past and current research has elucidated that E6-AP ubiquitin ligase is involved in the degradation of four proteins, listed below, but currently, no protein with a direct role in [[#Glossary | '''long-term potentiation (LTP)''']] as a target of E6-AP, has been identified.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12684449&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The identification of such target proteins would be a landmark discovery in further understanding of the pathogenesis, aetiology and prospective treatment strategies of AS, as LTP defects is one of the major neurological impairments of AS. &lt;br /&gt;
 &lt;br /&gt;
* p53 tumor suppressor protein &lt;br /&gt;
* yeast DNA repair protein Rad23 &lt;br /&gt;
* multicopy maintenance protein 7 subunit &lt;br /&gt;
* E6-AP&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Abnormal gene product'''&lt;br /&gt;
&lt;br /&gt;
Disruption to the gene,UBE3A, interferes with the normal functioning of the gene, which is its crucial role in UBE3A [[#Glossary | '''ubiquitylation''']]. Problems involving this pathway can lead to various diseases either from the loss or gain of function.&amp;lt;ref name=&amp;quot;PMID:9857172&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9857172&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In the case of AS, E6-AP is affected, leading to detrimental cognitive impairment in addition to other deficits.&amp;lt;ref name=&amp;quot;PMID:9857172&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9857172&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Regional functioning of UBE3A'''&lt;br /&gt;
&lt;br /&gt;
Despite the uncertain progression of UBE3A mutation and the neurological abnormalities characteristic of AS, animal models have illustrated the vital role of UBE3A in the normal functioning of the brain. This can be exemplified by a study which utilized a mouse model with target inactivation of the gene UBE3A resulting in the manifestation of classical features of AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11895368&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In addition, the fact that imprinting of UBE3A takes place only in specific brain regions (cerebellum, olfactory tracts and the hippocampus) confirms the hypothesis that the loss of this gene would be detrimental in the cognitive development.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20398390&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Most genes are inherited in copies of two, one paternal and the other maternal; however, some genes, such as UBE3A only have one functional copy as the other is silenced, coined 'imprinting'. Imprinting of the paternal copy of UBE3A takes place in some cell populations, such as the hippocampal neurons and Purkinje cells in the cerebellum.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9288101&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This means only the maternal UBE3A is functionally expressed in these particular brain regions. Thus a [[#Glossary | '''de novo mutation''']] in the maternal copy of the gene will result in the complete absence of functional E6-AP in the associated brain areas.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9288088&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
It is also known that UBE3A plays an important role in synaptic transmission, but exactly how it does so is still not completely understood.&amp;lt;ref name=&amp;quot;PMID:9808466&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9808466&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''UBE3A ubiquitylation'''&lt;br /&gt;
&lt;br /&gt;
As briefly mentioned above, UBE3A is a member of the E3 ubiquitin ligase family of enzymes, responsible for the addition of ubiquitin to the target protein for degradation of the ubiquitinated protein, as illustrated in the diagram below. These processes are required for normal human cognitive function.&amp;lt;ref name=&amp;quot;PMID:9808466&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9808466&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In this way synaptic protein [[#Glossary | '''Arc (activity-regulated cytoskeleton-associated protein)''']] is degraded to control synaptic function. Arc is a target protein of UBE3A in dendritic spines found in the hippocampal neurons.&amp;lt;ref name=&amp;quot;PMID:20668179&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20668179&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Deletion of UBE3A leads to the accumulation of Arc in neurons leading to trafficking of [[#Glossary | '''AMPA ( α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid)''']] receptors, resulting in impaired cognitive functions.&amp;lt;ref name=&amp;quot;PMID:20211139&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; [[File:UBE3A Ubiquitylation Pathway.png|thumb|350px|right|UBE3A Ubiquitylation Pathway.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
UBE3A ubiquitylation consists of:&amp;lt;ref name=&amp;quot;PMID:20668179&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20668179&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
# Activation of ubiquitin by E1 enzyme&lt;br /&gt;
# E1 ezyme transfers ubiquitin to E2 enzyme&lt;br /&gt;
# E2 enzyme transfers ubiquitin to UBE3A&lt;br /&gt;
# UBE3A attaches activated ubiquitin to target protein which is then polyubiquitylated &lt;br /&gt;
# Target protein is then degraded by 26S proteosome&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Phenotype-Genotype correlations'''&lt;br /&gt;
&lt;br /&gt;
[[File:Extent of microcephaly in Angelman Syndrome patients.png|thumb|250px|right|Extent of microcephaly in 20 AS patients with deletion and without deletion.&amp;lt;ref&amp;gt;http://www.nature.com/ejhg/index.html/&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
All AS patients show differing extents of cognitive impairment, movement disorder, characteristic behaviours and difficulty in speech and language.&amp;lt;ref name=&amp;quot;PMID:11748306&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11748306&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; However, there seems to be some phenotype-genotype correlations:&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
- 5-7Mb deletions result in the most severe phenotypes such as microcephaly, more sever [[#Glossary | '''epilepsy''']] and seizures, motor difficulties and language impairment.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9546330&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20445456&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; AS patients with large deletions also present with clinical [[#Glossary | '''hypopigmentation''']], light hair and eye colour due to the close association of OCA2 gene with UBE3A.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;16470747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Individuals under this category have in general no increased BMI&amp;lt;ref name=&amp;quot;PMID:15253756&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15253756&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This is indicated by the graph on the left, which shows more cases of AS patients with deletions having larger deviations from the mean head circumference measurement than non-deletion AS patients.&lt;br /&gt;
 &lt;br /&gt;
- AS patients with uniparental disomy (UPD) have better physical growth, fewer motor deficits and lower seizure occurrences.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16023557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
- Individuals with AS resulting from imprinting defects have the least debilitating features, such as higher developmental and language ability than AS caused by other mechanisms.&amp;lt;ref name=&amp;quot;PMID:11748306&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11748306&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
- The Body Mass Index (BMI) of 33% of the UBE3A mutation patients, and 47–64% of the patients from the classes II (UPD) and III (Imprinting defect) is above the 95th centile.&amp;lt;ref name=&amp;quot;PMID:15253756&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15253756&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Animal models'''&lt;br /&gt;
&lt;br /&gt;
* '''Drosophila'''&lt;br /&gt;
&lt;br /&gt;
Drosophila (common fruit fly) is an excellent model to use for better understanding of genetic diseases in humans as they are highly homologous to human UBE3A (hUBE3A), illustrating a high evolutionary conservation. Studies using the Drosophila model have shown that the functional absence of UBE3A resulted in decreased morphogenesis of dendritic branches. This is of interest as dendritic branches cover over 90% of the neuronal surface where [[#Glossary | '''synapse''']] between neurons occur. Proper formation and maturation of dendritic spines is also required so they come in contact with other neurons for effective transmission of neuronal signals. Thus proper formation of dendritic branching is pivitol for effective neuronal function and hence cognitive function.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18996915&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Interestingly, overexpression of dUBE3A also gave the same result, consisting of abnormal locomotion  and decreased dendritic branching in sensory neurons.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18701717&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;  This suggests a possible research field for some forms of [[#Glossary | '''autism''']] where the region containing UBE3A is duplicated, leading to delayed motor skills and seizures.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16433693&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;[[File:Normal and Angelman Syndrome mice models.jpg|thumb|250px|right|Normal and AS mice performance on the Rotarod apparatus.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
* '''Mice'''&lt;br /&gt;
&lt;br /&gt;
Absence of UBE3A in mice manifest similar phenotype to human AS, as illustrated by motor and learning deficits with inducible seizures.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21235769&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It has been shown through various mice model studies that larger deletions, ie. from UBE3A to GABRB3, more closely mirrors the large 6Mb deletions seen in human AS patients. Numerous tests, such as the Rotarod (for motor coordination and learning ability), Morris water maze test (for spatial learning and memory) and [[#Glossary | '''EEG''']] (electroencephalography), were carried out on  UBE3A null mutants, which showed the results to be abnormal or impaired.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20808828&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Other studies using mouse models have also outlined the obesity observed in 15% of AS children, albeit it is not the major characterisitics of AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17259980&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The diagram on the right clearly highlights the results obtained from such mouse model studies of AS, where the absence of UBE3A accumulated in deficits of motor function and obesity. In addition, excessive drooling and feeding difficulties were also highlighted by mice models with inactivated UBE3A, reflected by defects in fluid consumption and licking.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18413322&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Pathophysiology===&lt;br /&gt;
&lt;br /&gt;
'''Cognitive defects'''&lt;br /&gt;
&lt;br /&gt;
[[File:Role of UBE3A in dendritic spine neuronal synapses.png|thumb|250px|right|Role of UBE3A in dendritic spine neuronal synapses.]]&lt;br /&gt;
&lt;br /&gt;
AS patients present with abnormally high UBE3A, leading to neurological impairment. Recent identification of key target proteins of Ephexin-58 (Eph-5) and Arc (Activity-Regulated Cytoskeleton-associated protein) have aided in better understanding of the progression of UBE3A to cognitive defects. These two proteins are vital in the understanding of AS as Eph-5 determines synapse numbers and Arc contributes to plasticity and synapse function.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21164477&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Studies utilizing mice models have illustrated that UBE3A null mice could not ubiquitinate Eph-5, thus increasing its levels and limiting the growth of dendritic spines by the activation of RhoA. This subsequent activation of RhoA inhibits synapse formation and results in neuronal defects.&lt;br /&gt;
&lt;br /&gt;
In contrast, mice with normally functioning UBE3A showed phosphorylated Eph-5, resulting from the interaction of two neurons via the activation of EphB signalling receptor.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21029865&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Phosphorylation of Eph-5 allows UBE3A to ubiquitinate and degrade it. This degradation of Eph-5 permits new synaptic connections to form with cells they come into contact with. However, in AS, the absence of UBE3A means Eph-5 cannot be degraded, so RhoA activity is prolonged to reduce synaptic formation.&lt;br /&gt;
&lt;br /&gt;
As mentioned previously, Arc plays a pivitol role in synapse function as it removes synaptic receptors that respond to glutamate, a [[#Glossary | '''neurotransmitter''']].&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17088211&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In UBE3A present neurons, UBE3A ubiquitinates Arc, leading to it degradation as illustrated by the diagram on the left. However, in UBE3A deficient neurons, Arc accumulates and prevents the proper synaptic communications essential for normal cognitive functions.&amp;lt;ref name=&amp;quot;PMID20211139&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Signs and Symptoms==&lt;br /&gt;
&lt;br /&gt;
Angelman Syndrome presents a variety of different phenotypes, and the presented symptoms may vary at different ages.&amp;lt;ref name=&amp;quot;PMID7625442&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7625442&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
In 1995 Williams et al. embraced the observed clinical features of AS in a consensus statement, in order to present an appliance for clinicians. The diagnostic criteria were updated in 2005.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt; The following table shows the most frequently occurring characteristics in AS patients:&lt;br /&gt;
&lt;br /&gt;
'''4 characteristics appear in 100% of the cases:'''&lt;br /&gt;
&lt;br /&gt;
*Delayed development: become apparent by the age of 6 to 12 months.&lt;br /&gt;
*Motion and or balance malfunction&lt;br /&gt;
*Behaviour patterns like unmotivated laughter, frequent excitement; often including body movements,[[File:Electroencephalography of Angelman Syndrome.jpg|thumb|350px|right|EEG of AS and normal individuals.]] [[#Glossary | '''hypermotoric''']] behaviour&lt;br /&gt;
*Impairment of speech&lt;br /&gt;
&lt;br /&gt;
'''3 characteristics appear in more than 80% of the cases:'''&lt;br /&gt;
&lt;br /&gt;
*Abnormalities in head circumference, microcephaly&lt;br /&gt;
*Seizures&lt;br /&gt;
*EEG shows specific abnormal patterns&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Angelman Syndrome individuals show the most distinct disease pattern from 2 to 16 years of age.&lt;br /&gt;
In most cases at least 8 of the symptom traits are shown.&amp;lt;ref name=&amp;quot;PMID7625442&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Behavioural Characteristics'''&lt;br /&gt;
&lt;br /&gt;
A range of substantial characteristics appear in all AS cases, regardless of the genetic mechanisms, and are often responsible for diagnosing the syndrome. According to the original name, Happy Puppet syndrome, they have shown to exhibit traits such as a happy demeanor, with frequent laughter or smiling that can easily be triggered.&amp;lt;ref name=&amp;quot;PMID12566516&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12566516&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This behaviour can already be observed in 1 to 3 month old infants.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot; /&amp;gt; Uplifted hand flapping or waving motions are associated with laughter and excitement. Other characteristics manifesting in early childhood are sleep abnormalities with reduced sleep demand, and feeding problems. Breast and bottle feeding can be difficult due to non efficient attachment to the breast, tongue thrusting and uncoordinated sucking. Furthermore, there is an affection to crinkly and reflective surfaces, like some papers or plastic materials, especially water.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID12566516 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Communication Skills'''&lt;br /&gt;
&lt;br /&gt;
Communication is challenging for AS patients due to the fact that speech impairment is present in all cases. In the majority of affected people a lack of speech development is present. Only some of them have a minimal vocabulary consisting of two or three words, a few can speak in basic sentences. Some patients use gestures to articulate themselves, the [[#Glossary | '''Picture Exchange Communication System (PECS)''']] or sign languages such as [[#Glossary | '''Makaton''']] can be used for communication. Simple demands regarding their everyday occurrence can be understood by most patients.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID12566516 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Clinical and External Characteristics'''[[File:Angelman Syndrome patient.png|thumb|200px|right|4 year old AS patient.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Developmental delays are present in all patients. Motor milestones are delayed with children managing to sit unsupported with 12 months and crawl or bottom shuffle at the age of 18-24 months. The average age for walking is 4 years,however, ranging from 18 months to 7 years.&lt;br /&gt;
The [[#Glossary | '''gait''']] is characterised as slow, and flapping hands are a common trait.  The legs remain stiff during walking, arms are inflected by the wrists and elbows. The movements can appear ataxic, jerky or lurching. The muscle tone shows abnormalities with truncal [[#Glossary | '''hypotonia''']] and [[#Glossary | '''hypertonicity''']] of the limbs and alert reflexes.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID12566516 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The most striking external traits present in patients include broad-spaced teeth, and a wide mouth, light hair and eye colour, hypopigmented skin, deep set eyes, and a flat [[#Glossary | '''occiput''']].&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Seizures in Angelman Syndrome'''&lt;br /&gt;
&lt;br /&gt;
85% of AS patients suffer from epileptic seizures during their first three years. The first appearance can be within one month up to 20 year old patients. In infants with AS epilepsy manifests with [[#Glossary | '''febrile convulsions''']] and is hard to manage during childhood.&lt;br /&gt;
The most common type of seizures within 25% of patients are [[#Glossary | '''myoclonic seizures''']], followed by [[#Glossary | '''atonic seizures''']] as the second most frequent type, then 21% experience generalised [[#Glossary | '''tonic-clonic seizures''']] and lastly [[#Glossary | '''atypical absences''']] occur in 12% of patients.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20398390&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Angelman Syndrome in adults'''&lt;br /&gt;
&lt;br /&gt;
Patients with Angelman syndrome possess normal secondary sexual characteristics, and puberty sets in at a usual time. Limb hypertonicity, and [[#Glossary | '''thoracic scoliosis''']] lead to decreasing mobility. [[#Glossary | '''Oesophagus reflux''']] might induce severe problems, and the majority suffers from obesity. Furthermore, facial traits such as a prominent lower lip [[#Glossary | '''macrostomia''']] and [[#Glossary | '''mandibular prognathism''']] get manifested in adults. &lt;br /&gt;
In some cases the communication barrier can lead to frustration, resulting in aggressive behaviour. Nonetheless, patients gain a higher concentration span with age, and their nature becomes more quiet.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Complications===&lt;br /&gt;
&lt;br /&gt;
'''Hypopigmentation and Ocular albinism'''&lt;br /&gt;
&lt;br /&gt;
OCA2 gene, also known as the P gene, is closely located to the UBE3A gene. It encodes a protein vital to tyrosine metabolism, which plays a role in pigmentation development of skin, hair and eyes. However, AS caused by the large deletion of UBE3A leads to haploinsufficiency of OCA2 gene, resulting in hypopigmentation of the skin and the eyes. In some children with severe hypopigmentation, some form of [[#Glossary | '''albinism''']] is suspected.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12749060&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; When AS is caused by another mechanism, no abnormality of the skin and eye pigmentation is observed. However, not all AS children with OCA2 gene deletion will present with obvious hypopigmentation, they may just exhibit lighter skin colour than their parents.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8302318&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Diagnosis==&lt;br /&gt;
&lt;br /&gt;
The diagnosis of Angelman Syndrome is a clinical diagnosis confirmed by laboratory testing.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This involves both prenatal and/or postnatal diagnosis. &lt;br /&gt;
&lt;br /&gt;
===Prenatal Diagnosis===&lt;br /&gt;
[[File:Angelman Syndrome Prenatal Diagnosis.jpg|thumb|250px|right|Flowchart of AS Diagnosis.]]&lt;br /&gt;
&lt;br /&gt;
Prenatal detection of deletions of 15q11.2-q13, [[#Glossary | '''Paternal UPD''']] ([[#Glossary | '''Uniparental Disomy''']]), Imprinting defects and UBE3A mutations are done through DNA/chromosome/FISH analysis of fetal cells obtained by either [[#Glossary | '''Chorionic Villus Sampling''']](CVS) or [[#Glossary | '''Amniocentesis''']].&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot;/&amp;gt; &lt;br /&gt;
DNA methylation analysis using [[#Glossary | '''Amniocytes''']] is usually the first test carried out in molecular diagnosis of AS.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18059071&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; An abnormal result is followed up by either a FISH or array CGH analysis to search for a deletion on chromosome 15. If they produce a normal result, then UPD testing using DNA polymorphysims is carried out. If there is no evidence of UPD, other DNA analysis tests are used search for an imprinting centre deletion.&amp;lt;ref name=&amp;quot;PMID9792887&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9792887&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; A normal DNA methylation analysis is followed by a UBE3A sequence analysis.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt; In addition, a parent of origin test is also done to determine if the genetic disruption is of maternal origin or paternal origin. If it is maternally derived the fetus is diagnosed with AS (a paternally derived genetic disruption is indicative of Prader-Willi Syndrome).&amp;lt;ref name=&amp;quot;PMID17020468&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;17020468&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The flow chart summarizes the normal procedure used for prenatal diagnosis of AS. More information on important laboratory tests used for the diagnosis of Angelman Syndrome are provided below:&lt;br /&gt;
&lt;br /&gt;
*'''DNA Methylation Analysis'''&lt;br /&gt;
&lt;br /&gt;
Identifies approximately 80% of AS affected individuals and is usually the first test to be ordered.&amp;lt;ref name=&amp;quot;PMID7618904&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7618904&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Molecular disruptions such as deletions, paternal UPD and imprinting defects on chromosome 15 all demonstrate abnormal methylation patterns by either southern blot analysis or PCR amplification of bisulphate-treated DNA.&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot; /&amp;gt; An affected individual will only have an unmethylated (paternal) SNRPN (small nuclear ribonuclear protein-associated polypeptide N) allele compared with an unaffected individual who will have both a methylated and an unmethylated SNRPN allele.&amp;lt;ref name=&amp;quot;PMID9634532&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9634532&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
	  &lt;br /&gt;
*'''FISH (Fluorescent In Situ Hybridization)'''&lt;br /&gt;
&lt;br /&gt;
[[File:Critical_region_of_Angelman_Syndrome_on_chromosome_15.png‎|thumb|150px|right|FISH (fluorescence in situ hybridisation) image showing the critical region of Angelman Syndrome on chromosome 15.]]&lt;br /&gt;
&lt;br /&gt;
FISH analysis detects 5-7 Mb deletions in approximately 68% of affected individuals using detecting probes such as D15S10 and/or SNRPN.&amp;lt;ref name=&amp;quot;PMID7618904&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7618904&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It is also able to distinguish UPD from micro-deletions and imprinting defects. In simple terms, FISH analysis involves the binding of a fluorescent probe to a specific part of chromosome 15 and the detection of deletions within that region. FISH analysis is much more accurate in deletion detection compared to other high-resolution cytogenetics in the diagnosis of AS patients.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1511093&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
Array-based CGH is an advanced type of cytogenetic testing that can also be used to detect smaller deletions.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''UPD (Uniparental Disomy) Detection'''&lt;br /&gt;
&lt;br /&gt;
DNA Polymorphism testing detects paternal UPD in approximately 7% of affected AS individuals.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt; It is also able to distinguish between UPD and an Imprinting defect. It requires a DNA sample from the [[#Glossary | '''Proband''']] and from both parents. A homologous or non-homologous whole-arm translocation of the long arms of chromosome 15 is a sound indication for the need for prenatal UPD testing.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''IC (Imprinting Center) Analysis'''&lt;br /&gt;
&lt;br /&gt;
This type of analysis is used when individuals have an abnormal DNA methylation pattern but show normal results for  FISH, array CGH study and UPD analysis.&amp;lt;ref name=&amp;quot;PMID9792887&amp;quot;/&amp;gt; It is used to differentiate between the Imprinting defects caused by either microdeletions in the AS imprinting centre or by epigenetic mutations (that occur in maternal oogenesis or early embryogenesis).&amp;lt;ref name=&amp;quot;PMID9634532&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''Cytogenetic Testing'''&lt;br /&gt;
&lt;br /&gt;
Is used to detect a cytogenetically visible chromosomal rearrangement (large deletion, translocation or inversion) involving the 15q11.2-q13 region, which occurs in less than 1% of affected individuals.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''UBE3A Sequence Analysis'''&lt;br /&gt;
Sequence analysis of the UBE3A gene detects mutations in about 10% of the patients.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt; The test is used to detect either multiexonic (10 major coding exons of UBE3A) or whole gene deletions of UBE3A gene in individuals who produces a normal DNA methylation result but has characteristic clinical features of AS.&amp;lt;ref name=&amp;quot;PMID9792887&amp;quot;/&amp;gt;&lt;br /&gt;
This is recommended as a prenatal diagnostic tool in families that include multiple AS affected individuals because the imprinted pattern can be inherited from distant relatives.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Postnatal Diagnosis===&lt;br /&gt;
&lt;br /&gt;
Postnatal diagnosis is made though a combination of common clinical features of AS and UBESA gene sequence analysis.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt; The clinical features of AS include unsteady or shaky movements, muscle hypotonia, developmental delay and behavioral uniqueness such as frequent laughter/smiling and happy demeanor are features that are 100% consistent in all patients diagnosed with Angelman Syndrome.&amp;lt;ref name=&amp;quot;PMID18830393&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18830393&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; These clinical features become apparent between 6 months to 2 years of age. The onset of early or persistent smiling characteristic of this syndrome begin around the age of 1-3 months, but is often overlooked during infancy.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot;/&amp;gt; Thus early diagnosis of AS during infancy period is difficult because the clinical indicators of the syndrome takes time to manifest and characteristic features such as finger and hand tremors and excessive smiling/laughter are often overlooked and not considered as possible indicators of this syndrome.&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
*Rett Syndrome&lt;br /&gt;
&lt;br /&gt;
Some children with the clinical diagnosis of AS but no underlying genetic mechanism show mutations in ''MECP2'' gene, corresponding to Rett Syndrome. This should be suspected in AS test negative girls in the first few years of life.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17980307&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*Mowat-Wilson Syndrome&lt;br /&gt;
&lt;br /&gt;
Genetic mechanism is heterozygous deletion or truncation in ''ZFHX1B'' (''SIP1'') gene on 2q22. This presents with clinical features of severe intellectual disability, micrcephaly and seizures.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17958891&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Prader-Willi Syndrome patient.png|thumb|right|120px|12 year old PWS patient.]]&lt;br /&gt;
&lt;br /&gt;
*X-linked alpha-thalassemia/mental retardation syndrome (ATR-X)&lt;br /&gt;
&lt;br /&gt;
This arises from mutations in ''XNP'' gene on Xq13. ATR-X presents with severe intellectual disability, no speech development and seizures are common.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11449489&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*Phelan-McDermid Syndrome/22q13 deletion syndrome&lt;br /&gt;
&lt;br /&gt;
Deletions are usually submicroscopic and thus requires special molecular cytogenetic methods to confirm this deletion. Patients show moderate to profound intellectual disability and delay in speech development.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18505557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Related Disease'''&lt;br /&gt;
&lt;br /&gt;
*Prader-Willi Syndrome(PWS)&lt;br /&gt;
&lt;br /&gt;
PWS is a result from the absence of paternally expressed 15q11-q13 gene as a corollary of de novo deletion, maternal uniparental disomy of chromosome 15 or an imprinting defect on paternal chromosome 15 leading to the silencing of paternal alleles.&amp;lt;ref name=&amp;quot;PMID:20668179 &amp;quot;/&amp;gt; It is characterized by [[#Glossary | '''hyperphagia''']], obesity in later infancy and early childhood and difficulty in feeding during early infancy.&amp;lt;ref name=&amp;quot;PMID:20668179 &amp;quot;/&amp;gt; There is also cognitive impairment to some extent, though some PWS patients may exhibit intelligence in the normal IQ range. Behavioral phenotypes include stubbornness, manipulative tendency, obsessive compulsive characteristics.&amp;lt;ref name=&amp;quot;PMID:20668179 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Genetic Counselling==&lt;br /&gt;
&lt;br /&gt;
Genetic counselling is the process by which patients or relatives, at risk of an inherited disorder, are advised of the consequences and nature of the disorder, the probability of developing or transmitting it, and the options open to them in management and family planning. In the case for Angelman syndrome, types of risks associated are split into classes and formatted into the table below:&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20459762&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{|  style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
! Class&lt;br /&gt;
! Mechanism&lt;br /&gt;
! Risk to siblings&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! Ia                           &lt;br /&gt;
| De novo deletion                                                                                                               &lt;br /&gt;
| &amp;lt;1%                                                                                                                &lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! Ib&lt;br /&gt;
| Deletion due to chromosome rearrangement&lt;br /&gt;
| Up to 50%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! II&lt;br /&gt;
| Paternal uniparental disomy (UPD)&lt;br /&gt;
| &amp;lt;1%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! IIIa&lt;br /&gt;
| Imprinting defect with IC mutation&lt;br /&gt;
| Close to 100% if father has 15; 15 [[#Glossary | '''Robertsonian translocation''']]&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! IIIb&lt;br /&gt;
| Imprinting defect without IC mutation&lt;br /&gt;
| Up to 50% (if mother has IC deletion)&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! IIIc&lt;br /&gt;
| [[#Glossary | '''Mosaic''']] imprinting defect&lt;br /&gt;
| &amp;lt;1%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! IV&lt;br /&gt;
| ''UBE3A'' mutation&lt;br /&gt;
| Up to 50% (if mother has mutation)&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! V&lt;br /&gt;
| No identifiable genetic abnormality&lt;br /&gt;
| ?&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Ia''': Individuals with de novo deletion have 1% risk to siblings&lt;br /&gt;
&lt;br /&gt;
'''Ib''': Risk to siblings in individuals with chromosomal rearrangements is up to 50% &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9557895&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''II''': Paternal UPD with no Robertsonian translocation has a risk to sibling of less than 1%&lt;br /&gt;
&lt;br /&gt;
'''IIIa''': The risk to siblings in individuals with AS from an imprinting defect with a mutation in the imprinting center (IC) is close to 100% if father has 15;15 Robertsonian translocation&lt;br /&gt;
&lt;br /&gt;
'''IIIb''': Individuals with AS resulting from an imprinting defect without IC mutation, but with a carrier mother has a high risk to siblings of up to 50%. The mother could be phenotypically normal due to paternal inheritance of the genetic defect &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11283796&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''IIIc''': Individuals who are mosaic for the imprinting defect have less than 1% risk to siblings&lt;br /&gt;
&lt;br /&gt;
'''IV''': UBE3A mutation can be either inherited or de novo mutation. If the mother is a carrier for this genetic mutation, the risk to siblings is up to 50% &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11258627&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''V''': Individuals who present with AS clinically, but have no known underlying mechanism have an unknown risk to siblings.&lt;br /&gt;
&lt;br /&gt;
==Treatment and Management==&lt;br /&gt;
&lt;br /&gt;
Even though at present there is no known cure for Angelman syndrome, there are a number of treatments available that may alleviate symptons and improve daily life activities.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The below table describes the problems and management options that are used:&lt;br /&gt;
&lt;br /&gt;
[[File:Subtle Finger tremors-Angelman Syndrome.jpg|right|thumb|150px|A five months old boy with Angelman syndrome showing signs of Subtle Finger tremor.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
! Problems encountered&lt;br /&gt;
! Treatment and Management&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''Difficulty in feeding newborn AS babies'''&lt;br /&gt;
| Use of special nipples may improve feeding&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Oesophagus reflux'''&lt;br /&gt;
| Special motility medications requiried or upright positioning&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''Seizures'''&lt;br /&gt;
| Anticonvulsant medications&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19605773&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19453717&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Ocular problems'''&lt;br /&gt;
| Visual assessment is vital to encourage interactions and minimize chances of self-harm and autism development&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20656169&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''Drooling in developmental delayed AS patients'''&lt;br /&gt;
| Difficult to treat, but new surgical procedure on salivary duct reimplantation seems to be a promising alternative&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17699119&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Unstable children''' &lt;br /&gt;
| Physical therapy&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''AS patients become less active with increasing age'''&lt;br /&gt;
| Activity schedules to prevent scoliosis and obesity. Occupational therapy to stimulate fine motor and oral-motor control skills in conjunction to speech therapy&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Sleeping difficulty'''&lt;br /&gt;
| Sedative medication in severe cases. [[#Glossary | '''Melatonin''']] may be used to promote sleeping but some studies have found that it loses its therapeutic effects after several weeks in most AS patients&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19379289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|-&lt;br /&gt;
|colspan=&amp;quot;4&amp;quot; |&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Prognosis==&lt;br /&gt;
&lt;br /&gt;
Life expectancy of AS patients seems to be normal&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, but there is still a high degree of developmental delay and limited expressive language skills.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17019625&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This problem arises prominently in the assessment of the severity of coincidental medical conditions due to difficulties in communication. A visit to the dentist can become difficult if good communication is not conveyed between the parents, the dentist, and the child.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18271768&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Some problems require extreme measures, such as the procedure of lens implantation was performed in both eyes of a person diagnosed with AS, due to the inability to wear spectacles.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20656169&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
During adulthood, menstruation and puberty begin at around average age evidenced by females with Angelman syndrome that are fully capable of conceiving children.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11258627&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Most adult patients can feed themselves, but needed help with many other daily activities. Main troubles which have shown in adults are a tendency to become obese and start developing  thoracic scoliosis, which some adults with AS begin wheelchair bounded.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9072912&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Current and Future Research==&lt;br /&gt;
&lt;br /&gt;
Currently there is no cure for the treatment of AS, so much research is being carried out for therapeutic interventions. Findings in the last five years have suggested through various mice and fruit fly models that the absence of maternal UBE3A results in the same human AS features of neurological defects and seizures. However, more recently, studies have outlined that the symptoms of AS can be improved by modifying other gene products. In addition, restoring of a functional UBE3A protein into adult mice neurons have shown to reduce motor and neurological deficits and balance disorders. This shows promising research prospects in that improvements may be possible in human AS patients by restoring functional UBE3A proteins into their neurons. &lt;br /&gt;
&lt;br /&gt;
===Possible Treatment Pathways===&lt;br /&gt;
&lt;br /&gt;
*'''Cognitive and physical impairment'''&lt;br /&gt;
&lt;br /&gt;
Although everyone is born with two copies of the gene UBE3A, one maternal and one paternal copy, it is only the maternal UBE3A that is used in the brain. Most AS patients have a genetic mutation on the maternal chromosome 15 that results in dysfunctional UBE3A.&amp;lt;ref&amp;gt;http://www.cureangelman.org/what-hope.html&amp;lt;/ref&amp;gt; The above research focused on turning on the father's copy of UBE3A to restore its functions. Furthermore, mouse models were utilized to show that alpha-CaMKII could be increased to compensate the loss of UBE3A and restore compromised mental and physical abilities. However, this finding still requires much more research.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17259980&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''Epilepsy'''&lt;br /&gt;
&lt;br /&gt;
There is research being done on improving certain conditions that are involved in AS by nutritional benefits. The use of [[#Glossary | '''corticosteroids''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19666884&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, [[#Glossary | '''valproate''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19453717&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and [[#Glossary | '''clonazepam''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19605773&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and having a [[#Glossary | '''ketogenic diet''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20880305&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; has all been shown to aid in the treatment of epilepsy. It has also been reported to be efficient in the treatment of other conditions, such as behavioural disorders, reduction in seizures, ataxia, sleep patterns, developmental progress and sleep disturbances. [[#Glossary | '''Levetiracetam''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17326790&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; could be used in such a situation, especially when the patient has an intolerance to valproate and clonazepam.&lt;br /&gt;
&lt;br /&gt;
*'''Betaine and Folic acid'''&lt;br /&gt;
&lt;br /&gt;
This double-blind placebo-controlled study was done to examine the potential therapeutic role of [[#Glossary | '''betaine''']] and [[#Glossary | '''folic acid''']] in the treatment of the clinical phenotypes of AS. The aim of this protocol was to increase methylation and activate the paternally inherited UBE3A in hope to compensate for the inactive maternal UBE3A. Although there were no major differences in the control and treatment groups, a small number of patients in the treatment group showed some positive outcomes.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20635355&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&lt;br /&gt;
'''albinism''': A congenital disorder distincted by the complete or partial absence of pigment in the skin, hair and eyes due to defect of an enzyme involved in the production of melanin.&lt;br /&gt;
&lt;br /&gt;
'''allele''': Dissimilar variant of one gene. Organisms have two alleles for each gene inherited from their parents, one from each of them.&lt;br /&gt;
&lt;br /&gt;
'''alpha-CaMKII''': (alpha calcium calmodulin kinase II) Compound involved in synaptic plasticity, one of the most important theories behind learning and memory. Ability of a synapse between two neurons to change in strength due to the use or disuse of transmission.&lt;br /&gt;
&lt;br /&gt;
'''Amniocytes''': Cells that are shed by the fetus during fetal development to the surrounding amniotic fluid. They are a source of fetal DNA. &lt;br /&gt;
&lt;br /&gt;
'''Amniocentesis''': (AFT or amniotic fluid test) is a prenatal diagnostic test used to detect chromosomal abnormalities in the developing fetus by extracting amniotic fluid (a source of fetal DNA) surrounding the fetus. &lt;br /&gt;
&lt;br /&gt;
'''AMPA''': (2-amino-3-(5-methyl-3-oxo-1,2- oxazol-4-yl)propanoic acid) Compound that binds to the AMPA receptor to imitate glutamate neurotransmitter.&lt;br /&gt;
&lt;br /&gt;
'''Arc''': Activity-Regulated Cytoskeleton-associated protein; involved in learning and memory.&lt;br /&gt;
&lt;br /&gt;
'''ataxia''': Lack of coordination in muscle movements.&lt;br /&gt;
&lt;br /&gt;
'''atonic seizures''': A abrupt loss of muscle tone, this can lead to the limbs loosing strength, or the head may drop to the side. The patient remains conscious during this kind of epileptic seizure.&lt;br /&gt;
&lt;br /&gt;
'''atypical absences''': Seizure leads to unconsciousness in most cases.  &lt;br /&gt;
&lt;br /&gt;
'''autism''': A neural development disorder defined by limited social interaction and communication.&lt;br /&gt;
&lt;br /&gt;
'''betaine''': Also known as  betaine anhydrous or trimethylglycine (TMG), assists the body in metabolising the amino acid, homocysteine. Can be consumed via beets, broccoli, grains, shellfish, and spinach.&lt;br /&gt;
&lt;br /&gt;
'''Chorionic Villus Sampling''': A prenatal diagnostic test used to detect chromosomal abnormalities in the developing fetus by extracting and testing chorionic villus (placental tissue). &lt;br /&gt;
&lt;br /&gt;
'''chromosome''': Structure consisting of coiled DNA with DNA associated proteins such as histones.&lt;br /&gt;
&lt;br /&gt;
'''clonazepam''': A psychoactive drug having muscle relaxant properties and treats anxiety and epilepsy.&lt;br /&gt;
&lt;br /&gt;
'''corticosteroid''': A type of steroid hormones that are produced in the adrenal cortex.&lt;br /&gt;
&lt;br /&gt;
'''cytogenetics''': Study of the structure, function and abnormality of the cell, especially the chromosome.&lt;br /&gt;
&lt;br /&gt;
'''deletion''': Lack of a part of the DNA (deoxyribonucleic acid is a nucleic acid containing information for protein synthesis), can vary form a single base to a hole gene. &lt;br /&gt;
&lt;br /&gt;
'''de novo mutation''': Change in a gene of a family member for the first time due to a mutation in the egg or sperm of the parents or in the fertilized egg (zygote).&lt;br /&gt;
&lt;br /&gt;
'''disorder''': A mental or physical health disturbance or dysfunction.&lt;br /&gt;
&lt;br /&gt;
'''EEG''': Electroencephalography is a means of measuring electrical activity along the scalp by measuring the total electrical charges fired by thousands or millions of neurons.&lt;br /&gt;
&lt;br /&gt;
'''epilepsy''': Neurological disorder characterised by recurrent impairment of brain function that can cause seizures or unconsciousness. &lt;br /&gt;
&lt;br /&gt;
'''E6-AP''': E6-AP ubiquitin-protein ligase is an enzyme encoded by UBE3A which adds ubiquitin chain to target proteins to be degraded by proteasomes.&lt;br /&gt;
&lt;br /&gt;
'''febrile convulsions''': The occurrence of high fever, especially in children.&lt;br /&gt;
&lt;br /&gt;
'''FISH''': Fluorescent in situ hybridization is a technique used to identify and localize the presence or absence of DNA sequences on the chromosome. This is achieved by using fluorescently labelled DNA sequences which then binds to complementary DNA sequence on the chromosome. After hybridization (attachment), chromosome of interest will fluoresce under the microscope.&lt;br /&gt;
&lt;br /&gt;
'''folic acid''': B vitamin that helps the body make healthy new cells. Can be consumed via leafy green vegetables, fruits, dried beans, peas and nuts.&lt;br /&gt;
&lt;br /&gt;
'''gait''': A manner of walking, stepping or running.&lt;br /&gt;
&lt;br /&gt;
'''gene''': A molecular unit of heredity of a living organism.&lt;br /&gt;
&lt;br /&gt;
'''hyperphagia''': (Also referred to as Polyphagia) Excessive ingestion of food beyond the dietary and energy requirements of the body. &lt;br /&gt;
&lt;br /&gt;
'''hypermotoric''': Sudden appearance of uncontrolled movements such as striking or kicking inappropriately.&lt;br /&gt;
&lt;br /&gt;
'''hypertonicity''': Increase of muscle tension and a disability to stretch leading to an impairment of motor activity.&lt;br /&gt;
&lt;br /&gt;
'''hypopigmentation''': A lack of melanin pigments or melanocytes  affecting the colour of the skin, hair and iris. Features appear to be light-coloured due to loss of skin colour.&lt;br /&gt;
&lt;br /&gt;
'''hypotonia''': Decrease in the ability to stretch passively, due to a low muscle tone. &lt;br /&gt;
&lt;br /&gt;
'''imprinting''': This is a process to describe the modification of a maternally or paternally derived chromosome, which consequently influences the expression of certain genes on the altered chromosome.&lt;br /&gt;
&lt;br /&gt;
'''ketogenic diet''': A high-fat, low-carbohydrate diet that is used to treat epilepsy in children.&lt;br /&gt;
&lt;br /&gt;
'''levetiracetam''': An anticonvulsant drug used to treat epilepsy.&lt;br /&gt;
&lt;br /&gt;
'''locus''': Location of a gene on a chromosome(loci: plural for locus).&lt;br /&gt;
&lt;br /&gt;
'''LTP''': Long-term potentiation shares common features with long term memory. It strengthens and enhances signal transmission between neurons by improving the communication between two neurons.&lt;br /&gt;
&lt;br /&gt;
'''macrostomia''': A wide-spaced mouth.&lt;br /&gt;
&lt;br /&gt;
'''Makaton''': Language programme using symbols and signs to support speaking.&lt;br /&gt;
&lt;br /&gt;
'''mandibular prognathism''': The abnormal protrusion of the lower jaw. &lt;br /&gt;
&lt;br /&gt;
'''maxillary hypoplasia''':  The underdevelopment of the upper jaw.&lt;br /&gt;
&lt;br /&gt;
'''melatonin''': A hormone secreted by the pineal gland.&lt;br /&gt;
&lt;br /&gt;
'''microcephaly''': The circumference of the head is less than average due to abnormalities of the nervous system. This abnormality can be present at birth or emerge during the first few years of life and reduces both life expectancy and the cognitive functions of the individual affected.&lt;br /&gt;
&lt;br /&gt;
'''microdeletion''':  A genetic mutation in which a part of a chromosome or a sequence of DNA is missing.&lt;br /&gt;
&lt;br /&gt;
'''mosaic''': tissues or cells containing different mixture of genetic sequences&lt;br /&gt;
&lt;br /&gt;
'''mutation''': Event that changes the DNA (deoxyribonucleic acid is a nucleic acid, containing information for protein synthesis) or RNA (ribonucleic acid is a type of nucleic acid transmitting the information from the DNA to the proteins ) of a gene permanently.&lt;br /&gt;
&lt;br /&gt;
'''myoclonic seizures''': A quick jerk of the skeletal muscle, due to a irregular brain activity.&lt;br /&gt;
&lt;br /&gt;
'''neurogenetic''': Genetic basis of the nervous system.&lt;br /&gt;
&lt;br /&gt;
'''neurotransmitter''': Transmits neuronal signals to a target cell. They are first packaged in vesicles just beneath the membrane of presynaptic axon terminals and released into the synaptic cleft (space between the two interacting neurons) and enter the postsynaptic dendrite.&lt;br /&gt;
&lt;br /&gt;
'''occiput''': The back portion of the head.&lt;br /&gt;
&lt;br /&gt;
'''oesophagus reflux''': Impairment of a sphincter in the lower end of the oesophagus leads to the back flow of stomach acid into the oesophagus. Heartburn is a typical symptom.&lt;br /&gt;
&lt;br /&gt;
'''paediatrician''': Physicians that specialise on infants, children and adolescents.&lt;br /&gt;
&lt;br /&gt;
'''paternal UPD''': Inheritance of two copies of a chromosome from the father and none from the mother. &lt;br /&gt;
&lt;br /&gt;
'''phenotype''': Visible traites of an organism determined by genetic and environmental factors.&lt;br /&gt;
&lt;br /&gt;
'''Picture Exchange Communication System (PECS)''': Individuals communicate using images instead of words. It is frequently used by children with autism, to articulate their needs and wishes or to make comments about something.&lt;br /&gt;
&lt;br /&gt;
'''Proband''': Is the person (or animal) being studied or reported on in a genetic investigation. Most commonly it refers to the first affected family member who requires medical help for a genetic disorder. &lt;br /&gt;
&lt;br /&gt;
'''Robertsonian translocation''': Rearrangement of the chromosome, occurs in 5 chromosome including 13,14,15,21 and 22. This type of mutation occurs in chromosomes with the centromere not at the centre, resulting in long and short arm chromosomes. Translocation breaks the chromosome at the centromere so the long arm attaches to the other long arm, and the same for the short arm happens. Cell division will result in the loss of the short arms as they do not contain important genes.&lt;br /&gt;
&lt;br /&gt;
'''seizure''': Abnormal electrical activity in the brain that can result in a variety of physical symptoms like convulsion, body shaking, loss of consciousness, confusion, and mood changes.&lt;br /&gt;
&lt;br /&gt;
'''synapse''': Allows transmission of signal between neurons for effective neuronal function.&lt;br /&gt;
&lt;br /&gt;
'''thoracic scoliosis''': The spine is curved laterally(from side to side) in the thoracic region.&lt;br /&gt;
&lt;br /&gt;
'''tonic-clonic seizures''': This type of seizure is associated with unconsciousness due to electrical discharges in a big proportion of the brain.&lt;br /&gt;
&lt;br /&gt;
'''ubiquitin''': A polypeptide found in all eukaryotic cells, that participates in a variety of cellular functions including protein recycling.&lt;br /&gt;
&lt;br /&gt;
'''Uniparental disomy''': (UPD) the inheritance of two copies of a chromosome pair or part of a chromosme from one parent and no copy from the other parent. &lt;br /&gt;
&lt;br /&gt;
'''valproate''':  A mood-stabilizing drug that is also used for treatment for epilepsy and bipolar disorder.&lt;br /&gt;
&lt;br /&gt;
==Helpful Links==&lt;br /&gt;
&lt;br /&gt;
* Australia&lt;br /&gt;
:* [http://www.angelmansyndrome.org/research.html Angelman Syndrome Association] &lt;br /&gt;
:* [http://www.angelmansyndromeqld.org/ Queensland Angelman Association]&lt;br /&gt;
&lt;br /&gt;
* America&lt;br /&gt;
:* [http://www.angelman.org/ Angelman Syndrome Foundation]&lt;br /&gt;
:* [http://rarediseasesnetwork.epi.usf.edu/arpwsc/ Rare Clinical Diseases Research Network]&lt;br /&gt;
:* [http://www.rarediseases.org/rare-disease-information/rare-diseases/byID/411/viewAbstract National Organisation for Rare Disorders]&lt;br /&gt;
:* [http://www.epilepsyfoundation.org/ Epilepsy Foundation]&lt;br /&gt;
:* [http://www.cureangelman.org/ Foundation for Angelman Syndrome Therapeutics]&lt;br /&gt;
&lt;br /&gt;
* Search Pubmed &lt;br /&gt;
:* [http://www.ncbi.nlm.nih.gov/pubmed?term=angelman%20syndrome Angelman Syndrome] &lt;br /&gt;
&lt;br /&gt;
* OMIM entries for Angelman Syndrome&lt;br /&gt;
:* [http://omim.org/entry/105830 ANGELMAN SYNDROME; AS]&lt;br /&gt;
:* [http://omim.org/entry/601623 UBIQUITIN-PROTEIN LIGASE E3A; UBE3A]&lt;br /&gt;
&lt;br /&gt;
==Related Links==&lt;br /&gt;
&lt;br /&gt;
* [[Mouse Knockout]] - this page explains the current use of mouse models in disrupting genes to elucidate their genetic function, including the mouse gene knockouts for alpha calcium-calmodulin kinase II (alpha CaMKII)&lt;br /&gt;
* [[2009 Group Project 4]] - this page gives an extensive overview on the history of the mouse model and its various use in embryology and genetics. In addition, it also describes mouse knockout and the role they play in current research of various human diseases&lt;br /&gt;
* [[Fly Development]] - this page describes the use of drosophila flies as developmental models&lt;br /&gt;
* [[2009 Group Project 2]] - this page gives an extensive overview on the history of the fly model and its various use in embryology and genetics&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&lt;br /&gt;
&amp;lt;references /&amp;gt;&lt;/div&gt;</summary>
		<author><name>Z3291643</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_7&amp;diff=77578</id>
		<title>2011 Group Project 7</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_7&amp;diff=77578"/>
		<updated>2011-10-12T20:55:56Z</updated>

		<summary type="html">&lt;p&gt;Z3291643: /* Glossary */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;='''Angelman Syndrome'''=&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Introduction==&lt;br /&gt;
&lt;br /&gt;
[[File:Dr Harry Angelman.jpg|thumb|130px|right|Dr Harry Angelman.]]&lt;br /&gt;
Angelman syndrome (AS) is a rare [[#Glossary | '''neurogenetic''']] [[#Glossary | '''disorder''']] first described by Dr. Harry Angelman in 1965.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18754889&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Dr. Angelman was an English [[#Glossary | '''paediatrician''']] who first diagnosed the disease in 3 children with a developmental delay.&amp;lt;ref&amp;gt;http://www.ncbi.nlm.nih.gov/books/NBK22221/&amp;lt;/ref&amp;gt; AS occurs in 1 in 10000-20000 births, the exact number is still unknown.&amp;lt;ref name=&amp;quot;PMID7573182&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7573182&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;PMID8703225&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;8703225&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It is caused by maternal [[#Glossary | '''allele''']] disruptions of a single gene- UBE3A. Either [[#Glossary | '''mutations''']] or [[#Glossary | '''deletions''']] of the UBE3A gene results in AS. &lt;br /&gt;
&lt;br /&gt;
AS presents with well known [[#Glossary | '''phenotypes''']] during infancy and adulthood, such as [[#Glossary | '''microcephaly''']] and [[#Glossary | '''maxillary hypoplasia''']]. However, these features become more marked with age. Most frequent clinical features include delayed development,[[#Glossary | '''seizures''']],[[#Glossary | '''ataxia''']], impairment of speech, happy demeanor, behavioural problems such as hyperactivity, short attention span and sleeping difficulty.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21592595&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21484597&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;ASAwebsite&amp;quot;&amp;gt;http://www.angelmansyndrome.org/home.html&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
At present, there is no cure for the syndrome, though current research is focused at improving life quality of patients with Angelman syndrome through management of daily tasks.&amp;lt;ref&amp;gt;http://www.bbc.co.uk/health/physical_health/conditions/angelman1.shtml&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==History==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Dr. Harry Angelman first reported Angelman Syndrome on three handicapped children that were admitted to his ward in England in 1964.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt; He reported how these three independent and unconnected clinical cases all had the same characteristic features of severe developmental delay, jerky movements, seizures and a happy disposition.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt; However it was only when he stumbled upon an oil painting called ‘a Boy with a Puppet” while on a holiday in Italy he was able to connect the symptoms of all three children under one common cause.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20981772&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; He linked the happy face of the boy depicted on the painting with the jerky movements and happy disposition he observed on his three patients back in England. He reported his findings on a paper entitled “Puppet children (a report on three cases)” which was published in 1965.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
The syndrome was initially named ‘Puppet Syndrome’ but was later changed to Angelman Syndrome. Due to the extreme rarity of the syndrome and lack of sufficient clinical evidence the syndrome was soon forgotten.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt;&lt;br /&gt;
[[File:Dr Charles Williams.jpg|thumb|right|150px|Dr Charles Williams.]]&lt;br /&gt;
	&lt;br /&gt;
In 1987, a physician named Ellen Magenis, came across children with deletions on [[#Glossary | '''chromosome''']] 15 that were suffering from seizures and severe developmental delay.&amp;lt;ref&amp;gt;http://www.angelman.org/stay-informed/facts-about-angelman-syndrome---7th-edition/harry-angelman-and-the-history-of-as/&amp;lt;/ref&amp;gt; Even though genetically the children were expected to have [[#Diagnosis | '''Prader-Willi syndrome''']] that was characterised by deletions on chromosome 15, their characteristic symptoms of seizures and lack of development did not correspond with that of the syndrome. This led to the realization that these children had deletions on the maternally derived chromosome 15 and not on the paternally derived chromosome as was observed in Prader-Willi syndrome.  Thus the deleted genetic code on maternally derived chromosome 15 was identified as the genetic marker for Angelman Syndrome.&lt;br /&gt;
&lt;br /&gt;
In 1997, UBE3A gene was isolated by Dr. Joseph Wagstaff and Dr. Arthur Beaudet as the cause of Angelman Syndrome.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot; /&amp;gt; The discovery of this [[#Glossary | '''gene''']] led to the subsequent development of animal models and research aimed at finding a causal link between UBE3A gene abnormalities and characteristic features observed in Angelman Syndrome. &lt;br /&gt;
	&lt;br /&gt;
Currently, four different genetic abnormalities for Angelman Syndrome have been confirmed by genetic testing. They include: Deletion, [[#Glossary | '''Uniparental Disomy''']] (UPD), [[#Glossary | '''Imprinting''']] and UBE3A mutation.&amp;lt;ref name=&amp;quot;PMID20211139&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Below is a timeline, summarising the key discoveries and advancements of the Angelman Syndrome:&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|- bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
!Year&lt;br /&gt;
!Milestone&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1964'''&lt;br /&gt;
|First observed by Dr Harry Angelman on three handicapped children.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot; /&amp;gt; &lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''1965'''&lt;br /&gt;
|Harry Angelman publishes his finding in a report entitled 'Puppet Children'(a report on three cases).&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1980s'''&lt;br /&gt;
|First reports of AS reaches US and research into the disorder being at the University of Florida under the direction of Dr. Charles Williams.&amp;lt;ref&amp;gt;http://www.angelmanproject.com/history.htm&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''1982'''&lt;br /&gt;
|Name changed from 'Happy Puppet' to Angelman syndrome by Williams and Frias. &lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1987'''&lt;br /&gt;
|Discovery of a genetic marker for AS – an absent genetic code on maternally derived chromosome 15. &lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''1997'''&lt;br /&gt;
|The cause of AS discovered by Dr. Joseph Wagstaff and Dr. Arthur Beaudet – mutation or deletion in the UBE3A gene.&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1998'''&lt;br /&gt;
|Transgenic mice with absent maternal UBE3A created to illustrate motor and learning deficits in addition to seizures.&amp;lt;ref name=&amp;quot;PMID9808466&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9808466&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''2007'''&lt;br /&gt;
|AS mouse model shows that neurological deficits can be reversed by decreasing levels of [[#Glossary | '''alpha-CaMKII''']] inhibitory phosphorylation.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17259980&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''2010'''&lt;br /&gt;
|Discovery of a another gene mutation in TC4 gene (on chromosome 18) in a small number of clinically diagnosed patients with no identifiable genetic alternation in UBE3A.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20184619&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''2010'''&lt;br /&gt;
|Protein named Arc identified as a target of AS gene product; UBE3A.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Incidence'''&lt;br /&gt;
*The current population of people diagnosed with AS is unknown but studies have estimated the number to be around 1:10,000&amp;lt;ref name=&amp;quot;PMID7573182&amp;quot; /&amp;gt; and 1:20,000&amp;lt;ref name=&amp;quot;PMID8703225&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
'''Diagnosis'''&lt;br /&gt;
*The mean age of diagnosis for patients with AS lies between 6 and 6.5 years of age.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18664077&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15741136&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Gender'''&lt;br /&gt;
* Males appear to be at higher risk for some aspects of early developmental delays in comparison to females with AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17019625&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Demography'''&lt;br /&gt;
*Europe:&lt;br /&gt;
:Denmark- 1:10,000&amp;lt;ref name=&amp;quot;PMID7573182&amp;quot; /&amp;gt;&lt;br /&gt;
:Estonia- 1:52,000&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16906556&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
:Sweden- 1:20,000&amp;lt;ref name=&amp;quot;PMID8703225&amp;quot; /&amp;gt;&lt;br /&gt;
*Australia:&lt;br /&gt;
:Western Australia- 1:40,000&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16492624&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Aetiology==&lt;br /&gt;
&lt;br /&gt;
[[File:Chromosome 15 Deletion of 15q11.2 to 15q13.jpg|thumb|100px|Chromosome 15 - The deletion occurs at 15q11.2-15q13.]]&lt;br /&gt;
&lt;br /&gt;
'''Molecular Genetics'''&lt;br /&gt;
&lt;br /&gt;
* Location: 15q11-q13&lt;br /&gt;
* Protein product: Ubiquitin protein ligase E3A&lt;br /&gt;
* Gene name: UBE3A&lt;br /&gt;
* Phenotype: Angelman Syndrome&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Different genetic mechanisms lead to different clinical phenotypes of AS. The most common genetic mechanism leading to AS is the deletion or re-arrangement of maternal chromosome at [[#Glossary | '''locus''']] 15q11.2-q13,as the chromosome image shows on the right, accounting for 70% of AS occurrences.&amp;lt;ref name=&amp;quot;PMID8988171&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt; 8988171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This leads to more severe clinical phenotypes of microcephaly, motor difficulties, seizures and impaired speech development. The next most common genetic mechanism is mutation in the ''UBE3A'' gene responsible for 10% of AS cases and paternal uniparental disomy and mutation in the imprinting centre (IC), both accounting for 2-5% of AS observed.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
 &lt;br /&gt;
&lt;br /&gt;
AS is caused by the 4 major genetic mechanisms mentioned above and are thus divided into Classes I to IV based on their underlying genetic mechanism. AS patients with the clinical features of AS but no [[#Glossary | '''cytogenetic''']] or molecular abnormality in Chromosome 15q11.2-13 are grouped under Class V (summarised in table below).&amp;lt;ref name=&amp;quot;PMID8988171&amp;quot; /&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10364509&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Inheritance'''&lt;br /&gt;
&lt;br /&gt;
Angelman Syndrome from UBE3A mutations and deletions in the Imprinting Centre follow an inheritance pattern. A carrier father with the genetic defect can pass it on to his children, however, his children will be clinically normal. On the other hand, a carrier mother can pass the genetic defect onto her children, who will then have Angelman Syndrome. &lt;br /&gt;
&lt;br /&gt;
The image highlights the inheritance of Angelman Syndrome, which only results after a carrier mother passes it on to her children. &lt;br /&gt;
&lt;br /&gt;
{|  style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
! Class&lt;br /&gt;
! Mechanism&lt;br /&gt;
! Diagnostic Tests&lt;br /&gt;
! Frequency&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''Ia'''                           &lt;br /&gt;
| De novo deletion                                                                                           &lt;br /&gt;
| High resolution cytogenetics [[#Glossary | '''FISH''']]                                                                                                       &lt;br /&gt;
| 70%      &lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Ib'''&lt;br /&gt;
| Deletion due to chromosome rearrangement&lt;br /&gt;
| High resolution cytogenetics FISH&lt;br /&gt;
| &amp;lt;1%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''II'''&lt;br /&gt;
| Paternal uniparental disomy&lt;br /&gt;
| [[#Glossary | '''RFLP''']]  analysis&lt;br /&gt;
| 2%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''IIIa'''&lt;br /&gt;
| Imprinting defect with IC mutation&lt;br /&gt;
| Screening of [[#Glossary | '''IC''']]  for mutations is positive&lt;br /&gt;
| 2%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''IIIb'''&lt;br /&gt;
| Imprinting defect withouth IC mutation&lt;br /&gt;
| Screening of IC for mutations is negative&lt;br /&gt;
| 2%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''IIIc'''&lt;br /&gt;
| Mosaic imprinting defect&lt;br /&gt;
| Screening of IC for mutations is usually negative &lt;br /&gt;
| ?&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''IV'''&lt;br /&gt;
| ''UBE3A'' mutation&lt;br /&gt;
| Screening of ''UBE3A'' for mutations&lt;br /&gt;
| 5-10%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''V'''&lt;br /&gt;
| No identifiable genetic abnormality&lt;br /&gt;
| Consider other diagnoses&lt;br /&gt;
| 5-26%&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Pathogenesis==&lt;br /&gt;
&lt;br /&gt;
Chromosome 15 became associated with AS in the 1980s after the observation of many AS patients harboring [[#Glossary | '''microdeletions''']] of 15q11.2-15q13.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15668046&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The last decade has shed even more light in the aetiology of AS,as Kishino and Matsuura first identified UBE3A as the causative gene for AS in 1997.&amp;lt;ref name=&amp;quot;PMID:8988171&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;8988171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8988172&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Normal gene product: E6-AP ubiquitin ligase'''&lt;br /&gt;
&lt;br /&gt;
The function of UBE3A is to encode for [[#Glossary | '''E6-AP''']] ubiquitin ligase, however its function in the development of the nervous system and the process of UBE3A mutation leading to cognitive impairment in AS patients is still vague.&amp;lt;ref name=&amp;quot;PMID:20211139&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Past and current research has elucidated that E6-AP ubiquitin ligase is involved in the degradation of four proteins, listed below, but currently, no protein with a direct role in [[#Glossary | '''long-term potentiation (LTP)''']] as a target of E6-AP, has been identified.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12684449&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The identification of such target proteins would be a landmark discovery in further understanding of the pathogenesis, aetiology and prospective treatment strategies of AS, as LTP defects is one of the major neurological impairments of AS. &lt;br /&gt;
 &lt;br /&gt;
* p53 tumor suppressor protein &lt;br /&gt;
* yeast DNA repair protein Rad23 &lt;br /&gt;
* multicopy maintenance protein 7 subunit &lt;br /&gt;
* E6-AP&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Abnormal gene product'''&lt;br /&gt;
&lt;br /&gt;
Disruption to the gene,UBE3A, interferes with the normal functioning of the gene, which is its crucial role in UBE3A [[#Glossary | '''ubiquitylation''']]. Problems involving this pathway can lead to various diseases either from the loss or gain of function.&amp;lt;ref name=&amp;quot;PMID:9857172&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9857172&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In the case of AS, E6-AP is affected, leading to detrimental cognitive impairment in addition to other deficits.&amp;lt;ref name=&amp;quot;PMID:9857172&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9857172&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Regional functioning of UBE3A'''&lt;br /&gt;
&lt;br /&gt;
Despite the uncertain progression of UBE3A mutation and the neurological abnormalities characteristic of AS, animal models have illustrated the vital role of UBE3A in the normal functioning of the brain. This can be exemplified by a study which utilized a mouse model with target inactivation of the gene UBE3A resulting in the manifestation of classical features of AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11895368&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In addition, the fact that imprinting of UBE3A takes place only in specific brain regions (cerebellum, olfactory tracts and the hippocampus) confirms the hypothesis that the loss of this gene would be detrimental in the cognitive development.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20398390&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Most genes are inherited in copies of two, one paternal and the other maternal; however, some genes, such as UBE3A only have one functional copy as the other is silenced, coined 'imprinting'. Imprinting of the paternal copy of UBE3A takes place in some cell populations, such as the hippocampal neurons and Purkinje cells in the cerebellum.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9288101&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This means only the maternal UBE3A is functionally expressed in these particular brain regions. Thus a [[#Glossary | '''de novo mutation''']] in the maternal copy of the gene will result in the complete absence of functional E6-AP in the associated brain areas.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9288088&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
It is also known that UBE3A plays an important role in synaptic transmission, but exactly how it does so is still not completely understood.&amp;lt;ref name=&amp;quot;PMID:9808466&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9808466&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''UBE3A ubiquitylation'''&lt;br /&gt;
&lt;br /&gt;
As briefly mentioned above, UBE3A is a member of the E3 ubiquitin ligase family of enzymes, responsible for the addition of ubiquitin to the target protein for degradation of the ubiquitinated protein, as illustrated in the diagram below. These processes are required for normal human cognitive function.&amp;lt;ref name=&amp;quot;PMID:9808466&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9808466&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In this way synaptic protein [[#Glossary | '''Arc (activity-regulated cytoskeleton-associated protein)''']] is degraded to control synaptic function. Arc is a target protein of UBE3A in dendritic spines found in the hippocampal neurons.&amp;lt;ref name=&amp;quot;PMID:20668179&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20668179&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Deletion of UBE3A leads to the accumulation of Arc in neurons leading to trafficking of [[#Glossary | '''AMPA ( α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid)''']] receptors, resulting in impaired cognitive functions.&amp;lt;ref name=&amp;quot;PMID:20211139&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; [[File:UBE3A Ubiquitylation Pathway.png|thumb|350px|right|UBE3A Ubiquitylation Pathway.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
UBE3A ubiquitylation consists of:&amp;lt;ref name=&amp;quot;PMID:20668179&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20668179&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
# Activation of ubiquitin by E1 enzyme&lt;br /&gt;
# E1 ezyme transfers ubiquitin to E2 enzyme&lt;br /&gt;
# E2 enzyme transfers ubiquitin to UBE3A&lt;br /&gt;
# UBE3A attaches activated ubiquitin to target protein which is then polyubiquitylated &lt;br /&gt;
# Target protein is then degraded by 26S proteosome&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Phenotype-Genotype correlations'''&lt;br /&gt;
&lt;br /&gt;
[[File:Extent of microcephaly in Angelman Syndrome patients.png|thumb|250px|right|Extent of microcephaly in 20 AS patients with deletion and without deletion.&amp;lt;ref&amp;gt;http://www.nature.com/ejhg/index.html/&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
All AS patients show differing extents of cognitive impairment, movement disorder, characteristic behaviours and difficulty in speech and language.&amp;lt;ref name=&amp;quot;PMID:11748306&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11748306&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; However, there seems to be some phenotype-genotype correlations:&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
- 5-7Mb deletions result in the most severe phenotypes such as microcephaly, more sever [[#Glossary | '''epilepsy''']] and seizures, motor difficulties and language impairment.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9546330&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20445456&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; AS patients with large deletions also present with clinical [[#Glossary | '''hypopigmentation''']], light hair and eye colour due to the close association of OCA2 gene with UBE3A.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;16470747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Individuals under this category have in general no increased BMI&amp;lt;ref name=&amp;quot;PMID:15253756&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15253756&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This is indicated by the graph on the left, which shows more cases of AS patients with deletions having larger deviations from the mean head circumference measurement than non-deletion AS patients.&lt;br /&gt;
 &lt;br /&gt;
- AS patients with uniparental disomy (UPD) have better physical growth, fewer motor deficits and lower seizure occurrences.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16023557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
- Individuals with AS resulting from imprinting defects have the least debilitating features, such as higher developmental and language ability than AS caused by other mechanisms.&amp;lt;ref name=&amp;quot;PMID:11748306&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11748306&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
- The Body Mass Index (BMI) of 33% of the UBE3A mutation patients, and 47–64% of the patients from the classes II (UPD) and III (Imprinting defect) is above the 95th centile.&amp;lt;ref name=&amp;quot;PMID:15253756&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15253756&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Animal models'''&lt;br /&gt;
&lt;br /&gt;
* '''Drosophila'''&lt;br /&gt;
&lt;br /&gt;
Drosophila (common fruit fly) is an excellent model to use for better understanding of genetic diseases in humans as they are highly homologous to human UBE3A (hUBE3A), illustrating a high evolutionary conservation. Studies using the Drosophila model have shown that the functional absence of UBE3A resulted in decreased morphogenesis of dendritic branches. This is of interest as dendritic branches cover over 90% of the neuronal surface where [[#Glossary | '''synapse''']] between neurons occur. Proper formation and maturation of dendritic spines is also required so they come in contact with other neurons for effective transmission of neuronal signals. Thus proper formation of dendritic branching is pivitol for effective neuronal function and hence cognitive function.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18996915&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Interestingly, overexpression of dUBE3A also gave the same result, consisting of abnormal locomotion  and decreased dendritic branching in sensory neurons.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18701717&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;  This suggests a possible research field for some forms of [[#Glossary | '''autism''']] where the region containing UBE3A is duplicated, leading to delayed motor skills and seizures.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16433693&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;[[File:Normal and Angelman Syndrome mice models.jpg|thumb|250px|right|Normal and AS mice performance on the Rotarod apparatus.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
* '''Mice'''&lt;br /&gt;
&lt;br /&gt;
Absence of UBE3A in mice manifest similar phenotype to human AS, as illustrated by motor and learning deficits with inducible seizures.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21235769&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It has been shown through various mice model studies that larger deletions, ie. from UBE3A to GABRB3, more closely mirrors the large 6Mb deletions seen in human AS patients. Numerous tests, such as the Rotarod (for motor coordination and learning ability), Morris water maze test (for spatial learning and memory) and [[#Glossary | '''EEG''']] (electroencephalography), were carried out on  UBE3A null mutants, which showed the results to be abnormal or impaired.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20808828&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Other studies using mouse models have also outlined the obesity observed in 15% of AS children, albeit it is not the major characterisitics of AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17259980&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The diagram on the right clearly highlights the results obtained from such mouse model studies of AS, where the absence of UBE3A accumulated in deficits of motor function and obesity. In addition, excessive drooling and feeding difficulties were also highlighted by mice models with inactivated UBE3A, reflected by defects in fluid consumption and licking.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18413322&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Pathophysiology===&lt;br /&gt;
&lt;br /&gt;
'''Cognitive defects'''&lt;br /&gt;
&lt;br /&gt;
[[File:Role of UBE3A in dendritic spine neuronal synapses.png|thumb|250px|right|Role of UBE3A in dendritic spine neuronal synapses.]]&lt;br /&gt;
&lt;br /&gt;
AS patients present with abnormally high UBE3A, leading to neurological impairment. Recent identification of key target proteins of Ephexin-58 (Eph-5) and Arc (Activity-Regulated Cytoskeleton-associated protein) have aided in better understanding of the progression of UBE3A to cognitive defects. These two proteins are vital in the understanding of AS as Eph-5 determines synapse numbers and Arc contributes to plasticity and synapse function.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21164477&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Studies utilizing mice models have illustrated that UBE3A null mice could not ubiquitinate Eph-5, thus increasing its levels and limiting the growth of dendritic spines by the activation of RhoA. This subsequent activation of RhoA inhibits synapse formation and results in neuronal defects.&lt;br /&gt;
&lt;br /&gt;
In contrast, mice with normally functioning UBE3A showed phosphorylated Eph-5, resulting from the interaction of two neurons via the activation of EphB signalling receptor.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21029865&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Phosphorylation of Eph-5 allows UBE3A to ubiquitinate and degrade it. This degradation of Eph-5 permits new synaptic connections to form with cells they come into contact with. However, in AS, the absence of UBE3A means Eph-5 cannot be degraded, so RhoA activity is prolonged to reduce synaptic formation.&lt;br /&gt;
&lt;br /&gt;
As mentioned previously, Arc plays a pivitol role in synapse function as it removes synaptic receptors that respond to glutamate, a [[#Glossary | '''neurotransmitter''']].&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17088211&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In UBE3A present neurons, UBE3A ubiquitinates Arc, leading to it degradation as illustrated by the diagram on the left. However, in UBE3A deficient neurons, Arc accumulates and prevents the proper synaptic communications essential for normal cognitive functions.&amp;lt;ref name=&amp;quot;PMID20211139&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Signs and Symptoms==&lt;br /&gt;
&lt;br /&gt;
Angelman Syndrome presents a variety of different phenotypes, and the presented symptoms may vary at different ages.&amp;lt;ref name=&amp;quot;PMID7625442&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7625442&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
In 1995 Williams et al. embraced the observed clinical features of AS in a consensus statement, in order to present an appliance for clinicians. The diagnostic criteria were updated in 2005.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt; The following table shows the most frequently occurring characteristics in AS patients:&lt;br /&gt;
&lt;br /&gt;
'''4 characteristics appear in 100% of the cases:'''&lt;br /&gt;
&lt;br /&gt;
*Delayed development: become apparent by the age of 6 to 12 months.&lt;br /&gt;
*Motion and or balance malfunction&lt;br /&gt;
*Behaviour patterns like unmotivated laughter, frequent excitement; often including body movements,[[File:Electroencephalography of Angelman Syndrome.jpg|thumb|350px|right|EEG of AS and normal individuals.]] [[#Glossary | '''hypermotoric''']] behaviour&lt;br /&gt;
*Impairment of speech&lt;br /&gt;
&lt;br /&gt;
'''3 characteristics appear in more than 80% of the cases:'''&lt;br /&gt;
&lt;br /&gt;
*Abnormalities in head circumference, microcephaly&lt;br /&gt;
*Seizures&lt;br /&gt;
*EEG shows specific abnormal patterns&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Angelman Syndrome individuals show the most distinct disease pattern from 2 to 16 years of age.&lt;br /&gt;
In most cases at least 8 of the symptom traits are shown.&amp;lt;ref name=&amp;quot;PMID7625442&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Behavioural Characteristics'''&lt;br /&gt;
&lt;br /&gt;
A range of substantial characteristics appear in all AS cases, regardless of the genetic mechanisms, and are often responsible for diagnosing the syndrome. According to the original name, Happy Puppet syndrome, they have shown to exhibit traits such as a happy demeanor, with frequent laughter or smiling that can easily be triggered.&amp;lt;ref name=&amp;quot;PMID12566516&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12566516&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This behaviour can already be observed in 1 to 3 month old infants.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot; /&amp;gt; Uplifted hand flapping or waving motions are associated with laughter and excitement. Other characteristics manifesting in early childhood are sleep abnormalities with reduced sleep demand, and feeding problems. Breast and bottle feeding can be difficult due to non efficient attachment to the breast, tongue thrusting and uncoordinated sucking. Furthermore, there is an affection to crinkly and reflective surfaces, like some papers or plastic materials, especially water.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID12566516 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Communication Skills'''&lt;br /&gt;
&lt;br /&gt;
Communication is challenging for AS patients due to the fact that speech impairment is present in all cases. In the majority of affected people a lack of speech development is present. Only some of them have a minimal vocabulary consisting of two or three words, a few can speak in basic sentences. Some patients use gestures to articulate themselves, the [[#Glossary | '''Picture Exchange Communication System (PECS)''']] or sign languages such as [[#Glossary | '''Makaton''']] can be used for communication. Simple demands regarding their everyday occurrence can be understood by most patients.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID12566516 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Clinical and External Characteristics'''[[File:Angelman Syndrome patient.png|thumb|200px|right|4 year old AS patient.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Developmental delays are present in all patients. Motor milestones are delayed with children managing to sit unsupported with 12 months and crawl or bottom shuffle at the age of 18-24 months. The average age for walking is 4 years,however, ranging from 18 months to 7 years.&lt;br /&gt;
The [[#Glossary | '''gait''']] is characterised as slow, and flapping hands are a common trait.  The legs remain stiff during walking, arms are inflected by the wrists and elbows. The movements can appear ataxic, jerky or lurching. The muscle tone shows abnormalities with truncal [[#Glossary | '''hypotonia''']] and [[#Glossary | '''hypertonicity''']] of the limbs and alert reflexes.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID12566516 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The most striking external traits present in patients include broad-spaced teeth, and a wide mouth, light hair and eye colour, hypopigmented skin, deep set eyes, and a flat [[#Glossary | '''occiput''']].&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Seizures in Angelman Syndrome'''&lt;br /&gt;
&lt;br /&gt;
85% of AS patients suffer from epileptic seizures during their first three years. The first appearance can be within one month up to 20 year old patients. In infants with AS epilepsy manifests with [[#Glossary | '''febrile convulsions''']] and is hard to manage during childhood.&lt;br /&gt;
The most common type of seizures within 25% of patients are [[#Glossary | '''myoclonic seizures''']], followed by [[#Glossary | '''atonic seizures''']] as the second most frequent type, then 21% experience generalised [[#Glossary | '''tonic-clonic seizures''']] and lastly [[#Glossary | '''atypical absences''']] occur in 12% of patients.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20398390&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Angelman Syndrome in adults'''&lt;br /&gt;
&lt;br /&gt;
Patients with Angelman syndrome possess normal secondary sexual characteristics, and puberty sets in at a usual time. Limb hypertonicity, and [[#Glossary | '''thoracic scoliosis''']] lead to decreasing mobility. [[#Glossary | '''Oesophagus reflux''']] might induce severe problems, and the majority suffers from obesity. Furthermore, facial traits such as a prominent lower lip [[#Glossary | '''macrostomia''']] and [[#Glossary | '''mandibular prognathism''']] get manifested in adults. &lt;br /&gt;
In some cases the communication barrier can lead to frustration, resulting in aggressive behaviour. Nonetheless, patients gain a higher concentration span with age, and their nature becomes more quiet.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Complications===&lt;br /&gt;
&lt;br /&gt;
'''Hypopigmentation and Ocular albinism'''&lt;br /&gt;
&lt;br /&gt;
OCA2 gene, also known as the P gene, is closely located to the UBE3A gene. It encodes a protein vital to tyrosine metabolism, which plays a role in pigmentation development of skin, hair and eyes. However, AS caused by the large deletion of UBE3A leads to haploinsufficiency of OCA2 gene, resulting in hypopigmentation of the skin and the eyes. In some children with severe hypopigmentation, some form of [[#Glossary | '''albinism''']] is suspected.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12749060&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; When AS is caused by another mechanism, no abnormality of the skin and eye pigmentation is observed. However, not all AS children with OCA2 gene deletion will present with obvious hypopigmentation, they may just exhibit lighter skin colour than their parents.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8302318&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Diagnosis==&lt;br /&gt;
&lt;br /&gt;
The diagnosis of Angelman Syndrome is a clinical diagnosis confirmed by laboratory testing.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This involves both prenatal and/or postnatal diagnosis. &lt;br /&gt;
&lt;br /&gt;
===Prenatal Diagnosis===&lt;br /&gt;
[[File:Angelman Syndrome Prenatal Diagnosis.jpg|thumb|250px|right|Flowchart of AS Diagnosis.]]&lt;br /&gt;
&lt;br /&gt;
Prenatal detection of deletions of 15q11.2-q13, [[#Glossary | '''Paternal UPD''']] ([[#Glossary | '''Uniparental Disomy''']]), Imprinting defects and UBE3A mutations are done through DNA/chromosome/FISH analysis of fetal cells obtained by either [[#Glossary | '''Chorionic Villus Sampling''']](CVS) or [[#Glossary | '''Amniocentesis''']].&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot;/&amp;gt; &lt;br /&gt;
DNA methylation analysis using [[#Glossary | '''Amniocytes''']] is usually the first test carried out in molecular diagnosis of AS.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18059071&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; An abnormal result is followed up by either a FISH or array CGH analysis to search for a deletion on chromosome 15. If they produce a normal result, then UPD testing using DNA polymorphysims is carried out. If there is no evidence of UPD, other DNA analysis tests are used search for an imprinting centre deletion.&amp;lt;ref name=&amp;quot;PMID9792887&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9792887&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; A normal DNA methylation analysis is followed by a UBE3A sequence analysis.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt; In addition, a parent of origin test is also done to determine if the genetic disruption is of maternal origin or paternal origin. If it is maternally derived the fetus is diagnosed with AS (a paternally derived genetic disruption is indicative of Prader-Willi Syndrome).&amp;lt;ref name=&amp;quot;PMID17020468&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;17020468&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The flow chart summarizes the normal procedure used for prenatal diagnosis of AS. More information on important laboratory tests used for the diagnosis of Angelman Syndrome are provided below:&lt;br /&gt;
&lt;br /&gt;
*'''DNA Methylation Analysis'''&lt;br /&gt;
&lt;br /&gt;
Identifies approximately 80% of AS affected individuals and is usually the first test to be ordered.&amp;lt;ref name=&amp;quot;PMID7618904&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7618904&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Molecular disruptions such as deletions, paternal UPD and imprinting defects on chromosome 15 all demonstrate abnormal methylation patterns by either southern blot analysis or PCR amplification of bisulphate-treated DNA.&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot; /&amp;gt; An affected individual will only have an unmethylated (paternal) SNRPN (small nuclear ribonuclear protein-associated polypeptide N) allele compared with an unaffected individual who will have both a methylated and an unmethylated SNRPN allele.&amp;lt;ref name=&amp;quot;PMID9634532&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9634532&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
	  &lt;br /&gt;
*'''FISH (Fluorescent In Situ Hybridization)'''&lt;br /&gt;
&lt;br /&gt;
[[File:Critical_region_of_Angelman_Syndrome_on_chromosome_15.png‎|thumb|150px|right|FISH (fluorescence in situ hybridisation) image showing the critical region of Angelman Syndrome on chromosome 15.]]&lt;br /&gt;
&lt;br /&gt;
FISH analysis detects 5-7 Mb deletions in approximately 68% of affected individuals using detecting probes such as D15S10 and/or SNRPN.&amp;lt;ref name=&amp;quot;PMID7618904&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7618904&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It is also able to distinguish UPD from micro-deletions and imprinting defects. In simple terms, FISH analysis involves the binding of a fluorescent probe to a specific part of chromosome 15 and the detection of deletions within that region. FISH analysis is much more accurate in deletion detection compared to other high-resolution cytogenetics in the diagnosis of AS patients.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1511093&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
Array-based CGH is an advanced type of cytogenetic testing that can also be used to detect smaller deletions.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''UPD (Uniparental Disomy) Detection'''&lt;br /&gt;
&lt;br /&gt;
DNA Polymorphism testing detects paternal UPD in approximately 7% of affected AS individuals.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt; It is also able to distinguish between UPD and an Imprinting defect. It requires a DNA sample from the [[#Glossary | '''Proband''']] and from both parents. A homologous or non-homologous whole-arm translocation of the long arms of chromosome 15 is a sound indication for the need for prenatal UPD testing.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''IC (Imprinting Center) Analysis'''&lt;br /&gt;
&lt;br /&gt;
This type of analysis is used when individuals have an abnormal DNA methylation pattern but show normal results for  FISH, array CGH study and UPD analysis.&amp;lt;ref name=&amp;quot;PMID9792887&amp;quot;/&amp;gt; It is used to differentiate between the Imprinting defects caused by either microdeletions in the AS imprinting centre or by epigenetic mutations (that occur in maternal oogenesis or early embryogenesis).&amp;lt;ref name=&amp;quot;PMID9634532&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''Cytogenetic Testing'''&lt;br /&gt;
&lt;br /&gt;
Is used to detect a cytogenetically visible chromosomal rearrangement (large deletion, translocation or inversion) involving the 15q11.2-q13 region, which occurs in less than 1% of affected individuals.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''UBE3A Sequence Analysis'''&lt;br /&gt;
Sequence analysis of the UBE3A gene detects mutations in about 10% of the patients.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt; The test is used to detect either multiexonic (10 major coding exons of UBE3A) or whole gene deletions of UBE3A gene in individuals who produces a normal DNA methylation result but has characteristic clinical features of AS.&amp;lt;ref name=&amp;quot;PMID9792887&amp;quot;/&amp;gt;&lt;br /&gt;
This is recommended as a prenatal diagnostic tool in families that include multiple AS affected individuals because the imprinted pattern can be inherited from distant relatives.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Postnatal Diagnosis===&lt;br /&gt;
&lt;br /&gt;
Postnatal diagnosis is made though a combination of common clinical features of AS and UBESA gene sequence analysis.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt; The clinical features of AS include unsteady or shaky movements, muscle hypotonia, developmental delay and behavioral uniqueness such as frequent laughter/smiling and happy demeanor are features that are 100% consistent in all patients diagnosed with Angelman Syndrome.&amp;lt;ref name=&amp;quot;PMID18830393&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18830393&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; These clinical features become apparent between 6 months to 2 years of age. The onset of early or persistent smiling characteristic of this syndrome begin around the age of 1-3 months, but is often overlooked during infancy.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot;/&amp;gt; Thus early diagnosis of AS during infancy period is difficult because the clinical indicators of the syndrome takes time to manifest and characteristic features such as finger and hand tremors and excessive smiling/laughter are often overlooked and not considered as possible indicators of this syndrome.&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
*Rett Syndrome&lt;br /&gt;
&lt;br /&gt;
Some children with the clinical diagnosis of AS but no underlying genetic mechanism show mutations in ''MECP2'' gene, corresponding to Rett Syndrome. This should be suspected in AS test negative girls in the first few years of life.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17980307&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*Mowat-Wilson Syndrome&lt;br /&gt;
&lt;br /&gt;
Genetic mechanism is heterozygous deletion or truncation in ''ZFHX1B'' (''SIP1'') gene on 2q22. This presents with clinical features of severe intellectual disability, micrcephaly and seizures.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17958891&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Prader-Willi Syndrome patient.png|thumb|right|120px|12 year old PWS patient.]]&lt;br /&gt;
&lt;br /&gt;
*X-linked alpha-thalassemia/mental retardation syndrome (ATR-X)&lt;br /&gt;
&lt;br /&gt;
This arises from mutations in ''XNP'' gene on Xq13. ATR-X presents with severe intellectual disability, no speech development and seizures are common.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11449489&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*Phelan-McDermid Syndrome/22q13 deletion syndrome&lt;br /&gt;
&lt;br /&gt;
Deletions are usually submicroscopic and thus requires special molecular cytogenetic methods to confirm this deletion. Patients show moderate to profound intellectual disability and delay in speech development.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18505557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Related Disease'''&lt;br /&gt;
&lt;br /&gt;
*Prader-Willi Syndrome(PWS)&lt;br /&gt;
&lt;br /&gt;
PWS is a result from the absence of paternally expressed 15q11-q13 gene as a corollary of de novo deletion, maternal uniparental disomy of chromosome 15 or an imprinting defect on paternal chromosome 15 leading to the silencing of paternal alleles.&amp;lt;ref name=&amp;quot;PMID:20668179 &amp;quot;/&amp;gt; It is characterized by [[#Glossary | '''hyperphagia''']], obesity in later infancy and early childhood and difficulty in feeding during early infancy.&amp;lt;ref name=&amp;quot;PMID:20668179 &amp;quot;/&amp;gt; There is also cognitive impairment to some extent, though some PWS patients may exhibit intelligence in the normal IQ range. Behavioral phenotypes include stubbornness, manipulative tendency, obsessive compulsive characteristics.&amp;lt;ref name=&amp;quot;PMID:20668179 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Genetic Counselling==&lt;br /&gt;
&lt;br /&gt;
Genetic counselling is the process by which patients or relatives, at risk of an inherited disorder, are advised of the consequences and nature of the disorder, the probability of developing or transmitting it, and the options open to them in management and family planning. In the case for Angelman syndrome, types of risks associated are split into classes and formatted into the table below:&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20459762&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{|  style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
! Class&lt;br /&gt;
! Mechanism&lt;br /&gt;
! Risk to siblings&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! Ia                           &lt;br /&gt;
| De novo deletion                                                                                                               &lt;br /&gt;
| &amp;lt;1%                                                                                                                &lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! Ib&lt;br /&gt;
| Deletion due to chromosome rearrangement&lt;br /&gt;
| Up to 50%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! II&lt;br /&gt;
| Paternal uniparental disomy (UPD)&lt;br /&gt;
| &amp;lt;1%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! IIIa&lt;br /&gt;
| Imprinting defect with IC mutation&lt;br /&gt;
| Close to 100% if father has 15; 15 [[#Glossary | '''Robertsonian translocation''']]&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! IIIb&lt;br /&gt;
| Imprinting defect without IC mutation&lt;br /&gt;
| Up to 50% (if mother has IC deletion)&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! IIIc&lt;br /&gt;
| [[#Glossary | '''Mosaic''']] imprinting defect&lt;br /&gt;
| &amp;lt;1%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! IV&lt;br /&gt;
| ''UBE3A'' mutation&lt;br /&gt;
| Up to 50% (if mother has mutation)&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! V&lt;br /&gt;
| No identifiable genetic abnormality&lt;br /&gt;
| ?&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Ia''': Individuals with de novo deletion have 1% risk to siblings&lt;br /&gt;
&lt;br /&gt;
'''Ib''': Risk to siblings in individuals with chromosomal rearrangements is up to 50% &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9557895&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''II''': Paternal UPD with no Robertsonian translocation has a risk to sibling of less than 1%&lt;br /&gt;
&lt;br /&gt;
'''IIIa''': The risk to siblings in individuals with AS from an imprinting defect with a mutation in the imprinting center (IC) is close to 100% if father has 15;15 Robertsonian translocation&lt;br /&gt;
&lt;br /&gt;
'''IIIb''': Individuals with AS resulting from an imprinting defect without IC mutation, but with a carrier mother has a high risk to siblings of up to 50%. The mother could be phenotypically normal due to paternal inheritance of the genetic defect &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11283796&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''IIIc''': Individuals who are mosaic for the imprinting defect have less than 1% risk to siblings&lt;br /&gt;
&lt;br /&gt;
'''IV''': UBE3A mutation can be either inherited or de novo mutation. If the mother is a carrier for this genetic mutation, the risk to siblings is up to 50% &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11258627&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''V''': Individuals who present with AS clinically, but have no known underlying mechanism have an unknown risk to siblings.&lt;br /&gt;
&lt;br /&gt;
==Treatment and Management==&lt;br /&gt;
&lt;br /&gt;
Even though at present there is no known cure for Angelman syndrome, there are a number of treatments available that may alleviate symptons and improve daily life activities.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The below table describes the problems and management options that are used:&lt;br /&gt;
&lt;br /&gt;
[[File:Subtle Finger tremors-Angelman Syndrome.jpg|right|thumb|150px|A five months old boy with Angelman syndrome showing signs of Subtle Finger tremor.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
! Problems encountered&lt;br /&gt;
! Treatment and Management&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''Difficulty in feeding newborn AS babies'''&lt;br /&gt;
| Use of special nipples may improve feeding&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Oesophagus reflux'''&lt;br /&gt;
| Special motility medications requiried or upright positioning&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''Seizures'''&lt;br /&gt;
| Anticonvulsant medications&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19605773&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19453717&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Ocular problems'''&lt;br /&gt;
| Visual assessment is vital to encourage interactions and minimize chances of self-harm and autism development&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20656169&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''Drooling in developmental delayed AS patients'''&lt;br /&gt;
| Difficult to treat, but new surgical procedure on salivary duct reimplantation seems to be a promising alternative&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17699119&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Unstable children''' &lt;br /&gt;
| Physical therapy&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''AS patients become less active with increasing age'''&lt;br /&gt;
| Activity schedules to prevent scoliosis and obesity. Occupational therapy to stimulate fine motor and oral-motor control skills in conjunction to speech therapy&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Sleeping difficulty'''&lt;br /&gt;
| Sedative medication in severe cases. [[#Glossary | '''Melatonin''']] may be used to promote sleeping but some studies have found that it loses its therapeutic effects after several weeks in most AS patients&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19379289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|-&lt;br /&gt;
|colspan=&amp;quot;4&amp;quot; |&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Prognosis==&lt;br /&gt;
&lt;br /&gt;
Life expectancy of AS patients seems to be normal&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, but there is still a high degree of developmental delay and limited expressive language skills.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17019625&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This problem arises prominently in the assessment of the severity of coincidental medical conditions due to difficulties in communication. A visit to the dentist can become difficult if good communication is not conveyed between the parents, the dentist, and the child.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18271768&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Some problems require extreme measures, such as the procedure of lens implantation was performed in both eyes of a person diagnosed with AS, due to the inability to wear spectacles.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20656169&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
During adulthood, menstruation and puberty begin at around average age evidenced by females with Angelman syndrome that are fully capable of conceiving children.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11258627&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Most adult patients can feed themselves, but needed help with many other daily activities. Main troubles which have shown in adults are a tendency to become obese and start developing  thoracic scoliosis, which some adults with AS begin wheelchair bounded.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9072912&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Current and Future Research==&lt;br /&gt;
&lt;br /&gt;
Currently there is no cure for the treatment of AS, so much research is being carried out for therapeutic interventions. Findings in the last five years have suggested through various mice and fruit fly models that the absence of maternal UBE3A results in the same human AS features of neurological defects and seizures. However, more recently, studies have outlined that the symptoms of AS can be improved by modifying other gene products. In addition, restoring of a functional UBE3A protein into adult mice neurons have shown to reduce motor and neurological deficits and balance disorders. This shows promising research prospects in that improvements may be possible in human AS patients by restoring functional UBE3A proteins into their neurons. &lt;br /&gt;
&lt;br /&gt;
===Possible Treatment Pathways===&lt;br /&gt;
&lt;br /&gt;
*'''Cognitive and physical impairment'''&lt;br /&gt;
&lt;br /&gt;
Although everyone is born with two copies of the gene UBE3A, one maternal and one paternal copy, it is only the maternal UBE3A that is used in the brain. Most AS patients have a genetic mutation on the maternal chromosome 15 that results in dysfunctional UBE3A.&amp;lt;ref&amp;gt;http://www.cureangelman.org/what-hope.html&amp;lt;/ref&amp;gt; The above research focused on turning on the father's copy of UBE3A to restore its functions. Furthermore, mouse models were utilized to show that alpha-CaMKII could be increased to compensate the loss of UBE3A and restore compromised mental and physical abilities. However, this finding still requires much more research.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17259980&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''Epilepsy'''&lt;br /&gt;
&lt;br /&gt;
There is research being done on improving certain conditions that are involved in AS by nutritional benefits. The use of [[#Glossary | '''corticosteroids''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19666884&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, [[#Glossary | '''valproate''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19453717&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and [[#Glossary | '''clonazepam''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19605773&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and having a [[#Glossary | '''ketogenic diet''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20880305&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; has all been shown to aid in the treatment of epilepsy. It has also been reported to be efficient in the treatment of other conditions, such as behavioural disorders, reduction in seizures, ataxia, sleep patterns, developmental progress and sleep disturbances. [[#Glossary | '''Levetiracetam''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17326790&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; could be used in such a situation, especially when the patient has an intolerance to valproate and clonazepam.&lt;br /&gt;
&lt;br /&gt;
*'''Betaine and Folic acid'''&lt;br /&gt;
&lt;br /&gt;
This double-blind placebo-controlled study was done to examine the potential therapeutic role of [[#Glossary | '''betaine''']] and [[#Glossary | '''folic acid''']] in the treatment of the clinical phenotypes of AS. The aim of this protocol was to increase methylation and activate the paternally inherited UBE3A in hope to compensate for the inactive maternal UBE3A. Although there were no major differences in the control and treatment groups, a small number of patients in the treatment group showed some positive outcomes.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20635355&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&lt;br /&gt;
'''albinism''': A congenital disorder distincted by the complete or partial absence of pigment in the skin, hair and eyes due to defect of an enzyme involved in the production of melanin.&lt;br /&gt;
&lt;br /&gt;
'''allele''': Dissimilar variant of one gene. Organisms have two alleles for each gene inherited from their parents, one from each of them.&lt;br /&gt;
&lt;br /&gt;
'''alpha-CaMKII''': (alpha calcium calmodulin kinase II) Compound involved in synaptic plasticity, one of the most important theories behind learning and memory. Ability of a synapse between two neurons to change in strength due to the use or disuse of transmission.&lt;br /&gt;
&lt;br /&gt;
'''Amniocytes''': Cells that are shed by the fetus during fetal development to the surrounding amniotic fluid. They are a source of fetal DNA. &lt;br /&gt;
&lt;br /&gt;
'''Amniocentesis''': (AFT or amniotic fluid test) is a prenatal diagnostic test used to detect chromosomal abnormalities in the developing fetus by extracting amniotic fluid (a source of fetal DNA) surrounding the fetus. &lt;br /&gt;
&lt;br /&gt;
'''AMPA''': (2-amino-3-(5-methyl-3-oxo-1,2- oxazol-4-yl)propanoic acid) Compound that binds to the AMPA receptor to imitate glutamate neurotransmitter.&lt;br /&gt;
&lt;br /&gt;
'''Arc''': Activity-Regulated Cytoskeleton-associated protein; involved in learning and memory.&lt;br /&gt;
&lt;br /&gt;
'''ataxia''': Lack of coordination in muscle movements.&lt;br /&gt;
&lt;br /&gt;
'''atonic seizures''': A abrupt loss of muscle tone, this can lead to the limbs loosing strength, or the head may drop to the side. The patient remains conscious during this kind of epileptic seizure.&lt;br /&gt;
&lt;br /&gt;
'''atypical absences''': Seizure leads to unconsciousness in most cases.  &lt;br /&gt;
&lt;br /&gt;
'''autism''': A neural development disorder defined by limited social interaction and communication.&lt;br /&gt;
&lt;br /&gt;
'''betaine''': Also known as  betaine anhydrous or trimethylglycine (TMG), assists the body in metabolising the amino acid, homocysteine. Can be consumed via beets, broccoli, grains, shellfish, and spinach.&lt;br /&gt;
&lt;br /&gt;
'''Chorionic Villus Sampling''': A prenatal diagnostic test used to detect chromosomal abnormalities in the developing fetus by extracting and testing chorionic villus (placental tissue). &lt;br /&gt;
&lt;br /&gt;
'''chromosome''': Structure consisting of coiled DNA with DNA associated proteins such as histones.&lt;br /&gt;
&lt;br /&gt;
'''clonazepam''': A psychoactive drug having muscle relaxant properties and treats anxiety and epilepsy.&lt;br /&gt;
&lt;br /&gt;
'''corticosteroid''': A type of steroid hormones that are produced in the adrenal cortex.&lt;br /&gt;
&lt;br /&gt;
'''cytogenetics''': Study of the structure, function and abnormality of the cell, especially the chromosome.&lt;br /&gt;
&lt;br /&gt;
'''deletion''': Lack of a part of the DNA (deoxyribonucleic acid is a nucleic acid containing information for protein synthesis), can vary form a single base to a hole gene. &lt;br /&gt;
&lt;br /&gt;
'''de novo mutation''': Change in a gene of a family member for the first time due to a mutation in the egg or sperm of the parents or in the fertilized egg (zygote).&lt;br /&gt;
&lt;br /&gt;
'''disorder''': A mental or physical health disturbance or dysfunction.&lt;br /&gt;
&lt;br /&gt;
'''EEG''': Electroencephalography is a means of measuring electrical activity along the scalp by measuring the total electrical charges fired by thousands or millions of neurons.&lt;br /&gt;
&lt;br /&gt;
'''epilepsy''': Neurological disorder characterised by recurrent impairment of brain function that can cause seizures or unconsciousness. &lt;br /&gt;
&lt;br /&gt;
'''E6-AP''': E6-AP ubiquitin-protein ligase is an enzyme encoded by UBE3A which adds ubiquitin chain to target proteins to be degraded by proteasomes.&lt;br /&gt;
&lt;br /&gt;
'''febrile convulsions''': The occurrence of high fever, especially in children.&lt;br /&gt;
&lt;br /&gt;
'''FISH''': Fluorescent in situ hybridization is a technique used to identify and localize the presence or absence of DNA sequences on the chromosome. This is achieved by using fluorescently labelled DNA sequences which then binds to complementary DNA sequence on the chromosome. After hybridization (attachment), chromosome of interest will fluoresce under the microscope.&lt;br /&gt;
&lt;br /&gt;
'''folic acid''': B vitamin that helps the body make healthy new cells. Can be consumed via leafy green vegetables, fruits, dried beans, peas and nuts.&lt;br /&gt;
&lt;br /&gt;
'''gait''': A manner of walking, stepping or running.&lt;br /&gt;
&lt;br /&gt;
'''gene''': A molecular unit of heredity of a living organism.&lt;br /&gt;
&lt;br /&gt;
'''hyperphagia''': (Also referred to as Polyphagia) Excessive ingestion of food beyond the dietary and energy requirements of the body. &lt;br /&gt;
&lt;br /&gt;
'''hypermotoric''': Sudden appearance of uncontrolled movements such as striking or kicking inappropriately.&lt;br /&gt;
&lt;br /&gt;
'''hypertonicity''': Increase of muscle tension and a disability to stretch leading to an impairment of motor activity.&lt;br /&gt;
&lt;br /&gt;
'''hypopigmentation''': A lack of melanin pigments or melanocytes  affecting the colour of the skin, hair and iris. Features appear to be light-coloured due to loss of skin colour.&lt;br /&gt;
&lt;br /&gt;
'''hypotonia''': Decrease in the ability to stretch passively, due to a low muscle tone. &lt;br /&gt;
&lt;br /&gt;
'''imprinting''': This is a process to describe the modification of a maternally or paternally derived chromosome, which consequently influences the expression of certain genes on the altered chromosome.&lt;br /&gt;
&lt;br /&gt;
'''ketogenic diet''': A high-fat, low-carbohydrate diet that is used to treat epilepsy in children.&lt;br /&gt;
&lt;br /&gt;
'''levetiracetam''': An anticonvulsant drug used to treat epilepsy.&lt;br /&gt;
&lt;br /&gt;
'''locus''': Location of a gene on a chromosome(loci: plural for locus).&lt;br /&gt;
&lt;br /&gt;
'''LTP''': Long-term potentiation shares common features with long term memory. It strengthens and enhances signal transmission between neurons by improving the communication between two neurons.&lt;br /&gt;
&lt;br /&gt;
'''macrostomia''': A wide-spaced mouth.&lt;br /&gt;
&lt;br /&gt;
'''Makaton''': Language programme using symbols and signs to support speaking.&lt;br /&gt;
&lt;br /&gt;
'''mandibular prognathism''': The abnormal protrusion of the lower jaw. &lt;br /&gt;
&lt;br /&gt;
'''maxillary hypoplasia''':  The underdevelopment of the upper jaw.&lt;br /&gt;
&lt;br /&gt;
'''melatonin''': A hormone secreted by the pineal gland.&lt;br /&gt;
&lt;br /&gt;
'''microcephaly''': The circumference of the head is less than average due to abnormalities of the nervous system. This abnormality can be present at birth or emerge during the first few years of life and reduces both life expectancy and the cognitive functions of the individual affected.&lt;br /&gt;
&lt;br /&gt;
'''microdeletion''':  A genetic mutation in which a part of a chromosome or a sequence of DNA is missing.&lt;br /&gt;
&lt;br /&gt;
'''mosaic''': tissues or cells containing different mixture of genetic sequences&lt;br /&gt;
&lt;br /&gt;
'''mutation''': Event that changes the DNA (deoxyribonucleic acid is a nucleic acid, containing information for protein synthesis) or RNA (ribonucleic acid is a type of nucleic acid transmitting the information from the DNA to the proteins ) of a gene permanently.&lt;br /&gt;
&lt;br /&gt;
'''myoclonic seizures''': A quick jerk of the skeletal muscle, due to a irregular brain activity.&lt;br /&gt;
&lt;br /&gt;
'''neurogenetic''': Genetic basis of the nervous system.&lt;br /&gt;
&lt;br /&gt;
'''neurotransmitter''': Transmits neuronal signals to a target cell. They are first packaged in vesicles just beneath the membrane of presynaptic axon terminals and released into the synaptic cleft (space between the two interacting neurons) and enter the postsynaptic dendrite.&lt;br /&gt;
&lt;br /&gt;
'''occiput''': The back portion of the head.&lt;br /&gt;
&lt;br /&gt;
'''oesophagus reflux''': Impairment of a sphincter in the lower end of the oesophagus leads to the back flow of stomach acid into the oesophagus. Heartburn is a typical symptom.&lt;br /&gt;
&lt;br /&gt;
'''paediatrician''': Physicians that specialise on infants, children and adolescents.&lt;br /&gt;
&lt;br /&gt;
'''paternal UPD''': Inheritance of two copies of a chromosome from the father and none from the mother. &lt;br /&gt;
&lt;br /&gt;
'''phenotype''': Visible traites of an organism determined by genetic and environmental factors.&lt;br /&gt;
&lt;br /&gt;
'''Picture Exchange Communication System (PECS)''': Individuals communicate using images instead of words. It is frequently used by children with autism, to articulate their needs and wishes or to make comments about something.&lt;br /&gt;
&lt;br /&gt;
'''Proband''': Is the person (or animal) being studied or reported on in a genetic investigation. Most commonly it refers to the first affected family member who requires medical help for a genetic disorder. &lt;br /&gt;
&lt;br /&gt;
'''Robertsonian translocation''': Rearrangement of the chromosome, occurs in 5 chromosome including 13,14,15,21 and 22. This type of mutation occurs in chromosomes with the centromere not at the centre, resulting in long and short arm chromosomes. Translocation breaks the chromosome at the centromere so the long arm attaches to the other long arm, and the same for the short arm happens. Cell division will result in the loss of the short arms as they do not contain important genes.&lt;br /&gt;
&lt;br /&gt;
'''seizure''': Abnormal electrical activity in the brain that can result in a variety of physical symptoms like convulsion, body shaking, loss of consciousness, confusion, and mood changes.&lt;br /&gt;
&lt;br /&gt;
'''synapse''': Allows transmission of signal between neurons for effective neuronal function.&lt;br /&gt;
&lt;br /&gt;
'''thoracic scoliosis''': The spine is curved laterally(from side to side) in the thoracic region.&lt;br /&gt;
&lt;br /&gt;
'''tonic-clonic seizures''': This type of seizure is associated with unconsciousness due to electrical discharges in a big proportion of the brain.&lt;br /&gt;
&lt;br /&gt;
'''ubiquitin''': A polypeptide found in all eukaryotic cells, that participates in a variety of cellular functions including protein recycling.&lt;br /&gt;
&lt;br /&gt;
'''Uniparental disomy''': (UPD) the inheritance of two copies of a chromosome pair or part of a chromosme from one parent and no copy from the other parent. &lt;br /&gt;
&lt;br /&gt;
'''valproate''':  A mood-stabilizing drug that is also used for treatment for epilepsy and bipolar disorder.&lt;br /&gt;
&lt;br /&gt;
==Helpful Links==&lt;br /&gt;
&lt;br /&gt;
* Australia&lt;br /&gt;
:* [http://www.angelmansyndrome.org/research.html Angelman Syndrome Association] &lt;br /&gt;
:* [http://www.angelmansyndromeqld.org/ Queensland Angelman Association]&lt;br /&gt;
&lt;br /&gt;
* America&lt;br /&gt;
:* [http://www.angelman.org/ Angelman Syndrome Foundation]&lt;br /&gt;
:* [http://rarediseasesnetwork.epi.usf.edu/arpwsc/ Rare Clinical Diseases Research Network]&lt;br /&gt;
:* [http://www.rarediseases.org/rare-disease-information/rare-diseases/byID/411/viewAbstract National Organisation for Rare Disorders]&lt;br /&gt;
:* [http://www.epilepsyfoundation.org/ Epilepsy Foundation]&lt;br /&gt;
:* [http://www.cureangelman.org/ Foundation for Angelman Syndrome Therapeutics]&lt;br /&gt;
&lt;br /&gt;
* Search Pubmed &lt;br /&gt;
:* [http://www.ncbi.nlm.nih.gov/pubmed?term=angelman%20syndrome Angelman Syndrome] &lt;br /&gt;
&lt;br /&gt;
* OMIM entries for Angelman Syndrome&lt;br /&gt;
:* [http://omim.org/entry/105830 ANGELMAN SYNDROME; AS]&lt;br /&gt;
:* [http://omim.org/entry/601623 UBIQUITIN-PROTEIN LIGASE E3A; UBE3A]&lt;br /&gt;
&lt;br /&gt;
==Related Links==&lt;br /&gt;
&lt;br /&gt;
* [[Mouse Knockout]] - this page explains the current use of mouse models in disrupting genes to elucidate their genetic function, including the mouse gene knockouts for alpha calcium-calmodulin kinase II (alpha CaMKII)&lt;br /&gt;
* [[2009 Group Project 4]] - this page gives an extensive overview on the history of the mouse model and its various use in embryology and genetics. In addition, it also describes mouse knockout and the role they play in current research of various human diseases&lt;br /&gt;
* [[Fly Development]] - this page describes the use of drosophila flies as developmental models&lt;br /&gt;
* [[2009 Group Project 2]] - this page gives an extensive overview on the history of the fly model and its various use in embryology and genetics&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&lt;br /&gt;
&amp;lt;references /&amp;gt;&lt;/div&gt;</summary>
		<author><name>Z3291643</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_7&amp;diff=77576</id>
		<title>2011 Group Project 7</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_7&amp;diff=77576"/>
		<updated>2011-10-12T20:50:15Z</updated>

		<summary type="html">&lt;p&gt;Z3291643: /* Possible Treatment Pathways */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;='''Angelman Syndrome'''=&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Introduction==&lt;br /&gt;
&lt;br /&gt;
[[File:Dr Harry Angelman.jpg|thumb|130px|right|Dr Harry Angelman.]]&lt;br /&gt;
Angelman syndrome (AS) is a rare [[#Glossary | '''neurogenetic''']] [[#Glossary | '''disorder''']] first described by Dr. Harry Angelman in 1965.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18754889&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Dr. Angelman was an English [[#Glossary | '''paediatrician''']] who first diagnosed the disease in 3 children with a developmental delay.&amp;lt;ref&amp;gt;http://www.ncbi.nlm.nih.gov/books/NBK22221/&amp;lt;/ref&amp;gt; AS occurs in 1 in 10000-20000 births, the exact number is still unknown.&amp;lt;ref name=&amp;quot;PMID7573182&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7573182&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;PMID8703225&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;8703225&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It is caused by maternal [[#Glossary | '''allele''']] disruptions of a single gene- UBE3A. Either [[#Glossary | '''mutations''']] or [[#Glossary | '''deletions''']] of the UBE3A gene results in AS. &lt;br /&gt;
&lt;br /&gt;
AS presents with well known [[#Glossary | '''phenotypes''']] during infancy and adulthood, such as [[#Glossary | '''microcephaly''']] and [[#Glossary | '''maxillary hypoplasia''']]. However, these features become more marked with age. Most frequent clinical features include delayed development,[[#Glossary | '''seizures''']],[[#Glossary | '''ataxia''']], impairment of speech, happy demeanor, behavioural problems such as hyperactivity, short attention span and sleeping difficulty.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21592595&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21484597&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;ASAwebsite&amp;quot;&amp;gt;http://www.angelmansyndrome.org/home.html&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
At present, there is no cure for the syndrome, though current research is focused at improving life quality of patients with Angelman syndrome through management of daily tasks.&amp;lt;ref&amp;gt;http://www.bbc.co.uk/health/physical_health/conditions/angelman1.shtml&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==History==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Dr. Harry Angelman first reported Angelman Syndrome on three handicapped children that were admitted to his ward in England in 1964.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt; He reported how these three independent and unconnected clinical cases all had the same characteristic features of severe developmental delay, jerky movements, seizures and a happy disposition.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt; However it was only when he stumbled upon an oil painting called ‘a Boy with a Puppet” while on a holiday in Italy he was able to connect the symptoms of all three children under one common cause.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20981772&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; He linked the happy face of the boy depicted on the painting with the jerky movements and happy disposition he observed on his three patients back in England. He reported his findings on a paper entitled “Puppet children (a report on three cases)” which was published in 1965.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
The syndrome was initially named ‘Puppet Syndrome’ but was later changed to Angelman Syndrome. Due to the extreme rarity of the syndrome and lack of sufficient clinical evidence the syndrome was soon forgotten.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt;&lt;br /&gt;
[[File:Dr Charles Williams.jpg|thumb|right|150px|Dr Charles Williams.]]&lt;br /&gt;
	&lt;br /&gt;
In 1987, a physician named Ellen Magenis, came across children with deletions on [[#Glossary | '''chromosome''']] 15 that were suffering from seizures and severe developmental delay.&amp;lt;ref&amp;gt;http://www.angelman.org/stay-informed/facts-about-angelman-syndrome---7th-edition/harry-angelman-and-the-history-of-as/&amp;lt;/ref&amp;gt; Even though genetically the children were expected to have [[#Diagnosis | '''Prader-Willi syndrome''']] that was characterised by deletions on chromosome 15, their characteristic symptoms of seizures and lack of development did not correspond with that of the syndrome. This led to the realization that these children had deletions on the maternally derived chromosome 15 and not on the paternally derived chromosome as was observed in Prader-Willi syndrome.  Thus the deleted genetic code on maternally derived chromosome 15 was identified as the genetic marker for Angelman Syndrome.&lt;br /&gt;
&lt;br /&gt;
In 1997, UBE3A gene was isolated by Dr. Joseph Wagstaff and Dr. Arthur Beaudet as the cause of Angelman Syndrome.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot; /&amp;gt; The discovery of this [[#Glossary | '''gene''']] led to the subsequent development of animal models and research aimed at finding a causal link between UBE3A gene abnormalities and characteristic features observed in Angelman Syndrome. &lt;br /&gt;
	&lt;br /&gt;
Currently, four different genetic abnormalities for Angelman Syndrome have been confirmed by genetic testing. They include: Deletion, [[#Glossary | '''Uniparental Disomy''']] (UPD), [[#Glossary | '''Imprinting''']] and UBE3A mutation.&amp;lt;ref name=&amp;quot;PMID20211139&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Below is a timeline, summarising the key discoveries and advancements of the Angelman Syndrome:&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|- bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
!Year&lt;br /&gt;
!Milestone&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1964'''&lt;br /&gt;
|First observed by Dr Harry Angelman on three handicapped children.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot; /&amp;gt; &lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''1965'''&lt;br /&gt;
|Harry Angelman publishes his finding in a report entitled 'Puppet Children'(a report on three cases).&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1980s'''&lt;br /&gt;
|First reports of AS reaches US and research into the disorder being at the University of Florida under the direction of Dr. Charles Williams.&amp;lt;ref&amp;gt;http://www.angelmanproject.com/history.htm&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''1982'''&lt;br /&gt;
|Name changed from 'Happy Puppet' to Angelman syndrome by Williams and Frias. &lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1987'''&lt;br /&gt;
|Discovery of a genetic marker for AS – an absent genetic code on maternally derived chromosome 15. &lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''1997'''&lt;br /&gt;
|The cause of AS discovered by Dr. Joseph Wagstaff and Dr. Arthur Beaudet – mutation or deletion in the UBE3A gene.&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1998'''&lt;br /&gt;
|Transgenic mice with absent maternal UBE3A created to illustrate motor and learning deficits in addition to seizures.&amp;lt;ref name=&amp;quot;PMID9808466&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9808466&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''2007'''&lt;br /&gt;
|AS mouse model shows that neurological deficits can be reversed by decreasing levels of [[#Glossary | '''alpha-CaMKII''']] inhibitory phosphorylation.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17259980&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''2010'''&lt;br /&gt;
|Discovery of a another gene mutation in TC4 gene (on chromosome 18) in a small number of clinically diagnosed patients with no identifiable genetic alternation in UBE3A.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20184619&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''2010'''&lt;br /&gt;
|Protein named Arc identified as a target of AS gene product; UBE3A.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Incidence'''&lt;br /&gt;
*The current population of people diagnosed with AS is unknown but studies have estimated the number to be around 1:10,000&amp;lt;ref name=&amp;quot;PMID7573182&amp;quot; /&amp;gt; and 1:20,000&amp;lt;ref name=&amp;quot;PMID8703225&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
'''Diagnosis'''&lt;br /&gt;
*The mean age of diagnosis for patients with AS lies between 6 and 6.5 years of age.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18664077&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15741136&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Gender'''&lt;br /&gt;
* Males appear to be at higher risk for some aspects of early developmental delays in comparison to females with AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17019625&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Demography'''&lt;br /&gt;
*Europe:&lt;br /&gt;
:Denmark- 1:10,000&amp;lt;ref name=&amp;quot;PMID7573182&amp;quot; /&amp;gt;&lt;br /&gt;
:Estonia- 1:52,000&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16906556&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
:Sweden- 1:20,000&amp;lt;ref name=&amp;quot;PMID8703225&amp;quot; /&amp;gt;&lt;br /&gt;
*Australia:&lt;br /&gt;
:Western Australia- 1:40,000&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16492624&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Aetiology==&lt;br /&gt;
&lt;br /&gt;
[[File:Chromosome 15 Deletion of 15q11.2 to 15q13.jpg|thumb|100px|Chromosome 15 - The deletion occurs at 15q11.2-15q13.]]&lt;br /&gt;
&lt;br /&gt;
'''Molecular Genetics'''&lt;br /&gt;
&lt;br /&gt;
* Location: 15q11-q13&lt;br /&gt;
* Protein product: Ubiquitin protein ligase E3A&lt;br /&gt;
* Gene name: UBE3A&lt;br /&gt;
* Phenotype: Angelman Syndrome&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Different genetic mechanisms lead to different clinical phenotypes of AS. The most common genetic mechanism leading to AS is the deletion or re-arrangement of maternal chromosome at [[#Glossary | '''locus''']] 15q11.2-q13,as the chromosome image shows on the right, accounting for 70% of AS occurrences.&amp;lt;ref name=&amp;quot;PMID8988171&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt; 8988171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This leads to more severe clinical phenotypes of microcephaly, motor difficulties, seizures and impaired speech development. The next most common genetic mechanism is mutation in the ''UBE3A'' gene responsible for 10% of AS cases and paternal uniparental disomy and mutation in the imprinting centre (IC), both accounting for 2-5% of AS observed.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
 &lt;br /&gt;
&lt;br /&gt;
AS is caused by the 4 major genetic mechanisms mentioned above and are thus divided into Classes I to IV based on their underlying genetic mechanism. AS patients with the clinical features of AS but no [[#Glossary | '''cytogenetic''']] or molecular abnormality in Chromosome 15q11.2-13 are grouped under Class V (summarised in table below).&amp;lt;ref name=&amp;quot;PMID8988171&amp;quot; /&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10364509&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Inheritance'''&lt;br /&gt;
&lt;br /&gt;
Angelman Syndrome from UBE3A mutations and deletions in the Imprinting Centre follow an inheritance pattern. A carrier father with the genetic defect can pass it on to his children, however, his children will be clinically normal. On the other hand, a carrier mother can pass the genetic defect onto her children, who will then have Angelman Syndrome. &lt;br /&gt;
&lt;br /&gt;
The image highlights the inheritance of Angelman Syndrome, which only results after a carrier mother passes it on to her children. &lt;br /&gt;
&lt;br /&gt;
{|  style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
! Class&lt;br /&gt;
! Mechanism&lt;br /&gt;
! Diagnostic Tests&lt;br /&gt;
! Frequency&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''Ia'''                           &lt;br /&gt;
| De novo deletion                                                                                           &lt;br /&gt;
| High resolution cytogenetics [[#Glossary | '''FISH''']]                                                                                                       &lt;br /&gt;
| 70%      &lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Ib'''&lt;br /&gt;
| Deletion due to chromosome rearrangement&lt;br /&gt;
| High resolution cytogenetics FISH&lt;br /&gt;
| &amp;lt;1%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''II'''&lt;br /&gt;
| Paternal uniparental disomy&lt;br /&gt;
| [[#Glossary | '''RFLP''']]  analysis&lt;br /&gt;
| 2%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''IIIa'''&lt;br /&gt;
| Imprinting defect with IC mutation&lt;br /&gt;
| Screening of [[#Glossary | '''IC''']]  for mutations is positive&lt;br /&gt;
| 2%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''IIIb'''&lt;br /&gt;
| Imprinting defect withouth IC mutation&lt;br /&gt;
| Screening of IC for mutations is negative&lt;br /&gt;
| 2%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''IIIc'''&lt;br /&gt;
| Mosaic imprinting defect&lt;br /&gt;
| Screening of IC for mutations is usually negative &lt;br /&gt;
| ?&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''IV'''&lt;br /&gt;
| ''UBE3A'' mutation&lt;br /&gt;
| Screening of ''UBE3A'' for mutations&lt;br /&gt;
| 5-10%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''V'''&lt;br /&gt;
| No identifiable genetic abnormality&lt;br /&gt;
| Consider other diagnoses&lt;br /&gt;
| 5-26%&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Pathogenesis==&lt;br /&gt;
&lt;br /&gt;
Chromosome 15 became associated with AS in the 1980s after the observation of many AS patients harboring [[#Glossary | '''microdeletions''']] of 15q11.2-15q13.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15668046&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The last decade has shed even more light in the aetiology of AS,as Kishino and Matsuura first identified UBE3A as the causative gene for AS in 1997.&amp;lt;ref name=&amp;quot;PMID:8988171&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;8988171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8988172&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Normal gene product: E6-AP ubiquitin ligase'''&lt;br /&gt;
&lt;br /&gt;
The function of UBE3A is to encode for [[#Glossary | '''E6-AP''']] ubiquitin ligase, however its function in the development of the nervous system and the process of UBE3A mutation leading to cognitive impairment in AS patients is still vague.&amp;lt;ref name=&amp;quot;PMID:20211139&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Past and current research has elucidated that E6-AP ubiquitin ligase is involved in the degradation of four proteins, listed below, but currently, no protein with a direct role in [[#Glossary | '''long-term potentiation (LTP)''']] as a target of E6-AP, has been identified.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12684449&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The identification of such target proteins would be a landmark discovery in further understanding of the pathogenesis, aetiology and prospective treatment strategies of AS, as LTP defects is one of the major neurological impairments of AS. &lt;br /&gt;
 &lt;br /&gt;
* p53 tumor suppressor protein &lt;br /&gt;
* yeast DNA repair protein Rad23 &lt;br /&gt;
* multicopy maintenance protein 7 subunit &lt;br /&gt;
* E6-AP&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Abnormal gene product'''&lt;br /&gt;
&lt;br /&gt;
Disruption to the gene,UBE3A, interferes with the normal functioning of the gene, which is its crucial role in UBE3A [[#Glossary | '''ubiquitylation''']]. Problems involving this pathway can lead to various diseases either from the loss or gain of function.&amp;lt;ref name=&amp;quot;PMID:9857172&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9857172&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In the case of AS, E6-AP is affected, leading to detrimental cognitive impairment in addition to other deficits.&amp;lt;ref name=&amp;quot;PMID:9857172&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9857172&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Regional functioning of UBE3A'''&lt;br /&gt;
&lt;br /&gt;
Despite the uncertain progression of UBE3A mutation and the neurological abnormalities characteristic of AS, animal models have illustrated the vital role of UBE3A in the normal functioning of the brain. This can be exemplified by a study which utilized a mouse model with target inactivation of the gene UBE3A resulting in the manifestation of classical features of AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11895368&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In addition, the fact that imprinting of UBE3A takes place only in specific brain regions (cerebellum, olfactory tracts and the hippocampus) confirms the hypothesis that the loss of this gene would be detrimental in the cognitive development.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20398390&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Most genes are inherited in copies of two, one paternal and the other maternal; however, some genes, such as UBE3A only have one functional copy as the other is silenced, coined 'imprinting'. Imprinting of the paternal copy of UBE3A takes place in some cell populations, such as the hippocampal neurons and Purkinje cells in the cerebellum.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9288101&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This means only the maternal UBE3A is functionally expressed in these particular brain regions. Thus a [[#Glossary | '''de novo mutation''']] in the maternal copy of the gene will result in the complete absence of functional E6-AP in the associated brain areas.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9288088&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
It is also known that UBE3A plays an important role in synaptic transmission, but exactly how it does so is still not completely understood.&amp;lt;ref name=&amp;quot;PMID:9808466&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9808466&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''UBE3A ubiquitylation'''&lt;br /&gt;
&lt;br /&gt;
As briefly mentioned above, UBE3A is a member of the E3 ubiquitin ligase family of enzymes, responsible for the addition of ubiquitin to the target protein for degradation of the ubiquitinated protein, as illustrated in the diagram below. These processes are required for normal human cognitive function.&amp;lt;ref name=&amp;quot;PMID:9808466&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9808466&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In this way synaptic protein [[#Glossary | '''Arc (activity-regulated cytoskeleton-associated protein)''']] is degraded to control synaptic function. Arc is a target protein of UBE3A in dendritic spines found in the hippocampal neurons.&amp;lt;ref name=&amp;quot;PMID:20668179&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20668179&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Deletion of UBE3A leads to the accumulation of Arc in neurons leading to trafficking of [[#Glossary | '''AMPA ( α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid)''']] receptors, resulting in impaired cognitive functions.&amp;lt;ref name=&amp;quot;PMID:20211139&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; [[File:UBE3A Ubiquitylation Pathway.png|thumb|350px|right|UBE3A Ubiquitylation Pathway.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
UBE3A ubiquitylation consists of:&amp;lt;ref name=&amp;quot;PMID:20668179&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20668179&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
# Activation of ubiquitin by E1 enzyme&lt;br /&gt;
# E1 ezyme transfers ubiquitin to E2 enzyme&lt;br /&gt;
# E2 enzyme transfers ubiquitin to UBE3A&lt;br /&gt;
# UBE3A attaches activated ubiquitin to target protein which is then polyubiquitylated &lt;br /&gt;
# Target protein is then degraded by 26S proteosome&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Phenotype-Genotype correlations'''&lt;br /&gt;
&lt;br /&gt;
[[File:Extent of microcephaly in Angelman Syndrome patients.png|thumb|250px|right|Extent of microcephaly in 20 AS patients with deletion and without deletion.&amp;lt;ref&amp;gt;http://www.nature.com/ejhg/index.html/&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
All AS patients show differing extents of cognitive impairment, movement disorder, characteristic behaviours and difficulty in speech and language.&amp;lt;ref name=&amp;quot;PMID:11748306&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11748306&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; However, there seems to be some phenotype-genotype correlations:&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
- 5-7Mb deletions result in the most severe phenotypes such as microcephaly, more sever [[#Glossary | '''epilepsy''']] and seizures, motor difficulties and language impairment.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9546330&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20445456&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; AS patients with large deletions also present with clinical [[#Glossary | '''hypopigmentation''']], light hair and eye colour due to the close association of OCA2 gene with UBE3A.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;16470747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Individuals under this category have in general no increased BMI&amp;lt;ref name=&amp;quot;PMID:15253756&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15253756&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This is indicated by the graph on the left, which shows more cases of AS patients with deletions having larger deviations from the mean head circumference measurement than non-deletion AS patients.&lt;br /&gt;
 &lt;br /&gt;
- AS patients with uniparental disomy (UPD) have better physical growth, fewer motor deficits and lower seizure occurrences.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16023557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
- Individuals with AS resulting from imprinting defects have the least debilitating features, such as higher developmental and language ability than AS caused by other mechanisms.&amp;lt;ref name=&amp;quot;PMID:11748306&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11748306&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
- The Body Mass Index (BMI) of 33% of the UBE3A mutation patients, and 47–64% of the patients from the classes II (UPD) and III (Imprinting defect) is above the 95th centile.&amp;lt;ref name=&amp;quot;PMID:15253756&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15253756&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Animal models'''&lt;br /&gt;
&lt;br /&gt;
* '''Drosophila'''&lt;br /&gt;
&lt;br /&gt;
Drosophila (common fruit fly) is an excellent model to use for better understanding of genetic diseases in humans as they are highly homologous to human UBE3A (hUBE3A), illustrating a high evolutionary conservation. Studies using the Drosophila model have shown that the functional absence of UBE3A resulted in decreased morphogenesis of dendritic branches. This is of interest as dendritic branches cover over 90% of the neuronal surface where [[#Glossary | '''synapse''']] between neurons occur. Proper formation and maturation of dendritic spines is also required so they come in contact with other neurons for effective transmission of neuronal signals. Thus proper formation of dendritic branching is pivitol for effective neuronal function and hence cognitive function.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18996915&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Interestingly, overexpression of dUBE3A also gave the same result, consisting of abnormal locomotion  and decreased dendritic branching in sensory neurons.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18701717&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;  This suggests a possible research field for some forms of [[#Glossary | '''autism''']] where the region containing UBE3A is duplicated, leading to delayed motor skills and seizures.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16433693&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;[[File:Normal and Angelman Syndrome mice models.jpg|thumb|250px|right|Normal and AS mice performance on the Rotarod apparatus.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
* '''Mice'''&lt;br /&gt;
&lt;br /&gt;
Absence of UBE3A in mice manifest similar phenotype to human AS, as illustrated by motor and learning deficits with inducible seizures.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21235769&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It has been shown through various mice model studies that larger deletions, ie. from UBE3A to GABRB3, more closely mirrors the large 6Mb deletions seen in human AS patients. Numerous tests, such as the Rotarod (for motor coordination and learning ability), Morris water maze test (for spatial learning and memory) and [[#Glossary | '''EEG''']] (electroencephalography), were carried out on  UBE3A null mutants, which showed the results to be abnormal or impaired.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20808828&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Other studies using mouse models have also outlined the obesity observed in 15% of AS children, albeit it is not the major characterisitics of AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17259980&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The diagram on the right clearly highlights the results obtained from such mouse model studies of AS, where the absence of UBE3A accumulated in deficits of motor function and obesity. In addition, excessive drooling and feeding difficulties were also highlighted by mice models with inactivated UBE3A, reflected by defects in fluid consumption and licking.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18413322&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Pathophysiology===&lt;br /&gt;
&lt;br /&gt;
'''Cognitive defects'''&lt;br /&gt;
&lt;br /&gt;
[[File:Role of UBE3A in dendritic spine neuronal synapses.png|thumb|250px|right|Role of UBE3A in dendritic spine neuronal synapses.]]&lt;br /&gt;
&lt;br /&gt;
AS patients present with abnormally high UBE3A, leading to neurological impairment. Recent identification of key target proteins of Ephexin-58 (Eph-5) and Arc (Activity-Regulated Cytoskeleton-associated protein) have aided in better understanding of the progression of UBE3A to cognitive defects. These two proteins are vital in the understanding of AS as Eph-5 determines synapse numbers and Arc contributes to plasticity and synapse function.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21164477&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Studies utilizing mice models have illustrated that UBE3A null mice could not ubiquitinate Eph-5, thus increasing its levels and limiting the growth of dendritic spines by the activation of RhoA. This subsequent activation of RhoA inhibits synapse formation and results in neuronal defects.&lt;br /&gt;
&lt;br /&gt;
In contrast, mice with normally functioning UBE3A showed phosphorylated Eph-5, resulting from the interaction of two neurons via the activation of EphB signalling receptor.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21029865&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Phosphorylation of Eph-5 allows UBE3A to ubiquitinate and degrade it. This degradation of Eph-5 permits new synaptic connections to form with cells they come into contact with. However, in AS, the absence of UBE3A means Eph-5 cannot be degraded, so RhoA activity is prolonged to reduce synaptic formation.&lt;br /&gt;
&lt;br /&gt;
As mentioned previously, Arc plays a pivitol role in synapse function as it removes synaptic receptors that respond to glutamate, a [[#Glossary | '''neurotransmitter''']].&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17088211&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In UBE3A present neurons, UBE3A ubiquitinates Arc, leading to it degradation as illustrated by the diagram on the left. However, in UBE3A deficient neurons, Arc accumulates and prevents the proper synaptic communications essential for normal cognitive functions.&amp;lt;ref name=&amp;quot;PMID20211139&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Signs and Symptoms==&lt;br /&gt;
&lt;br /&gt;
Angelman Syndrome presents a variety of different phenotypes, and the presented symptoms may vary at different ages.&amp;lt;ref name=&amp;quot;PMID7625442&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7625442&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
In 1995 Williams et al. embraced the observed clinical features of AS in a consensus statement, in order to present an appliance for clinicians. The diagnostic criteria were updated in 2005.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt; The following table shows the most frequently occurring characteristics in AS patients:&lt;br /&gt;
&lt;br /&gt;
'''4 characteristics appear in 100% of the cases:'''&lt;br /&gt;
&lt;br /&gt;
*Delayed development: become apparent by the age of 6 to 12 months.&lt;br /&gt;
*Motion and or balance malfunction&lt;br /&gt;
*Behaviour patterns like unmotivated laughter, frequent excitement; often including body movements,[[File:Electroencephalography of Angelman Syndrome.jpg|thumb|350px|right|EEG of AS and normal individuals.]] [[#Glossary | '''hypermotoric''']] behaviour&lt;br /&gt;
*Impairment of speech&lt;br /&gt;
&lt;br /&gt;
'''3 characteristics appear in more than 80% of the cases:'''&lt;br /&gt;
&lt;br /&gt;
*Abnormalities in head circumference, microcephaly&lt;br /&gt;
*Seizures&lt;br /&gt;
*EEG shows specific abnormal patterns&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Angelman Syndrome individuals show the most distinct disease pattern from 2 to 16 years of age.&lt;br /&gt;
In most cases at least 8 of the symptom traits are shown.&amp;lt;ref name=&amp;quot;PMID7625442&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Behavioural Characteristics'''&lt;br /&gt;
&lt;br /&gt;
A range of substantial characteristics appear in all AS cases, regardless of the genetic mechanisms, and are often responsible for diagnosing the syndrome. According to the original name, Happy Puppet syndrome, they have shown to exhibit traits such as a happy demeanor, with frequent laughter or smiling that can easily be triggered.&amp;lt;ref name=&amp;quot;PMID12566516&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12566516&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This behaviour can already be observed in 1 to 3 month old infants.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot; /&amp;gt; Uplifted hand flapping or waving motions are associated with laughter and excitement. Other characteristics manifesting in early childhood are sleep abnormalities with reduced sleep demand, and feeding problems. Breast and bottle feeding can be difficult due to non efficient attachment to the breast, tongue thrusting and uncoordinated sucking. Furthermore, there is an affection to crinkly and reflective surfaces, like some papers or plastic materials, especially water.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID12566516 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Communication Skills'''&lt;br /&gt;
&lt;br /&gt;
Communication is challenging for AS patients due to the fact that speech impairment is present in all cases. In the majority of affected people a lack of speech development is present. Only some of them have a minimal vocabulary consisting of two or three words, a few can speak in basic sentences. Some patients use gestures to articulate themselves, the [[#Glossary | '''Picture Exchange Communication System (PECS)''']] or sign languages such as [[#Glossary | '''Makaton''']] can be used for communication. Simple demands regarding their everyday occurrence can be understood by most patients.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID12566516 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Clinical and External Characteristics'''[[File:Angelman Syndrome patient.png|thumb|200px|right|4 year old AS patient.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Developmental delays are present in all patients. Motor milestones are delayed with children managing to sit unsupported with 12 months and crawl or bottom shuffle at the age of 18-24 months. The average age for walking is 4 years,however, ranging from 18 months to 7 years.&lt;br /&gt;
The [[#Glossary | '''gait''']] is characterised as slow, and flapping hands are a common trait.  The legs remain stiff during walking, arms are inflected by the wrists and elbows. The movements can appear ataxic, jerky or lurching. The muscle tone shows abnormalities with truncal [[#Glossary | '''hypotonia''']] and [[#Glossary | '''hypertonicity''']] of the limbs and alert reflexes.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID12566516 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The most striking external traits present in patients include broad-spaced teeth, and a wide mouth, light hair and eye colour, hypopigmented skin, deep set eyes, and a flat [[#Glossary | '''occiput''']].&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Seizures in Angelman Syndrome'''&lt;br /&gt;
&lt;br /&gt;
85% of AS patients suffer from epileptic seizures during their first three years. The first appearance can be within one month up to 20 year old patients. In infants with AS epilepsy manifests with [[#Glossary | '''febrile convulsions''']] and is hard to manage during childhood.&lt;br /&gt;
The most common type of seizures within 25% of patients are [[#Glossary | '''myoclonic seizures''']], followed by [[#Glossary | '''atonic seizures''']] as the second most frequent type, then 21% experience generalised [[#Glossary | '''tonic-clonic seizures''']] and lastly [[#Glossary | '''atypical absences''']] occur in 12% of patients.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20398390&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Angelman Syndrome in adults'''&lt;br /&gt;
&lt;br /&gt;
Patients with Angelman syndrome possess normal secondary sexual characteristics, and puberty sets in at a usual time. Limb hypertonicity, and [[#Glossary | '''thoracic scoliosis''']] lead to decreasing mobility. [[#Glossary | '''Oesophagus reflux''']] might induce severe problems, and the majority suffers from obesity. Furthermore, facial traits such as a prominent lower lip [[#Glossary | '''macrostomia''']] and [[#Glossary | '''mandibular prognathism''']] get manifested in adults. &lt;br /&gt;
In some cases the communication barrier can lead to frustration, resulting in aggressive behaviour. Nonetheless, patients gain a higher concentration span with age, and their nature becomes more quiet.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Complications===&lt;br /&gt;
&lt;br /&gt;
'''Hypopigmentation and Ocular albinism'''&lt;br /&gt;
&lt;br /&gt;
OCA2 gene, also known as the P gene, is closely located to the UBE3A gene. It encodes a protein vital to tyrosine metabolism, which plays a role in pigmentation development of skin, hair and eyes. However, AS caused by the large deletion of UBE3A leads to haploinsufficiency of OCA2 gene, resulting in hypopigmentation of the skin and the eyes. In some children with severe hypopigmentation, some form of [[#Glossary | '''albinism''']] is suspected.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12749060&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; When AS is caused by another mechanism, no abnormality of the skin and eye pigmentation is observed. However, not all AS children with OCA2 gene deletion will present with obvious hypopigmentation, they may just exhibit lighter skin colour than their parents.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8302318&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Diagnosis==&lt;br /&gt;
&lt;br /&gt;
The diagnosis of Angelman Syndrome is a clinical diagnosis confirmed by laboratory testing.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This involves both prenatal and/or postnatal diagnosis. &lt;br /&gt;
&lt;br /&gt;
===Prenatal Diagnosis===&lt;br /&gt;
[[File:Angelman Syndrome Prenatal Diagnosis.jpg|thumb|250px|right|Flowchart of AS Diagnosis.]]&lt;br /&gt;
&lt;br /&gt;
Prenatal detection of deletions of 15q11.2-q13, [[#Glossary | '''Paternal UPD''']] ([[#Glossary | '''Uniparental Disomy''']]), Imprinting defects and UBE3A mutations are done through DNA/chromosome/FISH analysis of fetal cells obtained by either [[#Glossary | '''Chorionic Villus Sampling''']](CVS) or [[#Glossary | '''Amniocentesis''']].&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot;/&amp;gt; &lt;br /&gt;
DNA methylation analysis using [[#Glossary | '''Amniocytes''']] is usually the first test carried out in molecular diagnosis of AS.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18059071&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; An abnormal result is followed up by either a FISH or array CGH analysis to search for a deletion on chromosome 15. If they produce a normal result, then UPD testing using DNA polymorphysims is carried out. If there is no evidence of UPD, other DNA analysis tests are used search for an imprinting centre deletion.&amp;lt;ref name=&amp;quot;PMID9792887&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9792887&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; A normal DNA methylation analysis is followed by a UBE3A sequence analysis.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt; In addition, a parent of origin test is also done to determine if the genetic disruption is of maternal origin or paternal origin. If it is maternally derived the fetus is diagnosed with AS (a paternally derived genetic disruption is indicative of Prader-Willi Syndrome).&amp;lt;ref name=&amp;quot;PMID17020468&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;17020468&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The flow chart summarizes the normal procedure used for prenatal diagnosis of AS. More information on important laboratory tests used for the diagnosis of Angelman Syndrome are provided below:&lt;br /&gt;
&lt;br /&gt;
*'''DNA Methylation Analysis'''&lt;br /&gt;
&lt;br /&gt;
Identifies approximately 80% of AS affected individuals and is usually the first test to be ordered.&amp;lt;ref name=&amp;quot;PMID7618904&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7618904&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Molecular disruptions such as deletions, paternal UPD and imprinting defects on chromosome 15 all demonstrate abnormal methylation patterns by either southern blot analysis or PCR amplification of bisulphate-treated DNA.&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot; /&amp;gt; An affected individual will only have an unmethylated (paternal) SNRPN (small nuclear ribonuclear protein-associated polypeptide N) allele compared with an unaffected individual who will have both a methylated and an unmethylated SNRPN allele.&amp;lt;ref name=&amp;quot;PMID9634532&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9634532&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
	  &lt;br /&gt;
*'''FISH (Fluorescent In Situ Hybridization)'''&lt;br /&gt;
&lt;br /&gt;
[[File:Critical_region_of_Angelman_Syndrome_on_chromosome_15.png‎|thumb|150px|right|FISH (fluorescence in situ hybridisation) image showing the critical region of Angelman Syndrome on chromosome 15.]]&lt;br /&gt;
&lt;br /&gt;
FISH analysis detects 5-7 Mb deletions in approximately 68% of affected individuals using detecting probes such as D15S10 and/or SNRPN.&amp;lt;ref name=&amp;quot;PMID7618904&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7618904&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It is also able to distinguish UPD from micro-deletions and imprinting defects. In simple terms, FISH analysis involves the binding of a fluorescent probe to a specific part of chromosome 15 and the detection of deletions within that region. FISH analysis is much more accurate in deletion detection compared to other high-resolution cytogenetics in the diagnosis of AS patients.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1511093&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
Array-based CGH is an advanced type of cytogenetic testing that can also be used to detect smaller deletions.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''UPD (Uniparental Disomy) Detection'''&lt;br /&gt;
&lt;br /&gt;
DNA Polymorphism testing detects paternal UPD in approximately 7% of affected AS individuals.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt; It is also able to distinguish between UPD and an Imprinting defect. It requires a DNA sample from the [[#Glossary | '''Proband''']] and from both parents. A homologous or non-homologous whole-arm translocation of the long arms of chromosome 15 is a sound indication for the need for prenatal UPD testing.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''IC (Imprinting Center) Analysis'''&lt;br /&gt;
&lt;br /&gt;
This type of analysis is used when individuals have an abnormal DNA methylation pattern but show normal results for  FISH, array CGH study and UPD analysis.&amp;lt;ref name=&amp;quot;PMID9792887&amp;quot;/&amp;gt; It is used to differentiate between the Imprinting defects caused by either microdeletions in the AS imprinting centre or by epigenetic mutations (that occur in maternal oogenesis or early embryogenesis).&amp;lt;ref name=&amp;quot;PMID9634532&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''Cytogenetic Testing'''&lt;br /&gt;
&lt;br /&gt;
Is used to detect a cytogenetically visible chromosomal rearrangement (large deletion, translocation or inversion) involving the 15q11.2-q13 region, which occurs in less than 1% of affected individuals.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''UBE3A Sequence Analysis'''&lt;br /&gt;
Sequence analysis of the UBE3A gene detects mutations in about 10% of the patients.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt; The test is used to detect either multiexonic (10 major coding exons of UBE3A) or whole gene deletions of UBE3A gene in individuals who produces a normal DNA methylation result but has characteristic clinical features of AS.&amp;lt;ref name=&amp;quot;PMID9792887&amp;quot;/&amp;gt;&lt;br /&gt;
This is recommended as a prenatal diagnostic tool in families that include multiple AS affected individuals because the imprinted pattern can be inherited from distant relatives.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Postnatal Diagnosis===&lt;br /&gt;
&lt;br /&gt;
Postnatal diagnosis is made though a combination of common clinical features of AS and UBESA gene sequence analysis.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt; The clinical features of AS include unsteady or shaky movements, muscle hypotonia, developmental delay and behavioral uniqueness such as frequent laughter/smiling and happy demeanor are features that are 100% consistent in all patients diagnosed with Angelman Syndrome.&amp;lt;ref name=&amp;quot;PMID18830393&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18830393&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; These clinical features become apparent between 6 months to 2 years of age. The onset of early or persistent smiling characteristic of this syndrome begin around the age of 1-3 months, but is often overlooked during infancy.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot;/&amp;gt; Thus early diagnosis of AS during infancy period is difficult because the clinical indicators of the syndrome takes time to manifest and characteristic features such as finger and hand tremors and excessive smiling/laughter are often overlooked and not considered as possible indicators of this syndrome.&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
*Rett Syndrome&lt;br /&gt;
&lt;br /&gt;
Some children with the clinical diagnosis of AS but no underlying genetic mechanism show mutations in ''MECP2'' gene, corresponding to Rett Syndrome. This should be suspected in AS test negative girls in the first few years of life.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17980307&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*Mowat-Wilson Syndrome&lt;br /&gt;
&lt;br /&gt;
Genetic mechanism is heterozygous deletion or truncation in ''ZFHX1B'' (''SIP1'') gene on 2q22. This presents with clinical features of severe intellectual disability, micrcephaly and seizures.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17958891&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Prader-Willi Syndrome patient.png|thumb|right|120px|12 year old PWS patient.]]&lt;br /&gt;
&lt;br /&gt;
*X-linked alpha-thalassemia/mental retardation syndrome (ATR-X)&lt;br /&gt;
&lt;br /&gt;
This arises from mutations in ''XNP'' gene on Xq13. ATR-X presents with severe intellectual disability, no speech development and seizures are common.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11449489&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*Phelan-McDermid Syndrome/22q13 deletion syndrome&lt;br /&gt;
&lt;br /&gt;
Deletions are usually submicroscopic and thus requires special molecular cytogenetic methods to confirm this deletion. Patients show moderate to profound intellectual disability and delay in speech development.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18505557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Related Disease'''&lt;br /&gt;
&lt;br /&gt;
*Prader-Willi Syndrome(PWS)&lt;br /&gt;
&lt;br /&gt;
PWS is a result from the absence of paternally expressed 15q11-q13 gene as a corollary of de novo deletion, maternal uniparental disomy of chromosome 15 or an imprinting defect on paternal chromosome 15 leading to the silencing of paternal alleles.&amp;lt;ref name=&amp;quot;PMID:20668179 &amp;quot;/&amp;gt; It is characterized by [[#Glossary | '''hyperphagia''']], obesity in later infancy and early childhood and difficulty in feeding during early infancy.&amp;lt;ref name=&amp;quot;PMID:20668179 &amp;quot;/&amp;gt; There is also cognitive impairment to some extent, though some PWS patients may exhibit intelligence in the normal IQ range. Behavioral phenotypes include stubbornness, manipulative tendency, obsessive compulsive characteristics.&amp;lt;ref name=&amp;quot;PMID:20668179 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Genetic Counselling==&lt;br /&gt;
&lt;br /&gt;
Genetic counselling is the process by which patients or relatives, at risk of an inherited disorder, are advised of the consequences and nature of the disorder, the probability of developing or transmitting it, and the options open to them in management and family planning. In the case for Angelman syndrome, types of risks associated are split into classes and formatted into the table below:&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20459762&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{|  style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
! Class&lt;br /&gt;
! Mechanism&lt;br /&gt;
! Risk to siblings&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! Ia                           &lt;br /&gt;
| De novo deletion                                                                                                               &lt;br /&gt;
| &amp;lt;1%                                                                                                                &lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! Ib&lt;br /&gt;
| Deletion due to chromosome rearrangement&lt;br /&gt;
| Up to 50%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! II&lt;br /&gt;
| Paternal uniparental disomy (UPD)&lt;br /&gt;
| &amp;lt;1%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! IIIa&lt;br /&gt;
| Imprinting defect with IC mutation&lt;br /&gt;
| Close to 100% if father has 15; 15 [[#Glossary | '''Robertsonian translocation''']]&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! IIIb&lt;br /&gt;
| Imprinting defect without IC mutation&lt;br /&gt;
| Up to 50% (if mother has IC deletion)&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! IIIc&lt;br /&gt;
| [[#Glossary | '''Mosaic''']] imprinting defect&lt;br /&gt;
| &amp;lt;1%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! IV&lt;br /&gt;
| ''UBE3A'' mutation&lt;br /&gt;
| Up to 50% (if mother has mutation)&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! V&lt;br /&gt;
| No identifiable genetic abnormality&lt;br /&gt;
| ?&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Ia''': Individuals with de novo deletion have 1% risk to siblings&lt;br /&gt;
&lt;br /&gt;
'''Ib''': Risk to siblings in individuals with chromosomal rearrangements is up to 50% &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9557895&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''II''': Paternal UPD with no Robertsonian translocation has a risk to sibling of less than 1%&lt;br /&gt;
&lt;br /&gt;
'''IIIa''': The risk to siblings in individuals with AS from an imprinting defect with a mutation in the imprinting center (IC) is close to 100% if father has 15;15 Robertsonian translocation&lt;br /&gt;
&lt;br /&gt;
'''IIIb''': Individuals with AS resulting from an imprinting defect without IC mutation, but with a carrier mother has a high risk to siblings of up to 50%. The mother could be phenotypically normal due to paternal inheritance of the genetic defect &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11283796&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''IIIc''': Individuals who are mosaic for the imprinting defect have less than 1% risk to siblings&lt;br /&gt;
&lt;br /&gt;
'''IV''': UBE3A mutation can be either inherited or de novo mutation. If the mother is a carrier for this genetic mutation, the risk to siblings is up to 50% &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11258627&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''V''': Individuals who present with AS clinically, but have no known underlying mechanism have an unknown risk to siblings.&lt;br /&gt;
&lt;br /&gt;
==Treatment and Management==&lt;br /&gt;
&lt;br /&gt;
Even though at present there is no known cure for Angelman syndrome, there are a number of treatments available that may alleviate symptons and improve daily life activities.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The below table describes the problems and management options that are used:&lt;br /&gt;
&lt;br /&gt;
[[File:Subtle Finger tremors-Angelman Syndrome.jpg|right|thumb|150px|A five months old boy with Angelman syndrome showing signs of Subtle Finger tremor.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
! Problems encountered&lt;br /&gt;
! Treatment and Management&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''Difficulty in feeding newborn AS babies'''&lt;br /&gt;
| Use of special nipples may improve feeding&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Oesophagus reflux'''&lt;br /&gt;
| Special motility medications requiried or upright positioning&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''Seizures'''&lt;br /&gt;
| Anticonvulsant medications&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19605773&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19453717&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Ocular problems'''&lt;br /&gt;
| Visual assessment is vital to encourage interactions and minimize chances of self-harm and autism development&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20656169&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''Drooling in developmental delayed AS patients'''&lt;br /&gt;
| Difficult to treat, but new surgical procedure on salivary duct reimplantation seems to be a promising alternative&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17699119&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Unstable children''' &lt;br /&gt;
| Physical therapy&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''AS patients become less active with increasing age'''&lt;br /&gt;
| Activity schedules to prevent scoliosis and obesity. Occupational therapy to stimulate fine motor and oral-motor control skills in conjunction to speech therapy&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Sleeping difficulty'''&lt;br /&gt;
| Sedative medication in severe cases. [[#Glossary | '''Melatonin''']] may be used to promote sleeping but some studies have found that it loses its therapeutic effects after several weeks in most AS patients&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19379289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|-&lt;br /&gt;
|colspan=&amp;quot;4&amp;quot; |&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Prognosis==&lt;br /&gt;
&lt;br /&gt;
Life expectancy of AS patients seems to be normal&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, but there is still a high degree of developmental delay and limited expressive language skills.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17019625&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This problem arises prominently in the assessment of the severity of coincidental medical conditions due to difficulties in communication. A visit to the dentist can become difficult if good communication is not conveyed between the parents, the dentist, and the child.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18271768&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Some problems require extreme measures, such as the procedure of lens implantation was performed in both eyes of a person diagnosed with AS, due to the inability to wear spectacles.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20656169&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
During adulthood, menstruation and puberty begin at around average age evidenced by females with Angelman syndrome that are fully capable of conceiving children.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11258627&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Most adult patients can feed themselves, but needed help with many other daily activities. Main troubles which have shown in adults are a tendency to become obese and start developing  thoracic scoliosis, which some adults with AS begin wheelchair bounded.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9072912&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Current and Future Research==&lt;br /&gt;
&lt;br /&gt;
Currently there is no cure for the treatment of AS, so much research is being carried out for therapeutic interventions. Findings in the last five years have suggested through various mice and fruit fly models that the absence of maternal UBE3A results in the same human AS features of neurological defects and seizures. However, more recently, studies have outlined that the symptoms of AS can be improved by modifying other gene products. In addition, restoring of a functional UBE3A protein into adult mice neurons have shown to reduce motor and neurological deficits and balance disorders. This shows promising research prospects in that improvements may be possible in human AS patients by restoring functional UBE3A proteins into their neurons. &lt;br /&gt;
&lt;br /&gt;
===Possible Treatment Pathways===&lt;br /&gt;
&lt;br /&gt;
*'''Cognitive and physical impairment'''&lt;br /&gt;
&lt;br /&gt;
Although everyone is born with two copies of the gene UBE3A, one maternal and one paternal copy, it is only the maternal UBE3A that is used in the brain. Most AS patients have a genetic mutation on the maternal chromosome 15 that results in dysfunctional UBE3A.&amp;lt;ref&amp;gt;http://www.cureangelman.org/what-hope.html&amp;lt;/ref&amp;gt; The above research focused on turning on the father's copy of UBE3A to restore its functions. Furthermore, mouse models were utilized to show that alpha-CaMKII could be increased to compensate the loss of UBE3A and restore compromised mental and physical abilities. However, this finding still requires much more research.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17259980&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''Epilepsy'''&lt;br /&gt;
&lt;br /&gt;
There is research being done on improving certain conditions that are involved in AS by nutritional benefits. The use of [[#Glossary | '''corticosteroids''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19666884&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, [[#Glossary | '''valproate''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19453717&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and [[#Glossary | '''clonazepam''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19605773&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and having a [[#Glossary | '''ketogenic diet''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20880305&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; has all been shown to aid in the treatment of epilepsy. It has also been reported to be efficient in the treatment of other conditions, such as behavioural disorders, reduction in seizures, ataxia, sleep patterns, developmental progress and sleep disturbances. [[#Glossary | '''Levetiracetam''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17326790&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; could be used in such a situation, especially when the patient has an intolerance to valproate and clonazepam.&lt;br /&gt;
&lt;br /&gt;
*'''Betaine and Folic acid'''&lt;br /&gt;
&lt;br /&gt;
This double-blind placebo-controlled study was done to examine the potential therapeutic role of [[#Glossary | '''betaine''']] and [[#Glossary | '''folic acid''']] in the treatment of the clinical phenotypes of AS. The aim of this protocol was to increase methylation and activate the paternally inherited UBE3A in hope to compensate for the inactive maternal UBE3A. Although there were no major differences in the control and treatment groups, a small number of patients in the treatment group showed some positive outcomes.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20635355&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&lt;br /&gt;
'''albinism''': A congenital disorder distincted by the complete or partial absence of pigment in the skin, hair and eyes due to defect of an enzyme involved in the production of melanin.&lt;br /&gt;
&lt;br /&gt;
'''allele''': Dissimilar variant of one gene. Organisms have two alleles for each gene inherited from their parents, one from each of them.&lt;br /&gt;
&lt;br /&gt;
'''alpha-CaMKII''': (alpha calcium calmodulin kinase II) Compound involved in synaptic plasticity, one of the most important theories behind learning and memory. Ability of a synapse between two neurons to change in strength due to the use or disuse of transmission.&lt;br /&gt;
&lt;br /&gt;
'''Amniocytes''': Cells that are shed by the fetus during fetal development to the surrounding amniotic fluid. They are a source of fetal DNA. &lt;br /&gt;
&lt;br /&gt;
'''Amniocentesis''': (AFT or amniotic fluid test) is a prenatal diagnostic test used to detect chromosomal abnormalities in the developing fetus by extracting amniotic fluid (a source of fetal DNA) surrounding the fetus. &lt;br /&gt;
&lt;br /&gt;
'''AMPA''': (2-amino-3-(5-methyl-3-oxo-1,2- oxazol-4-yl)propanoic acid) Compound that binds to the AMPA receptor to imitate glutamate neurotransmitter.&lt;br /&gt;
&lt;br /&gt;
'''Arc''': Activity-Regulated Cytoskeleton-associated protein; involved in learning and memory.&lt;br /&gt;
&lt;br /&gt;
'''ataxia''': Lack of coordination in muscle movements.&lt;br /&gt;
&lt;br /&gt;
'''atonic seizures''': A abrupt loss of muscle tone, this can lead to the limbs loosing strength, or the head may drop to the side. The patient remains conscious during this kind of epileptic seizure.&lt;br /&gt;
&lt;br /&gt;
'''atypical absences''': Seizure leads to unconsciousness in most cases.  &lt;br /&gt;
&lt;br /&gt;
'''autism''': A neural development disorder defined by limited social interaction and communication.&lt;br /&gt;
&lt;br /&gt;
'''Chorionic Villus Sampling''': A prenatal diagnostic test used to detect chromosomal abnormalities in the developing fetus by extracting and testing chorionic villus (placental tissue). &lt;br /&gt;
&lt;br /&gt;
'''chromosome''': Structure consisting of coiled DNA with DNA associated proteins such as histones.&lt;br /&gt;
&lt;br /&gt;
'''clonazepam''': A psychoactive drug having muscle relaxant properties and treats anxiety and epilepsy.&lt;br /&gt;
&lt;br /&gt;
'''corticosteroid''': A type of steroid hormones that are produced in the adrenal cortex.&lt;br /&gt;
&lt;br /&gt;
'''cytogenetics''': Study of the structure, function and abnormality of the cell, especially the chromosome.&lt;br /&gt;
&lt;br /&gt;
'''deletion''': Lack of a part of the DNA (deoxyribonucleic acid is a nucleic acid containing information for protein synthesis), can vary form a single base to a hole gene. &lt;br /&gt;
&lt;br /&gt;
'''de novo mutation''': Change in a gene of a family member for the first time due to a mutation in the egg or sperm of the parents or in the fertilized egg (zygote).&lt;br /&gt;
&lt;br /&gt;
'''disorder''': A mental or physical health disturbance or dysfunction.&lt;br /&gt;
&lt;br /&gt;
'''EEG''': Electroencephalography is a means of measuring electrical activity along the scalp by measuring the total electrical charges fired by thousands or millions of neurons.&lt;br /&gt;
&lt;br /&gt;
'''epilepsy''': Neurological disorder characterised by recurrent impairment of brain function that can cause seizures or unconsciousness. &lt;br /&gt;
&lt;br /&gt;
'''E6-AP''': E6-AP ubiquitin-protein ligase is an enzyme encoded by UBE3A which adds ubiquitin chain to target proteins to be degraded by proteasomes.&lt;br /&gt;
&lt;br /&gt;
'''febrile convulsions''': The occurrence of high fever, especially in children.&lt;br /&gt;
&lt;br /&gt;
'''FISH''': Fluorescent in situ hybridization is a technique used to identify and localize the presence or absence of DNA sequences on the chromosome. This is achieved by using fluorescently labelled DNA sequences which then binds to complementary DNA sequence on the chromosome. After hybridization (attachment), chromosome of interest will fluoresce under the microscope.&lt;br /&gt;
&lt;br /&gt;
'''gait''': A manner of walking, stepping or running.&lt;br /&gt;
&lt;br /&gt;
'''gene''': A molecular unit of heredity of a living organism.&lt;br /&gt;
&lt;br /&gt;
'''hyperphagia''': (Also referred to as Polyphagia) Excessive ingestion of food beyond the dietary and energy requirements of the body. &lt;br /&gt;
&lt;br /&gt;
'''hypermotoric''': Sudden appearance of uncontrolled movements such as striking or kicking inappropriately.&lt;br /&gt;
&lt;br /&gt;
'''hypertonicity''': Increase of muscle tension and a disability to stretch leading to an impairment of motor activity.&lt;br /&gt;
&lt;br /&gt;
'''hypopigmentation''': A lack of melanin pigments or melanocytes  affecting the colour of the skin, hair and iris. Features appear to be light-coloured due to loss of skin colour.&lt;br /&gt;
&lt;br /&gt;
'''hypotonia''': Decrease in the ability to stretch passively, due to a low muscle tone. &lt;br /&gt;
&lt;br /&gt;
'''imprinting''': This is a process to describe the modification of a maternally or paternally derived chromosome, which consequently influences the expression of certain genes on the altered chromosome.&lt;br /&gt;
&lt;br /&gt;
'''ketogenic diet''': A high-fat, low-carbohydrate diet that is used to treat epilepsy in children.&lt;br /&gt;
&lt;br /&gt;
'''levetiracetam''': An anticonvulsant drug used to treat epilepsy.&lt;br /&gt;
&lt;br /&gt;
'''locus''': Location of a gene on a chromosome(loci: plural for locus).&lt;br /&gt;
&lt;br /&gt;
'''LTP''': Long-term potentiation shares common features with long term memory. It strengthens and enhances signal transmission between neurons by improving the communication between two neurons.&lt;br /&gt;
&lt;br /&gt;
'''macrostomia''': A wide-spaced mouth.&lt;br /&gt;
&lt;br /&gt;
'''Makaton''': Language programme using symbols and signs to support speaking.&lt;br /&gt;
&lt;br /&gt;
'''mandibular prognathism''': The abnormal protrusion of the lower jaw. &lt;br /&gt;
&lt;br /&gt;
'''maxillary hypoplasia''':  The underdevelopment of the upper jaw.&lt;br /&gt;
&lt;br /&gt;
'''melatonin''': A hormone secreted by the pineal gland.&lt;br /&gt;
&lt;br /&gt;
'''microcephaly''': The circumference of the head is less than average due to abnormalities of the nervous system. This abnormality can be present at birth or emerge during the first few years of life and reduces both life expectancy and the cognitive functions of the individual affected.&lt;br /&gt;
&lt;br /&gt;
'''microdeletion''':  A genetic mutation in which a part of a chromosome or a sequence of DNA is missing.&lt;br /&gt;
&lt;br /&gt;
'''mosaic''': tissues or cells containing different mixture of genetic sequences&lt;br /&gt;
&lt;br /&gt;
'''mutation''': Event that changes the DNA (deoxyribonucleic acid is a nucleic acid, containing information for protein synthesis) or RNA (ribonucleic acid is a type of nucleic acid transmitting the information from the DNA to the proteins ) of a gene permanently.&lt;br /&gt;
&lt;br /&gt;
'''myoclonic seizures''': A quick jerk of the skeletal muscle, due to a irregular brain activity.&lt;br /&gt;
&lt;br /&gt;
'''neurogenetic''': Genetic basis of the nervous system.&lt;br /&gt;
&lt;br /&gt;
'''neurotransmitter''': Transmits neuronal signals to a target cell. They are first packaged in vesicles just beneath the membrane of presynaptic axon terminals and released into the synaptic cleft (space between the two interacting neurons) and enter the postsynaptic dendrite.&lt;br /&gt;
&lt;br /&gt;
'''occiput''': The back portion of the head.&lt;br /&gt;
&lt;br /&gt;
'''oesophagus reflux''': Impairment of a sphincter in the lower end of the oesophagus leads to the back flow of stomach acid into the oesophagus. Heartburn is a typical symptom.&lt;br /&gt;
&lt;br /&gt;
'''paediatrician''': Physicians that specialise on infants, children and adolescents.&lt;br /&gt;
&lt;br /&gt;
'''paternal UPD''': Inheritance of two copies of a chromosome from the father and none from the mother. &lt;br /&gt;
&lt;br /&gt;
'''phenotype''': Visible traites of an organism determined by genetic and environmental factors.&lt;br /&gt;
&lt;br /&gt;
'''Picture Exchange Communication System (PECS)''': Individuals communicate using images instead of words. It is frequently used by children with autism, to articulate their needs and wishes or to make comments about something.&lt;br /&gt;
&lt;br /&gt;
'''Proband''': Is the person (or animal) being studied or reported on in a genetic investigation. Most commonly it refers to the first affected family member who requires medical help for a genetic disorder. &lt;br /&gt;
&lt;br /&gt;
'''Robertsonian translocation''': Rearrangement of the chromosome, occurs in 5 chromosome including 13,14,15,21 and 22. This type of mutation occurs in chromosomes with the centromere not at the centre, resulting in long and short arm chromosomes. Translocation breaks the chromosome at the centromere so the long arm attaches to the other long arm, and the same for the short arm happens. Cell division will result in the loss of the short arms as they do not contain important genes.&lt;br /&gt;
&lt;br /&gt;
'''seizure''': Abnormal electrical activity in the brain that can result in a variety of physical symptoms like convulsion, body shaking, loss of consciousness, confusion, and mood changes.&lt;br /&gt;
&lt;br /&gt;
'''synapse''': Allows transmission of signal between neurons for effective neuronal function.&lt;br /&gt;
&lt;br /&gt;
'''thoracic scoliosis''': The spine is curved laterally(from side to side) in the thoracic region.&lt;br /&gt;
&lt;br /&gt;
'''tonic-clonic seizures''': This type of seizure is associated with unconsciousness due to electrical discharges in a big proportion of the brain.&lt;br /&gt;
&lt;br /&gt;
'''ubiquitin''': A polypeptide found in all eukaryotic cells, that participates in a variety of cellular functions including protein recycling.&lt;br /&gt;
&lt;br /&gt;
'''Uniparental disomy''': (UPD) the inheritance of two copies of a chromosome pair or part of a chromosme from one parent and no copy from the other parent. &lt;br /&gt;
&lt;br /&gt;
'''valproate''':  A mood-stabilizing drug that is also used for treatment for epilepsy and bipolar disorder.&lt;br /&gt;
&lt;br /&gt;
==Helpful Links==&lt;br /&gt;
&lt;br /&gt;
* Australia&lt;br /&gt;
:* [http://www.angelmansyndrome.org/research.html Angelman Syndrome Association] &lt;br /&gt;
:* [http://www.angelmansyndromeqld.org/ Queensland Angelman Association]&lt;br /&gt;
&lt;br /&gt;
* America&lt;br /&gt;
:* [http://www.angelman.org/ Angelman Syndrome Foundation]&lt;br /&gt;
:* [http://rarediseasesnetwork.epi.usf.edu/arpwsc/ Rare Clinical Diseases Research Network]&lt;br /&gt;
:* [http://www.rarediseases.org/rare-disease-information/rare-diseases/byID/411/viewAbstract National Organisation for Rare Disorders]&lt;br /&gt;
:* [http://www.epilepsyfoundation.org/ Epilepsy Foundation]&lt;br /&gt;
:* [http://www.cureangelman.org/ Foundation for Angelman Syndrome Therapeutics]&lt;br /&gt;
&lt;br /&gt;
* Search Pubmed &lt;br /&gt;
:* [http://www.ncbi.nlm.nih.gov/pubmed?term=angelman%20syndrome Angelman Syndrome] &lt;br /&gt;
&lt;br /&gt;
* OMIM entries for Angelman Syndrome&lt;br /&gt;
:* [http://omim.org/entry/105830 ANGELMAN SYNDROME; AS]&lt;br /&gt;
:* [http://omim.org/entry/601623 UBIQUITIN-PROTEIN LIGASE E3A; UBE3A]&lt;br /&gt;
&lt;br /&gt;
==Related Links==&lt;br /&gt;
&lt;br /&gt;
* [[Mouse Knockout]] - this page explains the current use of mouse models in disrupting genes to elucidate their genetic function, including the mouse gene knockouts for alpha calcium-calmodulin kinase II (alpha CaMKII)&lt;br /&gt;
* [[2009 Group Project 4]] - this page gives an extensive overview on the history of the mouse model and its various use in embryology and genetics. In addition, it also describes mouse knockout and the role they play in current research of various human diseases&lt;br /&gt;
* [[Fly Development]] - this page describes the use of drosophila flies as developmental models&lt;br /&gt;
* [[2009 Group Project 2]] - this page gives an extensive overview on the history of the fly model and its various use in embryology and genetics&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&lt;br /&gt;
&amp;lt;references /&amp;gt;&lt;/div&gt;</summary>
		<author><name>Z3291643</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_7&amp;diff=77574</id>
		<title>2011 Group Project 7</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_7&amp;diff=77574"/>
		<updated>2011-10-12T20:39:55Z</updated>

		<summary type="html">&lt;p&gt;Z3291643: /* Aetiology */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;='''Angelman Syndrome'''=&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Introduction==&lt;br /&gt;
&lt;br /&gt;
[[File:Dr Harry Angelman.jpg|thumb|130px|right|Dr Harry Angelman.]]&lt;br /&gt;
Angelman syndrome (AS) is a rare [[#Glossary | '''neurogenetic''']] [[#Glossary | '''disorder''']] first described by Dr. Harry Angelman in 1965.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18754889&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Dr. Angelman was an English [[#Glossary | '''paediatrician''']] who first diagnosed the disease in 3 children with a developmental delay.&amp;lt;ref&amp;gt;http://www.ncbi.nlm.nih.gov/books/NBK22221/&amp;lt;/ref&amp;gt; AS occurs in 1 in 10000-20000 births, the exact number is still unknown.&amp;lt;ref name=&amp;quot;PMID7573182&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7573182&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;PMID8703225&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;8703225&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It is caused by maternal [[#Glossary | '''allele''']] disruptions of a single gene- UBE3A. Either [[#Glossary | '''mutations''']] or [[#Glossary | '''deletions''']] of the UBE3A gene results in AS. &lt;br /&gt;
&lt;br /&gt;
AS presents with well known [[#Glossary | '''phenotypes''']] during infancy and adulthood, such as [[#Glossary | '''microcephaly''']] and [[#Glossary | '''maxillary hypoplasia''']]. However, these features become more marked with age. Most frequent clinical features include delayed development,[[#Glossary | '''seizures''']],[[#Glossary | '''ataxia''']], impairment of speech, happy demeanor, behavioural problems such as hyperactivity, short attention span and sleeping difficulty.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21592595&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21484597&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;ASAwebsite&amp;quot;&amp;gt;http://www.angelmansyndrome.org/home.html&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
At present, there is no cure for the syndrome, though current research is focused at improving life quality of patients with Angelman syndrome through management of daily tasks.&amp;lt;ref&amp;gt;http://www.bbc.co.uk/health/physical_health/conditions/angelman1.shtml&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==History==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Dr. Harry Angelman first reported Angelman Syndrome on three handicapped children that were admitted to his ward in England in 1964.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt; He reported how these three independent and unconnected clinical cases all had the same characteristic features of severe developmental delay, jerky movements, seizures and a happy disposition.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt; However it was only when he stumbled upon an oil painting called ‘a Boy with a Puppet” while on a holiday in Italy he was able to connect the symptoms of all three children under one common cause.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20981772&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; He linked the happy face of the boy depicted on the painting with the jerky movements and happy disposition he observed on his three patients back in England. He reported his findings on a paper entitled “Puppet children (a report on three cases)” which was published in 1965.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
The syndrome was initially named ‘Puppet Syndrome’ but was later changed to Angelman Syndrome. Due to the extreme rarity of the syndrome and lack of sufficient clinical evidence the syndrome was soon forgotten.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt;&lt;br /&gt;
[[File:Dr Charles Williams.jpg|thumb|right|150px|Dr Charles Williams.]]&lt;br /&gt;
	&lt;br /&gt;
In 1987, a physician named Ellen Magenis, came across children with deletions on [[#Glossary | '''chromosome''']] 15 that were suffering from seizures and severe developmental delay.&amp;lt;ref&amp;gt;http://www.angelman.org/stay-informed/facts-about-angelman-syndrome---7th-edition/harry-angelman-and-the-history-of-as/&amp;lt;/ref&amp;gt; Even though genetically the children were expected to have [[#Diagnosis | '''Prader-Willi syndrome''']] that was characterised by deletions on chromosome 15, their characteristic symptoms of seizures and lack of development did not correspond with that of the syndrome. This led to the realization that these children had deletions on the maternally derived chromosome 15 and not on the paternally derived chromosome as was observed in Prader-Willi syndrome.  Thus the deleted genetic code on maternally derived chromosome 15 was identified as the genetic marker for Angelman Syndrome.&lt;br /&gt;
&lt;br /&gt;
In 1997, UBE3A gene was isolated by Dr. Joseph Wagstaff and Dr. Arthur Beaudet as the cause of Angelman Syndrome.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot; /&amp;gt; The discovery of this [[#Glossary | '''gene''']] led to the subsequent development of animal models and research aimed at finding a causal link between UBE3A gene abnormalities and characteristic features observed in Angelman Syndrome. &lt;br /&gt;
	&lt;br /&gt;
Currently, four different genetic abnormalities for Angelman Syndrome have been confirmed by genetic testing. They include: Deletion, [[#Glossary | '''Uniparental Disomy''']] (UPD), [[#Glossary | '''Imprinting''']] and UBE3A mutation.&amp;lt;ref name=&amp;quot;PMID20211139&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Below is a timeline, summarising the key discoveries and advancements of the Angelman Syndrome:&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|- bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
!Year&lt;br /&gt;
!Milestone&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1964'''&lt;br /&gt;
|First observed by Dr Harry Angelman on three handicapped children.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot; /&amp;gt; &lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''1965'''&lt;br /&gt;
|Harry Angelman publishes his finding in a report entitled 'Puppet Children'(a report on three cases).&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1980s'''&lt;br /&gt;
|First reports of AS reaches US and research into the disorder being at the University of Florida under the direction of Dr. Charles Williams.&amp;lt;ref&amp;gt;http://www.angelmanproject.com/history.htm&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''1982'''&lt;br /&gt;
|Name changed from 'Happy Puppet' to Angelman syndrome by Williams and Frias. &lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1987'''&lt;br /&gt;
|Discovery of a genetic marker for AS – an absent genetic code on maternally derived chromosome 15. &lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''1997'''&lt;br /&gt;
|The cause of AS discovered by Dr. Joseph Wagstaff and Dr. Arthur Beaudet – mutation or deletion in the UBE3A gene.&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1998'''&lt;br /&gt;
|Transgenic mice with absent maternal UBE3A created to illustrate motor and learning deficits in addition to seizures.&amp;lt;ref name=&amp;quot;PMID9808466&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9808466&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''2007'''&lt;br /&gt;
|AS mouse model shows that neurological deficits can be reversed by decreasing levels of [[#Glossary | '''alpha-CaMKII''']] inhibitory phosphorylation.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17259980&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''2010'''&lt;br /&gt;
|Discovery of a another gene mutation in TC4 gene (on chromosome 18) in a small number of clinically diagnosed patients with no identifiable genetic alternation in UBE3A.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20184619&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''2010'''&lt;br /&gt;
|Protein named Arc identified as a target of AS gene product; UBE3A.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Incidence'''&lt;br /&gt;
*The current population of people diagnosed with AS is unknown but studies have estimated the number to be around 1:10,000&amp;lt;ref name=&amp;quot;PMID7573182&amp;quot; /&amp;gt; and 1:20,000&amp;lt;ref name=&amp;quot;PMID8703225&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
'''Diagnosis'''&lt;br /&gt;
*The mean age of diagnosis for patients with AS lies between 6 and 6.5 years of age.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18664077&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15741136&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Gender'''&lt;br /&gt;
* Males appear to be at higher risk for some aspects of early developmental delays in comparison to females with AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17019625&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Demography'''&lt;br /&gt;
*Europe:&lt;br /&gt;
:Denmark- 1:10,000&amp;lt;ref name=&amp;quot;PMID7573182&amp;quot; /&amp;gt;&lt;br /&gt;
:Estonia- 1:52,000&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16906556&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
:Sweden- 1:20,000&amp;lt;ref name=&amp;quot;PMID8703225&amp;quot; /&amp;gt;&lt;br /&gt;
*Australia:&lt;br /&gt;
:Western Australia- 1:40,000&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16492624&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Aetiology==&lt;br /&gt;
&lt;br /&gt;
[[File:Chromosome 15 Deletion of 15q11.2 to 15q13.jpg|thumb|100px|Chromosome 15 - The deletion occurs at 15q11.2-15q13.]]&lt;br /&gt;
&lt;br /&gt;
'''Molecular Genetics'''&lt;br /&gt;
&lt;br /&gt;
* Location: 15q11-q13&lt;br /&gt;
* Protein product: Ubiquitin protein ligase E3A&lt;br /&gt;
* Gene name: UBE3A&lt;br /&gt;
* Phenotype: Angelman Syndrome&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Different genetic mechanisms lead to different clinical phenotypes of AS. The most common genetic mechanism leading to AS is the deletion or re-arrangement of maternal chromosome at [[#Glossary | '''locus''']] 15q11.2-q13,as the chromosome image shows on the right, accounting for 70% of AS occurrences.&amp;lt;ref name=&amp;quot;PMID8988171&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt; 8988171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This leads to more severe clinical phenotypes of microcephaly, motor difficulties, seizures and impaired speech development. The next most common genetic mechanism is mutation in the ''UBE3A'' gene responsible for 10% of AS cases and paternal uniparental disomy and mutation in the imprinting centre (IC), both accounting for 2-5% of AS observed.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
 &lt;br /&gt;
&lt;br /&gt;
AS is caused by the 4 major genetic mechanisms mentioned above and are thus divided into Classes I to IV based on their underlying genetic mechanism. AS patients with the clinical features of AS but no [[#Glossary | '''cytogenetic''']] or molecular abnormality in Chromosome 15q11.2-13 are grouped under Class V (summarised in table below).&amp;lt;ref name=&amp;quot;PMID8988171&amp;quot; /&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10364509&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Inheritance'''&lt;br /&gt;
&lt;br /&gt;
Angelman Syndrome from UBE3A mutations and deletions in the Imprinting Centre follow an inheritance pattern. A carrier father with the genetic defect can pass it on to his children, however, his children will be clinically normal. On the other hand, a carrier mother can pass the genetic defect onto her children, who will then have Angelman Syndrome. &lt;br /&gt;
&lt;br /&gt;
The image highlights the inheritance of Angelman Syndrome, which only results after a carrier mother passes it on to her children. &lt;br /&gt;
&lt;br /&gt;
{|  style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
! Class&lt;br /&gt;
! Mechanism&lt;br /&gt;
! Diagnostic Tests&lt;br /&gt;
! Frequency&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''Ia'''                           &lt;br /&gt;
| De novo deletion                                                                                           &lt;br /&gt;
| High resolution cytogenetics [[#Glossary | '''FISH''']]                                                                                                       &lt;br /&gt;
| 70%      &lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Ib'''&lt;br /&gt;
| Deletion due to chromosome rearrangement&lt;br /&gt;
| High resolution cytogenetics FISH&lt;br /&gt;
| &amp;lt;1%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''II'''&lt;br /&gt;
| Paternal uniparental disomy&lt;br /&gt;
| [[#Glossary | '''RFLP''']]  analysis&lt;br /&gt;
| 2%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''IIIa'''&lt;br /&gt;
| Imprinting defect with IC mutation&lt;br /&gt;
| Screening of [[#Glossary | '''IC''']]  for mutations is positive&lt;br /&gt;
| 2%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''IIIb'''&lt;br /&gt;
| Imprinting defect withouth IC mutation&lt;br /&gt;
| Screening of IC for mutations is negative&lt;br /&gt;
| 2%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''IIIc'''&lt;br /&gt;
| Mosaic imprinting defect&lt;br /&gt;
| Screening of IC for mutations is usually negative &lt;br /&gt;
| ?&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''IV'''&lt;br /&gt;
| ''UBE3A'' mutation&lt;br /&gt;
| Screening of ''UBE3A'' for mutations&lt;br /&gt;
| 5-10%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''V'''&lt;br /&gt;
| No identifiable genetic abnormality&lt;br /&gt;
| Consider other diagnoses&lt;br /&gt;
| 5-26%&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Pathogenesis==&lt;br /&gt;
&lt;br /&gt;
Chromosome 15 became associated with AS in the 1980s after the observation of many AS patients harboring [[#Glossary | '''microdeletions''']] of 15q11.2-15q13.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15668046&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The last decade has shed even more light in the aetiology of AS,as Kishino and Matsuura first identified UBE3A as the causative gene for AS in 1997.&amp;lt;ref name=&amp;quot;PMID:8988171&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;8988171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8988172&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Normal gene product: E6-AP ubiquitin ligase'''&lt;br /&gt;
&lt;br /&gt;
The function of UBE3A is to encode for [[#Glossary | '''E6-AP''']] ubiquitin ligase, however its function in the development of the nervous system and the process of UBE3A mutation leading to cognitive impairment in AS patients is still vague.&amp;lt;ref name=&amp;quot;PMID:20211139&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Past and current research has elucidated that E6-AP ubiquitin ligase is involved in the degradation of four proteins, listed below, but currently, no protein with a direct role in [[#Glossary | '''long-term potentiation (LTP)''']] as a target of E6-AP, has been identified.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12684449&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The identification of such target proteins would be a landmark discovery in further understanding of the pathogenesis, aetiology and prospective treatment strategies of AS, as LTP defects is one of the major neurological impairments of AS. &lt;br /&gt;
 &lt;br /&gt;
* p53 tumor suppressor protein &lt;br /&gt;
* yeast DNA repair protein Rad23 &lt;br /&gt;
* multicopy maintenance protein 7 subunit &lt;br /&gt;
* E6-AP&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Abnormal gene product'''&lt;br /&gt;
&lt;br /&gt;
Disruption to the gene,UBE3A, interferes with the normal functioning of the gene, which is its crucial role in UBE3A [[#Glossary | '''ubiquitylation''']]. Problems involving this pathway can lead to various diseases either from the loss or gain of function.&amp;lt;ref name=&amp;quot;PMID:9857172&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9857172&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In the case of AS, E6-AP is affected, leading to detrimental cognitive impairment in addition to other deficits.&amp;lt;ref name=&amp;quot;PMID:9857172&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9857172&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Regional functioning of UBE3A'''&lt;br /&gt;
&lt;br /&gt;
Despite the uncertain progression of UBE3A mutation and the neurological abnormalities characteristic of AS, animal models have illustrated the vital role of UBE3A in the normal functioning of the brain. This can be exemplified by a study which utilized a mouse model with target inactivation of the gene UBE3A resulting in the manifestation of classical features of AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11895368&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In addition, the fact that imprinting of UBE3A takes place only in specific brain regions (cerebellum, olfactory tracts and the hippocampus) confirms the hypothesis that the loss of this gene would be detrimental in the cognitive development.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20398390&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Most genes are inherited in copies of two, one paternal and the other maternal; however, some genes, such as UBE3A only have one functional copy as the other is silenced, coined 'imprinting'. Imprinting of the paternal copy of UBE3A takes place in some cell populations, such as the hippocampal neurons and Purkinje cells in the cerebellum.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9288101&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This means only the maternal UBE3A is functionally expressed in these particular brain regions. Thus a [[#Glossary | '''de novo mutation''']] in the maternal copy of the gene will result in the complete absence of functional E6-AP in the associated brain areas.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9288088&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
It is also known that UBE3A plays an important role in synaptic transmission, but exactly how it does so is still not completely understood.&amp;lt;ref name=&amp;quot;PMID:9808466&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9808466&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''UBE3A ubiquitylation'''&lt;br /&gt;
&lt;br /&gt;
As briefly mentioned above, UBE3A is a member of the E3 ubiquitin ligase family of enzymes, responsible for the addition of ubiquitin to the target protein for degradation of the ubiquitinated protein, as illustrated in the diagram below. These processes are required for normal human cognitive function.&amp;lt;ref name=&amp;quot;PMID:9808466&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9808466&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In this way synaptic protein [[#Glossary | '''Arc (activity-regulated cytoskeleton-associated protein)''']] is degraded to control synaptic function. Arc is a target protein of UBE3A in dendritic spines found in the hippocampal neurons.&amp;lt;ref name=&amp;quot;PMID:20668179&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20668179&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Deletion of UBE3A leads to the accumulation of Arc in neurons leading to trafficking of [[#Glossary | '''AMPA ( α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid)''']] receptors, resulting in impaired cognitive functions.&amp;lt;ref name=&amp;quot;PMID:20211139&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; [[File:UBE3A Ubiquitylation Pathway.png|thumb|350px|right|UBE3A Ubiquitylation Pathway.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
UBE3A ubiquitylation consists of:&amp;lt;ref name=&amp;quot;PMID:20668179&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20668179&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
# Activation of ubiquitin by E1 enzyme&lt;br /&gt;
# E1 ezyme transfers ubiquitin to E2 enzyme&lt;br /&gt;
# E2 enzyme transfers ubiquitin to UBE3A&lt;br /&gt;
# UBE3A attaches activated ubiquitin to target protein which is then polyubiquitylated &lt;br /&gt;
# Target protein is then degraded by 26S proteosome&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Phenotype-Genotype correlations'''&lt;br /&gt;
&lt;br /&gt;
[[File:Extent of microcephaly in Angelman Syndrome patients.png|thumb|250px|right|Extent of microcephaly in 20 AS patients with deletion and without deletion.&amp;lt;ref&amp;gt;http://www.nature.com/ejhg/index.html/&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
All AS patients show differing extents of cognitive impairment, movement disorder, characteristic behaviours and difficulty in speech and language.&amp;lt;ref name=&amp;quot;PMID:11748306&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11748306&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; However, there seems to be some phenotype-genotype correlations:&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
- 5-7Mb deletions result in the most severe phenotypes such as microcephaly, more sever [[#Glossary | '''epilepsy''']] and seizures, motor difficulties and language impairment.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9546330&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20445456&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; AS patients with large deletions also present with clinical [[#Glossary | '''hypopigmentation''']], light hair and eye colour due to the close association of OCA2 gene with UBE3A.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;16470747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Individuals under this category have in general no increased BMI&amp;lt;ref name=&amp;quot;PMID:15253756&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15253756&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This is indicated by the graph on the left, which shows more cases of AS patients with deletions having larger deviations from the mean head circumference measurement than non-deletion AS patients.&lt;br /&gt;
 &lt;br /&gt;
- AS patients with uniparental disomy (UPD) have better physical growth, fewer motor deficits and lower seizure occurrences.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16023557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
- Individuals with AS resulting from imprinting defects have the least debilitating features, such as higher developmental and language ability than AS caused by other mechanisms.&amp;lt;ref name=&amp;quot;PMID:11748306&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11748306&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
- The Body Mass Index (BMI) of 33% of the UBE3A mutation patients, and 47–64% of the patients from the classes II (UPD) and III (Imprinting defect) is above the 95th centile.&amp;lt;ref name=&amp;quot;PMID:15253756&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15253756&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Animal models'''&lt;br /&gt;
&lt;br /&gt;
* '''Drosophila'''&lt;br /&gt;
&lt;br /&gt;
Drosophila (common fruit fly) is an excellent model to use for better understanding of genetic diseases in humans as they are highly homologous to human UBE3A (hUBE3A), illustrating a high evolutionary conservation. Studies using the Drosophila model have shown that the functional absence of UBE3A resulted in decreased morphogenesis of dendritic branches. This is of interest as dendritic branches cover over 90% of the neuronal surface where [[#Glossary | '''synapse''']] between neurons occur. Proper formation and maturation of dendritic spines is also required so they come in contact with other neurons for effective transmission of neuronal signals. Thus proper formation of dendritic branching is pivitol for effective neuronal function and hence cognitive function.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18996915&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Interestingly, overexpression of dUBE3A also gave the same result, consisting of abnormal locomotion  and decreased dendritic branching in sensory neurons.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18701717&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;  This suggests a possible research field for some forms of [[#Glossary | '''autism''']] where the region containing UBE3A is duplicated, leading to delayed motor skills and seizures.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16433693&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;[[File:Normal and Angelman Syndrome mice models.jpg|thumb|250px|right|Normal and AS mice performance on the Rotarod apparatus.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
* '''Mice'''&lt;br /&gt;
&lt;br /&gt;
Absence of UBE3A in mice manifest similar phenotype to human AS, as illustrated by motor and learning deficits with inducible seizures.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21235769&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It has been shown through various mice model studies that larger deletions, ie. from UBE3A to GABRB3, more closely mirrors the large 6Mb deletions seen in human AS patients. Numerous tests, such as the Rotarod (for motor coordination and learning ability), Morris water maze test (for spatial learning and memory) and [[#Glossary | '''EEG''']] (electroencephalography), were carried out on  UBE3A null mutants, which showed the results to be abnormal or impaired.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20808828&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Other studies using mouse models have also outlined the obesity observed in 15% of AS children, albeit it is not the major characterisitics of AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17259980&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The diagram on the right clearly highlights the results obtained from such mouse model studies of AS, where the absence of UBE3A accumulated in deficits of motor function and obesity. In addition, excessive drooling and feeding difficulties were also highlighted by mice models with inactivated UBE3A, reflected by defects in fluid consumption and licking.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18413322&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Pathophysiology===&lt;br /&gt;
&lt;br /&gt;
'''Cognitive defects'''&lt;br /&gt;
&lt;br /&gt;
[[File:Role of UBE3A in dendritic spine neuronal synapses.png|thumb|250px|right|Role of UBE3A in dendritic spine neuronal synapses.]]&lt;br /&gt;
&lt;br /&gt;
AS patients present with abnormally high UBE3A, leading to neurological impairment. Recent identification of key target proteins of Ephexin-58 (Eph-5) and Arc (Activity-Regulated Cytoskeleton-associated protein) have aided in better understanding of the progression of UBE3A to cognitive defects. These two proteins are vital in the understanding of AS as Eph-5 determines synapse numbers and Arc contributes to plasticity and synapse function.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21164477&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Studies utilizing mice models have illustrated that UBE3A null mice could not ubiquitinate Eph-5, thus increasing its levels and limiting the growth of dendritic spines by the activation of RhoA. This subsequent activation of RhoA inhibits synapse formation and results in neuronal defects.&lt;br /&gt;
&lt;br /&gt;
In contrast, mice with normally functioning UBE3A showed phosphorylated Eph-5, resulting from the interaction of two neurons via the activation of EphB signalling receptor.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21029865&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Phosphorylation of Eph-5 allows UBE3A to ubiquitinate and degrade it. This degradation of Eph-5 permits new synaptic connections to form with cells they come into contact with. However, in AS, the absence of UBE3A means Eph-5 cannot be degraded, so RhoA activity is prolonged to reduce synaptic formation.&lt;br /&gt;
&lt;br /&gt;
As mentioned previously, Arc plays a pivitol role in synapse function as it removes synaptic receptors that respond to glutamate, a [[#Glossary | '''neurotransmitter''']].&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17088211&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In UBE3A present neurons, UBE3A ubiquitinates Arc, leading to it degradation as illustrated by the diagram on the left. However, in UBE3A deficient neurons, Arc accumulates and prevents the proper synaptic communications essential for normal cognitive functions.&amp;lt;ref name=&amp;quot;PMID20211139&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Signs and Symptoms==&lt;br /&gt;
&lt;br /&gt;
Angelman Syndrome presents a variety of different phenotypes, and the presented symptoms may vary at different ages.&amp;lt;ref name=&amp;quot;PMID7625442&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7625442&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
In 1995 Williams et al. embraced the observed clinical features of AS in a consensus statement, in order to present an appliance for clinicians. The diagnostic criteria were updated in 2005.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt; The following table shows the most frequently occurring characteristics in AS patients:&lt;br /&gt;
&lt;br /&gt;
'''4 characteristics appear in 100% of the cases:'''&lt;br /&gt;
&lt;br /&gt;
*Delayed development: become apparent by the age of 6 to 12 months.&lt;br /&gt;
*Motion and or balance malfunction&lt;br /&gt;
*Behaviour patterns like unmotivated laughter, frequent excitement; often including body movements,[[File:Electroencephalography of Angelman Syndrome.jpg|thumb|350px|right|EEG of AS and normal individuals.]] [[#Glossary | '''hypermotoric''']] behaviour&lt;br /&gt;
*Impairment of speech&lt;br /&gt;
&lt;br /&gt;
'''3 characteristics appear in more than 80% of the cases:'''&lt;br /&gt;
&lt;br /&gt;
*Abnormalities in head circumference, microcephaly&lt;br /&gt;
*Seizures&lt;br /&gt;
*EEG shows specific abnormal patterns&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Angelman Syndrome individuals show the most distinct disease pattern from 2 to 16 years of age.&lt;br /&gt;
In most cases at least 8 of the symptom traits are shown.&amp;lt;ref name=&amp;quot;PMID7625442&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Behavioural Characteristics'''&lt;br /&gt;
&lt;br /&gt;
A range of substantial characteristics appear in all AS cases, regardless of the genetic mechanisms, and are often responsible for diagnosing the syndrome. According to the original name, Happy Puppet syndrome, they have shown to exhibit traits such as a happy demeanor, with frequent laughter or smiling that can easily be triggered.&amp;lt;ref name=&amp;quot;PMID12566516&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12566516&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This behaviour can already be observed in 1 to 3 month old infants.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot; /&amp;gt; Uplifted hand flapping or waving motions are associated with laughter and excitement. Other characteristics manifesting in early childhood are sleep abnormalities with reduced sleep demand, and feeding problems. Breast and bottle feeding can be difficult due to non efficient attachment to the breast, tongue thrusting and uncoordinated sucking. Furthermore, there is an affection to crinkly and reflective surfaces, like some papers or plastic materials, especially water.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID12566516 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Communication Skills'''&lt;br /&gt;
&lt;br /&gt;
Communication is challenging for AS patients due to the fact that speech impairment is present in all cases. In the majority of affected people a lack of speech development is present. Only some of them have a minimal vocabulary consisting of two or three words, a few can speak in basic sentences. Some patients use gestures to articulate themselves, the [[#Glossary | '''Picture Exchange Communication System (PECS)''']] or sign languages such as [[#Glossary | '''Makaton''']] can be used for communication. Simple demands regarding their everyday occurrence can be understood by most patients.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID12566516 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Clinical and External Characteristics'''[[File:Angelman Syndrome patient.png|thumb|200px|right|4 year old AS patient.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Developmental delays are present in all patients. Motor milestones are delayed with children managing to sit unsupported with 12 months and crawl or bottom shuffle at the age of 18-24 months. The average age for walking is 4 years,however, ranging from 18 months to 7 years.&lt;br /&gt;
The [[#Glossary | '''gait''']] is characterised as slow, and flapping hands are a common trait.  The legs remain stiff during walking, arms are inflected by the wrists and elbows. The movements can appear ataxic, jerky or lurching. The muscle tone shows abnormalities with truncal [[#Glossary | '''hypotonia''']] and [[#Glossary | '''hypertonicity''']] of the limbs and alert reflexes.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID12566516 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The most striking external traits present in patients include broad-spaced teeth, and a wide mouth, light hair and eye colour, hypopigmented skin, deep set eyes, and a flat [[#Glossary | '''occiput''']].&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Seizures in Angelman Syndrome'''&lt;br /&gt;
&lt;br /&gt;
85% of AS patients suffer from epileptic seizures during their first three years. The first appearance can be within one month up to 20 year old patients. In infants with AS epilepsy manifests with [[#Glossary | '''febrile convulsions''']] and is hard to manage during childhood.&lt;br /&gt;
The most common type of seizures within 25% of patients are [[#Glossary | '''myoclonic seizures''']], followed by [[#Glossary | '''atonic seizures''']] as the second most frequent type, then 21% experience generalised [[#Glossary | '''tonic-clonic seizures''']] and lastly [[#Glossary | '''atypical absences''']] occur in 12% of patients.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20398390&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Angelman Syndrome in adults'''&lt;br /&gt;
&lt;br /&gt;
Patients with Angelman syndrome possess normal secondary sexual characteristics, and puberty sets in at a usual time. Limb hypertonicity, and [[#Glossary | '''thoracic scoliosis''']] lead to decreasing mobility. [[#Glossary | '''Oesophagus reflux''']] might induce severe problems, and the majority suffers from obesity. Furthermore, facial traits such as a prominent lower lip [[#Glossary | '''macrostomia''']] and [[#Glossary | '''mandibular prognathism''']] get manifested in adults. &lt;br /&gt;
In some cases the communication barrier can lead to frustration, resulting in aggressive behaviour. Nonetheless, patients gain a higher concentration span with age, and their nature becomes more quiet.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Complications===&lt;br /&gt;
&lt;br /&gt;
'''Hypopigmentation and Ocular albinism'''&lt;br /&gt;
&lt;br /&gt;
OCA2 gene, also known as the P gene, is closely located to the UBE3A gene. It encodes a protein vital to tyrosine metabolism, which plays a role in pigmentation development of skin, hair and eyes. However, AS caused by the large deletion of UBE3A leads to haploinsufficiency of OCA2 gene, resulting in hypopigmentation of the skin and the eyes. In some children with severe hypopigmentation, some form of [[#Glossary | '''albinism''']] is suspected.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12749060&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; When AS is caused by another mechanism, no abnormality of the skin and eye pigmentation is observed. However, not all AS children with OCA2 gene deletion will present with obvious hypopigmentation, they may just exhibit lighter skin colour than their parents.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8302318&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Diagnosis==&lt;br /&gt;
&lt;br /&gt;
The diagnosis of Angelman Syndrome is a clinical diagnosis confirmed by laboratory testing.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This involves both prenatal and/or postnatal diagnosis. &lt;br /&gt;
&lt;br /&gt;
===Prenatal Diagnosis===&lt;br /&gt;
[[File:Angelman Syndrome Prenatal Diagnosis.jpg|thumb|250px|right|Flowchart of AS Diagnosis.]]&lt;br /&gt;
&lt;br /&gt;
Prenatal detection of deletions of 15q11.2-q13, [[#Glossary | '''Paternal UPD''']] ([[#Glossary | '''Uniparental Disomy''']]), Imprinting defects and UBE3A mutations are done through DNA/chromosome/FISH analysis of fetal cells obtained by either [[#Glossary | '''Chorionic Villus Sampling''']](CVS) or [[#Glossary | '''Amniocentesis''']].&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot;/&amp;gt; &lt;br /&gt;
DNA methylation analysis using [[#Glossary | '''Amniocytes''']] is usually the first test carried out in molecular diagnosis of AS.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18059071&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; An abnormal result is followed up by either a FISH or array CGH analysis to search for a deletion on chromosome 15. If they produce a normal result, then UPD testing using DNA polymorphysims is carried out. If there is no evidence of UPD, other DNA analysis tests are used search for an imprinting centre deletion.&amp;lt;ref name=&amp;quot;PMID9792887&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9792887&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; A normal DNA methylation analysis is followed by a UBE3A sequence analysis.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt; In addition, a parent of origin test is also done to determine if the genetic disruption is of maternal origin or paternal origin. If it is maternally derived the fetus is diagnosed with AS (a paternally derived genetic disruption is indicative of Prader-Willi Syndrome).&amp;lt;ref name=&amp;quot;PMID17020468&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;17020468&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The flow chart summarizes the normal procedure used for prenatal diagnosis of AS. More information on important laboratory tests used for the diagnosis of Angelman Syndrome are provided below:&lt;br /&gt;
&lt;br /&gt;
*'''DNA Methylation Analysis'''&lt;br /&gt;
&lt;br /&gt;
Identifies approximately 80% of AS affected individuals and is usually the first test to be ordered.&amp;lt;ref name=&amp;quot;PMID7618904&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7618904&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Molecular disruptions such as deletions, paternal UPD and imprinting defects on chromosome 15 all demonstrate abnormal methylation patterns by either southern blot analysis or PCR amplification of bisulphate-treated DNA.&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot; /&amp;gt; An affected individual will only have an unmethylated (paternal) SNRPN (small nuclear ribonuclear protein-associated polypeptide N) allele compared with an unaffected individual who will have both a methylated and an unmethylated SNRPN allele.&amp;lt;ref name=&amp;quot;PMID9634532&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9634532&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
	  &lt;br /&gt;
*'''FISH (Fluorescent In Situ Hybridization)'''&lt;br /&gt;
&lt;br /&gt;
[[File:Critical_region_of_Angelman_Syndrome_on_chromosome_15.png‎|thumb|150px|right|FISH (fluorescence in situ hybridisation) image showing the critical region of Angelman Syndrome on chromosome 15.]]&lt;br /&gt;
&lt;br /&gt;
FISH analysis detects 5-7 Mb deletions in approximately 68% of affected individuals using detecting probes such as D15S10 and/or SNRPN.&amp;lt;ref name=&amp;quot;PMID7618904&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7618904&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It is also able to distinguish UPD from micro-deletions and imprinting defects. In simple terms, FISH analysis involves the binding of a fluorescent probe to a specific part of chromosome 15 and the detection of deletions within that region. FISH analysis is much more accurate in deletion detection compared to other high-resolution cytogenetics in the diagnosis of AS patients.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1511093&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
Array-based CGH is an advanced type of cytogenetic testing that can also be used to detect smaller deletions.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''UPD (Uniparental Disomy) Detection'''&lt;br /&gt;
&lt;br /&gt;
DNA Polymorphism testing detects paternal UPD in approximately 7% of affected AS individuals.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt; It is also able to distinguish between UPD and an Imprinting defect. It requires a DNA sample from the [[#Glossary | '''Proband''']] and from both parents. A homologous or non-homologous whole-arm translocation of the long arms of chromosome 15 is a sound indication for the need for prenatal UPD testing.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''IC (Imprinting Center) Analysis'''&lt;br /&gt;
&lt;br /&gt;
This type of analysis is used when individuals have an abnormal DNA methylation pattern but show normal results for  FISH, array CGH study and UPD analysis.&amp;lt;ref name=&amp;quot;PMID9792887&amp;quot;/&amp;gt; It is used to differentiate between the Imprinting defects caused by either microdeletions in the AS imprinting centre or by epigenetic mutations (that occur in maternal oogenesis or early embryogenesis).&amp;lt;ref name=&amp;quot;PMID9634532&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''Cytogenetic Testing'''&lt;br /&gt;
&lt;br /&gt;
Is used to detect a cytogenetically visible chromosomal rearrangement (large deletion, translocation or inversion) involving the 15q11.2-q13 region, which occurs in less than 1% of affected individuals.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''UBE3A Sequence Analysis'''&lt;br /&gt;
Sequence analysis of the UBE3A gene detects mutations in about 10% of the patients.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt; The test is used to detect either multiexonic (10 major coding exons of UBE3A) or whole gene deletions of UBE3A gene in individuals who produces a normal DNA methylation result but has characteristic clinical features of AS.&amp;lt;ref name=&amp;quot;PMID9792887&amp;quot;/&amp;gt;&lt;br /&gt;
This is recommended as a prenatal diagnostic tool in families that include multiple AS affected individuals because the imprinted pattern can be inherited from distant relatives.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Postnatal Diagnosis===&lt;br /&gt;
&lt;br /&gt;
Postnatal diagnosis is made though a combination of common clinical features of AS and UBESA gene sequence analysis.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt; The clinical features of AS include unsteady or shaky movements, muscle hypotonia, developmental delay and behavioral uniqueness such as frequent laughter/smiling and happy demeanor are features that are 100% consistent in all patients diagnosed with Angelman Syndrome.&amp;lt;ref name=&amp;quot;PMID18830393&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18830393&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; These clinical features become apparent between 6 months to 2 years of age. The onset of early or persistent smiling characteristic of this syndrome begin around the age of 1-3 months, but is often overlooked during infancy.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot;/&amp;gt; Thus early diagnosis of AS during infancy period is difficult because the clinical indicators of the syndrome takes time to manifest and characteristic features such as finger and hand tremors and excessive smiling/laughter are often overlooked and not considered as possible indicators of this syndrome.&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
*Rett Syndrome&lt;br /&gt;
&lt;br /&gt;
Some children with the clinical diagnosis of AS but no underlying genetic mechanism show mutations in ''MECP2'' gene, corresponding to Rett Syndrome. This should be suspected in AS test negative girls in the first few years of life.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17980307&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*Mowat-Wilson Syndrome&lt;br /&gt;
&lt;br /&gt;
Genetic mechanism is heterozygous deletion or truncation in ''ZFHX1B'' (''SIP1'') gene on 2q22. This presents with clinical features of severe intellectual disability, micrcephaly and seizures.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17958891&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Prader-Willi Syndrome patient.png|thumb|right|120px|12 year old PWS patient.]]&lt;br /&gt;
&lt;br /&gt;
*X-linked alpha-thalassemia/mental retardation syndrome (ATR-X)&lt;br /&gt;
&lt;br /&gt;
This arises from mutations in ''XNP'' gene on Xq13. ATR-X presents with severe intellectual disability, no speech development and seizures are common.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11449489&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*Phelan-McDermid Syndrome/22q13 deletion syndrome&lt;br /&gt;
&lt;br /&gt;
Deletions are usually submicroscopic and thus requires special molecular cytogenetic methods to confirm this deletion. Patients show moderate to profound intellectual disability and delay in speech development.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18505557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Related Disease'''&lt;br /&gt;
&lt;br /&gt;
*Prader-Willi Syndrome(PWS)&lt;br /&gt;
&lt;br /&gt;
PWS is a result from the absence of paternally expressed 15q11-q13 gene as a corollary of de novo deletion, maternal uniparental disomy of chromosome 15 or an imprinting defect on paternal chromosome 15 leading to the silencing of paternal alleles.&amp;lt;ref name=&amp;quot;PMID:20668179 &amp;quot;/&amp;gt; It is characterized by [[#Glossary | '''hyperphagia''']], obesity in later infancy and early childhood and difficulty in feeding during early infancy.&amp;lt;ref name=&amp;quot;PMID:20668179 &amp;quot;/&amp;gt; There is also cognitive impairment to some extent, though some PWS patients may exhibit intelligence in the normal IQ range. Behavioral phenotypes include stubbornness, manipulative tendency, obsessive compulsive characteristics.&amp;lt;ref name=&amp;quot;PMID:20668179 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Genetic Counselling==&lt;br /&gt;
&lt;br /&gt;
Genetic counselling is the process by which patients or relatives, at risk of an inherited disorder, are advised of the consequences and nature of the disorder, the probability of developing or transmitting it, and the options open to them in management and family planning. In the case for Angelman syndrome, types of risks associated are split into classes and formatted into the table below:&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20459762&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{|  style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
! Class&lt;br /&gt;
! Mechanism&lt;br /&gt;
! Risk to siblings&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! Ia                           &lt;br /&gt;
| De novo deletion                                                                                                               &lt;br /&gt;
| &amp;lt;1%                                                                                                                &lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! Ib&lt;br /&gt;
| Deletion due to chromosome rearrangement&lt;br /&gt;
| Up to 50%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! II&lt;br /&gt;
| Paternal uniparental disomy (UPD)&lt;br /&gt;
| &amp;lt;1%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! IIIa&lt;br /&gt;
| Imprinting defect with IC mutation&lt;br /&gt;
| Close to 100% if father has 15; 15 [[#Glossary | '''Robertsonian translocation''']]&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! IIIb&lt;br /&gt;
| Imprinting defect without IC mutation&lt;br /&gt;
| Up to 50% (if mother has IC deletion)&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! IIIc&lt;br /&gt;
| [[#Glossary | '''Mosaic''']] imprinting defect&lt;br /&gt;
| &amp;lt;1%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! IV&lt;br /&gt;
| ''UBE3A'' mutation&lt;br /&gt;
| Up to 50% (if mother has mutation)&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! V&lt;br /&gt;
| No identifiable genetic abnormality&lt;br /&gt;
| ?&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Ia''': Individuals with de novo deletion have 1% risk to siblings&lt;br /&gt;
&lt;br /&gt;
'''Ib''': Risk to siblings in individuals with chromosomal rearrangements is up to 50% &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9557895&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''II''': Paternal UPD with no Robertsonian translocation has a risk to sibling of less than 1%&lt;br /&gt;
&lt;br /&gt;
'''IIIa''': The risk to siblings in individuals with AS from an imprinting defect with a mutation in the imprinting center (IC) is close to 100% if father has 15;15 Robertsonian translocation&lt;br /&gt;
&lt;br /&gt;
'''IIIb''': Individuals with AS resulting from an imprinting defect without IC mutation, but with a carrier mother has a high risk to siblings of up to 50%. The mother could be phenotypically normal due to paternal inheritance of the genetic defect &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11283796&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''IIIc''': Individuals who are mosaic for the imprinting defect have less than 1% risk to siblings&lt;br /&gt;
&lt;br /&gt;
'''IV''': UBE3A mutation can be either inherited or de novo mutation. If the mother is a carrier for this genetic mutation, the risk to siblings is up to 50% &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11258627&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''V''': Individuals who present with AS clinically, but have no known underlying mechanism have an unknown risk to siblings.&lt;br /&gt;
&lt;br /&gt;
==Treatment and Management==&lt;br /&gt;
&lt;br /&gt;
Even though at present there is no known cure for Angelman syndrome, there are a number of treatments available that may alleviate symptons and improve daily life activities.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The below table describes the problems and management options that are used:&lt;br /&gt;
&lt;br /&gt;
[[File:Subtle Finger tremors-Angelman Syndrome.jpg|right|thumb|150px|A five months old boy with Angelman syndrome showing signs of Subtle Finger tremor.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
! Problems encountered&lt;br /&gt;
! Treatment and Management&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''Difficulty in feeding newborn AS babies'''&lt;br /&gt;
| Use of special nipples may improve feeding&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Oesophagus reflux'''&lt;br /&gt;
| Special motility medications requiried or upright positioning&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''Seizures'''&lt;br /&gt;
| Anticonvulsant medications&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19605773&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19453717&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Ocular problems'''&lt;br /&gt;
| Visual assessment is vital to encourage interactions and minimize chances of self-harm and autism development&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20656169&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''Drooling in developmental delayed AS patients'''&lt;br /&gt;
| Difficult to treat, but new surgical procedure on salivary duct reimplantation seems to be a promising alternative&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17699119&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Unstable children''' &lt;br /&gt;
| Physical therapy&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''AS patients become less active with increasing age'''&lt;br /&gt;
| Activity schedules to prevent scoliosis and obesity. Occupational therapy to stimulate fine motor and oral-motor control skills in conjunction to speech therapy&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Sleeping difficulty'''&lt;br /&gt;
| Sedative medication in severe cases. [[#Glossary | '''Melatonin''']] may be used to promote sleeping but some studies have found that it loses its therapeutic effects after several weeks in most AS patients&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19379289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|-&lt;br /&gt;
|colspan=&amp;quot;4&amp;quot; |&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Prognosis==&lt;br /&gt;
&lt;br /&gt;
Life expectancy of AS patients seems to be normal&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, but there is still a high degree of developmental delay and limited expressive language skills.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17019625&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This problem arises prominently in the assessment of the severity of coincidental medical conditions due to difficulties in communication. A visit to the dentist can become difficult if good communication is not conveyed between the parents, the dentist, and the child.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18271768&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Some problems require extreme measures, such as the procedure of lens implantation was performed in both eyes of a person diagnosed with AS, due to the inability to wear spectacles.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20656169&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
During adulthood, menstruation and puberty begin at around average age evidenced by females with Angelman syndrome that are fully capable of conceiving children.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11258627&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Most adult patients can feed themselves, but needed help with many other daily activities. Main troubles which have shown in adults are a tendency to become obese and start developing  thoracic scoliosis, which some adults with AS begin wheelchair bounded.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9072912&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Current and Future Research==&lt;br /&gt;
&lt;br /&gt;
Currently there is no cure for the treatment of AS, so much research is being carried out for therapeutic interventions. Findings in the last five years have suggested through various mice and fruit fly models that the absence of maternal UBE3A results in the same human AS features of neurological defects and seizures. However, more recently, studies have outlined that the symptoms of AS can be improved by modifying other gene products. In addition, restoring of a functional UBE3A protein into adult mice neurons have shown to reduce motor and neurological deficits and balance disorders. This shows promising research prospects in that improvements may be possible in human AS patients by restoring functional UBE3A proteins into their neurons. &lt;br /&gt;
&lt;br /&gt;
===Possible Treatment Pathways===&lt;br /&gt;
&lt;br /&gt;
*'''Cognitive and physical impairment'''&lt;br /&gt;
&lt;br /&gt;
Although everyone is born with two copies of the gene UBE3A, one maternal and one paternal copy, it is only the maternal UBE3A that is used in the brain. Most AS patients have a genetic mutation on the maternal chromosome 15 that results in dysfunctional UBE3A.&amp;lt;ref&amp;gt;http://www.cureangelman.org/what-hope.html&amp;lt;/ref&amp;gt; The above research focused on turning on the father's copy of UBE3A to restore its functions. Furthermore, mouse models were utilized to show that alpha-CaMKII could be increased to compensate the loss of UBE3A and restore compromised mental and physical abilities. However, this finding still requires much more research.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17259980&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''Epilepsy'''&lt;br /&gt;
&lt;br /&gt;
There is research being done on improving certain conditions that are involved in AS by nutritional benefits. The use of [[#Glossary | '''corticosteroids''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19666884&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, [[#Glossary | '''valproate''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19453717&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and [[#Glossary | '''clonazepam''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19605773&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and having a [[#Glossary | '''ketogenic diet''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20880305&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; has all been shown to aid in the treatment of epilepsy. It has also been reported to be efficient in the treatment of other conditions, such as behavioural disorders, reduction in seizures, ataxia, sleep patterns, developmental progress and sleep disturbances. [[#Glossary | '''Levetiracetam''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17326790&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; could be used in such a situation, especially when the patient has an intolerance to valproate and clonazepam.&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&lt;br /&gt;
'''albinism''': A congenital disorder distincted by the complete or partial absence of pigment in the skin, hair and eyes due to defect of an enzyme involved in the production of melanin.&lt;br /&gt;
&lt;br /&gt;
'''allele''': Dissimilar variant of one gene. Organisms have two alleles for each gene inherited from their parents, one from each of them.&lt;br /&gt;
&lt;br /&gt;
'''alpha-CaMKII''': (alpha calcium calmodulin kinase II) Compound involved in synaptic plasticity, one of the most important theories behind learning and memory. Ability of a synapse between two neurons to change in strength due to the use or disuse of transmission.&lt;br /&gt;
&lt;br /&gt;
'''Amniocytes''': Cells that are shed by the fetus during fetal development to the surrounding amniotic fluid. They are a source of fetal DNA. &lt;br /&gt;
&lt;br /&gt;
'''Amniocentesis''': (AFT or amniotic fluid test) is a prenatal diagnostic test used to detect chromosomal abnormalities in the developing fetus by extracting amniotic fluid (a source of fetal DNA) surrounding the fetus. &lt;br /&gt;
&lt;br /&gt;
'''AMPA''': (2-amino-3-(5-methyl-3-oxo-1,2- oxazol-4-yl)propanoic acid) Compound that binds to the AMPA receptor to imitate glutamate neurotransmitter.&lt;br /&gt;
&lt;br /&gt;
'''Arc''': Activity-Regulated Cytoskeleton-associated protein; involved in learning and memory.&lt;br /&gt;
&lt;br /&gt;
'''ataxia''': Lack of coordination in muscle movements.&lt;br /&gt;
&lt;br /&gt;
'''atonic seizures''': A abrupt loss of muscle tone, this can lead to the limbs loosing strength, or the head may drop to the side. The patient remains conscious during this kind of epileptic seizure.&lt;br /&gt;
&lt;br /&gt;
'''atypical absences''': Seizure leads to unconsciousness in most cases.  &lt;br /&gt;
&lt;br /&gt;
'''autism''': A neural development disorder defined by limited social interaction and communication.&lt;br /&gt;
&lt;br /&gt;
'''Chorionic Villus Sampling''': A prenatal diagnostic test used to detect chromosomal abnormalities in the developing fetus by extracting and testing chorionic villus (placental tissue). &lt;br /&gt;
&lt;br /&gt;
'''chromosome''': Structure consisting of coiled DNA with DNA associated proteins such as histones.&lt;br /&gt;
&lt;br /&gt;
'''clonazepam''': A psychoactive drug having muscle relaxant properties and treats anxiety and epilepsy.&lt;br /&gt;
&lt;br /&gt;
'''corticosteroid''': A type of steroid hormones that are produced in the adrenal cortex.&lt;br /&gt;
&lt;br /&gt;
'''cytogenetics''': Study of the structure, function and abnormality of the cell, especially the chromosome.&lt;br /&gt;
&lt;br /&gt;
'''deletion''': Lack of a part of the DNA (deoxyribonucleic acid is a nucleic acid containing information for protein synthesis), can vary form a single base to a hole gene. &lt;br /&gt;
&lt;br /&gt;
'''de novo mutation''': Change in a gene of a family member for the first time due to a mutation in the egg or sperm of the parents or in the fertilized egg (zygote).&lt;br /&gt;
&lt;br /&gt;
'''disorder''': A mental or physical health disturbance or dysfunction.&lt;br /&gt;
&lt;br /&gt;
'''EEG''': Electroencephalography is a means of measuring electrical activity along the scalp by measuring the total electrical charges fired by thousands or millions of neurons.&lt;br /&gt;
&lt;br /&gt;
'''epilepsy''': Neurological disorder characterised by recurrent impairment of brain function that can cause seizures or unconsciousness. &lt;br /&gt;
&lt;br /&gt;
'''E6-AP''': E6-AP ubiquitin-protein ligase is an enzyme encoded by UBE3A which adds ubiquitin chain to target proteins to be degraded by proteasomes.&lt;br /&gt;
&lt;br /&gt;
'''febrile convulsions''': The occurrence of high fever, especially in children.&lt;br /&gt;
&lt;br /&gt;
'''FISH''': Fluorescent in situ hybridization is a technique used to identify and localize the presence or absence of DNA sequences on the chromosome. This is achieved by using fluorescently labelled DNA sequences which then binds to complementary DNA sequence on the chromosome. After hybridization (attachment), chromosome of interest will fluoresce under the microscope.&lt;br /&gt;
&lt;br /&gt;
'''gait''': A manner of walking, stepping or running.&lt;br /&gt;
&lt;br /&gt;
'''gene''': A molecular unit of heredity of a living organism.&lt;br /&gt;
&lt;br /&gt;
'''hyperphagia''': (Also referred to as Polyphagia) Excessive ingestion of food beyond the dietary and energy requirements of the body. &lt;br /&gt;
&lt;br /&gt;
'''hypermotoric''': Sudden appearance of uncontrolled movements such as striking or kicking inappropriately.&lt;br /&gt;
&lt;br /&gt;
'''hypertonicity''': Increase of muscle tension and a disability to stretch leading to an impairment of motor activity.&lt;br /&gt;
&lt;br /&gt;
'''hypopigmentation''': A lack of melanin pigments or melanocytes  affecting the colour of the skin, hair and iris. Features appear to be light-coloured due to loss of skin colour.&lt;br /&gt;
&lt;br /&gt;
'''hypotonia''': Decrease in the ability to stretch passively, due to a low muscle tone. &lt;br /&gt;
&lt;br /&gt;
'''imprinting''': This is a process to describe the modification of a maternally or paternally derived chromosome, which consequently influences the expression of certain genes on the altered chromosome.&lt;br /&gt;
&lt;br /&gt;
'''ketogenic diet''': A high-fat, low-carbohydrate diet that is used to treat epilepsy in children.&lt;br /&gt;
&lt;br /&gt;
'''levetiracetam''': An anticonvulsant drug used to treat epilepsy.&lt;br /&gt;
&lt;br /&gt;
'''locus''': Location of a gene on a chromosome(loci: plural for locus).&lt;br /&gt;
&lt;br /&gt;
'''LTP''': Long-term potentiation shares common features with long term memory. It strengthens and enhances signal transmission between neurons by improving the communication between two neurons.&lt;br /&gt;
&lt;br /&gt;
'''macrostomia''': A wide-spaced mouth.&lt;br /&gt;
&lt;br /&gt;
'''Makaton''': Language programme using symbols and signs to support speaking.&lt;br /&gt;
&lt;br /&gt;
'''mandibular prognathism''': The abnormal protrusion of the lower jaw. &lt;br /&gt;
&lt;br /&gt;
'''maxillary hypoplasia''':  The underdevelopment of the upper jaw.&lt;br /&gt;
&lt;br /&gt;
'''melatonin''': A hormone secreted by the pineal gland.&lt;br /&gt;
&lt;br /&gt;
'''microcephaly''': The circumference of the head is less than average due to abnormalities of the nervous system. This abnormality can be present at birth or emerge during the first few years of life and reduces both life expectancy and the cognitive functions of the individual affected.&lt;br /&gt;
&lt;br /&gt;
'''microdeletion''':  A genetic mutation in which a part of a chromosome or a sequence of DNA is missing.&lt;br /&gt;
&lt;br /&gt;
'''mosaic''': tissues or cells containing different mixture of genetic sequences&lt;br /&gt;
&lt;br /&gt;
'''mutation''': Event that changes the DNA (deoxyribonucleic acid is a nucleic acid, containing information for protein synthesis) or RNA (ribonucleic acid is a type of nucleic acid transmitting the information from the DNA to the proteins ) of a gene permanently.&lt;br /&gt;
&lt;br /&gt;
'''myoclonic seizures''': A quick jerk of the skeletal muscle, due to a irregular brain activity.&lt;br /&gt;
&lt;br /&gt;
'''neurogenetic''': Genetic basis of the nervous system.&lt;br /&gt;
&lt;br /&gt;
'''neurotransmitter''': Transmits neuronal signals to a target cell. They are first packaged in vesicles just beneath the membrane of presynaptic axon terminals and released into the synaptic cleft (space between the two interacting neurons) and enter the postsynaptic dendrite.&lt;br /&gt;
&lt;br /&gt;
'''occiput''': The back portion of the head.&lt;br /&gt;
&lt;br /&gt;
'''oesophagus reflux''': Impairment of a sphincter in the lower end of the oesophagus leads to the back flow of stomach acid into the oesophagus. Heartburn is a typical symptom.&lt;br /&gt;
&lt;br /&gt;
'''paediatrician''': Physicians that specialise on infants, children and adolescents.&lt;br /&gt;
&lt;br /&gt;
'''paternal UPD''': Inheritance of two copies of a chromosome from the father and none from the mother. &lt;br /&gt;
&lt;br /&gt;
'''phenotype''': Visible traites of an organism determined by genetic and environmental factors.&lt;br /&gt;
&lt;br /&gt;
'''Picture Exchange Communication System (PECS)''': Individuals communicate using images instead of words. It is frequently used by children with autism, to articulate their needs and wishes or to make comments about something.&lt;br /&gt;
&lt;br /&gt;
'''Proband''': Is the person (or animal) being studied or reported on in a genetic investigation. Most commonly it refers to the first affected family member who requires medical help for a genetic disorder. &lt;br /&gt;
&lt;br /&gt;
'''Robertsonian translocation''': Rearrangement of the chromosome, occurs in 5 chromosome including 13,14,15,21 and 22. This type of mutation occurs in chromosomes with the centromere not at the centre, resulting in long and short arm chromosomes. Translocation breaks the chromosome at the centromere so the long arm attaches to the other long arm, and the same for the short arm happens. Cell division will result in the loss of the short arms as they do not contain important genes.&lt;br /&gt;
&lt;br /&gt;
'''seizure''': Abnormal electrical activity in the brain that can result in a variety of physical symptoms like convulsion, body shaking, loss of consciousness, confusion, and mood changes.&lt;br /&gt;
&lt;br /&gt;
'''synapse''': Allows transmission of signal between neurons for effective neuronal function.&lt;br /&gt;
&lt;br /&gt;
'''thoracic scoliosis''': The spine is curved laterally(from side to side) in the thoracic region.&lt;br /&gt;
&lt;br /&gt;
'''tonic-clonic seizures''': This type of seizure is associated with unconsciousness due to electrical discharges in a big proportion of the brain.&lt;br /&gt;
&lt;br /&gt;
'''ubiquitin''': A polypeptide found in all eukaryotic cells, that participates in a variety of cellular functions including protein recycling.&lt;br /&gt;
&lt;br /&gt;
'''Uniparental disomy''': (UPD) the inheritance of two copies of a chromosome pair or part of a chromosme from one parent and no copy from the other parent. &lt;br /&gt;
&lt;br /&gt;
'''valproate''':  A mood-stabilizing drug that is also used for treatment for epilepsy and bipolar disorder.&lt;br /&gt;
&lt;br /&gt;
==Helpful Links==&lt;br /&gt;
&lt;br /&gt;
* Australia&lt;br /&gt;
:* [http://www.angelmansyndrome.org/research.html Angelman Syndrome Association] &lt;br /&gt;
:* [http://www.angelmansyndromeqld.org/ Queensland Angelman Association]&lt;br /&gt;
&lt;br /&gt;
* America&lt;br /&gt;
:* [http://www.angelman.org/ Angelman Syndrome Foundation]&lt;br /&gt;
:* [http://rarediseasesnetwork.epi.usf.edu/arpwsc/ Rare Clinical Diseases Research Network]&lt;br /&gt;
:* [http://www.rarediseases.org/rare-disease-information/rare-diseases/byID/411/viewAbstract National Organisation for Rare Disorders]&lt;br /&gt;
:* [http://www.epilepsyfoundation.org/ Epilepsy Foundation]&lt;br /&gt;
:* [http://www.cureangelman.org/ Foundation for Angelman Syndrome Therapeutics]&lt;br /&gt;
&lt;br /&gt;
* Search Pubmed &lt;br /&gt;
:* [http://www.ncbi.nlm.nih.gov/pubmed?term=angelman%20syndrome Angelman Syndrome] &lt;br /&gt;
&lt;br /&gt;
* OMIM entries for Angelman Syndrome&lt;br /&gt;
:* [http://omim.org/entry/105830 ANGELMAN SYNDROME; AS]&lt;br /&gt;
:* [http://omim.org/entry/601623 UBIQUITIN-PROTEIN LIGASE E3A; UBE3A]&lt;br /&gt;
&lt;br /&gt;
==Related Links==&lt;br /&gt;
&lt;br /&gt;
* [[Mouse Knockout]] - this page explains the current use of mouse models in disrupting genes to elucidate their genetic function, including the mouse gene knockouts for alpha calcium-calmodulin kinase II (alpha CaMKII)&lt;br /&gt;
* [[2009 Group Project 4]] - this page gives an extensive overview on the history of the mouse model and its various use in embryology and genetics. In addition, it also describes mouse knockout and the role they play in current research of various human diseases&lt;br /&gt;
* [[Fly Development]] - this page describes the use of drosophila flies as developmental models&lt;br /&gt;
* [[2009 Group Project 2]] - this page gives an extensive overview on the history of the fly model and its various use in embryology and genetics&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&lt;br /&gt;
&amp;lt;references /&amp;gt;&lt;/div&gt;</summary>
		<author><name>Z3291643</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_7&amp;diff=77572</id>
		<title>2011 Group Project 7</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_7&amp;diff=77572"/>
		<updated>2011-10-12T20:34:04Z</updated>

		<summary type="html">&lt;p&gt;Z3291643: /* Helpful Links */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;='''Angelman Syndrome'''=&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Introduction==&lt;br /&gt;
&lt;br /&gt;
[[File:Dr Harry Angelman.jpg|thumb|130px|right|Dr Harry Angelman.]]&lt;br /&gt;
Angelman syndrome (AS) is a rare [[#Glossary | '''neurogenetic''']] [[#Glossary | '''disorder''']] first described by Dr. Harry Angelman in 1965.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18754889&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Dr. Angelman was an English [[#Glossary | '''paediatrician''']] who first diagnosed the disease in 3 children with a developmental delay.&amp;lt;ref&amp;gt;http://www.ncbi.nlm.nih.gov/books/NBK22221/&amp;lt;/ref&amp;gt; AS occurs in 1 in 10000-20000 births, the exact number is still unknown.&amp;lt;ref name=&amp;quot;PMID7573182&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7573182&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;PMID8703225&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;8703225&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It is caused by maternal [[#Glossary | '''allele''']] disruptions of a single gene- UBE3A. Either [[#Glossary | '''mutations''']] or [[#Glossary | '''deletions''']] of the UBE3A gene results in AS. &lt;br /&gt;
&lt;br /&gt;
AS presents with well known [[#Glossary | '''phenotypes''']] during infancy and adulthood, such as [[#Glossary | '''microcephaly''']] and [[#Glossary | '''maxillary hypoplasia''']]. However, these features become more marked with age. Most frequent clinical features include delayed development,[[#Glossary | '''seizures''']],[[#Glossary | '''ataxia''']], impairment of speech, happy demeanor, behavioural problems such as hyperactivity, short attention span and sleeping difficulty.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21592595&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21484597&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;ASAwebsite&amp;quot;&amp;gt;http://www.angelmansyndrome.org/home.html&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
At present, there is no cure for the syndrome, though current research is focused at improving life quality of patients with Angelman syndrome through management of daily tasks.&amp;lt;ref&amp;gt;http://www.bbc.co.uk/health/physical_health/conditions/angelman1.shtml&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==History==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Dr. Harry Angelman first reported Angelman Syndrome on three handicapped children that were admitted to his ward in England in 1964.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt; He reported how these three independent and unconnected clinical cases all had the same characteristic features of severe developmental delay, jerky movements, seizures and a happy disposition.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt; However it was only when he stumbled upon an oil painting called ‘a Boy with a Puppet” while on a holiday in Italy he was able to connect the symptoms of all three children under one common cause.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20981772&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; He linked the happy face of the boy depicted on the painting with the jerky movements and happy disposition he observed on his three patients back in England. He reported his findings on a paper entitled “Puppet children (a report on three cases)” which was published in 1965.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
The syndrome was initially named ‘Puppet Syndrome’ but was later changed to Angelman Syndrome. Due to the extreme rarity of the syndrome and lack of sufficient clinical evidence the syndrome was soon forgotten.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt;&lt;br /&gt;
[[File:Dr Charles Williams.jpg|thumb|right|150px|Dr Charles Williams.]]&lt;br /&gt;
	&lt;br /&gt;
In 1987, a physician named Ellen Magenis, came across children with deletions on [[#Glossary | '''chromosome''']] 15 that were suffering from seizures and severe developmental delay.&amp;lt;ref&amp;gt;http://www.angelman.org/stay-informed/facts-about-angelman-syndrome---7th-edition/harry-angelman-and-the-history-of-as/&amp;lt;/ref&amp;gt; Even though genetically the children were expected to have [[#Diagnosis | '''Prader-Willi syndrome''']] that was characterised by deletions on chromosome 15, their characteristic symptoms of seizures and lack of development did not correspond with that of the syndrome. This led to the realization that these children had deletions on the maternally derived chromosome 15 and not on the paternally derived chromosome as was observed in Prader-Willi syndrome.  Thus the deleted genetic code on maternally derived chromosome 15 was identified as the genetic marker for Angelman Syndrome.&lt;br /&gt;
&lt;br /&gt;
In 1997, UBE3A gene was isolated by Dr. Joseph Wagstaff and Dr. Arthur Beaudet as the cause of Angelman Syndrome.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot; /&amp;gt; The discovery of this [[#Glossary | '''gene''']] led to the subsequent development of animal models and research aimed at finding a causal link between UBE3A gene abnormalities and characteristic features observed in Angelman Syndrome. &lt;br /&gt;
	&lt;br /&gt;
Currently, four different genetic abnormalities for Angelman Syndrome have been confirmed by genetic testing. They include: Deletion, [[#Glossary | '''Uniparental Disomy''']] (UPD), [[#Glossary | '''Imprinting''']] and UBE3A mutation.&amp;lt;ref name=&amp;quot;PMID20211139&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Below is a timeline, summarising the key discoveries and advancements of the Angelman Syndrome:&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|- bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
!Year&lt;br /&gt;
!Milestone&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1964'''&lt;br /&gt;
|First observed by Dr Harry Angelman on three handicapped children.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot; /&amp;gt; &lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''1965'''&lt;br /&gt;
|Harry Angelman publishes his finding in a report entitled 'Puppet Children'(a report on three cases).&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1980s'''&lt;br /&gt;
|First reports of AS reaches US and research into the disorder being at the University of Florida under the direction of Dr. Charles Williams.&amp;lt;ref&amp;gt;http://www.angelmanproject.com/history.htm&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''1982'''&lt;br /&gt;
|Name changed from 'Happy Puppet' to Angelman syndrome by Williams and Frias. &lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1987'''&lt;br /&gt;
|Discovery of a genetic marker for AS – an absent genetic code on maternally derived chromosome 15. &lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''1997'''&lt;br /&gt;
|The cause of AS discovered by Dr. Joseph Wagstaff and Dr. Arthur Beaudet – mutation or deletion in the UBE3A gene.&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1998'''&lt;br /&gt;
|Transgenic mice with absent maternal UBE3A created to illustrate motor and learning deficits in addition to seizures.&amp;lt;ref name=&amp;quot;PMID9808466&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9808466&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''2007'''&lt;br /&gt;
|AS mouse model shows that neurological deficits can be reversed by decreasing levels of [[#Glossary | '''alpha-CaMKII''']] inhibitory phosphorylation.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17259980&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''2010'''&lt;br /&gt;
|Discovery of a another gene mutation in TC4 gene (on chromosome 18) in a small number of clinically diagnosed patients with no identifiable genetic alternation in UBE3A.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20184619&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''2010'''&lt;br /&gt;
|Protein named Arc identified as a target of AS gene product; UBE3A.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Incidence'''&lt;br /&gt;
*The current population of people diagnosed with AS is unknown but studies have estimated the number to be around 1:10,000&amp;lt;ref name=&amp;quot;PMID7573182&amp;quot; /&amp;gt; and 1:20,000&amp;lt;ref name=&amp;quot;PMID8703225&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
'''Diagnosis'''&lt;br /&gt;
*The mean age of diagnosis for patients with AS lies between 6 and 6.5 years of age.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18664077&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15741136&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Gender'''&lt;br /&gt;
* Males appear to be at higher risk for some aspects of early developmental delays in comparison to females with AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17019625&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Demography'''&lt;br /&gt;
*Europe:&lt;br /&gt;
:Denmark- 1:10,000&amp;lt;ref name=&amp;quot;PMID7573182&amp;quot; /&amp;gt;&lt;br /&gt;
:Estonia- 1:52,000&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16906556&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
:Sweden- 1:20,000&amp;lt;ref name=&amp;quot;PMID8703225&amp;quot; /&amp;gt;&lt;br /&gt;
*Australia:&lt;br /&gt;
:Western Australia- 1:40,000&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16492624&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Aetiology==&lt;br /&gt;
&lt;br /&gt;
[[File:Chromosome 15 Deletion of 15q11.2 to 15q13.jpg|thumb|100px|Chromosome 15 - The deletion occurs at 15q11.2-15q13.]]&lt;br /&gt;
&lt;br /&gt;
Different genetic mechanisms lead to different clinical phenotypes of AS. The most common genetic mechanism leading to AS is the deletion or re-arrangement of maternal chromosome at [[#Glossary | '''locus''']] 15q11.2-q13,as the chromosome image shows on the right, accounting for 70% of AS occurrences.&amp;lt;ref name=&amp;quot;PMID8988171&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt; 8988171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This leads to more severe clinical phenotypes of microcephaly, motor difficulties, seizures and impaired speech development. The next most common genetic mechanism is mutation in the ''UBE3A'' gene responsible for 10% of AS cases and paternal uniparental disomy and mutation in the imprinting centre (IC), both accounting for 2-5% of AS observed.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
 &lt;br /&gt;
&lt;br /&gt;
AS is caused by the 4 major genetic mechanisms mentioned above and are thus divided into Classes I to IV based on their underlying genetic mechanism. AS patients with the clinical features of AS but no [[#Glossary | '''cytogenetic''']] or molecular abnormality in Chromosome 15q11.2-13 are grouped under Class V (summarised in table below).&amp;lt;ref name=&amp;quot;PMID8988171&amp;quot; /&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10364509&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''Inheritance'''&lt;br /&gt;
&lt;br /&gt;
Angelman Syndrome from UBE3A mutations and deletions in the Imprinting Centre follow an inheritance pattern. A carrier father with the genetic defect can pass it on to his children, however, his children will be clinically normal. On the other hand, a carrier mother can pass the genetic defect onto her children, who will then have Angelman Syndrome. &lt;br /&gt;
&lt;br /&gt;
The image highlights the inheritance of Angelman Syndrome, which only results after a carrier mother passes it on to her children. &lt;br /&gt;
&lt;br /&gt;
{|  style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
! Class&lt;br /&gt;
! Mechanism&lt;br /&gt;
! Diagnostic Tests&lt;br /&gt;
! Frequency&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''Ia'''                           &lt;br /&gt;
| De novo deletion                                                                                           &lt;br /&gt;
| High resolution cytogenetics [[#Glossary | '''FISH''']]                                                                                                       &lt;br /&gt;
| 70%      &lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Ib'''&lt;br /&gt;
| Deletion due to chromosome rearrangement&lt;br /&gt;
| High resolution cytogenetics FISH&lt;br /&gt;
| &amp;lt;1%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''II'''&lt;br /&gt;
| Paternal uniparental disomy&lt;br /&gt;
| [[#Glossary | '''RFLP''']]  analysis&lt;br /&gt;
| 2%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''IIIa'''&lt;br /&gt;
| Imprinting defect with IC mutation&lt;br /&gt;
| Screening of [[#Glossary | '''IC''']]  for mutations is positive&lt;br /&gt;
| 2%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''IIIb'''&lt;br /&gt;
| Imprinting defect withouth IC mutation&lt;br /&gt;
| Screening of IC for mutations is negative&lt;br /&gt;
| 2%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''IIIc'''&lt;br /&gt;
| Mosaic imprinting defect&lt;br /&gt;
| Screening of IC for mutations is usually negative &lt;br /&gt;
| ?&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''IV'''&lt;br /&gt;
| ''UBE3A'' mutation&lt;br /&gt;
| Screening of ''UBE3A'' for mutations&lt;br /&gt;
| 5-10%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''V'''&lt;br /&gt;
| No identifiable genetic abnormality&lt;br /&gt;
| Consider other diagnoses&lt;br /&gt;
| 5-26%&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Pathogenesis==&lt;br /&gt;
&lt;br /&gt;
Chromosome 15 became associated with AS in the 1980s after the observation of many AS patients harboring [[#Glossary | '''microdeletions''']] of 15q11.2-15q13.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15668046&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The last decade has shed even more light in the aetiology of AS,as Kishino and Matsuura first identified UBE3A as the causative gene for AS in 1997.&amp;lt;ref name=&amp;quot;PMID:8988171&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;8988171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8988172&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Normal gene product: E6-AP ubiquitin ligase'''&lt;br /&gt;
&lt;br /&gt;
The function of UBE3A is to encode for [[#Glossary | '''E6-AP''']] ubiquitin ligase, however its function in the development of the nervous system and the process of UBE3A mutation leading to cognitive impairment in AS patients is still vague.&amp;lt;ref name=&amp;quot;PMID:20211139&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Past and current research has elucidated that E6-AP ubiquitin ligase is involved in the degradation of four proteins, listed below, but currently, no protein with a direct role in [[#Glossary | '''long-term potentiation (LTP)''']] as a target of E6-AP, has been identified.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12684449&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The identification of such target proteins would be a landmark discovery in further understanding of the pathogenesis, aetiology and prospective treatment strategies of AS, as LTP defects is one of the major neurological impairments of AS. &lt;br /&gt;
 &lt;br /&gt;
* p53 tumor suppressor protein &lt;br /&gt;
* yeast DNA repair protein Rad23 &lt;br /&gt;
* multicopy maintenance protein 7 subunit &lt;br /&gt;
* E6-AP&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Abnormal gene product'''&lt;br /&gt;
&lt;br /&gt;
Disruption to the gene,UBE3A, interferes with the normal functioning of the gene, which is its crucial role in UBE3A [[#Glossary | '''ubiquitylation''']]. Problems involving this pathway can lead to various diseases either from the loss or gain of function.&amp;lt;ref name=&amp;quot;PMID:9857172&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9857172&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In the case of AS, E6-AP is affected, leading to detrimental cognitive impairment in addition to other deficits.&amp;lt;ref name=&amp;quot;PMID:9857172&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9857172&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Regional functioning of UBE3A'''&lt;br /&gt;
&lt;br /&gt;
Despite the uncertain progression of UBE3A mutation and the neurological abnormalities characteristic of AS, animal models have illustrated the vital role of UBE3A in the normal functioning of the brain. This can be exemplified by a study which utilized a mouse model with target inactivation of the gene UBE3A resulting in the manifestation of classical features of AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11895368&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In addition, the fact that imprinting of UBE3A takes place only in specific brain regions (cerebellum, olfactory tracts and the hippocampus) confirms the hypothesis that the loss of this gene would be detrimental in the cognitive development.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20398390&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Most genes are inherited in copies of two, one paternal and the other maternal; however, some genes, such as UBE3A only have one functional copy as the other is silenced, coined 'imprinting'. Imprinting of the paternal copy of UBE3A takes place in some cell populations, such as the hippocampal neurons and Purkinje cells in the cerebellum.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9288101&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This means only the maternal UBE3A is functionally expressed in these particular brain regions. Thus a [[#Glossary | '''de novo mutation''']] in the maternal copy of the gene will result in the complete absence of functional E6-AP in the associated brain areas.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9288088&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
It is also known that UBE3A plays an important role in synaptic transmission, but exactly how it does so is still not completely understood.&amp;lt;ref name=&amp;quot;PMID:9808466&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9808466&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''UBE3A ubiquitylation'''&lt;br /&gt;
&lt;br /&gt;
As briefly mentioned above, UBE3A is a member of the E3 ubiquitin ligase family of enzymes, responsible for the addition of ubiquitin to the target protein for degradation of the ubiquitinated protein, as illustrated in the diagram below. These processes are required for normal human cognitive function.&amp;lt;ref name=&amp;quot;PMID:9808466&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9808466&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In this way synaptic protein [[#Glossary | '''Arc (activity-regulated cytoskeleton-associated protein)''']] is degraded to control synaptic function. Arc is a target protein of UBE3A in dendritic spines found in the hippocampal neurons.&amp;lt;ref name=&amp;quot;PMID:20668179&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20668179&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Deletion of UBE3A leads to the accumulation of Arc in neurons leading to trafficking of [[#Glossary | '''AMPA ( α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid)''']] receptors, resulting in impaired cognitive functions.&amp;lt;ref name=&amp;quot;PMID:20211139&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; [[File:UBE3A Ubiquitylation Pathway.png|thumb|350px|right|UBE3A Ubiquitylation Pathway.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
UBE3A ubiquitylation consists of:&amp;lt;ref name=&amp;quot;PMID:20668179&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20668179&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
# Activation of ubiquitin by E1 enzyme&lt;br /&gt;
# E1 ezyme transfers ubiquitin to E2 enzyme&lt;br /&gt;
# E2 enzyme transfers ubiquitin to UBE3A&lt;br /&gt;
# UBE3A attaches activated ubiquitin to target protein which is then polyubiquitylated &lt;br /&gt;
# Target protein is then degraded by 26S proteosome&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Phenotype-Genotype correlations'''&lt;br /&gt;
&lt;br /&gt;
[[File:Extent of microcephaly in Angelman Syndrome patients.png|thumb|250px|right|Extent of microcephaly in 20 AS patients with deletion and without deletion.&amp;lt;ref&amp;gt;http://www.nature.com/ejhg/index.html/&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
All AS patients show differing extents of cognitive impairment, movement disorder, characteristic behaviours and difficulty in speech and language.&amp;lt;ref name=&amp;quot;PMID:11748306&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11748306&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; However, there seems to be some phenotype-genotype correlations:&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
- 5-7Mb deletions result in the most severe phenotypes such as microcephaly, more sever [[#Glossary | '''epilepsy''']] and seizures, motor difficulties and language impairment.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9546330&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20445456&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; AS patients with large deletions also present with clinical [[#Glossary | '''hypopigmentation''']], light hair and eye colour due to the close association of OCA2 gene with UBE3A.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;16470747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Individuals under this category have in general no increased BMI&amp;lt;ref name=&amp;quot;PMID:15253756&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15253756&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This is indicated by the graph on the left, which shows more cases of AS patients with deletions having larger deviations from the mean head circumference measurement than non-deletion AS patients.&lt;br /&gt;
 &lt;br /&gt;
- AS patients with uniparental disomy (UPD) have better physical growth, fewer motor deficits and lower seizure occurrences.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16023557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
- Individuals with AS resulting from imprinting defects have the least debilitating features, such as higher developmental and language ability than AS caused by other mechanisms.&amp;lt;ref name=&amp;quot;PMID:11748306&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11748306&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
- The Body Mass Index (BMI) of 33% of the UBE3A mutation patients, and 47–64% of the patients from the classes II (UPD) and III (Imprinting defect) is above the 95th centile.&amp;lt;ref name=&amp;quot;PMID:15253756&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15253756&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Animal models'''&lt;br /&gt;
&lt;br /&gt;
* '''Drosophila'''&lt;br /&gt;
&lt;br /&gt;
Drosophila (common fruit fly) is an excellent model to use for better understanding of genetic diseases in humans as they are highly homologous to human UBE3A (hUBE3A), illustrating a high evolutionary conservation. Studies using the Drosophila model have shown that the functional absence of UBE3A resulted in decreased morphogenesis of dendritic branches. This is of interest as dendritic branches cover over 90% of the neuronal surface where [[#Glossary | '''synapse''']] between neurons occur. Proper formation and maturation of dendritic spines is also required so they come in contact with other neurons for effective transmission of neuronal signals. Thus proper formation of dendritic branching is pivitol for effective neuronal function and hence cognitive function.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18996915&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Interestingly, overexpression of dUBE3A also gave the same result, consisting of abnormal locomotion  and decreased dendritic branching in sensory neurons.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18701717&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;  This suggests a possible research field for some forms of [[#Glossary | '''autism''']] where the region containing UBE3A is duplicated, leading to delayed motor skills and seizures.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16433693&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;[[File:Normal and Angelman Syndrome mice models.jpg|thumb|250px|right|Normal and AS mice performance on the Rotarod apparatus.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
* '''Mice'''&lt;br /&gt;
&lt;br /&gt;
Absence of UBE3A in mice manifest similar phenotype to human AS, as illustrated by motor and learning deficits with inducible seizures.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21235769&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It has been shown through various mice model studies that larger deletions, ie. from UBE3A to GABRB3, more closely mirrors the large 6Mb deletions seen in human AS patients. Numerous tests, such as the Rotarod (for motor coordination and learning ability), Morris water maze test (for spatial learning and memory) and [[#Glossary | '''EEG''']] (electroencephalography), were carried out on  UBE3A null mutants, which showed the results to be abnormal or impaired.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20808828&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Other studies using mouse models have also outlined the obesity observed in 15% of AS children, albeit it is not the major characterisitics of AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17259980&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The diagram on the right clearly highlights the results obtained from such mouse model studies of AS, where the absence of UBE3A accumulated in deficits of motor function and obesity. In addition, excessive drooling and feeding difficulties were also highlighted by mice models with inactivated UBE3A, reflected by defects in fluid consumption and licking.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18413322&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Pathophysiology===&lt;br /&gt;
&lt;br /&gt;
'''Cognitive defects'''&lt;br /&gt;
&lt;br /&gt;
[[File:Role of UBE3A in dendritic spine neuronal synapses.png|thumb|250px|right|Role of UBE3A in dendritic spine neuronal synapses.]]&lt;br /&gt;
&lt;br /&gt;
AS patients present with abnormally high UBE3A, leading to neurological impairment. Recent identification of key target proteins of Ephexin-58 (Eph-5) and Arc (Activity-Regulated Cytoskeleton-associated protein) have aided in better understanding of the progression of UBE3A to cognitive defects. These two proteins are vital in the understanding of AS as Eph-5 determines synapse numbers and Arc contributes to plasticity and synapse function.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21164477&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Studies utilizing mice models have illustrated that UBE3A null mice could not ubiquitinate Eph-5, thus increasing its levels and limiting the growth of dendritic spines by the activation of RhoA. This subsequent activation of RhoA inhibits synapse formation and results in neuronal defects.&lt;br /&gt;
&lt;br /&gt;
In contrast, mice with normally functioning UBE3A showed phosphorylated Eph-5, resulting from the interaction of two neurons via the activation of EphB signalling receptor.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21029865&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Phosphorylation of Eph-5 allows UBE3A to ubiquitinate and degrade it. This degradation of Eph-5 permits new synaptic connections to form with cells they come into contact with. However, in AS, the absence of UBE3A means Eph-5 cannot be degraded, so RhoA activity is prolonged to reduce synaptic formation.&lt;br /&gt;
&lt;br /&gt;
As mentioned previously, Arc plays a pivitol role in synapse function as it removes synaptic receptors that respond to glutamate, a [[#Glossary | '''neurotransmitter''']].&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17088211&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In UBE3A present neurons, UBE3A ubiquitinates Arc, leading to it degradation as illustrated by the diagram on the left. However, in UBE3A deficient neurons, Arc accumulates and prevents the proper synaptic communications essential for normal cognitive functions.&amp;lt;ref name=&amp;quot;PMID20211139&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Signs and Symptoms==&lt;br /&gt;
&lt;br /&gt;
Angelman Syndrome presents a variety of different phenotypes, and the presented symptoms may vary at different ages.&amp;lt;ref name=&amp;quot;PMID7625442&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7625442&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
In 1995 Williams et al. embraced the observed clinical features of AS in a consensus statement, in order to present an appliance for clinicians. The diagnostic criteria were updated in 2005.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt; The following table shows the most frequently occurring characteristics in AS patients:&lt;br /&gt;
&lt;br /&gt;
'''4 characteristics appear in 100% of the cases:'''&lt;br /&gt;
&lt;br /&gt;
*Delayed development: become apparent by the age of 6 to 12 months.&lt;br /&gt;
*Motion and or balance malfunction&lt;br /&gt;
*Behaviour patterns like unmotivated laughter, frequent excitement; often including body movements,[[File:Electroencephalography of Angelman Syndrome.jpg|thumb|350px|right|EEG of AS and normal individuals.]] [[#Glossary | '''hypermotoric''']] behaviour&lt;br /&gt;
*Impairment of speech&lt;br /&gt;
&lt;br /&gt;
'''3 characteristics appear in more than 80% of the cases:'''&lt;br /&gt;
&lt;br /&gt;
*Abnormalities in head circumference, microcephaly&lt;br /&gt;
*Seizures&lt;br /&gt;
*EEG shows specific abnormal patterns&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Angelman Syndrome individuals show the most distinct disease pattern from 2 to 16 years of age.&lt;br /&gt;
In most cases at least 8 of the symptom traits are shown.&amp;lt;ref name=&amp;quot;PMID7625442&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Behavioural Characteristics'''&lt;br /&gt;
&lt;br /&gt;
A range of substantial characteristics appear in all AS cases, regardless of the genetic mechanisms, and are often responsible for diagnosing the syndrome. According to the original name, Happy Puppet syndrome, they have shown to exhibit traits such as a happy demeanor, with frequent laughter or smiling that can easily be triggered.&amp;lt;ref name=&amp;quot;PMID12566516&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12566516&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This behaviour can already be observed in 1 to 3 month old infants.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot; /&amp;gt; Uplifted hand flapping or waving motions are associated with laughter and excitement. Other characteristics manifesting in early childhood are sleep abnormalities with reduced sleep demand, and feeding problems. Breast and bottle feeding can be difficult due to non efficient attachment to the breast, tongue thrusting and uncoordinated sucking. Furthermore, there is an affection to crinkly and reflective surfaces, like some papers or plastic materials, especially water.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID12566516 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Communication Skills'''&lt;br /&gt;
&lt;br /&gt;
Communication is challenging for AS patients due to the fact that speech impairment is present in all cases. In the majority of affected people a lack of speech development is present. Only some of them have a minimal vocabulary consisting of two or three words, a few can speak in basic sentences. Some patients use gestures to articulate themselves, the [[#Glossary | '''Picture Exchange Communication System (PECS)''']] or sign languages such as [[#Glossary | '''Makaton''']] can be used for communication. Simple demands regarding their everyday occurrence can be understood by most patients.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID12566516 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Clinical and External Characteristics'''[[File:Angelman Syndrome patient.png|thumb|200px|right|4 year old AS patient.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Developmental delays are present in all patients. Motor milestones are delayed with children managing to sit unsupported with 12 months and crawl or bottom shuffle at the age of 18-24 months. The average age for walking is 4 years,however, ranging from 18 months to 7 years.&lt;br /&gt;
The [[#Glossary | '''gait''']] is characterised as slow, and flapping hands are a common trait.  The legs remain stiff during walking, arms are inflected by the wrists and elbows. The movements can appear ataxic, jerky or lurching. The muscle tone shows abnormalities with truncal [[#Glossary | '''hypotonia''']] and [[#Glossary | '''hypertonicity''']] of the limbs and alert reflexes.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID12566516 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The most striking external traits present in patients include broad-spaced teeth, and a wide mouth, light hair and eye colour, hypopigmented skin, deep set eyes, and a flat [[#Glossary | '''occiput''']].&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Seizures in Angelman Syndrome'''&lt;br /&gt;
&lt;br /&gt;
85% of AS patients suffer from epileptic seizures during their first three years. The first appearance can be within one month up to 20 year old patients. In infants with AS epilepsy manifests with [[#Glossary | '''febrile convulsions''']] and is hard to manage during childhood.&lt;br /&gt;
The most common type of seizures within 25% of patients are [[#Glossary | '''myoclonic seizures''']], followed by [[#Glossary | '''atonic seizures''']] as the second most frequent type, then 21% experience generalised [[#Glossary | '''tonic-clonic seizures''']] and lastly [[#Glossary | '''atypical absences''']] occur in 12% of patients.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20398390&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Angelman Syndrome in adults'''&lt;br /&gt;
&lt;br /&gt;
Patients with Angelman syndrome possess normal secondary sexual characteristics, and puberty sets in at a usual time. Limb hypertonicity, and [[#Glossary | '''thoracic scoliosis''']] lead to decreasing mobility. [[#Glossary | '''Oesophagus reflux''']] might induce severe problems, and the majority suffers from obesity. Furthermore, facial traits such as a prominent lower lip [[#Glossary | '''macrostomia''']] and [[#Glossary | '''mandibular prognathism''']] get manifested in adults. &lt;br /&gt;
In some cases the communication barrier can lead to frustration, resulting in aggressive behaviour. Nonetheless, patients gain a higher concentration span with age, and their nature becomes more quiet.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Complications===&lt;br /&gt;
&lt;br /&gt;
'''Hypopigmentation and Ocular albinism'''&lt;br /&gt;
&lt;br /&gt;
OCA2 gene, also known as the P gene, is closely located to the UBE3A gene. It encodes a protein vital to tyrosine metabolism, which plays a role in pigmentation development of skin, hair and eyes. However, AS caused by the large deletion of UBE3A leads to haploinsufficiency of OCA2 gene, resulting in hypopigmentation of the skin and the eyes. In some children with severe hypopigmentation, some form of [[#Glossary | '''albinism''']] is suspected.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12749060&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; When AS is caused by another mechanism, no abnormality of the skin and eye pigmentation is observed. However, not all AS children with OCA2 gene deletion will present with obvious hypopigmentation, they may just exhibit lighter skin colour than their parents.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8302318&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Diagnosis==&lt;br /&gt;
&lt;br /&gt;
The diagnosis of Angelman Syndrome is a clinical diagnosis confirmed by laboratory testing.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This involves both prenatal and/or postnatal diagnosis. &lt;br /&gt;
&lt;br /&gt;
===Prenatal Diagnosis===&lt;br /&gt;
[[File:Angelman Syndrome Prenatal Diagnosis.jpg|thumb|250px|right|Flowchart of AS Diagnosis.]]&lt;br /&gt;
&lt;br /&gt;
Prenatal detection of deletions of 15q11.2-q13, [[#Glossary | '''Paternal UPD''']] ([[#Glossary | '''Uniparental Disomy''']]), Imprinting defects and UBE3A mutations are done through DNA/chromosome/FISH analysis of fetal cells obtained by either [[#Glossary | '''Chorionic Villus Sampling''']](CVS) or [[#Glossary | '''Amniocentesis''']].&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot;/&amp;gt; &lt;br /&gt;
DNA methylation analysis using [[#Glossary | '''Amniocytes''']] is usually the first test carried out in molecular diagnosis of AS.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18059071&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; An abnormal result is followed up by either a FISH or array CGH analysis to search for a deletion on chromosome 15. If they produce a normal result, then UPD testing using DNA polymorphysims is carried out. If there is no evidence of UPD, other DNA analysis tests are used search for an imprinting centre deletion.&amp;lt;ref name=&amp;quot;PMID9792887&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9792887&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; A normal DNA methylation analysis is followed by a UBE3A sequence analysis.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt; In addition, a parent of origin test is also done to determine if the genetic disruption is of maternal origin or paternal origin. If it is maternally derived the fetus is diagnosed with AS (a paternally derived genetic disruption is indicative of Prader-Willi Syndrome).&amp;lt;ref name=&amp;quot;PMID17020468&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;17020468&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The flow chart summarizes the normal procedure used for prenatal diagnosis of AS. More information on important laboratory tests used for the diagnosis of Angelman Syndrome are provided below:&lt;br /&gt;
&lt;br /&gt;
*'''DNA Methylation Analysis'''&lt;br /&gt;
&lt;br /&gt;
Identifies approximately 80% of AS affected individuals and is usually the first test to be ordered.&amp;lt;ref name=&amp;quot;PMID7618904&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7618904&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Molecular disruptions such as deletions, paternal UPD and imprinting defects on chromosome 15 all demonstrate abnormal methylation patterns by either southern blot analysis or PCR amplification of bisulphate-treated DNA.&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot; /&amp;gt; An affected individual will only have an unmethylated (paternal) SNRPN (small nuclear ribonuclear protein-associated polypeptide N) allele compared with an unaffected individual who will have both a methylated and an unmethylated SNRPN allele.&amp;lt;ref name=&amp;quot;PMID9634532&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9634532&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
	  &lt;br /&gt;
*'''FISH (Fluorescent In Situ Hybridization)'''&lt;br /&gt;
&lt;br /&gt;
[[File:Critical_region_of_Angelman_Syndrome_on_chromosome_15.png‎|thumb|150px|right|FISH (fluorescence in situ hybridisation) image showing the critical region of Angelman Syndrome on chromosome 15.]]&lt;br /&gt;
&lt;br /&gt;
FISH analysis detects 5-7 Mb deletions in approximately 68% of affected individuals using detecting probes such as D15S10 and/or SNRPN.&amp;lt;ref name=&amp;quot;PMID7618904&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7618904&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It is also able to distinguish UPD from micro-deletions and imprinting defects. In simple terms, FISH analysis involves the binding of a fluorescent probe to a specific part of chromosome 15 and the detection of deletions within that region. FISH analysis is much more accurate in deletion detection compared to other high-resolution cytogenetics in the diagnosis of AS patients.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1511093&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
Array-based CGH is an advanced type of cytogenetic testing that can also be used to detect smaller deletions.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''UPD (Uniparental Disomy) Detection'''&lt;br /&gt;
&lt;br /&gt;
DNA Polymorphism testing detects paternal UPD in approximately 7% of affected AS individuals.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt; It is also able to distinguish between UPD and an Imprinting defect. It requires a DNA sample from the [[#Glossary | '''Proband''']] and from both parents. A homologous or non-homologous whole-arm translocation of the long arms of chromosome 15 is a sound indication for the need for prenatal UPD testing.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''IC (Imprinting Center) Analysis'''&lt;br /&gt;
&lt;br /&gt;
This type of analysis is used when individuals have an abnormal DNA methylation pattern but show normal results for  FISH, array CGH study and UPD analysis.&amp;lt;ref name=&amp;quot;PMID9792887&amp;quot;/&amp;gt; It is used to differentiate between the Imprinting defects caused by either microdeletions in the AS imprinting centre or by epigenetic mutations (that occur in maternal oogenesis or early embryogenesis).&amp;lt;ref name=&amp;quot;PMID9634532&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''Cytogenetic Testing'''&lt;br /&gt;
&lt;br /&gt;
Is used to detect a cytogenetically visible chromosomal rearrangement (large deletion, translocation or inversion) involving the 15q11.2-q13 region, which occurs in less than 1% of affected individuals.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''UBE3A Sequence Analysis'''&lt;br /&gt;
Sequence analysis of the UBE3A gene detects mutations in about 10% of the patients.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt; The test is used to detect either multiexonic (10 major coding exons of UBE3A) or whole gene deletions of UBE3A gene in individuals who produces a normal DNA methylation result but has characteristic clinical features of AS.&amp;lt;ref name=&amp;quot;PMID9792887&amp;quot;/&amp;gt;&lt;br /&gt;
This is recommended as a prenatal diagnostic tool in families that include multiple AS affected individuals because the imprinted pattern can be inherited from distant relatives.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Postnatal Diagnosis===&lt;br /&gt;
&lt;br /&gt;
Postnatal diagnosis is made though a combination of common clinical features of AS and UBESA gene sequence analysis.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt; The clinical features of AS include unsteady or shaky movements, muscle hypotonia, developmental delay and behavioral uniqueness such as frequent laughter/smiling and happy demeanor are features that are 100% consistent in all patients diagnosed with Angelman Syndrome.&amp;lt;ref name=&amp;quot;PMID18830393&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18830393&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; These clinical features become apparent between 6 months to 2 years of age. The onset of early or persistent smiling characteristic of this syndrome begin around the age of 1-3 months, but is often overlooked during infancy.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot;/&amp;gt; Thus early diagnosis of AS during infancy period is difficult because the clinical indicators of the syndrome takes time to manifest and characteristic features such as finger and hand tremors and excessive smiling/laughter are often overlooked and not considered as possible indicators of this syndrome.&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
*Rett Syndrome&lt;br /&gt;
&lt;br /&gt;
Some children with the clinical diagnosis of AS but no underlying genetic mechanism show mutations in ''MECP2'' gene, corresponding to Rett Syndrome. This should be suspected in AS test negative girls in the first few years of life.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17980307&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*Mowat-Wilson Syndrome&lt;br /&gt;
&lt;br /&gt;
Genetic mechanism is heterozygous deletion or truncation in ''ZFHX1B'' (''SIP1'') gene on 2q22. This presents with clinical features of severe intellectual disability, micrcephaly and seizures.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17958891&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Prader-Willi Syndrome patient.png|thumb|right|120px|12 year old PWS patient.]]&lt;br /&gt;
&lt;br /&gt;
*X-linked alpha-thalassemia/mental retardation syndrome (ATR-X)&lt;br /&gt;
&lt;br /&gt;
This arises from mutations in ''XNP'' gene on Xq13. ATR-X presents with severe intellectual disability, no speech development and seizures are common.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11449489&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*Phelan-McDermid Syndrome/22q13 deletion syndrome&lt;br /&gt;
&lt;br /&gt;
Deletions are usually submicroscopic and thus requires special molecular cytogenetic methods to confirm this deletion. Patients show moderate to profound intellectual disability and delay in speech development.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18505557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Related Disease'''&lt;br /&gt;
&lt;br /&gt;
*Prader-Willi Syndrome(PWS)&lt;br /&gt;
&lt;br /&gt;
PWS is a result from the absence of paternally expressed 15q11-q13 gene as a corollary of de novo deletion, maternal uniparental disomy of chromosome 15 or an imprinting defect on paternal chromosome 15 leading to the silencing of paternal alleles.&amp;lt;ref name=&amp;quot;PMID:20668179 &amp;quot;/&amp;gt; It is characterized by [[#Glossary | '''hyperphagia''']], obesity in later infancy and early childhood and difficulty in feeding during early infancy.&amp;lt;ref name=&amp;quot;PMID:20668179 &amp;quot;/&amp;gt; There is also cognitive impairment to some extent, though some PWS patients may exhibit intelligence in the normal IQ range. Behavioral phenotypes include stubbornness, manipulative tendency, obsessive compulsive characteristics.&amp;lt;ref name=&amp;quot;PMID:20668179 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Genetic Counselling==&lt;br /&gt;
&lt;br /&gt;
Genetic counselling is the process by which patients or relatives, at risk of an inherited disorder, are advised of the consequences and nature of the disorder, the probability of developing or transmitting it, and the options open to them in management and family planning. In the case for Angelman syndrome, types of risks associated are split into classes and formatted into the table below:&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20459762&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{|  style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
! Class&lt;br /&gt;
! Mechanism&lt;br /&gt;
! Risk to siblings&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! Ia                           &lt;br /&gt;
| De novo deletion                                                                                                               &lt;br /&gt;
| &amp;lt;1%                                                                                                                &lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! Ib&lt;br /&gt;
| Deletion due to chromosome rearrangement&lt;br /&gt;
| Up to 50%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! II&lt;br /&gt;
| Paternal uniparental disomy (UPD)&lt;br /&gt;
| &amp;lt;1%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! IIIa&lt;br /&gt;
| Imprinting defect with IC mutation&lt;br /&gt;
| Close to 100% if father has 15; 15 [[#Glossary | '''Robertsonian translocation''']]&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! IIIb&lt;br /&gt;
| Imprinting defect without IC mutation&lt;br /&gt;
| Up to 50% (if mother has IC deletion)&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! IIIc&lt;br /&gt;
| [[#Glossary | '''Mosaic''']] imprinting defect&lt;br /&gt;
| &amp;lt;1%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! IV&lt;br /&gt;
| ''UBE3A'' mutation&lt;br /&gt;
| Up to 50% (if mother has mutation)&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! V&lt;br /&gt;
| No identifiable genetic abnormality&lt;br /&gt;
| ?&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Ia''': Individuals with de novo deletion have 1% risk to siblings&lt;br /&gt;
&lt;br /&gt;
'''Ib''': Risk to siblings in individuals with chromosomal rearrangements is up to 50% &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9557895&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''II''': Paternal UPD with no Robertsonian translocation has a risk to sibling of less than 1%&lt;br /&gt;
&lt;br /&gt;
'''IIIa''': The risk to siblings in individuals with AS from an imprinting defect with a mutation in the imprinting center (IC) is close to 100% if father has 15;15 Robertsonian translocation&lt;br /&gt;
&lt;br /&gt;
'''IIIb''': Individuals with AS resulting from an imprinting defect without IC mutation, but with a carrier mother has a high risk to siblings of up to 50%. The mother could be phenotypically normal due to paternal inheritance of the genetic defect &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11283796&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''IIIc''': Individuals who are mosaic for the imprinting defect have less than 1% risk to siblings&lt;br /&gt;
&lt;br /&gt;
'''IV''': UBE3A mutation can be either inherited or de novo mutation. If the mother is a carrier for this genetic mutation, the risk to siblings is up to 50% &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11258627&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''V''': Individuals who present with AS clinically, but have no known underlying mechanism have an unknown risk to siblings.&lt;br /&gt;
&lt;br /&gt;
==Treatment and Management==&lt;br /&gt;
&lt;br /&gt;
Even though at present there is no known cure for Angelman syndrome, there are a number of treatments available that may alleviate symptons and improve daily life activities.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The below table describes the problems and management options that are used:&lt;br /&gt;
&lt;br /&gt;
[[File:Subtle Finger tremors-Angelman Syndrome.jpg|right|thumb|150px|A five months old boy with Angelman syndrome showing signs of Subtle Finger tremor.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
! Problems encountered&lt;br /&gt;
! Treatment and Management&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''Difficulty in feeding newborn AS babies'''&lt;br /&gt;
| Use of special nipples may improve feeding&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Oesophagus reflux'''&lt;br /&gt;
| Special motility medications requiried or upright positioning&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''Seizures'''&lt;br /&gt;
| Anticonvulsant medications&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19605773&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19453717&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Ocular problems'''&lt;br /&gt;
| Visual assessment is vital to encourage interactions and minimize chances of self-harm and autism development&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20656169&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''Drooling in developmental delayed AS patients'''&lt;br /&gt;
| Difficult to treat, but new surgical procedure on salivary duct reimplantation seems to be a promising alternative&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17699119&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Unstable children''' &lt;br /&gt;
| Physical therapy&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''AS patients become less active with increasing age'''&lt;br /&gt;
| Activity schedules to prevent scoliosis and obesity. Occupational therapy to stimulate fine motor and oral-motor control skills in conjunction to speech therapy&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Sleeping difficulty'''&lt;br /&gt;
| Sedative medication in severe cases. [[#Glossary | '''Melatonin''']] may be used to promote sleeping but some studies have found that it loses its therapeutic effects after several weeks in most AS patients&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19379289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|-&lt;br /&gt;
|colspan=&amp;quot;4&amp;quot; |&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Prognosis==&lt;br /&gt;
&lt;br /&gt;
Life expectancy of AS patients seems to be normal&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, but there is still a high degree of developmental delay and limited expressive language skills.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17019625&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This problem arises prominently in the assessment of the severity of coincidental medical conditions due to difficulties in communication. A visit to the dentist can become difficult if good communication is not conveyed between the parents, the dentist, and the child.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18271768&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Some problems require extreme measures, such as the procedure of lens implantation was performed in both eyes of a person diagnosed with AS, due to the inability to wear spectacles.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20656169&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
During adulthood, menstruation and puberty begin at around average age evidenced by females with Angelman syndrome that are fully capable of conceiving children.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11258627&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Most adult patients can feed themselves, but needed help with many other daily activities. Main troubles which have shown in adults are a tendency to become obese and start developing  thoracic scoliosis, which some adults with AS begin wheelchair bounded.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9072912&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Current and Future Research==&lt;br /&gt;
&lt;br /&gt;
Currently there is no cure for the treatment of AS, so much research is being carried out for therapeutic interventions. Findings in the last five years have suggested through various mice and fruit fly models that the absence of maternal UBE3A results in the same human AS features of neurological defects and seizures. However, more recently, studies have outlined that the symptoms of AS can be improved by modifying other gene products. In addition, restoring of a functional UBE3A protein into adult mice neurons have shown to reduce motor and neurological deficits and balance disorders. This shows promising research prospects in that improvements may be possible in human AS patients by restoring functional UBE3A proteins into their neurons. &lt;br /&gt;
&lt;br /&gt;
===Possible Treatment Pathways===&lt;br /&gt;
&lt;br /&gt;
*'''Cognitive and physical impairment'''&lt;br /&gt;
&lt;br /&gt;
Although everyone is born with two copies of the gene UBE3A, one maternal and one paternal copy, it is only the maternal UBE3A that is used in the brain. Most AS patients have a genetic mutation on the maternal chromosome 15 that results in dysfunctional UBE3A.&amp;lt;ref&amp;gt;http://www.cureangelman.org/what-hope.html&amp;lt;/ref&amp;gt; The above research focused on turning on the father's copy of UBE3A to restore its functions. Furthermore, mouse models were utilized to show that alpha-CaMKII could be increased to compensate the loss of UBE3A and restore compromised mental and physical abilities. However, this finding still requires much more research.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17259980&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''Epilepsy'''&lt;br /&gt;
&lt;br /&gt;
There is research being done on improving certain conditions that are involved in AS by nutritional benefits. The use of [[#Glossary | '''corticosteroids''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19666884&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, [[#Glossary | '''valproate''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19453717&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and [[#Glossary | '''clonazepam''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19605773&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and having a [[#Glossary | '''ketogenic diet''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20880305&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; has all been shown to aid in the treatment of epilepsy. It has also been reported to be efficient in the treatment of other conditions, such as behavioural disorders, reduction in seizures, ataxia, sleep patterns, developmental progress and sleep disturbances. [[#Glossary | '''Levetiracetam''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17326790&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; could be used in such a situation, especially when the patient has an intolerance to valproate and clonazepam.&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&lt;br /&gt;
'''albinism''': A congenital disorder distincted by the complete or partial absence of pigment in the skin, hair and eyes due to defect of an enzyme involved in the production of melanin.&lt;br /&gt;
&lt;br /&gt;
'''allele''': Dissimilar variant of one gene. Organisms have two alleles for each gene inherited from their parents, one from each of them.&lt;br /&gt;
&lt;br /&gt;
'''alpha-CaMKII''': (alpha calcium calmodulin kinase II) Compound involved in synaptic plasticity, one of the most important theories behind learning and memory. Ability of a synapse between two neurons to change in strength due to the use or disuse of transmission.&lt;br /&gt;
&lt;br /&gt;
'''Amniocytes''': Cells that are shed by the fetus during fetal development to the surrounding amniotic fluid. They are a source of fetal DNA. &lt;br /&gt;
&lt;br /&gt;
'''Amniocentesis''': (AFT or amniotic fluid test) is a prenatal diagnostic test used to detect chromosomal abnormalities in the developing fetus by extracting amniotic fluid (a source of fetal DNA) surrounding the fetus. &lt;br /&gt;
&lt;br /&gt;
'''AMPA''': (2-amino-3-(5-methyl-3-oxo-1,2- oxazol-4-yl)propanoic acid) Compound that binds to the AMPA receptor to imitate glutamate neurotransmitter.&lt;br /&gt;
&lt;br /&gt;
'''Arc''': Activity-Regulated Cytoskeleton-associated protein; involved in learning and memory.&lt;br /&gt;
&lt;br /&gt;
'''ataxia''': Lack of coordination in muscle movements.&lt;br /&gt;
&lt;br /&gt;
'''atonic seizures''': A abrupt loss of muscle tone, this can lead to the limbs loosing strength, or the head may drop to the side. The patient remains conscious during this kind of epileptic seizure.&lt;br /&gt;
&lt;br /&gt;
'''atypical absences''': Seizure leads to unconsciousness in most cases.  &lt;br /&gt;
&lt;br /&gt;
'''autism''': A neural development disorder defined by limited social interaction and communication.&lt;br /&gt;
&lt;br /&gt;
'''Chorionic Villus Sampling''': A prenatal diagnostic test used to detect chromosomal abnormalities in the developing fetus by extracting and testing chorionic villus (placental tissue). &lt;br /&gt;
&lt;br /&gt;
'''chromosome''': Structure consisting of coiled DNA with DNA associated proteins such as histones.&lt;br /&gt;
&lt;br /&gt;
'''clonazepam''': A psychoactive drug having muscle relaxant properties and treats anxiety and epilepsy.&lt;br /&gt;
&lt;br /&gt;
'''corticosteroid''': A type of steroid hormones that are produced in the adrenal cortex.&lt;br /&gt;
&lt;br /&gt;
'''cytogenetics''': Study of the structure, function and abnormality of the cell, especially the chromosome.&lt;br /&gt;
&lt;br /&gt;
'''deletion''': Lack of a part of the DNA (deoxyribonucleic acid is a nucleic acid containing information for protein synthesis), can vary form a single base to a hole gene. &lt;br /&gt;
&lt;br /&gt;
'''de novo mutation''': Change in a gene of a family member for the first time due to a mutation in the egg or sperm of the parents or in the fertilized egg (zygote).&lt;br /&gt;
&lt;br /&gt;
'''disorder''': A mental or physical health disturbance or dysfunction.&lt;br /&gt;
&lt;br /&gt;
'''EEG''': Electroencephalography is a means of measuring electrical activity along the scalp by measuring the total electrical charges fired by thousands or millions of neurons.&lt;br /&gt;
&lt;br /&gt;
'''epilepsy''': Neurological disorder characterised by recurrent impairment of brain function that can cause seizures or unconsciousness. &lt;br /&gt;
&lt;br /&gt;
'''E6-AP''': E6-AP ubiquitin-protein ligase is an enzyme encoded by UBE3A which adds ubiquitin chain to target proteins to be degraded by proteasomes.&lt;br /&gt;
&lt;br /&gt;
'''febrile convulsions''': The occurrence of high fever, especially in children.&lt;br /&gt;
&lt;br /&gt;
'''FISH''': Fluorescent in situ hybridization is a technique used to identify and localize the presence or absence of DNA sequences on the chromosome. This is achieved by using fluorescently labelled DNA sequences which then binds to complementary DNA sequence on the chromosome. After hybridization (attachment), chromosome of interest will fluoresce under the microscope.&lt;br /&gt;
&lt;br /&gt;
'''gait''': A manner of walking, stepping or running.&lt;br /&gt;
&lt;br /&gt;
'''gene''': A molecular unit of heredity of a living organism.&lt;br /&gt;
&lt;br /&gt;
'''hyperphagia''': (Also referred to as Polyphagia) Excessive ingestion of food beyond the dietary and energy requirements of the body. &lt;br /&gt;
&lt;br /&gt;
'''hypermotoric''': Sudden appearance of uncontrolled movements such as striking or kicking inappropriately.&lt;br /&gt;
&lt;br /&gt;
'''hypertonicity''': Increase of muscle tension and a disability to stretch leading to an impairment of motor activity.&lt;br /&gt;
&lt;br /&gt;
'''hypopigmentation''': A lack of melanin pigments or melanocytes  affecting the colour of the skin, hair and iris. Features appear to be light-coloured due to loss of skin colour.&lt;br /&gt;
&lt;br /&gt;
'''hypotonia''': Decrease in the ability to stretch passively, due to a low muscle tone. &lt;br /&gt;
&lt;br /&gt;
'''imprinting''': This is a process to describe the modification of a maternally or paternally derived chromosome, which consequently influences the expression of certain genes on the altered chromosome.&lt;br /&gt;
&lt;br /&gt;
'''ketogenic diet''': A high-fat, low-carbohydrate diet that is used to treat epilepsy in children.&lt;br /&gt;
&lt;br /&gt;
'''levetiracetam''': An anticonvulsant drug used to treat epilepsy.&lt;br /&gt;
&lt;br /&gt;
'''locus''': Location of a gene on a chromosome(loci: plural for locus).&lt;br /&gt;
&lt;br /&gt;
'''LTP''': Long-term potentiation shares common features with long term memory. It strengthens and enhances signal transmission between neurons by improving the communication between two neurons.&lt;br /&gt;
&lt;br /&gt;
'''macrostomia''': A wide-spaced mouth.&lt;br /&gt;
&lt;br /&gt;
'''Makaton''': Language programme using symbols and signs to support speaking.&lt;br /&gt;
&lt;br /&gt;
'''mandibular prognathism''': The abnormal protrusion of the lower jaw. &lt;br /&gt;
&lt;br /&gt;
'''maxillary hypoplasia''':  The underdevelopment of the upper jaw.&lt;br /&gt;
&lt;br /&gt;
'''melatonin''': A hormone secreted by the pineal gland.&lt;br /&gt;
&lt;br /&gt;
'''microcephaly''': The circumference of the head is less than average due to abnormalities of the nervous system. This abnormality can be present at birth or emerge during the first few years of life and reduces both life expectancy and the cognitive functions of the individual affected.&lt;br /&gt;
&lt;br /&gt;
'''microdeletion''':  A genetic mutation in which a part of a chromosome or a sequence of DNA is missing.&lt;br /&gt;
&lt;br /&gt;
'''mosaic''': tissues or cells containing different mixture of genetic sequences&lt;br /&gt;
&lt;br /&gt;
'''mutation''': Event that changes the DNA (deoxyribonucleic acid is a nucleic acid, containing information for protein synthesis) or RNA (ribonucleic acid is a type of nucleic acid transmitting the information from the DNA to the proteins ) of a gene permanently.&lt;br /&gt;
&lt;br /&gt;
'''myoclonic seizures''': A quick jerk of the skeletal muscle, due to a irregular brain activity.&lt;br /&gt;
&lt;br /&gt;
'''neurogenetic''': Genetic basis of the nervous system.&lt;br /&gt;
&lt;br /&gt;
'''neurotransmitter''': Transmits neuronal signals to a target cell. They are first packaged in vesicles just beneath the membrane of presynaptic axon terminals and released into the synaptic cleft (space between the two interacting neurons) and enter the postsynaptic dendrite.&lt;br /&gt;
&lt;br /&gt;
'''occiput''': The back portion of the head.&lt;br /&gt;
&lt;br /&gt;
'''oesophagus reflux''': Impairment of a sphincter in the lower end of the oesophagus leads to the back flow of stomach acid into the oesophagus. Heartburn is a typical symptom.&lt;br /&gt;
&lt;br /&gt;
'''paediatrician''': Physicians that specialise on infants, children and adolescents.&lt;br /&gt;
&lt;br /&gt;
'''paternal UPD''': Inheritance of two copies of a chromosome from the father and none from the mother. &lt;br /&gt;
&lt;br /&gt;
'''phenotype''': Visible traites of an organism determined by genetic and environmental factors.&lt;br /&gt;
&lt;br /&gt;
'''Picture Exchange Communication System (PECS)''': Individuals communicate using images instead of words. It is frequently used by children with autism, to articulate their needs and wishes or to make comments about something.&lt;br /&gt;
&lt;br /&gt;
'''Proband''': Is the person (or animal) being studied or reported on in a genetic investigation. Most commonly it refers to the first affected family member who requires medical help for a genetic disorder. &lt;br /&gt;
&lt;br /&gt;
'''Robertsonian translocation''': Rearrangement of the chromosome, occurs in 5 chromosome including 13,14,15,21 and 22. This type of mutation occurs in chromosomes with the centromere not at the centre, resulting in long and short arm chromosomes. Translocation breaks the chromosome at the centromere so the long arm attaches to the other long arm, and the same for the short arm happens. Cell division will result in the loss of the short arms as they do not contain important genes.&lt;br /&gt;
&lt;br /&gt;
'''seizure''': Abnormal electrical activity in the brain that can result in a variety of physical symptoms like convulsion, body shaking, loss of consciousness, confusion, and mood changes.&lt;br /&gt;
&lt;br /&gt;
'''synapse''': Allows transmission of signal between neurons for effective neuronal function.&lt;br /&gt;
&lt;br /&gt;
'''thoracic scoliosis''': The spine is curved laterally(from side to side) in the thoracic region.&lt;br /&gt;
&lt;br /&gt;
'''tonic-clonic seizures''': This type of seizure is associated with unconsciousness due to electrical discharges in a big proportion of the brain.&lt;br /&gt;
&lt;br /&gt;
'''ubiquitin''': A polypeptide found in all eukaryotic cells, that participates in a variety of cellular functions including protein recycling.&lt;br /&gt;
&lt;br /&gt;
'''Uniparental disomy''': (UPD) the inheritance of two copies of a chromosome pair or part of a chromosme from one parent and no copy from the other parent. &lt;br /&gt;
&lt;br /&gt;
'''valproate''':  A mood-stabilizing drug that is also used for treatment for epilepsy and bipolar disorder.&lt;br /&gt;
&lt;br /&gt;
==Helpful Links==&lt;br /&gt;
&lt;br /&gt;
* Australia&lt;br /&gt;
:* [http://www.angelmansyndrome.org/research.html Angelman Syndrome Association] &lt;br /&gt;
:* [http://www.angelmansyndromeqld.org/ Queensland Angelman Association]&lt;br /&gt;
&lt;br /&gt;
* America&lt;br /&gt;
:* [http://www.angelman.org/ Angelman Syndrome Foundation]&lt;br /&gt;
:* [http://rarediseasesnetwork.epi.usf.edu/arpwsc/ Rare Clinical Diseases Research Network]&lt;br /&gt;
:* [http://www.rarediseases.org/rare-disease-information/rare-diseases/byID/411/viewAbstract National Organisation for Rare Disorders]&lt;br /&gt;
:* [http://www.epilepsyfoundation.org/ Epilepsy Foundation]&lt;br /&gt;
:* [http://www.cureangelman.org/ Foundation for Angelman Syndrome Therapeutics]&lt;br /&gt;
&lt;br /&gt;
* Search Pubmed &lt;br /&gt;
:* [http://www.ncbi.nlm.nih.gov/pubmed?term=angelman%20syndrome Angelman Syndrome] &lt;br /&gt;
&lt;br /&gt;
* OMIM entries for Angelman Syndrome&lt;br /&gt;
:* [http://omim.org/entry/105830 ANGELMAN SYNDROME; AS]&lt;br /&gt;
:* [http://omim.org/entry/601623 UBIQUITIN-PROTEIN LIGASE E3A; UBE3A]&lt;br /&gt;
&lt;br /&gt;
==Related Links==&lt;br /&gt;
&lt;br /&gt;
* [[Mouse Knockout]] - this page explains the current use of mouse models in disrupting genes to elucidate their genetic function, including the mouse gene knockouts for alpha calcium-calmodulin kinase II (alpha CaMKII)&lt;br /&gt;
* [[2009 Group Project 4]] - this page gives an extensive overview on the history of the mouse model and its various use in embryology and genetics. In addition, it also describes mouse knockout and the role they play in current research of various human diseases&lt;br /&gt;
* [[Fly Development]] - this page describes the use of drosophila flies as developmental models&lt;br /&gt;
* [[2009 Group Project 2]] - this page gives an extensive overview on the history of the fly model and its various use in embryology and genetics&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&lt;br /&gt;
&amp;lt;references /&amp;gt;&lt;/div&gt;</summary>
		<author><name>Z3291643</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_7&amp;diff=77571</id>
		<title>2011 Group Project 7</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_7&amp;diff=77571"/>
		<updated>2011-10-12T20:31:01Z</updated>

		<summary type="html">&lt;p&gt;Z3291643: /* Glossary */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;='''Angelman Syndrome'''=&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Introduction==&lt;br /&gt;
&lt;br /&gt;
[[File:Dr Harry Angelman.jpg|thumb|130px|right|Dr Harry Angelman.]]&lt;br /&gt;
Angelman syndrome (AS) is a rare [[#Glossary | '''neurogenetic''']] [[#Glossary | '''disorder''']] first described by Dr. Harry Angelman in 1965.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18754889&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Dr. Angelman was an English [[#Glossary | '''paediatrician''']] who first diagnosed the disease in 3 children with a developmental delay.&amp;lt;ref&amp;gt;http://www.ncbi.nlm.nih.gov/books/NBK22221/&amp;lt;/ref&amp;gt; AS occurs in 1 in 10000-20000 births, the exact number is still unknown.&amp;lt;ref name=&amp;quot;PMID7573182&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7573182&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;PMID8703225&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;8703225&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It is caused by maternal [[#Glossary | '''allele''']] disruptions of a single gene- UBE3A. Either [[#Glossary | '''mutations''']] or [[#Glossary | '''deletions''']] of the UBE3A gene results in AS. &lt;br /&gt;
&lt;br /&gt;
AS presents with well known [[#Glossary | '''phenotypes''']] during infancy and adulthood, such as [[#Glossary | '''microcephaly''']] and [[#Glossary | '''maxillary hypoplasia''']]. However, these features become more marked with age. Most frequent clinical features include delayed development,[[#Glossary | '''seizures''']],[[#Glossary | '''ataxia''']], impairment of speech, happy demeanor, behavioural problems such as hyperactivity, short attention span and sleeping difficulty.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21592595&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21484597&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;ASAwebsite&amp;quot;&amp;gt;http://www.angelmansyndrome.org/home.html&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
At present, there is no cure for the syndrome, though current research is focused at improving life quality of patients with Angelman syndrome through management of daily tasks.&amp;lt;ref&amp;gt;http://www.bbc.co.uk/health/physical_health/conditions/angelman1.shtml&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==History==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Dr. Harry Angelman first reported Angelman Syndrome on three handicapped children that were admitted to his ward in England in 1964.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt; He reported how these three independent and unconnected clinical cases all had the same characteristic features of severe developmental delay, jerky movements, seizures and a happy disposition.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt; However it was only when he stumbled upon an oil painting called ‘a Boy with a Puppet” while on a holiday in Italy he was able to connect the symptoms of all three children under one common cause.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20981772&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; He linked the happy face of the boy depicted on the painting with the jerky movements and happy disposition he observed on his three patients back in England. He reported his findings on a paper entitled “Puppet children (a report on three cases)” which was published in 1965.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
The syndrome was initially named ‘Puppet Syndrome’ but was later changed to Angelman Syndrome. Due to the extreme rarity of the syndrome and lack of sufficient clinical evidence the syndrome was soon forgotten.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt;&lt;br /&gt;
[[File:Dr Charles Williams.jpg|thumb|right|150px|Dr Charles Williams.]]&lt;br /&gt;
	&lt;br /&gt;
In 1987, a physician named Ellen Magenis, came across children with deletions on [[#Glossary | '''chromosome''']] 15 that were suffering from seizures and severe developmental delay.&amp;lt;ref&amp;gt;http://www.angelman.org/stay-informed/facts-about-angelman-syndrome---7th-edition/harry-angelman-and-the-history-of-as/&amp;lt;/ref&amp;gt; Even though genetically the children were expected to have [[#Diagnosis | '''Prader-Willi syndrome''']] that was characterised by deletions on chromosome 15, their characteristic symptoms of seizures and lack of development did not correspond with that of the syndrome. This led to the realization that these children had deletions on the maternally derived chromosome 15 and not on the paternally derived chromosome as was observed in Prader-Willi syndrome.  Thus the deleted genetic code on maternally derived chromosome 15 was identified as the genetic marker for Angelman Syndrome.&lt;br /&gt;
&lt;br /&gt;
In 1997, UBE3A gene was isolated by Dr. Joseph Wagstaff and Dr. Arthur Beaudet as the cause of Angelman Syndrome.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot; /&amp;gt; The discovery of this [[#Glossary | '''gene''']] led to the subsequent development of animal models and research aimed at finding a causal link between UBE3A gene abnormalities and characteristic features observed in Angelman Syndrome. &lt;br /&gt;
	&lt;br /&gt;
Currently, four different genetic abnormalities for Angelman Syndrome have been confirmed by genetic testing. They include: Deletion, [[#Glossary | '''Uniparental Disomy''']] (UPD), [[#Glossary | '''Imprinting''']] and UBE3A mutation.&amp;lt;ref name=&amp;quot;PMID20211139&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Below is a timeline, summarising the key discoveries and advancements of the Angelman Syndrome:&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|- bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
!Year&lt;br /&gt;
!Milestone&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1964'''&lt;br /&gt;
|First observed by Dr Harry Angelman on three handicapped children.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot; /&amp;gt; &lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''1965'''&lt;br /&gt;
|Harry Angelman publishes his finding in a report entitled 'Puppet Children'(a report on three cases).&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1980s'''&lt;br /&gt;
|First reports of AS reaches US and research into the disorder being at the University of Florida under the direction of Dr. Charles Williams.&amp;lt;ref&amp;gt;http://www.angelmanproject.com/history.htm&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''1982'''&lt;br /&gt;
|Name changed from 'Happy Puppet' to Angelman syndrome by Williams and Frias. &lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1987'''&lt;br /&gt;
|Discovery of a genetic marker for AS – an absent genetic code on maternally derived chromosome 15. &lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''1997'''&lt;br /&gt;
|The cause of AS discovered by Dr. Joseph Wagstaff and Dr. Arthur Beaudet – mutation or deletion in the UBE3A gene.&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1998'''&lt;br /&gt;
|Transgenic mice with absent maternal UBE3A created to illustrate motor and learning deficits in addition to seizures.&amp;lt;ref name=&amp;quot;PMID9808466&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9808466&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''2007'''&lt;br /&gt;
|AS mouse model shows that neurological deficits can be reversed by decreasing levels of [[#Glossary | '''alpha-CaMKII''']] inhibitory phosphorylation.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17259980&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''2010'''&lt;br /&gt;
|Discovery of a another gene mutation in TC4 gene (on chromosome 18) in a small number of clinically diagnosed patients with no identifiable genetic alternation in UBE3A.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20184619&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''2010'''&lt;br /&gt;
|Protein named Arc identified as a target of AS gene product; UBE3A.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Incidence'''&lt;br /&gt;
*The current population of people diagnosed with AS is unknown but studies have estimated the number to be around 1:10,000&amp;lt;ref name=&amp;quot;PMID7573182&amp;quot; /&amp;gt; and 1:20,000&amp;lt;ref name=&amp;quot;PMID8703225&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
'''Diagnosis'''&lt;br /&gt;
*The mean age of diagnosis for patients with AS lies between 6 and 6.5 years of age.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18664077&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15741136&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Gender'''&lt;br /&gt;
* Males appear to be at higher risk for some aspects of early developmental delays in comparison to females with AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17019625&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Demography'''&lt;br /&gt;
*Europe:&lt;br /&gt;
:Denmark- 1:10,000&amp;lt;ref name=&amp;quot;PMID7573182&amp;quot; /&amp;gt;&lt;br /&gt;
:Estonia- 1:52,000&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16906556&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
:Sweden- 1:20,000&amp;lt;ref name=&amp;quot;PMID8703225&amp;quot; /&amp;gt;&lt;br /&gt;
*Australia:&lt;br /&gt;
:Western Australia- 1:40,000&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16492624&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Aetiology==&lt;br /&gt;
&lt;br /&gt;
[[File:Chromosome 15 Deletion of 15q11.2 to 15q13.jpg|thumb|100px|Chromosome 15 - The deletion occurs at 15q11.2-15q13.]]&lt;br /&gt;
&lt;br /&gt;
Different genetic mechanisms lead to different clinical phenotypes of AS. The most common genetic mechanism leading to AS is the deletion or re-arrangement of maternal chromosome at [[#Glossary | '''locus''']] 15q11.2-q13,as the chromosome image shows on the right, accounting for 70% of AS occurrences.&amp;lt;ref name=&amp;quot;PMID8988171&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt; 8988171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This leads to more severe clinical phenotypes of microcephaly, motor difficulties, seizures and impaired speech development. The next most common genetic mechanism is mutation in the ''UBE3A'' gene responsible for 10% of AS cases and paternal uniparental disomy and mutation in the imprinting centre (IC), both accounting for 2-5% of AS observed.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
 &lt;br /&gt;
&lt;br /&gt;
AS is caused by the 4 major genetic mechanisms mentioned above and are thus divided into Classes I to IV based on their underlying genetic mechanism. AS patients with the clinical features of AS but no [[#Glossary | '''cytogenetic''']] or molecular abnormality in Chromosome 15q11.2-13 are grouped under Class V (summarised in table below).&amp;lt;ref name=&amp;quot;PMID8988171&amp;quot; /&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10364509&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''Inheritance'''&lt;br /&gt;
&lt;br /&gt;
Angelman Syndrome from UBE3A mutations and deletions in the Imprinting Centre follow an inheritance pattern. A carrier father with the genetic defect can pass it on to his children, however, his children will be clinically normal. On the other hand, a carrier mother can pass the genetic defect onto her children, who will then have Angelman Syndrome. &lt;br /&gt;
&lt;br /&gt;
The image highlights the inheritance of Angelman Syndrome, which only results after a carrier mother passes it on to her children. &lt;br /&gt;
&lt;br /&gt;
{|  style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
! Class&lt;br /&gt;
! Mechanism&lt;br /&gt;
! Diagnostic Tests&lt;br /&gt;
! Frequency&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''Ia'''                           &lt;br /&gt;
| De novo deletion                                                                                           &lt;br /&gt;
| High resolution cytogenetics [[#Glossary | '''FISH''']]                                                                                                       &lt;br /&gt;
| 70%      &lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Ib'''&lt;br /&gt;
| Deletion due to chromosome rearrangement&lt;br /&gt;
| High resolution cytogenetics FISH&lt;br /&gt;
| &amp;lt;1%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''II'''&lt;br /&gt;
| Paternal uniparental disomy&lt;br /&gt;
| [[#Glossary | '''RFLP''']]  analysis&lt;br /&gt;
| 2%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''IIIa'''&lt;br /&gt;
| Imprinting defect with IC mutation&lt;br /&gt;
| Screening of [[#Glossary | '''IC''']]  for mutations is positive&lt;br /&gt;
| 2%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''IIIb'''&lt;br /&gt;
| Imprinting defect withouth IC mutation&lt;br /&gt;
| Screening of IC for mutations is negative&lt;br /&gt;
| 2%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''IIIc'''&lt;br /&gt;
| Mosaic imprinting defect&lt;br /&gt;
| Screening of IC for mutations is usually negative &lt;br /&gt;
| ?&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''IV'''&lt;br /&gt;
| ''UBE3A'' mutation&lt;br /&gt;
| Screening of ''UBE3A'' for mutations&lt;br /&gt;
| 5-10%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''V'''&lt;br /&gt;
| No identifiable genetic abnormality&lt;br /&gt;
| Consider other diagnoses&lt;br /&gt;
| 5-26%&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Pathogenesis==&lt;br /&gt;
&lt;br /&gt;
Chromosome 15 became associated with AS in the 1980s after the observation of many AS patients harboring [[#Glossary | '''microdeletions''']] of 15q11.2-15q13.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15668046&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The last decade has shed even more light in the aetiology of AS,as Kishino and Matsuura first identified UBE3A as the causative gene for AS in 1997.&amp;lt;ref name=&amp;quot;PMID:8988171&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;8988171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8988172&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Normal gene product: E6-AP ubiquitin ligase'''&lt;br /&gt;
&lt;br /&gt;
The function of UBE3A is to encode for [[#Glossary | '''E6-AP''']] ubiquitin ligase, however its function in the development of the nervous system and the process of UBE3A mutation leading to cognitive impairment in AS patients is still vague.&amp;lt;ref name=&amp;quot;PMID:20211139&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Past and current research has elucidated that E6-AP ubiquitin ligase is involved in the degradation of four proteins, listed below, but currently, no protein with a direct role in [[#Glossary | '''long-term potentiation (LTP)''']] as a target of E6-AP, has been identified.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12684449&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The identification of such target proteins would be a landmark discovery in further understanding of the pathogenesis, aetiology and prospective treatment strategies of AS, as LTP defects is one of the major neurological impairments of AS. &lt;br /&gt;
 &lt;br /&gt;
* p53 tumor suppressor protein &lt;br /&gt;
* yeast DNA repair protein Rad23 &lt;br /&gt;
* multicopy maintenance protein 7 subunit &lt;br /&gt;
* E6-AP&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Abnormal gene product'''&lt;br /&gt;
&lt;br /&gt;
Disruption to the gene,UBE3A, interferes with the normal functioning of the gene, which is its crucial role in UBE3A [[#Glossary | '''ubiquitylation''']]. Problems involving this pathway can lead to various diseases either from the loss or gain of function.&amp;lt;ref name=&amp;quot;PMID:9857172&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9857172&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In the case of AS, E6-AP is affected, leading to detrimental cognitive impairment in addition to other deficits.&amp;lt;ref name=&amp;quot;PMID:9857172&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9857172&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Regional functioning of UBE3A'''&lt;br /&gt;
&lt;br /&gt;
Despite the uncertain progression of UBE3A mutation and the neurological abnormalities characteristic of AS, animal models have illustrated the vital role of UBE3A in the normal functioning of the brain. This can be exemplified by a study which utilized a mouse model with target inactivation of the gene UBE3A resulting in the manifestation of classical features of AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11895368&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In addition, the fact that imprinting of UBE3A takes place only in specific brain regions (cerebellum, olfactory tracts and the hippocampus) confirms the hypothesis that the loss of this gene would be detrimental in the cognitive development.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20398390&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Most genes are inherited in copies of two, one paternal and the other maternal; however, some genes, such as UBE3A only have one functional copy as the other is silenced, coined 'imprinting'. Imprinting of the paternal copy of UBE3A takes place in some cell populations, such as the hippocampal neurons and Purkinje cells in the cerebellum.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9288101&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This means only the maternal UBE3A is functionally expressed in these particular brain regions. Thus a [[#Glossary | '''de novo mutation''']] in the maternal copy of the gene will result in the complete absence of functional E6-AP in the associated brain areas.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9288088&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
It is also known that UBE3A plays an important role in synaptic transmission, but exactly how it does so is still not completely understood.&amp;lt;ref name=&amp;quot;PMID:9808466&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9808466&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''UBE3A ubiquitylation'''&lt;br /&gt;
&lt;br /&gt;
As briefly mentioned above, UBE3A is a member of the E3 ubiquitin ligase family of enzymes, responsible for the addition of ubiquitin to the target protein for degradation of the ubiquitinated protein, as illustrated in the diagram below. These processes are required for normal human cognitive function.&amp;lt;ref name=&amp;quot;PMID:9808466&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9808466&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In this way synaptic protein [[#Glossary | '''Arc (activity-regulated cytoskeleton-associated protein)''']] is degraded to control synaptic function. Arc is a target protein of UBE3A in dendritic spines found in the hippocampal neurons.&amp;lt;ref name=&amp;quot;PMID:20668179&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20668179&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Deletion of UBE3A leads to the accumulation of Arc in neurons leading to trafficking of [[#Glossary | '''AMPA ( α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid)''']] receptors, resulting in impaired cognitive functions.&amp;lt;ref name=&amp;quot;PMID:20211139&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; [[File:UBE3A Ubiquitylation Pathway.png|thumb|350px|right|UBE3A Ubiquitylation Pathway.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
UBE3A ubiquitylation consists of:&amp;lt;ref name=&amp;quot;PMID:20668179&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20668179&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
# Activation of ubiquitin by E1 enzyme&lt;br /&gt;
# E1 ezyme transfers ubiquitin to E2 enzyme&lt;br /&gt;
# E2 enzyme transfers ubiquitin to UBE3A&lt;br /&gt;
# UBE3A attaches activated ubiquitin to target protein which is then polyubiquitylated &lt;br /&gt;
# Target protein is then degraded by 26S proteosome&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Phenotype-Genotype correlations'''&lt;br /&gt;
&lt;br /&gt;
[[File:Extent of microcephaly in Angelman Syndrome patients.png|thumb|250px|right|Extent of microcephaly in 20 AS patients with deletion and without deletion.&amp;lt;ref&amp;gt;http://www.nature.com/ejhg/index.html/&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
All AS patients show differing extents of cognitive impairment, movement disorder, characteristic behaviours and difficulty in speech and language.&amp;lt;ref name=&amp;quot;PMID:11748306&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11748306&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; However, there seems to be some phenotype-genotype correlations:&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
- 5-7Mb deletions result in the most severe phenotypes such as microcephaly, more sever [[#Glossary | '''epilepsy''']] and seizures, motor difficulties and language impairment.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9546330&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20445456&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; AS patients with large deletions also present with clinical [[#Glossary | '''hypopigmentation''']], light hair and eye colour due to the close association of OCA2 gene with UBE3A.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;16470747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Individuals under this category have in general no increased BMI&amp;lt;ref name=&amp;quot;PMID:15253756&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15253756&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This is indicated by the graph on the left, which shows more cases of AS patients with deletions having larger deviations from the mean head circumference measurement than non-deletion AS patients.&lt;br /&gt;
 &lt;br /&gt;
- AS patients with uniparental disomy (UPD) have better physical growth, fewer motor deficits and lower seizure occurrences.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16023557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
- Individuals with AS resulting from imprinting defects have the least debilitating features, such as higher developmental and language ability than AS caused by other mechanisms.&amp;lt;ref name=&amp;quot;PMID:11748306&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11748306&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
- The Body Mass Index (BMI) of 33% of the UBE3A mutation patients, and 47–64% of the patients from the classes II (UPD) and III (Imprinting defect) is above the 95th centile.&amp;lt;ref name=&amp;quot;PMID:15253756&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15253756&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Animal models'''&lt;br /&gt;
&lt;br /&gt;
* '''Drosophila'''&lt;br /&gt;
&lt;br /&gt;
Drosophila (common fruit fly) is an excellent model to use for better understanding of genetic diseases in humans as they are highly homologous to human UBE3A (hUBE3A), illustrating a high evolutionary conservation. Studies using the Drosophila model have shown that the functional absence of UBE3A resulted in decreased morphogenesis of dendritic branches. This is of interest as dendritic branches cover over 90% of the neuronal surface where [[#Glossary | '''synapse''']] between neurons occur. Proper formation and maturation of dendritic spines is also required so they come in contact with other neurons for effective transmission of neuronal signals. Thus proper formation of dendritic branching is pivitol for effective neuronal function and hence cognitive function.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18996915&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Interestingly, overexpression of dUBE3A also gave the same result, consisting of abnormal locomotion  and decreased dendritic branching in sensory neurons.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18701717&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;  This suggests a possible research field for some forms of [[#Glossary | '''autism''']] where the region containing UBE3A is duplicated, leading to delayed motor skills and seizures.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16433693&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;[[File:Normal and Angelman Syndrome mice models.jpg|thumb|250px|right|Normal and AS mice performance on the Rotarod apparatus.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
* '''Mice'''&lt;br /&gt;
&lt;br /&gt;
Absence of UBE3A in mice manifest similar phenotype to human AS, as illustrated by motor and learning deficits with inducible seizures.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21235769&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It has been shown through various mice model studies that larger deletions, ie. from UBE3A to GABRB3, more closely mirrors the large 6Mb deletions seen in human AS patients. Numerous tests, such as the Rotarod (for motor coordination and learning ability), Morris water maze test (for spatial learning and memory) and [[#Glossary | '''EEG''']] (electroencephalography), were carried out on  UBE3A null mutants, which showed the results to be abnormal or impaired.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20808828&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Other studies using mouse models have also outlined the obesity observed in 15% of AS children, albeit it is not the major characterisitics of AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17259980&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The diagram on the right clearly highlights the results obtained from such mouse model studies of AS, where the absence of UBE3A accumulated in deficits of motor function and obesity. In addition, excessive drooling and feeding difficulties were also highlighted by mice models with inactivated UBE3A, reflected by defects in fluid consumption and licking.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18413322&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Pathophysiology===&lt;br /&gt;
&lt;br /&gt;
'''Cognitive defects'''&lt;br /&gt;
&lt;br /&gt;
[[File:Role of UBE3A in dendritic spine neuronal synapses.png|thumb|250px|right|Role of UBE3A in dendritic spine neuronal synapses.]]&lt;br /&gt;
&lt;br /&gt;
AS patients present with abnormally high UBE3A, leading to neurological impairment. Recent identification of key target proteins of Ephexin-58 (Eph-5) and Arc (Activity-Regulated Cytoskeleton-associated protein) have aided in better understanding of the progression of UBE3A to cognitive defects. These two proteins are vital in the understanding of AS as Eph-5 determines synapse numbers and Arc contributes to plasticity and synapse function.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21164477&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Studies utilizing mice models have illustrated that UBE3A null mice could not ubiquitinate Eph-5, thus increasing its levels and limiting the growth of dendritic spines by the activation of RhoA. This subsequent activation of RhoA inhibits synapse formation and results in neuronal defects.&lt;br /&gt;
&lt;br /&gt;
In contrast, mice with normally functioning UBE3A showed phosphorylated Eph-5, resulting from the interaction of two neurons via the activation of EphB signalling receptor.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21029865&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Phosphorylation of Eph-5 allows UBE3A to ubiquitinate and degrade it. This degradation of Eph-5 permits new synaptic connections to form with cells they come into contact with. However, in AS, the absence of UBE3A means Eph-5 cannot be degraded, so RhoA activity is prolonged to reduce synaptic formation.&lt;br /&gt;
&lt;br /&gt;
As mentioned previously, Arc plays a pivitol role in synapse function as it removes synaptic receptors that respond to glutamate, a [[#Glossary | '''neurotransmitter''']].&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17088211&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In UBE3A present neurons, UBE3A ubiquitinates Arc, leading to it degradation as illustrated by the diagram on the left. However, in UBE3A deficient neurons, Arc accumulates and prevents the proper synaptic communications essential for normal cognitive functions.&amp;lt;ref name=&amp;quot;PMID20211139&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Signs and Symptoms==&lt;br /&gt;
&lt;br /&gt;
Angelman Syndrome presents a variety of different phenotypes, and the presented symptoms may vary at different ages.&amp;lt;ref name=&amp;quot;PMID7625442&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7625442&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
In 1995 Williams et al. embraced the observed clinical features of AS in a consensus statement, in order to present an appliance for clinicians. The diagnostic criteria were updated in 2005.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt; The following table shows the most frequently occurring characteristics in AS patients:&lt;br /&gt;
&lt;br /&gt;
'''4 characteristics appear in 100% of the cases:'''&lt;br /&gt;
&lt;br /&gt;
*Delayed development: become apparent by the age of 6 to 12 months.&lt;br /&gt;
*Motion and or balance malfunction&lt;br /&gt;
*Behaviour patterns like unmotivated laughter, frequent excitement; often including body movements,[[File:Electroencephalography of Angelman Syndrome.jpg|thumb|350px|right|EEG of AS and normal individuals.]] [[#Glossary | '''hypermotoric''']] behaviour&lt;br /&gt;
*Impairment of speech&lt;br /&gt;
&lt;br /&gt;
'''3 characteristics appear in more than 80% of the cases:'''&lt;br /&gt;
&lt;br /&gt;
*Abnormalities in head circumference, microcephaly&lt;br /&gt;
*Seizures&lt;br /&gt;
*EEG shows specific abnormal patterns&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Angelman Syndrome individuals show the most distinct disease pattern from 2 to 16 years of age.&lt;br /&gt;
In most cases at least 8 of the symptom traits are shown.&amp;lt;ref name=&amp;quot;PMID7625442&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Behavioural Characteristics'''&lt;br /&gt;
&lt;br /&gt;
A range of substantial characteristics appear in all AS cases, regardless of the genetic mechanisms, and are often responsible for diagnosing the syndrome. According to the original name, Happy Puppet syndrome, they have shown to exhibit traits such as a happy demeanor, with frequent laughter or smiling that can easily be triggered.&amp;lt;ref name=&amp;quot;PMID12566516&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12566516&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This behaviour can already be observed in 1 to 3 month old infants.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot; /&amp;gt; Uplifted hand flapping or waving motions are associated with laughter and excitement. Other characteristics manifesting in early childhood are sleep abnormalities with reduced sleep demand, and feeding problems. Breast and bottle feeding can be difficult due to non efficient attachment to the breast, tongue thrusting and uncoordinated sucking. Furthermore, there is an affection to crinkly and reflective surfaces, like some papers or plastic materials, especially water.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID12566516 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Communication Skills'''&lt;br /&gt;
&lt;br /&gt;
Communication is challenging for AS patients due to the fact that speech impairment is present in all cases. In the majority of affected people a lack of speech development is present. Only some of them have a minimal vocabulary consisting of two or three words, a few can speak in basic sentences. Some patients use gestures to articulate themselves, the [[#Glossary | '''Picture Exchange Communication System (PECS)''']] or sign languages such as [[#Glossary | '''Makaton''']] can be used for communication. Simple demands regarding their everyday occurrence can be understood by most patients.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID12566516 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Clinical and External Characteristics'''[[File:Angelman Syndrome patient.png|thumb|200px|right|4 year old AS patient.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Developmental delays are present in all patients. Motor milestones are delayed with children managing to sit unsupported with 12 months and crawl or bottom shuffle at the age of 18-24 months. The average age for walking is 4 years,however, ranging from 18 months to 7 years.&lt;br /&gt;
The [[#Glossary | '''gait''']] is characterised as slow, and flapping hands are a common trait.  The legs remain stiff during walking, arms are inflected by the wrists and elbows. The movements can appear ataxic, jerky or lurching. The muscle tone shows abnormalities with truncal [[#Glossary | '''hypotonia''']] and [[#Glossary | '''hypertonicity''']] of the limbs and alert reflexes.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID12566516 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The most striking external traits present in patients include broad-spaced teeth, and a wide mouth, light hair and eye colour, hypopigmented skin, deep set eyes, and a flat [[#Glossary | '''occiput''']].&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Seizures in Angelman Syndrome'''&lt;br /&gt;
&lt;br /&gt;
85% of AS patients suffer from epileptic seizures during their first three years. The first appearance can be within one month up to 20 year old patients. In infants with AS epilepsy manifests with [[#Glossary | '''febrile convulsions''']] and is hard to manage during childhood.&lt;br /&gt;
The most common type of seizures within 25% of patients are [[#Glossary | '''myoclonic seizures''']], followed by [[#Glossary | '''atonic seizures''']] as the second most frequent type, then 21% experience generalised [[#Glossary | '''tonic-clonic seizures''']] and lastly [[#Glossary | '''atypical absences''']] occur in 12% of patients.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20398390&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Angelman Syndrome in adults'''&lt;br /&gt;
&lt;br /&gt;
Patients with Angelman syndrome possess normal secondary sexual characteristics, and puberty sets in at a usual time. Limb hypertonicity, and [[#Glossary | '''thoracic scoliosis''']] lead to decreasing mobility. [[#Glossary | '''Oesophagus reflux''']] might induce severe problems, and the majority suffers from obesity. Furthermore, facial traits such as a prominent lower lip [[#Glossary | '''macrostomia''']] and [[#Glossary | '''mandibular prognathism''']] get manifested in adults. &lt;br /&gt;
In some cases the communication barrier can lead to frustration, resulting in aggressive behaviour. Nonetheless, patients gain a higher concentration span with age, and their nature becomes more quiet.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Complications===&lt;br /&gt;
&lt;br /&gt;
'''Hypopigmentation and Ocular albinism'''&lt;br /&gt;
&lt;br /&gt;
OCA2 gene, also known as the P gene, is closely located to the UBE3A gene. It encodes a protein vital to tyrosine metabolism, which plays a role in pigmentation development of skin, hair and eyes. However, AS caused by the large deletion of UBE3A leads to haploinsufficiency of OCA2 gene, resulting in hypopigmentation of the skin and the eyes. In some children with severe hypopigmentation, some form of [[#Glossary | '''albinism''']] is suspected.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12749060&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; When AS is caused by another mechanism, no abnormality of the skin and eye pigmentation is observed. However, not all AS children with OCA2 gene deletion will present with obvious hypopigmentation, they may just exhibit lighter skin colour than their parents.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8302318&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Diagnosis==&lt;br /&gt;
&lt;br /&gt;
The diagnosis of Angelman Syndrome is a clinical diagnosis confirmed by laboratory testing.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This involves both prenatal and/or postnatal diagnosis. &lt;br /&gt;
&lt;br /&gt;
===Prenatal Diagnosis===&lt;br /&gt;
[[File:Angelman Syndrome Prenatal Diagnosis.jpg|thumb|250px|right|Flowchart of AS Diagnosis.]]&lt;br /&gt;
&lt;br /&gt;
Prenatal detection of deletions of 15q11.2-q13, [[#Glossary | '''Paternal UPD''']] ([[#Glossary | '''Uniparental Disomy''']]), Imprinting defects and UBE3A mutations are done through DNA/chromosome/FISH analysis of fetal cells obtained by either [[#Glossary | '''Chorionic Villus Sampling''']](CVS) or [[#Glossary | '''Amniocentesis''']].&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot;/&amp;gt; &lt;br /&gt;
DNA methylation analysis using [[#Glossary | '''Amniocytes''']] is usually the first test carried out in molecular diagnosis of AS.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18059071&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; An abnormal result is followed up by either a FISH or array CGH analysis to search for a deletion on chromosome 15. If they produce a normal result, then UPD testing using DNA polymorphysims is carried out. If there is no evidence of UPD, other DNA analysis tests are used search for an imprinting centre deletion.&amp;lt;ref name=&amp;quot;PMID9792887&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9792887&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; A normal DNA methylation analysis is followed by a UBE3A sequence analysis.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt; In addition, a parent of origin test is also done to determine if the genetic disruption is of maternal origin or paternal origin. If it is maternally derived the fetus is diagnosed with AS (a paternally derived genetic disruption is indicative of Prader-Willi Syndrome).&amp;lt;ref name=&amp;quot;PMID17020468&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;17020468&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The flow chart summarizes the normal procedure used for prenatal diagnosis of AS. More information on important laboratory tests used for the diagnosis of Angelman Syndrome are provided below:&lt;br /&gt;
&lt;br /&gt;
*'''DNA Methylation Analysis'''&lt;br /&gt;
&lt;br /&gt;
Identifies approximately 80% of AS affected individuals and is usually the first test to be ordered.&amp;lt;ref name=&amp;quot;PMID7618904&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7618904&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Molecular disruptions such as deletions, paternal UPD and imprinting defects on chromosome 15 all demonstrate abnormal methylation patterns by either southern blot analysis or PCR amplification of bisulphate-treated DNA.&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot; /&amp;gt; An affected individual will only have an unmethylated (paternal) SNRPN (small nuclear ribonuclear protein-associated polypeptide N) allele compared with an unaffected individual who will have both a methylated and an unmethylated SNRPN allele.&amp;lt;ref name=&amp;quot;PMID9634532&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9634532&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
	  &lt;br /&gt;
*'''FISH (Fluorescent In Situ Hybridization)'''&lt;br /&gt;
&lt;br /&gt;
[[File:Critical_region_of_Angelman_Syndrome_on_chromosome_15.png‎|thumb|150px|right|FISH (fluorescence in situ hybridisation) image showing the critical region of Angelman Syndrome on chromosome 15.]]&lt;br /&gt;
&lt;br /&gt;
FISH analysis detects 5-7 Mb deletions in approximately 68% of affected individuals using detecting probes such as D15S10 and/or SNRPN.&amp;lt;ref name=&amp;quot;PMID7618904&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7618904&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It is also able to distinguish UPD from micro-deletions and imprinting defects. In simple terms, FISH analysis involves the binding of a fluorescent probe to a specific part of chromosome 15 and the detection of deletions within that region. FISH analysis is much more accurate in deletion detection compared to other high-resolution cytogenetics in the diagnosis of AS patients.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1511093&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
Array-based CGH is an advanced type of cytogenetic testing that can also be used to detect smaller deletions.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''UPD (Uniparental Disomy) Detection'''&lt;br /&gt;
&lt;br /&gt;
DNA Polymorphism testing detects paternal UPD in approximately 7% of affected AS individuals.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt; It is also able to distinguish between UPD and an Imprinting defect. It requires a DNA sample from the [[#Glossary | '''Proband''']] and from both parents. A homologous or non-homologous whole-arm translocation of the long arms of chromosome 15 is a sound indication for the need for prenatal UPD testing.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''IC (Imprinting Center) Analysis'''&lt;br /&gt;
&lt;br /&gt;
This type of analysis is used when individuals have an abnormal DNA methylation pattern but show normal results for  FISH, array CGH study and UPD analysis.&amp;lt;ref name=&amp;quot;PMID9792887&amp;quot;/&amp;gt; It is used to differentiate between the Imprinting defects caused by either microdeletions in the AS imprinting centre or by epigenetic mutations (that occur in maternal oogenesis or early embryogenesis).&amp;lt;ref name=&amp;quot;PMID9634532&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''Cytogenetic Testing'''&lt;br /&gt;
&lt;br /&gt;
Is used to detect a cytogenetically visible chromosomal rearrangement (large deletion, translocation or inversion) involving the 15q11.2-q13 region, which occurs in less than 1% of affected individuals.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''UBE3A Sequence Analysis'''&lt;br /&gt;
Sequence analysis of the UBE3A gene detects mutations in about 10% of the patients.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt; The test is used to detect either multiexonic (10 major coding exons of UBE3A) or whole gene deletions of UBE3A gene in individuals who produces a normal DNA methylation result but has characteristic clinical features of AS.&amp;lt;ref name=&amp;quot;PMID9792887&amp;quot;/&amp;gt;&lt;br /&gt;
This is recommended as a prenatal diagnostic tool in families that include multiple AS affected individuals because the imprinted pattern can be inherited from distant relatives.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Postnatal Diagnosis===&lt;br /&gt;
&lt;br /&gt;
Postnatal diagnosis is made though a combination of common clinical features of AS and UBESA gene sequence analysis.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt; The clinical features of AS include unsteady or shaky movements, muscle hypotonia, developmental delay and behavioral uniqueness such as frequent laughter/smiling and happy demeanor are features that are 100% consistent in all patients diagnosed with Angelman Syndrome.&amp;lt;ref name=&amp;quot;PMID18830393&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18830393&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; These clinical features become apparent between 6 months to 2 years of age. The onset of early or persistent smiling characteristic of this syndrome begin around the age of 1-3 months, but is often overlooked during infancy.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot;/&amp;gt; Thus early diagnosis of AS during infancy period is difficult because the clinical indicators of the syndrome takes time to manifest and characteristic features such as finger and hand tremors and excessive smiling/laughter are often overlooked and not considered as possible indicators of this syndrome.&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
*Rett Syndrome&lt;br /&gt;
&lt;br /&gt;
Some children with the clinical diagnosis of AS but no underlying genetic mechanism show mutations in ''MECP2'' gene, corresponding to Rett Syndrome. This should be suspected in AS test negative girls in the first few years of life.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17980307&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*Mowat-Wilson Syndrome&lt;br /&gt;
&lt;br /&gt;
Genetic mechanism is heterozygous deletion or truncation in ''ZFHX1B'' (''SIP1'') gene on 2q22. This presents with clinical features of severe intellectual disability, micrcephaly and seizures.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17958891&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Prader-Willi Syndrome patient.png|thumb|right|120px|12 year old PWS patient.]]&lt;br /&gt;
&lt;br /&gt;
*X-linked alpha-thalassemia/mental retardation syndrome (ATR-X)&lt;br /&gt;
&lt;br /&gt;
This arises from mutations in ''XNP'' gene on Xq13. ATR-X presents with severe intellectual disability, no speech development and seizures are common.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11449489&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*Phelan-McDermid Syndrome/22q13 deletion syndrome&lt;br /&gt;
&lt;br /&gt;
Deletions are usually submicroscopic and thus requires special molecular cytogenetic methods to confirm this deletion. Patients show moderate to profound intellectual disability and delay in speech development.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18505557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Related Disease'''&lt;br /&gt;
&lt;br /&gt;
*Prader-Willi Syndrome(PWS)&lt;br /&gt;
&lt;br /&gt;
PWS is a result from the absence of paternally expressed 15q11-q13 gene as a corollary of de novo deletion, maternal uniparental disomy of chromosome 15 or an imprinting defect on paternal chromosome 15 leading to the silencing of paternal alleles.&amp;lt;ref name=&amp;quot;PMID:20668179 &amp;quot;/&amp;gt; It is characterized by [[#Glossary | '''hyperphagia''']], obesity in later infancy and early childhood and difficulty in feeding during early infancy.&amp;lt;ref name=&amp;quot;PMID:20668179 &amp;quot;/&amp;gt; There is also cognitive impairment to some extent, though some PWS patients may exhibit intelligence in the normal IQ range. Behavioral phenotypes include stubbornness, manipulative tendency, obsessive compulsive characteristics.&amp;lt;ref name=&amp;quot;PMID:20668179 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Genetic Counselling==&lt;br /&gt;
&lt;br /&gt;
Genetic counselling is the process by which patients or relatives, at risk of an inherited disorder, are advised of the consequences and nature of the disorder, the probability of developing or transmitting it, and the options open to them in management and family planning. In the case for Angelman syndrome, types of risks associated are split into classes and formatted into the table below:&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20459762&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{|  style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
! Class&lt;br /&gt;
! Mechanism&lt;br /&gt;
! Risk to siblings&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! Ia                           &lt;br /&gt;
| De novo deletion                                                                                                               &lt;br /&gt;
| &amp;lt;1%                                                                                                                &lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! Ib&lt;br /&gt;
| Deletion due to chromosome rearrangement&lt;br /&gt;
| Up to 50%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! II&lt;br /&gt;
| Paternal uniparental disomy (UPD)&lt;br /&gt;
| &amp;lt;1%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! IIIa&lt;br /&gt;
| Imprinting defect with IC mutation&lt;br /&gt;
| Close to 100% if father has 15; 15 [[#Glossary | '''Robertsonian translocation''']]&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! IIIb&lt;br /&gt;
| Imprinting defect without IC mutation&lt;br /&gt;
| Up to 50% (if mother has IC deletion)&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! IIIc&lt;br /&gt;
| [[#Glossary | '''Mosaic''']] imprinting defect&lt;br /&gt;
| &amp;lt;1%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! IV&lt;br /&gt;
| ''UBE3A'' mutation&lt;br /&gt;
| Up to 50% (if mother has mutation)&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! V&lt;br /&gt;
| No identifiable genetic abnormality&lt;br /&gt;
| ?&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Ia''': Individuals with de novo deletion have 1% risk to siblings&lt;br /&gt;
&lt;br /&gt;
'''Ib''': Risk to siblings in individuals with chromosomal rearrangements is up to 50% &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9557895&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''II''': Paternal UPD with no Robertsonian translocation has a risk to sibling of less than 1%&lt;br /&gt;
&lt;br /&gt;
'''IIIa''': The risk to siblings in individuals with AS from an imprinting defect with a mutation in the imprinting center (IC) is close to 100% if father has 15;15 Robertsonian translocation&lt;br /&gt;
&lt;br /&gt;
'''IIIb''': Individuals with AS resulting from an imprinting defect without IC mutation, but with a carrier mother has a high risk to siblings of up to 50%. The mother could be phenotypically normal due to paternal inheritance of the genetic defect &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11283796&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''IIIc''': Individuals who are mosaic for the imprinting defect have less than 1% risk to siblings&lt;br /&gt;
&lt;br /&gt;
'''IV''': UBE3A mutation can be either inherited or de novo mutation. If the mother is a carrier for this genetic mutation, the risk to siblings is up to 50% &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11258627&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''V''': Individuals who present with AS clinically, but have no known underlying mechanism have an unknown risk to siblings.&lt;br /&gt;
&lt;br /&gt;
==Treatment and Management==&lt;br /&gt;
&lt;br /&gt;
Even though at present there is no known cure for Angelman syndrome, there are a number of treatments available that may alleviate symptons and improve daily life activities.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The below table describes the problems and management options that are used:&lt;br /&gt;
&lt;br /&gt;
[[File:Subtle Finger tremors-Angelman Syndrome.jpg|right|thumb|150px|A five months old boy with Angelman syndrome showing signs of Subtle Finger tremor.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
! Problems encountered&lt;br /&gt;
! Treatment and Management&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''Difficulty in feeding newborn AS babies'''&lt;br /&gt;
| Use of special nipples may improve feeding&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Oesophagus reflux'''&lt;br /&gt;
| Special motility medications requiried or upright positioning&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''Seizures'''&lt;br /&gt;
| Anticonvulsant medications&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19605773&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19453717&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Ocular problems'''&lt;br /&gt;
| Visual assessment is vital to encourage interactions and minimize chances of self-harm and autism development&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20656169&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''Drooling in developmental delayed AS patients'''&lt;br /&gt;
| Difficult to treat, but new surgical procedure on salivary duct reimplantation seems to be a promising alternative&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17699119&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Unstable children''' &lt;br /&gt;
| Physical therapy&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''AS patients become less active with increasing age'''&lt;br /&gt;
| Activity schedules to prevent scoliosis and obesity. Occupational therapy to stimulate fine motor and oral-motor control skills in conjunction to speech therapy&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Sleeping difficulty'''&lt;br /&gt;
| Sedative medication in severe cases. [[#Glossary | '''Melatonin''']] may be used to promote sleeping but some studies have found that it loses its therapeutic effects after several weeks in most AS patients&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19379289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|-&lt;br /&gt;
|colspan=&amp;quot;4&amp;quot; |&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Prognosis==&lt;br /&gt;
&lt;br /&gt;
Life expectancy of AS patients seems to be normal&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, but there is still a high degree of developmental delay and limited expressive language skills.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17019625&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This problem arises prominently in the assessment of the severity of coincidental medical conditions due to difficulties in communication. A visit to the dentist can become difficult if good communication is not conveyed between the parents, the dentist, and the child.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18271768&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Some problems require extreme measures, such as the procedure of lens implantation was performed in both eyes of a person diagnosed with AS, due to the inability to wear spectacles.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20656169&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
During adulthood, menstruation and puberty begin at around average age evidenced by females with Angelman syndrome that are fully capable of conceiving children.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11258627&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Most adult patients can feed themselves, but needed help with many other daily activities. Main troubles which have shown in adults are a tendency to become obese and start developing  thoracic scoliosis, which some adults with AS begin wheelchair bounded.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9072912&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Current and Future Research==&lt;br /&gt;
&lt;br /&gt;
Currently there is no cure for the treatment of AS, so much research is being carried out for therapeutic interventions. Findings in the last five years have suggested through various mice and fruit fly models that the absence of maternal UBE3A results in the same human AS features of neurological defects and seizures. However, more recently, studies have outlined that the symptoms of AS can be improved by modifying other gene products. In addition, restoring of a functional UBE3A protein into adult mice neurons have shown to reduce motor and neurological deficits and balance disorders. This shows promising research prospects in that improvements may be possible in human AS patients by restoring functional UBE3A proteins into their neurons. &lt;br /&gt;
&lt;br /&gt;
===Possible Treatment Pathways===&lt;br /&gt;
&lt;br /&gt;
*'''Cognitive and physical impairment'''&lt;br /&gt;
&lt;br /&gt;
Although everyone is born with two copies of the gene UBE3A, one maternal and one paternal copy, it is only the maternal UBE3A that is used in the brain. Most AS patients have a genetic mutation on the maternal chromosome 15 that results in dysfunctional UBE3A.&amp;lt;ref&amp;gt;http://www.cureangelman.org/what-hope.html&amp;lt;/ref&amp;gt; The above research focused on turning on the father's copy of UBE3A to restore its functions. Furthermore, mouse models were utilized to show that alpha-CaMKII could be increased to compensate the loss of UBE3A and restore compromised mental and physical abilities. However, this finding still requires much more research.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17259980&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''Epilepsy'''&lt;br /&gt;
&lt;br /&gt;
There is research being done on improving certain conditions that are involved in AS by nutritional benefits. The use of [[#Glossary | '''corticosteroids''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19666884&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, [[#Glossary | '''valproate''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19453717&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and [[#Glossary | '''clonazepam''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19605773&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and having a [[#Glossary | '''ketogenic diet''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20880305&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; has all been shown to aid in the treatment of epilepsy. It has also been reported to be efficient in the treatment of other conditions, such as behavioural disorders, reduction in seizures, ataxia, sleep patterns, developmental progress and sleep disturbances. [[#Glossary | '''Levetiracetam''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17326790&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; could be used in such a situation, especially when the patient has an intolerance to valproate and clonazepam.&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&lt;br /&gt;
'''albinism''': A congenital disorder distincted by the complete or partial absence of pigment in the skin, hair and eyes due to defect of an enzyme involved in the production of melanin.&lt;br /&gt;
&lt;br /&gt;
'''allele''': Dissimilar variant of one gene. Organisms have two alleles for each gene inherited from their parents, one from each of them.&lt;br /&gt;
&lt;br /&gt;
'''alpha-CaMKII''': (alpha calcium calmodulin kinase II) Compound involved in synaptic plasticity, one of the most important theories behind learning and memory. Ability of a synapse between two neurons to change in strength due to the use or disuse of transmission.&lt;br /&gt;
&lt;br /&gt;
'''Amniocytes''': Cells that are shed by the fetus during fetal development to the surrounding amniotic fluid. They are a source of fetal DNA. &lt;br /&gt;
&lt;br /&gt;
'''Amniocentesis''': (AFT or amniotic fluid test) is a prenatal diagnostic test used to detect chromosomal abnormalities in the developing fetus by extracting amniotic fluid (a source of fetal DNA) surrounding the fetus. &lt;br /&gt;
&lt;br /&gt;
'''AMPA''': (2-amino-3-(5-methyl-3-oxo-1,2- oxazol-4-yl)propanoic acid) Compound that binds to the AMPA receptor to imitate glutamate neurotransmitter.&lt;br /&gt;
&lt;br /&gt;
'''Arc''': Activity-Regulated Cytoskeleton-associated protein; involved in learning and memory.&lt;br /&gt;
&lt;br /&gt;
'''ataxia''': Lack of coordination in muscle movements.&lt;br /&gt;
&lt;br /&gt;
'''atonic seizures''': A abrupt loss of muscle tone, this can lead to the limbs loosing strength, or the head may drop to the side. The patient remains conscious during this kind of epileptic seizure.&lt;br /&gt;
&lt;br /&gt;
'''atypical absences''': Seizure leads to unconsciousness in most cases.  &lt;br /&gt;
&lt;br /&gt;
'''autism''': A neural development disorder defined by limited social interaction and communication.&lt;br /&gt;
&lt;br /&gt;
'''Chorionic Villus Sampling''': A prenatal diagnostic test used to detect chromosomal abnormalities in the developing fetus by extracting and testing chorionic villus (placental tissue). &lt;br /&gt;
&lt;br /&gt;
'''chromosome''': Structure consisting of coiled DNA with DNA associated proteins such as histones.&lt;br /&gt;
&lt;br /&gt;
'''clonazepam''': A psychoactive drug having muscle relaxant properties and treats anxiety and epilepsy.&lt;br /&gt;
&lt;br /&gt;
'''corticosteroid''': A type of steroid hormones that are produced in the adrenal cortex.&lt;br /&gt;
&lt;br /&gt;
'''cytogenetics''': Study of the structure, function and abnormality of the cell, especially the chromosome.&lt;br /&gt;
&lt;br /&gt;
'''deletion''': Lack of a part of the DNA (deoxyribonucleic acid is a nucleic acid containing information for protein synthesis), can vary form a single base to a hole gene. &lt;br /&gt;
&lt;br /&gt;
'''de novo mutation''': Change in a gene of a family member for the first time due to a mutation in the egg or sperm of the parents or in the fertilized egg (zygote).&lt;br /&gt;
&lt;br /&gt;
'''disorder''': A mental or physical health disturbance or dysfunction.&lt;br /&gt;
&lt;br /&gt;
'''EEG''': Electroencephalography is a means of measuring electrical activity along the scalp by measuring the total electrical charges fired by thousands or millions of neurons.&lt;br /&gt;
&lt;br /&gt;
'''epilepsy''': Neurological disorder characterised by recurrent impairment of brain function that can cause seizures or unconsciousness. &lt;br /&gt;
&lt;br /&gt;
'''E6-AP''': E6-AP ubiquitin-protein ligase is an enzyme encoded by UBE3A which adds ubiquitin chain to target proteins to be degraded by proteasomes.&lt;br /&gt;
&lt;br /&gt;
'''febrile convulsions''': The occurrence of high fever, especially in children.&lt;br /&gt;
&lt;br /&gt;
'''FISH''': Fluorescent in situ hybridization is a technique used to identify and localize the presence or absence of DNA sequences on the chromosome. This is achieved by using fluorescently labelled DNA sequences which then binds to complementary DNA sequence on the chromosome. After hybridization (attachment), chromosome of interest will fluoresce under the microscope.&lt;br /&gt;
&lt;br /&gt;
'''gait''': A manner of walking, stepping or running.&lt;br /&gt;
&lt;br /&gt;
'''gene''': A molecular unit of heredity of a living organism.&lt;br /&gt;
&lt;br /&gt;
'''hyperphagia''': (Also referred to as Polyphagia) Excessive ingestion of food beyond the dietary and energy requirements of the body. &lt;br /&gt;
&lt;br /&gt;
'''hypermotoric''': Sudden appearance of uncontrolled movements such as striking or kicking inappropriately.&lt;br /&gt;
&lt;br /&gt;
'''hypertonicity''': Increase of muscle tension and a disability to stretch leading to an impairment of motor activity.&lt;br /&gt;
&lt;br /&gt;
'''hypopigmentation''': A lack of melanin pigments or melanocytes  affecting the colour of the skin, hair and iris. Features appear to be light-coloured due to loss of skin colour.&lt;br /&gt;
&lt;br /&gt;
'''hypotonia''': Decrease in the ability to stretch passively, due to a low muscle tone. &lt;br /&gt;
&lt;br /&gt;
'''imprinting''': This is a process to describe the modification of a maternally or paternally derived chromosome, which consequently influences the expression of certain genes on the altered chromosome.&lt;br /&gt;
&lt;br /&gt;
'''ketogenic diet''': A high-fat, low-carbohydrate diet that is used to treat epilepsy in children.&lt;br /&gt;
&lt;br /&gt;
'''levetiracetam''': An anticonvulsant drug used to treat epilepsy.&lt;br /&gt;
&lt;br /&gt;
'''locus''': Location of a gene on a chromosome(loci: plural for locus).&lt;br /&gt;
&lt;br /&gt;
'''LTP''': Long-term potentiation shares common features with long term memory. It strengthens and enhances signal transmission between neurons by improving the communication between two neurons.&lt;br /&gt;
&lt;br /&gt;
'''macrostomia''': A wide-spaced mouth.&lt;br /&gt;
&lt;br /&gt;
'''Makaton''': Language programme using symbols and signs to support speaking.&lt;br /&gt;
&lt;br /&gt;
'''mandibular prognathism''': The abnormal protrusion of the lower jaw. &lt;br /&gt;
&lt;br /&gt;
'''maxillary hypoplasia''':  The underdevelopment of the upper jaw.&lt;br /&gt;
&lt;br /&gt;
'''melatonin''': A hormone secreted by the pineal gland.&lt;br /&gt;
&lt;br /&gt;
'''microcephaly''': The circumference of the head is less than average due to abnormalities of the nervous system. This abnormality can be present at birth or emerge during the first few years of life and reduces both life expectancy and the cognitive functions of the individual affected.&lt;br /&gt;
&lt;br /&gt;
'''microdeletion''':  A genetic mutation in which a part of a chromosome or a sequence of DNA is missing.&lt;br /&gt;
&lt;br /&gt;
'''mosaic''': tissues or cells containing different mixture of genetic sequences&lt;br /&gt;
&lt;br /&gt;
'''mutation''': Event that changes the DNA (deoxyribonucleic acid is a nucleic acid, containing information for protein synthesis) or RNA (ribonucleic acid is a type of nucleic acid transmitting the information from the DNA to the proteins ) of a gene permanently.&lt;br /&gt;
&lt;br /&gt;
'''myoclonic seizures''': A quick jerk of the skeletal muscle, due to a irregular brain activity.&lt;br /&gt;
&lt;br /&gt;
'''neurogenetic''': Genetic basis of the nervous system.&lt;br /&gt;
&lt;br /&gt;
'''neurotransmitter''': Transmits neuronal signals to a target cell. They are first packaged in vesicles just beneath the membrane of presynaptic axon terminals and released into the synaptic cleft (space between the two interacting neurons) and enter the postsynaptic dendrite.&lt;br /&gt;
&lt;br /&gt;
'''occiput''': The back portion of the head.&lt;br /&gt;
&lt;br /&gt;
'''oesophagus reflux''': Impairment of a sphincter in the lower end of the oesophagus leads to the back flow of stomach acid into the oesophagus. Heartburn is a typical symptom.&lt;br /&gt;
&lt;br /&gt;
'''paediatrician''': Physicians that specialise on infants, children and adolescents.&lt;br /&gt;
&lt;br /&gt;
'''paternal UPD''': Inheritance of two copies of a chromosome from the father and none from the mother. &lt;br /&gt;
&lt;br /&gt;
'''phenotype''': Visible traites of an organism determined by genetic and environmental factors.&lt;br /&gt;
&lt;br /&gt;
'''Picture Exchange Communication System (PECS)''': Individuals communicate using images instead of words. It is frequently used by children with autism, to articulate their needs and wishes or to make comments about something.&lt;br /&gt;
&lt;br /&gt;
'''Proband''': Is the person (or animal) being studied or reported on in a genetic investigation. Most commonly it refers to the first affected family member who requires medical help for a genetic disorder. &lt;br /&gt;
&lt;br /&gt;
'''Robertsonian translocation''': Rearrangement of the chromosome, occurs in 5 chromosome including 13,14,15,21 and 22. This type of mutation occurs in chromosomes with the centromere not at the centre, resulting in long and short arm chromosomes. Translocation breaks the chromosome at the centromere so the long arm attaches to the other long arm, and the same for the short arm happens. Cell division will result in the loss of the short arms as they do not contain important genes.&lt;br /&gt;
&lt;br /&gt;
'''seizure''': Abnormal electrical activity in the brain that can result in a variety of physical symptoms like convulsion, body shaking, loss of consciousness, confusion, and mood changes.&lt;br /&gt;
&lt;br /&gt;
'''synapse''': Allows transmission of signal between neurons for effective neuronal function.&lt;br /&gt;
&lt;br /&gt;
'''thoracic scoliosis''': The spine is curved laterally(from side to side) in the thoracic region.&lt;br /&gt;
&lt;br /&gt;
'''tonic-clonic seizures''': This type of seizure is associated with unconsciousness due to electrical discharges in a big proportion of the brain.&lt;br /&gt;
&lt;br /&gt;
'''ubiquitin''': A polypeptide found in all eukaryotic cells, that participates in a variety of cellular functions including protein recycling.&lt;br /&gt;
&lt;br /&gt;
'''Uniparental disomy''': (UPD) the inheritance of two copies of a chromosome pair or part of a chromosme from one parent and no copy from the other parent. &lt;br /&gt;
&lt;br /&gt;
'''valproate''':  A mood-stabilizing drug that is also used for treatment for epilepsy and bipolar disorder.&lt;br /&gt;
&lt;br /&gt;
==Helpful Links==&lt;br /&gt;
&lt;br /&gt;
* Australia&lt;br /&gt;
:* [http://www.angelmansyndrome.org/research.html Angelman Syndrome Association] &lt;br /&gt;
:* [http://www.angelmansyndromeqld.org/ Queensland Angelman Association]&lt;br /&gt;
&lt;br /&gt;
* America&lt;br /&gt;
:* [http://www.angelman.org/ Angelman Syndrome Foundation]&lt;br /&gt;
:* [http://rarediseasesnetwork.epi.usf.edu/arpwsc/ Rare Clinical Diseases Research Network]&lt;br /&gt;
:* [http://www.rarediseases.org/rare-disease-information/rare-diseases/byID/411/viewAbstract National Organisation for Rare Disorders]&lt;br /&gt;
:* [http://www.epilepsyfoundation.org/ Epilepsy Foundation]&lt;br /&gt;
:* [http://www.cureangelman.org/ Foundation for Angelman Syndrome Therapeutics]&lt;br /&gt;
&lt;br /&gt;
* Search Pubmed &lt;br /&gt;
:* [http://www.ncbi.nlm.nih.gov/pubmed?term=(Angelman+Syndrome[MAJR]) Angelman Syndrome] &lt;br /&gt;
&lt;br /&gt;
* OMIM&lt;br /&gt;
:* [http://omim.org/entry/105830 Genetic Disorder catalog]&lt;br /&gt;
&lt;br /&gt;
==Related Links==&lt;br /&gt;
&lt;br /&gt;
* [[Mouse Knockout]] - this page explains the current use of mouse models in disrupting genes to elucidate their genetic function, including the mouse gene knockouts for alpha calcium-calmodulin kinase II (alpha CaMKII)&lt;br /&gt;
* [[2009 Group Project 4]] - this page gives an extensive overview on the history of the mouse model and its various use in embryology and genetics. In addition, it also describes mouse knockout and the role they play in current research of various human diseases&lt;br /&gt;
* [[Fly Development]] - this page describes the use of drosophila flies as developmental models&lt;br /&gt;
* [[2009 Group Project 2]] - this page gives an extensive overview on the history of the fly model and its various use in embryology and genetics&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&lt;br /&gt;
&amp;lt;references /&amp;gt;&lt;/div&gt;</summary>
		<author><name>Z3291643</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_7&amp;diff=77570</id>
		<title>2011 Group Project 7</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_7&amp;diff=77570"/>
		<updated>2011-10-12T20:26:40Z</updated>

		<summary type="html">&lt;p&gt;Z3291643: /* Genetic Counselling */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;='''Angelman Syndrome'''=&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Introduction==&lt;br /&gt;
&lt;br /&gt;
[[File:Dr Harry Angelman.jpg|thumb|130px|right|Dr Harry Angelman.]]&lt;br /&gt;
Angelman syndrome (AS) is a rare [[#Glossary | '''neurogenetic''']] [[#Glossary | '''disorder''']] first described by Dr. Harry Angelman in 1965.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18754889&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Dr. Angelman was an English [[#Glossary | '''paediatrician''']] who first diagnosed the disease in 3 children with a developmental delay.&amp;lt;ref&amp;gt;http://www.ncbi.nlm.nih.gov/books/NBK22221/&amp;lt;/ref&amp;gt; AS occurs in 1 in 10000-20000 births, the exact number is still unknown.&amp;lt;ref name=&amp;quot;PMID7573182&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7573182&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;PMID8703225&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;8703225&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It is caused by maternal [[#Glossary | '''allele''']] disruptions of a single gene- UBE3A. Either [[#Glossary | '''mutations''']] or [[#Glossary | '''deletions''']] of the UBE3A gene results in AS. &lt;br /&gt;
&lt;br /&gt;
AS presents with well known [[#Glossary | '''phenotypes''']] during infancy and adulthood, such as [[#Glossary | '''microcephaly''']] and [[#Glossary | '''maxillary hypoplasia''']]. However, these features become more marked with age. Most frequent clinical features include delayed development,[[#Glossary | '''seizures''']],[[#Glossary | '''ataxia''']], impairment of speech, happy demeanor, behavioural problems such as hyperactivity, short attention span and sleeping difficulty.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21592595&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21484597&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;ASAwebsite&amp;quot;&amp;gt;http://www.angelmansyndrome.org/home.html&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
At present, there is no cure for the syndrome, though current research is focused at improving life quality of patients with Angelman syndrome through management of daily tasks.&amp;lt;ref&amp;gt;http://www.bbc.co.uk/health/physical_health/conditions/angelman1.shtml&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==History==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Dr. Harry Angelman first reported Angelman Syndrome on three handicapped children that were admitted to his ward in England in 1964.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt; He reported how these three independent and unconnected clinical cases all had the same characteristic features of severe developmental delay, jerky movements, seizures and a happy disposition.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt; However it was only when he stumbled upon an oil painting called ‘a Boy with a Puppet” while on a holiday in Italy he was able to connect the symptoms of all three children under one common cause.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20981772&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; He linked the happy face of the boy depicted on the painting with the jerky movements and happy disposition he observed on his three patients back in England. He reported his findings on a paper entitled “Puppet children (a report on three cases)” which was published in 1965.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
The syndrome was initially named ‘Puppet Syndrome’ but was later changed to Angelman Syndrome. Due to the extreme rarity of the syndrome and lack of sufficient clinical evidence the syndrome was soon forgotten.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt;&lt;br /&gt;
[[File:Dr Charles Williams.jpg|thumb|right|150px|Dr Charles Williams.]]&lt;br /&gt;
	&lt;br /&gt;
In 1987, a physician named Ellen Magenis, came across children with deletions on [[#Glossary | '''chromosome''']] 15 that were suffering from seizures and severe developmental delay.&amp;lt;ref&amp;gt;http://www.angelman.org/stay-informed/facts-about-angelman-syndrome---7th-edition/harry-angelman-and-the-history-of-as/&amp;lt;/ref&amp;gt; Even though genetically the children were expected to have [[#Diagnosis | '''Prader-Willi syndrome''']] that was characterised by deletions on chromosome 15, their characteristic symptoms of seizures and lack of development did not correspond with that of the syndrome. This led to the realization that these children had deletions on the maternally derived chromosome 15 and not on the paternally derived chromosome as was observed in Prader-Willi syndrome.  Thus the deleted genetic code on maternally derived chromosome 15 was identified as the genetic marker for Angelman Syndrome.&lt;br /&gt;
&lt;br /&gt;
In 1997, UBE3A gene was isolated by Dr. Joseph Wagstaff and Dr. Arthur Beaudet as the cause of Angelman Syndrome.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot; /&amp;gt; The discovery of this [[#Glossary | '''gene''']] led to the subsequent development of animal models and research aimed at finding a causal link between UBE3A gene abnormalities and characteristic features observed in Angelman Syndrome. &lt;br /&gt;
	&lt;br /&gt;
Currently, four different genetic abnormalities for Angelman Syndrome have been confirmed by genetic testing. They include: Deletion, [[#Glossary | '''Uniparental Disomy''']] (UPD), [[#Glossary | '''Imprinting''']] and UBE3A mutation.&amp;lt;ref name=&amp;quot;PMID20211139&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Below is a timeline, summarising the key discoveries and advancements of the Angelman Syndrome:&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|- bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
!Year&lt;br /&gt;
!Milestone&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1964'''&lt;br /&gt;
|First observed by Dr Harry Angelman on three handicapped children.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot; /&amp;gt; &lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''1965'''&lt;br /&gt;
|Harry Angelman publishes his finding in a report entitled 'Puppet Children'(a report on three cases).&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1980s'''&lt;br /&gt;
|First reports of AS reaches US and research into the disorder being at the University of Florida under the direction of Dr. Charles Williams.&amp;lt;ref&amp;gt;http://www.angelmanproject.com/history.htm&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''1982'''&lt;br /&gt;
|Name changed from 'Happy Puppet' to Angelman syndrome by Williams and Frias. &lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1987'''&lt;br /&gt;
|Discovery of a genetic marker for AS – an absent genetic code on maternally derived chromosome 15. &lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''1997'''&lt;br /&gt;
|The cause of AS discovered by Dr. Joseph Wagstaff and Dr. Arthur Beaudet – mutation or deletion in the UBE3A gene.&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1998'''&lt;br /&gt;
|Transgenic mice with absent maternal UBE3A created to illustrate motor and learning deficits in addition to seizures.&amp;lt;ref name=&amp;quot;PMID9808466&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9808466&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''2007'''&lt;br /&gt;
|AS mouse model shows that neurological deficits can be reversed by decreasing levels of [[#Glossary | '''alpha-CaMKII''']] inhibitory phosphorylation.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17259980&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''2010'''&lt;br /&gt;
|Discovery of a another gene mutation in TC4 gene (on chromosome 18) in a small number of clinically diagnosed patients with no identifiable genetic alternation in UBE3A.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20184619&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''2010'''&lt;br /&gt;
|Protein named Arc identified as a target of AS gene product; UBE3A.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Incidence'''&lt;br /&gt;
*The current population of people diagnosed with AS is unknown but studies have estimated the number to be around 1:10,000&amp;lt;ref name=&amp;quot;PMID7573182&amp;quot; /&amp;gt; and 1:20,000&amp;lt;ref name=&amp;quot;PMID8703225&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
'''Diagnosis'''&lt;br /&gt;
*The mean age of diagnosis for patients with AS lies between 6 and 6.5 years of age.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18664077&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15741136&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Gender'''&lt;br /&gt;
* Males appear to be at higher risk for some aspects of early developmental delays in comparison to females with AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17019625&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Demography'''&lt;br /&gt;
*Europe:&lt;br /&gt;
:Denmark- 1:10,000&amp;lt;ref name=&amp;quot;PMID7573182&amp;quot; /&amp;gt;&lt;br /&gt;
:Estonia- 1:52,000&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16906556&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
:Sweden- 1:20,000&amp;lt;ref name=&amp;quot;PMID8703225&amp;quot; /&amp;gt;&lt;br /&gt;
*Australia:&lt;br /&gt;
:Western Australia- 1:40,000&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16492624&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Aetiology==&lt;br /&gt;
&lt;br /&gt;
[[File:Chromosome 15 Deletion of 15q11.2 to 15q13.jpg|thumb|100px|Chromosome 15 - The deletion occurs at 15q11.2-15q13.]]&lt;br /&gt;
&lt;br /&gt;
Different genetic mechanisms lead to different clinical phenotypes of AS. The most common genetic mechanism leading to AS is the deletion or re-arrangement of maternal chromosome at [[#Glossary | '''locus''']] 15q11.2-q13,as the chromosome image shows on the right, accounting for 70% of AS occurrences.&amp;lt;ref name=&amp;quot;PMID8988171&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt; 8988171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This leads to more severe clinical phenotypes of microcephaly, motor difficulties, seizures and impaired speech development. The next most common genetic mechanism is mutation in the ''UBE3A'' gene responsible for 10% of AS cases and paternal uniparental disomy and mutation in the imprinting centre (IC), both accounting for 2-5% of AS observed.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
 &lt;br /&gt;
&lt;br /&gt;
AS is caused by the 4 major genetic mechanisms mentioned above and are thus divided into Classes I to IV based on their underlying genetic mechanism. AS patients with the clinical features of AS but no [[#Glossary | '''cytogenetic''']] or molecular abnormality in Chromosome 15q11.2-13 are grouped under Class V (summarised in table below).&amp;lt;ref name=&amp;quot;PMID8988171&amp;quot; /&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10364509&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''Inheritance'''&lt;br /&gt;
&lt;br /&gt;
Angelman Syndrome from UBE3A mutations and deletions in the Imprinting Centre follow an inheritance pattern. A carrier father with the genetic defect can pass it on to his children, however, his children will be clinically normal. On the other hand, a carrier mother can pass the genetic defect onto her children, who will then have Angelman Syndrome. &lt;br /&gt;
&lt;br /&gt;
The image highlights the inheritance of Angelman Syndrome, which only results after a carrier mother passes it on to her children. &lt;br /&gt;
&lt;br /&gt;
{|  style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
! Class&lt;br /&gt;
! Mechanism&lt;br /&gt;
! Diagnostic Tests&lt;br /&gt;
! Frequency&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''Ia'''                           &lt;br /&gt;
| De novo deletion                                                                                           &lt;br /&gt;
| High resolution cytogenetics [[#Glossary | '''FISH''']]                                                                                                       &lt;br /&gt;
| 70%      &lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Ib'''&lt;br /&gt;
| Deletion due to chromosome rearrangement&lt;br /&gt;
| High resolution cytogenetics FISH&lt;br /&gt;
| &amp;lt;1%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''II'''&lt;br /&gt;
| Paternal uniparental disomy&lt;br /&gt;
| [[#Glossary | '''RFLP''']]  analysis&lt;br /&gt;
| 2%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''IIIa'''&lt;br /&gt;
| Imprinting defect with IC mutation&lt;br /&gt;
| Screening of [[#Glossary | '''IC''']]  for mutations is positive&lt;br /&gt;
| 2%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''IIIb'''&lt;br /&gt;
| Imprinting defect withouth IC mutation&lt;br /&gt;
| Screening of IC for mutations is negative&lt;br /&gt;
| 2%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''IIIc'''&lt;br /&gt;
| Mosaic imprinting defect&lt;br /&gt;
| Screening of IC for mutations is usually negative &lt;br /&gt;
| ?&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''IV'''&lt;br /&gt;
| ''UBE3A'' mutation&lt;br /&gt;
| Screening of ''UBE3A'' for mutations&lt;br /&gt;
| 5-10%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''V'''&lt;br /&gt;
| No identifiable genetic abnormality&lt;br /&gt;
| Consider other diagnoses&lt;br /&gt;
| 5-26%&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Pathogenesis==&lt;br /&gt;
&lt;br /&gt;
Chromosome 15 became associated with AS in the 1980s after the observation of many AS patients harboring [[#Glossary | '''microdeletions''']] of 15q11.2-15q13.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15668046&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The last decade has shed even more light in the aetiology of AS,as Kishino and Matsuura first identified UBE3A as the causative gene for AS in 1997.&amp;lt;ref name=&amp;quot;PMID:8988171&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;8988171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8988172&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Normal gene product: E6-AP ubiquitin ligase'''&lt;br /&gt;
&lt;br /&gt;
The function of UBE3A is to encode for [[#Glossary | '''E6-AP''']] ubiquitin ligase, however its function in the development of the nervous system and the process of UBE3A mutation leading to cognitive impairment in AS patients is still vague.&amp;lt;ref name=&amp;quot;PMID:20211139&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Past and current research has elucidated that E6-AP ubiquitin ligase is involved in the degradation of four proteins, listed below, but currently, no protein with a direct role in [[#Glossary | '''long-term potentiation (LTP)''']] as a target of E6-AP, has been identified.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12684449&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The identification of such target proteins would be a landmark discovery in further understanding of the pathogenesis, aetiology and prospective treatment strategies of AS, as LTP defects is one of the major neurological impairments of AS. &lt;br /&gt;
 &lt;br /&gt;
* p53 tumor suppressor protein &lt;br /&gt;
* yeast DNA repair protein Rad23 &lt;br /&gt;
* multicopy maintenance protein 7 subunit &lt;br /&gt;
* E6-AP&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Abnormal gene product'''&lt;br /&gt;
&lt;br /&gt;
Disruption to the gene,UBE3A, interferes with the normal functioning of the gene, which is its crucial role in UBE3A [[#Glossary | '''ubiquitylation''']]. Problems involving this pathway can lead to various diseases either from the loss or gain of function.&amp;lt;ref name=&amp;quot;PMID:9857172&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9857172&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In the case of AS, E6-AP is affected, leading to detrimental cognitive impairment in addition to other deficits.&amp;lt;ref name=&amp;quot;PMID:9857172&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9857172&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Regional functioning of UBE3A'''&lt;br /&gt;
&lt;br /&gt;
Despite the uncertain progression of UBE3A mutation and the neurological abnormalities characteristic of AS, animal models have illustrated the vital role of UBE3A in the normal functioning of the brain. This can be exemplified by a study which utilized a mouse model with target inactivation of the gene UBE3A resulting in the manifestation of classical features of AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11895368&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In addition, the fact that imprinting of UBE3A takes place only in specific brain regions (cerebellum, olfactory tracts and the hippocampus) confirms the hypothesis that the loss of this gene would be detrimental in the cognitive development.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20398390&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Most genes are inherited in copies of two, one paternal and the other maternal; however, some genes, such as UBE3A only have one functional copy as the other is silenced, coined 'imprinting'. Imprinting of the paternal copy of UBE3A takes place in some cell populations, such as the hippocampal neurons and Purkinje cells in the cerebellum.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9288101&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This means only the maternal UBE3A is functionally expressed in these particular brain regions. Thus a [[#Glossary | '''de novo mutation''']] in the maternal copy of the gene will result in the complete absence of functional E6-AP in the associated brain areas.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9288088&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
It is also known that UBE3A plays an important role in synaptic transmission, but exactly how it does so is still not completely understood.&amp;lt;ref name=&amp;quot;PMID:9808466&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9808466&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''UBE3A ubiquitylation'''&lt;br /&gt;
&lt;br /&gt;
As briefly mentioned above, UBE3A is a member of the E3 ubiquitin ligase family of enzymes, responsible for the addition of ubiquitin to the target protein for degradation of the ubiquitinated protein, as illustrated in the diagram below. These processes are required for normal human cognitive function.&amp;lt;ref name=&amp;quot;PMID:9808466&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9808466&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In this way synaptic protein [[#Glossary | '''Arc (activity-regulated cytoskeleton-associated protein)''']] is degraded to control synaptic function. Arc is a target protein of UBE3A in dendritic spines found in the hippocampal neurons.&amp;lt;ref name=&amp;quot;PMID:20668179&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20668179&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Deletion of UBE3A leads to the accumulation of Arc in neurons leading to trafficking of [[#Glossary | '''AMPA ( α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid)''']] receptors, resulting in impaired cognitive functions.&amp;lt;ref name=&amp;quot;PMID:20211139&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; [[File:UBE3A Ubiquitylation Pathway.png|thumb|350px|right|UBE3A Ubiquitylation Pathway.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
UBE3A ubiquitylation consists of:&amp;lt;ref name=&amp;quot;PMID:20668179&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20668179&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
# Activation of ubiquitin by E1 enzyme&lt;br /&gt;
# E1 ezyme transfers ubiquitin to E2 enzyme&lt;br /&gt;
# E2 enzyme transfers ubiquitin to UBE3A&lt;br /&gt;
# UBE3A attaches activated ubiquitin to target protein which is then polyubiquitylated &lt;br /&gt;
# Target protein is then degraded by 26S proteosome&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Phenotype-Genotype correlations'''&lt;br /&gt;
&lt;br /&gt;
[[File:Extent of microcephaly in Angelman Syndrome patients.png|thumb|250px|right|Extent of microcephaly in 20 AS patients with deletion and without deletion.&amp;lt;ref&amp;gt;http://www.nature.com/ejhg/index.html/&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
All AS patients show differing extents of cognitive impairment, movement disorder, characteristic behaviours and difficulty in speech and language.&amp;lt;ref name=&amp;quot;PMID:11748306&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11748306&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; However, there seems to be some phenotype-genotype correlations:&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
- 5-7Mb deletions result in the most severe phenotypes such as microcephaly, more sever [[#Glossary | '''epilepsy''']] and seizures, motor difficulties and language impairment.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9546330&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20445456&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; AS patients with large deletions also present with clinical [[#Glossary | '''hypopigmentation''']], light hair and eye colour due to the close association of OCA2 gene with UBE3A.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;16470747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Individuals under this category have in general no increased BMI&amp;lt;ref name=&amp;quot;PMID:15253756&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15253756&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This is indicated by the graph on the left, which shows more cases of AS patients with deletions having larger deviations from the mean head circumference measurement than non-deletion AS patients.&lt;br /&gt;
 &lt;br /&gt;
- AS patients with uniparental disomy (UPD) have better physical growth, fewer motor deficits and lower seizure occurrences.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16023557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
- Individuals with AS resulting from imprinting defects have the least debilitating features, such as higher developmental and language ability than AS caused by other mechanisms.&amp;lt;ref name=&amp;quot;PMID:11748306&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11748306&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
- The Body Mass Index (BMI) of 33% of the UBE3A mutation patients, and 47–64% of the patients from the classes II (UPD) and III (Imprinting defect) is above the 95th centile.&amp;lt;ref name=&amp;quot;PMID:15253756&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15253756&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Animal models'''&lt;br /&gt;
&lt;br /&gt;
* '''Drosophila'''&lt;br /&gt;
&lt;br /&gt;
Drosophila (common fruit fly) is an excellent model to use for better understanding of genetic diseases in humans as they are highly homologous to human UBE3A (hUBE3A), illustrating a high evolutionary conservation. Studies using the Drosophila model have shown that the functional absence of UBE3A resulted in decreased morphogenesis of dendritic branches. This is of interest as dendritic branches cover over 90% of the neuronal surface where [[#Glossary | '''synapse''']] between neurons occur. Proper formation and maturation of dendritic spines is also required so they come in contact with other neurons for effective transmission of neuronal signals. Thus proper formation of dendritic branching is pivitol for effective neuronal function and hence cognitive function.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18996915&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Interestingly, overexpression of dUBE3A also gave the same result, consisting of abnormal locomotion  and decreased dendritic branching in sensory neurons.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18701717&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;  This suggests a possible research field for some forms of [[#Glossary | '''autism''']] where the region containing UBE3A is duplicated, leading to delayed motor skills and seizures.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16433693&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;[[File:Normal and Angelman Syndrome mice models.jpg|thumb|250px|right|Normal and AS mice performance on the Rotarod apparatus.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
* '''Mice'''&lt;br /&gt;
&lt;br /&gt;
Absence of UBE3A in mice manifest similar phenotype to human AS, as illustrated by motor and learning deficits with inducible seizures.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21235769&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It has been shown through various mice model studies that larger deletions, ie. from UBE3A to GABRB3, more closely mirrors the large 6Mb deletions seen in human AS patients. Numerous tests, such as the Rotarod (for motor coordination and learning ability), Morris water maze test (for spatial learning and memory) and [[#Glossary | '''EEG''']] (electroencephalography), were carried out on  UBE3A null mutants, which showed the results to be abnormal or impaired.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20808828&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Other studies using mouse models have also outlined the obesity observed in 15% of AS children, albeit it is not the major characterisitics of AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17259980&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The diagram on the right clearly highlights the results obtained from such mouse model studies of AS, where the absence of UBE3A accumulated in deficits of motor function and obesity. In addition, excessive drooling and feeding difficulties were also highlighted by mice models with inactivated UBE3A, reflected by defects in fluid consumption and licking.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18413322&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Pathophysiology===&lt;br /&gt;
&lt;br /&gt;
'''Cognitive defects'''&lt;br /&gt;
&lt;br /&gt;
[[File:Role of UBE3A in dendritic spine neuronal synapses.png|thumb|250px|right|Role of UBE3A in dendritic spine neuronal synapses.]]&lt;br /&gt;
&lt;br /&gt;
AS patients present with abnormally high UBE3A, leading to neurological impairment. Recent identification of key target proteins of Ephexin-58 (Eph-5) and Arc (Activity-Regulated Cytoskeleton-associated protein) have aided in better understanding of the progression of UBE3A to cognitive defects. These two proteins are vital in the understanding of AS as Eph-5 determines synapse numbers and Arc contributes to plasticity and synapse function.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21164477&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Studies utilizing mice models have illustrated that UBE3A null mice could not ubiquitinate Eph-5, thus increasing its levels and limiting the growth of dendritic spines by the activation of RhoA. This subsequent activation of RhoA inhibits synapse formation and results in neuronal defects.&lt;br /&gt;
&lt;br /&gt;
In contrast, mice with normally functioning UBE3A showed phosphorylated Eph-5, resulting from the interaction of two neurons via the activation of EphB signalling receptor.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21029865&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Phosphorylation of Eph-5 allows UBE3A to ubiquitinate and degrade it. This degradation of Eph-5 permits new synaptic connections to form with cells they come into contact with. However, in AS, the absence of UBE3A means Eph-5 cannot be degraded, so RhoA activity is prolonged to reduce synaptic formation.&lt;br /&gt;
&lt;br /&gt;
As mentioned previously, Arc plays a pivitol role in synapse function as it removes synaptic receptors that respond to glutamate, a [[#Glossary | '''neurotransmitter''']].&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17088211&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In UBE3A present neurons, UBE3A ubiquitinates Arc, leading to it degradation as illustrated by the diagram on the left. However, in UBE3A deficient neurons, Arc accumulates and prevents the proper synaptic communications essential for normal cognitive functions.&amp;lt;ref name=&amp;quot;PMID20211139&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Signs and Symptoms==&lt;br /&gt;
&lt;br /&gt;
Angelman Syndrome presents a variety of different phenotypes, and the presented symptoms may vary at different ages.&amp;lt;ref name=&amp;quot;PMID7625442&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7625442&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
In 1995 Williams et al. embraced the observed clinical features of AS in a consensus statement, in order to present an appliance for clinicians. The diagnostic criteria were updated in 2005.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt; The following table shows the most frequently occurring characteristics in AS patients:&lt;br /&gt;
&lt;br /&gt;
'''4 characteristics appear in 100% of the cases:'''&lt;br /&gt;
&lt;br /&gt;
*Delayed development: become apparent by the age of 6 to 12 months.&lt;br /&gt;
*Motion and or balance malfunction&lt;br /&gt;
*Behaviour patterns like unmotivated laughter, frequent excitement; often including body movements,[[File:Electroencephalography of Angelman Syndrome.jpg|thumb|350px|right|EEG of AS and normal individuals.]] [[#Glossary | '''hypermotoric''']] behaviour&lt;br /&gt;
*Impairment of speech&lt;br /&gt;
&lt;br /&gt;
'''3 characteristics appear in more than 80% of the cases:'''&lt;br /&gt;
&lt;br /&gt;
*Abnormalities in head circumference, microcephaly&lt;br /&gt;
*Seizures&lt;br /&gt;
*EEG shows specific abnormal patterns&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Angelman Syndrome individuals show the most distinct disease pattern from 2 to 16 years of age.&lt;br /&gt;
In most cases at least 8 of the symptom traits are shown.&amp;lt;ref name=&amp;quot;PMID7625442&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Behavioural Characteristics'''&lt;br /&gt;
&lt;br /&gt;
A range of substantial characteristics appear in all AS cases, regardless of the genetic mechanisms, and are often responsible for diagnosing the syndrome. According to the original name, Happy Puppet syndrome, they have shown to exhibit traits such as a happy demeanor, with frequent laughter or smiling that can easily be triggered.&amp;lt;ref name=&amp;quot;PMID12566516&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12566516&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This behaviour can already be observed in 1 to 3 month old infants.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot; /&amp;gt; Uplifted hand flapping or waving motions are associated with laughter and excitement. Other characteristics manifesting in early childhood are sleep abnormalities with reduced sleep demand, and feeding problems. Breast and bottle feeding can be difficult due to non efficient attachment to the breast, tongue thrusting and uncoordinated sucking. Furthermore, there is an affection to crinkly and reflective surfaces, like some papers or plastic materials, especially water.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID12566516 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Communication Skills'''&lt;br /&gt;
&lt;br /&gt;
Communication is challenging for AS patients due to the fact that speech impairment is present in all cases. In the majority of affected people a lack of speech development is present. Only some of them have a minimal vocabulary consisting of two or three words, a few can speak in basic sentences. Some patients use gestures to articulate themselves, the [[#Glossary | '''Picture Exchange Communication System (PECS)''']] or sign languages such as [[#Glossary | '''Makaton''']] can be used for communication. Simple demands regarding their everyday occurrence can be understood by most patients.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID12566516 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Clinical and External Characteristics'''[[File:Angelman Syndrome patient.png|thumb|200px|right|4 year old AS patient.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Developmental delays are present in all patients. Motor milestones are delayed with children managing to sit unsupported with 12 months and crawl or bottom shuffle at the age of 18-24 months. The average age for walking is 4 years,however, ranging from 18 months to 7 years.&lt;br /&gt;
The [[#Glossary | '''gait''']] is characterised as slow, and flapping hands are a common trait.  The legs remain stiff during walking, arms are inflected by the wrists and elbows. The movements can appear ataxic, jerky or lurching. The muscle tone shows abnormalities with truncal [[#Glossary | '''hypotonia''']] and [[#Glossary | '''hypertonicity''']] of the limbs and alert reflexes.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID12566516 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The most striking external traits present in patients include broad-spaced teeth, and a wide mouth, light hair and eye colour, hypopigmented skin, deep set eyes, and a flat [[#Glossary | '''occiput''']].&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Seizures in Angelman Syndrome'''&lt;br /&gt;
&lt;br /&gt;
85% of AS patients suffer from epileptic seizures during their first three years. The first appearance can be within one month up to 20 year old patients. In infants with AS epilepsy manifests with [[#Glossary | '''febrile convulsions''']] and is hard to manage during childhood.&lt;br /&gt;
The most common type of seizures within 25% of patients are [[#Glossary | '''myoclonic seizures''']], followed by [[#Glossary | '''atonic seizures''']] as the second most frequent type, then 21% experience generalised [[#Glossary | '''tonic-clonic seizures''']] and lastly [[#Glossary | '''atypical absences''']] occur in 12% of patients.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20398390&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Angelman Syndrome in adults'''&lt;br /&gt;
&lt;br /&gt;
Patients with Angelman syndrome possess normal secondary sexual characteristics, and puberty sets in at a usual time. Limb hypertonicity, and [[#Glossary | '''thoracic scoliosis''']] lead to decreasing mobility. [[#Glossary | '''Oesophagus reflux''']] might induce severe problems, and the majority suffers from obesity. Furthermore, facial traits such as a prominent lower lip [[#Glossary | '''macrostomia''']] and [[#Glossary | '''mandibular prognathism''']] get manifested in adults. &lt;br /&gt;
In some cases the communication barrier can lead to frustration, resulting in aggressive behaviour. Nonetheless, patients gain a higher concentration span with age, and their nature becomes more quiet.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Complications===&lt;br /&gt;
&lt;br /&gt;
'''Hypopigmentation and Ocular albinism'''&lt;br /&gt;
&lt;br /&gt;
OCA2 gene, also known as the P gene, is closely located to the UBE3A gene. It encodes a protein vital to tyrosine metabolism, which plays a role in pigmentation development of skin, hair and eyes. However, AS caused by the large deletion of UBE3A leads to haploinsufficiency of OCA2 gene, resulting in hypopigmentation of the skin and the eyes. In some children with severe hypopigmentation, some form of [[#Glossary | '''albinism''']] is suspected.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12749060&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; When AS is caused by another mechanism, no abnormality of the skin and eye pigmentation is observed. However, not all AS children with OCA2 gene deletion will present with obvious hypopigmentation, they may just exhibit lighter skin colour than their parents.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8302318&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Diagnosis==&lt;br /&gt;
&lt;br /&gt;
The diagnosis of Angelman Syndrome is a clinical diagnosis confirmed by laboratory testing.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This involves both prenatal and/or postnatal diagnosis. &lt;br /&gt;
&lt;br /&gt;
===Prenatal Diagnosis===&lt;br /&gt;
[[File:Angelman Syndrome Prenatal Diagnosis.jpg|thumb|250px|right|Flowchart of AS Diagnosis.]]&lt;br /&gt;
&lt;br /&gt;
Prenatal detection of deletions of 15q11.2-q13, [[#Glossary | '''Paternal UPD''']] ([[#Glossary | '''Uniparental Disomy''']]), Imprinting defects and UBE3A mutations are done through DNA/chromosome/FISH analysis of fetal cells obtained by either [[#Glossary | '''Chorionic Villus Sampling''']](CVS) or [[#Glossary | '''Amniocentesis''']].&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot;/&amp;gt; &lt;br /&gt;
DNA methylation analysis using [[#Glossary | '''Amniocytes''']] is usually the first test carried out in molecular diagnosis of AS.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18059071&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; An abnormal result is followed up by either a FISH or array CGH analysis to search for a deletion on chromosome 15. If they produce a normal result, then UPD testing using DNA polymorphysims is carried out. If there is no evidence of UPD, other DNA analysis tests are used search for an imprinting centre deletion.&amp;lt;ref name=&amp;quot;PMID9792887&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9792887&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; A normal DNA methylation analysis is followed by a UBE3A sequence analysis.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt; In addition, a parent of origin test is also done to determine if the genetic disruption is of maternal origin or paternal origin. If it is maternally derived the fetus is diagnosed with AS (a paternally derived genetic disruption is indicative of Prader-Willi Syndrome).&amp;lt;ref name=&amp;quot;PMID17020468&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;17020468&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The flow chart summarizes the normal procedure used for prenatal diagnosis of AS. More information on important laboratory tests used for the diagnosis of Angelman Syndrome are provided below:&lt;br /&gt;
&lt;br /&gt;
*'''DNA Methylation Analysis'''&lt;br /&gt;
&lt;br /&gt;
Identifies approximately 80% of AS affected individuals and is usually the first test to be ordered.&amp;lt;ref name=&amp;quot;PMID7618904&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7618904&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Molecular disruptions such as deletions, paternal UPD and imprinting defects on chromosome 15 all demonstrate abnormal methylation patterns by either southern blot analysis or PCR amplification of bisulphate-treated DNA.&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot; /&amp;gt; An affected individual will only have an unmethylated (paternal) SNRPN (small nuclear ribonuclear protein-associated polypeptide N) allele compared with an unaffected individual who will have both a methylated and an unmethylated SNRPN allele.&amp;lt;ref name=&amp;quot;PMID9634532&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9634532&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
	  &lt;br /&gt;
*'''FISH (Fluorescent In Situ Hybridization)'''&lt;br /&gt;
&lt;br /&gt;
[[File:Critical_region_of_Angelman_Syndrome_on_chromosome_15.png‎|thumb|150px|right|FISH (fluorescence in situ hybridisation) image showing the critical region of Angelman Syndrome on chromosome 15.]]&lt;br /&gt;
&lt;br /&gt;
FISH analysis detects 5-7 Mb deletions in approximately 68% of affected individuals using detecting probes such as D15S10 and/or SNRPN.&amp;lt;ref name=&amp;quot;PMID7618904&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7618904&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It is also able to distinguish UPD from micro-deletions and imprinting defects. In simple terms, FISH analysis involves the binding of a fluorescent probe to a specific part of chromosome 15 and the detection of deletions within that region. FISH analysis is much more accurate in deletion detection compared to other high-resolution cytogenetics in the diagnosis of AS patients.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1511093&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
Array-based CGH is an advanced type of cytogenetic testing that can also be used to detect smaller deletions.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''UPD (Uniparental Disomy) Detection'''&lt;br /&gt;
&lt;br /&gt;
DNA Polymorphism testing detects paternal UPD in approximately 7% of affected AS individuals.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt; It is also able to distinguish between UPD and an Imprinting defect. It requires a DNA sample from the [[#Glossary | '''Proband''']] and from both parents. A homologous or non-homologous whole-arm translocation of the long arms of chromosome 15 is a sound indication for the need for prenatal UPD testing.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''IC (Imprinting Center) Analysis'''&lt;br /&gt;
&lt;br /&gt;
This type of analysis is used when individuals have an abnormal DNA methylation pattern but show normal results for  FISH, array CGH study and UPD analysis.&amp;lt;ref name=&amp;quot;PMID9792887&amp;quot;/&amp;gt; It is used to differentiate between the Imprinting defects caused by either microdeletions in the AS imprinting centre or by epigenetic mutations (that occur in maternal oogenesis or early embryogenesis).&amp;lt;ref name=&amp;quot;PMID9634532&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''Cytogenetic Testing'''&lt;br /&gt;
&lt;br /&gt;
Is used to detect a cytogenetically visible chromosomal rearrangement (large deletion, translocation or inversion) involving the 15q11.2-q13 region, which occurs in less than 1% of affected individuals.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''UBE3A Sequence Analysis'''&lt;br /&gt;
Sequence analysis of the UBE3A gene detects mutations in about 10% of the patients.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt; The test is used to detect either multiexonic (10 major coding exons of UBE3A) or whole gene deletions of UBE3A gene in individuals who produces a normal DNA methylation result but has characteristic clinical features of AS.&amp;lt;ref name=&amp;quot;PMID9792887&amp;quot;/&amp;gt;&lt;br /&gt;
This is recommended as a prenatal diagnostic tool in families that include multiple AS affected individuals because the imprinted pattern can be inherited from distant relatives.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Postnatal Diagnosis===&lt;br /&gt;
&lt;br /&gt;
Postnatal diagnosis is made though a combination of common clinical features of AS and UBESA gene sequence analysis.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt; The clinical features of AS include unsteady or shaky movements, muscle hypotonia, developmental delay and behavioral uniqueness such as frequent laughter/smiling and happy demeanor are features that are 100% consistent in all patients diagnosed with Angelman Syndrome.&amp;lt;ref name=&amp;quot;PMID18830393&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18830393&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; These clinical features become apparent between 6 months to 2 years of age. The onset of early or persistent smiling characteristic of this syndrome begin around the age of 1-3 months, but is often overlooked during infancy.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot;/&amp;gt; Thus early diagnosis of AS during infancy period is difficult because the clinical indicators of the syndrome takes time to manifest and characteristic features such as finger and hand tremors and excessive smiling/laughter are often overlooked and not considered as possible indicators of this syndrome.&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
*Rett Syndrome&lt;br /&gt;
&lt;br /&gt;
Some children with the clinical diagnosis of AS but no underlying genetic mechanism show mutations in ''MECP2'' gene, corresponding to Rett Syndrome. This should be suspected in AS test negative girls in the first few years of life.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17980307&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*Mowat-Wilson Syndrome&lt;br /&gt;
&lt;br /&gt;
Genetic mechanism is heterozygous deletion or truncation in ''ZFHX1B'' (''SIP1'') gene on 2q22. This presents with clinical features of severe intellectual disability, micrcephaly and seizures.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17958891&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Prader-Willi Syndrome patient.png|thumb|right|120px|12 year old PWS patient.]]&lt;br /&gt;
&lt;br /&gt;
*X-linked alpha-thalassemia/mental retardation syndrome (ATR-X)&lt;br /&gt;
&lt;br /&gt;
This arises from mutations in ''XNP'' gene on Xq13. ATR-X presents with severe intellectual disability, no speech development and seizures are common.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11449489&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*Phelan-McDermid Syndrome/22q13 deletion syndrome&lt;br /&gt;
&lt;br /&gt;
Deletions are usually submicroscopic and thus requires special molecular cytogenetic methods to confirm this deletion. Patients show moderate to profound intellectual disability and delay in speech development.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18505557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Related Disease'''&lt;br /&gt;
&lt;br /&gt;
*Prader-Willi Syndrome(PWS)&lt;br /&gt;
&lt;br /&gt;
PWS is a result from the absence of paternally expressed 15q11-q13 gene as a corollary of de novo deletion, maternal uniparental disomy of chromosome 15 or an imprinting defect on paternal chromosome 15 leading to the silencing of paternal alleles.&amp;lt;ref name=&amp;quot;PMID:20668179 &amp;quot;/&amp;gt; It is characterized by [[#Glossary | '''hyperphagia''']], obesity in later infancy and early childhood and difficulty in feeding during early infancy.&amp;lt;ref name=&amp;quot;PMID:20668179 &amp;quot;/&amp;gt; There is also cognitive impairment to some extent, though some PWS patients may exhibit intelligence in the normal IQ range. Behavioral phenotypes include stubbornness, manipulative tendency, obsessive compulsive characteristics.&amp;lt;ref name=&amp;quot;PMID:20668179 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Genetic Counselling==&lt;br /&gt;
&lt;br /&gt;
Genetic counselling is the process by which patients or relatives, at risk of an inherited disorder, are advised of the consequences and nature of the disorder, the probability of developing or transmitting it, and the options open to them in management and family planning. In the case for Angelman syndrome, types of risks associated are split into classes and formatted into the table below:&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20459762&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{|  style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
! Class&lt;br /&gt;
! Mechanism&lt;br /&gt;
! Risk to siblings&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! Ia                           &lt;br /&gt;
| De novo deletion                                                                                                               &lt;br /&gt;
| &amp;lt;1%                                                                                                                &lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! Ib&lt;br /&gt;
| Deletion due to chromosome rearrangement&lt;br /&gt;
| Up to 50%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! II&lt;br /&gt;
| Paternal uniparental disomy (UPD)&lt;br /&gt;
| &amp;lt;1%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! IIIa&lt;br /&gt;
| Imprinting defect with IC mutation&lt;br /&gt;
| Close to 100% if father has 15; 15 [[#Glossary | '''Robertsonian translocation''']]&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! IIIb&lt;br /&gt;
| Imprinting defect without IC mutation&lt;br /&gt;
| Up to 50% (if mother has IC deletion)&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! IIIc&lt;br /&gt;
| [[#Glossary | '''Mosaic''']] imprinting defect&lt;br /&gt;
| &amp;lt;1%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! IV&lt;br /&gt;
| ''UBE3A'' mutation&lt;br /&gt;
| Up to 50% (if mother has mutation)&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! V&lt;br /&gt;
| No identifiable genetic abnormality&lt;br /&gt;
| ?&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Ia''': Individuals with de novo deletion have 1% risk to siblings&lt;br /&gt;
&lt;br /&gt;
'''Ib''': Risk to siblings in individuals with chromosomal rearrangements is up to 50% &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9557895&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''II''': Paternal UPD with no Robertsonian translocation has a risk to sibling of less than 1%&lt;br /&gt;
&lt;br /&gt;
'''IIIa''': The risk to siblings in individuals with AS from an imprinting defect with a mutation in the imprinting center (IC) is close to 100% if father has 15;15 Robertsonian translocation&lt;br /&gt;
&lt;br /&gt;
'''IIIb''': Individuals with AS resulting from an imprinting defect without IC mutation, but with a carrier mother has a high risk to siblings of up to 50%. The mother could be phenotypically normal due to paternal inheritance of the genetic defect &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11283796&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''IIIc''': Individuals who are mosaic for the imprinting defect have less than 1% risk to siblings&lt;br /&gt;
&lt;br /&gt;
'''IV''': UBE3A mutation can be either inherited or de novo mutation. If the mother is a carrier for this genetic mutation, the risk to siblings is up to 50% &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11258627&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''V''': Individuals who present with AS clinically, but have no known underlying mechanism have an unknown risk to siblings.&lt;br /&gt;
&lt;br /&gt;
==Treatment and Management==&lt;br /&gt;
&lt;br /&gt;
Even though at present there is no known cure for Angelman syndrome, there are a number of treatments available that may alleviate symptons and improve daily life activities.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The below table describes the problems and management options that are used:&lt;br /&gt;
&lt;br /&gt;
[[File:Subtle Finger tremors-Angelman Syndrome.jpg|right|thumb|150px|A five months old boy with Angelman syndrome showing signs of Subtle Finger tremor.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
! Problems encountered&lt;br /&gt;
! Treatment and Management&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''Difficulty in feeding newborn AS babies'''&lt;br /&gt;
| Use of special nipples may improve feeding&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Oesophagus reflux'''&lt;br /&gt;
| Special motility medications requiried or upright positioning&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''Seizures'''&lt;br /&gt;
| Anticonvulsant medications&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19605773&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19453717&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Ocular problems'''&lt;br /&gt;
| Visual assessment is vital to encourage interactions and minimize chances of self-harm and autism development&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20656169&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''Drooling in developmental delayed AS patients'''&lt;br /&gt;
| Difficult to treat, but new surgical procedure on salivary duct reimplantation seems to be a promising alternative&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17699119&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Unstable children''' &lt;br /&gt;
| Physical therapy&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''AS patients become less active with increasing age'''&lt;br /&gt;
| Activity schedules to prevent scoliosis and obesity. Occupational therapy to stimulate fine motor and oral-motor control skills in conjunction to speech therapy&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Sleeping difficulty'''&lt;br /&gt;
| Sedative medication in severe cases. [[#Glossary | '''Melatonin''']] may be used to promote sleeping but some studies have found that it loses its therapeutic effects after several weeks in most AS patients&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19379289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|-&lt;br /&gt;
|colspan=&amp;quot;4&amp;quot; |&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Prognosis==&lt;br /&gt;
&lt;br /&gt;
Life expectancy of AS patients seems to be normal&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, but there is still a high degree of developmental delay and limited expressive language skills.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17019625&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This problem arises prominently in the assessment of the severity of coincidental medical conditions due to difficulties in communication. A visit to the dentist can become difficult if good communication is not conveyed between the parents, the dentist, and the child.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18271768&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Some problems require extreme measures, such as the procedure of lens implantation was performed in both eyes of a person diagnosed with AS, due to the inability to wear spectacles.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20656169&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
During adulthood, menstruation and puberty begin at around average age evidenced by females with Angelman syndrome that are fully capable of conceiving children.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11258627&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Most adult patients can feed themselves, but needed help with many other daily activities. Main troubles which have shown in adults are a tendency to become obese and start developing  thoracic scoliosis, which some adults with AS begin wheelchair bounded.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9072912&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Current and Future Research==&lt;br /&gt;
&lt;br /&gt;
Currently there is no cure for the treatment of AS, so much research is being carried out for therapeutic interventions. Findings in the last five years have suggested through various mice and fruit fly models that the absence of maternal UBE3A results in the same human AS features of neurological defects and seizures. However, more recently, studies have outlined that the symptoms of AS can be improved by modifying other gene products. In addition, restoring of a functional UBE3A protein into adult mice neurons have shown to reduce motor and neurological deficits and balance disorders. This shows promising research prospects in that improvements may be possible in human AS patients by restoring functional UBE3A proteins into their neurons. &lt;br /&gt;
&lt;br /&gt;
===Possible Treatment Pathways===&lt;br /&gt;
&lt;br /&gt;
*'''Cognitive and physical impairment'''&lt;br /&gt;
&lt;br /&gt;
Although everyone is born with two copies of the gene UBE3A, one maternal and one paternal copy, it is only the maternal UBE3A that is used in the brain. Most AS patients have a genetic mutation on the maternal chromosome 15 that results in dysfunctional UBE3A.&amp;lt;ref&amp;gt;http://www.cureangelman.org/what-hope.html&amp;lt;/ref&amp;gt; The above research focused on turning on the father's copy of UBE3A to restore its functions. Furthermore, mouse models were utilized to show that alpha-CaMKII could be increased to compensate the loss of UBE3A and restore compromised mental and physical abilities. However, this finding still requires much more research.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17259980&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''Epilepsy'''&lt;br /&gt;
&lt;br /&gt;
There is research being done on improving certain conditions that are involved in AS by nutritional benefits. The use of [[#Glossary | '''corticosteroids''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19666884&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, [[#Glossary | '''valproate''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19453717&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and [[#Glossary | '''clonazepam''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19605773&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and having a [[#Glossary | '''ketogenic diet''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20880305&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; has all been shown to aid in the treatment of epilepsy. It has also been reported to be efficient in the treatment of other conditions, such as behavioural disorders, reduction in seizures, ataxia, sleep patterns, developmental progress and sleep disturbances. [[#Glossary | '''Levetiracetam''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17326790&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; could be used in such a situation, especially when the patient has an intolerance to valproate and clonazepam.&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&lt;br /&gt;
'''albinism''': A congenital disorder distincted by the complete or partial absence of pigment in the skin, hair and eyes due to defect of an enzyme involved in the production of melanin.&lt;br /&gt;
&lt;br /&gt;
'''allele''': Dissimilar variant of one gene. Organisms have two alleles for each gene inherited from their parents, one from each of them.&lt;br /&gt;
&lt;br /&gt;
'''alpha-CaMKII''': (alpha calcium calmodulin kinase II) Compound involved in synaptic plasticity, one of the most important theories behind learning and memory. Ability of a synapse between two neurons to change in strength due to the use or disuse of transmission.&lt;br /&gt;
&lt;br /&gt;
'''Amniocytes''': Cells that are shed by the fetus during fetal development to the surrounding amniotic fluid. They are a source of fetal DNA. &lt;br /&gt;
&lt;br /&gt;
'''Amniocentesis''': (AFT or amniotic fluid test) is a prenatal diagnostic test used to detect chromosomal abnormalities in the developing fetus by extracting amniotic fluid (a source of fetal DNA) surrounding the fetus. &lt;br /&gt;
&lt;br /&gt;
'''AMPA''': (2-amino-3-(5-methyl-3-oxo-1,2- oxazol-4-yl)propanoic acid) Compound that binds to the AMPA receptor to imitate glutamate neurotransmitter.&lt;br /&gt;
&lt;br /&gt;
'''Arc''': Activity-Regulated Cytoskeleton-associated protein; involved in learning and memory.&lt;br /&gt;
&lt;br /&gt;
'''ataxia''': Lack of coordination in muscle movements.&lt;br /&gt;
&lt;br /&gt;
'''atonic seizures''': A abrupt loss of muscle tone, this can lead to the limbs loosing strength, or the head may drop to the side. The patient remains conscious during this kind of epileptic seizure.&lt;br /&gt;
&lt;br /&gt;
'''atypical absences''': Seizure leads to unconsciousness in most cases.  &lt;br /&gt;
&lt;br /&gt;
'''autism''': A neural development disorder defined by limited social interaction and communication.&lt;br /&gt;
&lt;br /&gt;
'''Chorionic Villus Sampling''': A prenatal diagnostic test used to detect chromosomal abnormalities in the developing fetus by extracting and testing chorionic villus (placental tissue). &lt;br /&gt;
&lt;br /&gt;
'''chromosome''': Structure consisting of coiled DNA with DNA associated proteins such as histones.&lt;br /&gt;
&lt;br /&gt;
'''clonazepam''': A psychoactive drug having muscle relaxant properties and treats anxiety and epilepsy.&lt;br /&gt;
&lt;br /&gt;
'''corticosteroid''': A type of steroid hormones that are produced in the adrenal cortex.&lt;br /&gt;
&lt;br /&gt;
'''cytogenetics''': Study of the structure, function and abnormality of the cell, especially the chromosome.&lt;br /&gt;
&lt;br /&gt;
'''deletion''': Lack of a part of the DNA (deoxyribonucleic acid is a nucleic acid containing information for protein synthesis), can vary form a single base to a hole gene. &lt;br /&gt;
&lt;br /&gt;
'''de novo mutation''': Change in a gene of a family member for the first time due to a mutation in the egg or sperm of the parents or in the fertilized egg (zygote).&lt;br /&gt;
&lt;br /&gt;
'''disorder''': A mental or physical health disturbance or dysfunction.&lt;br /&gt;
&lt;br /&gt;
'''EEG''': Electroencephalography is a means of measuring electrical activity along the scalp by measuring the total electrical charges fired by thousands or millions of neurons.&lt;br /&gt;
&lt;br /&gt;
'''epilepsy''': Neurological disorder characterised by recurrent impairment of brain function that can cause seizures or unconsciousness. &lt;br /&gt;
&lt;br /&gt;
'''E6-AP''': E6-AP ubiquitin-protein ligase is an enzyme encoded by UBE3A which adds ubiquitin chain to target proteins to be degraded by proteasomes.&lt;br /&gt;
&lt;br /&gt;
'''febrile convulsions''': The occurrence of high fever, especially in children.&lt;br /&gt;
&lt;br /&gt;
'''FISH''': Fluorescent in situ hybridization is a technique used to identify and localize the presence or absence of DNA sequences on the chromosome. This is achieved by using fluorescently labelled DNA sequences which then binds to complementary DNA sequence on the chromosome. After hybridization (attachment), chromosome of interest will fluoresce under the microscope.&lt;br /&gt;
&lt;br /&gt;
'''gait''': A manner of walking, stepping or running.&lt;br /&gt;
&lt;br /&gt;
'''gene''': A molecular unit of heredity of a living organism.&lt;br /&gt;
&lt;br /&gt;
'''hyperphagia''': (Also referred to as Polyphagia) Excessive ingestion of food beyond the dietary and energy requirements of the body. &lt;br /&gt;
&lt;br /&gt;
'''hypermotoric''': Sudden appearance of uncontrolled movements such as striking or kicking inappropriately.&lt;br /&gt;
&lt;br /&gt;
'''hypertonicity''': Increase of muscle tension and a disability to stretch leading to an impairment of motor activity.&lt;br /&gt;
&lt;br /&gt;
'''hypopigmentation''': A lack of melanin pigments or melanocytes  affecting the colour of the skin, hair and iris. Features appear to be light-coloured due to loss of skin colour.&lt;br /&gt;
&lt;br /&gt;
'''hypotonia''': Decrease in the ability to stretch passively, due to a low muscle tone. &lt;br /&gt;
&lt;br /&gt;
'''imprinting''': This is a process to describe the modification of a maternally or paternally derived chromosome, which consequently influences the expression of certain genes on the altered chromosome.&lt;br /&gt;
&lt;br /&gt;
'''ketogenic diet''': A high-fat, low-carbohydrate diet that is used to treat epilepsy in children.&lt;br /&gt;
&lt;br /&gt;
'''levetiracetam''': An anticonvulsant drug used to treat epilepsy.&lt;br /&gt;
&lt;br /&gt;
'''locus''': Location of a gene on a chromosome(loci: plural for locus).&lt;br /&gt;
&lt;br /&gt;
'''LTP''': Long-term potentiation shares common features with long term memory. It strengthens and enhances signal transmission between neurons by improving the communication between two neurons.&lt;br /&gt;
&lt;br /&gt;
'''macrostomia''': A wide-spaced mouth.&lt;br /&gt;
&lt;br /&gt;
'''Makaton''': Language programme using symbols and signs to support speaking.&lt;br /&gt;
&lt;br /&gt;
'''mandibular prognathism''': The abnormal protrusion of the lower jaw. &lt;br /&gt;
&lt;br /&gt;
'''maxillary hypoplasia''':  The underdevelopment of the upper jaw.&lt;br /&gt;
&lt;br /&gt;
'''melatonin''': A hormone secreted by the pineal gland.&lt;br /&gt;
&lt;br /&gt;
'''microcephaly''': The circumference of the head is less than average due to abnormalities of the nervous system. This abnormality can be present at birth or emerge during the first few years of life and reduces both life expectancy and the cognitive functions of the individual affected.&lt;br /&gt;
&lt;br /&gt;
'''microdeletion''':  A genetic mutation in which a part of a chromosome or a sequence of DNA is missing.&lt;br /&gt;
&lt;br /&gt;
'''mutation''': Event that changes the DNA (deoxyribonucleic acid is a nucleic acid, containing information for protein synthesis) or RNA (ribonucleic acid is a type of nucleic acid transmitting the information from the DNA to the proteins ) of a gene permanently.&lt;br /&gt;
&lt;br /&gt;
'''myoclonic seizures''': A quick jerk of the skeletal muscle, due to a irregular brain activity.&lt;br /&gt;
&lt;br /&gt;
'''neurogenetic''': Genetic basis of the nervous system.&lt;br /&gt;
&lt;br /&gt;
'''neurotransmitter''': Transmits neuronal signals to a target cell. They are first packaged in vesicles just beneath the membrane of presynaptic axon terminals and released into the synaptic cleft (space between the two interacting neurons) and enter the postsynaptic dendrite.&lt;br /&gt;
&lt;br /&gt;
'''occiput''': The back portion of the head.&lt;br /&gt;
&lt;br /&gt;
'''oesophagus reflux''': Impairment of a sphincter in the lower end of the oesophagus leads to the back flow of stomach acid into the oesophagus. Heartburn is a typical symptom.&lt;br /&gt;
&lt;br /&gt;
'''paediatrician''': Physicians that specialise on infants, children and adolescents.&lt;br /&gt;
&lt;br /&gt;
'''paternal UPD''': Inheritance of two copies of a chromosome from the father and none from the mother. &lt;br /&gt;
&lt;br /&gt;
'''phenotype''': Visible traites of an organism determined by genetic and environmental factors.&lt;br /&gt;
&lt;br /&gt;
'''Picture Exchange Communication System (PECS)''': Individuals communicate using images instead of words. It is frequently used by children with autism, to articulate their needs and wishes or to make comments about something.&lt;br /&gt;
&lt;br /&gt;
'''Proband''': Is the person (or animal) being studied or reported on in a genetic investigation. Most commonly it refers to the first affected family member who requires medical help for a genetic disorder. &lt;br /&gt;
&lt;br /&gt;
'''Robertsonian translocation''': Rearrangement of the chromosome, occurs in 5 chromosome including 13,14,15,21 and 22. This type of mutation occurs in chromosomes with the centromere not at the centre, resulting in long and short arm chromosomes. Translocation breaks the chromosome at the centromere so the long arm attaches to the other long arm, and the same for the short arm happens. Cell division will result in the loss of the short arms as they do not contain important genes.&lt;br /&gt;
&lt;br /&gt;
'''seizure''': Abnormal electrical activity in the brain that can result in a variety of physical symptoms like convulsion, body shaking, loss of consciousness, confusion, and mood changes.&lt;br /&gt;
&lt;br /&gt;
'''synapse''': Allows transmission of signal between neurons for effective neuronal function.&lt;br /&gt;
&lt;br /&gt;
'''thoracic scoliosis''': The spine is curved laterally(from side to side) in the thoracic region.&lt;br /&gt;
&lt;br /&gt;
'''tonic-clonic seizures''': This type of seizure is associated with unconsciousness due to electrical discharges in a big proportion of the brain.&lt;br /&gt;
&lt;br /&gt;
'''ubiquitin''': A polypeptide found in all eukaryotic cells, that participates in a variety of cellular functions including protein recycling.&lt;br /&gt;
&lt;br /&gt;
'''Uniparental disomy''': (UPD) the inheritance of two copies of a chromosome pair or part of a chromosme from one parent and no copy from the other parent. &lt;br /&gt;
&lt;br /&gt;
'''valproate''':  A mood-stabilizing drug that is also used for treatment for epilepsy and bipolar disorder.&lt;br /&gt;
&lt;br /&gt;
==Helpful Links==&lt;br /&gt;
&lt;br /&gt;
* Australia&lt;br /&gt;
:* [http://www.angelmansyndrome.org/research.html Angelman Syndrome Association] &lt;br /&gt;
:* [http://www.angelmansyndromeqld.org/ Queensland Angelman Association]&lt;br /&gt;
&lt;br /&gt;
* America&lt;br /&gt;
:* [http://www.angelman.org/ Angelman Syndrome Foundation]&lt;br /&gt;
:* [http://rarediseasesnetwork.epi.usf.edu/arpwsc/ Rare Clinical Diseases Research Network]&lt;br /&gt;
:* [http://www.rarediseases.org/rare-disease-information/rare-diseases/byID/411/viewAbstract National Organisation for Rare Disorders]&lt;br /&gt;
:* [http://www.epilepsyfoundation.org/ Epilepsy Foundation]&lt;br /&gt;
:* [http://www.cureangelman.org/ Foundation for Angelman Syndrome Therapeutics]&lt;br /&gt;
&lt;br /&gt;
* Search Pubmed &lt;br /&gt;
:* [http://www.ncbi.nlm.nih.gov/pubmed?term=(Angelman+Syndrome[MAJR]) Angelman Syndrome] &lt;br /&gt;
&lt;br /&gt;
* OMIM&lt;br /&gt;
:* [http://omim.org/entry/105830 Genetic Disorder catalog]&lt;br /&gt;
&lt;br /&gt;
==Related Links==&lt;br /&gt;
&lt;br /&gt;
* [[Mouse Knockout]] - this page explains the current use of mouse models in disrupting genes to elucidate their genetic function, including the mouse gene knockouts for alpha calcium-calmodulin kinase II (alpha CaMKII)&lt;br /&gt;
* [[2009 Group Project 4]] - this page gives an extensive overview on the history of the mouse model and its various use in embryology and genetics. In addition, it also describes mouse knockout and the role they play in current research of various human diseases&lt;br /&gt;
* [[Fly Development]] - this page describes the use of drosophila flies as developmental models&lt;br /&gt;
* [[2009 Group Project 2]] - this page gives an extensive overview on the history of the fly model and its various use in embryology and genetics&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&lt;br /&gt;
&amp;lt;references /&amp;gt;&lt;/div&gt;</summary>
		<author><name>Z3291643</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_7&amp;diff=77562</id>
		<title>2011 Group Project 7</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_7&amp;diff=77562"/>
		<updated>2011-10-12T19:34:05Z</updated>

		<summary type="html">&lt;p&gt;Z3291643: /* Aetiology */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;='''Angelman Syndrome'''=&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Introduction==&lt;br /&gt;
&lt;br /&gt;
[[File:Dr Harry Angelman.jpg|thumb|130px|right|Dr Harry Angelman.]]&lt;br /&gt;
Angelman syndrome (AS) is a rare [[#Glossary | '''neurogenetic''']] [[#Glossary | '''disorder''']] first described by Dr. Harry Angelman in 1965.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18754889&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Dr. Angelman was an English [[#Glossary | '''paediatrician''']] who first diagnosed the disease in 3 children with a developmental delay.&amp;lt;ref&amp;gt;http://www.ncbi.nlm.nih.gov/books/NBK22221/&amp;lt;/ref&amp;gt; AS occurs in 1 in 10000-20000 births, the exact number is still unknown.&amp;lt;ref name=&amp;quot;PMID7573182&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7573182&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;PMID8703225&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;8703225&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It is caused by maternal [[#Glossary | '''allele''']] disruptions of a single gene- UBE3A. Either [[#Glossary | '''mutations''']] or [[#Glossary | '''deletions''']] of the UBE3A gene results in AS. &lt;br /&gt;
&lt;br /&gt;
AS presents with well known [[#Glossary | '''phenotypes''']] during infancy and adulthood, such as [[#Glossary | '''microcephaly''']] and [[#Glossary | '''maxillary hypoplasia''']]. However, these features become more marked with age. Most frequent clinical features include delayed development,[[#Glossary | '''seizures''']],[[#Glossary | '''ataxia''']], impairment of speech, happy demeanor, behavioural problems such as hyperactivity, short attention span and sleeping difficulty.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21592595&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21484597&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;ASAwebsite&amp;quot;&amp;gt;http://www.angelmansyndrome.org/home.html&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
At present, there is no cure for the syndrome, though current research is focused at improving life quality of patients with Angelman syndrome through management of daily tasks.&amp;lt;ref&amp;gt;http://www.bbc.co.uk/health/physical_health/conditions/angelman1.shtml&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==History==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Dr. Harry Angelman first reported Angelman Syndrome on three handicapped children that were admitted to his ward in England in 1964.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt; He reported how these three independent and unconnected clinical cases all had the same characteristic features of severe developmental delay, jerky movements, seizures and a happy disposition.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt; However it was only when he stumbled upon an oil painting called ‘a Boy with a Puppet” while on a holiday in Italy he was able to connect the symptoms of all three children under one common cause.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20981772&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; He linked the happy face of the boy depicted on the painting with the jerky movements and happy disposition he observed on his three patients back in England. He reported his findings on a paper entitled “Puppet children (a report on three cases)” which was published in 1965.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
The syndrome was initially named ‘Puppet Syndrome’ but was later changed to Angelman Syndrome. Due to the extreme rarity of the syndrome and lack of sufficient clinical evidence the syndrome was soon forgotten.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt;&lt;br /&gt;
[[File:Dr Charles Williams.jpg|thumb|right|150px|Dr Charles Williams.]]&lt;br /&gt;
	&lt;br /&gt;
In 1987, a physician named Ellen Magenis, came across children with deletions on [[#Glossary | '''chromosome''']] 15 that were suffering from seizures and severe developmental delay.&amp;lt;ref&amp;gt;http://www.angelman.org/stay-informed/facts-about-angelman-syndrome---7th-edition/harry-angelman-and-the-history-of-as/&amp;lt;/ref&amp;gt; Even though genetically the children were expected to have [[#Diagnosis | '''Prader-Willi syndrome''']] that was characterised by deletions on chromosome 15, their characteristic symptoms of seizures and lack of development did not correspond with that of the syndrome. This led to the realization that these children had deletions on the maternally derived chromosome 15 and not on the paternally derived chromosome as was observed in Prader-Willi syndrome.  Thus the deleted genetic code on maternally derived chromosome 15 was identified as the genetic marker for Angelman Syndrome.&lt;br /&gt;
&lt;br /&gt;
In 1997, UBE3A gene was isolated by Dr. Joseph Wagstaff and Dr. Arthur Beaudet as the cause of Angelman Syndrome.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot; /&amp;gt; The discovery of this [[#Glossary | '''gene''']] led to the subsequent development of animal models and research aimed at finding a causal link between UBE3A gene abnormalities and characteristic features observed in Angelman Syndrome. &lt;br /&gt;
	&lt;br /&gt;
Currently, four different genetic abnormalities for Angelman Syndrome have been confirmed by genetic testing. They include: Deletion, [[#Glossary | '''Uniparental Disomy''']] (UPD), [[#Glossary | '''Imprinting''']] and UBE3A mutation.&amp;lt;ref name=&amp;quot;PMID20211139&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Below is a timeline, summarising the key discoveries and advancements of the Angelman Syndrome:&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|- bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
!Year&lt;br /&gt;
!Milestone&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1964'''&lt;br /&gt;
|First observed by Dr Harry Angelman on three handicapped children.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot; /&amp;gt; &lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''1965'''&lt;br /&gt;
|Harry Angelman publishes his finding in a report entitled 'Puppet Children'(a report on three cases).&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1980s'''&lt;br /&gt;
|First reports of AS reaches US and research into the disorder being at the University of Florida under the direction of Dr. Charles Williams.&amp;lt;ref&amp;gt;http://www.angelmanproject.com/history.htm&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''1982'''&lt;br /&gt;
|Name changed from 'Happy Puppet' to Angelman syndrome by Williams and Frias. &lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1987'''&lt;br /&gt;
|Discovery of a genetic marker for AS – an absent genetic code on maternally derived chromosome 15. &lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''1997'''&lt;br /&gt;
|The cause of AS discovered by Dr. Joseph Wagstaff and Dr. Arthur Beaudet – mutation or deletion in the UBE3A gene.&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1998'''&lt;br /&gt;
|Transgenic mice with absent maternal UBE3A created to illustrate motor and learning deficits in addition to seizures.&amp;lt;ref name=&amp;quot;PMID9808466&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9808466&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''2007'''&lt;br /&gt;
|AS mouse model shows that neurological deficits can be reversed by decreasing levels of [[#Glossary | '''alpha-CaMKII''']] inhibitory phosphorylation.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17259980&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''2010'''&lt;br /&gt;
|Discovery of a another gene mutation in TC4 gene (on chromosome 18) in a small number of clinically diagnosed patients with no identifiable genetic alternation in UBE3A.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20184619&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''2010'''&lt;br /&gt;
|Protein named Arc identified as a target of AS gene product; UBE3A.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Incidence'''&lt;br /&gt;
*The current population of people diagnosed with AS is unknown but studies have estimated the number to be around 1:10,000&amp;lt;ref name=&amp;quot;PMID7573182&amp;quot; /&amp;gt; and 1:20,000&amp;lt;ref name=&amp;quot;PMID8703225&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
'''Diagnosis'''&lt;br /&gt;
*The mean age of diagnosis for patients with AS lies between 6 and 6.5 years of age.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18664077&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15741136&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Gender'''&lt;br /&gt;
* Males appear to be at higher risk for some aspects of early developmental delays in comparison to females with AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17019625&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Demography'''&lt;br /&gt;
*Europe:&lt;br /&gt;
:Denmark- 1:10,000&amp;lt;ref name=&amp;quot;PMID7573182&amp;quot; /&amp;gt;&lt;br /&gt;
:Estonia- 1:52,000&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16906556&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
:Sweden- 1:20,000&amp;lt;ref name=&amp;quot;PMID8703225&amp;quot; /&amp;gt;&lt;br /&gt;
*Australia:&lt;br /&gt;
:Western Australia- 1:40,000&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16492624&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Aetiology==&lt;br /&gt;
&lt;br /&gt;
[[File:Chromosome 15 Deletion of 15q11.2 to 15q13.jpg|thumb|100px|Chromosome 15 - The deletion occurs at 15q11.2-15q13.]]&lt;br /&gt;
&lt;br /&gt;
Different genetic mechanisms lead to different clinical phenotypes of AS. The most common genetic mechanism leading to AS is the deletion or re-arrangement of maternal chromosome at [[#Glossary | '''locus''']] 15q11.2-q13,as the chromosome image shows on the right, accounting for 70% of AS occurrences.&amp;lt;ref name=&amp;quot;PMID8988171&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt; 8988171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This leads to more severe clinical phenotypes of microcephaly, motor difficulties, seizures and impaired speech development. The next most common genetic mechanism is mutation in the ''UBE3A'' gene responsible for 10% of AS cases and paternal uniparental disomy and mutation in the imprinting centre (IC), both accounting for 2-5% of AS observed.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
 &lt;br /&gt;
&lt;br /&gt;
AS is caused by the 4 major genetic mechanisms mentioned above and are thus divided into Classes I to IV based on their underlying genetic mechanism. AS patients with the clinical features of AS but no [[#Glossary | '''cytogenetic''']] or molecular abnormality in Chromosome 15q11.2-13 are grouped under Class V (summarised in table below).&amp;lt;ref name=&amp;quot;PMID8988171&amp;quot; /&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10364509&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''Inheritance'''&lt;br /&gt;
&lt;br /&gt;
Angelman Syndrome from UBE3A mutations and deletions in the Imprinting Centre follow an inheritance pattern. A carrier father with the genetic defect can pass it on to his children, however, his children will be clinically normal. On the other hand, a carrier mother can pass the genetic defect onto her children, who will then have Angelman Syndrome. &lt;br /&gt;
&lt;br /&gt;
The image highlights the inheritance of Angelman Syndrome, which only results after a carrier mother passes it on to her children. &lt;br /&gt;
&lt;br /&gt;
{|  style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
! Class&lt;br /&gt;
! Mechanism&lt;br /&gt;
! Diagnostic Tests&lt;br /&gt;
! Frequency&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''Ia'''                           &lt;br /&gt;
| De novo deletion                                                                                           &lt;br /&gt;
| High resolution cytogenetics [[#Glossary | '''FISH''']]                                                                                                       &lt;br /&gt;
| 70%      &lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Ib'''&lt;br /&gt;
| Deletion due to chromosome rearrangement&lt;br /&gt;
| High resolution cytogenetics FISH&lt;br /&gt;
| &amp;lt;1%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''II'''&lt;br /&gt;
| Paternal uniparental disomy&lt;br /&gt;
| [[#Glossary | '''RFLP''']]  analysis&lt;br /&gt;
| 2%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''IIIa'''&lt;br /&gt;
| Imprinting defect with IC mutation&lt;br /&gt;
| Screening of [[#Glossary | '''IC''']]  for mutations is positive&lt;br /&gt;
| 2%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''IIIb'''&lt;br /&gt;
| Imprinting defect withouth IC mutation&lt;br /&gt;
| Screening of IC for mutations is negative&lt;br /&gt;
| 2%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''IIIc'''&lt;br /&gt;
| Mosaic imprinting defect&lt;br /&gt;
| Screening of IC for mutations is usually negative &lt;br /&gt;
| ?&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''IV'''&lt;br /&gt;
| ''UBE3A'' mutation&lt;br /&gt;
| Screening of ''UBE3A'' for mutations&lt;br /&gt;
| 5-10%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''V'''&lt;br /&gt;
| No identifiable genetic abnormality&lt;br /&gt;
| Consider other diagnoses&lt;br /&gt;
| 5-26%&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Pathogenesis==&lt;br /&gt;
&lt;br /&gt;
Chromosome 15 became associated with AS in the 1980s after the observation of many AS patients harboring [[#Glossary | '''microdeletions''']] of 15q11.2-15q13.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15668046&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The last decade has shed even more light in the aetiology of AS,as Kishino and Matsuura first identified UBE3A as the causative gene for AS in 1997.&amp;lt;ref name=&amp;quot;PMID:8988171&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;8988171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8988172&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Normal gene product: E6-AP ubiquitin ligase'''&lt;br /&gt;
&lt;br /&gt;
The function of UBE3A is to encode for [[#Glossary | '''E6-AP''']] ubiquitin ligase, however its function in the development of the nervous system and the process of UBE3A mutation leading to cognitive impairment in AS patients is still vague.&amp;lt;ref name=&amp;quot;PMID:20211139&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Past and current research has elucidated that E6-AP ubiquitin ligase is involved in the degradation of four proteins, listed below, but currently, no protein with a direct role in [[#Glossary | '''long-term potentiation (LTP)''']] as a target of E6-AP, has been identified.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12684449&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The identification of such target proteins would be a landmark discovery in further understanding of the pathogenesis, aetiology and prospective treatment strategies of AS, as LTP defects is one of the major neurological impairments of AS. &lt;br /&gt;
 &lt;br /&gt;
* p53 tumor suppressor protein &lt;br /&gt;
* yeast DNA repair protein Rad23 &lt;br /&gt;
* multicopy maintenance protein 7 subunit &lt;br /&gt;
* E6-AP&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Abnormal gene product'''&lt;br /&gt;
&lt;br /&gt;
Disruption to the gene,UBE3A, interferes with the normal functioning of the gene, which is its crucial role in UBE3A [[#Glossary | '''ubiquitylation''']]. Problems involving this pathway can lead to various diseases either from the loss or gain of function.&amp;lt;ref name=&amp;quot;PMID:9857172&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9857172&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In the case of AS, E6-AP is affected, leading to detrimental cognitive impairment in addition to other deficits.&amp;lt;ref name=&amp;quot;PMID:9857172&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9857172&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Regional functioning of UBE3A'''&lt;br /&gt;
&lt;br /&gt;
Despite the uncertain progression of UBE3A mutation and the neurological abnormalities characteristic of AS, animal models have illustrated the vital role of UBE3A in the normal functioning of the brain. This can be exemplified by a study which utilized a mouse model with target inactivation of the gene UBE3A resulting in the manifestation of classical features of AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11895368&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In addition, the fact that imprinting of UBE3A takes place only in specific brain regions (cerebellum, olfactory tracts and the hippocampus) confirms the hypothesis that the loss of this gene would be detrimental in the cognitive development.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20398390&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Most genes are inherited in copies of two, one paternal and the other maternal; however, some genes, such as UBE3A only have one functional copy as the other is silenced, coined 'imprinting'. Imprinting of the paternal copy of UBE3A takes place in some cell populations, such as the hippocampal neurons and Purkinje cells in the cerebellum.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9288101&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This means only the maternal UBE3A is functionally expressed in these particular brain regions. Thus a [[#Glossary | '''de novo mutation''']] in the maternal copy of the gene will result in the complete absence of functional E6-AP in the associated brain areas.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9288088&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
It is also known that UBE3A plays an important role in synaptic transmission, but exactly how it does so is still not completely understood.&amp;lt;ref name=&amp;quot;PMID:9808466&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9808466&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''UBE3A ubiquitylation'''&lt;br /&gt;
&lt;br /&gt;
As briefly mentioned above, UBE3A is a member of the E3 ubiquitin ligase family of enzymes, responsible for the addition of ubiquitin to the target protein for degradation of the ubiquitinated protein, as illustrated in the diagram below. These processes are required for normal human cognitive function.&amp;lt;ref name=&amp;quot;PMID:9808466&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9808466&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In this way synaptic protein [[#Glossary | '''Arc (activity-regulated cytoskeleton-associated protein)''']] is degraded to control synaptic function. Arc is a target protein of UBE3A in dendritic spines found in the hippocampal neurons.&amp;lt;ref name=&amp;quot;PMID:20668179&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20668179&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Deletion of UBE3A leads to the accumulation of Arc in neurons leading to trafficking of [[#Glossary | '''AMPA ( α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid)''']] receptors, resulting in impaired cognitive functions.&amp;lt;ref name=&amp;quot;PMID:20211139&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; [[File:UBE3A Ubiquitylation Pathway.png|thumb|350px|right|UBE3A Ubiquitylation Pathway.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
UBE3A ubiquitylation consists of:&amp;lt;ref name=&amp;quot;PMID:20668179&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20668179&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
# Activation of ubiquitin by E1 enzyme&lt;br /&gt;
# E1 ezyme transfers ubiquitin to E2 enzyme&lt;br /&gt;
# E2 enzyme transfers ubiquitin to UBE3A&lt;br /&gt;
# UBE3A attaches activated ubiquitin to target protein which is then polyubiquitylated &lt;br /&gt;
# Target protein is then degraded by 26S proteosome&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Phenotype-Genotype correlations'''&lt;br /&gt;
&lt;br /&gt;
[[File:Extent of microcephaly in Angelman Syndrome patients.png|thumb|250px|right|Extent of microcephaly in 20 AS patients with deletion and without deletion.&amp;lt;ref&amp;gt;http://www.nature.com/ejhg/index.html/&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
All AS patients show differing extents of cognitive impairment, movement disorder, characteristic behaviours and difficulty in speech and language.&amp;lt;ref name=&amp;quot;PMID:11748306&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11748306&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; However, there seems to be some phenotype-genotype correlations:&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
- 5-7Mb deletions result in the most severe phenotypes such as microcephaly, more sever [[#Glossary | '''epilepsy''']] and seizures, motor difficulties and language impairment.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9546330&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20445456&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; AS patients with large deletions also present with clinical [[#Glossary | '''hypopigmentation''']], light hair and eye colour due to the close association of OCA2 gene with UBE3A.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;16470747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Individuals under this category have in general no increased BMI&amp;lt;ref name=&amp;quot;PMID:15253756&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15253756&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This is indicated by the graph on the left, which shows more cases of AS patients with deletions having larger deviations from the mean head circumference measurement than non-deletion AS patients.&lt;br /&gt;
 &lt;br /&gt;
- AS patients with uniparental disomy (UPD) have better physical growth, fewer motor deficits and lower seizure occurrences.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16023557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
- Individuals with AS resulting from imprinting defects have the least debilitating features, such as higher developmental and language ability than AS caused by other mechanisms.&amp;lt;ref name=&amp;quot;PMID:11748306&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11748306&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
- The Body Mass Index (BMI) of 33% of the UBE3A mutation patients, and 47–64% of the patients from the classes II (UPD) and III (Imprinting defect) is above the 95th centile.&amp;lt;ref name=&amp;quot;PMID:15253756&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15253756&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Animal models'''&lt;br /&gt;
&lt;br /&gt;
* '''Drosophila'''&lt;br /&gt;
&lt;br /&gt;
Drosophila (common fruit fly) is an excellent model to use for better understanding of genetic diseases in humans as they are highly homologous to human UBE3A (hUBE3A), illustrating a high evolutionary conservation. Studies using the Drosophila model have shown that the functional absence of UBE3A resulted in decreased morphogenesis of dendritic branches. This is of interest as dendritic branches cover over 90% of the neuronal surface where [[#Glossary | '''synapse''']] between neurons occur. Proper formation and maturation of dendritic spines is also required so they come in contact with other neurons for effective transmission of neuronal signals. Thus proper formation of dendritic branching is pivitol for effective neuronal function and hence cognitive function.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18996915&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Interestingly, overexpression of dUBE3A also gave the same result, consisting of abnormal locomotion  and decreased dendritic branching in sensory neurons.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18701717&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;  This suggests a possible research field for some forms of [[#Glossary | '''autism''']] where the region containing UBE3A is duplicated, leading to delayed motor skills and seizures.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16433693&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;[[File:Normal and Angelman Syndrome mice models.jpg|thumb|250px|right|Normal and AS mice performance on the Rotarod apparatus.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
* '''Mice'''&lt;br /&gt;
&lt;br /&gt;
Absence of UBE3A in mice manifest similar phenotype to human AS, as illustrated by motor and learning deficits with inducible seizures.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21235769&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It has been shown through various mice model studies that larger deletions, ie. from UBE3A to GABRB3, more closely mirrors the large 6Mb deletions seen in human AS patients. Numerous tests, such as the Rotarod (for motor coordination and learning ability), Morris water maze test (for spatial learning and memory) and [[#Glossary | '''EEG''']] (electroencephalography), were carried out on  UBE3A null mutants, which showed the results to be abnormal or impaired.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20808828&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Other studies using mouse models have also outlined the obesity observed in 15% of AS children, albeit it is not the major characterisitics of AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17259980&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The diagram on the right clearly highlights the results obtained from such mouse model studies of AS, where the absence of UBE3A accumulated in deficits of motor function and obesity. In addition, excessive drooling and feeding difficulties were also highlighted by mice models with inactivated UBE3A, reflected by defects in fluid consumption and licking.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18413322&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Pathophysiology===&lt;br /&gt;
&lt;br /&gt;
'''Cognitive defects'''&lt;br /&gt;
&lt;br /&gt;
[[File:Role of UBE3A in dendritic spine neuronal synapses.png|thumb|250px|right|Role of UBE3A in dendritic spine neuronal synapses.]]&lt;br /&gt;
&lt;br /&gt;
AS patients present with abnormally high UBE3A, leading to neurological impairment. Recent identification of key target proteins of Ephexin-58 (Eph-5) and Arc (Activity-Regulated Cytoskeleton-associated protein) have aided in better understanding of the progression of UBE3A to cognitive defects. These two proteins are vital in the understanding of AS as Eph-5 determines synapse numbers and Arc contributes to plasticity and synapse function.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21164477&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Studies utilizing mice models have illustrated that UBE3A null mice could not ubiquitinate Eph-5, thus increasing its levels and limiting the growth of dendritic spines by the activation of RhoA. This subsequent activation of RhoA inhibits synapse formation and results in neuronal defects.&lt;br /&gt;
&lt;br /&gt;
In contrast, mice with normally functioning UBE3A showed phosphorylated Eph-5, resulting from the interaction of two neurons via the activation of EphB signalling receptor.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21029865&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Phosphorylation of Eph-5 allows UBE3A to ubiquitinate and degrade it. This degradation of Eph-5 permits new synaptic connections to form with cells they come into contact with. However, in AS, the absence of UBE3A means Eph-5 cannot be degraded, so RhoA activity is prolonged to reduce synaptic formation.&lt;br /&gt;
&lt;br /&gt;
As mentioned previously, Arc plays a pivitol role in synapse function as it removes synaptic receptors that respond to glutamate, a [[#Glossary | '''neurotransmitter''']].&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17088211&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In UBE3A present neurons, UBE3A ubiquitinates Arc, leading to it degradation as illustrated by the diagram on the left. However, in UBE3A deficient neurons, Arc accumulates and prevents the proper synaptic communications essential for normal cognitive functions.&amp;lt;ref name=&amp;quot;PMID20211139&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Signs and Symptoms==&lt;br /&gt;
&lt;br /&gt;
Angelman Syndrome presents a variety of different phenotypes, and the presented symptoms may vary at different ages.&amp;lt;ref name=&amp;quot;PMID7625442&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7625442&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
In 1995 Williams et al. embraced the observed clinical features of AS in a consensus statement, in order to present an appliance for clinicians. The diagnostic criteria were updated in 2005.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt; The following table shows the most frequently occurring characteristics in AS patients:&lt;br /&gt;
&lt;br /&gt;
'''4 characteristics appear in 100% of the cases:'''&lt;br /&gt;
&lt;br /&gt;
*Delayed development: become apparent by the age of 6 to 12 months.&lt;br /&gt;
*Motion and or balance malfunction&lt;br /&gt;
*Behaviour patterns like unmotivated laughter, frequent excitement; often including body movements,[[File:Electroencephalography of Angelman Syndrome.jpg|thumb|350px|right|EEG of AS and normal individuals.]] [[#Glossary | '''hypermotoric''']] behaviour&lt;br /&gt;
*Impairment of speech&lt;br /&gt;
&lt;br /&gt;
'''3 characteristics appear in more than 80% of the cases:'''&lt;br /&gt;
&lt;br /&gt;
*Abnormalities in head circumference, microcephaly&lt;br /&gt;
*Seizures&lt;br /&gt;
*EEG shows specific abnormal patterns&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Angelman Syndrome individuals show the most distinct disease pattern from 2 to 16 years of age.&lt;br /&gt;
In most cases at least 8 of the symptom traits are shown.&amp;lt;ref name=&amp;quot;PMID7625442&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Behavioural Characteristics'''&lt;br /&gt;
&lt;br /&gt;
A range of substantial characteristics appear in all AS cases, regardless of the genetic mechanisms, and are often responsible for diagnosing the syndrome. According to the original name, Happy Puppet syndrome, they have shown to exhibit traits such as a happy demeanor, with frequent laughter or smiling that can easily be triggered.&amp;lt;ref name=&amp;quot;PMID12566516&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12566516&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This behaviour can already be observed in 1 to 3 month old infants.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot; /&amp;gt; Uplifted hand flapping or waving motions are associated with laughter and excitement. Other characteristics manifesting in early childhood are sleep abnormalities with reduced sleep demand, and feeding problems. Breast and bottle feeding can be difficult due to non efficient attachment to the breast, tongue thrusting and uncoordinated sucking. Furthermore, there is an affection to crinkly and reflective surfaces, like some papers or plastic materials, especially water.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID12566516 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Communication Skills'''&lt;br /&gt;
&lt;br /&gt;
Communication is challenging for AS patients due to the fact that speech impairment is present in all cases. In the majority of affected people a lack of speech development is present. Only some of them have a minimal vocabulary consisting of two or three words, a few can speak in basic sentences. Some patients use gestures to articulate themselves, the [[#Glossary | '''Picture Exchange Communication System (PECS)''']] or sign languages such as [[#Glossary | '''Makaton''']] can be used for communication. Simple demands regarding their everyday occurrence can be understood by most patients.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID12566516 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Clinical and External Characteristics'''[[File:Angelman Syndrome patient.png|thumb|200px|right|4 year old AS patient.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Developmental delays are present in all patients. Motor milestones are delayed with children managing to sit unsupported with 12 months and crawl or bottom shuffle at the age of 18-24 months. The average age for walking is 4 years,however, ranging from 18 months to 7 years.&lt;br /&gt;
The [[#Glossary | '''gait''']] is characterised as slow, and flapping hands are a common trait.  The legs remain stiff during walking, arms are inflected by the wrists and elbows. The movements can appear ataxic, jerky or lurching. The muscle tone shows abnormalities with truncal [[#Glossary | '''hypotonia''']] and [[#Glossary | '''hypertonicity''']] of the limbs and alert reflexes.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID12566516 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The most striking external traits present in patients include broad-spaced teeth, and a wide mouth, light hair and eye colour, hypopigmented skin, deep set eyes, and a flat [[#Glossary | '''occiput''']].&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Seizures in Angelman Syndrome'''&lt;br /&gt;
&lt;br /&gt;
85% of AS patients suffer from epileptic seizures during their first three years. The first appearance can be within one month up to 20 year old patients. In infants with AS epilepsy manifests with [[#Glossary | '''febrile convulsions''']] and is hard to manage during childhood.&lt;br /&gt;
The most common type of seizures within 25% of patients are [[#Glossary | '''myoclonic seizures''']], followed by [[#Glossary | '''atonic seizures''']] as the second most frequent type, then 21% experience generalised [[#Glossary | '''tonic-clonic seizures''']] and lastly [[#Glossary | '''atypical absences''']] occur in 12% of patients.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20398390&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Angelman Syndrome in adults'''&lt;br /&gt;
&lt;br /&gt;
Patients with Angelman syndrome possess normal secondary sexual characteristics, and puberty sets in at a usual time. Limb hypertonicity, and [[#Glossary | '''thoracic scoliosis''']] lead to decreasing mobility. [[#Glossary | '''Oesophagus reflux''']] might induce severe problems, and the majority suffers from obesity. Furthermore, facial traits such as a prominent lower lip [[#Glossary | '''macrostomia''']] and [[#Glossary | '''mandibular prognathism''']] get manifested in adults. &lt;br /&gt;
In some cases the communication barrier can lead to frustration, resulting in aggressive behaviour. Nonetheless, patients gain a higher concentration span with age, and their nature becomes more quiet.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Complications===&lt;br /&gt;
&lt;br /&gt;
'''Hypopigmentation and Ocular albinism'''&lt;br /&gt;
&lt;br /&gt;
OCA2 gene, also known as the P gene, is closely located to the UBE3A gene. It encodes a protein vital to tyrosine metabolism, which plays a role in pigmentation development of skin, hair and eyes. However, AS caused by the large deletion of UBE3A leads to haploinsufficiency of OCA2 gene, resulting in hypopigmentation of the skin and the eyes. In some children with severe hypopigmentation, some form of [[#Glossary | '''albinism''']] is suspected.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12749060&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; When AS is caused by another mechanism, no abnormality of the skin and eye pigmentation is observed. However, not all AS children with OCA2 gene deletion will present with obvious hypopigmentation, they may just exhibit lighter skin colour than their parents.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8302318&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Diagnosis==&lt;br /&gt;
&lt;br /&gt;
The diagnosis of Angelman Syndrome is a clinical diagnosis confirmed by laboratory testing.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This involves both prenatal and/or postnatal diagnosis. &lt;br /&gt;
&lt;br /&gt;
===Prenatal Diagnosis===&lt;br /&gt;
[[File:Angelman Syndrome Prenatal Diagnosis.jpg|thumb|250px|right|Flowchart of AS Diagnosis.]]&lt;br /&gt;
&lt;br /&gt;
Prenatal detection of deletions of 15q11.2-q13, [[#Glossary | '''Paternal UPD''']] ([[#Glossary | '''Uniparental Disomy''']]), Imprinting defects and UBE3A mutations are done through DNA/chromosome/FISH analysis of fetal cells obtained by either [[#Glossary | '''Chorionic Villus Sampling''']](CVS) or [[#Glossary | '''Amniocentesis''']].&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot;/&amp;gt; &lt;br /&gt;
DNA methylation analysis using [[#Glossary | '''Amniocytes''']] is usually the first test carried out in molecular diagnosis of AS.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18059071&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; An abnormal result is followed up by either a FISH or array CGH analysis to search for a deletion on chromosome 15. If they produce a normal result, then UPD testing using DNA polymorphysims is carried out. If there is no evidence of UPD, other DNA analysis tests are used search for an imprinting centre deletion.&amp;lt;ref name=&amp;quot;PMID9792887&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9792887&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; A normal DNA methylation analysis is followed by a UBE3A sequence analysis.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt; In addition, a parent of origin test is also done to determine if the genetic disruption is of maternal origin or paternal origin. If it is maternally derived the fetus is diagnosed with AS (a paternally derived genetic disruption is indicative of Prader-Willi Syndrome).&amp;lt;ref name=&amp;quot;PMID17020468&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;17020468&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The flow chart summarizes the normal procedure used for prenatal diagnosis of AS. More information on important laboratory tests used for the diagnosis of Angelman Syndrome are provided below:&lt;br /&gt;
&lt;br /&gt;
*'''DNA Methylation Analysis'''&lt;br /&gt;
&lt;br /&gt;
Identifies approximately 80% of AS affected individuals and is usually the first test to be ordered.&amp;lt;ref name=&amp;quot;PMID7618904&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7618904&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Molecular disruptions such as deletions, paternal UPD and imprinting defects on chromosome 15 all demonstrate abnormal methylation patterns by either southern blot analysis or PCR amplification of bisulphate-treated DNA.&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot; /&amp;gt; An affected individual will only have an unmethylated (paternal) SNRPN (small nuclear ribonuclear protein-associated polypeptide N) allele compared with an unaffected individual who will have both a methylated and an unmethylated SNRPN allele.&amp;lt;ref name=&amp;quot;PMID9634532&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9634532&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
	  &lt;br /&gt;
*'''FISH (Fluorescent In Situ Hybridization)'''&lt;br /&gt;
&lt;br /&gt;
[[File:Critical_region_of_Angelman_Syndrome_on_chromosome_15.png‎|thumb|150px|right|FISH (fluorescence in situ hybridisation) image showing the critical region of Angelman Syndrome on chromosome 15.]]&lt;br /&gt;
&lt;br /&gt;
FISH analysis detects 5-7 Mb deletions in approximately 68% of affected individuals using detecting probes such as D15S10 and/or SNRPN.&amp;lt;ref name=&amp;quot;PMID7618904&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7618904&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It is also able to distinguish UPD from micro-deletions and imprinting defects. In simple terms, FISH analysis involves the binding of a fluorescent probe to a specific part of chromosome 15 and the detection of deletions within that region. FISH analysis is much more accurate in deletion detection compared to other high-resolution cytogenetics in the diagnosis of AS patients.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1511093&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
Array-based CGH is an advanced type of cytogenetic testing that can also be used to detect smaller deletions.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''UPD (Uniparental Disomy) Detection'''&lt;br /&gt;
&lt;br /&gt;
DNA Polymorphism testing detects paternal UPD in approximately 7% of affected AS individuals.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt; It is also able to distinguish between UPD and an Imprinting defect. It requires a DNA sample from the [[#Glossary | '''Proband''']] and from both parents. A homologous or non-homologous whole-arm translocation of the long arms of chromosome 15 is a sound indication for the need for prenatal UPD testing.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''IC (Imprinting Center) Analysis'''&lt;br /&gt;
&lt;br /&gt;
This type of analysis is used when individuals have an abnormal DNA methylation pattern but show normal results for  FISH, array CGH study and UPD analysis.&amp;lt;ref name=&amp;quot;PMID9792887&amp;quot;/&amp;gt; It is used to differentiate between the Imprinting defects caused by either microdeletions in the AS imprinting centre or by epigenetic mutations (that occur in maternal oogenesis or early embryogenesis).&amp;lt;ref name=&amp;quot;PMID9634532&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''Cytogenetic Testing'''&lt;br /&gt;
&lt;br /&gt;
Is used to detect a cytogenetically visible chromosomal rearrangement (large deletion, translocation or inversion) involving the 15q11.2-q13 region, which occurs in less than 1% of affected individuals.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''UBE3A Sequence Analysis'''&lt;br /&gt;
Sequence analysis of the UBE3A gene detects mutations in about 10% of the patients.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt; The test is used to detect either multiexonic (10 major coding exons of UBE3A) or whole gene deletions of UBE3A gene in individuals who produces a normal DNA methylation result but has characteristic clinical features of AS.&amp;lt;ref name=&amp;quot;PMID9792887&amp;quot;/&amp;gt;&lt;br /&gt;
This is recommended as a prenatal diagnostic tool in families that include multiple AS affected individuals because the imprinted pattern can be inherited from distant relatives.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Postnatal Diagnosis===&lt;br /&gt;
&lt;br /&gt;
Postnatal diagnosis is made though a combination of common clinical features of AS and UBESA gene sequence analysis.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt; The clinical features of AS include unsteady or shaky movements, muscle hypotonia, developmental delay and behavioral uniqueness such as frequent laughter/smiling and happy demeanor are features that are 100% consistent in all patients diagnosed with Angelman Syndrome.&amp;lt;ref name=&amp;quot;PMID18830393&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18830393&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; These clinical features become apparent between 6 months to 2 years of age. The onset of early or persistent smiling characteristic of this syndrome begin around the age of 1-3 months, but is often overlooked during infancy.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot;/&amp;gt; Thus early diagnosis of AS during infancy period is difficult because the clinical indicators of the syndrome takes time to manifest and characteristic features such as finger and hand tremors and excessive smiling/laughter are often overlooked and not considered as possible indicators of this syndrome.&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
*Rett Syndrome&lt;br /&gt;
&lt;br /&gt;
Some children with the clinical diagnosis of AS but no underlying genetic mechanism show mutations in ''MECP2'' gene, corresponding to Rett Syndrome. This should be suspected in AS test negative girls in the first few years of life.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17980307&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*Mowat-Wilson Syndrome&lt;br /&gt;
&lt;br /&gt;
Genetic mechanism is heterozygous deletion or truncation in ''ZFHX1B'' (''SIP1'') gene on 2q22. This presents with clinical features of severe intellectual disability, micrcephaly and seizures.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17958891&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Prader-Willi Syndrome patient.png|thumb|right|120px|12 year old PWS patient.]]&lt;br /&gt;
&lt;br /&gt;
*X-linked alpha-thalassemia/mental retardation syndrome (ATR-X)&lt;br /&gt;
&lt;br /&gt;
This arises from mutations in ''XNP'' gene on Xq13. ATR-X presents with severe intellectual disability, no speech development and seizures are common.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11449489&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*Phelan-McDermid Syndrome/22q13 deletion syndrome&lt;br /&gt;
&lt;br /&gt;
Deletions are usually submicroscopic and thus requires special molecular cytogenetic methods to confirm this deletion. Patients show moderate to profound intellectual disability and delay in speech development.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18505557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Related Disease'''&lt;br /&gt;
&lt;br /&gt;
*Prader-Willi Syndrome(PWS)&lt;br /&gt;
&lt;br /&gt;
PWS is a result from the absence of paternally expressed 15q11-q13 gene as a corollary of de novo deletion, maternal uniparental disomy of chromosome 15 or an imprinting defect on paternal chromosome 15 leading to the silencing of paternal alleles.&amp;lt;ref name=&amp;quot;PMID:20668179 &amp;quot;/&amp;gt; It is characterized by [[#Glossary | '''hyperphagia''']], obesity in later infancy and early childhood and difficulty in feeding during early infancy.&amp;lt;ref name=&amp;quot;PMID:20668179 &amp;quot;/&amp;gt; There is also cognitive impairment to some extent, though some PWS patients may exhibit intelligence in the normal IQ range. Behavioral phenotypes include stubbornness, manipulative tendency, obsessive compulsive characteristics.&amp;lt;ref name=&amp;quot;PMID:20668179 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Genetic Counselling==&lt;br /&gt;
&lt;br /&gt;
Genetic counselling is the process by which patients or relatives, at risk of an inherited disorder, are advised of the consequences and nature of the disorder, the probability of developing or transmitting it, and the options open to them in management and family planning. In the case for Angelman syndrome, types of risks associated are split into classes and formatted into the table below:&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20459762&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{|  style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
! Class&lt;br /&gt;
! Mechanism&lt;br /&gt;
! Risk to siblings&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! Ia                           &lt;br /&gt;
| De novo deletion                                                                                                               &lt;br /&gt;
| &amp;lt;1%                                                                                                                &lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! Ib&lt;br /&gt;
| Deletion due to chromosome rearrangement&lt;br /&gt;
| Up to 50%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! II&lt;br /&gt;
| Paternal uniparental disomy&lt;br /&gt;
| &amp;lt;1%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! IIIa&lt;br /&gt;
| Imprinting defect with IC mutation&lt;br /&gt;
| Close to 100% if father has 15; 15 [[#Glossary | '''Robertsonian translocation''']]&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! IIIb&lt;br /&gt;
| Imprinting defect withouth IC mutation&lt;br /&gt;
| Up to 50% (if mother has IC deletion)&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! IIIc&lt;br /&gt;
| Mosaic imprinting defect&lt;br /&gt;
| &amp;lt;1%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! IV&lt;br /&gt;
| ''UBE3A'' mutation&lt;br /&gt;
| Up to 50% (is mother has mutation)&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! V&lt;br /&gt;
| No identifiable genetic abnormality&lt;br /&gt;
| ?&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Treatment and Management==&lt;br /&gt;
&lt;br /&gt;
Even though at present there is no known cure for Angelman syndrome, there are a number of treatments available that may alleviate symptons and improve daily life activities.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The below table describes the problems and management options that are used:&lt;br /&gt;
&lt;br /&gt;
[[File:Subtle Finger tremors-Angelman Syndrome.jpg|right|thumb|150px|A five months old boy with Angelman syndrome showing signs of Subtle Finger tremor.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
! Problems encountered&lt;br /&gt;
! Treatment and Management&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''Difficulty in feeding newborn AS babies'''&lt;br /&gt;
| Use of special nipples may improve feeding&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Oesophagus reflux'''&lt;br /&gt;
| Special motility medications requiried or upright positioning&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''Seizures'''&lt;br /&gt;
| Anticonvulsant medications&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19605773&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19453717&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Ocular problems'''&lt;br /&gt;
| Visual assessment is vital to encourage interactions and minimize chances of self-harm and autism development&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20656169&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''Drooling in developmental delayed AS patients'''&lt;br /&gt;
| Difficult to treat, but new surgical procedure on salivary duct reimplantation seems to be a promising alternative&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17699119&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Unstable children''' &lt;br /&gt;
| Physical therapy&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''AS patients become less active with increasing age'''&lt;br /&gt;
| Activity schedules to prevent scoliosis and obesity. Occupational therapy to stimulate fine motor and oral-motor control skills in conjunction to speech therapy&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Sleeping difficulty'''&lt;br /&gt;
| Sedative medication in severe cases. [[#Glossary | '''Melatonin''']] may be used to promote sleeping but some studies have found that it loses its therapeutic effects after several weeks in most AS patients&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19379289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|-&lt;br /&gt;
|colspan=&amp;quot;4&amp;quot; |&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Prognosis==&lt;br /&gt;
&lt;br /&gt;
Life expectancy of AS patients seems to be normal&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, but there is still a high degree of developmental delay and limited expressive language skills.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17019625&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This problem arises prominently in the assessment of the severity of coincidental medical conditions due to difficulties in communication. A visit to the dentist can become difficult if good communication is not conveyed between the parents, the dentist, and the child.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18271768&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Some problems require extreme measures, such as the procedure of lens implantation was performed in both eyes of a person diagnosed with AS, due to the inability to wear spectacles.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20656169&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
During adulthood, menstruation and puberty begin at around average age evidenced by females with Angelman syndrome that are fully capable of conceiving children.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11258627&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Most adult patients can feed themselves, but needed help with many other daily activities. Main troubles which have shown in adults are a tendency to become obese and start developing  thoracic scoliosis, which some adults with AS begin wheelchair bounded.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9072912&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Current and Future Research==&lt;br /&gt;
&lt;br /&gt;
Currently there is no cure for the treatment of AS, so much research is being carried out for therapeutic interventions. Findings in the last five years have suggested through various mice and fruit fly models that the absence of maternal UBE3A results in the same human AS features of neurological defects and seizures. However, more recently, studies have outlined that the symptoms of AS can be improved by modifying other gene products. In addition, restoring of a functional UBE3A protein into adult mice neurons have shown to reduce motor and neurological deficits and balance disorders. This shows promising research prospects in that improvements may be possible in human AS patients by restoring functional UBE3A proteins into their neurons. &lt;br /&gt;
&lt;br /&gt;
===Possible Treatment Pathways===&lt;br /&gt;
&lt;br /&gt;
*'''Cognitive and physical impairment'''&lt;br /&gt;
&lt;br /&gt;
Although everyone is born with two copies of the gene UBE3A, one maternal and one paternal copy, it is only the maternal UBE3A that is used in the brain. Most AS patients have a genetic mutation on the maternal chromosome 15 that results in dysfunctional UBE3A.&amp;lt;ref&amp;gt;http://www.cureangelman.org/what-hope.html&amp;lt;/ref&amp;gt; The above research focused on turning on the father's copy of UBE3A to restore its functions. Furthermore, mouse models were utilized to show that alpha-CaMKII could be increased to compensate the loss of UBE3A and restore compromised mental and physical abilities. However, this finding still requires much more research.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17259980&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''Epilepsy'''&lt;br /&gt;
&lt;br /&gt;
There is research being done on improving certain conditions that are involved in AS by nutritional benefits. The use of [[#Glossary | '''corticosteroids''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19666884&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, [[#Glossary | '''valproate''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19453717&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and [[#Glossary | '''clonazepam''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19605773&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and having a [[#Glossary | '''ketogenic diet''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20880305&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; has all been shown to aid in the treatment of epilepsy. It has also been reported to be efficient in the treatment of other conditions, such as behavioural disorders, reduction in seizures, ataxia, sleep patterns, developmental progress and sleep disturbances. [[#Glossary | '''Levetiracetam''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17326790&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; could be used in such a situation, especially when the patient has an intolerance to valproate and clonazepam.&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&lt;br /&gt;
'''albinism''': A congenital disorder distincted by the complete or partial absence of pigment in the skin, hair and eyes due to defect of an enzyme involved in the production of melanin.&lt;br /&gt;
&lt;br /&gt;
'''allele''': Dissimilar variant of one gene. Organisms have two alleles for each gene inherited from their parents, one from each of them.&lt;br /&gt;
&lt;br /&gt;
'''alpha-CaMKII''': (alpha calcium calmodulin kinase II) Compound involved in synaptic plasticity, one of the most important theories behind learning and memory. Ability of a synapse between two neurons to change in strength due to the use or disuse of transmission.&lt;br /&gt;
&lt;br /&gt;
'''Amniocytes''': Cells that are shed by the fetus during fetal development to the surrounding amniotic fluid. They are a source of fetal DNA. &lt;br /&gt;
&lt;br /&gt;
'''Amniocentesis''': (AFT or amniotic fluid test) is a prenatal diagnostic test used to detect chromosomal abnormalities in the developing fetus by extracting amniotic fluid (a source of fetal DNA) surrounding the fetus. &lt;br /&gt;
&lt;br /&gt;
'''AMPA''': (2-amino-3-(5-methyl-3-oxo-1,2- oxazol-4-yl)propanoic acid) Compound that binds to the AMPA receptor to imitate glutamate neurotransmitter.&lt;br /&gt;
&lt;br /&gt;
'''Arc''': Activity-Regulated Cytoskeleton-associated protein; involved in learning and memory.&lt;br /&gt;
&lt;br /&gt;
'''ataxia''': Lack of coordination in muscle movements.&lt;br /&gt;
&lt;br /&gt;
'''atonic seizures''': A abrupt loss of muscle tone, this can lead to the limbs loosing strength, or the head may drop to the side. The patient remains conscious during this kind of epileptic seizure.&lt;br /&gt;
&lt;br /&gt;
'''atypical absences''': Seizure leads to unconsciousness in most cases.  &lt;br /&gt;
&lt;br /&gt;
'''autism''': A neural development disorder defined by limited social interaction and communication.&lt;br /&gt;
&lt;br /&gt;
'''Chorionic Villus Sampling''': A prenatal diagnostic test used to detect chromosomal abnormalities in the developing fetus by extracting and testing chorionic villus (placental tissue). &lt;br /&gt;
&lt;br /&gt;
'''chromosome''': Structure consisting of coiled DNA with DNA associated proteins such as histones.&lt;br /&gt;
&lt;br /&gt;
'''clonazepam''': A psychoactive drug having muscle relaxant properties and treats anxiety and epilepsy.&lt;br /&gt;
&lt;br /&gt;
'''corticosteroid''': A type of steroid hormones that are produced in the adrenal cortex.&lt;br /&gt;
&lt;br /&gt;
'''cytogenetics''': Study of the structure, function and abnormality of the cell, especially the chromosome.&lt;br /&gt;
&lt;br /&gt;
'''deletion''': Lack of a part of the DNA (deoxyribonucleic acid is a nucleic acid containing information for protein synthesis), can vary form a single base to a hole gene. &lt;br /&gt;
&lt;br /&gt;
'''de novo mutation''': Change in a gene of a family member for the first time due to a mutation in the egg or sperm of the parents or in the fertilized egg (zygote).&lt;br /&gt;
&lt;br /&gt;
'''disorder''': A mental or physical health disturbance or dysfunction.&lt;br /&gt;
&lt;br /&gt;
'''EEG''': Electroencephalography is a means of measuring electrical activity along the scalp by measuring the total electrical charges fired by thousands or millions of neurons.&lt;br /&gt;
&lt;br /&gt;
'''epilepsy''': Neurological disorder characterised by recurrent impairment of brain function that can cause seizures or unconsciousness. &lt;br /&gt;
&lt;br /&gt;
'''E6-AP''': E6-AP ubiquitin-protein ligase is an enzyme encoded by UBE3A which adds ubiquitin chain to target proteins to be degraded by proteasomes.&lt;br /&gt;
&lt;br /&gt;
'''febrile convulsions''': The occurrence of high fever, especially in children.&lt;br /&gt;
&lt;br /&gt;
'''FISH''': Fluorescent in situ hybridization is a technique used to identify and localize the presence or absence of DNA sequences on the chromosome. This is achieved by using fluorescently labelled DNA sequences which then binds to complementary DNA sequence on the chromosome. After hybridization (attachment), chromosome of interest will fluoresce under the microscope.&lt;br /&gt;
&lt;br /&gt;
'''gait''': A manner of walking, stepping or running.&lt;br /&gt;
&lt;br /&gt;
'''gene''': A molecular unit of heredity of a living organism.&lt;br /&gt;
&lt;br /&gt;
'''hyperphagia''': (Also referred to as Polyphagia) Excessive ingestion of food beyond the dietary and energy requirements of the body. &lt;br /&gt;
&lt;br /&gt;
'''hypermotoric''': Sudden appearance of uncontrolled movements such as striking or kicking inappropriately.&lt;br /&gt;
&lt;br /&gt;
'''hypertonicity''': Increase of muscle tension and a disability to stretch leading to an impairment of motor activity.&lt;br /&gt;
&lt;br /&gt;
'''hypopigmentation''': A lack of melanin pigments or melanocytes  affecting the colour of the skin, hair and iris. Features appear to be light-coloured due to loss of skin colour.&lt;br /&gt;
&lt;br /&gt;
'''hypotonia''': Decrease in the ability to stretch passively, due to a low muscle tone. &lt;br /&gt;
&lt;br /&gt;
'''imprinting''': This is a process to describe the modification of a maternally or paternally derived chromosome, which consequently influences the expression of certain genes on the altered chromosome.&lt;br /&gt;
&lt;br /&gt;
'''ketogenic diet''': A high-fat, low-carbohydrate diet that is used to treat epilepsy in children.&lt;br /&gt;
&lt;br /&gt;
'''levetiracetam''': An anticonvulsant drug used to treat epilepsy.&lt;br /&gt;
&lt;br /&gt;
'''locus''': Location of a gene on a chromosome(loci: plural for locus).&lt;br /&gt;
&lt;br /&gt;
'''LTP''': Long-term potentiation shares common features with long term memory. It strengthens and enhances signal transmission between neurons by improving the communication between two neurons.&lt;br /&gt;
&lt;br /&gt;
'''macrostomia''': A wide-spaced mouth.&lt;br /&gt;
&lt;br /&gt;
'''Makaton''': Language programme using symbols and signs to support speaking.&lt;br /&gt;
&lt;br /&gt;
'''mandibular prognathism''': The abnormal protrusion of the lower jaw. &lt;br /&gt;
&lt;br /&gt;
'''maxillary hypoplasia''':  The underdevelopment of the upper jaw.&lt;br /&gt;
&lt;br /&gt;
'''melatonin''': A hormone secreted by the pineal gland.&lt;br /&gt;
&lt;br /&gt;
'''microcephaly''': The circumference of the head is less than average due to abnormalities of the nervous system. This abnormality can be present at birth or emerge during the first few years of life and reduces both life expectancy and the cognitive functions of the individual affected.&lt;br /&gt;
&lt;br /&gt;
'''microdeletion''':  A genetic mutation in which a part of a chromosome or a sequence of DNA is missing.&lt;br /&gt;
&lt;br /&gt;
'''mutation''': Event that changes the DNA (deoxyribonucleic acid is a nucleic acid, containing information for protein synthesis) or RNA (ribonucleic acid is a type of nucleic acid transmitting the information from the DNA to the proteins ) of a gene permanently.&lt;br /&gt;
&lt;br /&gt;
'''myoclonic seizures''': A quick jerk of the skeletal muscle, due to a irregular brain activity.&lt;br /&gt;
&lt;br /&gt;
'''neurogenetic''': Genetic basis of the nervous system.&lt;br /&gt;
&lt;br /&gt;
'''neurotransmitter''': Transmits neuronal signals to a target cell. They are first packaged in vesicles just beneath the membrane of presynaptic axon terminals and released into the synaptic cleft (space between the two interacting neurons) and enter the postsynaptic dendrite.&lt;br /&gt;
&lt;br /&gt;
'''occiput''': The back portion of the head.&lt;br /&gt;
&lt;br /&gt;
'''oesophagus reflux''': Impairment of a sphincter in the lower end of the oesophagus leads to the back flow of stomach acid into the oesophagus. Heartburn is a typical symptom.&lt;br /&gt;
&lt;br /&gt;
'''paediatrician''': Physicians that specialise on infants, children and adolescents.&lt;br /&gt;
&lt;br /&gt;
'''paternal UPD''': Inheritance of two copies of a chromosome from the father and none from the mother. &lt;br /&gt;
&lt;br /&gt;
'''phenotype''': Visible traites of an organism determined by genetic and environmental factors.&lt;br /&gt;
&lt;br /&gt;
'''Picture Exchange Communication System (PECS)''': Individuals communicate using images instead of words. It is frequently used by children with autism, to articulate their needs and wishes or to make comments about something.&lt;br /&gt;
&lt;br /&gt;
'''Proband''': Is the person (or animal) being studied or reported on in a genetic investigation. Most commonly it refers to the first affected family member who requires medical help for a genetic disorder. &lt;br /&gt;
&lt;br /&gt;
'''Robertsonian translocation''': Rearrangement of the chromosome, occurs in 5 chromosome including 13,14,15,21 and 22. This type of mutation occurs in chromosomes with the centromere not at the centre, resulting in long and short arm chromosomes. Translocation breaks the chromosome at the centromere so the long arm attaches to the other long arm, and the same for the short arm happens. Cell division will result in the loss of the short arms as they do not contain important genes.&lt;br /&gt;
&lt;br /&gt;
'''seizure''': Abnormal electrical activity in the brain that can result in a variety of physical symptoms like convulsion, body shaking, loss of consciousness, confusion, and mood changes.&lt;br /&gt;
&lt;br /&gt;
'''synapse''': Allows transmission of signal between neurons for effective neuronal function.&lt;br /&gt;
&lt;br /&gt;
'''thoracic scoliosis''': The spine is curved laterally(from side to side) in the thoracic region.&lt;br /&gt;
&lt;br /&gt;
'''tonic-clonic seizures''': This type of seizure is associated with unconsciousness due to electrical discharges in a big proportion of the brain.&lt;br /&gt;
&lt;br /&gt;
'''ubiquitin''': A polypeptide found in all eukaryotic cells, that participates in a variety of cellular functions including protein recycling.&lt;br /&gt;
&lt;br /&gt;
'''Uniparental disomy''': (UPD) the inheritance of two copies of a chromosome pair or part of a chromosme from one parent and no copy from the other parent. &lt;br /&gt;
&lt;br /&gt;
'''valproate''':  A mood-stabilizing drug that is also used for treatment for epilepsy and bipolar disorder.&lt;br /&gt;
&lt;br /&gt;
==Helpful Links==&lt;br /&gt;
&lt;br /&gt;
* Australia&lt;br /&gt;
:* [http://www.angelmansyndrome.org/research.html Angelman Syndrome Association] &lt;br /&gt;
:* [http://www.angelmansyndromeqld.org/ Queensland Angelman Association]&lt;br /&gt;
&lt;br /&gt;
* America&lt;br /&gt;
:* [http://www.angelman.org/ Angelman Syndrome Foundation]&lt;br /&gt;
:* [http://rarediseasesnetwork.epi.usf.edu/arpwsc/ Rare Clinical Diseases Research Network]&lt;br /&gt;
:* [http://www.rarediseases.org/rare-disease-information/rare-diseases/byID/411/viewAbstract National Organisation for Rare Disorders]&lt;br /&gt;
:* [http://www.epilepsyfoundation.org/ Epilepsy Foundation]&lt;br /&gt;
:* [http://www.cureangelman.org/ Foundation for Angelman Syndrome Therapeutics]&lt;br /&gt;
&lt;br /&gt;
* Search Pubmed &lt;br /&gt;
:* [http://www.ncbi.nlm.nih.gov/pubmed?term=(Angelman+Syndrome[MAJR]) Angelman Syndrome] &lt;br /&gt;
&lt;br /&gt;
* OMIM&lt;br /&gt;
:* [http://omim.org/entry/105830 Genetic Disorder catalog]&lt;br /&gt;
&lt;br /&gt;
==Related Links==&lt;br /&gt;
&lt;br /&gt;
* [[Mouse Knockout]] - this page explains the current use of mouse models in disrupting genes to elucidate their genetic function, including the mouse gene knockouts for alpha calcium-calmodulin kinase II (alpha CaMKII)&lt;br /&gt;
* [[2009 Group Project 4]] - this page gives an extensive overview on the history of the mouse model and its various use in embryology and genetics. In addition, it also describes mouse knockout and the role they play in current research of various human diseases&lt;br /&gt;
* [[Fly Development]] - this page describes the use of drosophila flies as developmental models&lt;br /&gt;
* [[2009 Group Project 2]] - this page gives an extensive overview on the history of the fly model and its various use in embryology and genetics&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&lt;br /&gt;
&amp;lt;references /&amp;gt;&lt;/div&gt;</summary>
		<author><name>Z3291643</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=File:Imprint_defect_inheritance_in_Angelman_Syndrome.png&amp;diff=77561</id>
		<title>File:Imprint defect inheritance in Angelman Syndrome.png</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=File:Imprint_defect_inheritance_in_Angelman_Syndrome.png&amp;diff=77561"/>
		<updated>2011-10-12T19:27:31Z</updated>

		<summary type="html">&lt;p&gt;Z3291643: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;This family tree of the inheritance pattern of Angelman Syndrome highlights that only the carrier mother can pass on the genetic defect to her children, resulting in Angelman Syndrome. A carrier father with the genetic defect can pass it on to his children as well, but they will be clinically normal.&lt;br /&gt;
&lt;br /&gt;
===Reference===&lt;br /&gt;
&lt;br /&gt;
Illustration by z3291643. Beginning six months after publication, I (3291643) grant the public the non-exclusive right to copy, distribute, or display the Work under a Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/ and http://creativecommons.org/licenses/by-nc-sa/3.0/legalcode&lt;br /&gt;
&lt;br /&gt;
{{Template:2011 Student Image}}&lt;/div&gt;</summary>
		<author><name>Z3291643</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=File:Imprint_defect_inheritance_in_Angelman_Syndrome.png&amp;diff=77560</id>
		<title>File:Imprint defect inheritance in Angelman Syndrome.png</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=File:Imprint_defect_inheritance_in_Angelman_Syndrome.png&amp;diff=77560"/>
		<updated>2011-10-12T19:24:58Z</updated>

		<summary type="html">&lt;p&gt;Z3291643: ===Reference===

Illustration by z3291643. Beginning six months after publication, I (3291643) grant the public the non-exclusive right to copy, distribute, or display the Work under a Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported li&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&lt;br /&gt;
&lt;br /&gt;
===Reference===&lt;br /&gt;
&lt;br /&gt;
Illustration by z3291643. Beginning six months after publication, I (3291643) grant the public the non-exclusive right to copy, distribute, or display the Work under a Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/ and http://creativecommons.org/licenses/by-nc-sa/3.0/legalcode&lt;br /&gt;
&lt;br /&gt;
{{Template:2011 Student Image}}&lt;/div&gt;</summary>
		<author><name>Z3291643</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_7&amp;diff=77460</id>
		<title>2011 Group Project 7</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_7&amp;diff=77460"/>
		<updated>2011-10-12T12:55:35Z</updated>

		<summary type="html">&lt;p&gt;Z3291643: /* External Links */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;='''Angelman Syndrome'''=&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Introduction==&lt;br /&gt;
&lt;br /&gt;
[[File:Dr Harry Angelman.jpg|thumb|130px|right|Dr Harry Angelman.]]&lt;br /&gt;
Angelman syndrome (AS) is a rare [[#Glossary | '''neurogenetic''']] [[#Glossary | '''disorder''']] first described by Dr. Harry Angelman in 1965.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18754889&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Dr. Angelman was an English [[#Glossary | '''paediatrician''']] who first diagnosed the disease in 3 children with a developmental delay.&amp;lt;ref&amp;gt;http://www.ncbi.nlm.nih.gov/books/NBK22221/&amp;lt;/ref&amp;gt; AS occurs in 1 in 10000-20000 births, the exact number is still unknown.&amp;lt;ref name=&amp;quot;PMID7573182&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7573182&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;PMID8703225&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;8703225&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It is caused by maternal [[#Glossary | '''allele''']] disruptions of a single gene- UBE3A. Either [[#Glossary | '''mutations''']] or [[#Glossary | '''deletions''']] of the UBE3A gene results in AS. &lt;br /&gt;
&lt;br /&gt;
AS presents with well known [[#Glossary | '''phenotypes''']] during infancy and adulthood, such as [[#Glossary | '''microcephaly''']] and [[#Glossary | '''maxillary hypoplasia''']]. However, these features become more marked with age. Most frequent clinical features include delayed development,[[#Glossary | '''seizures''']],[[#Glossary | '''ataxia''']], impairment of speech, happy demeanor, behavioural problems such as hyperactivity, short attention span and sleeping difficulty.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21592595&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21484597&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;ASAwebsite&amp;quot;&amp;gt;http://www.angelmansyndrome.org/home.html&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
At present, there is no cure for the syndrome, though current research is focused at improving life quality of patients with Angelman syndrome through management of daily tasks.&amp;lt;ref&amp;gt;http://www.bbc.co.uk/health/physical_health/conditions/angelman1.shtml&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==History==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Dr. Harry Angelman first reported Angelman Syndrome on three handicapped children that were admitted to his ward in England in 1964.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt; He reported how these three independent and unconnected clinical cases all had the same characteristic features of severe developmental delay, jerky movements, seizures and a happy disposition.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt; However it was only when he stumbled upon an oil painting called ‘a Boy with a Puppet” while on a holiday in Italy he was able to connect the symptoms of all three children under one common cause.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20981772&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; He linked the happy face of the boy depicted on the painting with the jerky movements and happy disposition he observed on his three patients back in England. He reported his findings on a paper entitled “Puppet children (a report on three cases)” which was published in 1965.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
The syndrome was initially named ‘Puppet Syndrome’ but was later changed to Angelman Syndrome. Due to the extreme rarity of the syndrome and lack of sufficient clinical evidence the syndrome was soon forgotten.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt;&lt;br /&gt;
[[File:Dr Charles Williams.jpg|thumb|right|150px|Dr Charles Williams.]]&lt;br /&gt;
	&lt;br /&gt;
In 1987, a physician named Ellen Magenis, came across children with deletions on [[#Glossary | '''chromosome''']] 15 that were suffering from seizures and severe developmental delay.&amp;lt;ref&amp;gt;http://www.angelman.org/stay-informed/facts-about-angelman-syndrome---7th-edition/harry-angelman-and-the-history-of-as/&amp;lt;/ref&amp;gt; Even though genetically the children were expected to have [[#Diagnosis | '''Prader-Willi syndrome''']] that was characterised by deletions on chromosome 15, their characteristic symptoms of seizures and lack of development did not correspond with that of the syndrome. This led to the realization that these children had deletions on the maternally derived chromosome 15 and not on the paternally derived chromosome as was observed in Prader-Willi syndrome.  Thus the deleted genetic code on maternally derived chromosome 15 was identified as the genetic marker for Angelman Syndrome.&lt;br /&gt;
&lt;br /&gt;
In 1997, UBE3A gene was isolated by Dr. Joseph Wagstaff and Dr. Arthur Beaudet as the cause of Angelman Syndrome.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot; /&amp;gt; The discovery of this [[#Glossary | '''gene''']] led to the subsequent development of animal models and research aimed at finding a causal link between UBE3A gene abnormalities and characteristic features observed in Angelman Syndrome. &lt;br /&gt;
	&lt;br /&gt;
Currently, four different genetic abnormalities for Angelman Syndrome have been confirmed by genetic testing. They include: Deletion, [[#Glossary | '''Uniparental Disomy''']] (UPD), [[#Glossary | '''Imprinting''']] and UBE3A mutation.&amp;lt;ref name=&amp;quot;PMID20211139&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Below is a timeline, summarising the key discoveries and advancements of the Angelman Syndrome:&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|- bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
!Year&lt;br /&gt;
!Milestone&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1964'''&lt;br /&gt;
|First observed by Dr Harry Angelman on three handicapped children.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot; /&amp;gt; &lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''1965'''&lt;br /&gt;
|Harry Angelman publishes his finding in a report entitled 'Puppet Children'(a report on three cases).&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1980s'''&lt;br /&gt;
|First reports of AS reaches US and research into the disorder being at the University of Florida under the direction of Dr. Charles Williams.&amp;lt;ref&amp;gt;http://www.angelmanproject.com/history.htm&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''1982'''&lt;br /&gt;
|Name changed from 'Happy Puppet' to Angelman syndrome by Williams and Frias. &lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1987'''&lt;br /&gt;
|Discovery of a genetic marker for AS – an absent genetic code on maternally derived chromosome 15. &lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''1997'''&lt;br /&gt;
|The cause of AS discovered by Dr. Joseph Wagstaff and Dr. Arthur Beaudet – mutation or deletion in the UBE3A gene.&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1998'''&lt;br /&gt;
|Transgenic mice with absent maternal UBE3A created to illustrate motor and learning deficits in addition to seizures.&amp;lt;ref name=&amp;quot;PMID9808466&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9808466&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''2007'''&lt;br /&gt;
|AS mouse model shows that neurological deficits can be reversed by decreasing levels of [[#Glossary | '''alpha-CaMKII''']] inhibitory phosphorylation.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17259980&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''2010'''&lt;br /&gt;
|Discovery of a another gene mutation in TC4 gene (on chromosome 18) in a small number of clinically diagnosed patients with no identifiable genetic alternation in UBE3A.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20184619&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''2010'''&lt;br /&gt;
|Protein named Arc identified as a target of AS gene product; UBE3A.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Incidence'''&lt;br /&gt;
*The current population of people diagnosed with AS is unknown but studies have estimated the number to be around 1:10,000&amp;lt;ref name=&amp;quot;PMID7573182&amp;quot; /&amp;gt; and 1:20,000&amp;lt;ref name=&amp;quot;PMID8703225&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
'''Diagnosis'''&lt;br /&gt;
*The mean age of diagnosis for patients with AS lies between 6 and 6.5 years of age.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18664077&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15741136&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Gender'''&lt;br /&gt;
* Males appear to be at higher risk for some aspects of early developmental delays in comparison to females with AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17019625&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Demography'''&lt;br /&gt;
*Europe:&lt;br /&gt;
:Denmark- 1:10,000&amp;lt;ref name=&amp;quot;PMID7573182&amp;quot; /&amp;gt;&lt;br /&gt;
:Estonia- 1:52,000&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16906556&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
:Sweden- 1:20,000&amp;lt;ref name=&amp;quot;PMID8703225&amp;quot; /&amp;gt;&lt;br /&gt;
*Australia:&lt;br /&gt;
:Western Australia- 1:40,000&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16492624&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Aetiology==&lt;br /&gt;
&lt;br /&gt;
[[File:Chromosome 15 Deletion of 15q11.2 to 15q13.jpg|thumb|100px|Chromosome 15 - The deletion occurs at 15q11.2-15q13.]]&lt;br /&gt;
&lt;br /&gt;
Different genetic mechanisms lead to different clinical phenotypes of AS. The most common genetic mechanism leading to AS is the deletion or re-arrangement of maternal chromosome at [[#Glossary | '''locus''']] 15q11.2-q13,as the chromosome image shows on the right, accounting for 70% of AS occurrences.&amp;lt;ref name=&amp;quot;PMID8988171&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt; 8988171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This leads to more severe clinical phenotypes of microcephaly, motor difficulties, seizures and impaired speech development. The next most common genetic mechanism is mutation in the ''UBE3A'' gene responsible for 10% of AS cases and paternal uniparental disomy and mutation in the imprinting centre (IC), both accounting for 2-5% of AS observed.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
 &lt;br /&gt;
&lt;br /&gt;
AS is caused by the 4 major genetic mechanisms mentioned above and are thus divided into Classes I to IV based on their underlying genetic mechanism. AS patients with the clinical features of AS but no [[#Glossary | '''cytogenetic''']] or molecular abnormality in Chromosome 15q11.2-13 are grouped under Class V (summarised in table below).&amp;lt;ref name=&amp;quot;PMID8988171&amp;quot; /&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10364509&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{|  style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
! Class&lt;br /&gt;
! Mechanism&lt;br /&gt;
! Diagnostic Tests&lt;br /&gt;
! Frequency&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''Ia'''                           &lt;br /&gt;
| De novo deletion                                                                                           &lt;br /&gt;
| High resolution cytogenetics [[#Glossary | '''FISH''']]                                                                                                       &lt;br /&gt;
| 70%      &lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Ib'''&lt;br /&gt;
| Deletion due to chromosome rearrangement&lt;br /&gt;
| High resolution cytogenetics FISH&lt;br /&gt;
| &amp;lt;1%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''II'''&lt;br /&gt;
| Paternal uniparental disomy&lt;br /&gt;
| [[#Glossary | '''RFLP''']]  analysis&lt;br /&gt;
| 2%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''IIIa'''&lt;br /&gt;
| Imprinting defect with IC mutation&lt;br /&gt;
| Screening of [[#Glossary | '''IC''']]  for mutations is positive&lt;br /&gt;
| 2%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''IIIb'''&lt;br /&gt;
| Imprinting defect withouth IC mutation&lt;br /&gt;
| Screening of IC for mutations is negative&lt;br /&gt;
| 2%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''IIIc'''&lt;br /&gt;
| Mosaic imprinting defect&lt;br /&gt;
| Screening of IC for mutations is usually negative &lt;br /&gt;
| ?&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''IV'''&lt;br /&gt;
| ''UBE3A'' mutation&lt;br /&gt;
| Screening of ''UBE3A'' for mutations&lt;br /&gt;
| 5-10%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''V'''&lt;br /&gt;
| No identifiable genetic abnormality&lt;br /&gt;
| Consider other diagnoses&lt;br /&gt;
| 5-26%&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Pathogenesis==&lt;br /&gt;
&lt;br /&gt;
Chromosome 15 became associated with AS in the 1980s after the observation of many AS patients harboring [[#Glossary | '''microdeletions''']] of 15q11.2-15q13.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15668046&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The last decade has shed even more light in the aetiology of AS,as Kishino and Matsuura first identified UBE3A as the causative gene for AS in 1997.&amp;lt;ref name=&amp;quot;PMID:8988171&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;8988171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8988172&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Normal gene product: E6-AP ubiquitin ligase'''&lt;br /&gt;
&lt;br /&gt;
The function of UBE3A is to encode for [[#Glossary | '''E6-AP''']] ubiquitin ligase, however its function in the development of the nervous system and the process of UBE3A mutation leading to cognitive impairment in AS patients is still vague.&amp;lt;ref name=&amp;quot;PMID:20211139&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Past and current research has elucidated that E6-AP ubiquitin ligase is involved in the degradation of four proteins, listed below, but currently, no protein with a direct role in [[#Glossary | '''long-term potentiation (LTP)''']] as a target of E6-AP, has been identified.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12684449&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The identification of such target proteins would be a landmark discovery in further understanding of the pathogenesis, aetiology and prospective treatment strategies of AS, as LTP defects is one of the major neurological impairments of AS. &lt;br /&gt;
 &lt;br /&gt;
* p53 tumor suppressor protein &lt;br /&gt;
* yeast DNA repair protein Rad23 &lt;br /&gt;
* multicopy maintenance protein 7 subunit &lt;br /&gt;
* E6-AP&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Abnormal gene product'''&lt;br /&gt;
&lt;br /&gt;
Disruption to the gene,UBE3A, interferes with the normal functioning of the gene, which is its crucial role in UBE3A [[#Glossary | '''ubiquitylation''']]. Problems involving this pathway can lead to various diseases either from the loss or gain of function.&amp;lt;ref name=&amp;quot;PMID:9857172&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9857172&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In the case of AS, E6-AP is affected, leading to detrimental cognitive impairment in addition to other deficits.&amp;lt;ref name=&amp;quot;PMID:9857172&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9857172&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Regional functioning of UBE3A'''&lt;br /&gt;
&lt;br /&gt;
Despite the uncertain progression of UBE3A mutation and the neurological abnormalities characteristic of AS, animal models have illustrated the vital role of UBE3A in the normal functioning of the brain. This can be exemplified by a study which utilized a mouse model with target inactivation of the gene UBE3A resulting in the manifestation of classical features of AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11895368&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In addition, the fact that imprinting of UBE3A takes place only in specific brain regions (cerebellum, olfactory tracts and the hippocampus) confirms the hypothesis that the loss of this gene would be detrimental in the cognitive development.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20398390&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Most genes are inherited in copies of two, one paternal and the other maternal; however, some genes, such as UBE3A only have one functional copy as the other is silenced, coined 'imprinting'. Imprinting of the paternal copy of UBE3A takes place in some cell populations, such as the hippocampal neurons and Purkinje cells in the cerebellum.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9288101&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This means only the maternal UBE3A is functionally expressed in these particular brain regions. Thus a [[#Glossary | '''de novo mutation''']] in the maternal copy of the gene will result in the complete absence of functional E6-AP in the associated brain areas.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9288088&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
It is also known that UBE3A plays an important role in synaptic transmission, but exactly how it does so is still not completely understood.&amp;lt;ref name=&amp;quot;PMID:9808466&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9808466&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''UBE3A ubiquitylation'''&lt;br /&gt;
&lt;br /&gt;
As briefly mentioned above, UBE3A is a member of the E3 ubiquitin ligase family of enzymes, responsible for the addition of ubiquitin to the target protein for degradation of the ubiquitinated protein, as illustrated in the diagram below. These processes are required for normal human cognitive function.&amp;lt;ref name=&amp;quot;PMID:9808466&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9808466&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In this way synaptic protein [[#Glossary | '''Arc (activity-regulated cytoskeleton-associated protein)''']] is degraded to control synaptic function. Arc is a target protein of UBE3A in dendritic spines found in the hippocampal neurons.&amp;lt;ref name=&amp;quot;PMID:20668179&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20668179&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Deletion of UBE3A leads to the accumulation of Arc in neurons leading to trafficking of [[#Glossary | '''AMPA ( α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid)''']] receptors, resulting in impaired cognitive functions.&amp;lt;ref name=&amp;quot;PMID:20211139&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; [[File:UBE3A Ubiquitylation Pathway.png|thumb|350px|right|UBE3A Ubiquitylation Pathway.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
UBE3A ubiquitylation consists of:&amp;lt;ref name=&amp;quot;PMID:20668179&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20668179&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
# Activation of ubiquitin by E1 enzyme&lt;br /&gt;
# E1 ezyme transfers ubiquitin to E2 enzyme&lt;br /&gt;
# E2 enzyme transfers ubiquitin to UBE3A&lt;br /&gt;
# UBE3A attaches activated ubiquitin to target protein which is then polyubiquitylated &lt;br /&gt;
# Target protein is then degraded by 26S proteosome&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Phenotype-Genotype correlations'''&lt;br /&gt;
&lt;br /&gt;
[[File:Extent of microcephaly in Angelman Syndrome patients.png|thumb|250px|right|Extent of microcephaly in 20 AS patients with deletion and without deletion.&amp;lt;ref&amp;gt;http://www.nature.com/ejhg/index.html/&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
All AS patients show differing extents of cognitive impairment, movement disorder, characteristic behaviours and difficulty in speech and language.&amp;lt;ref name=&amp;quot;PMID:11748306&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11748306&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; However, there seems to be some phenotype-genotype correlations:&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
- 5-7Mb deletions result in the most severe phenotypes such as microcephaly, more sever [[#Glossary | '''epilepsy''']] and seizures, motor difficulties and language impairment.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9546330&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20445456&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; AS patients with large deletions also present with clinical [[#Glossary | '''hypopigmentation''']], light hair and eye colour due to the close association of OCA2 gene with UBE3A.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;16470747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Individuals under this category have in general no increased BMI&amp;lt;ref name=&amp;quot;PMID:15253756&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15253756&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This is indicated by the graph on the left, which shows more cases of AS patients with deletions having larger deviations from the mean head circumference measurement than non-deletion AS patients.&lt;br /&gt;
 &lt;br /&gt;
- AS patients with uniparental disomy (UPD) have better physical growth, fewer motor deficits and lower seizure occurrences.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16023557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
- Individuals with AS resulting from imprinting defects have the least debilitating features, such as higher developmental and language ability than AS caused by other mechanisms.&amp;lt;ref name=&amp;quot;PMID:11748306&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11748306&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
- The Body Mass Index (BMI) of 33% of the UBE3A mutation patients, and 47–64% of the patients from the classes II (UPD) and III (Imprinting defect) is above the 95th centile.&amp;lt;ref name=&amp;quot;PMID:15253756&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15253756&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Animal models'''&lt;br /&gt;
&lt;br /&gt;
* '''Drosophila'''&lt;br /&gt;
&lt;br /&gt;
Drosophila (common fruit fly) is an excellent model to use for better understanding of genetic diseases in humans as they are highly homologous to human UBE3A (hUBE3A), illustrating a high evolutionary conservation. Studies using the Drosophila model have shown that the functional absence of UBE3A resulted in decreased morphogenesis of dendritic branches. This is of interest as dendritic branches cover over 90% of the neuronal surface where [[#Glossary | '''synapse''']] between neurons occur. Proper formation and maturation of dendritic spines is also required so they come in contact with other neurons for effective transmission of neuronal signals. Thus proper formation of dendritic branching is pivitol for effective neuronal function and hence cognitive function.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18996915&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Interestingly, overexpression of dUBE3A also gave the same result, consisting of abnormal locomotion  and decreased dendritic branching in sensory neurons.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18701717&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;  This suggests a possible research field for some forms of [[#Glossary | '''autism''']] where the region containing UBE3A is duplicated, leading to delayed motor skills and seizures.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16433693&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;[[File:Normal and Angelman Syndrome mice models.jpg|thumb|250px|right|Normal and AS mice performance on the Rotarod apparatus.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
* '''Mice'''&lt;br /&gt;
&lt;br /&gt;
Absence of UBE3A in mice manifest similar phenotype to human AS, as illustrated by motor and learning deficits with inducible seizures.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21235769&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It has been shown through various mice model studies that larger deletions, ie. from UBE3A to GABRB3, more closely mirrors the large 6Mb deletions seen in human AS patients. Numerous tests, such as the Rotarod (for motor coordination and learning ability), Morris water maze test (for spatial learning and memory) and [[#Glossary | '''EEG''']] (electroencephalography), were carried out on  UBE3A null mutants, which showed the results to be abnormal or impaired.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20808828&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Other studies using mouse models have also outlined the obesity observed in 15% of AS children, albeit it is not the major characterisitics of AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17259980&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The diagram on the right clearly highlights the results obtained from such mouse model studies of AS, where the absence of UBE3A accumulated in deficits of motor function and obesity. In addition, excessive drooling and feeding difficulties were also highlighted by mice models with inactivated UBE3A, reflected by defects in fluid consumption and licking.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18413322&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Pathophysiology===&lt;br /&gt;
&lt;br /&gt;
'''Cognitive defects'''&lt;br /&gt;
&lt;br /&gt;
[[File:Role of UBE3A in dendritic spine neuronal synapses.png|thumb|250px|right|Role of UBE3A in dendritic spine neuronal synapses.]]&lt;br /&gt;
&lt;br /&gt;
AS patients present with abnormally high UBE3A, leading to neurological impairment. Recent identification of key target proteins of Ephexin-58 (Eph-5) and Arc (Activity-Regulated Cytoskeleton-associated protein) have aided in better understanding of the progression of UBE3A to cognitive defects. These two proteins are vital in the understanding of AS as Eph-5 determines synapse numbers and Arc contributes to plasticity and synapse function.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21164477&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Studies utilizing mice models have illustrated that UBE3A null mice could not ubiquitinate Eph-5, thus increasing its levels and limiting the growth of dendritic spines by the activation of RhoA. This subsequent activation of RhoA inhibits synapse formation and results in neuronal defects.&lt;br /&gt;
&lt;br /&gt;
In contrast, mice with normally functioning UBE3A showed phosphorylated Eph-5, resulting from the interaction of two neurons via the activation of EphB signalling receptor.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21029865&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Phosphorylation of Eph-5 allows UBE3A to ubiquitinate and degrade it. This degradation of Eph-5 permits new synaptic connections to form with cells they come into contact with. However, in AS, the absence of UBE3A means Eph-5 cannot be degraded, so RhoA activity is prolonged to reduce synaptic formation.&lt;br /&gt;
&lt;br /&gt;
As mentioned previously, Arc plays a pivitol role in synapse function as it removes synaptic receptors that respond to glutamate, a [[#Glossary | '''neurotransmitter''']].&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17088211&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In UBE3A present neurons, UBE3A ubiquitinates Arc, leading to it degradation as illustrated by the diagram on the left. However, in UBE3A deficient neurons, Arc accumulates and prevents the proper synaptic communications essential for normal cognitive functions.&amp;lt;ref name=&amp;quot;PMID20211139&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Signs and Symptoms==&lt;br /&gt;
&lt;br /&gt;
Angelman Syndrome presents a variety of different phenotypes, and the presented symptoms may vary at different ages.&amp;lt;ref name=&amp;quot;PMID7625442&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7625442&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
In 1995 Williams et al. embraced the observed clinical features of AS in a consensus statement, in order to present an appliance for clinicians. The diagnostic criteria were updated in 2005.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt; The following table shows the most frequently occurring characteristics in AS patients:&lt;br /&gt;
&lt;br /&gt;
'''4 characteristics appear in 100% of the cases:'''&lt;br /&gt;
&lt;br /&gt;
*Delayed development: become apparent by the age of 6 to 12 months.&lt;br /&gt;
*Motion and or balance malfunction&lt;br /&gt;
*Behaviour patterns like unmotivated laughter, frequent excitement; often including body movements,[[File:Electroencephalography of Angelman Syndrome.jpg|thumb|350px|right|EEG of AS and normal individuals.]] [[#Glossary | '''hypermotoric''']] behaviour&lt;br /&gt;
*Impairment of speech&lt;br /&gt;
&lt;br /&gt;
'''3 characteristics appear in more than 80% of the cases:'''&lt;br /&gt;
&lt;br /&gt;
*Abnormalities in head circumference, microcephaly&lt;br /&gt;
*Seizures&lt;br /&gt;
*EEG shows specific abnormal patterns&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Angelman Syndrome individuals show the most distinct disease pattern from 2 to 16 years of age.&lt;br /&gt;
In most cases at least 8 of the symptom traits are shown.&amp;lt;ref name=&amp;quot;PMID7625442&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Behavioural Characteristics'''&lt;br /&gt;
&lt;br /&gt;
A range of substantial characteristics appear in all AS cases, regardless of the genetic mechanisms, and are often responsible for diagnosing the syndrome. According to the original name, Happy Puppet syndrome, they have shown to exhibit traits such as a happy demeanor, with frequent laughter or smiling that can easily be triggered.&amp;lt;ref name=&amp;quot;PMID12566516&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12566516&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This behaviour can already be observed in 1 to 3 month old infants.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot; /&amp;gt; Uplifted hand flapping or waving motions are associated with laughter and excitement. Other characteristics manifesting in early childhood are sleep abnormalities with reduced sleep demand, and feeding problems. Breast and bottle feeding can be difficult due to non efficient attachment to the breast, tongue thrusting and uncoordinated sucking. Furthermore, there is an affection to crinkly and reflective surfaces, like some papers or plastic materials, especially water.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID12566516 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Communication Skills'''&lt;br /&gt;
&lt;br /&gt;
Communication is challenging for AS patients due to the fact that speech impairment is present in all cases. In the majority of affected people a lack of speech development is present. Only some of them have a minimal vocabulary consisting of two or three words, a few can speak in basic sentences. Some patients use gestures to articulate themselves, the [[#Glossary | '''Picture Exchange Communication System (PECS)''']] or sign languages such as [[#Glossary | '''Makaton''']] can be used for communication. Simple demands regarding their everyday occurrence can be understood by most patients.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID12566516 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Clinical and External Characteristics'''[[File:Angelman Syndrome patient.png|thumb|200px|right|4 year old AS patient.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Developmental delays are present in all patients. Motor milestones are delayed with children managing to sit unsupported with 12 months and crawl or bottom shuffle at the age of 18-24 months. The average age for walking is 4 years,however, ranging from 18 months to 7 years.&lt;br /&gt;
The [[#Glossary | '''gait''']] is characterised as slow, and flapping hands are a common trait.  The legs remain stiff during walking, arms are inflected by the wrists and elbows. The movements can appear ataxic, jerky or lurching. The muscle tone shows abnormalities with truncal [[#Glossary | '''hypotonia''']] and [[#Glossary | '''hypertonicity''']] of the limbs and alert reflexes.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID12566516 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The most striking external traits present in patients include broad-spaced teeth, and a wide mouth, light hair and eye colour, hypopigmented skin, deep set eyes, and a flat [[#Glossary | '''occiput''']].&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Seizures in Angelman Syndrome'''&lt;br /&gt;
&lt;br /&gt;
85% of AS patients suffer from epileptic seizures during their first three years. The first appearance can be within one month up to 20 year old patients. In infants with AS epilepsy manifests with [[#Glossary | '''febrile convulsions''']] and is hard to manage during childhood.&lt;br /&gt;
The most common type of seizures within 25% of patients are [[#Glossary | '''myoclonic seizures''']], followed by [[#Glossary | '''atonic seizures''']] as the second most frequent type, then 21% experience generalised [[#Glossary | '''tonic-clonic seizures''']] and lastly [[#Glossary | '''atypical absences''']] occur in 12% of patients.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20398390&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Angelman Syndrome in adults'''&lt;br /&gt;
&lt;br /&gt;
Patients with Angelman syndrome possess normal secondary sexual characteristics, and puberty sets in at a usual time. Limb hypertonicity, and [[#Glossary | '''thoracic scoliosis''']] lead to decreasing mobility. [[#Glossary | '''Oesophagus reflux''']] might induce severe problems, and the majority suffers from obesity. Furthermore, facial traits such as a prominent lower lip [[#Glossary | '''macrostomia''']] and [[#Glossary | '''mandibular prognathism''']] get manifested in adults. &lt;br /&gt;
In some cases the communication barrier can lead to frustration, resulting in aggressive behaviour. Nonetheless, patients gain a higher concentration span with age, and their nature becomes more quiet.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Complications===&lt;br /&gt;
&lt;br /&gt;
'''Hypopigmentation and Ocular albinism'''&lt;br /&gt;
&lt;br /&gt;
OCA2 gene, also known as the P gene, is closely located to the UBE3A gene. It encodes a protein vital to tyrosine metabolism, which plays a role in pigmentation development of skin, hair and eyes. However, AS caused by the large deletion of UBE3A leads to haploinsufficiency of OCA2 gene, resulting in hypopigmentation of the skin and the eyes. In some children with severe hypopigmentation, some form of [[#Glossary | '''albinism''']] is suspected.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12749060&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; When AS is caused by another mechanism, no abnormality of the skin and eye pigmentation is observed. However, not all AS children with OCA2 gene deletion will present with obvious hypopigmentation, they may just exhibit lighter skin colour than their parents.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8302318&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Diagnosis==&lt;br /&gt;
&lt;br /&gt;
The diagnosis of Angelman Syndrome is a clinical diagnosis confirmed by laboratory testing.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This involves both prenatal and/or postnatal diagnosis. &lt;br /&gt;
&lt;br /&gt;
===Prenatal Diagnosis===&lt;br /&gt;
[[File:Angelman Syndrome Prenatal Diagnosis.jpg|thumb|250px|right|Flowchart of AS Diagnosis.]]&lt;br /&gt;
&lt;br /&gt;
Prenatal detection of deletions of 15q11.2-q13, [[#Glossary | '''Paternal UPD''']] ([[#Glossary | '''Uniparental Disomy''']]), Imprinting defects and UBE3A mutations are done through DNA/chromosome/FISH analysis of fetal cells obtained by either [[#Glossary | '''Chorionic Villus Sampling''']](CVS) or [[#Glossary | '''Amniocentesis''']].&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot;/&amp;gt; &lt;br /&gt;
DNA methylation analysis using [[#Glossary | '''Amniocytes''']] is usually the first test carried out in molecular diagnosis of AS.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18059071&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; An abnormal result is followed up by either a FISH or array CGH analysis to search for a deletion on chromosome 15. If they produce a normal result, then UPD testing using DNA polymorphysims is carried out. If there is no evidence of UPD, other DNA analysis tests are used search for an imprinting centre deletion.&amp;lt;ref name=&amp;quot;PMID9792887&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9792887&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; A normal DNA methylation analysis is followed by a UBE3A sequence analysis.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt; In addition, a parent of origin test is also done to determine if the genetic disruption is of maternal origin or paternal origin. If it is maternally derived the fetus is diagnosed with AS (a paternally derived genetic disruption is indicative of Prader-Willi Syndrome).&amp;lt;ref name=&amp;quot;PMID17020468&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;17020468&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The flow chart summarizes the normal procedure used for prenatal diagnosis of AS. More information on important laboratory tests used for the diagnosis of Angelman Syndrome are provided below:&lt;br /&gt;
&lt;br /&gt;
*'''DNA Methylation Analysis'''&lt;br /&gt;
&lt;br /&gt;
Identifies approximately 80% of AS affected individuals and is usually the first test to be ordered.&amp;lt;ref name=&amp;quot;PMID7618904&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7618904&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Molecular disruptions such as deletions, paternal UPD and imprinting defects on chromosome 15 all demonstrate abnormal methylation patterns by either southern blot analysis or PCR amplification of bisulphate-treated DNA.&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot; /&amp;gt; An affected individual will only have an unmethylated (paternal) SNRPN (small nuclear ribonuclear protein-associated polypeptide N) allele compared with an unaffected individual who will have both a methylated and an unmethylated SNRPN allele.&amp;lt;ref name=&amp;quot;PMID9634532&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9634532&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
	  &lt;br /&gt;
*'''FISH (Fluorescent In Situ Hybridization)'''&lt;br /&gt;
&lt;br /&gt;
[[File:Critical_region_of_Angelman_Syndrome_on_chromosome_15.png‎|thumb|150px|right|FISH (fluorescence in situ hybridisation) image showing the critical region of Angelman Syndrome on chromosome 15.]]&lt;br /&gt;
&lt;br /&gt;
FISH analysis detects 5-7 Mb deletions in approximately 68% of affected individuals using detecting probes such as D15S10 and/or SNRPN.&amp;lt;ref name=&amp;quot;PMID7618904&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7618904&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It is also able to distinguish UPD from micro-deletions and imprinting defects. In simple terms, FISH analysis involves the binding of a fluorescent probe to a specific part of chromosome 15 and the detection of deletions within that region. FISH analysis is much more accurate in deletion detection compared to other high-resolution cytogenetics in the diagnosis of AS patients.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1511093&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
Array-based CGH is an advanced type of cytogenetic testing that can also be used to detect smaller deletions.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''UPD (Uniparental Disomy) Detection'''&lt;br /&gt;
&lt;br /&gt;
DNA Polymorphism testing detects paternal UPD in approximately 7% of affected AS individuals.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt; It is also able to distinguish between UPD and an Imprinting defect. It requires a DNA sample from the [[#Glossary | '''Proband''']] and from both parents. A homologous or non-homologous whole-arm translocation of the long arms of chromosome 15 is a sound indication for the need for prenatal UPD testing.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''IC (Imprinting Center) Analysis'''&lt;br /&gt;
&lt;br /&gt;
This type of analysis is used when individuals have an abnormal DNA methylation pattern but show normal results for  FISH, array CGH study and UPD analysis.&amp;lt;ref name=&amp;quot;PMID9792887&amp;quot;/&amp;gt; It is used to differentiate between the Imprinting defects caused by either microdeletions in the AS imprinting centre or by epigenetic mutations (that occur in maternal oogenesis or early embryogenesis).&amp;lt;ref name=&amp;quot;PMID9634532&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''Cytogenetic Testing'''&lt;br /&gt;
&lt;br /&gt;
Is used to detect a cytogenetically visible chromosomal rearrangement (large deletion, translocation or inversion) involving the 15q11.2-q13 region, which occurs in less than 1% of affected individuals.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''UBE3A Sequence Analysis'''&lt;br /&gt;
Sequence analysis of the UBE3A gene detects mutations in about 10% of the patients.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt; The test is used to detect either multiexonic (10 major coding exons of UBE3A) or whole gene deletions of UBE3A gene in individuals who produces a normal DNA methylation result but has characteristic clinical features of AS.&amp;lt;ref name=&amp;quot;PMID9792887&amp;quot;/&amp;gt;&lt;br /&gt;
This is recommended as a prenatal diagnostic tool in families that include multiple AS affected individuals because the imprinted pattern can be inherited from distant relatives.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Postnatal Diagnosis===&lt;br /&gt;
&lt;br /&gt;
Postnatal diagnosis is made though a combination of common clinical features of AS and UBESA gene sequence analysis.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt; The clinical features of AS include unsteady or shaky movements, muscle hypotonia, developmental delay and behavioral uniqueness such as frequent laughter/smiling and happy demeanor are features that are 100% consistent in all patients diagnosed with Angelman Syndrome.&amp;lt;ref name=&amp;quot;PMID18830393&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18830393&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; These clinical features become apparent between 6 months to 2 years of age. The onset of early or persistent smiling characteristic of this syndrome begin around the age of 1-3 months, but is often overlooked during infancy.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot;/&amp;gt; Thus early diagnosis of AS during infancy period is difficult because the clinical indicators of the syndrome takes time to manifest and characteristic features such as finger and hand tremors and excessive smiling/laughter are often overlooked and not considered as possible indicators of this syndrome.&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
*Rett Syndrome&lt;br /&gt;
&lt;br /&gt;
Some children with the clinical diagnosis of AS but no underlying genetic mechanism show mutations in ''MECP2'' gene, corresponding to Rett Syndrome. This should be suspected in AS test negative girls in the first few years of life.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17980307&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*Mowat-Wilson Syndrome&lt;br /&gt;
&lt;br /&gt;
Genetic mechanism is heterozygous deletion or truncation in ''ZFHX1B'' (''SIP1'') gene on 2q22. This presents with clinical features of severe intellectual disability, micrcephaly and seizures.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17958891&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Prader-Willi Syndrome patient.png|thumb|right|120px|12 year old PWS patient.]]&lt;br /&gt;
&lt;br /&gt;
*X-linked alpha-thalassemia/mental retardation syndrome (ATR-X)&lt;br /&gt;
&lt;br /&gt;
This arises from mutations in ''XNP'' gene on Xq13. ATR-X presents with severe intellectual disability, no speech development and seizures are common.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11449489&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*Phelan-McDermid Syndrome/22q13 deletion syndrome&lt;br /&gt;
&lt;br /&gt;
Deletions are usually submicroscopic and thus requires special molecular cytogenetic methods to confirm this deletion. Patients show moderate to profound intellectual disability and delay in speech development.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18505557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Related Disease'''&lt;br /&gt;
&lt;br /&gt;
*Prader-Willi Syndrome(PWS)&lt;br /&gt;
&lt;br /&gt;
PWS is a result from the absence of paternally expressed 15q11-q13 gene as a corollary of de novo deletion, maternal uniparental disomy of chromosome 15 or an imprinting defect on paternal chromosome 15 leading to the silencing of paternal alleles.&amp;lt;ref name=&amp;quot;PMID:20668179 &amp;quot;/&amp;gt; It is characterized by [[#Glossary | '''hyperphagia''']], obesity in later infancy and early childhood and difficulty in feeding during early infancy.&amp;lt;ref name=&amp;quot;PMID:20668179 &amp;quot;/&amp;gt; There is also cognitive impairment to some extent, though some PWS patients may exhibit intelligence in the normal IQ range. Behavioral phenotypes include stubbornness, manipulative tendency, obsessive compulsive characteristics.&amp;lt;ref name=&amp;quot;PMID:20668179 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Genetic Counselling==&lt;br /&gt;
&lt;br /&gt;
Genetic counselling is the process by which patients or relatives, at risk of an inherited disorder, are advised of the consequences and nature of the disorder, the probability of developing or transmitting it, and the options open to them in management and family planning. In the case for Angelman syndrome, types of risks associated are split into classes and formatted into the table below:&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20459762&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{|  style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
! Class&lt;br /&gt;
! Mechanism&lt;br /&gt;
! Risk to siblings&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! Ia                           &lt;br /&gt;
| De novo deletion                                                                                                               &lt;br /&gt;
| &amp;lt;1%                                                                                                                &lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! Ib&lt;br /&gt;
| Deletion due to chromosome rearrangement&lt;br /&gt;
| Up to 50%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! II&lt;br /&gt;
| Paternal uniparental disomy&lt;br /&gt;
| &amp;lt;1%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! IIIa&lt;br /&gt;
| Imprinting defect with IC mutation&lt;br /&gt;
| Close to 100% if father has 15; 15 [[#Glossary | '''Robertsonian translocation''']]&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! IIIb&lt;br /&gt;
| Imprinting defect withouth IC mutation&lt;br /&gt;
| Up to 50% (if mother has IC deletion)&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! IIIc&lt;br /&gt;
| Mosaic imprinting defect&lt;br /&gt;
| &amp;lt;1%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! IV&lt;br /&gt;
| ''UBE3A'' mutation&lt;br /&gt;
| Up to 50% (is mother has mutation)&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! V&lt;br /&gt;
| No identifiable genetic abnormality&lt;br /&gt;
| ?&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Treatment and Management==&lt;br /&gt;
&lt;br /&gt;
Even though at present there is no known cure for Angelman syndrome, there are a number of treatments available that may alleviate symptons and improve daily life activities.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The below table describes the problems and management options that are used:&lt;br /&gt;
&lt;br /&gt;
[[File:Subtle Finger tremors-Angelman Syndrome.jpg|right|thumb|150px|A five months old boy with Angelman syndrome showing signs of Subtle Finger tremor.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
! Problems encountered&lt;br /&gt;
! Treatment and Management&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''Difficulty in feeding newborn AS babies'''&lt;br /&gt;
| Use of special nipples may improve feeding&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Oesophagus reflux'''&lt;br /&gt;
| Special motility medications requiried or upright positioning&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''Seizures'''&lt;br /&gt;
| Anticonvulsant medications&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19605773&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19453717&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Ocular problems'''&lt;br /&gt;
| Visual assessment is vital to encourage interactions and minimize chances of self-harm and autism development&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20656169&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''Drooling in developmental delayed AS patients'''&lt;br /&gt;
| Difficult to treat, but new surgical procedure on salivary duct reimplantation seems to be a promising alternative&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17699119&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Unstable children''' &lt;br /&gt;
| Physical therapy&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''AS patients become less active with increasing age'''&lt;br /&gt;
| Activity schedules to prevent scoliosis and obesity. Occupational therapy to stimulate fine motor and oral-motor control skills in conjunction to speech therapy&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Sleeping difficulty'''&lt;br /&gt;
| Sedative medication in severe cases. [[#Glossary | '''Melatonin''']] may be used to promote sleeping but some studies have found that it loses its therapeutic effects after several weeks in most AS patients&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19379289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|-&lt;br /&gt;
|colspan=&amp;quot;4&amp;quot; |&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Prognosis==&lt;br /&gt;
&lt;br /&gt;
Life expectancy of AS patients seems to be normal&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, but there is still a high degree of developmental delay and limited expressive language skills.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17019625&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This problem arises prominently in the assessment of the severity of coincidental medical conditions due to difficulties in communication. A visit to the dentist can become difficult if good communication is not conveyed between the parents, the dentist, and the child.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18271768&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Some problems require extreme measures, such as the procedure of lens implantation was performed in both eyes of a person diagnosed with AS, due to the inability to wear spectacles.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20656169&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
During adulthood, menstruation and puberty begin at around average age evidenced by females with Angelman syndrome that are fully capable of conceiving children.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11258627&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Most adult patients can feed themselves, but needed help with many other daily activities. Main troubles which have shown in adults are a tendency to become obese and start developing  thoracic scoliosis, which some adults with AS begin wheelchair bounded.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9072912&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Current and Future Research==&lt;br /&gt;
&lt;br /&gt;
Currently there is no cure for the treatment of AS, so much research is being carried out for therapeutic interventions. Findings in the last five years have suggested through various mice and fruit fly models that the absence of maternal UBE3A results in the same human AS features of neurological defects and seizures. However, more recently, studies have outlined that the symptoms of AS can be improved by modifying other gene products. In addition, restoring of a functional UBE3A protein into adult mice neurons have shown to reduce motor and neurological deficits and balance disorders. This shows promising research prospects in that improvements may be possible in human AS patients by restoring functional UBE3A proteins into their neurons. &lt;br /&gt;
&lt;br /&gt;
===Possible Treatment Pathways===&lt;br /&gt;
&lt;br /&gt;
*'''Cognitive and physical impairment'''&lt;br /&gt;
&lt;br /&gt;
Although everyone is born with two copies of the gene UBE3A, one maternal and one paternal copy, it is only the maternal UBE3A that is used in the brain. Most AS patients have a genetic mutation on the maternal chromosome 15 that results in dysfunctional UBE3A.&amp;lt;ref&amp;gt;http://www.cureangelman.org/what-hope.html&amp;lt;/ref&amp;gt; The above research focused on turning on the father's copy of UBE3A to restore its functions. Furthermore, mouse models were utilized to show that alpha-CaMKII could be increased to compensate the loss of UBE3A and restore compromised mental and physical abilities. However, this finding still requires much more research.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17259980&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''Epilepsy'''&lt;br /&gt;
&lt;br /&gt;
There is research being done on improving certain conditions that are involved in AS by nutritional benefits. The use of [[#Glossary | '''corticosteroids''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19666884&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, [[#Glossary | '''valproate''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19453717&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and [[#Glossary | '''clonazepam''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19605773&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and having a [[#Glossary | '''ketogenic diet''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20880305&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; has all been shown to aid in the treatment of epilepsy. It has also been reported to be efficient in the treatment of other conditions, such as behavioural disorders, reduction in seizures, ataxia, sleep patterns, developmental progress and sleep disturbances. [[#Glossary | '''Levetiracetam''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17326790&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; could be used in such a situation, especially when the patient has an intolerance to valproate and clonazepam.&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&lt;br /&gt;
'''albinism''': A congenital disorder distincted by the complete or partial absence of pigment in the skin, hair and eyes due to defect of an enzyme involved in the production of melanin.&lt;br /&gt;
&lt;br /&gt;
'''allele''': Dissimilar variant of one gene. Organisms have two alleles for each gene inherited from their parents, one from each of them.&lt;br /&gt;
&lt;br /&gt;
'''alpha-CaMKII''': (alpha calcium calmodulin kinase II) Compound involved in synaptic plasticity, one of the most important theories behind learning and memory. Ability of a synapse between two neurons to change in strength due to the use or disuse of transmission.&lt;br /&gt;
&lt;br /&gt;
'''Amniocytes''': Cells that are shed by the fetus during fetal development to the surrounding amniotic fluid. They are a source of fetal DNA. &lt;br /&gt;
&lt;br /&gt;
'''Amniocentesis''': (AFT or amniotic fluid test) is a prenatal diagnostic test used to detect chromosomal abnormalities in the developing fetus by extracting amniotic fluid (a source of fetal DNA) surrounding the fetus. &lt;br /&gt;
&lt;br /&gt;
'''AMPA''': (2-amino-3-(5-methyl-3-oxo-1,2- oxazol-4-yl)propanoic acid) Compound that binds to the AMPA receptor to imitate glutamate neurotransmitter.&lt;br /&gt;
&lt;br /&gt;
'''Arc''': Activity-Regulated Cytoskeleton-associated protein; involved in learning and memory.&lt;br /&gt;
&lt;br /&gt;
'''ataxia''': Lack of coordination in muscle movements.&lt;br /&gt;
&lt;br /&gt;
'''atonic seizures''': A abrupt loss of muscle tone, this can lead to the limbs loosing strength, or the head may drop to the side. The patient remains conscious during this kind of epileptic seizure.&lt;br /&gt;
&lt;br /&gt;
'''atypical absences''': Seizure leads to unconsciousness in most cases.  &lt;br /&gt;
&lt;br /&gt;
'''autism''': A neural development disorder defined by limited social interaction and communication.&lt;br /&gt;
&lt;br /&gt;
'''Chorionic Villus Sampling''': A prenatal diagnostic test used to detect chromosomal abnormalities in the developing fetus by extracting and testing chorionic villus (placental tissue). &lt;br /&gt;
&lt;br /&gt;
'''chromosome''': Structure consisting of coiled DNA with DNA associated proteins such as histones.&lt;br /&gt;
&lt;br /&gt;
'''clonazepam''': A psychoactive drug having muscle relaxant properties and treats anxiety and epilepsy.&lt;br /&gt;
&lt;br /&gt;
'''corticosteroid''': A type of steroid hormones that are produced in the adrenal cortex.&lt;br /&gt;
&lt;br /&gt;
'''cytogenetics''': Study of the structure, function and abnormality of the cell, especially the chromosome.&lt;br /&gt;
&lt;br /&gt;
'''deletion''': Lack of a part of the DNA (deoxyribonucleic acid is a nucleic acid containing information for protein synthesis), can vary form a single base to a hole gene. &lt;br /&gt;
&lt;br /&gt;
'''de novo mutation''': Change in a gene of a family member for the first time due to a mutation in the egg or sperm of the parents or in the fertilized egg (zygote).&lt;br /&gt;
&lt;br /&gt;
'''disorder''': A mental or physical health disturbance or dysfunction.&lt;br /&gt;
&lt;br /&gt;
'''EEG''': Electroencephalography is a means of measuring electrical activity along the scalp by measuring the total electrical charges fired by thousands or millions of neurons.&lt;br /&gt;
&lt;br /&gt;
'''epilepsy''': Neurological disorder characterised by recurrent impairment of brain function that can cause seizures or unconsciousness. &lt;br /&gt;
&lt;br /&gt;
'''E6-AP''': E6-AP ubiquitin-protein ligase is an enzyme encoded by UBE3A which adds ubiquitin chain to target proteins to be degraded by proteasomes.&lt;br /&gt;
&lt;br /&gt;
'''febrile convulsions''': The occurrence of high fever, especially in children.&lt;br /&gt;
&lt;br /&gt;
'''FISH''': Fluorescent in situ hybridization is a technique used to identify and localize the presence or absence of DNA sequences on the chromosome. This is achieved by using fluorescently labelled DNA sequences which then binds to complementary DNA sequence on the chromosome. After hybridization (attachment), chromosome of interest will fluoresce under the microscope.&lt;br /&gt;
&lt;br /&gt;
'''gait''': A manner of walking, stepping or running.&lt;br /&gt;
&lt;br /&gt;
'''gene''': A molecular unit of heredity of a living organism.&lt;br /&gt;
&lt;br /&gt;
'''hyperphagia''': (Also referred to as Polyphagia) Excessive ingestion of food beyond the dietary and energy requirements of the body. &lt;br /&gt;
&lt;br /&gt;
'''hypermotoric''': Sudden appearance of uncontrolled movements such as striking or kicking inappropriately.&lt;br /&gt;
&lt;br /&gt;
'''hypertonicity''': Increase of muscle tension and a disability to stretch leading to an impairment of motor activity.&lt;br /&gt;
&lt;br /&gt;
'''hypopigmentation''': A lack of melanin pigments or melanocytes  affecting the colour of the skin, hair and iris. Features appear to be light-coloured due to loss of skin colour.&lt;br /&gt;
&lt;br /&gt;
'''hypotonia''': Decrease in the ability to stretch passively, due to a low muscle tone. &lt;br /&gt;
&lt;br /&gt;
'''imprinting''': This is a process to describe the modification of a maternally or paternally derived chromosome, which consequently influences the expression of certain genes on the altered chromosome.&lt;br /&gt;
&lt;br /&gt;
'''ketogenic diet''': A high-fat, low-carbohydrate diet that is used to treat epilepsy in children.&lt;br /&gt;
&lt;br /&gt;
'''levetiracetam''': An anticonvulsant drug used to treat epilepsy.&lt;br /&gt;
&lt;br /&gt;
'''locus''': Location of a gene on a chromosome(loci: plural for locus).&lt;br /&gt;
&lt;br /&gt;
'''LTP''': Long-term potentiation shares common features with long term memory. It strengthens and enhances signal transmission between neurons by improving the communication between two neurons.&lt;br /&gt;
&lt;br /&gt;
'''macrostomia''': A wide-spaced mouth.&lt;br /&gt;
&lt;br /&gt;
'''Makaton''': Language programme using symbols and signs to support speaking.&lt;br /&gt;
&lt;br /&gt;
'''mandibular prognathism''': The abnormal protrusion of the lower jaw. &lt;br /&gt;
&lt;br /&gt;
'''maxillary hypoplasia''':  The underdevelopment of the upper jaw.&lt;br /&gt;
&lt;br /&gt;
'''melatonin''': A hormone secreted by the pineal gland.&lt;br /&gt;
&lt;br /&gt;
'''microcephaly''': The circumference of the head is less than average due to abnormalities of the nervous system. This abnormality can be present at birth or emerge during the first few years of life and reduces both life expectancy and the cognitive functions of the individual affected.&lt;br /&gt;
&lt;br /&gt;
'''microdeletion''':  A genetic mutation in which a part of a chromosome or a sequence of DNA is missing.&lt;br /&gt;
&lt;br /&gt;
'''mutation''': Event that changes the DNA (deoxyribonucleic acid is a nucleic acid, containing information for protein synthesis) or RNA (ribonucleic acid is a type of nucleic acid transmitting the information from the DNA to the proteins ) of a gene permanently.&lt;br /&gt;
&lt;br /&gt;
'''myoclonic seizures''': A quick jerk of the skeletal muscle, due to a irregular brain activity.&lt;br /&gt;
&lt;br /&gt;
'''neurogenetic''': Genetic basis of the nervous system.&lt;br /&gt;
&lt;br /&gt;
'''neurotransmitter''': Transmits neuronal signals to a target cell. They are first packaged in vesicles just beneath the membrane of presynaptic axon terminals and released into the synaptic cleft (space between the two interacting neurons) and enter the postsynaptic dendrite.&lt;br /&gt;
&lt;br /&gt;
'''occiput''': The back portion of the head.&lt;br /&gt;
&lt;br /&gt;
'''oesophagus reflux''': Impairment of a sphincter in the lower end of the oesophagus leads to the back flow of stomach acid into the oesophagus. Heartburn is a typical symptom.&lt;br /&gt;
&lt;br /&gt;
'''paediatrician''': Physicians that specialise on infants, children and adolescents.&lt;br /&gt;
&lt;br /&gt;
'''paternal UPD''': Inheritance of two copies of a chromosome from the father and none from the mother. &lt;br /&gt;
&lt;br /&gt;
'''phenotype''': Visible traites of an organism determined by genetic and environmental factors.&lt;br /&gt;
&lt;br /&gt;
'''Picture Exchange Communication System (PECS)''': Individuals communicate using images instead of words. It is frequently used by children with autism, to articulate their needs and wishes or to make comments about something.&lt;br /&gt;
&lt;br /&gt;
'''Proband''': Is the person (or animal) being studied or reported on in a genetic investigation. Most commonly it refers to the first affected family member who requires medical help for a genetic disorder. &lt;br /&gt;
&lt;br /&gt;
'''Robertsonian translocation''': Rearrangement of the chromosome, occurs in 5 chromosome including 13,14,15,21 and 22. This type of mutation occurs in chromosomes with the centromere not at the centre, resulting in long and short arm chromosomes. Translocation breaks the chromosome at the centromere so the long arm attaches to the other long arm, and the same for the short arm happens. Cell division will result in the loss of the short arms as they do not contain important genes.&lt;br /&gt;
&lt;br /&gt;
'''seizure''': Abnormal electrical activity in the brain that can result in a variety of physical symptoms like convulsion, body shaking, loss of consciousness, confusion, and mood changes.&lt;br /&gt;
&lt;br /&gt;
'''synapse''': Allows transmission of signal between neurons for effective neuronal function.&lt;br /&gt;
&lt;br /&gt;
'''thoracic scoliosis''': The spine is curved laterally(from side to side) in the thoracic region.&lt;br /&gt;
&lt;br /&gt;
'''tonic-clonic seizures''': This type of seizure is associated with unconsciousness due to electrical discharges in a big proportion of the brain.&lt;br /&gt;
&lt;br /&gt;
'''ubiquitin''': A polypeptide found in all eukaryotic cells, that participates in a variety of cellular functions including protein recycling.&lt;br /&gt;
&lt;br /&gt;
'''Uniparental disomy''': (UPD) the inheritance of two copies of a chromosome pair or part of a chromosme from one parent and no copy from the other parent. &lt;br /&gt;
&lt;br /&gt;
'''valproate''':  A mood-stabilizing drug that is also used for treatment for epilepsy and bipolar disorder.&lt;br /&gt;
&lt;br /&gt;
==Helpful Links==&lt;br /&gt;
&lt;br /&gt;
* Australia&lt;br /&gt;
:* [http://www.angelmansyndrome.org/research.html Angelman Syndrome Association] &lt;br /&gt;
:* [http://www.angelmansyndromeqld.org/ Queensland Angelman Association]&lt;br /&gt;
&lt;br /&gt;
* America&lt;br /&gt;
:* [http://www.angelman.org/ Angelman Syndrome Foundation]&lt;br /&gt;
:* [http://rarediseasesnetwork.epi.usf.edu/arpwsc/ Rare Clinical Diseases Research Network]&lt;br /&gt;
:* [http://www.rarediseases.org/rare-disease-information/rare-diseases/byID/411/viewAbstract National Organisation for Rare Disorders]&lt;br /&gt;
:* [http://www.epilepsyfoundation.org/ Epilepsy Foundation]&lt;br /&gt;
:* [http://www.cureangelman.org/ Foundation for Angelman Syndrome Therapeutics]&lt;br /&gt;
&lt;br /&gt;
* Search Pubmed &lt;br /&gt;
:* [http://www.ncbi.nlm.nih.gov/pubmed?term=(Angelman+Syndrome[MAJR]) Angelman Syndrome] &lt;br /&gt;
&lt;br /&gt;
* OMIM&lt;br /&gt;
:* [http://omim.org/entry/105830 Genetic Disorder catalog]&lt;br /&gt;
&lt;br /&gt;
==Related Links==&lt;br /&gt;
&lt;br /&gt;
* [[Mouse Knockout]] - this page explains the current use of mouse models in disrupting genes to elucidate their genetic function, including the mouse gene knockouts for alpha calcium-calmodulin kinase II (alpha CaMKII)&lt;br /&gt;
* [[2009 Group Project 4]] - this page gives an extensive overview on the history of the mouse model and its various use in embryology and genetics. In addition, it also describes mouse knockout and the role they play in current research of various human diseases&lt;br /&gt;
* [[Fly Development]] - this page describes the use of drosophila flies as developmental models&lt;br /&gt;
* [[2009 Group Project 2]] - this page gives an extensive overview on the history of the fly model and its various use in embryology and genetics&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&lt;br /&gt;
&amp;lt;references /&amp;gt;&lt;/div&gt;</summary>
		<author><name>Z3291643</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_7&amp;diff=77439</id>
		<title>2011 Group Project 7</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_7&amp;diff=77439"/>
		<updated>2011-10-12T12:18:03Z</updated>

		<summary type="html">&lt;p&gt;Z3291643: /* Pathogenesis */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;='''Angelman Syndrome'''=&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Introduction==&lt;br /&gt;
&lt;br /&gt;
[[File:Dr Harry Angelman.jpg|thumb|130px|right|Dr Harry Angelman.]]&lt;br /&gt;
Angelman syndrome (AS) is a rare [[#Glossary | '''neurogenetic''']] [[#Glossary | '''disorder''']] first described by Dr. Harry Angelman in 1965.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18754889&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Dr. Angelman was an English [[#Glossary | '''paediatrician''']] who first diagnosed the disease in 3 children with a developmental delay.&amp;lt;ref&amp;gt;http://www.ncbi.nlm.nih.gov/books/NBK22221/&amp;lt;/ref&amp;gt; AS occurs in 1 in 10000-20000 births, the exact number is still unknown.&amp;lt;ref name=&amp;quot;PMID7573182&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7573182&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;PMID8703225&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;8703225&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It is caused by maternal [[#Glossary | '''allele''']] disruptions of a single gene- UBE3A. Either [[#Glossary | '''mutations''']] or [[#Glossary | '''deletions''']] of the UBE3A gene results in AS. &lt;br /&gt;
&lt;br /&gt;
AS presents with well known [[#Glossary | '''phenotypes''']] during infancy and adulthood, such as [[#Glossary | '''microcephaly''']] and [[#Glossary | '''maxillary hypoplasia''']]. However, these features become more marked with age. Most frequent clinical features include delayed development,[[#Glossary | '''seizures''']],[[#Glossary | '''ataxia''']], impairment of speech, happy demeanor, behavioural problems such as hyperactivity, short attention span and sleeping difficulty.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21592595&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21484597&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;ASAwebsite&amp;quot;&amp;gt;http://www.angelmansyndrome.org/home.html&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
At present, there is no cure for the syndrome, though current research is focused at improving life quality of patients with Angelman syndrome through management of daily tasks.&amp;lt;ref&amp;gt;http://www.bbc.co.uk/health/physical_health/conditions/angelman1.shtml&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==History==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Dr. Harry Angelman first reported Angelman Syndrome on three handicapped children that were admitted to his ward in England in 1964.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt; He reported how these three independent and unconnected clinical cases all had the same characteristic features of severe developmental delay, jerky movements, seizures and a happy disposition.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt; However it was only when he stumbled upon an oil painting called ‘a Boy with a Puppet” while on a holiday in Italy he was able to connect the symptoms of all three children under one common cause.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20981772&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; He linked the happy face of the boy depicted on the painting with the jerky movements and happy disposition he observed on his three patients back in England. He reported his findings on a paper entitled “Puppet children (a report on three cases)” which was published in 1965.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
The syndrome was initially named ‘Puppet Syndrome’ but was later changed to Angelman Syndrome. Due to the extreme rarity of the syndrome and lack of sufficient clinical evidence the syndrome was soon forgotten.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt;&lt;br /&gt;
[[File:Dr Charles Williams.jpg|thumb|right|150px|Dr Charles Williams.]]&lt;br /&gt;
	&lt;br /&gt;
In 1987, a physician named Ellen Magenis, came across children with deletions on [[#Glossary | '''chromosome''']] 15 that were suffering from seizures and severe developmental delay.&amp;lt;ref&amp;gt;http://www.angelman.org/stay-informed/facts-about-angelman-syndrome---7th-edition/harry-angelman-and-the-history-of-as/&amp;lt;/ref&amp;gt; Even though genetically the children were expected to have [[#Diagnosis | '''Prader-Willi syndrome''']] that was characterised by deletions on chromosome 15, their characteristic symptoms of seizures and lack of development did not correspond with that of the syndrome. This led to the realization that these children had deletions on the maternally derived chromosome 15 and not on the paternally derived chromosome as was observed in Prader-Willi syndrome.  Thus the deleted genetic code on maternally derived chromosome 15 was identified as the genetic marker for Angelman Syndrome.&lt;br /&gt;
&lt;br /&gt;
In 1997, UBE3A gene was isolated by Dr. Joseph Wagstaff and Dr. Arthur Beaudet as the cause of Angelman Syndrome.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot; /&amp;gt; The discovery of this [[#Glossary | '''gene''']] led to the subsequent development of animal models and research aimed at finding a causal link between UBE3A gene abnormalities and characteristic features observed in Angelman Syndrome. &lt;br /&gt;
	&lt;br /&gt;
Currently, four different genetic abnormalities for Angelman Syndrome have been confirmed by genetic testing. They include: Deletion, [[#Glossary | '''Uniparental Disomy''']] (UPD), [[#Glossary | '''Imprinting''']] and UBE3A mutation.&amp;lt;ref name=&amp;quot;PMID20211139&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Below is a timeline, summarising the key discoveries and advancements of the Angelman Syndrome:&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|- bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
!Year&lt;br /&gt;
!Milestone&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1964'''&lt;br /&gt;
|First observed by Dr Harry Angelman on three handicapped children.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot; /&amp;gt; &lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''1965'''&lt;br /&gt;
|Harry Angelman publishes his finding in a report entitled 'Puppet Children'(a report on three cases).&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1980s'''&lt;br /&gt;
|First reports of AS reaches US and research into the disorder being at the University of Florida under the direction of Dr. Charles Williams.&amp;lt;ref&amp;gt;http://www.angelmanproject.com/history.htm&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''1982'''&lt;br /&gt;
|Name changed from 'Happy Puppet' to Angelman syndrome by Williams and Frias. &lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1987'''&lt;br /&gt;
|Discovery of a genetic marker for AS – an absent genetic code on maternally derived chromosome 15. &lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''1997'''&lt;br /&gt;
|The cause of AS discovered by Dr. Joseph Wagstaff and Dr. Arthur Beaudet – mutation or deletion in the UBE3A gene.&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1998'''&lt;br /&gt;
|Transgenic mice with absent maternal UBE3A created to illustrate motor and learning deficits in addition to seizures.&amp;lt;ref name=&amp;quot;PMID9808466&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9808466&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''2007'''&lt;br /&gt;
|AS mouse model shows that neurological deficits can be reversed by decreasing levels of [[#Glossary | '''alpha-CaMKII''']] inhibitory phosphorylation.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17259980&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''2010'''&lt;br /&gt;
|Discovery of a another gene mutation in TC4 gene (on chromosome 18) in a small number of clinically diagnosed patients with no identifiable genetic alternation in UBE3A.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20184619&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''2010'''&lt;br /&gt;
|Protein named Arc identified as a target of AS gene product; UBE3A.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Incidence'''&lt;br /&gt;
*The current population of people diagnosed with AS is unknown but studies have estimated the number to be around 1:10,000&amp;lt;ref name=&amp;quot;PMID7573182&amp;quot; /&amp;gt; and 1:20,000&amp;lt;ref name=&amp;quot;PMID8703225&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
'''Diagnosis'''&lt;br /&gt;
*The mean age of diagnosis for patients with AS lies between 6 and 6.5 years of age.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18664077&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15741136&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Gender'''&lt;br /&gt;
* Males appear to be at higher risk for some aspects of early developmental delays in comparison to females with AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17019625&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Demography'''&lt;br /&gt;
*Europe:&lt;br /&gt;
:Denmark- 1:10,000&amp;lt;ref name=&amp;quot;PMID7573182&amp;quot; /&amp;gt;&lt;br /&gt;
:Estonia- 1:52,000&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16906556&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
:Sweden- 1:20,000&amp;lt;ref name=&amp;quot;PMID8703225&amp;quot; /&amp;gt;&lt;br /&gt;
*Australia:&lt;br /&gt;
:Western Australia- 1:40,000&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16492624&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Aetiology==&lt;br /&gt;
&lt;br /&gt;
[[File:Chromosome 15 Deletion of 15q11.2 to 15q13.jpg|thumb|100px|Chromosome 15 - The deletion occurs at 15q11.2-15q13.]]&lt;br /&gt;
&lt;br /&gt;
Different genetic mechanisms lead to different clinical phenotypes of AS. The most common genetic mechanism leading to AS is the deletion or re-arrangement of maternal chromosome at [[#Glossary | '''locus''']] 15q11.2-q13,as the chromosome image shows on the right, accounting for 70% of AS occurrences.&amp;lt;ref name=&amp;quot;PMID8988171&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt; 8988171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This leads to more severe clinical phenotypes of microcephaly, motor difficulties, seizures and impaired speech development. The next most common genetic mechanism is mutation in the ''UBE3A'' gene responsible for 10% of AS cases and paternal uniparental disomy and mutation in the imprinting centre (IC), both accounting for 2-5% of AS observed.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
 &lt;br /&gt;
&lt;br /&gt;
AS is caused by the 4 major genetic mechanisms mentioned above and are thus divided into Classes I to IV based on their underlying genetic mechanism. AS patients with the clinical features of AS but no [[#Glossary | '''cytogenetic''']] or molecular abnormality in Chromosome 15q11.2-13 are grouped under Class V (summarised in table below).&amp;lt;ref name=&amp;quot;PMID8988171&amp;quot; /&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10364509&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{|  style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
! Class&lt;br /&gt;
! Mechanism&lt;br /&gt;
! Diagnostic Tests&lt;br /&gt;
! Frequency&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''Ia'''                           &lt;br /&gt;
| De novo deletion                                                                                           &lt;br /&gt;
| High resolution cytogenetics [[#Glossary | '''FISH''']]                                                                                                       &lt;br /&gt;
| 70%      &lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Ib'''&lt;br /&gt;
| Deletion due to chromosome rearrangement&lt;br /&gt;
| High resolution cytogenetics FISH&lt;br /&gt;
| &amp;lt;1%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''II'''&lt;br /&gt;
| Paternal uniparental disomy&lt;br /&gt;
| [[#Glossary | '''RFLP''']]  analysis&lt;br /&gt;
| 2%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''IIIa'''&lt;br /&gt;
| Imprinting defect with IC mutation&lt;br /&gt;
| Screening of [[#Glossary | '''IC''']]  for mutations is positive&lt;br /&gt;
| 2%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''IIIb'''&lt;br /&gt;
| Imprinting defect withouth IC mutation&lt;br /&gt;
| Screening of IC for mutations is negative&lt;br /&gt;
| 2%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''IIIc'''&lt;br /&gt;
| Mosaic imprinting defect&lt;br /&gt;
| Screening of IC for mutations is usually negative &lt;br /&gt;
| ?&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''IV'''&lt;br /&gt;
| ''UBE3A'' mutation&lt;br /&gt;
| Screening of ''UBE3A'' for mutations&lt;br /&gt;
| 5-10%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''V'''&lt;br /&gt;
| No identifiable genetic abnormality&lt;br /&gt;
| Consider other diagnoses&lt;br /&gt;
| 5-26%&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Pathogenesis==&lt;br /&gt;
&lt;br /&gt;
Chromosome 15 became associated with AS in the 1980s after the observation of many AS patients harboring [[#Glossary | '''microdeletions''']] of 15q11.2-15q13.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15668046&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The last decade has shed even more light in the aetiology of AS,as Kishino and Matsuura first identified UBE3A as the causative gene for AS in 1997.&amp;lt;ref name=&amp;quot;PMID:8988171&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;8988171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8988172&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Normal gene product: E6-AP ubiquitin ligase'''&lt;br /&gt;
&lt;br /&gt;
The function of UBE3A is to encode for [[#Glossary | '''E6-AP''']] ubiquitin ligase, however its function in the development of the nervous system and the process of UBE3A mutation leading to cognitive impairment in AS patients is still vague.&amp;lt;ref name=&amp;quot;PMID:20211139&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Past and current research has elucidated that E6-AP ubiquitin ligase is involved in the degradation of four proteins, listed below, but currently, no protein with a direct role in [[#Glossary | '''long-term potentiation (LTP)''']] as a target of E6-AP, has been identified.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12684449&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The identification of such target proteins would be a landmark discovery in further understanding of the pathogenesis, aetiology and prospective treatment strategies of AS, as LTP defects is one of the major neurological impairments of AS. &lt;br /&gt;
 &lt;br /&gt;
* p53 tumor suppressor protein &lt;br /&gt;
* yeast DNA repair protein Rad23 &lt;br /&gt;
* multicopy maintenance protein 7 subunit &lt;br /&gt;
* E6-AP&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Abnormal gene product'''&lt;br /&gt;
&lt;br /&gt;
Disruption to the gene,UBE3A, interferes with the normal functioning of the gene, which is its crucial role in UBE3A [[#Glossary | '''ubiquitylation''']]. Problems involving this pathway can lead to various diseases either from the loss or gain of function.&amp;lt;ref name=&amp;quot;PMID:9857172&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9857172&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In the case of AS, E6-AP is affected, leading to detrimental cognitive impairment in addition to other deficits.&amp;lt;ref name=&amp;quot;PMID:9857172&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9857172&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Regional functioning of UBE3A'''&lt;br /&gt;
&lt;br /&gt;
Despite the uncertain progression of UBE3A mutation and the neurological abnormalities characteristic of AS, animal models have illustrated the vital role of UBE3A in the normal functioning of the brain. This can be exemplified by a study which utilized a mouse model with target inactivation of the gene UBE3A resulting in the manifestation of classical features of AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11895368&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In addition, the fact that imprinting of UBE3A takes place only in specific brain regions (cerebellum, olfactory tracts and the hippocampus) confirms the hypothesis that the loss of this gene would be detrimental in the cognitive development.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20398390&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Most genes are inherited in copies of two, one paternal and the other maternal; however, some genes, such as UBE3A only have one functional copy as the other is silenced, coined 'imprinting'. Imprinting of the paternal copy of UBE3A takes place in some cell populations, such as the hippocampal neurons and Purkinje cells in the cerebellum.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9288101&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This means only the maternal UBE3A is functionally expressed in these particular brain regions. Thus a [[#Glossary | '''de novo mutation''']] in the maternal copy of the gene will result in the complete absence of functional E6-AP in the associated brain areas.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9288088&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
It is also known that UBE3A plays an important role in synaptic transmission, but exactly how it does so is still not completely understood.&amp;lt;ref name=&amp;quot;PMID:9808466&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9808466&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''UBE3A ubiquitylation'''&lt;br /&gt;
&lt;br /&gt;
As briefly mentioned above, UBE3A is a member of the E3 ubiquitin ligase family of enzymes, responsible for the addition of ubiquitin to the target protein for degradation of the ubiquitinated protein, as illustrated in the diagram below. These processes are required for normal human cognitive function.&amp;lt;ref name=&amp;quot;PMID:9808466&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9808466&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In this way synaptic protein [[#Glossary | '''Arc (activity-regulated cytoskeleton-associated protein)''']] is degraded to control synaptic function. Arc is a target protein of UBE3A in dendritic spines found in the hippocampal neurons.&amp;lt;ref name=&amp;quot;PMID:20668179&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20668179&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Deletion of UBE3A leads to the accumulation of Arc in neurons leading to trafficking of [[#Glossary | '''AMPA ( α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid)''']] receptors, resulting in impaired cognitive functions.&amp;lt;ref name=&amp;quot;PMID:20211139&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; [[File:UBE3A Ubiquitylation Pathway.png|thumb|350px|right|UBE3A Ubiquitylation Pathway.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
UBE3A ubiquitylation consists of:&amp;lt;ref name=&amp;quot;PMID:20668179&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20668179&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
# Activation of ubiquitin by E1 enzyme&lt;br /&gt;
# E1 ezyme transfers ubiquitin to E2 enzyme&lt;br /&gt;
# E2 enzyme transfers ubiquitin to UBE3A&lt;br /&gt;
# UBE3A attaches activated ubiquitin to target protein which is then polyubiquitylated &lt;br /&gt;
# Target protein is then degraded by 26S proteosome&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Phenotype-Genotype correlations'''&lt;br /&gt;
&lt;br /&gt;
[[File:Extent of microcephaly in Angelman Syndrome patients.png|thumb|250px|right|Extent of microcephaly in 20 AS patients with deletion and without deletion.&amp;lt;ref&amp;gt;http://www.nature.com/ejhg/index.html/&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
All AS patients show differing extents of cognitive impairment, movement disorder, characteristic behaviours and difficulty in speech and language.&amp;lt;ref name=&amp;quot;PMID:11748306&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11748306&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; However, there seems to be some phenotype-genotype correlations:&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
- 5-7Mb deletions result in the most severe phenotypes such as microcephaly, more sever [[#Glossary | '''epilepsy''']] and seizures, motor difficulties and language impairment.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9546330&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20445456&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; AS patients with large deletions also present with clinical [[#Glossary | '''hypopigmentation''']], light hair and eye colour due to the close association of OCA2 gene with UBE3A.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;16470747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Individuals under this category have in general no increased BMI&amp;lt;ref name=&amp;quot;PMID:15253756&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15253756&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This is indicated by the graph on the left, which shows more cases of AS patients with deletions having larger deviations from the mean head circumference measurement than non-deletion AS patients.&lt;br /&gt;
 &lt;br /&gt;
- AS patients with uniparental disomy (UPD) have better physical growth, fewer motor deficits and lower seizure occurrences.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16023557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
- Individuals with AS resulting from imprinting defects have the least debilitating features, such as higher developmental and language ability than AS caused by other mechanisms.&amp;lt;ref name=&amp;quot;PMID:11748306&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11748306&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
- The Body Mass Index (BMI) of 33% of the UBE3A mutation patients, and 47–64% of the patients from the classes II (UPD) and III (Imprinting defect) is above the 95th centile.&amp;lt;ref name=&amp;quot;PMID:15253756&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15253756&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Animal models'''&lt;br /&gt;
&lt;br /&gt;
* '''Drosophila'''&lt;br /&gt;
&lt;br /&gt;
Drosophila (common fruit fly) is an excellent model to use for better understanding of genetic diseases in humans as they are highly homologous to human UBE3A (hUBE3A), illustrating a high evolutionary conservation. Studies using the Drosophila model have shown that the functional absence of UBE3A resulted in decreased morphogenesis of dendritic branches. This is of interest as dendritic branches cover over 90% of the neuronal surface where [[#Glossary | '''synapse''']] between neurons occur. Proper formation and maturation of dendritic spines is also required so they come in contact with other neurons for effective transmission of neuronal signals. Thus proper formation of dendritic branching is pivitol for effective neuronal function and hence cognitive function.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18996915&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Interestingly, overexpression of dUBE3A also gave the same result, consisting of abnormal locomotion  and decreased dendritic branching in sensory neurons.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18701717&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;  This suggests a possible research field for some forms of [[#Glossary | '''autism''']] where the region containing UBE3A is duplicated, leading to delayed motor skills and seizures.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16433693&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;[[File:Normal and Angelman Syndrome mice models.jpg|thumb|250px|right|Normal and AS mice performance on the Rotarod apparatus.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
* '''Mice'''&lt;br /&gt;
&lt;br /&gt;
Absence of UBE3A in mice manifest similar phenotype to human AS, as illustrated by motor and learning deficits with inducible seizures.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21235769&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It has been shown through various mice model studies that larger deletions, ie. from UBE3A to GABRB3, more closely mirrors the large 6Mb deletions seen in human AS patients. Numerous tests, such as the Rotarod (for motor coordination and learning ability), Morris water maze test (for spatial learning and memory) and [[#Glossary | '''EEG''']] (electroencephalography), were carried out on  UBE3A null mutants, which showed the results to be abnormal or impaired.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20808828&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Other studies using mouse models have also outlined the obesity observed in 15% of AS children, albeit it is not the major characterisitics of AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17259980&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The diagram on the right clearly highlights the results obtained from such mouse model studies of AS, where the absence of UBE3A accumulated in deficits of motor function and obesity. In addition, excessive drooling and feeding difficulties were also highlighted by mice models with inactivated UBE3A, reflected by defects in fluid consumption and licking.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18413322&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Pathophysiology===&lt;br /&gt;
&lt;br /&gt;
'''Cognitive defects'''&lt;br /&gt;
&lt;br /&gt;
[[File:Role of UBE3A in dendritic spine neuronal synapses.png|thumb|250px|right|Role of UBE3A in dendritic spine neuronal synapses.]]&lt;br /&gt;
&lt;br /&gt;
AS patients present with abnormally high UBE3A, leading to neurological impairment. Recent identification of key target proteins of Ephexin-58 (Eph-5) and Arc (Activity-Regulated Cytoskeleton-associated protein) have aided in better understanding of the progression of UBE3A to cognitive defects. These two proteins are vital in the understanding of AS as Eph-5 determines synapse numbers and Arc contributes to plasticity and synapse function.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21164477&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Studies utilizing mice models have illustrated that UBE3A null mice could not ubiquitinate Eph-5, thus increasing its levels and limiting the growth of dendritic spines by the activation of RhoA. This subsequent activation of RhoA inhibits synapse formation and results in neuronal defects.&lt;br /&gt;
&lt;br /&gt;
In contrast, mice with normally functioning UBE3A showed phosphorylated Eph-5, resulting from the interaction of two neurons via the activation of EphB signalling receptor.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21029865&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Phosphorylation of Eph-5 allows UBE3A to ubiquitinate and degrade it. This degradation of Eph-5 permits new synaptic connections to form with cells they come into contact with. However, in AS, the absence of UBE3A means Eph-5 cannot be degraded, so RhoA activity is prolonged to reduce synaptic formation.&lt;br /&gt;
&lt;br /&gt;
As mentioned previously, Arc plays a pivitol role in synapse function as it removes synaptic receptors that respond to glutamate, a [[#Glossary | '''neurotransmitter''']].&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17088211&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In UBE3A present neurons, UBE3A ubiquitinates Arc, leading to it degradation as illustrated by the diagram on the left. However, in UBE3A deficient neurons, Arc accumulates and prevents the proper synaptic communications essential for normal cognitive functions.&amp;lt;ref name=&amp;quot;PMID20211139&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Signs and Symptoms==&lt;br /&gt;
&lt;br /&gt;
Angelman Syndrome presents a variety of different phenotypes, and the presented symptoms may vary at different ages.&amp;lt;ref name=&amp;quot;PMID7625442&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7625442&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
In 1995 Williams et al. embraced the observed clinical features of AS in a consensus statement, in order to present an appliance for clinicians. The diagnostic criteria were updated in 2005.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt; The following table shows the most frequently occurring characteristics in AS patients:&lt;br /&gt;
&lt;br /&gt;
'''4 characteristics appear in 100% of the cases:'''&lt;br /&gt;
&lt;br /&gt;
*Delayed development: become apparent by the age of 6 to 12 months.&lt;br /&gt;
*Motion and or balance malfunction&lt;br /&gt;
*Behaviour patterns like unmotivated laughter, frequent excitement; often including body movements,[[File:Electroencephalography of Angelman Syndrome.jpg|thumb|350px|right|EEG of AS and normal individuals.]] [[#Glossary | '''hypermotoric''']] behaviour&lt;br /&gt;
*Impairment of speech&lt;br /&gt;
&lt;br /&gt;
'''3 characteristics appear in more than 80% of the cases:'''&lt;br /&gt;
&lt;br /&gt;
*Abnormalities in head circumference, microcephaly&lt;br /&gt;
*Seizures&lt;br /&gt;
*EEG shows specific abnormal patterns&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Angelman Syndrome individuals show the most distinct disease pattern from 2 to 16 years of age.&lt;br /&gt;
In most cases at least 8 of the symptom traits are shown.&amp;lt;ref name=&amp;quot;PMID7625442&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Behavioural Characteristics'''&lt;br /&gt;
&lt;br /&gt;
A range of substantial characteristics appear in all AS cases, regardless of the genetic mechanisms, and are often responsible for diagnosing the syndrome. According to the original name, Happy Puppet syndrome, they have shown to exhibit traits such as a happy demeanor, with frequent laughter or smiling that can easily be triggered.&amp;lt;ref name=&amp;quot;PMID12566516&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12566516&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This behaviour can already be observed in 1 to 3 month old infants.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot; /&amp;gt; Uplifted hand flapping or waving motions are associated with laughter and excitement. Other characteristics manifesting in early childhood are sleep abnormalities with reduced sleep demand, and feeding problems. Breast and bottle feeding can be difficult due to non efficient attachment to the breast, tongue thrusting and uncoordinated sucking. Furthermore, there is an affection to crinkly and reflective surfaces, like some papers or plastic materials, especially water.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID12566516 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Communication Skills'''&lt;br /&gt;
&lt;br /&gt;
Communication is challenging for AS patients due to the fact that speech impairment is present in all cases. In the majority of affected people a lack of speech development is present. Only some of them have a minimal vocabulary consisting of two or three words, a few can speak in basic sentences. Some patients use gestures to articulate themselves, the [[#Glossary | '''Picture Exchange Communication System (PECS)''']] or sign languages such as [[#Glossary | '''Makaton''']] can be used for communication. Simple demands regarding their everyday occurrence can be understood by most patients.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID12566516 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Clinical and External Characteristics'''[[File:Angelman Syndrome patient.png|thumb|200px|right|4 year old AS patient.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Developmental delays are present in all patients. Motor milestones are delayed with children managing to sit unsupported with 12 months and crawl or bottom shuffle at the age of 18-24 months. The average age for walking is 4 years,however, ranging from 18 months to 7 years.&lt;br /&gt;
The [[#Glossary | '''gait''']] is characterised as slow, and flapping hands are a common trait.  The legs remain stiff during walking, arms are inflected by the wrists and elbows. The movements can appear ataxic, jerky or lurching. The muscle tone shows abnormalities with truncal [[#Glossary | '''hypotonia''']] and [[#Glossary | '''hypertonicity''']] of the limbs and alert reflexes.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID12566516 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The most striking external traits present in patients include broad-spaced teeth, and a wide mouth, light hair and eye colour, hypopigmented skin, deep set eyes, and a flat [[#Glossary | '''occiput''']].&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Seizures in Angelman Syndrome'''&lt;br /&gt;
&lt;br /&gt;
85% of AS patients suffer from epileptic seizures during their first three years. The first appearance can be within one month up to 20 year old patients. In infants with AS epilepsy manifests with [[#Glossary | '''febrile convulsions''']] and is hard to manage during childhood.&lt;br /&gt;
The most common type of seizures within 25% of patients are [[#Glossary | '''myoclonic seizures''']], followed by [[#Glossary | '''atonic seizures''']] as the second most frequent type, then 21% experience generalised [[#Glossary | '''tonic-clonic seizures''']] and lastly [[#Glossary | '''atypical absences''']] occur in 12% of patients.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20398390&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Angelman Syndrome in adults'''&lt;br /&gt;
&lt;br /&gt;
Patients with Angelman syndrome possess normal secondary sexual characteristics, and puberty sets in at a usual time. Limb hypertonicity, and [[#Glossary | '''thoracic scoliosis''']] lead to decreasing mobility. [[#Glossary | '''Oesophagus reflux''']] might induce severe problems, and the majority suffers from obesity. Furthermore, facial traits such as a prominent lower lip [[#Glossary | '''macrostomia''']] and [[#Glossary | '''mandibular prognathism''']] get manifested in adults. &lt;br /&gt;
In some cases the communication barrier can lead to frustration, resulting in aggressive behaviour. Nonetheless, patients gain a higher concentration span with age, and their nature becomes more quiet.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Complications===&lt;br /&gt;
&lt;br /&gt;
'''Hypopigmentation and Ocular albinism'''&lt;br /&gt;
&lt;br /&gt;
OCA2 gene, also known as the P gene, is closely located to the UBE3A gene. It encodes a protein vital to tyrosine metabolism, which plays a role in pigmentation development of skin, hair and eyes. However, AS caused by the large deletion of UBE3A leads to haploinsufficiency of OCA2 gene, resulting in hypopigmentation of the skin and the eyes. In some children with severe hypopigmentation, some form of [[#Glossary | '''albinism''']] is suspected.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12749060&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; When AS is caused by another mechanism, no abnormality of the skin and eye pigmentation is observed. However, not all AS children with OCA2 gene deletion will present with obvious hypopigmentation, they may just exhibit lighter skin colour than their parents.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8302318&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Diagnosis==&lt;br /&gt;
&lt;br /&gt;
The diagnosis of Angelman Syndrome is a clinical diagnosis confirmed by laboratory testing.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This involves both prenatal and/or postnatal diagnosis. &lt;br /&gt;
&lt;br /&gt;
===Prenatal Diagnosis===&lt;br /&gt;
[[File:Angelman Syndrome Prenatal Diagnosis.jpg|thumb|250px|right|Flowchart of AS Diagnosis.]]&lt;br /&gt;
&lt;br /&gt;
Prenatal detection of deletions of 15q11.2-q13, [[#Glossary | '''Paternal UPD''']] ([[#Glossary | '''Uniparental Disomy''']]), Imprinting defects and UBE3A mutations are done through DNA/chromosome/FISH analysis of fetal cells obtained by either [[#Glossary | '''Chorionic Villus Sampling''']](CVS) or [[#Glossary | '''Amniocentesis''']].&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot;/&amp;gt; &lt;br /&gt;
DNA methylation analysis using [[#Glossary | '''Amniocytes''']] is usually the first test carried out in molecular diagnosis of AS.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18059071&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; An abnormal result is followed up by either a FISH or array CGH analysis to search for a deletion on chromosome 15. If they produce a normal result, then UPD testing using DNA polymorphysims is carried out. If there is no evidence of UPD, other DNA analysis tests are used search for an imprinting centre deletion.&amp;lt;ref name=&amp;quot;PMID9792887&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9792887&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; A normal DNA methylation analysis is followed by a UBE3A sequence analysis.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt; In addition, a parent of origin test is also done to determine if the genetic disruption is of maternal origin or paternal origin. If it is maternally derived the fetus is diagnosed with AS (a paternally derived genetic disruption is indicative of Prader-Willi Syndrome).&amp;lt;ref name=&amp;quot;PMID17020468&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;17020468&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The flow chart summarizes the normal procedure used for prenatal diagnosis of AS. More information on important laboratory tests used for the diagnosis of Angelman Syndrome are provided below:&lt;br /&gt;
&lt;br /&gt;
*'''DNA Methylation Analysis'''&lt;br /&gt;
&lt;br /&gt;
Identifies approximately 80% of AS affected individuals and is usually the first test to be ordered.&amp;lt;ref name=&amp;quot;PMID7618904&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7618904&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Molecular disruptions such as deletions, paternal UPD and imprinting defects on chromosome 15 all demonstrate abnormal methylation patterns by either southern blot analysis or PCR amplification of bisulphate-treated DNA.&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot; /&amp;gt; An affected individual will only have an unmethylated (paternal) SNRPN (small nuclear ribonuclear protein-associated polypeptide N) allele compared with an unaffected individual who will have both a methylated and an unmethylated SNRPN allele.&amp;lt;ref name=&amp;quot;PMID9634532&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9634532&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
	  &lt;br /&gt;
*'''FISH (Fluorescent In Situ Hybridization)'''&lt;br /&gt;
&lt;br /&gt;
[[File:Critical_region_of_Angelman_Syndrome_on_chromosome_15.png‎|thumb|150px|right|FISH (fluorescence in situ hybridisation) image showing the critical region of Angelman Syndrome on chromosome 15.]]&lt;br /&gt;
&lt;br /&gt;
FISH analysis detects 5-7 Mb deletions in approximately 68% of affected individuals using detecting probes such as D15S10 and/or SNRPN.&amp;lt;ref name=&amp;quot;PMID7618904&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7618904&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It is also able to distinguish UPD from micro-deletions and imprinting defects. In simple terms, FISH analysis involves the binding of a fluorescent probe to a specific part of chromosome 15 and the detection of deletions within that region. FISH analysis is much more accurate in deletion detection compared to other high-resolution cytogenetics in the diagnosis of AS patients.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1511093&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
Array-based CGH is an advanced type of cytogenetic testing that can also be used to detect smaller deletions.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''UPD (Uniparental Disomy) Detection'''&lt;br /&gt;
&lt;br /&gt;
DNA Polymorphism testing detects paternal UPD in approximately 7% of affected AS individuals.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt; It is also able to distinguish between UPD and an Imprinting defect. It requires a DNA sample from the [[#Glossary | '''Proband''']] and from both parents. A homologous or non-homologous whole-arm translocation of the long arms of chromosome 15 is a sound indication for the need for prenatal UPD testing.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''IC (Imprinting Center) Analysis'''&lt;br /&gt;
&lt;br /&gt;
This type of analysis is used when individuals have an abnormal DNA methylation pattern but show normal results for  FISH, array CGH study and UPD analysis.&amp;lt;ref name=&amp;quot;PMID9792887&amp;quot;/&amp;gt; It is used to differentiate between the Imprinting defects caused by either microdeletions in the AS imprinting centre or by epigenetic mutations (that occur in maternal oogenesis or early embryogenesis).&amp;lt;ref name=&amp;quot;PMID9634532&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''Cytogenetic Testing'''&lt;br /&gt;
&lt;br /&gt;
Is used to detect a cytogenetically visible chromosomal rearrangement (large deletion, translocation or inversion) involving the 15q11.2-q13 region, which occurs in less than 1% of affected individuals.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''UBE3A Sequence Analysis'''&lt;br /&gt;
Sequence analysis of the UBE3A gene detects mutations in about 10% of the patients.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt; The test is used to detect either multiexonic (10 major coding exons of UBE3A) or whole gene deletions of UBE3A gene in individuals who produces a normal DNA methylation result but has characteristic clinical features of AS.&amp;lt;ref name=&amp;quot;PMID9792887&amp;quot;/&amp;gt;&lt;br /&gt;
This is recommended as a prenatal diagnostic tool in families that include multiple AS affected individuals because the imprinted pattern can be inherited from distant relatives.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Postnatal Diagnosis===&lt;br /&gt;
&lt;br /&gt;
Postnatal diagnosis is made though a combination of common clinical features of AS and UBESA gene sequence analysis.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt; The clinical features of AS include unsteady or shaky movements, muscle hypotonia, developmental delay and behavioral uniqueness such as frequent laughter/smiling and happy demeanor are features that are 100% consistent in all patients diagnosed with Angelman Syndrome.&amp;lt;ref name=&amp;quot;PMID18830393&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18830393&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; These clinical features become apparent between 6 months to 2 years of age. The onset of early or persistent smiling characteristic of this syndrome begin around the age of 1-3 months, but is often overlooked during infancy.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot;/&amp;gt; Thus early diagnosis of AS during infancy period is difficult because the clinical indicators of the syndrome takes time to manifest and characteristic features such as finger and hand tremors and excessive smiling/laughter are often overlooked and not considered as possible indicators of this syndrome.&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
*Rett Syndrome&lt;br /&gt;
&lt;br /&gt;
Some children with the clinical diagnosis of AS but no underlying genetic mechanism show mutations in ''MECP2'' gene, corresponding to Rett Syndrome. This should be suspected in AS test negative girls in the first few years of life.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17980307&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*Mowat-Wilson Syndrome&lt;br /&gt;
&lt;br /&gt;
Genetic mechanism is heterozygous deletion or truncation in ''ZFHX1B'' (''SIP1'') gene on 2q22. This presents with clinical features of severe intellectual disability, micrcephaly and seizures.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17958891&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Prader-Willi Syndrome patient.png|thumb|right|120px|12 year old PWS patient.]]&lt;br /&gt;
&lt;br /&gt;
*X-linked alpha-thalassemia/mental retardation syndrome (ATR-X)&lt;br /&gt;
&lt;br /&gt;
This arises from mutations in ''XNP'' gene on Xq13. ATR-X presents with severe intellectual disability, no speech development and seizures are common.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11449489&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*Phelan-McDermid Syndrome/22q13 deletion syndrome&lt;br /&gt;
&lt;br /&gt;
Deletions are usually submicroscopic and thus requires special molecular cytogenetic methods to confirm this deletion. Patients show moderate to profound intellectual disability and delay in speech development.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18505557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Related Disease'''&lt;br /&gt;
&lt;br /&gt;
*Prader-Willi Syndrome(PWS)&lt;br /&gt;
&lt;br /&gt;
PWS is a result from the absence of paternally expressed 15q11-q13 gene as a corollary of de novo deletion, maternal uniparental disomy of chromosome 15 or an imprinting defect on paternal chromosome 15 leading to the silencing of paternal alleles.&amp;lt;ref name=&amp;quot;PMID:20668179 &amp;quot;/&amp;gt; It is characterized by [[#Glossary | '''hyperphagia''']], obesity in later infancy and early childhood and difficulty in feeding during early infancy.&amp;lt;ref name=&amp;quot;PMID:20668179 &amp;quot;/&amp;gt; There is also cognitive impairment to some extent, though some PWS patients may exhibit intelligence in the normal IQ range. Behavioral phenotypes include stubbornness, manipulative tendency, obsessive compulsive characteristics.&amp;lt;ref name=&amp;quot;PMID:20668179 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Genetic Counselling==&lt;br /&gt;
&lt;br /&gt;
Genetic counselling is the process by which patients or relatives, at risk of an inherited disorder, are advised of the consequences and nature of the disorder, the probability of developing or transmitting it, and the options open to them in management and family planning. In the case for Angelman syndrome, types of risks associated are split into classes and formatted into the table below:&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20459762&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{|  style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
! Class&lt;br /&gt;
! Mechanism&lt;br /&gt;
! Risk to siblings&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! Ia                           &lt;br /&gt;
| De novo deletion                                                                                                               &lt;br /&gt;
| &amp;lt;1%                                                                                                                &lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! Ib&lt;br /&gt;
| Deletion due to chromosome rearrangement&lt;br /&gt;
| Up to 50%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! II&lt;br /&gt;
| Paternal uniparental disomy&lt;br /&gt;
| &amp;lt;1%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! IIIa&lt;br /&gt;
| Imprinting defect with IC mutation&lt;br /&gt;
| Close to 100% if father has 15; 15 [[#Glossary | '''Robertsonian translocation''']]&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! IIIb&lt;br /&gt;
| Imprinting defect withouth IC mutation&lt;br /&gt;
| Up to 50% (if mother has IC deletion)&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! IIIc&lt;br /&gt;
| Mosaic imprinting defect&lt;br /&gt;
| &amp;lt;1%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! IV&lt;br /&gt;
| ''UBE3A'' mutation&lt;br /&gt;
| Up to 50% (is mother has mutation)&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! V&lt;br /&gt;
| No identifiable genetic abnormality&lt;br /&gt;
| ?&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Treatment and Management==&lt;br /&gt;
&lt;br /&gt;
Even though at present there is no known cure for Angelman syndrome, there are a number of treatments available that may alleviate symptons and improve daily life activities.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The below table describes the problems and management options that are used:&lt;br /&gt;
&lt;br /&gt;
[[File:Subtle Finger tremors-Angelman Syndrome.jpg|right|thumb|150px|A five months old boy with Angelman syndrome showing signs of Subtle Finger tremor.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
! Problems encountered&lt;br /&gt;
! Treatment and Management&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''Difficulty in feeding newborn AS babies'''&lt;br /&gt;
| Use of special nipples may improve feeding&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Oesophagus reflux'''&lt;br /&gt;
| Special motility medications requiried or upright positioning&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''Seizures'''&lt;br /&gt;
| Anticonvulsant medications&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19605773&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19453717&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Ocular problems'''&lt;br /&gt;
| Visual assessment is vital to encourage interactions and minimize chances of self-harm and autism development&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20656169&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''Drooling in developmental delayed AS patients'''&lt;br /&gt;
| Difficult to treat, but new surgical procedure on salivary duct reimplantation seems to be a promising alternative&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17699119&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Unstable children''' &lt;br /&gt;
| Physical therapy&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''AS patients become less active with increasing age'''&lt;br /&gt;
| Activity schedules to prevent scoliosis and obesity. Occupational therapy to stimulate fine motor and oral-motor control skills in conjunction to speech therapy&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Sleeping difficulty'''&lt;br /&gt;
| Sedative medication in severe cases. [[#Glossary | '''Melatonin''']] may be used to promote sleeping but some studies have found that it loses its therapeutic effects after several weeks in most AS patients&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19379289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|-&lt;br /&gt;
|colspan=&amp;quot;4&amp;quot; |&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Prognosis==&lt;br /&gt;
&lt;br /&gt;
Life expectancy of AS patients seems to be normal&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, but there is still a high degree of developmental delay and limited expressive language skills.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17019625&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This problem arises prominently in the assessment of the severity of coincidental medical conditions due to difficulties in communication. A visit to the dentist can become difficult if good communication is not conveyed between the parents, the dentist, and the child.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18271768&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Some problems require extreme measures, such as the procedure of lens implantation was performed in both eyes of a person diagnosed with AS, due to the inability to wear spectacles.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20656169&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
During adulthood, menstruation and puberty begin at around average age evidenced by females with Angelman syndrome that are fully capable of conceiving children.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11258627&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Most adult patients can feed themselves, but needed help with many other daily activities. Main troubles which have shown in adults are a tendency to become obese and start developing  thoracic scoliosis, which some adults with AS begin wheelchair bounded.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9072912&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Current and Future Research==&lt;br /&gt;
&lt;br /&gt;
Currently there is no cure for the treatment of AS, so much research is being carried out for therapeutic interventions. Findings in the last five years have suggested through various mice and fruit fly models that the absence of maternal UBE3A results in the same human AS features of neurological defects and seizures. However, more recently, studies have outlined that the symptoms of AS can be improved by modifying other gene products. In addition, restoring of a functional UBE3A protein into adult mice neurons have shown to reduce motor and neurological deficits and balance disorders. This shows promising research prospects in that improvements may be possible in human AS patients by restoring functional UBE3A proteins into their neurons. &lt;br /&gt;
&lt;br /&gt;
===Possible Treatment Pathways===&lt;br /&gt;
&lt;br /&gt;
*'''Cognitive and physical impairment'''&lt;br /&gt;
&lt;br /&gt;
Although everyone is born with two copies of the gene UBE3A, one maternal and one paternal copy, it is only the maternal UBE3A that is used in the brain. Most AS patients have a genetic mutation on the maternal chromosome 15 that results in dysfunctional UBE3A.&amp;lt;ref&amp;gt;http://www.cureangelman.org/what-hope.html&amp;lt;/ref&amp;gt; The above research focused on turning on the father's copy of UBE3A to restore its functions. Furthermore, mouse models were utilized to show that alpha-CaMKII could be increased to compensate the loss of UBE3A and restore compromised mental and physical abilities. However, this finding still requires much more research.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17259980&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''Epilepsy'''&lt;br /&gt;
&lt;br /&gt;
There is research being done on improving certain conditions that are involved in AS by nutritional benefits. The use of [[#Glossary | '''corticosteroids''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19666884&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, [[#Glossary | '''valproate''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19453717&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and [[#Glossary | '''clonazepam''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19605773&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and having a [[#Glossary | '''ketogenic diet''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20880305&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; has all been shown to aid in the treatment of epilepsy. It has also been reported to be efficient in the treatment of other conditions, such as behavioural disorders, reduction in seizures, ataxia, sleep patterns, developmental progress and sleep disturbances. [[#Glossary | '''Levetiracetam''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17326790&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; could be used in such a situation, especially when the patient has an intolerance to valproate and clonazepam.&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&lt;br /&gt;
'''albinism''': A congenital disorder distincted by the complete or partial absence of pigment in the skin, hair and eyes due to defect of an enzyme involved in the production of melanin.&lt;br /&gt;
&lt;br /&gt;
'''allele''': Dissimilar variant of one gene. Organisms have two alleles for each gene inherited from their parents, one from each of them.&lt;br /&gt;
&lt;br /&gt;
'''alpha-CaMKII''': (alpha calcium calmodulin kinase II) Compound involved in synaptic plasticity, one of the most important theories behind learning and memory. Ability of a synapse between two neurons to change in strength due to the use or disuse of transmission.&lt;br /&gt;
&lt;br /&gt;
'''Amniocytes''': Cells that are shed by the fetus during fetal development to the surrounding amniotic fluid. They are a source of fetal DNA. &lt;br /&gt;
&lt;br /&gt;
'''Amniocentesis''': (AFT or amniotic fluid test) is a prenatal diagnostic test used to detect chromosomal abnormalities in the developing fetus by extracting amniotic fluid (a source of fetal DNA) surrounding the fetus. &lt;br /&gt;
&lt;br /&gt;
'''AMPA''': (2-amino-3-(5-methyl-3-oxo-1,2- oxazol-4-yl)propanoic acid) Compound that binds to the AMPA receptor to imitate glutamate neurotransmitter.&lt;br /&gt;
&lt;br /&gt;
'''Arc''': Activity-Regulated Cytoskeleton-associated protein; involved in learning and memory.&lt;br /&gt;
&lt;br /&gt;
'''ataxia''': Lack of coordination in muscle movements.&lt;br /&gt;
&lt;br /&gt;
'''atonic seizures''': A abrupt loss of muscle tone, this can lead to the limbs loosing strength, or the head may drop to the side. The patient remains conscious during this kind of epileptic seizure.&lt;br /&gt;
&lt;br /&gt;
'''atypical absences''': Seizure leads to unconsciousness in most cases.  &lt;br /&gt;
&lt;br /&gt;
'''autism''': A neural development disorder defined by limited social interaction and communication.&lt;br /&gt;
&lt;br /&gt;
'''Chorionic Villus Sampling''': A prenatal diagnostic test used to detect chromosomal abnormalities in the developing fetus by extracting and testing chorionic villus (placental tissue). &lt;br /&gt;
&lt;br /&gt;
'''chromosome''': Structure consisting of coiled DNA with DNA associated proteins such as histones.&lt;br /&gt;
&lt;br /&gt;
'''clonazepam''': A psychoactive drug having muscle relaxant properties and treats anxiety and epilepsy.&lt;br /&gt;
&lt;br /&gt;
'''corticosteroid''': A type of steroid hormones that are produced in the adrenal cortex.&lt;br /&gt;
&lt;br /&gt;
'''cytogenetics''': Study of the structure, function and abnormality of the cell, especially the chromosome.&lt;br /&gt;
&lt;br /&gt;
'''deletion''': Lack of a part of the DNA (deoxyribonucleic acid is a nucleic acid containing information for protein synthesis), can vary form a single base to a hole gene. &lt;br /&gt;
&lt;br /&gt;
'''de novo mutation''': Change in a gene of a family member for the first time due to a mutation in the egg or sperm of the parents or in the fertilized egg (zygote).&lt;br /&gt;
&lt;br /&gt;
'''disorder''': A mental or physical health disturbance or dysfunction.&lt;br /&gt;
&lt;br /&gt;
'''EEG''': Electroencephalography is a means of measuring electrical activity along the scalp by measuring the total electrical charges fired by thousands or millions of neurons.&lt;br /&gt;
&lt;br /&gt;
'''epilepsy''': Neurological disorder characterised by recurrent impairment of brain function that can cause seizures or unconsciousness. &lt;br /&gt;
&lt;br /&gt;
'''E6-AP''': E6-AP ubiquitin-protein ligase is an enzyme encoded by UBE3A which adds ubiquitin chain to target proteins to be degraded by proteasomes.&lt;br /&gt;
&lt;br /&gt;
'''febrile convulsions''': The occurrence of high fever, especially in children.&lt;br /&gt;
&lt;br /&gt;
'''FISH''': Fluorescent in situ hybridization is a technique used to identify and localize the presence or absence of DNA sequences on the chromosome. This is achieved by using fluorescently labelled DNA sequences which then binds to complementary DNA sequence on the chromosome. After hybridization (attachment), chromosome of interest will fluoresce under the microscope.&lt;br /&gt;
&lt;br /&gt;
'''gait''': A manner of walking, stepping or running.&lt;br /&gt;
&lt;br /&gt;
'''gene''': A molecular unit of heredity of a living organism.&lt;br /&gt;
&lt;br /&gt;
'''hyperphagia''': (Also referred to as Polyphagia) Excessive ingestion of food beyond the dietary and energy requirements of the body. &lt;br /&gt;
&lt;br /&gt;
'''hypermotoric''': Sudden appearance of uncontrolled movements such as striking or kicking inappropriately.&lt;br /&gt;
&lt;br /&gt;
'''hypertonicity''': Increase of muscle tension and a disability to stretch leading to an impairment of motor activity.&lt;br /&gt;
&lt;br /&gt;
'''hypopigmentation''': A lack of melanin pigments or melanocytes  affecting the colour of the skin, hair and iris. Features appear to be light-coloured due to loss of skin colour.&lt;br /&gt;
&lt;br /&gt;
'''hypotonia''': Decrease in the ability to stretch passively, due to a low muscle tone. &lt;br /&gt;
&lt;br /&gt;
'''imprinting''': This is a process to describe the modification of a maternally or paternally derived chromosome, which consequently influences the expression of certain genes on the altered chromosome.&lt;br /&gt;
&lt;br /&gt;
'''ketogenic diet''': A high-fat, low-carbohydrate diet that is used to treat epilepsy in children.&lt;br /&gt;
&lt;br /&gt;
'''levetiracetam''': An anticonvulsant drug used to treat epilepsy.&lt;br /&gt;
&lt;br /&gt;
'''locus''': Location of a gene on a chromosome(loci: plural for locus).&lt;br /&gt;
&lt;br /&gt;
'''LTP''': Long-term potentiation shares common features with long term memory. It strengthens and enhances signal transmission between neurons by improving the communication between two neurons.&lt;br /&gt;
&lt;br /&gt;
'''macrostomia''': A wide-spaced mouth.&lt;br /&gt;
&lt;br /&gt;
'''Makaton''': Language programme using symbols and signs to support speaking.&lt;br /&gt;
&lt;br /&gt;
'''mandibular prognathism''': The abnormal protrusion of the lower jaw. &lt;br /&gt;
&lt;br /&gt;
'''maxillary hypoplasia''':  The underdevelopment of the upper jaw.&lt;br /&gt;
&lt;br /&gt;
'''melatonin''': A hormone secreted by the pineal gland.&lt;br /&gt;
&lt;br /&gt;
'''microcephaly''': The circumference of the head is less than average due to abnormalities of the nervous system. This abnormality can be present at birth or emerge during the first few years of life and reduces both life expectancy and the cognitive functions of the individual affected.&lt;br /&gt;
&lt;br /&gt;
'''microdeletion''':  A genetic mutation in which a part of a chromosome or a sequence of DNA is missing.&lt;br /&gt;
&lt;br /&gt;
'''mutation''': Event that changes the DNA (deoxyribonucleic acid is a nucleic acid, containing information for protein synthesis) or RNA (ribonucleic acid is a type of nucleic acid transmitting the information from the DNA to the proteins ) of a gene permanently.&lt;br /&gt;
&lt;br /&gt;
'''myoclonic seizures''': A quick jerk of the skeletal muscle, due to a irregular brain activity.&lt;br /&gt;
&lt;br /&gt;
'''neurogenetic''': Genetic basis of the nervous system.&lt;br /&gt;
&lt;br /&gt;
'''neurotransmitter''': Transmits neuronal signals to a target cell. They are first packaged in vesicles just beneath the membrane of presynaptic axon terminals and released into the synaptic cleft (space between the two interacting neurons) and enter the postsynaptic dendrite.&lt;br /&gt;
&lt;br /&gt;
'''occiput''': The back portion of the head.&lt;br /&gt;
&lt;br /&gt;
'''oesophagus reflux''': Impairment of a sphincter in the lower end of the oesophagus leads to the back flow of stomach acid into the oesophagus. Heartburn is a typical symptom.&lt;br /&gt;
&lt;br /&gt;
'''paediatrician''': Physicians that specialise on infants, children and adolescents.&lt;br /&gt;
&lt;br /&gt;
'''paternal UPD''': Inheritance of two copies of a chromosome from the father and none from the mother. &lt;br /&gt;
&lt;br /&gt;
'''phenotype''': Visible traites of an organism determined by genetic and environmental factors.&lt;br /&gt;
&lt;br /&gt;
'''Picture Exchange Communication System (PECS)''': Individuals communicate using images instead of words. It is frequently used by children with autism, to articulate their needs and wishes or to make comments about something.&lt;br /&gt;
&lt;br /&gt;
'''Proband''': Is the person (or animal) being studied or reported on in a genetic investigation. Most commonly it refers to the first affected family member who requires medical help for a genetic disorder. &lt;br /&gt;
&lt;br /&gt;
'''Robertsonian translocation''': Rearrangement of the chromosome, occurs in 5 chromosome including 13,14,15,21 and 22. This type of mutation occurs in chromosomes with the centromere not at the centre, resulting in long and short arm chromosomes. Translocation breaks the chromosome at the centromere so the long arm attaches to the other long arm, and the same for the short arm happens. Cell division will result in the loss of the short arms as they do not contain important genes.&lt;br /&gt;
&lt;br /&gt;
'''seizure''': Abnormal electrical activity in the brain that can result in a variety of physical symptoms like convulsion, body shaking, loss of consciousness, confusion, and mood changes.&lt;br /&gt;
&lt;br /&gt;
'''synapse''': Allows transmission of signal between neurons for effective neuronal function.&lt;br /&gt;
&lt;br /&gt;
'''thoracic scoliosis''': The spine is curved laterally(from side to side) in the thoracic region.&lt;br /&gt;
&lt;br /&gt;
'''tonic-clonic seizures''': This type of seizure is associated with unconsciousness due to electrical discharges in a big proportion of the brain.&lt;br /&gt;
&lt;br /&gt;
'''ubiquitin''': A polypeptide found in all eukaryotic cells, that participates in a variety of cellular functions including protein recycling.&lt;br /&gt;
&lt;br /&gt;
'''Uniparental disomy''': (UPD) the inheritance of two copies of a chromosome pair or part of a chromosme from one parent and no copy from the other parent. &lt;br /&gt;
&lt;br /&gt;
'''valproate''':  A mood-stabilizing drug that is also used for treatment for epilepsy and bipolar disorder.&lt;br /&gt;
&lt;br /&gt;
==External Links==&lt;br /&gt;
&lt;br /&gt;
: http://www.angelmansyndrome.org/research.html&lt;br /&gt;
: http://www.angelman.org/&lt;br /&gt;
: http://rarediseasesnetwork.epi.usf.edu/arpwsc/&lt;br /&gt;
: http://www.rarediseases.org/rare-disease-information/rare-diseases/byID/411/viewAbstract&lt;br /&gt;
: http://www.epilepsyfoundation.org/&lt;br /&gt;
: http://www.kumc.edu/gec/support/angelman.html&lt;br /&gt;
: http://www.cureangelman.org/&lt;br /&gt;
: http://www.angelmansyndromeqld.org/&lt;br /&gt;
: http://ghr.nlm.nih.gov/condition/angelman-syndrome&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&lt;br /&gt;
&amp;lt;references /&amp;gt;&lt;/div&gt;</summary>
		<author><name>Z3291643</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_7&amp;diff=77419</id>
		<title>2011 Group Project 7</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_7&amp;diff=77419"/>
		<updated>2011-10-12T11:58:10Z</updated>

		<summary type="html">&lt;p&gt;Z3291643: /* Possible Treatment Pathways */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;='''Angelman Syndrome'''=&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Introduction==&lt;br /&gt;
&lt;br /&gt;
[[File:Dr Harry Angelman.jpg|thumb|130px|right|Dr Harry Angelman.]]&lt;br /&gt;
Angelman syndrome (AS) is a rare [[#Glossary | '''neurogenetic''']] [[#Glossary | '''disorder''']] first described by Dr. Harry Angelman in 1965.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18754889&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Dr. Angelman was an English [[#Glossary | '''paediatrician''']] who first diagnosed the disease in 3 children with a developmental delay.&amp;lt;ref&amp;gt;http://www.ncbi.nlm.nih.gov/books/NBK22221/&amp;lt;/ref&amp;gt; AS occurs in 1 in 10000-20000 births, the exact number is still unknown.&amp;lt;ref name=&amp;quot;PMID7573182&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7573182&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;PMID8703225&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;8703225&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It is caused by maternal [[#Glossary | '''allele''']] disruptions of a single gene- UBE3A. Either [[#Glossary | '''mutations''']] or [[#Glossary | '''deletions''']] of the UBE3A gene results in AS. &lt;br /&gt;
&lt;br /&gt;
AS presents with well known [[#Glossary | '''phenotypes''']] during infancy and adulthood, such as [[#Glossary | '''microcephaly''']] and [[#Glossary | '''maxillary hypoplasia''']]. However, these features become more marked with age. Most frequent clinical features include delayed development,[[#Glossary | '''seizures''']],[[#Glossary | '''ataxia''']], impairment of speech, happy demeanor, behavioural problems such as hyperactivity, short attention span and sleeping difficulty.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21592595&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21484597&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;ASAwebsite&amp;quot;&amp;gt;http://www.angelmansyndrome.org/home.html&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
At present, there is no cure for the syndrome, though current research is focused at improving life quality of patients with Angelman syndrome through management of daily tasks.&amp;lt;ref&amp;gt;http://www.bbc.co.uk/health/physical_health/conditions/angelman1.shtml&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==History==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Dr. Harry Angelman first reported Angelman Syndrome on three handicapped children that were admitted to his ward in England in 1964.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt; He reported how these three independent and unconnected clinical cases all had the same characteristic features of severe developmental delay, jerky movements, seizures and a happy disposition.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt; However it was only when he stumbled upon an oil painting called ‘a Boy with a Puppet” while on a holiday in Italy he was able to connect the symptoms of all three children under one common cause.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20981772&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; He linked the happy face of the boy depicted on the painting with the jerky movements and happy disposition he observed on his three patients back in England. He reported his findings on a paper entitled “Puppet children (a report on three cases)” which was published in 1965.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
The syndrome was initially named ‘Puppet Syndrome’ but was later changed to Angelman Syndrome. Due to the extreme rarity of the syndrome and lack of sufficient clinical evidence the syndrome was soon forgotten.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt;&lt;br /&gt;
[[File:Dr Charles Williams.jpg|thumb|right|150px|Dr Charles Williams.]]&lt;br /&gt;
	&lt;br /&gt;
In 1987, a physician named Ellen Magenis, came across children with deletions on [[#Glossary | '''chromosome''']] 15 that were suffering from seizures and severe developmental delay.&amp;lt;ref&amp;gt;http://www.angelman.org/stay-informed/facts-about-angelman-syndrome---7th-edition/harry-angelman-and-the-history-of-as/&amp;lt;/ref&amp;gt; Even though genetically the children were expected to have [[#Diagnosis | '''Prader-Willi syndrome''']] that was characterised by deletions on chromosome 15, their characteristic symptoms of seizures and lack of development did not correspond with that of the syndrome. This led to the realization that these children had deletions on the maternally derived chromosome 15 and not on the paternally derived chromosome as was observed in Prader-Willi syndrome.  Thus the deleted genetic code on maternally derived chromosome 15 was identified as the genetic marker for Angelman Syndrome.&lt;br /&gt;
&lt;br /&gt;
In 1997, UBE3A gene was isolated by Dr. Joseph Wagstaff and Dr. Arthur Beaudet as the cause of Angelman Syndrome.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot; /&amp;gt; The discovery of this [[#Glossary | '''gene''']] led to the subsequent development of animal models and research aimed at finding a causal link between UBE3A gene abnormalities and characteristic features observed in Angelman Syndrome. &lt;br /&gt;
	&lt;br /&gt;
Currently, four different genetic abnormalities for Angelman Syndrome have been confirmed by genetic testing. They include: Deletion, [[#Glossary | '''Uniparental Disomy''']] (UPD), [[#Glossary | '''Imprinting''']] and UBE3A mutation.&amp;lt;ref name=&amp;quot;PMID20211139&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Below is a timeline, summarising the key discoveries and advancements of the Angelman Syndrome:&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|- bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
!Year&lt;br /&gt;
!Milestone&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1964'''&lt;br /&gt;
|First observed by Dr Harry Angelman on three handicapped children.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot; /&amp;gt; &lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''1965'''&lt;br /&gt;
|Harry Angelman publishes his finding in a report entitled 'Puppet Children'(a report on three cases).&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1980s'''&lt;br /&gt;
|First reports of AS reaches US and research into the disorder being at the University of Florida under the direction of Dr. Charles Williams.&amp;lt;ref&amp;gt;http://www.angelmanproject.com/history.htm&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''1982'''&lt;br /&gt;
|Name changed from 'Happy Puppet' to Angelman syndrome by Williams and Frias. &lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1987'''&lt;br /&gt;
|Discovery of a genetic marker for AS – an absent genetic code on maternally derived chromosome 15. &lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''1997'''&lt;br /&gt;
|The cause of AS discovered by Dr. Joseph Wagstaff and Dr. Arthur Beaudet – mutation or deletion in the UBE3A gene.&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1998'''&lt;br /&gt;
|Transgenic mice with absent maternal UBE3A created to illustrate motor and learning deficits in addition to seizures.&amp;lt;ref name=&amp;quot;PMID9808466&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9808466&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''2007'''&lt;br /&gt;
|AS mouse model shows that neurological deficits can be reversed by decreasing levels of [[#Glossary | '''alpha-CaMKII''']] inhibitory phosphorylation.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17259980&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''2010'''&lt;br /&gt;
|Discovery of a another gene mutation in TC4 gene (on chromosome 18) in a small number of clinically diagnosed patients with no identifiable genetic alternation in UBE3A.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20184619&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''2010'''&lt;br /&gt;
|Protein named Arc identified as a target of AS gene product; UBE3A.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Incidence'''&lt;br /&gt;
*The current population of people diagnosed with AS is unknown but studies have estimated the number to be around 1:10,000&amp;lt;ref name=&amp;quot;PMID7573182&amp;quot; /&amp;gt; and 1:20,000&amp;lt;ref name=&amp;quot;PMID8703225&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
'''Diagnosis'''&lt;br /&gt;
*The mean age of diagnosis for patients with AS lies between 6 and 6.5 years of age.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18664077&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15741136&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Gender'''&lt;br /&gt;
* Males appear to be at higher risk for some aspects of early developmental delays in comparison to females with AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17019625&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Demography'''&lt;br /&gt;
*Europe:&lt;br /&gt;
:Denmark- 1:10,000&amp;lt;ref name=&amp;quot;PMID7573182&amp;quot; /&amp;gt;&lt;br /&gt;
:Estonia- 1:52,000&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16906556&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
:Sweden- 1:20,000&amp;lt;ref name=&amp;quot;PMID8703225&amp;quot; /&amp;gt;&lt;br /&gt;
*Australia:&lt;br /&gt;
:Western Australia- 1:40,000&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16492624&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Aetiology==&lt;br /&gt;
&lt;br /&gt;
[[File:Chromosome 15 Deletion of 15q11.2 to 15q13.jpg|thumb|100px|Chromosome 15 - The deletion occurs at 15q11.2-15q13.]]&lt;br /&gt;
&lt;br /&gt;
Different genetic mechanisms lead to different clinical phenotypes of AS. The most common genetic mechanism leading to AS is the deletion or re-arrangement of maternal chromosome at [[#Glossary | '''locus''']] 15q11.2-q13,as the chromosome image shows on the right, accounting for 70% of AS occurrences.&amp;lt;ref name=&amp;quot;PMID8988171&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt; 8988171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This leads to more severe clinical phenotypes of microcephaly, motor difficulties, seizures and impaired speech development. The next most common genetic mechanism is mutation in the ''UBE3A'' gene responsible for 10% of AS cases and paternal uniparental disomy and mutation in the imprinting centre (IC), both accounting for 2-5% of AS observed.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
 &lt;br /&gt;
&lt;br /&gt;
AS is caused by the 4 major genetic mechanisms mentioned above and are thus divided into Classes I to IV based on their underlying genetic mechanism. AS patients with the clinical features of AS but no [[#Glossary | '''cytogenetic''']] or molecular abnormality in Chromosome 15q11.2-13 are grouped under Class V (summarised in table below).&amp;lt;ref name=&amp;quot;PMID8988171&amp;quot; /&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10364509&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{|  style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
! Class&lt;br /&gt;
! Mechanism&lt;br /&gt;
! Diagnostic Tests&lt;br /&gt;
! Frequency&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''Ia'''                           &lt;br /&gt;
| De novo deletion                                                                                           &lt;br /&gt;
| High resolution cytogenetics [[#Glossary | '''FISH''']]                                                                                                       &lt;br /&gt;
| 70%      &lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Ib'''&lt;br /&gt;
| Deletion due to chromosome rearrangement&lt;br /&gt;
| High resolution cytogenetics FISH&lt;br /&gt;
| &amp;lt;1%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''II'''&lt;br /&gt;
| Paternal uniparental disomy&lt;br /&gt;
| [[#Glossary | '''RFLP''']]  analysis&lt;br /&gt;
| 2%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''IIIa'''&lt;br /&gt;
| Imprinting defect with IC mutation&lt;br /&gt;
| Screening of [[#Glossary | '''IC''']]  for mutations is positive&lt;br /&gt;
| 2%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''IIIb'''&lt;br /&gt;
| Imprinting defect withouth IC mutation&lt;br /&gt;
| Screening of IC for mutations is negative&lt;br /&gt;
| 2%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''IIIc'''&lt;br /&gt;
| Mosaic imprinting defect&lt;br /&gt;
| Screening of IC for mutations is usually negative &lt;br /&gt;
| ?&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''IV'''&lt;br /&gt;
| ''UBE3A'' mutation&lt;br /&gt;
| Screening of ''UBE3A'' for mutations&lt;br /&gt;
| 5-10%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''V'''&lt;br /&gt;
| No identifiable genetic abnormality&lt;br /&gt;
| Consider other diagnoses&lt;br /&gt;
| 5-26%&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Pathogenesis==&lt;br /&gt;
&lt;br /&gt;
Chromosome 15 became associated with AS in the 1980s after the observation of many AS patients harboring [[#Glossary | '''microdeletions''']] of 15q11.2-15q13.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15668046&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The last decade has shed even more light in the aetiology of AS,as Kishino and Matsuura first identified UBE3A as the causative gene for AS in 1997.&amp;lt;ref name=&amp;quot;PMID:8988171&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;8988171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8988172&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Normal gene product: E6-AP ubiquitin ligase'''&lt;br /&gt;
&lt;br /&gt;
The function of UBE3A is to encode for [[#Glossary | '''E6-AP''']] ubiquitin ligase, however its function in the development of the nervous system and the process of UBE3A mutation leading to cognitive impairment in AS patients is still vague.&amp;lt;ref name=&amp;quot;PMID:20211139&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Past and current research has elucidated that E6-AP ubiquitin ligase is involved in the degradation of four proteins, listed below, but currently, no protein with a direct role in [[#Glossary | '''long-term potentiation (LTP)''']] as a target of E6-AP, has been identified.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12684449&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The identification of such target proteins would be a landmark discovery in further understanding of the pathogenesis, aetiology and prospective treatment strategies of AS, as LTP defects is one of the major neurological impairments of AS. &lt;br /&gt;
 &lt;br /&gt;
* p53 tumor suppressor protein &lt;br /&gt;
* yeast DNA repair protein Rad23 &lt;br /&gt;
* multicopy maintenance protein 7 subunit &lt;br /&gt;
* E6-AP&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Abnormal gene product'''&lt;br /&gt;
&lt;br /&gt;
Disruption to the gene,UBE3A, interferes with the normal functioning of the gene, which is its crucial role in UBE3A [[#Glossary | '''ubiquitylation''']]. Problems involving this pathway can lead to various diseases either from the loss or gain of function.&amp;lt;ref name=&amp;quot;PMID:9857172&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9857172&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In the case of AS, E6-AP is affected, leading to detrimental cognitive impairment in addition to other deficits.&amp;lt;ref name=&amp;quot;PMID:9857172&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9857172&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Regional functioning of UBE3A'''&lt;br /&gt;
&lt;br /&gt;
Despite the uncertain progression of UBE3A mutation and the neurological abnormalities characteristic of AS, animal models have illustrated the vital role of UBE3A in the normal functioning of the brain. This can be exemplified by a study which utilized a mouse model with target inactivation of the gene UBE3A resulting in the manifestation of classical features of AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11895368&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In addition, the fact that imprinting of UBE3A takes place only in specific brain regions (cerebellum, olfactory tracts and the hippocampus) confirms the hypothesis that the loss of this gene would be detrimental in the cognitive development.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20398390&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Most genes are inherited in copies of two, one paternal and the other maternal; however, some genes, such as UBE3A only have one functional copy as the other is silenced, coined 'imprinting'. Imprinting of the paternal copy of UBE3A takes place in some cell populations, such as the hippocampal neurons and Purkinje cells in the cerebellum.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9288101&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This means only the maternal UBE3A is functionally expressed in these particular brain regions. Thus a [[#Glossary | '''de novo mutation''']] in the maternal copy of the gene will result in the complete absence of functional E6-AP in the associated brain areas.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9288088&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
It is also known that UBE3A plays an important role in synaptic transmission, but exactly how it does so is still not completely understood.&amp;lt;ref name=&amp;quot;PMID:9808466&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9808466&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''UBE3A ubiquitylation'''&lt;br /&gt;
&lt;br /&gt;
As briefly mentioned above, UBE3A is a member of the E3 ubiquitin ligase family of enzymes, responsible for the addition of ubiquitin to the target protein for degradation of the ubiquitinated protein, as illustrated in the diagram below. These processes are required for normal human cognitive function.&amp;lt;ref name=&amp;quot;PMID:9808466&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9808466&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In this way synaptic protein [[#Glossary | '''Arc (activity-regulated cytoskeleton-associated protein)''']] is degraded to control synaptic function. Arc is a target protein of UBE3A in dendritic spines found in the hippocampal neurons.&amp;lt;ref name=&amp;quot;PMID:20668179&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20668179&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Deletion of UBE3A leads to the accumulation of Arc in neurons leading to trafficking of [[#Glossary | '''AMPA''']] receptors, resulting in impaired cognitive functions.&amp;lt;ref name=&amp;quot;PMID:20211139&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; [[File:UBE3A Ubiquitylation Pathway.png|thumb|350px|right|UBE3A Ubiquitylation Pathway.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
UBE3A ubiquitylation consists of:&amp;lt;ref name=&amp;quot;PMID:20668179&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20668179&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
# Activation of ubiquitin by E1 enzyme&lt;br /&gt;
# E1 ezyme transfers ubiquitin to E2 enzyme&lt;br /&gt;
# E2 enzyme transfers ubiquitin to UBE3A&lt;br /&gt;
# UBE3A attaches activated ubiquitin to target protein which is then polyubiquitylated &lt;br /&gt;
# Target protein is then degraded by 26S proteosome&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Phenotype-Genotype correlations'''&lt;br /&gt;
&lt;br /&gt;
[[File:Extent of microcephaly in Angelman Syndrome patients.png|thumb|250px|right|Extent of microcephaly in 20 AS patients with deletion and without deletion.&amp;lt;ref&amp;gt;http://www.nature.com/ejhg/index.html/&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
All AS patients show differing extents of cognitive impairment, movement disorder, characteristic behaviours and difficulty in speech and language.&amp;lt;ref name=&amp;quot;PMID:11748306&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11748306&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; However, there seems to be some phenotype-genotype correlations:&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
- 5-7Mb deletions result in the most severe phenotypes such as microcephaly, more sever [[#Glossary | '''epilepsy''']] and seizures, motor difficulties and language impairment.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9546330&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20445456&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; AS patients with large deletions also present with clinical [[#Glossary | '''hypopigmentation''']], light hair and eye colour due to the close association of OCA2 gene with UBE3A.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;16470747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Individuals under this category have in general no increased BMI&amp;lt;ref name=&amp;quot;PMID:15253756&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15253756&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This is indicated by the graph on the left, which shows more cases of AS patients with deletions having larger deviations from the mean head circumference measurement than non-deletion AS patients.&lt;br /&gt;
 &lt;br /&gt;
- AS patients with uniparental disomy (UPD) have better physical growth, fewer motor deficits and lower seizure occurrences.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16023557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
- Individuals with AS resulting from imprinting defects have the least debilitating features, such as higher developmental and language ability than AS caused by other mechanisms.&amp;lt;ref name=&amp;quot;PMID:11748306&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11748306&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
- The Body Mass Index (BMI) of 33% of the UBE3A mutation patients, and 47–64% of the patients from the classes II (UPD) and III (Imprinting defect) is above the 95th centile.&amp;lt;ref name=&amp;quot;PMID:15253756&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15253756&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Animal models'''&lt;br /&gt;
&lt;br /&gt;
* '''Drosophila'''&lt;br /&gt;
&lt;br /&gt;
Drosophila (common fruit fly) is an excellent model to use for better understanding of genetic diseases in humans as they are highly homologous to human UBE3A (hUBE3A), illustrating a high evolutionary conservation. Studies using the Drosophila model have shown that the functional absence of UBE3A resulted in decreased morphogenesis of dendritic branches. This is of interest as dendritic branches cover over 90% of the neuronal surface where [[#Glossary | '''synapse''']] between neurons occur. Proper formation and maturation of dendritic spines is also required so they come in contact with other neurons for effective transmission of neuronal signals. Thus proper formation of dendritic branching is pivitol for effective neuronal function and hence cognitive function.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18996915&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Interestingly, overexpression of dUBE3A also gave the same result, consisting of abnormal locomotion  and decreased dendritic branching in sensory neurons.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18701717&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;  This suggests a possible research field for some forms of [[#Glossary | '''autism''']] where the region containing UBE3A is duplicated, leading to delayed motor skills and seizures.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16433693&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;[[File:Normal and Angelman Syndrome mice models.jpg|thumb|250px|right|Normal and AS mice performance on the Rotarod apparatus.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
* '''Mice'''&lt;br /&gt;
&lt;br /&gt;
Absence of UBE3A in mice manifest similar phenotype to human AS, as illustrated by motor and learning deficits with inducible seizures.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21235769&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It has been shown through various mice model studies that larger deletions, ie. from UBE3A to GABRB3, more closely mirrors the large 6Mb deletions seen in human AS patients. Numerous tests, such as the Rotarod (for motor coordination and learning ability), Morris water maze test (for spatial learning and memory) and [[#Glossary | '''EEG''']] (electroencephalography), were carried out on  UBE3A null mutants, which showed the results to be abnormal or impaired.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20808828&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Other studies using mouse models have also outlined the obesity observed in 15% of AS children, albeit it is not the major characterisitics of AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17259980&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The diagram on the right clearly highlights the results obtained from such mouse model studies of AS, where the absence of UBE3A accumulated in deficits of motor function and obesity. In addition, excessive drooling and feeding difficulties were also highlighted by mice models with inactivated UBE3A, reflected by defects in fluid consumption and licking.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18413322&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Pathophysiology===&lt;br /&gt;
&lt;br /&gt;
'''Cognitive defects'''&lt;br /&gt;
&lt;br /&gt;
[[File:Role of UBE3A in dendritic spine neuronal synapses.png|thumb|250px|right|Role of UBE3A in dendritic spine neuronal synapses.]]&lt;br /&gt;
&lt;br /&gt;
AS patients present with abnormally high UBE3A, leading to neurological impairment. Recent identification of key target proteins of Ephexin-58 (Eph-5) and Arc (Activity-Regulated Cytoskeleton-associated protein) have aided in better understanding of the progression of UBE3A to cognitive defects. These two proteins are vital in the understanding of AS as Eph-5 determines synapse numbers and Arc contributes to plasticity and synapse function.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21164477&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Studies utilizing mice models have illustrated that UBE3A null mice could not ubiquitinate Eph-5, thus increasing its levels and limiting the growth of dendritic spines by the activation of RhoA. This subsequent activation of RhoA inhibits synapse formation and results in neuronal defects.&lt;br /&gt;
&lt;br /&gt;
In contrast, mice with normally functioning UBE3A showed phosphorylated Eph-5, resulting from the interaction of two neurons via the activation of EphB signalling receptor.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21029865&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Phosphorylation of Eph-5 allows UBE3A to ubiquitinate and degrade it. This degradation of Eph-5 permits new synaptic connections to form with cells they come into contact with. However, in AS, the absence of UBE3A means Eph-5 cannot be degraded, so RhoA activity is prolonged to reduce synaptic formation.&lt;br /&gt;
&lt;br /&gt;
As mentioned previously, Arc plays a pivitol role in synapse function as it removes synaptic receptors that respond to glutamate, a [[#Glossary | '''neurotransmitter''']].&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17088211&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In UBE3A present neurons, UBE3A ubiquitinates Arc, leading to it degradation as illustrated by the diagram on the left. However, in UBE3A deficient neurons, Arc accumulates and prevents the proper synaptic communications essential for normal cognitive functions.&amp;lt;ref name=&amp;quot;PMID20211139&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Signs and Symptoms==&lt;br /&gt;
&lt;br /&gt;
Angelman Syndrome presents a variety of different phenotypes, and the presented symptoms may vary at different ages.&amp;lt;ref name=&amp;quot;PMID7625442&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7625442&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
In 1995 Williams et al. embraced the observed clinical features of AS in a consensus statement, in order to present an appliance for clinicians. The diagnostic criteria were updated in 2005.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt; The following table shows the most frequently occurring characteristics in AS patients:&lt;br /&gt;
&lt;br /&gt;
'''4 characteristics appear in 100% of the cases:'''&lt;br /&gt;
&lt;br /&gt;
*Delayed development: become apparent by the age of 6 to 12 months.&lt;br /&gt;
*Motion and or balance malfunction&lt;br /&gt;
*Behaviour patterns like unmotivated laughter, frequent excitement; often including body movements,[[File:Electroencephalography of Angelman Syndrome.jpg|thumb|350px|right|EEG of AS and normal individuals.]] [[#Glossary | '''hypermotoric''']] behaviour&lt;br /&gt;
*Impairment of speech&lt;br /&gt;
&lt;br /&gt;
'''3 characteristics appear in more than 80% of the cases:'''&lt;br /&gt;
&lt;br /&gt;
*Abnormalities in head circumference, microcephaly&lt;br /&gt;
*Seizures&lt;br /&gt;
*EEG shows specific abnormal patterns&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Angelman Syndrome individuals show the most distinct disease pattern from 2 to 16 years of age.&lt;br /&gt;
In most cases at least 8 of the symptom traits are shown.&amp;lt;ref name=&amp;quot;PMID7625442&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Behavioural Characteristics'''&lt;br /&gt;
&lt;br /&gt;
A range of substantial characteristics appear in all AS cases, regardless of the genetic mechanisms, and are often responsible for diagnosing the syndrome. According to the original name, Happy Puppet syndrome, they have shown to exhibit traits such as a happy demeanor, with frequent laughter or smiling that can easily be triggered.&amp;lt;ref name=&amp;quot;PMID12566516&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12566516&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This behaviour can already be observed in 1 to 3 month old infants.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot; /&amp;gt; Uplifted hand flapping or waving motions are associated with laughter and excitement. Other characteristics manifesting in early childhood are sleep abnormalities with reduced sleep demand, and feeding problems. Breast and bottle feeding can be difficult due to non efficient attachment to the breast, tongue thrusting and uncoordinated sucking. Furthermore, there is an affection to crinkly and reflective surfaces, like some papers or plastic materials, especially water.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID12566516 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Communication Skills'''&lt;br /&gt;
&lt;br /&gt;
Communication is challenging for AS patients due to the fact that speech impairment is present in all cases. In the majority of affected people a lack of speech development is present. Only some of them have a minimal vocabulary consisting of two or three words, a few can speak in basic sentences. Some patients use gestures to articulate themselves, the [[#Glossary | '''Picture Exchange Communication System (PECS)''']] or sign languages such as [[#Glossary | '''Makaton''']] can be used for communication. Simple demands regarding their everyday occurrence can be understood by most patients.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID12566516 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Clinical and External Characteristics'''[[File:Angelman Syndrome patient.png|thumb|200px|right|4 year old AS patient.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Developmental delays are present in all patients. Motor milestones are delayed with children managing to sit unsupported with 12 months and crawl or bottom shuffle at the age of 18-24 months. The average age for walking is 4 years,however, ranging from 18 months to 7 years.&lt;br /&gt;
The [[#Glossary | '''gait''']] is characterised as slow, and flapping hands are a common trait.  The legs remain stiff during walking, arms are inflected by the wrists and elbows. The movements can appear ataxic, jerky or lurching. The muscle tone shows abnormalities with truncal [[#Glossary | '''hypotonia''']] and [[#Glossary | '''hypertonicity''']] of the limbs and alert reflexes.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID12566516 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The most striking external traits present in patients include broad-spaced teeth, and a wide mouth, light hair and eye colour, hypopigmented skin, deep set eyes, and a flat [[#Glossary | '''occiput''']].&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Seizures in Angelman Syndrome'''&lt;br /&gt;
&lt;br /&gt;
85% of AS patients suffer from epileptic seizures during their first three years. The first appearance can be within one month up to 20 year old patients. In infants with AS epilepsy manifests with [[#Glossary | '''febrile convulsions''']] and is hard to manage during childhood.&lt;br /&gt;
The most common type of seizures within 25% of patients are [[#Glossary | '''myoclonic seizures''']], followed by [[#Glossary | '''atonic seizures''']] as the second most frequent type, then 21% experience generalised [[#Glossary | '''tonic-clonic seizures''']] and lastly [[#Glossary | '''atypical absences''']] occur in 12% of patients.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20398390&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Angelman Syndrome in adults'''&lt;br /&gt;
&lt;br /&gt;
Patients with Angelman syndrome possess normal secondary sexual characteristics, and puberty sets in at a usual time. Limb hypertonicity, and [[#Glossary | '''thoracic scoliosis''']] lead to decreasing mobility. [[#Glossary | '''Oesophagus reflux''']] might induce severe problems, and the majority suffers from obesity. Furthermore, facial traits such as a prominent lower lip [[#Glossary | '''macrostomia''']] and [[#Glossary | '''mandibular prognathism''']] get manifested in adults. &lt;br /&gt;
In some cases the communication barrier can lead to frustration, resulting in aggressive behaviour. Nonetheless, patients gain a higher concentration span with age, and their nature becomes more quiet.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Complications===&lt;br /&gt;
&lt;br /&gt;
'''Hypopigmentation and Ocular albinism'''&lt;br /&gt;
&lt;br /&gt;
OCA2 gene, also known as the P gene, is closely located to the UBE3A gene. It encodes a protein vital to tyrosine metabolism, which plays a role in pigmentation development of skin, hair and eyes. However, AS caused by the large deletion of UBE3A leads to haploinsufficiency of OCA2 gene, resulting in hypopigmentation of the skin and the eyes. In some children with severe hypopigmentation, some form of [[#Glossary | '''albinism''']] is suspected.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12749060&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; When AS is caused by another mechanism, no abnormality of the skin and eye pigmentation is observed. However, not all AS children with OCA2 gene deletion will present with obvious hypopigmentation, they may just exhibit lighter skin colour than their parents.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8302318&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Diagnosis==&lt;br /&gt;
&lt;br /&gt;
The diagnosis of Angelman Syndrome is a clinical diagnosis confirmed by laboratory testing.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This involves both prenatal and/or postnatal diagnosis. &lt;br /&gt;
&lt;br /&gt;
===Prenatal Diagnosis===&lt;br /&gt;
[[File:Angelman Syndrome Prenatal Diagnosis.jpg|thumb|250px|right|Flowchart of AS Diagnosis.]]&lt;br /&gt;
&lt;br /&gt;
Prenatal detection of deletions of 15q11.2-q13, [[#Glossary | '''Paternal UPD''']] ([[#Glossary | '''Uniparental Disomy''']]), Imprinting defects and UBE3A mutations are done through DNA/chromosome/FISH analysis of fetal cells obtained by either [[#Glossary | '''Chorionic Villus Sampling''']](CVS) or [[#Glossary | '''Amniocentesis''']].&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot;/&amp;gt; &lt;br /&gt;
DNA methylation analysis using [[#Glossary | '''Amniocytes''']] is usually the first test carried out in molecular diagnosis of AS.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18059071&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; An abnormal result is followed up by either a FISH or array CGH analysis to search for a deletion on chromosome 15. If they produce a normal result, then UPD testing using DNA polymorphysims is carried out. If there is no evidence of UPD, other DNA analysis tests are used search for an imprinting centre deletion.&amp;lt;ref name=&amp;quot;PMID9792887&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9792887&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; A normal DNA methylation analysis is followed by a UBE3A sequence analysis.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt; In addition, a parent of origin test is also done to determine if the genetic disruption is of maternal origin or paternal origin. If it is maternally derived the fetus is diagnosed with AS (a paternally derived genetic disruption is indicative of Prader-Willi Syndrome).&amp;lt;ref name=&amp;quot;PMID17020468&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;17020468&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The flow chart summarizes the normal procedure used for prenatal diagnosis of AS. More information on important laboratory tests used for the diagnosis of Angelman Syndrome are provided below:&lt;br /&gt;
&lt;br /&gt;
*'''DNA Methylation Analysis'''&lt;br /&gt;
&lt;br /&gt;
Identifies approximately 80% of AS affected individuals and is usually the first test to be ordered.&amp;lt;ref name=&amp;quot;PMID7618904&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7618904&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Molecular disruptions such as deletions, paternal UPD and imprinting defects on chromosome 15 all demonstrate abnormal methylation patterns by either southern blot analysis or PCR amplification of bisulphate-treated DNA.&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot; /&amp;gt; An affected individual will only have an unmethylated (paternal) SNRPN (small nuclear ribonuclear protein-associated polypeptide N) allele compared with an unaffected individual who will have both a methylated and an unmethylated SNRPN allele.&amp;lt;ref name=&amp;quot;PMID9634532&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9634532&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
	  &lt;br /&gt;
*'''FISH (Fluorescent In Situ Hybridization)'''&lt;br /&gt;
&lt;br /&gt;
[[File:Critical_region_of_Angelman_Syndrome_on_chromosome_15.png‎|thumb|150px|right|FISH (fluorescence in situ hybridisation) image showing the critical region of Angelman Syndrome on chromosome 15.]]&lt;br /&gt;
&lt;br /&gt;
FISH analysis detects 5-7 Mb deletions in approximately 68% of affected individuals using detecting probes such as D15S10 and/or SNRPN.&amp;lt;ref name=&amp;quot;PMID7618904&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7618904&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It is also able to distinguish UPD from micro-deletions and imprinting defects. In simple terms, FISH analysis involves the binding of a fluorescent probe to a specific part of chromosome 15 and the detection of deletions within that region. FISH analysis is much more accurate in deletion detection compared to other high-resolution cytogenetics in the diagnosis of AS patients.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1511093&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
Array-based CGH is an advanced type of cytogenetic testing that can also be used to detect smaller deletions.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''UPD (Uniparental Disomy) Detection'''&lt;br /&gt;
&lt;br /&gt;
DNA Polymorphism testing detects paternal UPD in approximately 7% of affected AS individuals.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt; It is also able to distinguish between UPD and an Imprinting defect. It requires a DNA sample from the [[#Glossary | '''Proband''']] and from both parents. A homologous or non-homologous whole-arm translocation of the long arms of chromosome 15 is a sound indication for the need for prenatal UPD testing.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''IC (Imprinting Center) Analysis'''&lt;br /&gt;
&lt;br /&gt;
This type of analysis is used when individuals have an abnormal DNA methylation pattern but show normal results for  FISH, array CGH study and UPD analysis.&amp;lt;ref name=&amp;quot;PMID9792887&amp;quot;/&amp;gt; It is used to differentiate between the Imprinting defects caused by either microdeletions in the AS imprinting centre or by epigenetic mutations (that occur in maternal oogenesis or early embryogenesis).&amp;lt;ref name=&amp;quot;PMID9634532&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''Cytogenetic Testing'''&lt;br /&gt;
&lt;br /&gt;
Is used to detect a cytogenetically visible chromosomal rearrangement (large deletion, translocation or inversion) involving the 15q11.2-q13 region, which occurs in less than 1% of affected individuals.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''UBE3A Sequence Analysis'''&lt;br /&gt;
Sequence analysis of the UBE3A gene detects mutations in about 10% of the patients.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt; The test is used to detect either multiexonic (10 major coding exons of UBE3A) or whole gene deletions of UBE3A gene in individuals who produces a normal DNA methylation result but has characteristic clinical features of AS.&amp;lt;ref name=&amp;quot;PMID9792887&amp;quot;/&amp;gt;&lt;br /&gt;
This is recommended as a prenatal diagnostic tool in families that include multiple AS affected individuals because the imprinted pattern can be inherited from distant relatives.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Postnatal Diagnosis===&lt;br /&gt;
&lt;br /&gt;
Postnatal diagnosis is made though a combination of common clinical features of AS and UBESA gene sequence analysis.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt; The clinical features of AS include unsteady or shaky movements, muscle hypotonia, developmental delay and behavioral uniqueness such as frequent laughter/smiling and happy demeanor are features that are 100% consistent in all patients diagnosed with Angelman Syndrome.&amp;lt;ref name=&amp;quot;PMID18830393&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18830393&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; These clinical features become apparent between 6 months to 2 years of age. The onset of early or persistent smiling characteristic of this syndrome begin around the age of 1-3 months, but is often overlooked during infancy.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot;/&amp;gt; Thus early diagnosis of AS during infancy period is difficult because the clinical indicators of the syndrome takes time to manifest and characteristic features such as finger and hand tremors and excessive smiling/laughter are often overlooked and not considered as possible indicators of this syndrome.&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
*Rett Syndrome&lt;br /&gt;
&lt;br /&gt;
Some children with the clinical diagnosis of AS but no underlying genetic mechanism show mutations in ''MECP2'' gene, corresponding to Rett Syndrome. This should be suspected in AS test negative girls in the first few years of life.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17980307&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*Mowat-Wilson Syndrome&lt;br /&gt;
&lt;br /&gt;
Genetic mechanism is heterozygous deletion or truncation in ''ZFHX1B'' (''SIP1'') gene on 2q22. This presents with clinical features of severe intellectual disability, micrcephaly and seizures.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17958891&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Prader-Willi Syndrome patient.png|thumb|right|120px|12 year old PWS patient.]]&lt;br /&gt;
&lt;br /&gt;
*X-linked alpha-thalassemia/mental retardation syndrome (ATR-X)&lt;br /&gt;
&lt;br /&gt;
This arises from mutations in ''XNP'' gene on Xq13. ATR-X presents with severe intellectual disability, no speech development and seizures are common.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11449489&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*Phelan-McDermid Syndrome/22q13 deletion syndrome&lt;br /&gt;
&lt;br /&gt;
Deletions are usually submicroscopic and thus requires special molecular cytogenetic methods to confirm this deletion. Patients show moderate to profound intellectual disability and delay in speech development.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18505557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Related Disease'''&lt;br /&gt;
&lt;br /&gt;
*Prader-Willi Syndrome(PWS)&lt;br /&gt;
&lt;br /&gt;
PWS is a result from the absence of paternally expressed 15q11-q13 gene as a corollary of de novo deletion, maternal uniparental disomy of chromosome 15 or an imprinting defect on paternal chromosome 15 leading to the silencing of paternal alleles.&amp;lt;ref name=&amp;quot;PMID:20668179 &amp;quot;/&amp;gt; It is characterized by [[#Glossary | '''hyperphagia''']], obesity in later infancy and early childhood and difficulty in feeding during early infancy.&amp;lt;ref name=&amp;quot;PMID:20668179 &amp;quot;/&amp;gt; There is also cognitive impairment to some extent, though some PWS patients may exhibit intelligence in the normal IQ range. Behavioral phenotypes include stubbornness, manipulative tendency, obsessive compulsive characteristics.&amp;lt;ref name=&amp;quot;PMID:20668179 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Genetic Counselling==&lt;br /&gt;
&lt;br /&gt;
Genetic counselling is the process by which patients or relatives, at risk of an inherited disorder, are advised of the consequences and nature of the disorder, the probability of developing or transmitting it, and the options open to them in management and family planning. In the case for Angelman syndrome, types of risks associated are split into classes and formatted into the table below:&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20459762&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{|  style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
! Class&lt;br /&gt;
! Mechanism&lt;br /&gt;
! Risk to siblings&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! Ia                           &lt;br /&gt;
| De novo deletion                                                                                                               &lt;br /&gt;
| &amp;lt;1%                                                                                                                &lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! Ib&lt;br /&gt;
| Deletion due to chromosome rearrangement&lt;br /&gt;
| Up to 50%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! II&lt;br /&gt;
| Paternal uniparental disomy&lt;br /&gt;
| &amp;lt;1%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! IIIa&lt;br /&gt;
| Imprinting defect with IC mutation&lt;br /&gt;
| Close to 100% if father has 15; 15 [[#Glossary | '''Robertsonian translocation''']]&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! IIIb&lt;br /&gt;
| Imprinting defect withouth IC mutation&lt;br /&gt;
| Up to 50% (if mother has IC deletion)&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! IIIc&lt;br /&gt;
| Mosaic imprinting defect&lt;br /&gt;
| &amp;lt;1%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! IV&lt;br /&gt;
| ''UBE3A'' mutation&lt;br /&gt;
| Up to 50% (is mother has mutation)&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! V&lt;br /&gt;
| No identifiable genetic abnormality&lt;br /&gt;
| ?&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Treatment and Management==&lt;br /&gt;
&lt;br /&gt;
Even though at present there is no known cure for Angelman syndrome, there are a number of treatments available that may alleviate symptons and improve daily life activities.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The below table describes the problems and management options that are used:&lt;br /&gt;
&lt;br /&gt;
[[File:Subtle Finger tremors-Angelman Syndrome.jpg|right|thumb|150px|A five months old boy with Angelman syndrome showing signs of Subtle Finger tremor.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
! Problems encountered&lt;br /&gt;
! Treatment and Management&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''Difficulty in feeding newborn AS babies'''&lt;br /&gt;
| Use of special nipples may improve feeding&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Oesophagus reflux'''&lt;br /&gt;
| Special motility medications requiried or upright positioning&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''Seizures'''&lt;br /&gt;
| Anticonvulsant medications&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19605773&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19453717&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Ocular problems'''&lt;br /&gt;
| Visual assessment is vital to encourage interactions and minimize chances of self-harm and autism development&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20656169&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''Drooling in developmental delayed AS patients'''&lt;br /&gt;
| Difficult to treat, but new surgical procedure on salivary duct reimplantation seems to be a promising alternative&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17699119&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Unstable children''' &lt;br /&gt;
| Physical therapy&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''AS patients become less active with increasing age'''&lt;br /&gt;
| Activity schedules to prevent scoliosis and obesity. Occupational therapy to stimulate fine motor and oral-motor control skills in conjunction to speech therapy&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Sleeping difficulty'''&lt;br /&gt;
| Sedative medication in severe cases. [[#Glossary | '''Melatonin''']] may be used to promote sleeping but some studies have found that it loses its therapeutic effects after several weeks in most AS patients&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19379289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|-&lt;br /&gt;
|colspan=&amp;quot;4&amp;quot; |&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Prognosis==&lt;br /&gt;
&lt;br /&gt;
Life expectancy of AS patients seems to be normal&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, but there is still a high degree of developmental delay and limited expressive language skills.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17019625&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This problem arises prominently in the assessment of the severity of coincidental medical conditions due to difficulties in communication. A visit to the dentist can become difficult if good communication is not conveyed between the parents, the dentist, and the child.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18271768&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Some problems require extreme measures, such as the procedure of lens implantation was performed in both eyes of a person diagnosed with AS, due to the inability to wear spectacles.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20656169&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
During adulthood, menstruation and puberty begin at around average age evidenced by females with Angelman syndrome that are fully capable of conceiving children.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11258627&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Most adult patients can feed themselves, but needed help with many other daily activities. Main troubles which have shown in adults are a tendency to become obese and start developing  thoracic scoliosis, which some adults with AS begin wheelchair bounded.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9072912&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Current and Future Research==&lt;br /&gt;
&lt;br /&gt;
Currently there is no cure for the treatment of AS, so much research is being carried out for therapeutic interventions. Findings in the last five years have suggested through various mice and fruit fly models that the absence of maternal UBE3A results in the same human AS features of neurological defects and seizures. However, more recently, studies have outlined that the symptoms of AS can be improved by modifying other gene products. In addition, restoring of a functional UBE3A protein into adult mice neurons have shown to reduce motor and neurological deficits and balance disorders. This shows promising research prospects in that improvements may be possible in human AS patients by restoring functional UBE3A proteins into their neurons. &lt;br /&gt;
&lt;br /&gt;
===Possible Treatment Pathways===&lt;br /&gt;
&lt;br /&gt;
*'''Cognitive and physical impairment'''&lt;br /&gt;
&lt;br /&gt;
Although everyone is born with two copies of the gene UBE3A, one maternal and one paternal copy, it is only the maternal UBE3A that is used in the brain. Most AS patients have a genetic mutation on the maternal chromosome 15 that results in dysfunctional UBE3A.&amp;lt;ref&amp;gt;http://www.cureangelman.org/what-hope.html&amp;lt;/ref&amp;gt; The above research focused on turning on the father's copy of UBE3A to restore its functions. Furthermore, mouse models were utilized to show that alpha-CaMKII could be increased to compensate the loss of UBE3A and restore compromised mental and physical abilities. However, this finding still requires much more research.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17259980&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''Epilepsy'''&lt;br /&gt;
&lt;br /&gt;
There is research being done on improving certain conditions that are involved in AS by nutritional benefits. The use of [[#Glossary | '''corticosteroids''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19666884&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, [[#Glossary | '''valproate''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19453717&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and [[#Glossary | '''clonazepam''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19605773&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and having a [[#Glossary | '''ketogenic diet''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20880305&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; has all been shown to aid in the treatment of epilepsy. It has also been reported to be efficient in the treatment of other conditions, such as behavioural disorders, reduction in seizures, ataxia, sleep patterns, developmental progress and sleep disturbances. [[#Glossary | '''Levetiracetam''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17326790&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; could be used in such a situation, especially when the patient has an intolerance to valproate and clonazepam.&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&lt;br /&gt;
'''albinism''': A congenital disorder distincted by the complete or partial absence of pigment in the skin, hair and eyes due to defect of an enzyme involved in the production of melanin.&lt;br /&gt;
&lt;br /&gt;
'''allele''': Dissimilar variant of one gene. Organisms have two alleles for each gene inherited from their parents, one from each of them.&lt;br /&gt;
&lt;br /&gt;
'''alpha-CaMKII''': (alpha calcium calmodulin kinase II) Compound involved in synaptic plasticity, one of the most important theories behind learning and memory. Ability of a synapse between two neurons to change in strength due to the use or disuse of transmission.&lt;br /&gt;
&lt;br /&gt;
'''Amniocytes''': Cells that are shed by the fetus during fetal development to the surrounding amniotic fluid. They are a source of fetal DNA. &lt;br /&gt;
&lt;br /&gt;
'''Amniocentesis''': (AFT or amniotic fluid test) is a prenatal diagnostic test used to detect chromosomal abnormalities in the developing fetus by extracting amniotic fluid (a source of fetal DNA) surrounding the fetus. &lt;br /&gt;
&lt;br /&gt;
'''AMPA''': (2-amino-3-(5-methyl-3-oxo-1,2- oxazol-4-yl)propanoic acid) Compound that binds to the AMPA receptor to imitate glutamate neurotransmitter.&lt;br /&gt;
&lt;br /&gt;
'''Arc''': Activity-Regulated Cytoskeleton-associated protein; involved in learning and memory.&lt;br /&gt;
&lt;br /&gt;
'''ataxia''': Lack of coordination in muscle movements.&lt;br /&gt;
&lt;br /&gt;
'''atonic seizures''': A abrupt loss of muscle tone, this can lead to the limbs loosing strength, or the head may drop to the side. The patient remains conscious during this kind of epileptic seizure.&lt;br /&gt;
&lt;br /&gt;
'''atypical absences''': Seizure leads to unconsciousness in most cases.  &lt;br /&gt;
&lt;br /&gt;
'''autism''': A neural development disorder defined by limited social interaction and communication.&lt;br /&gt;
&lt;br /&gt;
'''Chorionic Villus Sampling''': A prenatal diagnostic test used to detect chromosomal abnormalities in the developing fetus by extracting and testing chorionic villus (placental tissue). &lt;br /&gt;
&lt;br /&gt;
'''chromosome''': Structure consisting of coiled DNA with DNA associated proteins such as histones.&lt;br /&gt;
&lt;br /&gt;
'''clonazepam''': A psychoactive drug having muscle relaxant properties and treats anxiety and epilepsy.&lt;br /&gt;
&lt;br /&gt;
'''corticosteroid''': A type of steroid hormones that are produced in the adrenal cortex.&lt;br /&gt;
&lt;br /&gt;
'''cytogenetics''': Study of the structure, function and abnormality of the cell, especially the chromosome.&lt;br /&gt;
&lt;br /&gt;
'''deletion''': Lack of a part of the DNA (deoxyribonucleic acid is a nucleic acid containing information for protein synthesis), can vary form a single base to a hole gene. &lt;br /&gt;
&lt;br /&gt;
'''de novo mutation''': Change in a gene of a family member for the first time due to a mutation in the egg or sperm of the parents or in the fertilized egg (zygote).&lt;br /&gt;
&lt;br /&gt;
'''disorder''': A mental or physical health disturbance or dysfunction.&lt;br /&gt;
&lt;br /&gt;
'''EEG''': Electroencephalography is a means of measuring electrical activity along the scalp by measuring the total electrical charges fired by thousands or millions of neurons.&lt;br /&gt;
&lt;br /&gt;
'''epilepsy''': Neurological disorder characterised by recurrent impairment of brain function that can cause seizures or unconsciousness. &lt;br /&gt;
&lt;br /&gt;
'''E6-AP''': E6-AP ubiquitin-protein ligase is an enzyme encoded by UBE3A which adds ubiquitin chain to target proteins to be degraded by proteasomes.&lt;br /&gt;
&lt;br /&gt;
'''febrile convulsions''': The occurrence of high fever, especially in children.&lt;br /&gt;
&lt;br /&gt;
'''FISH''': Fluorescent in situ hybridization is a technique used to identify and localize the presence or absence of DNA sequences on the chromosome. This is achieved by using fluorescently labelled DNA sequences which then binds to complementary DNA sequence on the chromosome. After hybridization (attachment), chromosome of interest will fluoresce under the microscope.&lt;br /&gt;
&lt;br /&gt;
'''gait''': A manner of walking, stepping or running.&lt;br /&gt;
&lt;br /&gt;
'''gene''': A molecular unit of heredity of a living organism.&lt;br /&gt;
&lt;br /&gt;
'''hyperphagia''': (Also referred to as Polyphagia) Excessive ingestion of food beyond the dietary and energy requirements of the body. &lt;br /&gt;
&lt;br /&gt;
'''hypermotoric''': Sudden appearance of uncontrolled movements such as striking or kicking inappropriately.&lt;br /&gt;
&lt;br /&gt;
'''hypertonicity''': Increase of muscle tension and a disability to stretch leading to an impairment of motor activity.&lt;br /&gt;
&lt;br /&gt;
'''hypopigmentation''': A lack of melanin pigments or melanocytes  affecting the colour of the skin, hair and iris. Features appear to be light-coloured due to loss of skin colour.&lt;br /&gt;
&lt;br /&gt;
'''hypotonia''': Decrease in the ability to stretch passively, due to a low muscle tone. &lt;br /&gt;
&lt;br /&gt;
'''imprinting''': This is a process to describe the modification of a maternally or paternally derived chromosome, which consequently influences the expression of certain genes on the altered chromosome.&lt;br /&gt;
&lt;br /&gt;
'''ketogenic diet''': A high-fat, low-carbohydrate diet that is used to treat epilepsy in children.&lt;br /&gt;
&lt;br /&gt;
'''levetiracetam''': An anticonvulsant drug used to treat epilepsy.&lt;br /&gt;
&lt;br /&gt;
'''locus''': Location of a gene on a chromosome(loci: plural for locus).&lt;br /&gt;
&lt;br /&gt;
'''LTP''': Long-term potentiation shares common features with long term memory. It strengthens and enhances signal transmission between neurons by improving the communication between two neurons.&lt;br /&gt;
&lt;br /&gt;
'''macrostomia''': A wide-spaced mouth.&lt;br /&gt;
&lt;br /&gt;
'''Makaton''': Language programme using symbols and signs to support speaking.&lt;br /&gt;
&lt;br /&gt;
'''mandibular prognathism''': The abnormal protrusion of the lower jaw. &lt;br /&gt;
&lt;br /&gt;
'''maxillary hypoplasia''':  The underdevelopment of the upper jaw.&lt;br /&gt;
&lt;br /&gt;
'''melatonin''': A hormone secreted by the pineal gland.&lt;br /&gt;
&lt;br /&gt;
'''microcephaly''': The circumference of the head is less than average due to abnormalities of the nervous system. This abnormality can be present at birth or emerge during the first few years of life and reduces both life expectancy and the cognitive functions of the individual affected.&lt;br /&gt;
&lt;br /&gt;
'''microdeletion''':  A genetic mutation in which a part of a chromosome or a sequence of DNA is missing.&lt;br /&gt;
&lt;br /&gt;
'''mutation''': Event that changes the DNA (deoxyribonucleic acid is a nucleic acid, containing information for protein synthesis) or RNA (ribonucleic acid is a type of nucleic acid transmitting the information from the DNA to the proteins ) of a gene permanently.&lt;br /&gt;
&lt;br /&gt;
'''myoclonic seizures''': A quick jerk of the skeletal muscle, due to a irregular brain activity.&lt;br /&gt;
&lt;br /&gt;
'''neurogenetic''': Genetic basis of the nervous system.&lt;br /&gt;
&lt;br /&gt;
'''neurotransmitter''': Transmits neuronal signals to a target cell. They are first packaged in vesicles just beneath the membrane of presynaptic axon terminals and released into the synaptic cleft (space between the two interacting neurons) and enter the postsynaptic dendrite.&lt;br /&gt;
&lt;br /&gt;
'''occiput''': The back portion of the head.&lt;br /&gt;
&lt;br /&gt;
'''oesophagus reflux''': Impairment of a sphincter in the lower end of the oesophagus leads to the back flow of stomach acid into the oesophagus. Heartburn is a typical symptom.&lt;br /&gt;
&lt;br /&gt;
'''paediatrician''': Physicians that specialise on infants, children and adolescents.&lt;br /&gt;
&lt;br /&gt;
'''paternal UPD''': Inheritance of two copies of a chromosome from the father and none from the mother. &lt;br /&gt;
&lt;br /&gt;
'''phenotype''': Visible traites of an organism determined by genetic and environmental factors.&lt;br /&gt;
&lt;br /&gt;
'''Picture Exchange Communication System (PECS)''': Individuals communicate using images instead of words. It is frequently used by children with autism, to articulate their needs and wishes or to make comments about something.&lt;br /&gt;
&lt;br /&gt;
'''Proband''': Is the person (or animal) being studied or reported on in a genetic investigation. Most commonly it refers to the first affected family member who requires medical help for a genetic disorder. &lt;br /&gt;
&lt;br /&gt;
'''Robertsonian translocation''': Rearrangement of the chromosome, occurs in 5 chromosome including 13,14,15,21 and 22. This type of mutation occurs in chromosomes with the centromere not at the centre, resulting in long and short arm chromosomes. Translocation breaks the chromosome at the centromere so the long arm attaches to the other long arm, and the same for the short arm happens. Cell division will result in the loss of the short arms as they do not contain important genes.&lt;br /&gt;
&lt;br /&gt;
'''seizure''': Abnormal electrical activity in the brain that can result in a variety of physical symptoms like convulsion, body shaking, loss of consciousness, confusion, and mood changes.&lt;br /&gt;
&lt;br /&gt;
'''synapse''': Allows transmission of signal between neurons for effective neuronal function.&lt;br /&gt;
&lt;br /&gt;
'''thoracic scoliosis''': The spine is curved laterally(from side to side) in the thoracic region.&lt;br /&gt;
&lt;br /&gt;
'''tonic-clonic seizures''': This type of seizure is associated with unconsciousness due to electrical discharges in a big proportion of the brain.&lt;br /&gt;
&lt;br /&gt;
'''ubiquitin''': A polypeptide found in all eukaryotic cells, that participates in a variety of cellular functions including protein recycling.&lt;br /&gt;
&lt;br /&gt;
'''Uniparental disomy''': (UPD) the inheritance of two copies of a chromosome pair or part of a chromosme from one parent and no copy from the other parent. &lt;br /&gt;
&lt;br /&gt;
'''valproate''':  A mood-stabilizing drug that is also used for treatment for epilepsy and bipolar disorder.&lt;br /&gt;
&lt;br /&gt;
==External Links==&lt;br /&gt;
&lt;br /&gt;
: http://www.angelmansyndrome.org/research.html&lt;br /&gt;
: http://www.angelman.org/&lt;br /&gt;
: http://rarediseasesnetwork.epi.usf.edu/arpwsc/&lt;br /&gt;
: http://www.rarediseases.org/rare-disease-information/rare-diseases/byID/411/viewAbstract&lt;br /&gt;
: http://www.epilepsyfoundation.org/&lt;br /&gt;
: http://www.kumc.edu/gec/support/angelman.html&lt;br /&gt;
: http://www.cureangelman.org/&lt;br /&gt;
: http://www.angelmansyndromeqld.org/&lt;br /&gt;
: http://ghr.nlm.nih.gov/condition/angelman-syndrome&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&lt;br /&gt;
&amp;lt;references /&amp;gt;&lt;/div&gt;</summary>
		<author><name>Z3291643</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_7&amp;diff=77417</id>
		<title>2011 Group Project 7</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_7&amp;diff=77417"/>
		<updated>2011-10-12T11:56:49Z</updated>

		<summary type="html">&lt;p&gt;Z3291643: /* Current and Future Research */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;='''Angelman Syndrome'''=&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Introduction==&lt;br /&gt;
&lt;br /&gt;
[[File:Dr Harry Angelman.jpg|thumb|130px|right|Dr Harry Angelman.]]&lt;br /&gt;
Angelman syndrome (AS) is a rare [[#Glossary | '''neurogenetic''']] [[#Glossary | '''disorder''']] first described by Dr. Harry Angelman in 1965.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18754889&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Dr. Angelman was an English [[#Glossary | '''paediatrician''']] who first diagnosed the disease in 3 children with a developmental delay.&amp;lt;ref&amp;gt;http://www.ncbi.nlm.nih.gov/books/NBK22221/&amp;lt;/ref&amp;gt; AS occurs in 1 in 10000-20000 births, the exact number is still unknown.&amp;lt;ref name=&amp;quot;PMID7573182&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7573182&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;PMID8703225&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;8703225&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It is caused by maternal [[#Glossary | '''allele''']] disruptions of a single gene- UBE3A. Either [[#Glossary | '''mutations''']] or [[#Glossary | '''deletions''']] of the UBE3A gene results in AS. &lt;br /&gt;
&lt;br /&gt;
AS presents with well known [[#Glossary | '''phenotypes''']] during infancy and adulthood, such as [[#Glossary | '''microcephaly''']] and [[#Glossary | '''maxillary hypoplasia''']]. However, these features become more marked with age. Most frequent clinical features include delayed development,[[#Glossary | '''seizures''']],[[#Glossary | '''ataxia''']], impairment of speech, happy demeanor, behavioural problems such as hyperactivity, short attention span and sleeping difficulty.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21592595&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21484597&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;ASAwebsite&amp;quot;&amp;gt;http://www.angelmansyndrome.org/home.html&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
At present, there is no cure for the syndrome, though current research is focused at improving life quality of patients with Angelman syndrome through management of daily tasks.&amp;lt;ref&amp;gt;http://www.bbc.co.uk/health/physical_health/conditions/angelman1.shtml&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==History==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Dr. Harry Angelman first reported Angelman Syndrome on three handicapped children that were admitted to his ward in England in 1964.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt; He reported how these three independent and unconnected clinical cases all had the same characteristic features of severe developmental delay, jerky movements, seizures and a happy disposition.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt; However it was only when he stumbled upon an oil painting called ‘a Boy with a Puppet” while on a holiday in Italy he was able to connect the symptoms of all three children under one common cause.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20981772&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; He linked the happy face of the boy depicted on the painting with the jerky movements and happy disposition he observed on his three patients back in England. He reported his findings on a paper entitled “Puppet children (a report on three cases)” which was published in 1965.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
The syndrome was initially named ‘Puppet Syndrome’ but was later changed to Angelman Syndrome. Due to the extreme rarity of the syndrome and lack of sufficient clinical evidence the syndrome was soon forgotten.&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt;&lt;br /&gt;
[[File:Dr Charles Williams.jpg|thumb|right|150px|Dr Charles Williams.]]&lt;br /&gt;
	&lt;br /&gt;
In 1987, a physician named Ellen Magenis, came across children with deletions on [[#Glossary | '''chromosome''']] 15 that were suffering from seizures and severe developmental delay.&amp;lt;ref&amp;gt;http://www.angelman.org/stay-informed/facts-about-angelman-syndrome---7th-edition/harry-angelman-and-the-history-of-as/&amp;lt;/ref&amp;gt; Even though genetically the children were expected to have [[#Diagnosis | '''Prader-Willi syndrome''']] that was characterised by deletions on chromosome 15, their characteristic symptoms of seizures and lack of development did not correspond with that of the syndrome. This led to the realization that these children had deletions on the maternally derived chromosome 15 and not on the paternally derived chromosome as was observed in Prader-Willi syndrome.  Thus the deleted genetic code on maternally derived chromosome 15 was identified as the genetic marker for Angelman Syndrome.&lt;br /&gt;
&lt;br /&gt;
In 1997, UBE3A gene was isolated by Dr. Joseph Wagstaff and Dr. Arthur Beaudet as the cause of Angelman Syndrome.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot; /&amp;gt; The discovery of this [[#Glossary | '''gene''']] led to the subsequent development of animal models and research aimed at finding a causal link between UBE3A gene abnormalities and characteristic features observed in Angelman Syndrome. &lt;br /&gt;
	&lt;br /&gt;
Currently, four different genetic abnormalities for Angelman Syndrome have been confirmed by genetic testing. They include: Deletion, [[#Glossary | '''Uniparental Disomy''']] (UPD), [[#Glossary | '''Imprinting''']] and UBE3A mutation.&amp;lt;ref name=&amp;quot;PMID20211139&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Below is a timeline, summarising the key discoveries and advancements of the Angelman Syndrome:&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|- bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
!Year&lt;br /&gt;
!Milestone&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1964'''&lt;br /&gt;
|First observed by Dr Harry Angelman on three handicapped children.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot; /&amp;gt; &lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''1965'''&lt;br /&gt;
|Harry Angelman publishes his finding in a report entitled 'Puppet Children'(a report on three cases).&amp;lt;ref name=&amp;quot;PMID18754889&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1980s'''&lt;br /&gt;
|First reports of AS reaches US and research into the disorder being at the University of Florida under the direction of Dr. Charles Williams.&amp;lt;ref&amp;gt;http://www.angelmanproject.com/history.htm&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''1982'''&lt;br /&gt;
|Name changed from 'Happy Puppet' to Angelman syndrome by Williams and Frias. &lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1987'''&lt;br /&gt;
|Discovery of a genetic marker for AS – an absent genetic code on maternally derived chromosome 15. &lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''1997'''&lt;br /&gt;
|The cause of AS discovered by Dr. Joseph Wagstaff and Dr. Arthur Beaudet – mutation or deletion in the UBE3A gene.&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''1998'''&lt;br /&gt;
|Transgenic mice with absent maternal UBE3A created to illustrate motor and learning deficits in addition to seizures.&amp;lt;ref name=&amp;quot;PMID9808466&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9808466&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''2007'''&lt;br /&gt;
|AS mouse model shows that neurological deficits can be reversed by decreasing levels of [[#Glossary | '''alpha-CaMKII''']] inhibitory phosphorylation.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17259980&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|'''2010'''&lt;br /&gt;
|Discovery of a another gene mutation in TC4 gene (on chromosome 18) in a small number of clinically diagnosed patients with no identifiable genetic alternation in UBE3A.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20184619&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|'''2010'''&lt;br /&gt;
|Protein named Arc identified as a target of AS gene product; UBE3A.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;width:100%&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Incidence'''&lt;br /&gt;
*The current population of people diagnosed with AS is unknown but studies have estimated the number to be around 1:10,000&amp;lt;ref name=&amp;quot;PMID7573182&amp;quot; /&amp;gt; and 1:20,000&amp;lt;ref name=&amp;quot;PMID8703225&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
'''Diagnosis'''&lt;br /&gt;
*The mean age of diagnosis for patients with AS lies between 6 and 6.5 years of age.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18664077&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15741136&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Gender'''&lt;br /&gt;
* Males appear to be at higher risk for some aspects of early developmental delays in comparison to females with AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17019625&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Demography'''&lt;br /&gt;
*Europe:&lt;br /&gt;
:Denmark- 1:10,000&amp;lt;ref name=&amp;quot;PMID7573182&amp;quot; /&amp;gt;&lt;br /&gt;
:Estonia- 1:52,000&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16906556&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
:Sweden- 1:20,000&amp;lt;ref name=&amp;quot;PMID8703225&amp;quot; /&amp;gt;&lt;br /&gt;
*Australia:&lt;br /&gt;
:Western Australia- 1:40,000&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16492624&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Aetiology==&lt;br /&gt;
&lt;br /&gt;
[[File:Chromosome 15 Deletion of 15q11.2 to 15q13.jpg|thumb|100px|Chromosome 15 - The deletion occurs at 15q11.2-15q13.]]&lt;br /&gt;
&lt;br /&gt;
Different genetic mechanisms lead to different clinical phenotypes of AS. The most common genetic mechanism leading to AS is the deletion or re-arrangement of maternal chromosome at [[#Glossary | '''locus''']] 15q11.2-q13,as the chromosome image shows on the right, accounting for 70% of AS occurrences.&amp;lt;ref name=&amp;quot;PMID8988171&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt; 8988171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This leads to more severe clinical phenotypes of microcephaly, motor difficulties, seizures and impaired speech development. The next most common genetic mechanism is mutation in the ''UBE3A'' gene responsible for 10% of AS cases and paternal uniparental disomy and mutation in the imprinting centre (IC), both accounting for 2-5% of AS observed.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
 &lt;br /&gt;
&lt;br /&gt;
AS is caused by the 4 major genetic mechanisms mentioned above and are thus divided into Classes I to IV based on their underlying genetic mechanism. AS patients with the clinical features of AS but no [[#Glossary | '''cytogenetic''']] or molecular abnormality in Chromosome 15q11.2-13 are grouped under Class V (summarised in table below).&amp;lt;ref name=&amp;quot;PMID8988171&amp;quot; /&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10364509&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{|  style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
! Class&lt;br /&gt;
! Mechanism&lt;br /&gt;
! Diagnostic Tests&lt;br /&gt;
! Frequency&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''Ia'''                           &lt;br /&gt;
| De novo deletion                                                                                           &lt;br /&gt;
| High resolution cytogenetics [[#Glossary | '''FISH''']]                                                                                                       &lt;br /&gt;
| 70%      &lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Ib'''&lt;br /&gt;
| Deletion due to chromosome rearrangement&lt;br /&gt;
| High resolution cytogenetics FISH&lt;br /&gt;
| &amp;lt;1%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''II'''&lt;br /&gt;
| Paternal uniparental disomy&lt;br /&gt;
| [[#Glossary | '''RFLP''']]  analysis&lt;br /&gt;
| 2%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''IIIa'''&lt;br /&gt;
| Imprinting defect with IC mutation&lt;br /&gt;
| Screening of [[#Glossary | '''IC''']]  for mutations is positive&lt;br /&gt;
| 2%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''IIIb'''&lt;br /&gt;
| Imprinting defect withouth IC mutation&lt;br /&gt;
| Screening of IC for mutations is negative&lt;br /&gt;
| 2%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''IIIc'''&lt;br /&gt;
| Mosaic imprinting defect&lt;br /&gt;
| Screening of IC for mutations is usually negative &lt;br /&gt;
| ?&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
| '''IV'''&lt;br /&gt;
| ''UBE3A'' mutation&lt;br /&gt;
| Screening of ''UBE3A'' for mutations&lt;br /&gt;
| 5-10%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''V'''&lt;br /&gt;
| No identifiable genetic abnormality&lt;br /&gt;
| Consider other diagnoses&lt;br /&gt;
| 5-26%&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Pathogenesis==&lt;br /&gt;
&lt;br /&gt;
Chromosome 15 became associated with AS in the 1980s after the observation of many AS patients harboring [[#Glossary | '''microdeletions''']] of 15q11.2-15q13.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15668046&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The last decade has shed even more light in the aetiology of AS,as Kishino and Matsuura first identified UBE3A as the causative gene for AS in 1997.&amp;lt;ref name=&amp;quot;PMID:8988171&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;8988171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8988172&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Normal gene product: E6-AP ubiquitin ligase'''&lt;br /&gt;
&lt;br /&gt;
The function of UBE3A is to encode for [[#Glossary | '''E6-AP''']] ubiquitin ligase, however its function in the development of the nervous system and the process of UBE3A mutation leading to cognitive impairment in AS patients is still vague.&amp;lt;ref name=&amp;quot;PMID:20211139&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Past and current research has elucidated that E6-AP ubiquitin ligase is involved in the degradation of four proteins, listed below, but currently, no protein with a direct role in [[#Glossary | '''long-term potentiation (LTP)''']] as a target of E6-AP, has been identified.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12684449&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The identification of such target proteins would be a landmark discovery in further understanding of the pathogenesis, aetiology and prospective treatment strategies of AS, as LTP defects is one of the major neurological impairments of AS. &lt;br /&gt;
 &lt;br /&gt;
* p53 tumor suppressor protein &lt;br /&gt;
* yeast DNA repair protein Rad23 &lt;br /&gt;
* multicopy maintenance protein 7 subunit &lt;br /&gt;
* E6-AP&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Abnormal gene product'''&lt;br /&gt;
&lt;br /&gt;
Disruption to the gene,UBE3A, interferes with the normal functioning of the gene, which is its crucial role in UBE3A [[#Glossary | '''ubiquitylation''']]. Problems involving this pathway can lead to various diseases either from the loss or gain of function.&amp;lt;ref name=&amp;quot;PMID:9857172&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9857172&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In the case of AS, E6-AP is affected, leading to detrimental cognitive impairment in addition to other deficits.&amp;lt;ref name=&amp;quot;PMID:9857172&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9857172&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Regional functioning of UBE3A'''&lt;br /&gt;
&lt;br /&gt;
Despite the uncertain progression of UBE3A mutation and the neurological abnormalities characteristic of AS, animal models have illustrated the vital role of UBE3A in the normal functioning of the brain. This can be exemplified by a study which utilized a mouse model with target inactivation of the gene UBE3A resulting in the manifestation of classical features of AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11895368&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In addition, the fact that imprinting of UBE3A takes place only in specific brain regions (cerebellum, olfactory tracts and the hippocampus) confirms the hypothesis that the loss of this gene would be detrimental in the cognitive development.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20398390&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Most genes are inherited in copies of two, one paternal and the other maternal; however, some genes, such as UBE3A only have one functional copy as the other is silenced, coined 'imprinting'. Imprinting of the paternal copy of UBE3A takes place in some cell populations, such as the hippocampal neurons and Purkinje cells in the cerebellum.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9288101&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This means only the maternal UBE3A is functionally expressed in these particular brain regions. Thus a [[#Glossary | '''de novo mutation''']] in the maternal copy of the gene will result in the complete absence of functional E6-AP in the associated brain areas.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9288088&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
It is also known that UBE3A plays an important role in synaptic transmission, but exactly how it does so is still not completely understood.&amp;lt;ref name=&amp;quot;PMID:9808466&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9808466&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''UBE3A ubiquitylation'''&lt;br /&gt;
&lt;br /&gt;
As briefly mentioned above, UBE3A is a member of the E3 ubiquitin ligase family of enzymes, responsible for the addition of ubiquitin to the target protein for degradation of the ubiquitinated protein, as illustrated in the diagram below. These processes are required for normal human cognitive function.&amp;lt;ref name=&amp;quot;PMID:9808466&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9808466&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In this way synaptic protein [[#Glossary | '''Arc (activity-regulated cytoskeleton-associated protein)''']] is degraded to control synaptic function. Arc is a target protein of UBE3A in dendritic spines found in the hippocampal neurons.&amp;lt;ref name=&amp;quot;PMID:20668179&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20668179&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Deletion of UBE3A leads to the accumulation of Arc in neurons leading to trafficking of [[#Glossary | '''AMPA''']] receptors, resulting in impaired cognitive functions.&amp;lt;ref name=&amp;quot;PMID:20211139&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; [[File:UBE3A Ubiquitylation Pathway.png|thumb|350px|right|UBE3A Ubiquitylation Pathway.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
UBE3A ubiquitylation consists of:&amp;lt;ref name=&amp;quot;PMID:20668179&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20668179&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
# Activation of ubiquitin by E1 enzyme&lt;br /&gt;
# E1 ezyme transfers ubiquitin to E2 enzyme&lt;br /&gt;
# E2 enzyme transfers ubiquitin to UBE3A&lt;br /&gt;
# UBE3A attaches activated ubiquitin to target protein which is then polyubiquitylated &lt;br /&gt;
# Target protein is then degraded by 26S proteosome&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Phenotype-Genotype correlations'''&lt;br /&gt;
&lt;br /&gt;
[[File:Extent of microcephaly in Angelman Syndrome patients.png|thumb|250px|right|Extent of microcephaly in 20 AS patients with deletion and without deletion.&amp;lt;ref&amp;gt;http://www.nature.com/ejhg/index.html/&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
All AS patients show differing extents of cognitive impairment, movement disorder, characteristic behaviours and difficulty in speech and language.&amp;lt;ref name=&amp;quot;PMID:11748306&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11748306&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; However, there seems to be some phenotype-genotype correlations:&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
- 5-7Mb deletions result in the most severe phenotypes such as microcephaly, more sever [[#Glossary | '''epilepsy''']] and seizures, motor difficulties and language impairment.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9546330&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20445456&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; AS patients with large deletions also present with clinical [[#Glossary | '''hypopigmentation''']], light hair and eye colour due to the close association of OCA2 gene with UBE3A.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;16470747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Individuals under this category have in general no increased BMI&amp;lt;ref name=&amp;quot;PMID:15253756&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15253756&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This is indicated by the graph on the left, which shows more cases of AS patients with deletions having larger deviations from the mean head circumference measurement than non-deletion AS patients.&lt;br /&gt;
 &lt;br /&gt;
- AS patients with uniparental disomy (UPD) have better physical growth, fewer motor deficits and lower seizure occurrences.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16023557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
- Individuals with AS resulting from imprinting defects have the least debilitating features, such as higher developmental and language ability than AS caused by other mechanisms.&amp;lt;ref name=&amp;quot;PMID:11748306&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11748306&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
- The Body Mass Index (BMI) of 33% of the UBE3A mutation patients, and 47–64% of the patients from the classes II (UPD) and III (Imprinting defect) is above the 95th centile.&amp;lt;ref name=&amp;quot;PMID:15253756&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15253756&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Animal models'''&lt;br /&gt;
&lt;br /&gt;
* '''Drosophila'''&lt;br /&gt;
&lt;br /&gt;
Drosophila (common fruit fly) is an excellent model to use for better understanding of genetic diseases in humans as they are highly homologous to human UBE3A (hUBE3A), illustrating a high evolutionary conservation. Studies using the Drosophila model have shown that the functional absence of UBE3A resulted in decreased morphogenesis of dendritic branches. This is of interest as dendritic branches cover over 90% of the neuronal surface where [[#Glossary | '''synapse''']] between neurons occur. Proper formation and maturation of dendritic spines is also required so they come in contact with other neurons for effective transmission of neuronal signals. Thus proper formation of dendritic branching is pivitol for effective neuronal function and hence cognitive function.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18996915&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Interestingly, overexpression of dUBE3A also gave the same result, consisting of abnormal locomotion  and decreased dendritic branching in sensory neurons.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18701717&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;  This suggests a possible research field for some forms of [[#Glossary | '''autism''']] where the region containing UBE3A is duplicated, leading to delayed motor skills and seizures.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16433693&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;[[File:Normal and Angelman Syndrome mice models.jpg|thumb|250px|right|Normal and AS mice performance on the Rotarod apparatus.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
* '''Mice'''&lt;br /&gt;
&lt;br /&gt;
Absence of UBE3A in mice manifest similar phenotype to human AS, as illustrated by motor and learning deficits with inducible seizures.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21235769&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It has been shown through various mice model studies that larger deletions, ie. from UBE3A to GABRB3, more closely mirrors the large 6Mb deletions seen in human AS patients. Numerous tests, such as the Rotarod (for motor coordination and learning ability), Morris water maze test (for spatial learning and memory) and [[#Glossary | '''EEG''']] (electroencephalography), were carried out on  UBE3A null mutants, which showed the results to be abnormal or impaired.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20808828&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Other studies using mouse models have also outlined the obesity observed in 15% of AS children, albeit it is not the major characterisitics of AS.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17259980&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The diagram on the right clearly highlights the results obtained from such mouse model studies of AS, where the absence of UBE3A accumulated in deficits of motor function and obesity. In addition, excessive drooling and feeding difficulties were also highlighted by mice models with inactivated UBE3A, reflected by defects in fluid consumption and licking.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18413322&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Pathophysiology===&lt;br /&gt;
&lt;br /&gt;
'''Cognitive defects'''&lt;br /&gt;
&lt;br /&gt;
[[File:Role of UBE3A in dendritic spine neuronal synapses.png|thumb|250px|right|Role of UBE3A in dendritic spine neuronal synapses.]]&lt;br /&gt;
&lt;br /&gt;
AS patients present with abnormally high UBE3A, leading to neurological impairment. Recent identification of key target proteins of Ephexin-58 (Eph-5) and Arc (Activity-Regulated Cytoskeleton-associated protein) have aided in better understanding of the progression of UBE3A to cognitive defects. These two proteins are vital in the understanding of AS as Eph-5 determines synapse numbers and Arc contributes to plasticity and synapse function.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21164477&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Studies utilizing mice models have illustrated that UBE3A null mice could not ubiquitinate Eph-5, thus increasing its levels and limiting the growth of dendritic spines by the activation of RhoA. This subsequent activation of RhoA inhibits synapse formation and results in neuronal defects.&lt;br /&gt;
&lt;br /&gt;
In contrast, mice with normally functioning UBE3A showed phosphorylated Eph-5, resulting from the interaction of two neurons via the activation of EphB signalling receptor.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21029865&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Phosphorylation of Eph-5 allows UBE3A to ubiquitinate and degrade it. This degradation of Eph-5 permits new synaptic connections to form with cells they come into contact with. However, in AS, the absence of UBE3A means Eph-5 cannot be degraded, so RhoA activity is prolonged to reduce synaptic formation.&lt;br /&gt;
&lt;br /&gt;
As mentioned previously, Arc plays a pivitol role in synapse function as it removes synaptic receptors that respond to glutamate, a [[#Glossary | '''neurotransmitter''']].&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17088211&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In UBE3A present neurons, UBE3A ubiquitinates Arc, leading to it degradation as illustrated by the diagram on the left. However, in UBE3A deficient neurons, Arc accumulates and prevents the proper synaptic communications essential for normal cognitive functions.&amp;lt;ref name=&amp;quot;PMID20211139&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20211139&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Signs and Symptoms==&lt;br /&gt;
&lt;br /&gt;
Angelman Syndrome presents a variety of different phenotypes, and the presented symptoms may vary at different ages.&amp;lt;ref name=&amp;quot;PMID7625442&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7625442&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
In 1995 Williams et al. embraced the observed clinical features of AS in a consensus statement, in order to present an appliance for clinicians. The diagnostic criteria were updated in 2005.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt; The following table shows the most frequently occurring characteristics in AS patients:&lt;br /&gt;
&lt;br /&gt;
'''4 characteristics appear in 100% of the cases:'''&lt;br /&gt;
&lt;br /&gt;
*Delayed development: become apparent by the age of 6 to 12 months.&lt;br /&gt;
*Motion and or balance malfunction&lt;br /&gt;
*Behaviour patterns like unmotivated laughter, frequent excitement; often including body movements,[[File:Electroencephalography of Angelman Syndrome.jpg|thumb|350px|right|EEG of AS and normal individuals.]] [[#Glossary | '''hypermotoric''']] behaviour&lt;br /&gt;
*Impairment of speech&lt;br /&gt;
&lt;br /&gt;
'''3 characteristics appear in more than 80% of the cases:'''&lt;br /&gt;
&lt;br /&gt;
*Abnormalities in head circumference, microcephaly&lt;br /&gt;
*Seizures&lt;br /&gt;
*EEG shows specific abnormal patterns&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Angelman Syndrome individuals show the most distinct disease pattern from 2 to 16 years of age.&lt;br /&gt;
In most cases at least 8 of the symptom traits are shown.&amp;lt;ref name=&amp;quot;PMID7625442&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Behavioural Characteristics'''&lt;br /&gt;
&lt;br /&gt;
A range of substantial characteristics appear in all AS cases, regardless of the genetic mechanisms, and are often responsible for diagnosing the syndrome. According to the original name, Happy Puppet syndrome, they have shown to exhibit traits such as a happy demeanor, with frequent laughter or smiling that can easily be triggered.&amp;lt;ref name=&amp;quot;PMID12566516&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12566516&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This behaviour can already be observed in 1 to 3 month old infants.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot; /&amp;gt; Uplifted hand flapping or waving motions are associated with laughter and excitement. Other characteristics manifesting in early childhood are sleep abnormalities with reduced sleep demand, and feeding problems. Breast and bottle feeding can be difficult due to non efficient attachment to the breast, tongue thrusting and uncoordinated sucking. Furthermore, there is an affection to crinkly and reflective surfaces, like some papers or plastic materials, especially water.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID12566516 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Communication Skills'''&lt;br /&gt;
&lt;br /&gt;
Communication is challenging for AS patients due to the fact that speech impairment is present in all cases. In the majority of affected people a lack of speech development is present. Only some of them have a minimal vocabulary consisting of two or three words, a few can speak in basic sentences. Some patients use gestures to articulate themselves, the [[#Glossary | '''Picture Exchange Communication System (PECS)''']] or sign languages such as [[#Glossary | '''Makaton''']] can be used for communication. Simple demands regarding their everyday occurrence can be understood by most patients.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID12566516 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Clinical and External Characteristics'''[[File:Angelman Syndrome patient.png|thumb|200px|right|4 year old AS patient.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Developmental delays are present in all patients. Motor milestones are delayed with children managing to sit unsupported with 12 months and crawl or bottom shuffle at the age of 18-24 months. The average age for walking is 4 years,however, ranging from 18 months to 7 years.&lt;br /&gt;
The [[#Glossary | '''gait''']] is characterised as slow, and flapping hands are a common trait.  The legs remain stiff during walking, arms are inflected by the wrists and elbows. The movements can appear ataxic, jerky or lurching. The muscle tone shows abnormalities with truncal [[#Glossary | '''hypotonia''']] and [[#Glossary | '''hypertonicity''']] of the limbs and alert reflexes.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PMID12566516 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The most striking external traits present in patients include broad-spaced teeth, and a wide mouth, light hair and eye colour, hypopigmented skin, deep set eyes, and a flat [[#Glossary | '''occiput''']].&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Seizures in Angelman Syndrome'''&lt;br /&gt;
&lt;br /&gt;
85% of AS patients suffer from epileptic seizures during their first three years. The first appearance can be within one month up to 20 year old patients. In infants with AS epilepsy manifests with [[#Glossary | '''febrile convulsions''']] and is hard to manage during childhood.&lt;br /&gt;
The most common type of seizures within 25% of patients are [[#Glossary | '''myoclonic seizures''']], followed by [[#Glossary | '''atonic seizures''']] as the second most frequent type, then 21% experience generalised [[#Glossary | '''tonic-clonic seizures''']] and lastly [[#Glossary | '''atypical absences''']] occur in 12% of patients.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20398390&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Angelman Syndrome in adults'''&lt;br /&gt;
&lt;br /&gt;
Patients with Angelman syndrome possess normal secondary sexual characteristics, and puberty sets in at a usual time. Limb hypertonicity, and [[#Glossary | '''thoracic scoliosis''']] lead to decreasing mobility. [[#Glossary | '''Oesophagus reflux''']] might induce severe problems, and the majority suffers from obesity. Furthermore, facial traits such as a prominent lower lip [[#Glossary | '''macrostomia''']] and [[#Glossary | '''mandibular prognathism''']] get manifested in adults. &lt;br /&gt;
In some cases the communication barrier can lead to frustration, resulting in aggressive behaviour. Nonetheless, patients gain a higher concentration span with age, and their nature becomes more quiet.&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Complications===&lt;br /&gt;
&lt;br /&gt;
'''Hypopigmentation and Ocular albinism'''&lt;br /&gt;
&lt;br /&gt;
OCA2 gene, also known as the P gene, is closely located to the UBE3A gene. It encodes a protein vital to tyrosine metabolism, which plays a role in pigmentation development of skin, hair and eyes. However, AS caused by the large deletion of UBE3A leads to haploinsufficiency of OCA2 gene, resulting in hypopigmentation of the skin and the eyes. In some children with severe hypopigmentation, some form of [[#Glossary | '''albinism''']] is suspected.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12749060&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; When AS is caused by another mechanism, no abnormality of the skin and eye pigmentation is observed. However, not all AS children with OCA2 gene deletion will present with obvious hypopigmentation, they may just exhibit lighter skin colour than their parents.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8302318&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Diagnosis==&lt;br /&gt;
&lt;br /&gt;
The diagnosis of Angelman Syndrome is a clinical diagnosis confirmed by laboratory testing.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This involves both prenatal and/or postnatal diagnosis. &lt;br /&gt;
&lt;br /&gt;
===Prenatal Diagnosis===&lt;br /&gt;
[[File:Angelman Syndrome Prenatal Diagnosis.jpg|thumb|250px|right|Flowchart of AS Diagnosis.]]&lt;br /&gt;
&lt;br /&gt;
Prenatal detection of deletions of 15q11.2-q13, [[#Glossary | '''Paternal UPD''']] ([[#Glossary | '''Uniparental Disomy''']]), Imprinting defects and UBE3A mutations are done through DNA/chromosome/FISH analysis of fetal cells obtained by either [[#Glossary | '''Chorionic Villus Sampling''']](CVS) or [[#Glossary | '''Amniocentesis''']].&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot;/&amp;gt; &lt;br /&gt;
DNA methylation analysis using [[#Glossary | '''Amniocytes''']] is usually the first test carried out in molecular diagnosis of AS.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18059071&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; An abnormal result is followed up by either a FISH or array CGH analysis to search for a deletion on chromosome 15. If they produce a normal result, then UPD testing using DNA polymorphysims is carried out. If there is no evidence of UPD, other DNA analysis tests are used search for an imprinting centre deletion.&amp;lt;ref name=&amp;quot;PMID9792887&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9792887&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; A normal DNA methylation analysis is followed by a UBE3A sequence analysis.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt; In addition, a parent of origin test is also done to determine if the genetic disruption is of maternal origin or paternal origin. If it is maternally derived the fetus is diagnosed with AS (a paternally derived genetic disruption is indicative of Prader-Willi Syndrome).&amp;lt;ref name=&amp;quot;PMID17020468&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;17020468&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The flow chart summarizes the normal procedure used for prenatal diagnosis of AS. More information on important laboratory tests used for the diagnosis of Angelman Syndrome are provided below:&lt;br /&gt;
&lt;br /&gt;
*'''DNA Methylation Analysis'''&lt;br /&gt;
&lt;br /&gt;
Identifies approximately 80% of AS affected individuals and is usually the first test to be ordered.&amp;lt;ref name=&amp;quot;PMID7618904&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7618904&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Molecular disruptions such as deletions, paternal UPD and imprinting defects on chromosome 15 all demonstrate abnormal methylation patterns by either southern blot analysis or PCR amplification of bisulphate-treated DNA.&amp;lt;ref name=&amp;quot;PMID20445456&amp;quot; /&amp;gt; An affected individual will only have an unmethylated (paternal) SNRPN (small nuclear ribonuclear protein-associated polypeptide N) allele compared with an unaffected individual who will have both a methylated and an unmethylated SNRPN allele.&amp;lt;ref name=&amp;quot;PMID9634532&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9634532&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
	  &lt;br /&gt;
*'''FISH (Fluorescent In Situ Hybridization)'''&lt;br /&gt;
&lt;br /&gt;
[[File:Critical_region_of_Angelman_Syndrome_on_chromosome_15.png‎|thumb|150px|right|FISH (fluorescence in situ hybridisation) image showing the critical region of Angelman Syndrome on chromosome 15.]]&lt;br /&gt;
&lt;br /&gt;
FISH analysis detects 5-7 Mb deletions in approximately 68% of affected individuals using detecting probes such as D15S10 and/or SNRPN.&amp;lt;ref name=&amp;quot;PMID7618904&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7618904&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It is also able to distinguish UPD from micro-deletions and imprinting defects. In simple terms, FISH analysis involves the binding of a fluorescent probe to a specific part of chromosome 15 and the detection of deletions within that region. FISH analysis is much more accurate in deletion detection compared to other high-resolution cytogenetics in the diagnosis of AS patients.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1511093&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
Array-based CGH is an advanced type of cytogenetic testing that can also be used to detect smaller deletions.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''UPD (Uniparental Disomy) Detection'''&lt;br /&gt;
&lt;br /&gt;
DNA Polymorphism testing detects paternal UPD in approximately 7% of affected AS individuals.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt; It is also able to distinguish between UPD and an Imprinting defect. It requires a DNA sample from the [[#Glossary | '''Proband''']] and from both parents. A homologous or non-homologous whole-arm translocation of the long arms of chromosome 15 is a sound indication for the need for prenatal UPD testing.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''IC (Imprinting Center) Analysis'''&lt;br /&gt;
&lt;br /&gt;
This type of analysis is used when individuals have an abnormal DNA methylation pattern but show normal results for  FISH, array CGH study and UPD analysis.&amp;lt;ref name=&amp;quot;PMID9792887&amp;quot;/&amp;gt; It is used to differentiate between the Imprinting defects caused by either microdeletions in the AS imprinting centre or by epigenetic mutations (that occur in maternal oogenesis or early embryogenesis).&amp;lt;ref name=&amp;quot;PMID9634532&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''Cytogenetic Testing'''&lt;br /&gt;
&lt;br /&gt;
Is used to detect a cytogenetically visible chromosomal rearrangement (large deletion, translocation or inversion) involving the 15q11.2-q13 region, which occurs in less than 1% of affected individuals.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*'''UBE3A Sequence Analysis'''&lt;br /&gt;
Sequence analysis of the UBE3A gene detects mutations in about 10% of the patients.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt; The test is used to detect either multiexonic (10 major coding exons of UBE3A) or whole gene deletions of UBE3A gene in individuals who produces a normal DNA methylation result but has characteristic clinical features of AS.&amp;lt;ref name=&amp;quot;PMID9792887&amp;quot;/&amp;gt;&lt;br /&gt;
This is recommended as a prenatal diagnostic tool in families that include multiple AS affected individuals because the imprinted pattern can be inherited from distant relatives.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Postnatal Diagnosis===&lt;br /&gt;
&lt;br /&gt;
Postnatal diagnosis is made though a combination of common clinical features of AS and UBESA gene sequence analysis.&amp;lt;ref name=&amp;quot;PMID18059071&amp;quot;/&amp;gt; The clinical features of AS include unsteady or shaky movements, muscle hypotonia, developmental delay and behavioral uniqueness such as frequent laughter/smiling and happy demeanor are features that are 100% consistent in all patients diagnosed with Angelman Syndrome.&amp;lt;ref name=&amp;quot;PMID18830393&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18830393&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; These clinical features become apparent between 6 months to 2 years of age. The onset of early or persistent smiling characteristic of this syndrome begin around the age of 1-3 months, but is often overlooked during infancy.&amp;lt;ref name=&amp;quot;PMID20981772&amp;quot;/&amp;gt; Thus early diagnosis of AS during infancy period is difficult because the clinical indicators of the syndrome takes time to manifest and characteristic features such as finger and hand tremors and excessive smiling/laughter are often overlooked and not considered as possible indicators of this syndrome.&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
*Rett Syndrome&lt;br /&gt;
&lt;br /&gt;
Some children with the clinical diagnosis of AS but no underlying genetic mechanism show mutations in ''MECP2'' gene, corresponding to Rett Syndrome. This should be suspected in AS test negative girls in the first few years of life.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17980307&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*Mowat-Wilson Syndrome&lt;br /&gt;
&lt;br /&gt;
Genetic mechanism is heterozygous deletion or truncation in ''ZFHX1B'' (''SIP1'') gene on 2q22. This presents with clinical features of severe intellectual disability, micrcephaly and seizures.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17958891&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Prader-Willi Syndrome patient.png|thumb|right|120px|12 year old PWS patient.]]&lt;br /&gt;
&lt;br /&gt;
*X-linked alpha-thalassemia/mental retardation syndrome (ATR-X)&lt;br /&gt;
&lt;br /&gt;
This arises from mutations in ''XNP'' gene on Xq13. ATR-X presents with severe intellectual disability, no speech development and seizures are common.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11449489&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*Phelan-McDermid Syndrome/22q13 deletion syndrome&lt;br /&gt;
&lt;br /&gt;
Deletions are usually submicroscopic and thus requires special molecular cytogenetic methods to confirm this deletion. Patients show moderate to profound intellectual disability and delay in speech development.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18505557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Related Disease'''&lt;br /&gt;
&lt;br /&gt;
*Prader-Willi Syndrome(PWS)&lt;br /&gt;
&lt;br /&gt;
PWS is a result from the absence of paternally expressed 15q11-q13 gene as a corollary of de novo deletion, maternal uniparental disomy of chromosome 15 or an imprinting defect on paternal chromosome 15 leading to the silencing of paternal alleles.&amp;lt;ref name=&amp;quot;PMID:20668179 &amp;quot;/&amp;gt; It is characterized by [[#Glossary | '''hyperphagia''']], obesity in later infancy and early childhood and difficulty in feeding during early infancy.&amp;lt;ref name=&amp;quot;PMID:20668179 &amp;quot;/&amp;gt; There is also cognitive impairment to some extent, though some PWS patients may exhibit intelligence in the normal IQ range. Behavioral phenotypes include stubbornness, manipulative tendency, obsessive compulsive characteristics.&amp;lt;ref name=&amp;quot;PMID:20668179 &amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Genetic Counselling==&lt;br /&gt;
&lt;br /&gt;
Genetic counselling is the process by which patients or relatives, at risk of an inherited disorder, are advised of the consequences and nature of the disorder, the probability of developing or transmitting it, and the options open to them in management and family planning. In the case for Angelman syndrome, types of risks associated are split into classes and formatted into the table below:&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20459762&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{|  style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
! Class&lt;br /&gt;
! Mechanism&lt;br /&gt;
! Risk to siblings&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! Ia                           &lt;br /&gt;
| De novo deletion                                                                                                               &lt;br /&gt;
| &amp;lt;1%                                                                                                                &lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! Ib&lt;br /&gt;
| Deletion due to chromosome rearrangement&lt;br /&gt;
| Up to 50%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! II&lt;br /&gt;
| Paternal uniparental disomy&lt;br /&gt;
| &amp;lt;1%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! IIIa&lt;br /&gt;
| Imprinting defect with IC mutation&lt;br /&gt;
| Close to 100% if father has 15; 15 [[#Glossary | '''Robertsonian translocation''']]&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! IIIb&lt;br /&gt;
| Imprinting defect withouth IC mutation&lt;br /&gt;
| Up to 50% (if mother has IC deletion)&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! IIIc&lt;br /&gt;
| Mosaic imprinting defect&lt;br /&gt;
| &amp;lt;1%&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
! IV&lt;br /&gt;
| ''UBE3A'' mutation&lt;br /&gt;
| Up to 50% (is mother has mutation)&lt;br /&gt;
|-style=&amp;quot;width:100%; height:25px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
! V&lt;br /&gt;
| No identifiable genetic abnormality&lt;br /&gt;
| ?&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Treatment and Management==&lt;br /&gt;
&lt;br /&gt;
Even though at present there is no known cure for Angelman syndrome, there are a number of treatments available that may alleviate symptons and improve daily life activities.&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The below table describes the problems and management options that are used:&lt;br /&gt;
&lt;br /&gt;
[[File:Subtle Finger tremors-Angelman Syndrome.jpg|right|thumb|150px|A five months old boy with Angelman syndrome showing signs of Subtle Finger tremor.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;lightpink&amp;quot;&lt;br /&gt;
! Problems encountered&lt;br /&gt;
! Treatment and Management&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''Difficulty in feeding newborn AS babies'''&lt;br /&gt;
| Use of special nipples may improve feeding&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Oesophagus reflux'''&lt;br /&gt;
| Special motility medications requiried or upright positioning&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''Seizures'''&lt;br /&gt;
| Anticonvulsant medications&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19605773&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19453717&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Ocular problems'''&lt;br /&gt;
| Visual assessment is vital to encourage interactions and minimize chances of self-harm and autism development&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20656169&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''Drooling in developmental delayed AS patients'''&lt;br /&gt;
| Difficult to treat, but new surgical procedure on salivary duct reimplantation seems to be a promising alternative&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17699119&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Unstable children''' &lt;br /&gt;
| Physical therapy&amp;lt;ref name=&amp;quot;PMID19455185&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
| '''AS patients become less active with increasing age'''&lt;br /&gt;
| Activity schedules to prevent scoliosis and obesity. Occupational therapy to stimulate fine motor and oral-motor control skills in conjunction to speech therapy&amp;lt;ref name=&amp;quot;PMID16470747&amp;quot; /&amp;gt;&lt;br /&gt;
|-style=&amp;quot;height:50px&amp;quot;&lt;br /&gt;
|-bgcolor=&amp;quot;mistyrose&amp;quot;&lt;br /&gt;
| '''Sleeping difficulty'''&lt;br /&gt;
| Sedative medication in severe cases. [[#Glossary | '''Melatonin''']] may be used to promote sleeping but some studies have found that it loses its therapeutic effects after several weeks in most AS patients&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19379289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|-&lt;br /&gt;
|colspan=&amp;quot;4&amp;quot; |&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Prognosis==&lt;br /&gt;
&lt;br /&gt;
Life expectancy of AS patients seems to be normal&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19455185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, but there is still a high degree of developmental delay and limited expressive language skills.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17019625&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This problem arises prominently in the assessment of the severity of coincidental medical conditions due to difficulties in communication. A visit to the dentist can become difficult if good communication is not conveyed between the parents, the dentist, and the child.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18271768&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Some problems require extreme measures, such as the procedure of lens implantation was performed in both eyes of a person diagnosed with AS, due to the inability to wear spectacles.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20656169&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
During adulthood, menstruation and puberty begin at around average age evidenced by females with Angelman syndrome that are fully capable of conceiving children.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11258627&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Most adult patients can feed themselves, but needed help with many other daily activities. Main troubles which have shown in adults are a tendency to become obese and start developing  thoracic scoliosis, which some adults with AS begin wheelchair bounded.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9072912&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Current and Future Research==&lt;br /&gt;
&lt;br /&gt;
Currently there is no cure for the treatment of AS, so much research is being carried out for therapeutic interventions. Findings in the last five years have suggested through various mice and fruit fly models that the absence of maternal UBE3A results in the same human AS features of neurological defects and seizures. However, more recently, studies have outlined that the symptoms of AS can be improved by modifying other gene products. In addition, restoring of a functional UBE3A protein into adult mice neurons have shown to reduce motor and neurological deficits and balance disorders. This shows promising research prospects in that improvements may be possible in human AS patients by restoring functional UBE3A proteins into their neurons. &lt;br /&gt;
&lt;br /&gt;
===Possible Treatment Pathways===&lt;br /&gt;
&lt;br /&gt;
*'''Cognitive and physical impairment'''&lt;br /&gt;
&lt;br /&gt;
Although everyone is born with two copies of the gene UBE3A, one maternal and one paternal copy, it is only the maternal UBE3A that is used in the brain. Most AS patients have a genetic mutation on the maternal chromosome 15 that results in dysfunctional UBE3A.&amp;lt;ref&amp;gt;http://www.cureangelman.org/what-hope.html&amp;lt;/ref&amp;gt; The above research focused on turning on the father's copy of UBE3A to restore its functions. Furthermore, mouse models were utilized to show that alpha-CaMKII could be increased to compensate the loss of UBE3A and restore compromised mental and physical abilities. However, this finding still requires much more research.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17259980&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
*'''Epilepsy'''&lt;br /&gt;
&lt;br /&gt;
There is research being done on improving certain conditions that are involved in AS by nutritional benefits. The use of [[#Glossary | '''corticosteroids''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19666884&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, [[#Glossary | '''valproate''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19453717&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and [[#Glossary | '''clonazepam''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19605773&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and having a [[#Glossary | '''ketogenic diet''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20880305&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; has all been shown to aid in the treatment of epilepsy. It has also been reported to be efficient in the treatment of other conditions, such as behavioural disorders, reduction in seizures, ataxia, sleep patterns, developmental progress and sleep disturbances. [[#Glossary | '''Levetiracetam''']]&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17326790&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; could be used in such a situation, especially when the patient has an intolerance to valproate and clonazepam.&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&lt;br /&gt;
'''albinism''': A congenital disorder distincted by the complete or partial absence of pigment in the skin, hair and eyes due to defect of an enzyme involved in the production of melanin.&lt;br /&gt;
&lt;br /&gt;
'''allele''': Dissimilar variant of one gene. Organisms have two alleles for each gene inherited from their parents, one from each of them.&lt;br /&gt;
&lt;br /&gt;
'''alpha-CaMKII''': (alpha calcium calmodulin kinase II) Compound involved in synaptic plasticity, one of the most important theories behind learning and memory. Ability of a synapse between two neurons to change in strength due to the use or disuse of transmission.&lt;br /&gt;
&lt;br /&gt;
'''Amniocytes''': Cells that are shed by the fetus during fetal development to the surrounding amniotic fluid. They are a source of fetal DNA. &lt;br /&gt;
&lt;br /&gt;
'''Amniocentesis''': (AFT or amniotic fluid test) is a prenatal diagnostic test used to detect chromosomal abnormalities in the developing fetus by extracting amniotic fluid (a source of fetal DNA) surrounding the fetus. &lt;br /&gt;
&lt;br /&gt;
'''AMPA''': (2-amino-3-(5-methyl-3-oxo-1,2- oxazol-4-yl)propanoic acid) Compound that binds to the AMPA receptor to imitate glutamate neurotransmitter.&lt;br /&gt;
&lt;br /&gt;
'''Arc''': Activity-Regulated Cytoskeleton-associated protein; involved in learning and memory.&lt;br /&gt;
&lt;br /&gt;
'''ataxia''': Lack of coordination in muscle movements.&lt;br /&gt;
&lt;br /&gt;
'''atonic seizures''': A abrupt loss of muscle tone, this can lead to the limbs loosing strength, or the head may drop to the side. The patient remains conscious during this kind of epileptic seizure.&lt;br /&gt;
&lt;br /&gt;
'''atypical absences''': Seizure leads to unconsciousness in most cases.  &lt;br /&gt;
&lt;br /&gt;
'''autism''': A neural development disorder defined by limited social interaction and communication.&lt;br /&gt;
&lt;br /&gt;
'''Chorionic Villus Sampling''': A prenatal diagnostic test used to detect chromosomal abnormalities in the developing fetus by extracting and testing chorionic villus (placental tissue). &lt;br /&gt;
&lt;br /&gt;
'''chromosome''': Structure consisting of coiled DNA with DNA associated proteins such as histones.&lt;br /&gt;
&lt;br /&gt;
'''clonazepam''': A psychoactive drug having muscle relaxant properties and treats anxiety and epilepsy.&lt;br /&gt;
&lt;br /&gt;
'''corticosteroid''': A type of steroid hormones that are produced in the adrenal cortex.&lt;br /&gt;
&lt;br /&gt;
'''cytogenetics''': Study of the structure, function and abnormality of the cell, especially the chromosome.&lt;br /&gt;
&lt;br /&gt;
'''deletion''': Lack of a part of the DNA (deoxyribonucleic acid is a nucleic acid containing information for protein synthesis), can vary form a single base to a hole gene. &lt;br /&gt;
&lt;br /&gt;
'''de novo mutation''': Change in a gene of a family member for the first time due to a mutation in the egg or sperm of the parents or in the fertilized egg (zygote).&lt;br /&gt;
&lt;br /&gt;
'''disorder''': A mental or physical health disturbance or dysfunction.&lt;br /&gt;
&lt;br /&gt;
'''EEG''': Electroencephalography is a means of measuring electrical activity along the scalp by measuring the total electrical charges fired by thousands or millions of neurons.&lt;br /&gt;
&lt;br /&gt;
'''epilepsy''': Neurological disorder characterised by recurrent impairment of brain function that can cause seizures or unconsciousness. &lt;br /&gt;
&lt;br /&gt;
'''E6-AP''': E6-AP ubiquitin-protein ligase is an enzyme encoded by UBE3A which adds ubiquitin chain to target proteins to be degraded by proteasomes.&lt;br /&gt;
&lt;br /&gt;
'''febrile convulsions''': The occurrence of high fever, especially in children.&lt;br /&gt;
&lt;br /&gt;
'''FISH''': Fluorescent in situ hybridization is a technique used to identify and localize the presence or absence of DNA sequences on the chromosome. This is achieved by using fluorescently labelled DNA sequences which then binds to complementary DNA sequence on the chromosome. After hybridization (attachment), chromosome of interest will fluoresce under the microscope.&lt;br /&gt;
&lt;br /&gt;
'''gait''': A manner of walking, stepping or running.&lt;br /&gt;
&lt;br /&gt;
'''gene''': A molecular unit of heredity of a living organism.&lt;br /&gt;
&lt;br /&gt;
'''hyperphagia''': (Also referred to as Polyphagia) Excessive ingestion of food beyond the dietary and energy requirements of the body. &lt;br /&gt;
&lt;br /&gt;
'''hypermotoric''': Sudden appearance of uncontrolled movements such as striking or kicking inappropriately.&lt;br /&gt;
&lt;br /&gt;
'''hypertonicity''': Increase of muscle tension and a disability to stretch leading to an impairment of motor activity.&lt;br /&gt;
&lt;br /&gt;
'''hypopigmentation''': A lack of melanin pigments or melanocytes  affecting the colour of the skin, hair and iris. Features appear to be light-coloured due to loss of skin colour.&lt;br /&gt;
&lt;br /&gt;
'''hypotonia''': Decrease in the ability to stretch passively, due to a low muscle tone. &lt;br /&gt;
&lt;br /&gt;
'''imprinting''': This is a process to describe the modification of a maternally or paternally derived chromosome, which consequently influences the expression of certain genes on the altered chromosome.&lt;br /&gt;
&lt;br /&gt;
'''ketogenic diet''': A high-fat, low-carbohydrate diet that is used to treat epilepsy in children.&lt;br /&gt;
&lt;br /&gt;
'''levetiracetam''': An anticonvulsant drug used to treat epilepsy.&lt;br /&gt;
&lt;br /&gt;
'''locus''': Location of a gene on a chromosome(loci: plural for locus).&lt;br /&gt;
&lt;br /&gt;
'''LTP''': Long-term potentiation shares common features with long term memory. It strengthens and enhances signal transmission between neurons by improving the communication between two neurons.&lt;br /&gt;
&lt;br /&gt;
'''macrostomia''': A wide-spaced mouth.&lt;br /&gt;
&lt;br /&gt;
'''Makaton''': Language programme using symbols and signs to support speaking.&lt;br /&gt;
&lt;br /&gt;
'''mandibular prognathism''': The abnormal protrusion of the lower jaw. &lt;br /&gt;
&lt;br /&gt;
'''maxillary hypoplasia''':  The underdevelopment of the upper jaw.&lt;br /&gt;
&lt;br /&gt;
'''melatonin''': A hormone secreted by the pineal gland.&lt;br /&gt;
&lt;br /&gt;
'''microcephaly''': The circumference of the head is less than average due to abnormalities of the nervous system. This abnormality can be present at birth or emerge during the first few years of life and reduces both life expectancy and the cognitive functions of the individual affected.&lt;br /&gt;
&lt;br /&gt;
'''microdeletion''':  A genetic mutation in which a part of a chromosome or a sequence of DNA is missing.&lt;br /&gt;
&lt;br /&gt;
'''mutation''': Event that changes the DNA (deoxyribonucleic acid is a nucleic acid, containing information for protein synthesis) or RNA (ribonucleic acid is a type of nucleic acid transmitting the information from the DNA to the proteins ) of a gene permanently.&lt;br /&gt;
&lt;br /&gt;
'''myoclonic seizures''': A quick jerk of the skeletal muscle, due to a irregular brain activity.&lt;br /&gt;
&lt;br /&gt;
'''neurogenetic''': Genetic basis of the nervous system.&lt;br /&gt;
&lt;br /&gt;
'''neurotransmitter''': Transmits neuronal signals to a target cell. They are first packaged in vesicles just beneath the membrane of presynaptic axon terminals and released into the synaptic cleft (space between the two interacting neurons) and enter the postsynaptic dendrite.&lt;br /&gt;
&lt;br /&gt;
'''occiput''': The back portion of the head.&lt;br /&gt;
&lt;br /&gt;
'''oesophagus reflux''': Impairment of a sphincter in the lower end of the oesophagus leads to the back flow of stomach acid into the oesophagus. Heartburn is a typical symptom.&lt;br /&gt;
&lt;br /&gt;
'''paediatrician''': Physicians that specialise on infants, children and adolescents.&lt;br /&gt;
&lt;br /&gt;
'''paternal UPD''': Inheritance of two copies of a chromosome from the father and none from the mother. &lt;br /&gt;
&lt;br /&gt;
'''phenotype''': Visible traites of an organism determined by genetic and environmental factors.&lt;br /&gt;
&lt;br /&gt;
'''Picture Exchange Communication System (PECS)''': Individuals communicate using images instead of words. It is frequently used by children with autism, to articulate their needs and wishes or to make comments about something.&lt;br /&gt;
&lt;br /&gt;
'''Proband''': Is the person (or animal) being studied or reported on in a genetic investigation. Most commonly it refers to the first affected family member who requires medical help for a genetic disorder. &lt;br /&gt;
&lt;br /&gt;
'''Robertsonian translocation''': Rearrangement of the chromosome, occurs in 5 chromosome including 13,14,15,21 and 22. This type of mutation occurs in chromosomes with the centromere not at the centre, resulting in long and short arm chromosomes. Translocation breaks the chromosome at the centromere so the long arm attaches to the other long arm, and the same for the short arm happens. Cell division will result in the loss of the short arms as they do not contain important genes.&lt;br /&gt;
&lt;br /&gt;
'''seizure''': Abnormal electrical activity in the brain that can result in a variety of physical symptoms like convulsion, body shaking, loss of consciousness, confusion, and mood changes.&lt;br /&gt;
&lt;br /&gt;
'''synapse''': Allows transmission of signal between neurons for effective neuronal function.&lt;br /&gt;
&lt;br /&gt;
'''thoracic scoliosis''': The spine is curved laterally(from side to side) in the thoracic region.&lt;br /&gt;
&lt;br /&gt;
'''tonic-clonic seizures''': This type of seizure is associated with unconsciousness due to electrical discharges in a big proportion of the brain.&lt;br /&gt;
&lt;br /&gt;
'''ubiquitin''': A polypeptide found in all eukaryotic cells, that participates in a variety of cellular functions including protein recycling.&lt;br /&gt;
&lt;br /&gt;
'''Uniparental disomy''': (UPD) the inheritance of two copies of a chromosome pair or part of a chromosme from one parent and no copy from the other parent. &lt;br /&gt;
&lt;br /&gt;
'''valproate''':  A mood-stabilizing drug that is also used for treatment for epilepsy and bipolar disorder.&lt;br /&gt;
&lt;br /&gt;
==External Links==&lt;br /&gt;
&lt;br /&gt;
: http://www.angelmansyndrome.org/research.html&lt;br /&gt;
: http://www.angelman.org/&lt;br /&gt;
: http://rarediseasesnetwork.epi.usf.edu/arpwsc/&lt;br /&gt;
: http://www.rarediseases.org/rare-disease-information/rare-diseases/byID/411/viewAbstract&lt;br /&gt;
: http://www.epilepsyfoundation.org/&lt;br /&gt;
: http://www.kumc.edu/gec/support/angelman.html&lt;br /&gt;
: http://www.cureangelman.org/&lt;br /&gt;
: http://www.angelmansyndromeqld.org/&lt;br /&gt;
: http://ghr.nlm.nih.gov/condition/angelman-syndrome&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&lt;br /&gt;
&amp;lt;references /&amp;gt;&lt;/div&gt;</summary>
		<author><name>Z3291643</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=File:Subtle_Finger_tremors-Angelman_Syndrome.jpg&amp;diff=77411</id>
		<title>File:Subtle Finger tremors-Angelman Syndrome.jpg</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=File:Subtle_Finger_tremors-Angelman_Syndrome.jpg&amp;diff=77411"/>
		<updated>2011-10-12T11:53:43Z</updated>

		<summary type="html">&lt;p&gt;Z3291643: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;==Subtle Finger tremors - Angelman Syndrome==&lt;br /&gt;
&lt;br /&gt;
Subtle finger tremors. A five months old boy with Angelman syndrome and drug resistant infantile spasms.&lt;br /&gt;
&lt;br /&gt;
===Reference===&lt;br /&gt;
&lt;br /&gt;
&amp;lt;pubmed&amp;gt;20398390&amp;lt;/pubmed&amp;gt;| [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2865483 PMC:2865483]&lt;br /&gt;
&lt;br /&gt;
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.&lt;br /&gt;
&lt;br /&gt;
{{Template:2011 Student Image}}&lt;/div&gt;</summary>
		<author><name>Z3291643</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=File:Prader-Willi_Syndrome_patient.png&amp;diff=77409</id>
		<title>File:Prader-Willi Syndrome patient.png</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=File:Prader-Willi_Syndrome_patient.png&amp;diff=77409"/>
		<updated>2011-10-12T11:52:40Z</updated>

		<summary type="html">&lt;p&gt;Z3291643: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;A 12 year old Prader Willi Syndrome patient with the common characteristic of obesity&lt;br /&gt;
&lt;br /&gt;
===Reference===&lt;br /&gt;
&lt;br /&gt;
FRIDMAN, Cintia  and  KOIFFMANN, Célia P.. Genomic imprinting: genetic mechanisms and phenotypic consequences in Prader-Willi and Angelman syndromes. Genet. Mol. Biol. [online]. 2000, vol.23, n.4, pp. 715-724 . Available from: &amp;lt;http://www.scielo.br/scielo.php?script=sci_arttext&amp;amp;pid=S1415-47572000000400004&amp;amp;lng=en&amp;amp;nrm=iso&amp;gt;. ISSN 1415-4757.  http://dx.doi.org/10.1590/S1415-47572000000400004&lt;br /&gt;
&lt;br /&gt;
All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License &lt;br /&gt;
You are free:&lt;br /&gt;
to Share — to copy, distribute and transmit the work to Remix — to adapt the work &lt;br /&gt;
&lt;br /&gt;
http://creativecommons.org/licenses/by-nc/3.0/&lt;br /&gt;
&lt;br /&gt;
{{Template:2011 Student Image}}&lt;/div&gt;</summary>
		<author><name>Z3291643</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=File:Angelman_Syndrome_patient.png&amp;diff=77402</id>
		<title>File:Angelman Syndrome patient.png</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=File:Angelman_Syndrome_patient.png&amp;diff=77402"/>
		<updated>2011-10-12T11:45:46Z</updated>

		<summary type="html">&lt;p&gt;Z3291643: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;This is a photograph of a 4 year old Angelman syndrome (AS) patient, highlighting the typical facial characteristics of AS, such as big gapped teeth&lt;br /&gt;
&lt;br /&gt;
===Reference===&lt;br /&gt;
&lt;br /&gt;
FRIDMAN, Cintia  and  KOIFFMANN, Célia P.. Genomic imprinting: genetic mechanisms and phenotypic consequences in Prader-Willi and Angelman syndromes. Genet. Mol. Biol. [online]. 2000, vol.23, n.4, pp. 715-724 . Available from: &amp;lt;http://www.scielo.br/scielo.php?script=sci_arttext&amp;amp;pid=S1415-47572000000400004&amp;amp;lng=en&amp;amp;nrm=iso&amp;gt;. ISSN 1415-4757.  http://dx.doi.org/10.1590/S1415-47572000000400004&lt;br /&gt;
&lt;br /&gt;
All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License &lt;br /&gt;
You are free:&lt;br /&gt;
to Share — to copy, distribute and transmit the work to Remix — to adapt the work &lt;br /&gt;
&lt;br /&gt;
http://creativecommons.org/licenses/by-nc/3.0/&lt;br /&gt;
&lt;br /&gt;
{{Template:2011 Student Image}}&lt;/div&gt;</summary>
		<author><name>Z3291643</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=File:Angelman_Syndrome_Prenatal_Diagnosis.jpg&amp;diff=77401</id>
		<title>File:Angelman Syndrome Prenatal Diagnosis.jpg</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=File:Angelman_Syndrome_Prenatal_Diagnosis.jpg&amp;diff=77401"/>
		<updated>2011-10-12T11:44:01Z</updated>

		<summary type="html">&lt;p&gt;Z3291643: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;A student drawn flow chart showing the key steps involved in the prenatal diagnosis of Angelman syndrome. UPD; Uniparental Disomy.&lt;br /&gt;
&lt;br /&gt;
===Image Copyright Information===&lt;br /&gt;
&lt;br /&gt;
Illustration by z3291622. &lt;br /&gt;
&lt;br /&gt;
Beginning six months after publication, I, z3291622, grant the public the non-exclusive right to copy, distribute, or display the Work under a Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/ and http://creativecommons.org/licenses/by-nc-sa/3.0/legalcode.&lt;br /&gt;
&lt;br /&gt;
{{Student Image}}&lt;/div&gt;</summary>
		<author><name>Z3291643</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=File:Angelman_Syndrome_patient.png&amp;diff=77400</id>
		<title>File:Angelman Syndrome patient.png</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=File:Angelman_Syndrome_patient.png&amp;diff=77400"/>
		<updated>2011-10-12T11:43:20Z</updated>

		<summary type="html">&lt;p&gt;Z3291643: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;This is a photograph of a 4 year old Angelman syndrome (AS) patient, highlighting the typical facial characteristics of AS, such as big gapped teeth&lt;br /&gt;
&lt;br /&gt;
===Reference===&lt;br /&gt;
&lt;br /&gt;
FRIDMAN, Cintia  and  KOIFFMANN, Célia P.. Genomic imprinting: genetic mechanisms and phenotypic consequences in Prader-Willi and Angelman syndromes. Genet. Mol. Biol. [online]. 2000, vol.23, n.4, pp. 715-724 . Available from: &amp;lt;http://www.scielo.br/scielo.php?script=sci_arttext&amp;amp;pid=S1415-47572000000400004&amp;amp;lng=en&amp;amp;nrm=iso&amp;gt;. ISSN 1415-4757.  http://dx.doi.org/10.1590/S1415-47572000000400004&lt;br /&gt;
&lt;br /&gt;
All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License &lt;br /&gt;
You are free:&lt;br /&gt;
to Share — to copy, distribute and transmit the work to Remix — to adapt the work &lt;br /&gt;
&lt;br /&gt;
http://www.scielo.br/scielo.php?script=sci_arttext&amp;amp;pid=S1415-47572000000400004#figura1&lt;br /&gt;
&lt;br /&gt;
{{Template:2011 Student Image}}&lt;/div&gt;</summary>
		<author><name>Z3291643</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=File:UBE3A_Ubiquitylation_Pathway.png&amp;diff=77397</id>
		<title>File:UBE3A Ubiquitylation Pathway.png</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=File:UBE3A_Ubiquitylation_Pathway.png&amp;diff=77397"/>
		<updated>2011-10-12T11:38:49Z</updated>

		<summary type="html">&lt;p&gt;Z3291643: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;Ubiquitin is activated by E1 enzyme, followed by the subsequent transfer to E2 enzyme and to UBE3A. UBE3A attaches ubiquitin to the target protein for degradation by proteasome after polyubiquitylation.&lt;br /&gt;
&lt;br /&gt;
===Reference===&lt;br /&gt;
&lt;br /&gt;
Illustration by z3291643 &lt;br /&gt;
&lt;br /&gt;
Beginning six months after publication, I (3291643) grant the public the non-exclusive right to copy, distribute, or display the Work under a Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/ and http://creativecommons.org/licenses/by-nc-sa/3.0/legalcode&lt;br /&gt;
&lt;br /&gt;
{{Template:2011 Student Image}}&lt;/div&gt;</summary>
		<author><name>Z3291643</name></author>
	</entry>
</feed>